data_2k06_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2k06 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 89.7 mttt . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.456 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 61.9 mtt180 -122.67 152.94 40.03 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.228 -0.92 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.572 ' CE2' ' OE1' ' A' ' 72' ' ' GLN . 74.9 m95 -95.01 133.89 38.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CE2' ' O ' ' A' ' 73' ' ' MET . 28.3 m-85 -122.69 149.39 44.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -0.873 . . . . 0.0 109.308 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 25.0 t -97.68 142.62 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.491 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.75 130.81 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.478 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.451 ' HB3' ' HB2' ' A' ' 90' ' ' MET . 57.3 tt0 -96.96 128.1 43.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 109.464 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -142.08 164.23 30.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.214 -0.928 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -69.22 145.33 53.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.2 p -66.19 149.49 50.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.31 -33.03 4.69 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -109.53 1.6 19.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.3 -1.118 . . . . 0.0 109.623 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.459 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 85.6 tt0 -53.45 -40.07 64.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.44 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.57 -47.77 74.4 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -63.65 -39.36 94.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -1.171 . . . . 0.0 109.461 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 88' ' ' ARG . 60.6 t -52.18 -44.69 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.473 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.76 -42.79 98.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.333 -0.854 . . . . 0.0 109.465 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.1 m -61.2 -39.0 88.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.462 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 24.1 m -58.95 -39.18 80.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.505 ' CD2' HG23 ' A' ' 86' ' ' VAL . 48.3 mt -56.11 -46.61 79.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttt85 -56.15 -41.89 76.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -0.89 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -66.78 -58.73 4.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 25' ' ' SER . 73.4 m-70 -57.22 -48.63 78.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 0.0 109.498 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.555 HG12 ' CE1' ' A' ' 39' ' ' PHE . 89.7 mt -61.9 -49.52 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.251 -0.906 . . . . 0.0 109.446 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -57.87 -45.56 86.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.467 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 45.3 mt -63.26 -48.62 77.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.444 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -83.44 5.5 23.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.251 -0.906 . . . . 0.0 109.52 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 30' ' ' ILE . 38.1 t30 54.69 46.13 25.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.33 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.539 ' CG ' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -96.54 3.89 52.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.579 -179.914 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.1 mt-10 -53.4 -35.61 60.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -54.3 -40.46 67.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.22 -0.925 . . . . 0.0 109.463 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.539 ' CD1' ' CG ' ' A' ' 35' ' ' MET . 0.7 OUTLIER -73.9 -48.77 28.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.288 -0.883 . . . . 0.0 109.294 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.569 ' CE1' ' SD ' ' A' ' 73' ' ' MET . 89.4 m-85 -70.41 130.12 41.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.358 -0.839 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.14 -63.16 0.58 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -141.44 115.46 9.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -1.19 . . . . 0.0 109.66 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.476 HG23 ' CG2' ' A' ' 71' ' ' VAL . 8.2 p -89.5 147.08 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.39 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.563 ' HE3' ' CH2' ' A' ' 9' ' ' TRP . 46.3 mtt -112.88 148.98 33.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 35.3 t . . . . . 0 N--CA 1.491 1.575 0 O-C-N 121.342 -0.849 . . . . 0.0 109.274 179.919 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.459 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -117.59 128.51 55.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -1.14 . . . . 0.0 109.492 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.446 HG23 ' OE2' ' A' ' 19' ' ' GLU . 65.8 t -130.73 143.44 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.273 -0.892 . . . . 0.0 109.538 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.575 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.1 mp -107.32 133.04 52.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.322 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.476 ' CG2' HG23 ' A' ' 42' ' ' VAL . 43.1 t -139.51 131.15 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.684 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.572 ' OE1' ' CE2' ' A' ' 9' ' ' TRP . 23.2 tt0 -88.05 128.5 35.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.218 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 55.7 ttp -173.98 163.96 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.179 -0.951 . . . . 0.0 109.682 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.514 ' N ' ' HG2' ' A' ' 73' ' ' MET . 28.6 m -87.45 138.24 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.267 -0.896 . . . . 0.0 109.459 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.496 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 1.1 ttm -76.68 116.76 17.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.434 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 52.8 p-10 -145.01 170.71 15.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.428 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -67.88 -33.66 75.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -0.919 . . . . 0.0 109.915 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.521 ' CB ' ' HE2' ' A' ' 35' ' ' MET . . . -67.7 -69.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 0.0 109.7 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 80' ' ' TRP . 9.9 p -46.6 -59.52 2.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -0.892 . . . . 0.0 109.645 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.49 ' N ' ' OG ' ' A' ' 79' ' ' SER . 68.0 t90 -42.84 -58.09 2.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.638 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -58.34 -37.69 75.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.944 . . . . 0.0 109.493 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.511 ' CD1' ' HB3' ' A' ' 29' ' ' HIS . 67.4 tp -63.41 -39.7 95.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.568 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.533 ' CG1' ' CE2' ' A' ' 92' ' ' PHE . 85.4 t -59.93 -47.29 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 109.584 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.59 -37.69 76.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.543 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 82' ' ' LEU . 80.4 p -64.67 -26.28 68.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -0.914 . . . . 0.0 109.499 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.505 HG23 ' CD2' ' A' ' 26' ' ' LEU . 98.7 t -60.79 124.51 79.73 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.486 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.444 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.4 Cg_endo -70.35 156.41 61.88 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.696 2.264 . . . . 0.0 111.795 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.449 ' O ' HG23 ' A' ' 22' ' ' VAL . 68.2 mtt-85 61.28 46.07 8.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.395 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.462 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.4 t -132.85 118.65 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.593 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.451 ' HB2' ' HB3' ' A' ' 13' ' ' GLN . 64.2 mtt -69.03 -42.82 75.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.423 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.0 -152.81 24.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.533 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 3.4 m-85 -109.99 161.82 15.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.232 -1.158 . . . . 0.0 109.537 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.459 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 14.5 mm -115.9 116.35 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.507 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -172.88 -148.1 6.14 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.59 -35.01 67.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.6 t -138.9 175.6 9.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -1.189 . . . . 0.0 109.665 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 p -93.56 19.44 8.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.288 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -131.19 -0.83 4.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 109.429 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.403 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtt180 -168.28 96.39 0.58 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.88 . . . . 0.0 109.003 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.496 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.9 Cg_endo -67.52 116.88 4.46 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.798 2.332 . . . . 0.0 112.16 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -60.72 135.5 92.44 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.267 -0.896 . . . . 0.0 109.304 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.1 Cg_endo -69.92 153.32 68.32 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.674 2.25 . . . . 0.0 111.785 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.458 ' CD1' HG21 ' A' ' 108' ' ' VAL . 28.3 pt -126.42 157.6 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.386 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 38.7 m -63.27 147.81 49.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.4 -39.31 83.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.428 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.2 tttt -59.74 -39.28 84.23 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.456 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -59.95 -41.4 91.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.256 -0.903 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.526 HG23 ' CG ' ' A' ' 9' ' ' TRP . 97.7 t -61.89 -35.96 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.515 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -67.33 -33.82 76.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.274 -0.891 . . . . 0.0 109.485 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.73 96.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.226 -0.921 . . . . 0.0 109.422 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.409 HG22 HD13 ' A' ' 111' ' ' ILE . 70.2 mt -56.86 -51.93 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 109.482 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 89.1 mtp . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.457 -179.983 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 76.9 mttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.529 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 49.0 mtt180 -80.59 148.32 30.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.523 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.533 ' CH2' ' HG3' ' A' ' 43' ' ' MET . 77.2 m95 -78.01 135.68 37.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.947 . . . . 0.0 109.639 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.615 ' CZ ' ' CG ' ' A' ' 75' ' ' MET . 76.0 m-85 -132.21 139.02 48.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -0.92 . . . . 0.0 109.372 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.51 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.7 t -83.17 148.94 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.108 -0.995 . . . . 0.0 109.519 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.91 122.94 57.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.423 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.499 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 13.4 mt-30 -78.83 145.0 34.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.266 -0.896 . . . . 0.0 109.588 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -157.03 157.09 34.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.299 -0.876 . . . . 0.0 109.401 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -63.86 142.86 58.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.481 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.1 p -68.12 151.0 47.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.463 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.21 -34.08 4.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -112.08 9.22 20.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.453 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.52 ' OE2' ' CG2' ' A' ' 69' ' ' VAL . 85.6 tt0 -54.18 -41.0 68.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.87 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.53 -44.33 83.38 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.7 ttm-85 -62.44 -35.39 79.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -1.147 . . . . 0.0 109.498 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.447 HG21 ' O ' ' A' ' 88' ' ' ARG . 53.7 t -56.51 -38.21 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.65 -37.41 86.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -0.894 . . . . 0.0 109.445 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 54.8 m -73.54 -40.68 63.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 26.6 m -64.48 -33.48 75.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.552 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.523 HD11 ' CG2' ' A' ' 86' ' ' VAL . 20.2 tp -63.32 -49.92 72.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.439 ' HG2' ' NZ ' ' A' ' 31' ' ' LYS . 18.4 ttp180 -43.21 -51.86 5.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.334 -0.854 . . . . 0.0 109.52 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -51.38 -49.18 62.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.528 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.448 ' HB3' ' CD1' ' A' ' 82' ' ' LEU . 90.3 m-70 -57.76 -26.08 61.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.474 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.636 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 20.7 mm -72.22 -51.95 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.454 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 58.7 mttp -66.9 -39.66 87.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.304 -0.872 . . . . 0.0 109.435 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 41.4 mt -57.45 -57.85 10.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.491 ' CD2' HD11 ' A' ' 82' ' ' LEU . 85.1 m-70 -89.5 5.39 45.65 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 30' ' ' ILE . 69.9 m-20 55.18 48.4 19.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.551 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.523 ' CE ' ' CD1' ' A' ' 38' ' ' LEU . 49.0 mmm -98.17 15.06 25.5 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 98.0 mt-10 -55.01 -29.27 57.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.481 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -67.69 -38.3 83.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.338 -0.851 . . . . 0.0 109.508 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 6.3 mt -72.63 -52.85 13.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.425 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.636 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 93.2 m-85 -69.91 133.77 47.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 109.335 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.52 -64.06 0.61 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -146.6 153.07 39.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.168 -1.195 . . . . 0.0 109.556 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.509 ' CG1' HG23 ' A' ' 71' ' ' VAL . 38.9 t -114.44 149.72 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.455 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.533 ' HG3' ' CH2' ' A' ' 9' ' ' TRP . 58.4 mtm -132.08 140.36 48.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.167 -0.958 . . . . 0.0 109.562 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.3 t . . . . . 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.969 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -117.89 109.49 16.59 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -1.141 . . . . 0.0 109.437 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.52 ' CG2' ' OE2' ' A' ' 19' ' ' GLU . 77.0 t -137.25 133.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.275 -0.891 . . . . 0.0 109.585 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.55 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 2.1 mp -101.26 147.1 26.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.285 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.509 HG23 ' CG1' ' A' ' 42' ' ' VAL . 65.0 t -145.49 113.78 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.246 -0.909 . . . . 0.0 109.638 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.452 ' NE2' ' CZ2' ' A' ' 9' ' ' TRP . 0.0 OUTLIER -54.06 124.35 15.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.209 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.564 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 38.1 ttp -177.21 155.22 1.12 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 0.0 109.533 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.483 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.1 t -91.52 140.45 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.302 -0.874 . . . . 0.0 109.402 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.615 ' CG ' ' CZ ' ' A' ' 10' ' ' TYR . 30.6 mmm -84.02 109.33 17.57 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.278 -0.889 . . . . 0.0 109.597 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.515 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 51.2 p-10 -138.27 173.89 11.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -64.18 -26.16 68.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.249 -0.907 . . . . 0.0 109.562 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -78.25 -70.14 0.51 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.51 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 25.1 p -54.67 -45.99 73.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -0.896 . . . . 0.0 109.736 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 73.1 t90 -51.15 -54.38 25.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.6 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -61.57 -39.09 89.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.925 . . . . 0.0 109.559 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.514 ' CD2' ' HG3' ' A' ' 35' ' ' MET . 58.4 tp -63.21 -41.64 99.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.152 -0.967 . . . . 0.0 109.503 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.555 ' CG1' ' CE2' ' A' ' 92' ' ' PHE . 55.6 t -56.32 -43.89 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.139 -0.976 . . . . 0.0 109.534 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -61.83 -35.65 78.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.175 -0.953 . . . . 0.0 109.481 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 29.8 t -66.76 -28.34 68.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.479 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.523 ' CG2' HD11 ' A' ' 26' ' ' LEU . 49.8 t -54.9 124.93 53.99 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.464 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.457 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.2 155.08 65.29 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.745 2.296 . . . . 0.0 111.789 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.457 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 82.6 mmt-85 63.36 43.43 6.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.254 -0.904 . . . . 0.0 109.526 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 86' ' ' VAL . 53.6 t -128.79 115.58 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.5 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.499 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.7 mtp -68.5 -40.16 80.98 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.907 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.59 -158.86 31.43 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.555 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 0.2 OUTLIER -112.69 166.68 11.13 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.218 -1.166 . . . . 0.0 109.514 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.51 HD12 ' CG1' ' A' ' 11' ' ' VAL . 67.4 mt -118.24 137.5 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.878 . . . . 0.0 109.379 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.456 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 161.18 -147.08 13.24 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -78.08 -44.09 12.46 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.3 p -127.73 173.38 9.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.156 -1.202 . . . . 0.0 109.53 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.1 m -89.89 18.09 6.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.274 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 87.6 m-20 -130.17 -33.24 1.74 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.574 -0.704 . . . . 0.0 109.134 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.55 88.58 38.46 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.264 -0.898 . . . . 0.0 108.836 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.562 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.46 128.76 18.8 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.71 2.274 . . . . 0.0 112.048 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 137.14 82.56 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.291 -0.88 . . . . 0.0 109.361 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.529 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.3 Cg_endo -69.7 153.23 69.47 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.699 2.266 . . . . 0.0 111.841 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.455 ' HB ' ' OE1' ' A' ' 107' ' ' GLU . 26.7 pt -112.65 154.96 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.369 -0.832 . . . . 0.0 109.481 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.9 m -65.38 146.26 55.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.152 -0.968 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -58.13 -41.01 82.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.278 -0.889 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 42.5 tttt -57.98 -43.42 86.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.449 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.455 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 86.5 tt0 -51.85 -43.75 63.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.902 . . . . 0.0 109.441 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.414 HG23 HD11 ' A' ' 103' ' ' ILE . 74.8 t -57.17 -38.69 62.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.303 -0.873 . . . . 0.0 109.375 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -68.41 -31.75 71.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.23 -0.919 . . . . 0.0 109.465 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -62.93 -42.28 99.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.435 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 50.9 mt -52.43 -53.69 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.211 -0.93 . . . . 0.0 109.395 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.4 mtt . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.926 . . . . 0.0 109.377 179.911 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.462 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 47.1 mttt . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.462 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 78.8 mtt-85 -128.92 156.48 43.66 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 67.4 m95 -91.55 128.15 37.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.177 -0.952 . . . . 0.0 109.617 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.561 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.9 m-85 -120.9 150.11 41.58 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.46 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.46 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 53.0 t -102.27 136.04 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.245 -0.909 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.79 126.68 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.508 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 69.9 tp60 -90.35 130.64 36.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.425 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.403 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -142.67 154.74 44.61 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.528 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -55.12 149.67 11.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.423 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.8 t -67.93 147.71 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.498 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 -33.94 4.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.511 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 93.5 m-85 -109.53 7.15 24.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -1.155 . . . . 0.0 109.592 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.42 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 23.0 pt-20 -56.12 -39.31 72.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.441 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -75.44 -54.2 5.66 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -57.86 -39.21 77.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -1.136 . . . . 0.0 109.497 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 50.9 t -53.05 -40.75 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.29 96.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.894 . . . . 0.0 109.433 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.8 m -64.48 -43.51 93.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.524 ' CB ' HG22 ' A' ' 86' ' ' VAL . 58.1 m -58.41 -41.68 85.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.568 HD23 ' CE1' ' A' ' 39' ' ' PHE . 4.8 tp -59.14 -39.41 82.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 109.272 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -58.48 -26.03 62.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.321 -0.862 . . . . 0.0 109.392 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.471 ' HB2' ' O ' ' A' ' 25' ' ' SER . 71.2 mt-10 -68.66 -47.65 65.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.325 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.567 ' CD2' ' HB ' ' A' ' 86' ' ' VAL . 79.8 m-70 -68.06 -43.47 78.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.632 ' CD1' ' CD2' ' A' ' 39' ' ' PHE . 54.9 mt -57.94 -50.44 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.52 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 58.2 tttp -60.49 -41.48 94.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.611 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 32.3 mt -69.27 -50.88 42.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.547 ' CD2' HD12 ' A' ' 82' ' ' LEU . 97.3 m-70 -77.49 -6.89 55.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.217 -0.927 . . . . 0.0 109.528 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.487 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.1 t30 66.14 42.98 2.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.514 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.511 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 45.8 mmm -92.04 5.19 51.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.45 ' O ' ' O ' ' A' ' 39' ' ' PHE . 96.5 mt-10 -48.76 -37.79 19.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.461 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -53.26 -44.25 68.03 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.214 -0.929 . . . . 0.0 109.362 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.52 HD22 ' CG1' ' A' ' 74' ' ' VAL . 1.2 mt -72.19 -52.66 15.5 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.302 -0.874 . . . . 0.0 109.4 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.632 ' CD2' ' CD1' ' A' ' 30' ' ' ILE . 98.1 m-85 -70.97 129.09 38.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.187 -0.946 . . . . 0.0 109.441 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.32 -69.19 0.66 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -139.71 147.15 40.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -1.163 . . . . 0.0 109.583 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.456 HG11 ' O ' ' A' ' 70' ' ' LEU . 39.0 t -113.99 154.01 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.374 -0.829 . . . . 0.0 109.351 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.443 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 64.3 mtm -137.78 144.05 41.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.566 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.6 t . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.438 179.918 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -118.64 124.25 46.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -1.199 . . . . 0.0 109.445 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.2 146.49 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.567 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.2 mp -106.85 130.09 54.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.408 HG23 HG23 ' A' ' 42' ' ' VAL . 99.1 t -136.63 124.77 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.176 -0.952 . . . . 0.0 109.642 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.462 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 7.5 tt0 -81.02 128.37 33.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.171 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.561 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 50.9 ttp -173.83 165.12 4.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.65 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.526 ' N ' ' CG ' ' A' ' 73' ' ' MET . 14.5 p -88.53 143.36 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.353 -0.842 . . . . 0.0 109.218 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.522 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 16.9 tpp -82.91 113.82 20.78 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.593 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.0 p30 -142.14 168.94 18.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.318 -0.864 . . . . 0.0 109.427 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.572 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.6 m-20 -68.61 -30.12 68.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.217 -0.927 . . . . 0.0 109.47 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.441 ' HB1' ' HE2' ' A' ' 35' ' ' MET . . . -70.02 -71.88 0.22 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.905 . . . . 0.0 109.55 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.472 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 7.5 m -48.27 -49.61 32.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 66.3 t90 -49.63 -52.3 31.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.873 . . . . 0.0 109.73 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 56.5 m-70 -66.6 -24.19 66.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.6 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.547 HD12 ' CD2' ' A' ' 33' ' ' HIS . 56.9 tp -68.74 -45.21 72.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.526 ' CG2' ' CZ ' ' A' ' 92' ' ' PHE . 70.0 t -50.92 -44.05 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.573 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 36.2 ttp180 -62.92 -23.02 67.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.139 -0.976 . . . . 0.0 109.368 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.5 t -61.6 -63.86 1.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 0.0 109.415 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.567 ' HB ' ' CD2' ' A' ' 29' ' ' HIS . 1.8 p -59.62 125.8 80.89 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.164 -0.96 . . . . 0.0 109.467 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.474 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.1 Cg_endo -69.65 -177.77 1.99 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.732 2.288 . . . . 0.0 111.834 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.474 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.1 mtt85 62.94 23.01 13.77 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.314 -0.866 . . . . 0.0 109.582 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.462 HG21 ' O ' ' A' ' 87' ' ' PRO . 22.2 t -116.88 116.48 52.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.482 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.508 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 44.8 mtt -65.93 -43.68 87.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.346 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.19 -150.86 22.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.526 ' CZ ' ' CG2' ' A' ' 83' ' ' VAL . 4.6 m-85 -111.8 161.4 16.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.4 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.46 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 15.8 mm -114.88 123.12 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.306 -0.871 . . . . 0.0 109.548 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.86 -152.76 11.57 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -64.95 -45.04 93.62 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.9 p -129.32 172.86 11.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.183 -1.187 . . . . 0.0 109.565 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 14.4 p -89.82 20.05 4.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.2 -0.937 . . . . 0.0 109.412 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -123.12 -22.65 5.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.449 -0.782 . . . . 0.0 109.37 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.53 103.18 3.27 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.328 -0.857 . . . . 0.0 108.94 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.522 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.4 Cg_endo -68.77 111.46 2.61 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.756 2.304 . . . . 0.0 111.996 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.98 140.7 81.95 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 109.427 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.462 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.9 Cg_endo -70.15 153.34 67.24 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.637 2.225 . . . . 0.0 111.81 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.62 155.11 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.255 -0.903 . . . . 0.0 109.408 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.7 m -71.74 151.34 43.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -52.29 -41.7 63.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -55.82 -41.52 74.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.921 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -52.88 -45.12 67.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.333 -0.854 . . . . 0.0 109.377 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.418 ' CG1' ' HE3' ' A' ' 43' ' ' MET . 98.1 t -56.78 -38.03 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -67.54 -34.2 76.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.229 -0.919 . . . . 0.0 109.445 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -56.48 -46.3 80.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.332 -0.855 . . . . 0.0 109.415 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 50.5 mt -49.69 -56.36 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.6 mtt . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.276 179.812 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 77.5 mttt . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.285 0.564 . . . . 0.0 109.561 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.514 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 44.9 mtm180 -132.72 159.55 39.35 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.493 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.54 ' CH2' ' SD ' ' A' ' 43' ' ' MET . 46.3 m95 -99.34 132.54 44.59 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.892 . . . . 0.0 109.556 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.582 ' CD2' ' HE3' ' A' ' 75' ' ' MET . 66.1 m-85 -130.93 155.23 47.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.443 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.471 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 10.7 t -96.18 145.93 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.226 -0.921 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.0 t -119.03 123.57 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 109.364 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.514 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 64.5 tt0 -93.1 131.67 37.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.923 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.4 ' HB3' HG22 ' A' ' 22' ' ' VAL . . . -138.72 -153.23 0.46 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 109.369 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 61.7 t80 -98.23 133.49 42.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.452 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 31.3 t -54.77 126.0 22.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.214 -0.929 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.11 -27.15 19.67 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 19.2 m-85 -105.09 7.52 33.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -1.116 . . . . 0.0 109.493 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -56.89 -34.72 68.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.915 . . . . 0.0 109.374 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -71.13 -37.87 63.68 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.458 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 17.9 ttm180 -63.81 -49.86 71.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.204 -1.174 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.442 HG13 HG13 ' A' ' 86' ' ' VAL . 39.1 t -50.37 -38.78 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.235 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.73 -39.72 91.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.929 . . . . 0.0 109.251 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.6 m -69.01 -46.6 67.55 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.388 -0.82 . . . . 0.0 109.376 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.479 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.4 m -65.72 -39.63 91.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.438 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.494 ' HG ' ' CD1' ' A' ' 30' ' ' ILE . 30.8 tp -54.34 -43.55 71.34 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.6 ttm-85 -57.83 -36.89 72.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -67.94 -52.58 34.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.203 -0.936 . . . . 0.0 109.474 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.517 ' HB3' ' CD1' ' A' ' 82' ' ' LEU . 68.1 m-70 -58.44 -48.06 81.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.93 . . . . 0.0 109.443 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.564 HG12 ' CE2' ' A' ' 39' ' ' PHE . 89.2 mt -57.69 -52.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.305 -0.872 . . . . 0.0 109.515 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.4 tttm -57.61 -43.39 84.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.29 -0.881 . . . . 0.0 109.497 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 40.2 mt -68.25 -49.48 60.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.229 -0.92 . . . . 0.0 109.416 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.466 ' CD2' HD11 ' A' ' 82' ' ' LEU . 98.5 m-70 -80.35 4.19 18.7 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 109.577 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 30' ' ' ILE . 40.5 t30 52.75 50.53 17.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.403 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.522 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 53.3 mmm -102.88 4.74 37.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.427 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.3 mt-10 -49.78 -34.93 20.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -57.77 -43.03 85.23 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.413 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.511 HD23 ' ND2' ' A' ' 76' ' ' ASN . 1.4 mt -72.84 -50.12 25.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.287 -0.883 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.564 ' CE2' HG12 ' A' ' 30' ' ' ILE . 96.4 m-85 -71.2 130.83 42.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.295 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.56 -65.4 0.55 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -137.19 122.68 19.6 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -1.204 . . . . 0.0 109.675 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.441 ' CG2' HG21 ' A' ' 71' ' ' VAL . 8.2 p -92.53 136.0 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.34 -0.85 . . . . 0.0 109.145 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.54 ' SD ' ' CH2' ' A' ' 9' ' ' TRP . 97.2 mtp -125.12 117.42 23.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.192 -0.942 . . . . 0.0 109.768 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CG1' ' A' ' 44' ' ' VAL . 12.0 p . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.323 -0.861 . . . . 0.0 109.099 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -111.95 120.79 43.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.485 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 43' ' ' MET . 96.5 t -133.34 146.88 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -0.888 . . . . 0.0 109.577 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.58 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 1.2 mm? -105.03 131.0 53.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.886 . . . . 0.0 109.341 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.441 HG21 ' CG2' ' A' ' 42' ' ' VAL . 64.3 t -138.55 125.74 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 109.709 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.449 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.7 tt0 -78.8 119.58 22.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.826 . . . . 0.0 109.299 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.552 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 48.6 ttp -165.99 163.46 18.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.602 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.51 ' N ' ' HG2' ' A' ' 73' ' ' MET . 32.3 t -91.48 147.61 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.582 ' HE3' ' CD2' ' A' ' 10' ' ' TYR . 10.2 mmt -86.5 114.14 23.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.935 . . . . 0.0 109.653 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.511 ' ND2' HD23 ' A' ' 38' ' ' LEU . 51.1 p-10 -143.25 167.92 21.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.305 -0.872 . . . . 0.0 109.324 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.6 m-20 -66.36 -24.29 66.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.257 -0.902 . . . . 0.0 109.696 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.57 -70.26 0.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.235 -0.916 . . . . 0.0 109.526 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.462 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 12.4 p -56.07 -49.72 73.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.168 -0.957 . . . . 0.0 109.682 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.451 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.8 t90 -43.97 -44.93 7.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 33.0 m-70 -73.54 -32.01 63.96 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 109.484 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.522 ' CD2' ' HG3' ' A' ' 35' ' ' MET . 54.9 tp -63.07 -45.88 90.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.549 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 82.8 t -55.4 -45.64 78.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -62.95 -36.39 83.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.638 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 41.0 m -61.48 -38.89 88.95 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.133 -0.979 . . . . 0.0 109.471 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.511 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 38.5 t -51.73 126.14 31.14 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.289 -0.882 . . . . 0.0 109.531 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.467 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -71.17 156.36 59.55 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.69 2.26 . . . . 0.0 111.714 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 82.0 mtt-85 62.06 35.86 15.68 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.857 . . . . 0.0 109.672 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.511 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 8.2 p -129.09 128.31 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.158 -0.964 . . . . 0.0 109.571 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.48 ' CG ' ' HG2' ' A' ' 13' ' ' GLN . 92.4 mmm -71.96 -54.59 9.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.285 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 162.03 -148.01 14.87 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.549 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 5.3 m-85 -104.62 160.6 14.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -1.162 . . . . 0.0 109.499 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.514 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 17.3 mm -118.14 119.11 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.453 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.476 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -171.63 -143.57 4.11 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -71.98 -35.42 61.36 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.0 t -140.93 176.16 9.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.211 -1.17 . . . . 0.0 109.633 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 13.1 p -92.96 21.57 5.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.43 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -137.05 8.79 2.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.46 -0.775 . . . . 0.0 109.133 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -176.69 92.51 0.25 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.343 -0.848 . . . . 0.0 108.948 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.516 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 46.0 Cg_endo -68.48 120.78 7.71 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.688 2.259 . . . . 0.0 111.988 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -64.37 148.61 95.95 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.285 -0.884 . . . . 0.0 109.317 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.469 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 49.5 Cg_endo -70.07 153.28 67.68 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.68 2.253 . . . . 0.0 111.82 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 9' ' ' TRP . 26.1 pt -125.21 157.91 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.336 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.452 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 39.0 m -75.64 148.71 38.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.554 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -56.51 -40.8 75.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -58.15 -40.37 81.17 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -0.882 . . . . 0.0 109.417 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.452 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 93.3 mt-10 -56.03 -43.78 78.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.197 -0.939 . . . . 0.0 109.389 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.413 HG22 ' CG ' ' A' ' 9' ' ' TRP . 54.1 t -57.35 -37.83 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -0.902 . . . . 0.0 109.343 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -73.81 -34.1 64.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.326 -0.859 . . . . 0.0 109.367 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.39 -43.41 81.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.388 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.423 HG13 ' O ' ' A' ' 107' ' ' GLU . 89.7 mt -50.05 -50.09 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.454 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.3 mtp . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.414 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.429 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 80.1 mttt . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.289 0.566 . . . . 0.0 109.493 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.531 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 51.3 mtt85 -117.27 156.01 28.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.19 -0.944 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.466 ' O ' HG12 ' A' ' 103' ' ' ILE . 83.7 m95 -87.78 128.06 35.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.587 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.618 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 91.2 m-85 -121.18 160.67 23.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.912 . . . . 0.0 109.542 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.489 HG11 ' CD1' ' A' ' 93' ' ' ILE . 21.1 t -95.13 154.64 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.207 -0.933 . . . . 0.0 109.588 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.44 115.94 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.302 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.519 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 78.4 mt-30 -81.01 150.47 28.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.692 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -157.56 158.42 35.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 109.405 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.452 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.7 m-85 -62.44 143.97 56.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 34.0 t -67.78 147.34 52.72 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.25 -33.52 4.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.451 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.5 m-85 -108.07 10.66 28.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -1.139 . . . . 0.0 109.476 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -61.15 -36.78 80.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.433 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.81 -50.02 38.54 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.0 ttt85 -63.77 -37.48 87.51 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -1.144 . . . . 0.0 109.424 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 18' ' ' PHE . 50.3 t -52.21 -41.67 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -0.934 . . . . 0.0 109.271 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.16 -48.93 79.8 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.298 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 78.7 m -59.39 -46.39 88.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.39 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.421 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.9 m -51.3 -44.79 61.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.295 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.472 ' O ' HG12 ' A' ' 30' ' ' ILE . 47.5 mt -51.29 -69.68 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.36 -0.838 . . . . 0.0 109.388 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HA ' HG12 ' A' ' 30' ' ' ILE . 48.6 ttt85 -42.78 -42.81 3.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.386 -0.821 . . . . 0.0 109.72 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -55.78 -37.81 69.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.208 -0.932 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.432 ' N ' ' O ' ' A' ' 26' ' ' LEU . 93.3 m-70 -79.85 -27.28 40.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.274 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.643 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 11.8 mm -64.01 -43.45 97.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.302 -0.874 . . . . 0.0 109.321 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -70.38 -36.41 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 39.4 mt -70.61 -55.75 8.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.335 -0.853 . . . . 0.0 109.472 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.497 ' CG ' HD12 ' A' ' 82' ' ' LEU . 93.0 m-70 -81.18 4.82 18.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.195 -0.941 . . . . 0.0 109.559 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.6 t30 50.09 46.64 24.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.19 -0.944 . . . . 0.0 109.517 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.492 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 40.3 mmm -100.05 14.99 28.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.357 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.533 ' HA ' ' CG2' ' A' ' 30' ' ' ILE . 99.4 mt-10 -52.49 -31.31 34.5 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.276 -0.89 . . . . 0.0 109.492 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -60.34 -42.38 95.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.216 -0.927 . . . . 0.0 109.507 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.501 HD22 ' CG1' ' A' ' 74' ' ' VAL . 2.4 mt -74.06 -53.97 8.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.351 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.643 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 94.2 m-85 -69.99 130.0 41.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.29 -64.27 0.48 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -138.93 146.34 40.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.164 -1.198 . . . . 0.0 109.525 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.479 ' CG1' HG22 ' A' ' 71' ' ' VAL . 48.2 t -111.12 153.83 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.5 ' CE ' ' SD ' ' A' ' 112' ' ' MET . 89.5 mtp -123.62 143.81 50.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.499 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 N--CA 1.488 1.458 0 O-C-N 121.152 -0.967 . . . . 0.0 109.428 179.917 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -115.36 119.18 35.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -1.174 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.27 138.39 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.219 -0.926 . . . . 0.0 109.591 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.576 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.1 mp -108.22 131.03 55.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.311 -0.868 . . . . 0.0 109.337 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.479 HG22 ' CG1' ' A' ' 42' ' ' VAL . 86.3 t -138.42 120.58 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.702 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.469 ' O ' ' HB2' ' A' ' 73' ' ' MET . 36.4 tt0 -69.15 135.55 50.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.228 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.571 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 52.8 ttp 172.94 156.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.99 . . . . 0.0 109.66 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.506 ' N ' ' HG2' ' A' ' 73' ' ' MET . 13.9 p -88.96 134.91 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.284 -0.885 . . . . 0.0 109.36 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.618 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 24.6 mmm -79.33 116.94 19.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.248 -0.907 . . . . 0.0 109.469 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.519 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 49.5 p-10 -143.43 171.03 14.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.227 -0.921 . . . . 0.0 109.468 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.556 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.1 m-20 -59.76 -33.3 71.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.462 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -72.02 -70.96 0.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.506 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 6.7 m -52.76 -51.82 59.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.422 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.519 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 29.8 t90 -44.57 -46.65 10.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.312 -0.868 . . . . 0.0 109.593 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.556 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 34.7 m-70 -70.39 -36.38 74.06 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.928 . . . . 0.0 109.422 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.497 HD12 ' CG ' ' A' ' 33' ' ' HIS . 3.0 tp -53.34 -45.01 68.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.952 . . . . 0.0 109.461 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.435 ' HA ' HG22 ' A' ' 86' ' ' VAL . 11.6 t -62.02 -31.77 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.405 -0.81 . . . . 0.0 109.591 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 80' ' ' TRP . 40.5 mtt-85 -70.98 -33.2 70.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.934 . . . . 0.0 109.407 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.9 p -79.7 -20.22 47.04 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.297 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 89' ' ' VAL . 88.5 t -67.29 127.33 93.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.343 -0.848 . . . . 0.0 109.326 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.21 153.06 67.22 Favored 'Trans proline' 0 C--O 1.214 -0.708 0 C-N-CA 122.687 2.258 . . . . 0.0 111.853 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 33.7 mtt85 63.09 47.34 4.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.605 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 86' ' ' VAL . 69.1 t -127.33 123.44 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 109.527 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.519 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 85.5 mtp -78.16 -50.72 11.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.41 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 164.07 -160.87 33.84 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.444 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 6.7 m-85 -109.57 160.52 16.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -1.154 . . . . 0.0 109.667 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.489 ' CD1' HG11 ' A' ' 11' ' ' VAL . 3.7 mt -117.51 134.16 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.339 -0.851 . . . . 0.0 109.251 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 168.22 -142.22 7.32 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.25 -50.75 42.9 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.0 p -126.77 179.13 5.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -1.163 . . . . 0.0 109.587 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.47 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 25.6 p -94.38 22.54 5.97 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.261 -0.899 . . . . 0.0 109.309 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 97' ' ' SER . 92.2 m-20 -137.0 6.42 2.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.476 -0.765 . . . . 0.0 109.459 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER -170.88 95.72 0.44 Allowed Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.292 -0.88 . . . . 0.0 109.019 -179.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.525 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.5 Cg_endo -68.5 116.78 4.57 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.79 2.327 . . . . 0.0 111.947 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.27 148.51 98.46 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.327 -0.858 . . . . 0.0 109.302 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.531 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.9 Cg_endo -69.43 153.15 70.82 Favored 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 122.688 2.259 . . . . 0.0 111.777 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 9' ' ' TRP . 29.3 pt -126.62 160.05 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.9 m -74.89 153.06 38.81 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.936 . . . . 0.0 109.348 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -62.4 -33.36 74.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 18.7 tttp -61.58 -35.65 78.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.868 . . . . 0.0 109.475 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 -63.28 -40.69 98.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.434 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.513 ' CG1' HD22 ' A' ' 70' ' ' LEU . 76.0 t -65.81 -36.62 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -0.94 . . . . 0.0 109.361 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -68.45 -31.16 70.27 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.301 -0.875 . . . . 0.0 109.515 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.57 -40.12 84.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.473 HG21 HD13 ' A' ' 111' ' ' ILE . 54.8 mt -55.41 -51.46 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 109.415 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.5 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 86.2 mtp . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.24 -0.912 . . . . 0.0 109.372 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.404 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 36.3 mttm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.282 0.563 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 79.1 mtt85 -125.95 154.17 43.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.259 -0.9 . . . . 0.0 109.467 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.428 ' CZ3' ' HG3' ' A' ' 43' ' ' MET . 90.1 m95 -91.0 130.11 36.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.211 -0.931 . . . . 0.0 109.502 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.459 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 93.3 m-85 -123.63 154.33 39.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.498 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 53.2 t -90.98 148.24 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.506 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -126.5 122.07 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.219 -0.926 . . . . 0.0 109.404 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.494 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 48.6 tt0 -84.9 133.71 34.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.211 -0.931 . . . . 0.0 109.432 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.39 161.88 36.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.481 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.4 m-85 -70.38 145.64 50.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.887 . . . . 0.0 109.544 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.9 t -60.32 139.31 57.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.458 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.67 -30.28 6.66 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.451 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 10.3 m-85 -103.69 8.52 37.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -1.129 . . . . 0.0 109.517 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.513 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 67.0 tt0 -53.08 -29.72 32.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.62 -55.44 2.04 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -55.91 -34.53 65.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.239 -1.153 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 54.9 t -58.82 -38.18 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.326 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.92 -34.32 77.86 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.483 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 42.5 m -63.38 -32.94 74.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.928 . . . . 0.0 109.426 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.405 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 28.6 m -65.17 -32.57 74.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.472 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.454 ' O ' HG13 ' A' ' 30' ' ' ILE . 59.3 mt -60.77 -44.93 96.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.462 ' O ' ' HB2' ' A' ' 31' ' ' LYS . 74.2 ttt180 -58.03 -41.46 83.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 109.654 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -69.01 -60.37 2.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.243 -0.911 . . . . 0.0 109.596 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.513 ' NE2' ' HD2' ' A' ' 87' ' ' PRO . 91.0 m-70 -54.77 -47.09 74.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.219 -0.925 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.58 HG12 ' CE1' ' A' ' 39' ' ' PHE . 87.4 mt -66.21 -44.67 91.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -0.876 . . . . 0.0 109.634 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 27' ' ' ARG . 15.3 ttpp -59.27 -41.47 88.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 45.8 mt -70.63 -52.67 19.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.324 -0.86 . . . . 0.0 109.41 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.448 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 99.0 m-70 -74.79 -6.97 51.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.9 . . . . 0.0 109.391 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.499 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.0 m-20 61.42 46.15 7.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.505 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 45.3 mmm -91.87 -2.32 56.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.605 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.443 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.2 mt-10 -44.28 -38.81 4.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -52.13 -43.11 63.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.347 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.463 ' CD2' ' ND2' ' A' ' 76' ' ' ASN . 1.1 mt -73.01 -43.98 61.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.37 -0.831 . . . . 0.0 109.336 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CE1' HG12 ' A' ' 30' ' ' ILE . 96.2 m-85 -73.19 137.32 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.282 -0.886 . . . . 0.0 109.427 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.78 -66.69 0.52 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.405 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 82.6 tt0 -136.68 152.04 49.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.567 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.521 ' CG1' HG21 ' A' ' 71' ' ' VAL . 48.1 t -117.51 147.61 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.29 -0.881 . . . . 0.0 109.359 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.512 ' CE ' ' HE2' ' A' ' 112' ' ' MET . 90.6 mtp -120.64 141.5 50.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.141 -0.974 . . . . 0.0 109.527 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.446 HG21 ' O ' ' A' ' 43' ' ' MET . 53.0 t . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.241 -0.912 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.507 ' OH ' ' CG2' ' A' ' 93' ' ' ILE . 1.7 m-85 -109.68 126.27 53.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -1.154 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.513 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 86.3 t -134.15 142.72 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.388 -0.82 . . . . 0.0 109.505 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.57 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.8 mp -103.91 132.53 50.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.471 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.521 HG21 ' CG1' ' A' ' 42' ' ' VAL . 88.0 t -143.77 122.06 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.263 -0.898 . . . . 0.0 109.557 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.404 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 43.1 tt0 -78.36 130.33 36.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.224 -0.923 . . . . 0.0 109.187 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.57 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 41.1 ttp -162.67 154.67 18.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.502 ' N ' ' HG2' ' A' ' 73' ' ' MET . 59.2 t -69.81 151.19 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -0.948 . . . . 0.0 109.224 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.534 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -94.33 112.97 24.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 109.496 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.463 ' ND2' ' CD2' ' A' ' 38' ' ' LEU . 42.0 p-10 -148.51 169.17 20.86 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.573 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 86.2 m-20 -72.38 -31.22 65.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -63.48 -61.45 2.33 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.513 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.462 ' CB ' ' OD1' ' A' ' 76' ' ' ASN . 17.4 p -53.36 -48.07 68.87 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.275 -0.891 . . . . 0.0 109.753 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.517 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 39.1 t90 -44.03 -49.32 8.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.888 . . . . 0.0 109.581 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 89.8 m-70 -67.87 -39.38 83.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.206 -0.934 . . . . 0.0 109.471 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.505 ' CD1' ' HG3' ' A' ' 35' ' ' MET . 0.4 OUTLIER -56.92 -45.2 82.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.726 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 78.0 t -62.48 -48.43 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.507 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 23.7 mtp85 -62.45 -37.24 85.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.57 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -66.63 -26.75 67.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -0.948 . . . . 0.0 109.491 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.44 HG13 HD22 ' A' ' 26' ' ' LEU . 56.5 t -65.4 129.66 94.46 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.513 ' HD2' ' NE2' ' A' ' 29' ' ' HIS . 49.7 Cg_endo -70.17 161.03 47.48 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.703 2.269 . . . . 0.0 111.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.481 ' HA ' ' CD2' ' A' ' 15' ' ' PHE . 93.0 mtt-85 61.51 35.76 17.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.432 HG21 ' HB ' ' A' ' 86' ' ' VAL . 91.5 t -129.39 115.51 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.288 -0.882 . . . . 0.0 109.566 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.494 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 84.3 mtp -69.97 -43.43 71.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.177 -0.952 . . . . 0.0 109.471 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.57 -146.99 14.03 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.454 ' HB3' ' HB3' ' A' ' 100' ' ' PRO . 51.6 m-85 -107.45 163.08 13.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.292 -1.122 . . . . 0.0 109.574 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.507 ' CG2' ' OH ' ' A' ' 68' ' ' TYR . 31.9 mm -119.4 124.22 72.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 109.337 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . . . 147.87 -141.12 8.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' GLY . . . -43.43 -89.36 0.01 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 18.9 p -123.7 -179.33 4.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.297 -1.12 . . . . 0.0 109.652 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 m -90.9 22.03 3.84 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.338 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.517 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 91.4 m-20 -118.49 -23.52 7.13 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.41 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 3.3 mtm180 -155.98 96.86 2.3 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.534 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 42.2 Cg_endo -65.13 119.99 7.13 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.865 2.376 . . . . 0.0 112.135 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.97 141.85 97.75 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.436 -0.79 . . . . 0.0 109.482 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.33 154.49 61.16 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.706 2.271 . . . . 0.0 111.854 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.483 ' CD1' ' CG2' ' A' ' 108' ' ' VAL . 34.0 pt -124.57 158.16 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.874 . . . . 0.0 109.378 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.454 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 42.2 m -69.51 148.18 49.83 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.916 . . . . 0.0 109.439 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.41 -37.74 78.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.399 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -61.3 -38.77 87.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.454 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 98.5 mt-10 -59.88 -42.21 93.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.483 ' CG2' ' CD1' ' A' ' 103' ' ' ILE . 78.3 t -61.61 -36.99 76.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.377 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -69.7 -33.24 72.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.69 -39.67 91.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.44 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.501 ' CD1' HD22 ' A' ' 70' ' ' LEU . 56.2 mt -56.84 -52.25 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.525 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.512 ' HE2' ' CE ' ' A' ' 43' ' ' MET . 53.7 ttm . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 46.0 mttp . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.323 0.582 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.443 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 63.4 mtt180 -116.99 153.08 33.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.454 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.538 ' CG ' HG23 ' A' ' 108' ' ' VAL . 82.5 m95 -99.69 131.97 45.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.47 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 62.5 m-85 -122.36 141.83 51.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.463 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.429 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.3 t -86.65 145.66 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.711 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -125.8 125.19 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 109.284 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.498 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 64.0 tp60 -87.58 131.96 34.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.609 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -139.33 164.82 28.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.324 -0.86 . . . . 0.0 109.418 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -68.61 140.34 55.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 109.448 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.8 m -66.57 149.42 50.49 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.307 -0.87 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.63 -33.28 4.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -109.45 8.46 25.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.18 -1.188 . . . . 0.0 109.506 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.76 -39.34 73.84 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.62 -52.29 44.21 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 56.7 ttt-85 -62.62 -38.74 91.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -1.149 . . . . 0.0 109.491 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 88' ' ' ARG . 79.7 t -56.01 -39.88 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.424 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.08 -37.88 89.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.267 -0.896 . . . . 0.0 109.413 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.5 m -65.16 -38.94 92.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.223 -0.923 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.565 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 97.1 p -60.02 -38.42 82.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.462 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.413 ' O ' HG13 ' A' ' 30' ' ' ILE . 44.4 mt -56.66 -49.45 75.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -0.871 . . . . 0.0 109.469 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttp85 -65.79 -37.06 85.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.515 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.457 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 80.1 tt0 -66.27 -44.76 82.68 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.26 -0.9 . . . . 0.0 109.499 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.565 ' CD2' ' O ' ' A' ' 25' ' ' SER . 94.9 m-70 -71.82 -51.5 22.2 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.457 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.55 HD11 ' CD2' ' A' ' 39' ' ' PHE . 83.4 mt -56.91 -45.3 83.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.917 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 39.8 tttt -56.59 -48.46 77.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -0.904 . . . . 0.0 109.465 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.457 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 48.6 mt -64.84 -51.24 63.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.934 . . . . 0.0 109.45 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.537 ' CD2' HD13 ' A' ' 82' ' ' LEU . 97.8 m-70 -74.86 -2.08 25.2 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.241 -0.912 . . . . 0.0 109.575 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.466 ' N ' ' O ' ' A' ' 30' ' ' ILE . 55.2 t30 55.0 45.44 26.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -0.927 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.492 ' CA ' HD22 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.66 5.17 47.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.521 179.982 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.507 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.9 mt-10 -61.02 -16.95 49.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 109.447 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -62.26 -40.57 96.64 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.292 -0.88 . . . . 0.0 109.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.492 HD22 ' CA ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -86.37 -31.39 21.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.353 179.887 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.55 ' CD2' HD11 ' A' ' 30' ' ' ILE . 42.6 m-85 -76.44 132.08 39.44 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -96.67 -78.12 1.39 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.8 tp10 -139.44 136.53 34.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.519 ' CG2' HG21 ' A' ' 71' ' ' VAL . 10.0 p -97.79 143.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.265 -0.897 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.454 ' HE2' HG11 ' A' ' 108' ' ' VAL . 58.3 mtt -108.53 141.21 40.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.982 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.432 ' CZ ' ' OE1' ' A' ' 13' ' ' GLN . 7.2 m-85 -121.74 122.68 40.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.282 -1.128 . . . . 0.0 109.388 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.31 142.65 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.913 . . . . 0.0 109.514 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.565 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.6 mp -102.77 129.13 49.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.872 . . . . 0.0 109.428 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.519 HG21 ' CG2' ' A' ' 42' ' ' VAL . 56.7 t -137.43 127.35 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -84.22 138.75 32.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.284 -0.885 . . . . 0.0 109.32 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.516 ' HB2' ' CD1' ' A' ' 39' ' ' PHE . 6.1 tmm? -177.89 149.09 0.56 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.485 ' CG1' ' HB2' ' A' ' 38' ' ' LEU . 7.4 p -75.03 122.87 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.186 -0.946 . . . . 0.0 109.458 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.511 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -52.82 112.97 0.94 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.682 -179.824 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.421 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 48.1 p-10 -146.2 161.79 39.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.371 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.488 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.2 m-20 -72.37 -27.48 62.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.185 -0.947 . . . . 0.0 109.466 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.52 -62.94 1.4 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.436 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 24.3 p -53.7 -51.43 63.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.263 -0.898 . . . . 0.0 109.56 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 30.7 t90 -44.31 -55.84 4.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.551 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.488 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 87.7 m-70 -59.7 -40.79 89.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.521 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.537 HD13 ' CD2' ' A' ' 33' ' ' HIS . 65.1 tp -60.3 -36.45 77.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.262 -0.899 . . . . 0.0 109.657 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.446 ' CG2' ' CE2' ' A' ' 92' ' ' PHE . 74.1 t -61.6 -44.69 99.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.525 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 48.5 tpt85 -57.92 -40.81 81.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.4 p -64.45 -27.53 69.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.459 ' HB ' HG22 ' A' ' 89' ' ' VAL . 79.1 t -61.84 123.18 76.29 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.4 150.42 64.28 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.602 2.202 . . . . 0.0 111.769 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.463 ' O ' HG23 ' A' ' 22' ' ' VAL . 31.8 mtt-85 62.05 51.11 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.184 -0.947 . . . . 0.0 109.434 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.459 HG22 ' HB ' ' A' ' 86' ' ' VAL . 66.9 t -126.3 116.84 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.488 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.498 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.9 mmm -65.57 -45.66 82.45 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.42 -148.32 18.67 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.446 ' CE2' ' CG2' ' A' ' 83' ' ' VAL . 3.6 m-85 -117.84 164.49 14.95 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.238 -1.154 . . . . 0.0 109.54 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.429 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 9.2 mm -121.76 120.89 62.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.355 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 177.88 -144.13 6.4 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.27 -43.84 37.16 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 p -129.39 174.34 9.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.264 -1.139 . . . . 0.0 109.549 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 72.3 m -89.86 17.89 6.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -0.964 . . . . 0.0 109.369 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.7 m-20 -127.84 -30.73 2.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.518 -0.739 . . . . 0.0 109.273 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -134.57 91.51 21.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.309 -0.869 . . . . 0.0 108.916 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.511 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.6 Cg_endo -67.86 116.66 4.41 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.634 2.223 . . . . 0.0 112.001 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.42 146.5 79.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.443 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 50.0 Cg_endo -70.14 154.58 66.1 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.7 2.267 . . . . 0.0 111.759 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.416 HD11 HG21 ' A' ' 108' ' ' VAL . 28.7 pt -118.02 158.36 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.46 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.2 m -70.66 152.27 44.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.33 -0.856 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -57.22 -38.67 74.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.212 -0.93 . . . . 0.0 109.359 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.62 -38.29 80.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.389 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -56.92 -45.77 82.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.315 -0.866 . . . . 0.0 109.408 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.538 HG23 ' CG ' ' A' ' 9' ' ' TRP . 96.4 t -60.07 -40.83 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.364 -0.835 . . . . 0.0 109.368 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -65.81 -36.76 84.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.399 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.88 -53.49 57.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 109.463 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.518 ' CD1' HD22 ' A' ' 70' ' ' LEU . 49.1 mt -48.03 -54.05 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.183 -0.948 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.2 mtp . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.27 -0.894 . . . . 0.0 109.348 179.885 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 23.4 mmtp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.471 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 93.6 mtt180 -125.38 152.94 44.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.375 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.472 ' CB ' HG22 ' A' ' 108' ' ' VAL . 85.6 m95 -96.4 129.38 43.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.541 ' CE1' ' HA ' ' A' ' 102' ' ' PRO . 64.0 m-85 -129.07 154.19 46.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.264 -0.898 . . . . 0.0 109.408 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.422 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 22.3 t -99.54 143.59 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.326 -0.858 . . . . 0.0 109.57 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -117.62 125.87 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.379 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.447 ' HG2' ' HB2' ' A' ' 90' ' ' MET . 52.3 tt0 -88.79 135.35 33.57 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.158 -0.964 . . . . 0.0 109.521 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -140.04 -165.24 1.86 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -104.55 139.8 38.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.186 -0.946 . . . . 0.0 109.468 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.2 m -56.61 150.87 14.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.03 -34.48 4.25 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.556 ' CG ' ' HD3' ' A' ' 88' ' ' ARG . 77.5 m-85 -118.98 10.18 12.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.309 -1.113 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.458 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.8 tt0 -58.02 -29.31 65.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.213 -0.929 . . . . 0.0 109.534 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -77.62 -53.05 5.2 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -59.63 -39.43 84.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -1.181 . . . . 0.0 109.46 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.453 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 99.0 t -50.5 -43.84 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.373 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.32 -41.52 85.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.469 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.9 m -64.62 -36.36 83.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.538 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 37.5 m -64.65 -37.78 88.74 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.954 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.476 ' O ' HG12 ' A' ' 30' ' ' ILE . 51.2 mt -53.77 -59.71 4.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -0.928 . . . . 0.0 109.579 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' LEU . 71.9 ttt180 -42.98 -51.11 5.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.852 . . . . 0.0 109.788 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.431 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 94.9 mt-10 -54.1 -41.79 68.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.138 -0.976 . . . . 0.0 109.503 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' A' ' 25' ' ' SER . 98.9 m-70 -66.96 -31.1 71.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.419 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.601 ' CD1' ' CD2' ' A' ' 39' ' ' PHE . 13.1 mm -67.32 -52.65 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.537 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.8 mttt -64.21 -43.38 95.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.262 -0.899 . . . . 0.0 109.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.431 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 27.3 mt -60.46 -51.16 70.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.527 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.622 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 92.6 m-70 -87.27 10.25 17.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.264 -0.898 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 18.1 m120 49.37 49.45 19.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.189 -0.944 . . . . 0.0 109.434 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.452 ' SD ' ' HB3' ' A' ' 33' ' ' HIS . 0.0 OUTLIER -106.48 21.21 17.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.425 -179.926 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 70.7 mm-40 -66.22 -12.53 56.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.199 -0.938 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.38 -52.67 24.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.288 -0.882 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.575 HD13 ' CE2' ' A' ' 39' ' ' PHE . 0.6 OUTLIER -75.96 -37.77 58.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.33 -0.856 . . . . 0.0 109.781 -179.825 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.601 ' CD2' ' CD1' ' A' ' 30' ' ' ILE . 52.0 m-85 -76.68 139.91 40.7 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.177 -0.952 . . . . 0.0 109.253 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.22 0.62 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.518 ' HG3' ' N ' ' A' ' 42' ' ' VAL . 45.9 tp10 -131.49 152.74 50.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -1.13 . . . . 0.0 109.569 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.525 HG22 ' CG1' ' A' ' 71' ' ' VAL . 91.9 t -119.42 154.43 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.289 -0.882 . . . . 0.0 109.383 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.485 ' HE3' ' CG1' ' A' ' 108' ' ' VAL . 61.2 mtm -135.68 145.11 46.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.1 t . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.211 -0.931 . . . . 0.0 109.546 179.989 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.458 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -111.58 116.03 30.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -1.141 . . . . 0.0 109.536 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.98 151.91 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.58 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.3 mp -108.05 129.02 55.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -0.93 . . . . 0.0 109.417 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.525 ' CG1' HG22 ' A' ' 42' ' ' VAL . 90.6 t -138.76 125.21 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.722 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.419 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 43.3 tt0 -78.12 120.14 22.52 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.248 -0.907 . . . . 0.0 109.08 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.578 ' HB2' ' CD1' ' A' ' 39' ' ' PHE . 8.0 tmm? -167.97 149.24 5.24 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -0.918 . . . . 0.0 109.569 -179.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 45.3 t -85.43 128.56 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.923 . . . . 0.0 109.163 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.532 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 11.7 mmt -64.72 107.69 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.705 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.488 ' OD1' ' N ' ' A' ' 79' ' ' SER . 53.0 p-10 -128.77 -179.66 5.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -75.09 -23.2 57.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.852 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -82.27 -67.11 0.81 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.201 -0.937 . . . . 0.0 109.621 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.488 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 6.3 p -49.62 -49.78 45.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 48.4 t90 -51.66 -59.56 4.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.351 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -58.95 -37.91 77.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.296 -0.878 . . . . 0.0 109.459 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.622 ' CD1' ' CD2' ' A' ' 33' ' ' HIS . 39.6 tp -63.61 -37.62 88.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.933 . . . . 0.0 109.401 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.518 HG11 ' CE2' ' A' ' 92' ' ' PHE . 54.8 t -56.92 -50.13 76.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.468 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -55.01 -41.54 71.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.2 t -57.08 -33.15 66.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.885 . . . . 0.0 109.497 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.458 ' O ' HG22 ' A' ' 89' ' ' VAL . 22.6 t -61.08 121.91 65.85 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.269 -0.895 . . . . 0.0 109.387 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.455 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -70.32 158.29 56.69 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.691 2.261 . . . . 0.0 111.777 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.556 ' HD3' ' CG ' ' A' ' 18' ' ' PHE . 8.9 mtt85 63.11 45.77 5.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.932 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 86' ' ' VAL . 96.8 t -130.92 118.89 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.172 -0.955 . . . . 0.0 109.549 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.447 ' HB2' ' HG2' ' A' ' 13' ' ' GLN . 85.9 mtp -68.83 -44.57 73.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -0.937 . . . . 0.0 109.404 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.71 -151.8 22.35 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.518 ' CE2' HG11 ' A' ' 83' ' ' VAL . 2.3 m-85 -111.8 164.25 13.27 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -1.203 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.422 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 20.9 mm -118.46 120.3 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.647 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.64 -149.76 9.17 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.46 -38.8 91.16 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.3 t -140.53 176.57 8.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -1.186 . . . . 0.0 109.47 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.8 p -92.62 17.99 9.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 109.414 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -121.72 -14.35 8.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.515 -0.741 . . . . 0.0 109.264 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.42 99.24 1.25 Allowed Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.349 -0.844 . . . . 0.0 109.008 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.532 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 46.4 Cg_endo -68.09 120.51 7.49 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.706 2.27 . . . . 0.0 112.015 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -63.27 138.31 97.31 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.88 . . . . 0.0 109.39 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.541 ' HA ' ' CE1' ' A' ' 10' ' ' TYR . 51.2 Cg_endo -70.51 153.74 65.28 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.649 2.233 . . . . 0.0 111.765 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 108' ' ' VAL . 35.1 pt -124.32 156.23 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.438 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 32.3 m -71.97 151.11 43.49 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.311 -0.868 . . . . 0.0 109.423 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -54.76 -40.99 69.94 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.358 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -59.31 -38.64 80.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -58.86 -44.36 91.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.276 -0.89 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.485 ' CG1' ' HE3' ' A' ' 43' ' ' MET . 58.1 t -57.93 -39.33 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -66.42 -40.95 89.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.261 -0.899 . . . . 0.0 109.416 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -63.43 -44.63 94.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 107' ' ' GLU . 68.8 mt -52.48 -51.39 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.332 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.6 mtp . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.925 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.409 ' HA ' ' OE1' ' A' ' 72' ' ' GLN . 8.6 mmtp . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.406 ' HD3' ' HA ' ' A' ' 8' ' ' ARG . 17.1 mmt85 -110.48 153.13 25.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.334 -0.854 . . . . 0.0 109.455 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.486 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 56.5 m95 -103.81 129.24 51.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.928 . . . . 0.0 109.506 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.424 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 87.1 m-85 -124.18 163.83 20.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.407 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.507 HG13 ' CG1' ' A' ' 93' ' ' ILE . 24.5 t -98.7 147.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.6 t -124.83 123.64 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.329 -0.857 . . . . 0.0 109.331 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.523 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 6.1 tt0 -90.8 137.83 32.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -145.45 159.98 42.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.488 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -67.9 143.26 55.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.164 -0.96 . . . . 0.0 109.56 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 46.0 m -59.14 147.62 34.44 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.44 -33.54 4.31 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.524 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 99.1 m-85 -107.22 5.21 27.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -1.149 . . . . 0.0 109.562 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.438 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 85.1 tt0 -53.55 -36.23 61.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.361 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.36 -58.64 3.08 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 45.4 ttm105 -56.5 -42.43 78.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.415 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 53.2 t -49.14 -47.57 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.351 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.81 -44.66 82.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.265 -0.897 . . . . 0.0 109.411 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -64.09 -45.52 88.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.389 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 50.8 m -52.03 -56.45 14.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.46 HD12 HG13 ' A' ' 86' ' ' VAL . 16.9 tp -48.15 -55.52 10.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.307 -0.871 . . . . 0.0 109.365 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HA ' HD11 ' A' ' 30' ' ' ILE . 25.2 ttt85 -53.74 -30.65 45.16 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.946 . . . . 0.0 109.136 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.453 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.9 tt0 -63.1 -44.45 95.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.309 -0.87 . . . . 0.0 109.36 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.567 ' CD2' ' HB ' ' A' ' 86' ' ' VAL . 74.3 m-70 -75.79 -33.92 60.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.574 HG12 ' CE2' ' A' ' 39' ' ' PHE . 79.8 mt -54.93 -48.83 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.283 -0.885 . . . . 0.0 109.292 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -60.26 -43.15 96.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.531 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.5 mt -64.2 -50.81 66.62 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.45 ' CD2' HD11 ' A' ' 82' ' ' LEU . 91.5 m-70 -82.15 3.1 28.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.244 -0.91 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.409 ' N ' ' O ' ' A' ' 30' ' ' ILE . 21.4 m120 59.4 50.62 7.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.338 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.555 ' CE ' ' CD1' ' A' ' 38' ' ' LEU . 68.5 mmm -99.58 3.92 45.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.29 -0.881 . . . . 0.0 109.706 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.471 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.2 mt-10 -54.89 -34.33 62.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.173 -0.954 . . . . 0.0 109.451 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -60.88 -42.47 98.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.894 . . . . 0.0 109.358 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.555 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.1 mt -70.88 -50.33 36.27 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.311 -0.868 . . . . 0.0 109.347 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.574 ' CE2' HG12 ' A' ' 30' ' ' ILE . 98.9 m-85 -75.99 134.47 40.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.385 -0.822 . . . . 0.0 109.418 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.08 -68.77 0.59 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 83.3 tt0 -127.6 155.9 43.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -1.128 . . . . 0.0 109.533 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.424 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 51.9 t -121.11 150.39 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.388 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.486 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 88.7 mmm -120.98 161.86 20.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.462 ' CG2' ' O ' ' A' ' 43' ' ' MET . 75.5 t . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.304 -0.873 . . . . 0.0 109.378 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.182 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.438 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.7 m-85 -121.28 119.04 31.08 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -1.158 . . . . 0.0 109.511 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.434 HG13 ' N ' ' A' ' 70' ' ' LEU . 95.1 t -132.03 142.35 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.226 -0.921 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.566 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 2.4 mm? -106.37 129.55 54.35 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 70' ' ' LEU . 84.4 t -139.69 128.88 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.541 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.409 ' OE1' ' HA ' ' A' ' 7' ' ' LYS . 6.6 tt0 -76.94 137.7 39.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.256 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.522 ' HE2' ' CZ ' ' A' ' 39' ' ' PHE . 7.5 tmm? 177.83 151.19 0.23 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.454 ' O ' ' SD ' ' A' ' 73' ' ' MET . 40.4 t -85.22 124.03 39.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.915 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.515 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 10.4 mmt -66.43 120.48 13.43 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.298 -0.876 . . . . 0.0 109.439 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.495 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.7 p-10 -150.3 179.16 8.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.261 -0.9 . . . . 0.0 109.47 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.576 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 93.5 m-20 -65.58 -35.19 80.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.348 -0.845 . . . . 0.0 109.548 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.407 ' HB3' ' HE2' ' A' ' 35' ' ' MET . . . -74.02 -72.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.193 -0.942 . . . . 0.0 109.653 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.495 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 3.7 m -45.2 -52.81 8.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.608 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.452 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 80.2 t90 -55.53 -53.07 60.93 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.242 -0.911 . . . . 0.0 109.571 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.576 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 24.8 m-70 -62.81 -34.84 78.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.256 -0.903 . . . . 0.0 109.524 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.504 ' CD2' ' HG3' ' A' ' 35' ' ' MET . 52.5 tp -58.05 -42.34 85.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 86' ' ' VAL . 79.5 t -57.88 -45.53 87.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.214 -0.929 . . . . 0.0 109.537 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -67.36 -29.84 69.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.203 -0.936 . . . . 0.0 109.461 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 67.5 m -59.59 -50.76 72.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.334 -0.854 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.567 ' HB ' ' CD2' ' A' ' 29' ' ' HIS . 7.4 p -78.78 128.67 76.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.677 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.465 ' O ' HG23 ' A' ' 89' ' ' VAL . 50.3 Cg_endo -70.13 -171.06 0.46 Allowed 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.752 2.301 . . . . 0.0 111.664 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 31.6 mtt-85 61.38 21.7 12.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.877 . . . . 0.0 109.48 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.467 HG22 HG11 ' A' ' 86' ' ' VAL . 43.6 t -119.78 107.93 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.447 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.479 ' CE ' ' OE1' ' A' ' 13' ' ' GLN . 74.6 mtp -60.22 -43.43 96.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.177 -0.952 . . . . 0.0 109.468 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.07 -149.41 21.21 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.46 ' HB3' ' HB3' ' A' ' 100' ' ' PRO . 45.4 m-85 -110.36 160.65 16.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.277 -1.131 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.523 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 22.1 mm -115.29 129.95 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.385 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 95' ' ' GLY . . . 140.53 -141.47 11.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 94' ' ' GLY . . . -44.0 -89.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -125.16 -178.25 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.247 -1.149 . . . . 0.0 109.435 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.2 p -90.38 21.57 3.81 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -0.918 . . . . 0.0 109.351 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -117.55 -22.94 7.88 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.82 94.68 2.68 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.515 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 41.4 Cg_endo -63.85 118.4 5.34 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.922 2.414 . . . . 0.0 112.138 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.44 142.1 82.6 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.493 -0.754 . . . . 0.0 109.59 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.54 153.34 65.43 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.784 2.322 . . . . 0.0 111.814 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.488 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -126.13 156.78 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 49.8 m -70.46 143.55 51.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 109.586 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.46 -35.87 68.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.386 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 51.0 tttm -62.43 -40.36 96.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.191 -0.943 . . . . 0.0 109.448 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.453 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 87.4 tt0 -54.56 -44.76 73.19 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.488 ' CG2' HD11 ' A' ' 103' ' ' ILE . 68.8 t -57.91 -40.44 76.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.345 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -63.91 -37.24 86.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.454 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.11 -47.27 86.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.407 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 68.7 mt -51.9 -48.01 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.3 mmm . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.357 -179.98 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 82.8 mttt . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.571 ' HB2' ' CE1' ' A' ' 10' ' ' TYR . 41.7 mtt-85 -126.38 161.53 27.65 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.159 -0.963 . . . . 0.0 109.509 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.492 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 69.2 m95 -91.35 124.79 35.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.606 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 95.8 m-85 -120.85 147.46 45.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.528 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 55.2 t -87.04 159.4 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.393 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 64.4 t -144.56 103.94 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.237 -0.915 . . . . 0.0 109.173 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.451 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 50.0 tt0 -42.18 -47.4 4.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.54 -0.725 . . . . 0.0 109.657 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.464 ' O ' ' HG2' ' A' ' 90' ' ' MET . . . 53.62 -168.28 0.06 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.283 -0.885 . . . . 0.0 109.471 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 57.5 t80 -103.17 142.08 34.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.878 . . . . 0.0 109.341 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.416 ' HA ' ' OE2' ' A' ' 19' ' ' GLU . 28.3 p -66.96 131.07 45.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.62 -28.04 9.84 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 17.9 m-30 -103.29 18.26 22.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.223 -1.163 . . . . 0.0 109.506 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.517 ' OE2' ' N ' ' A' ' 67' ' ' GLY . 33.3 mp0 -51.64 -40.94 60.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.191 -0.943 . . . . 0.0 109.251 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.03 -58.39 3.21 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.1 ttm-85 -55.05 -47.48 74.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.155 -1.203 . . . . 0.0 109.426 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 46.8 t -46.7 -45.9 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 109.31 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.77 -45.01 66.92 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.386 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 86.0 m -62.03 -42.99 99.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.336 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 1.2 t -50.07 -54.97 16.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.215 -0.928 . . . . 0.0 109.289 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.439 ' O ' HG13 ' A' ' 30' ' ' ILE . 82.8 mt -47.68 -56.33 7.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.267 -0.895 . . . . 0.0 109.235 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.458 ' HA ' ' HB ' ' A' ' 30' ' ' ILE . 70.0 ttt-85 -52.72 -34.1 50.98 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.894 . . . . 0.0 109.127 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.4 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.7 tt0 -61.38 -46.09 91.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.183 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.57 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 69.3 m-70 -83.45 -30.1 27.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.249 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.57 HG12 ' CE1' ' A' ' 39' ' ' PHE . 86.5 mt -64.44 -45.09 96.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -60.18 -40.56 90.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.9 . . . . 0.0 109.271 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.8 mt -69.61 -51.77 32.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.299 -0.876 . . . . 0.0 109.354 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.406 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 97.4 m-70 -79.23 0.02 30.24 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.59 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 30' ' ' ILE . 83.9 m-20 59.57 49.03 8.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.521 ' HB2' ' CG2' ' A' ' 30' ' ' ILE . 65.7 mmm -95.38 1.37 54.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.327 -0.858 . . . . 0.0 109.554 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -48.8 -36.48 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.563 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -57.1 -45.2 83.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.441 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -70.88 -53.72 14.09 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -0.883 . . . . 0.0 109.443 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.576 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 91.7 m-85 -68.76 138.5 54.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.863 . . . . 0.0 109.422 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.03 -70.39 0.22 Allowed Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -128.63 157.48 41.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -1.16 . . . . 0.0 109.649 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.408 HG13 HG22 ' A' ' 71' ' ' VAL . 57.6 t -121.56 156.98 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.492 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 87.3 mmm -121.64 150.78 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.265 -0.897 . . . . 0.0 109.398 179.848 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.517 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -123.48 122.2 37.62 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -1.157 . . . . 0.0 109.41 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.444 HG12 ' N ' ' A' ' 70' ' ' LEU . 88.1 t -133.02 140.81 46.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 109.516 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.57 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.1 mp -105.66 134.99 47.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.38 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.408 HG22 HG13 ' A' ' 42' ' ' VAL . 77.2 t -139.98 117.86 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.303 -0.873 . . . . 0.0 109.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.441 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.2 tt0 -67.61 135.49 52.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.42 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 44.6 ttp 173.57 154.69 0.11 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.511 ' N ' ' HG2' ' A' ' 73' ' ' MET . 97.1 t -84.21 140.78 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.606 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 19.3 mmm -84.8 125.71 32.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.536 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 47.8 p-10 -152.65 173.54 15.09 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -64.84 -29.4 70.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.247 -0.908 . . . . 0.0 109.542 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.507 ' HB2' ' CE ' ' A' ' 35' ' ' MET . . . -74.87 -72.41 0.3 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.665 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.515 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 10.6 m -44.38 -56.82 3.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.257 -0.902 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.517 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 51.7 t90 -44.62 -54.04 6.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.278 -0.889 . . . . 0.0 109.385 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -61.1 -35.79 77.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.362 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.576 HD22 ' CZ ' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -57.25 -37.24 72.03 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.27 -0.894 . . . . 0.0 109.413 179.892 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.515 ' CG1' HG12 ' A' ' 89' ' ' VAL . 44.1 t -73.04 -45.96 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -68.94 -31.31 70.1 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 95.1 p -64.8 -45.6 85.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.906 . . . . 0.0 109.362 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.57 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 11.1 p -82.35 133.49 50.23 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.395 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.463 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.3 Cg_endo -69.12 -166.87 0.18 Allowed 'Trans proline' 0 C--O 1.214 -0.722 0 C-N-CA 122.697 2.265 . . . . 0.0 111.876 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.463 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 89.6 mtt-85 63.01 16.73 9.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.433 -0.792 . . . . 0.0 109.535 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.515 HG12 ' CG1' ' A' ' 83' ' ' VAL . 11.6 t -119.99 109.27 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.409 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' A' ' 14' ' ' ALA . 90.9 mmm -65.3 -39.89 93.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 109.576 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.92 -169.59 35.23 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.452 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 15.3 m-85 -100.37 158.56 15.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.653 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.528 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 34.3 mm -117.7 115.69 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.298 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 179.8 -142.71 5.28 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.95 -37.55 50.14 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 p -132.39 169.89 15.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -1.156 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.0 p -88.84 14.93 9.22 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.251 -0.906 . . . . 0.0 109.336 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.517 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 88.5 m-20 -125.15 -22.49 4.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.566 -0.709 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -140.8 101.27 6.5 Favored Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.191 -0.943 . . . . 0.0 109.15 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.522 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.7 Cg_endo -69.02 109.69 2.23 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.744 2.296 . . . . 0.0 111.922 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.94 139.64 78.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 154.04 67.41 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.72 2.28 . . . . 0.0 111.842 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.417 HD13 HG21 ' A' ' 103' ' ' ILE . 34.5 pt -123.83 158.13 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 m -70.21 147.74 49.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -55.01 -38.86 68.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -58.62 -40.34 83.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -51.77 -48.67 63.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.281 -0.887 . . . . 0.0 109.403 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.456 HG23 ' CG ' ' A' ' 9' ' ' TRP . 74.2 t -57.67 -44.09 84.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -60.9 -41.38 95.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.184 -0.948 . . . . 0.0 109.344 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.45 -52.82 64.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.326 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.443 HG23 HD12 ' A' ' 111' ' ' ILE . 69.0 mt -49.79 -53.98 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.378 -0.826 . . . . 0.0 109.373 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 95.3 mmm . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.254 179.873 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.42 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 94.9 mttt . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.451 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 95.4 mtt-85 -139.51 150.27 44.93 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.396 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.431 ' O ' HG12 ' A' ' 103' ' ' ILE . 72.4 m95 -100.67 136.72 40.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.642 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -130.21 149.85 51.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.328 -0.857 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.42 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 12.8 t -98.93 139.16 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.188 -0.945 . . . . 0.0 109.524 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.423 HG23 ' CE1' ' A' ' 92' ' ' PHE . 46.3 t -119.18 130.0 74.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.872 . . . . 0.0 109.41 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.508 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 95.8 mt-30 -87.68 147.47 25.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.329 -0.857 . . . . 0.0 109.468 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.3 154.63 38.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.921 . . . . 0.0 109.462 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -66.38 146.47 54.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.286 -0.884 . . . . 0.0 109.457 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 42.0 m -58.08 135.97 57.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.73 -29.28 7.49 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -104.08 7.15 36.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.2 -1.176 . . . . 0.0 109.545 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.86 -37.33 71.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.432 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -79.7 -35.0 29.72 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 63.4 ttt-85 -63.18 -47.4 82.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.233 -1.157 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.463 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 45.6 t -50.71 -39.12 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.451 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.21 -39.55 94.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 67.9 m -67.43 -36.0 80.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.572 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.487 ' HB2' ' CG1' ' A' ' 86' ' ' VAL . 31.8 m -63.72 -41.38 98.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.157 -0.964 . . . . 0.0 109.484 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.522 HD22 ' CG2' ' A' ' 86' ' ' VAL . 61.9 mt -56.48 -43.78 79.98 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.539 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.519 ' CG ' ' HE3' ' A' ' 31' ' ' LYS . 41.4 ttm180 -57.19 -39.46 75.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -73.97 -59.82 2.54 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.514 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.453 ' CD2' ' O ' ' A' ' 25' ' ' SER . 93.6 m-70 -52.44 -45.81 66.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.564 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.563 HG12 ' CE1' ' A' ' 39' ' ' PHE . 96.5 mt -64.1 -55.58 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.477 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.519 ' HE3' ' CG ' ' A' ' 27' ' ' ARG . 82.6 mttt -53.89 -37.13 63.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 51.3 mt -73.06 -48.19 38.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.539 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -81.38 0.87 35.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.939 . . . . 0.0 109.615 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 30' ' ' ILE . 77.7 m-20 59.08 49.77 8.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.524 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 40.0 mmm -101.8 8.98 41.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.557 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.436 ' OE2' ' HG2' ' A' ' 31' ' ' LYS . 97.5 mt-10 -51.73 -37.02 49.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.461 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -60.35 -37.83 81.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.407 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.522 HD22 ' CG2' ' A' ' 74' ' ' VAL . 5.8 mt -73.61 -55.06 6.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.252 -0.905 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.568 ' CZ ' ' SD ' ' A' ' 73' ' ' MET . 92.0 m-85 -72.47 136.17 45.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 109.407 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.39 -66.49 0.5 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -137.94 152.76 49.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.203 -1.175 . . . . 0.0 109.562 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.507 ' CG1' HG21 ' A' ' 71' ' ' VAL . 42.8 t -116.81 155.3 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.481 ' CE ' ' HE1' ' A' ' 112' ' ' MET . 87.9 mtp -120.65 138.7 53.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.887 . . . . 0.0 109.568 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 179.916 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.234 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.98 125.84 49.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -1.178 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.418 HG12 ' O ' ' A' ' 43' ' ' MET . 91.0 t -132.06 143.25 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.575 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.3 mp -107.65 127.41 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.385 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.507 HG21 ' CG1' ' A' ' 42' ' ' VAL . 96.9 t -133.27 133.17 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.538 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.42 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.3 tt0 -84.49 133.94 34.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.377 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.568 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 28.5 ttp -175.04 162.71 3.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.475 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.522 ' CG2' HD22 ' A' ' 38' ' ' LEU . 33.3 m -103.51 145.66 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.364 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.521 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 11.7 mmt -79.42 122.44 26.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.454 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 36.0 p-10 -133.74 -143.76 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.29 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.2 p30 -117.91 0.85 12.0 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.025 -1.047 . . . . 0.0 110.067 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -122.8 -20.02 6.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.103 -0.998 . . . . 0.0 109.785 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.455 ' OG ' HD12 ' A' ' 38' ' ' LEU . 4.5 m -79.1 -36.66 40.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.24 -0.912 . . . . 0.0 109.581 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 85.6 t90 -56.24 -51.25 68.78 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.293 -0.879 . . . . 0.0 109.595 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -66.22 -32.21 73.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.689 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.563 HD22 ' CZ ' ' A' ' 39' ' ' PHE . 0.6 OUTLIER -62.86 -37.12 85.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.214 -0.929 . . . . 0.0 109.475 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.549 HG12 ' CE2' ' A' ' 92' ' ' PHE . 55.8 t -68.96 -50.02 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 23.1 ttp85 -60.98 -35.69 77.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.506 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.3 t -60.5 -30.83 69.96 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.93 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.523 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 22.0 t -61.84 117.9 33.25 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.413 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.13 167.71 24.15 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.584 2.189 . . . . 0.0 111.693 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 39.0 mmt180 60.91 29.85 19.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 7.7 p -122.79 130.09 74.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.212 -0.93 . . . . 0.0 109.407 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.508 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.5 mtp -70.12 -50.93 35.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.21 -0.931 . . . . 0.0 109.508 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 169.36 -151.24 16.96 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.549 ' CE2' HG12 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -115.63 170.21 8.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.27 -1.135 . . . . 0.0 109.516 179.998 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.5 HD12 ' NE2' ' A' ' 13' ' ' GLN . 39.6 mm -121.78 125.48 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.355 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 169.71 -163.23 36.73 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -54.57 -56.77 20.51 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 p -125.49 178.96 5.34 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -1.162 . . . . 0.0 109.593 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.3 p -93.76 16.91 12.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -120.11 -28.64 5.06 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 10.1 mtp85 -142.56 90.75 7.78 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.0 Cg_endo -66.43 120.26 7.37 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.92 2.413 . . . . 0.0 112.239 -179.307 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.28 146.93 97.1 Favored Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.451 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.2 Cg_endo -69.85 152.84 68.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.598 2.198 . . . . 0.0 111.903 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.505 ' CD1' HG21 ' A' ' 108' ' ' VAL . 30.2 pt -113.1 156.12 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.316 -0.865 . . . . 0.0 109.4 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.0 m -74.52 152.21 39.4 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -56.6 -37.83 71.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.35 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -58.14 -42.08 85.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.223 -0.923 . . . . 0.0 109.404 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.405 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 90.1 mt-10 -58.76 -45.06 90.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.485 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.522 ' CG1' HD22 ' A' ' 70' ' ' LEU . 73.4 t -59.43 -39.62 79.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.322 -0.861 . . . . 0.0 109.379 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.6 -34.21 73.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.267 -0.896 . . . . 0.0 109.388 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.27 -44.43 95.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.349 -0.844 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.51 ' CD1' HD23 ' A' ' 70' ' ' LEU . 73.9 mt -54.21 -54.16 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.474 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.481 ' HE1' ' CE ' ' A' ' 43' ' ' MET . 55.9 ttm . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.515 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.511 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 46.9 mttt . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.279 0.561 . . . . 0.0 109.571 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.446 ' HD2' ' OH ' ' A' ' 10' ' ' TYR . 78.3 mtt180 -125.27 156.72 38.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.392 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.45 ' CZ2' ' HB2' ' A' ' 72' ' ' GLN . 59.4 m95 -104.42 126.8 51.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.184 -0.948 . . . . 0.0 109.591 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE1' ' HE2' ' A' ' 75' ' ' MET . 85.6 m-85 -125.15 148.13 48.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.417 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.482 HG21 ' CD1' ' A' ' 70' ' ' LEU . 22.8 t -92.06 143.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -0.926 . . . . 0.0 109.615 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.3 t -120.61 132.79 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.516 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 58.1 mt-30 -84.53 151.99 24.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.9 . . . . 0.0 109.483 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.436 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -163.96 150.47 11.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 0.0 109.506 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -61.14 143.67 55.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.224 -0.923 . . . . 0.0 109.509 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.9 t -61.62 136.45 58.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.82 -31.53 5.53 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.416 ' HB3' ' HD3' ' A' ' 88' ' ' ARG . 87.2 m-85 -105.08 -2.62 24.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.202 -1.175 . . . . 0.0 109.536 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.466 ' HG3' ' N ' ' A' ' 20' ' ' GLY . 15.7 pt-20 -56.52 -41.82 77.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.194 -0.941 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.466 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -63.15 -39.09 97.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.421 ' O ' ' C ' ' A' ' 22' ' ' VAL . 58.1 ttt85 -59.07 -48.73 80.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -1.129 . . . . 0.0 109.432 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' A' ' 21' ' ' ARG . 40.5 t -43.79 -39.18 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.881 . . . . 0.0 109.268 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -54.63 -56.01 23.57 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.252 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.9 m -63.45 -48.55 77.24 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.361 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.485 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 17.0 m -56.27 -49.04 75.37 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 0.0 109.328 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.572 HD23 ' CE2' ' A' ' 39' ' ' PHE . 5.1 tp -48.33 -56.46 8.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 43.1 ttt180 -55.08 -37.48 66.84 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.332 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 71.5 tt0 -56.88 -47.78 79.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.257 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' A' ' 25' ' ' SER . 62.0 m-70 -71.23 -41.62 69.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.243 -0.91 . . . . 0.0 109.344 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.623 ' CD1' ' CD1' ' A' ' 39' ' ' PHE . 76.1 mt -59.15 -52.2 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.394 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -54.23 -43.5 70.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.448 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.3 mt -65.44 -48.4 72.88 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -0.915 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.443 ' CB ' ' SD ' ' A' ' 35' ' ' MET . 96.2 m-70 -85.17 6.39 25.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.56 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.516 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.6 t30 51.97 47.14 25.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.566 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.517 ' HG2' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.36 6.12 47.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.252 -0.905 . . . . 0.0 109.419 179.921 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.573 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.24 -35.5 49.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.158 -0.964 . . . . 0.0 109.523 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -55.25 -42.47 73.51 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.517 ' CD1' ' HG2' ' A' ' 35' ' ' MET . 0.9 OUTLIER -71.1 -54.47 11.0 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.201 -0.937 . . . . 0.0 109.322 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.623 ' CD1' ' CD1' ' A' ' 30' ' ' ILE . 96.0 m-85 -64.46 137.79 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.9 -67.48 0.38 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -132.76 149.74 52.24 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.251 -1.147 . . . . 0.0 109.707 -179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.471 HG12 ' CG2' ' A' ' 71' ' ' VAL . 98.6 t -120.01 149.14 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.881 . . . . 0.0 109.289 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.521 ' HE3' ' CG1' ' A' ' 108' ' ' VAL . 73.4 mtm -130.37 146.14 51.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.144 -0.973 . . . . 0.0 109.578 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.9 t . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.272 -0.893 . . . . 0.0 109.301 179.882 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -110.02 128.86 55.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.222 -1.164 . . . . 0.0 109.583 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.427 HG12 ' N ' ' A' ' 70' ' ' LEU . 99.9 t -133.55 141.58 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.576 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 2.3 mm? -106.27 131.5 53.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.354 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.471 ' CG2' HG12 ' A' ' 42' ' ' VAL . 83.9 t -140.52 120.85 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.262 -0.899 . . . . 0.0 109.754 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 4.4 tt0 -76.62 124.74 28.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.567 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.2 ttp -162.82 155.97 19.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.683 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.495 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.7 t -86.14 130.11 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.551 ' HE2' ' CE1' ' A' ' 10' ' ' TYR . 18.9 ttm -75.26 135.49 40.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 44.7 p-10 -151.58 -161.0 1.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -102.99 34.35 2.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.417 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -149.88 -50.21 0.14 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.495 ' OG ' ' CD1' ' A' ' 38' ' ' LEU . 14.8 m -63.24 -44.06 96.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.51 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 70.3 t90 -50.78 -47.02 59.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -69.25 -34.05 74.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.412 ' CD1' ' HB3' ' A' ' 29' ' ' HIS . 53.9 tp -63.43 -38.69 92.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.28 -0.887 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.436 ' HA ' HG21 ' A' ' 86' ' ' VAL . 70.6 t -60.69 -49.57 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.383 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -58.8 -35.3 72.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.306 -0.871 . . . . 0.0 109.439 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 24.1 m -62.73 -33.96 76.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.426 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.525 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 49.0 t -49.18 127.71 15.8 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.467 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.7 Cg_endo -70.8 156.77 60.02 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.617 2.211 . . . . 0.0 111.803 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.9 mtt-85 63.51 34.19 12.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 109.678 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 8.4 p -128.52 134.41 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.516 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 73.2 mtm -79.56 -44.56 20.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.241 -0.912 . . . . 0.0 109.488 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.74 -147.04 12.25 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.436 ' CE2' HG23 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -113.25 167.07 10.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -1.114 . . . . 0.0 109.55 -179.976 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.486 HD13 ' CG ' ' A' ' 13' ' ' GLN . 33.5 mm -121.25 137.65 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.854 . . . . 0.0 109.438 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.471 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 163.09 -148.07 14.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.59 -46.55 14.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.2 p -121.64 171.2 9.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -1.192 . . . . 0.0 109.804 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 59.9 m -91.61 18.56 7.3 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.23 -0.919 . . . . 0.0 109.322 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.51 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 90.2 m-20 -124.82 -30.92 3.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.525 -0.734 . . . . 0.0 109.099 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 6.2 mtt180 -144.64 98.67 4.88 Favored Pre-proline 0 N--CA 1.488 1.464 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.509 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 44.3 Cg_endo -67.12 132.28 27.49 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.695 2.263 . . . . 0.0 112.101 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.07 137.02 96.93 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.387 -0.821 . . . . 0.0 109.36 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.19 152.69 72.26 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.645 2.23 . . . . 0.0 111.741 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.536 ' CD1' ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -123.53 164.46 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.407 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.6 p -83.52 155.32 23.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -0.928 . . . . 0.0 109.447 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -63.74 -30.39 71.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.257 -0.902 . . . . 0.0 109.494 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -65.43 -37.1 85.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -0.906 . . . . 0.0 109.4 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.444 ' O ' HG13 ' A' ' 111' ' ' ILE . 85.2 tt0 -65.0 -39.86 94.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.254 -0.904 . . . . 0.0 109.385 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.536 ' CG2' ' CD1' ' A' ' 103' ' ' ILE . 76.3 t -67.02 -34.08 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.354 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -70.5 -34.11 71.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.88 . . . . 0.0 109.453 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -69.34 -39.51 78.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.334 -0.854 . . . . 0.0 109.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.444 HG13 ' O ' ' A' ' 107' ' ' GLU . 71.9 mt -56.93 -51.37 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.234 -0.916 . . . . 0.0 109.541 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.5 mtp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.226 -0.921 . . . . 0.0 109.496 -179.99 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.433 ' HD2' ' NE2' ' A' ' 72' ' ' GLN . 16.0 pttt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.0 mtt-85 -133.53 153.5 51.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.237 -0.914 . . . . 0.0 109.491 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 70.4 m95 -101.38 135.81 42.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.909 . . . . 0.0 109.415 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CE2' ' O ' ' A' ' 73' ' ' MET . 22.9 m-85 -124.58 151.62 44.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.468 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 18.4 t -101.1 137.89 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.333 -0.855 . . . . 0.0 109.489 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 30.6 t -115.11 128.7 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.306 -0.871 . . . . 0.0 109.234 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.519 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 60.4 tt0 -95.6 129.96 42.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.913 . . . . 0.0 109.617 -179.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.416 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -147.42 -178.2 6.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -75.03 134.26 41.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.7 m -57.79 140.6 51.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.39 -25.44 15.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.467 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.4 m-85 -112.05 13.57 20.71 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.23 -1.159 . . . . 0.0 109.39 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.485 ' OE2' ' N ' ' A' ' 67' ' ' GLY . 87.2 mt-10 -54.07 -45.31 71.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.12 -42.25 91.85 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.423 ' HD3' ' NE ' ' A' ' 88' ' ' ARG . 52.7 ttt85 -52.16 -54.53 29.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.228 -1.16 . . . . 0.0 109.389 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.412 HG21 ' HB2' ' A' ' 14' ' ' ALA . 26.1 t -50.35 -37.23 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.203 -0.936 . . . . 0.0 109.119 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.72 -36.79 85.43 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.211 -0.931 . . . . 0.0 109.231 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -58.83 -43.03 90.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.397 -0.815 . . . . 0.0 109.158 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.46 ' HB3' ' NE2' ' A' ' 29' ' ' HIS . 20.3 m -58.77 -41.04 85.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 109.319 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.513 HD23 ' CG2' ' A' ' 86' ' ' VAL . 50.1 mt -53.45 -44.51 68.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.865 . . . . 0.0 109.409 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 31' ' ' LYS . 65.9 ttt180 -52.6 -42.49 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.34 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.409 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 64.6 mm-40 -75.02 -57.77 3.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.46 ' NE2' ' HB3' ' A' ' 25' ' ' SER . 87.2 m-70 -55.15 -38.03 67.73 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -0.942 . . . . 0.0 109.268 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.58 HG12 ' CE1' ' A' ' 39' ' ' PHE . 82.2 mt -77.17 -54.46 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.293 -0.879 . . . . 0.0 109.49 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 27' ' ' ARG . 42.2 tttm -59.97 -38.24 81.92 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.906 . . . . 0.0 109.286 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 25.2 mt -70.64 -52.05 23.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.194 -0.942 . . . . 0.0 109.388 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -81.17 0.84 34.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.536 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.509 ' N ' ' O ' ' A' ' 30' ' ' ILE . 20.2 m120 60.37 51.49 5.33 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.242 -0.911 . . . . 0.0 109.408 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.467 ' HG3' HD13 ' A' ' 82' ' ' LEU . 59.9 mmm -99.84 -0.15 40.3 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.291 -0.88 . . . . 0.0 109.599 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.516 ' N ' HG23 ' A' ' 30' ' ' ILE . 96.1 mt-10 -45.67 -37.94 6.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.402 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -53.45 -44.24 68.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.922 . . . . 0.0 109.436 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.475 HD21 ' CG1' ' A' ' 74' ' ' VAL . 1.0 OUTLIER -74.62 -46.92 35.19 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.376 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CE1' HG12 ' A' ' 30' ' ' ILE . 92.0 m-85 -75.41 125.87 29.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.9 . . . . 0.0 109.497 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.69 -67.06 0.6 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -132.46 144.74 50.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -1.154 . . . . 0.0 109.524 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.421 HG13 HG22 ' A' ' 71' ' ' VAL . 19.5 t -109.06 147.65 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.247 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.458 ' O ' HG22 ' A' ' 44' ' ' VAL . 88.2 mtp -122.73 152.32 40.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.118 -0.988 . . . . 0.0 109.757 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 43' ' ' MET . 12.3 t . . . . . 0 N--CA 1.49 1.525 0 O-C-N 121.365 -0.835 . . . . 0.0 109.228 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.485 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.01 118.29 22.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -1.125 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 70' ' ' LEU . 79.0 t -130.64 148.82 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.559 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.564 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.0 mp -116.05 132.66 56.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.292 -0.88 . . . . 0.0 109.314 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.421 HG22 HG13 ' A' ' 42' ' ' VAL . 92.4 t -137.03 129.91 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.649 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.433 ' NE2' ' HD2' ' A' ' 7' ' ' LYS . 37.6 tt0 -79.87 132.74 36.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.225 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 50.3 ttp 174.07 165.19 0.2 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.162 -0.961 . . . . 0.0 109.621 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.524 ' N ' ' CG ' ' A' ' 73' ' ' MET . 15.0 p -94.6 138.57 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.286 -0.884 . . . . 0.0 109.237 179.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.514 ' HE1' ' CG ' ' A' ' 100' ' ' PRO . 34.3 tpp -79.15 119.52 22.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.3 p-10 -141.94 179.06 7.09 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.35 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -64.97 -36.7 85.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.464 ' CB ' ' HE1' ' A' ' 35' ' ' MET . . . -74.47 -72.78 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.173 -0.954 . . . . 0.0 109.827 -179.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.517 ' HB3' ' CE ' ' A' ' 73' ' ' MET . 3.6 m -42.24 -47.5 4.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.392 -0.818 . . . . 0.0 109.741 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.556 ' CZ2' ' HD2' ' A' ' 84' ' ' ARG . 63.7 t90 -50.63 -49.72 56.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.226 -0.921 . . . . 0.0 109.577 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -68.34 -25.16 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.527 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.553 HD22 ' CE1' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -60.52 -54.75 41.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.297 -0.877 . . . . 0.0 109.562 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.52 ' CG2' ' CZ ' ' A' ' 92' ' ' PHE . 2.7 t -62.26 -49.09 85.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.504 -0.747 . . . . 0.0 109.896 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.556 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 58.2 mtp180 -62.77 -29.38 70.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.134 -0.979 . . . . 0.0 109.509 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.1 p -79.6 -17.8 53.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.408 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.528 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 71.8 t -73.01 125.9 90.79 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.449 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.01 160.34 49.65 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.626 2.218 . . . . 0.0 111.782 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.526 ' CZ ' ' HB2' ' A' ' 88' ' ' ARG . 13.0 ttm105 64.74 31.72 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 8.9 p -126.59 130.93 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.192 -0.942 . . . . 0.0 109.451 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.488 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 95.7 mmm -71.29 -46.85 59.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.09 -155.5 26.35 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.52 ' CZ ' ' CG2' ' A' ' 83' ' ' VAL . 2.0 m-85 -104.74 162.45 13.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -1.086 . . . . 0.0 109.588 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.519 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 10.7 mm -119.02 118.27 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.41 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.447 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -174.52 -145.57 5.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.93 -46.01 24.62 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.8 p -127.36 173.37 9.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.195 -1.179 . . . . 0.0 109.604 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.2 p -90.49 18.78 5.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.111 -0.993 . . . . 0.0 109.253 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -126.62 -6.3 6.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.579 -0.701 . . . . 0.0 109.428 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -164.73 99.57 0.85 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.252 -0.905 . . . . 0.0 109.07 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.514 ' CG ' ' HE1' ' A' ' 75' ' ' MET . 47.6 Cg_endo -68.55 114.21 3.41 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.678 2.252 . . . . 0.0 111.891 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.57 137.37 82.19 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.519 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.82 153.9 68.12 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.707 2.271 . . . . 0.0 111.813 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.461 ' CD1' HG21 ' A' ' 108' ' ' VAL . 32.1 pt -124.44 161.04 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.444 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.442 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 49.9 m -70.94 147.95 48.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -62.26 -36.28 81.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.197 -0.94 . . . . 0.0 109.34 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -61.59 -35.96 79.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.442 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 99.8 mt-10 -60.8 -43.15 98.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.887 . . . . 0.0 109.366 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.461 HG21 ' CD1' ' A' ' 103' ' ' ILE . 75.4 t -62.53 -35.14 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.455 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -66.99 -38.04 85.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.885 . . . . 0.0 109.412 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.6 -44.31 91.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.955 . . . . 0.0 109.441 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.5 HD12 HG22 ' A' ' 111' ' ' ILE . 67.9 mt -53.53 -52.54 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -0.922 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.428 ' CG ' ' HE1' ' A' ' 43' ' ' MET . 93.2 mmm . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.498 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.6 mttt . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.312 0.577 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.461 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 54.3 mtt180 -123.42 153.96 39.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.427 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.549 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 73.8 m95 -96.16 123.74 39.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.227 -0.92 . . . . 0.0 109.581 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.57 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 88.1 m-85 -119.19 159.64 23.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -0.943 . . . . 0.0 109.473 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.458 ' O ' ' CD1' ' A' ' 92' ' ' PHE . 27.0 t -94.33 149.18 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.637 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.454 ' N ' HG12 ' A' ' 11' ' ' VAL . 57.3 t -124.64 118.74 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.246 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.519 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 59.3 tt0 -84.85 140.07 31.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.58 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.438 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -156.92 -153.39 0.41 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.934 . . . . 0.0 109.391 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.96 140.62 46.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.446 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 t -59.24 132.73 54.89 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.48 -16.92 60.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -109.48 0.19 19.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -1.143 . . . . 0.0 109.576 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.492 ' OE2' ' N ' ' A' ' 68' ' ' TYR . 99.0 mt-10 -56.35 -44.34 79.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.367 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.55 -50.15 67.11 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.512 ' NH2' ' HG3' ' A' ' 88' ' ' ARG . 12.4 ttp180 -57.3 -56.26 24.12 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -1.123 . . . . 0.0 109.416 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.403 ' C ' ' O ' ' A' ' 21' ' ' ARG . 40.7 t -45.46 -38.68 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.87 -44.85 96.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.342 -0.849 . . . . 0.0 109.266 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.4 m -69.44 -47.28 64.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.531 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 15.3 t -57.4 -56.21 24.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.338 -0.851 . . . . 0.0 109.489 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.427 HD13 ' CG2' ' A' ' 86' ' ' VAL . 14.0 tp -46.82 -49.71 19.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.377 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.465 ' CG ' ' HE2' ' A' ' 31' ' ' LYS . 46.7 ttm-85 -60.71 -34.59 74.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.186 -0.946 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -64.18 -48.07 77.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.225 -0.922 . . . . 0.0 109.322 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 25' ' ' SER . 60.1 m-70 -66.3 -37.29 85.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 109.341 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.588 ' CD1' ' CD2' ' A' ' 39' ' ' PHE . 90.8 mt -65.26 -49.03 81.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.256 -0.903 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.465 ' HE2' ' CG ' ' A' ' 27' ' ' ARG . 25.3 mttm -56.84 -40.05 75.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 29.8 mt -69.91 -52.02 28.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.45 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.7 m-70 -81.12 4.34 20.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.591 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' ILE . 78.8 m-20 54.76 47.65 21.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.248 -0.907 . . . . 0.0 109.511 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.523 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 61.1 mmm -94.2 6.54 48.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.932 . . . . 0.0 109.594 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.502 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.53 -31.19 34.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.394 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -61.85 -41.84 98.31 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.351 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.491 ' CD1' ' HE1' ' A' ' 35' ' ' MET . 10.3 mt -70.93 -53.68 14.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.588 ' CD2' ' CD1' ' A' ' 30' ' ' ILE . 73.9 m-85 -75.2 143.33 43.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.306 -0.871 . . . . 0.0 109.474 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.34 -58.84 0.24 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -136.29 156.48 48.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -1.223 . . . . 0.0 109.734 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.455 HG12 HG21 ' A' ' 71' ' ' VAL . 54.5 t -121.01 154.66 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.549 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 88.7 mmm -121.99 147.68 45.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.159 -0.963 . . . . 0.0 109.633 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.379 179.915 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.492 ' N ' ' OE2' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -111.0 119.47 39.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 109.366 179.946 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.4 ' O ' ' N ' ' A' ' 12' ' ' VAL . 86.0 t -134.17 140.62 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.554 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.0 mp -104.3 141.76 35.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.382 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.455 HG21 HG12 ' A' ' 42' ' ' VAL . 68.9 t -145.26 123.67 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -0.951 . . . . 0.0 109.705 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -73.96 124.87 27.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.309 -0.869 . . . . 0.0 109.127 179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.458 ' SD ' ' OG ' ' A' ' 79' ' ' SER . 8.8 tmm? -169.22 151.52 4.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.293 -0.88 . . . . 0.0 109.398 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 28.6 m -77.59 118.97 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.585 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.57 ' HG2' ' CE2' ' A' ' 10' ' ' TYR . 8.5 mmt -61.72 115.84 4.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.172 -0.955 . . . . 0.0 109.585 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.2 p-10 -151.28 172.74 15.39 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.36 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -63.4 -33.78 76.29 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.645 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -71.5 -72.36 0.22 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 109.661 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.524 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 18.0 p -46.63 -57.59 4.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.525 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 44.0 t90 -43.65 -53.89 5.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.34 -0.85 . . . . 0.0 109.574 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.53 -43.41 98.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.61 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.57 HD23 ' CE2' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -55.81 -43.1 76.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 0.0 109.491 -179.843 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 98.2 t -61.01 -52.11 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 57.4 ttt85 -55.63 -35.08 65.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.566 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 39.9 m -59.58 -37.22 77.93 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.187 -0.946 . . . . 0.0 109.555 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.518 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 91.8 t -54.99 125.56 56.92 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 109.516 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.462 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.7 Cg_endo -71.25 160.28 49.39 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.624 2.216 . . . . 0.0 111.769 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.512 ' HG3' ' NH2' ' A' ' 21' ' ' ARG . 50.1 mmt-85 63.66 30.79 14.79 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.695 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 6.1 p -129.24 130.63 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.157 -0.964 . . . . 0.0 109.375 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.492 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.1 mmm -76.46 -54.98 5.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 166.67 -150.12 16.74 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.569 ' CE1' ' HE1' ' A' ' 75' ' ' MET . 6.5 m-85 -105.5 161.86 13.98 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -1.131 . . . . 0.0 109.561 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.519 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 19.3 mm -120.3 122.13 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.415 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -179.66 -144.39 5.88 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.62 -45.25 95.04 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 p -130.76 171.01 13.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.219 -1.165 . . . . 0.0 109.463 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.9 p -89.02 16.61 6.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.144 -0.972 . . . . 0.0 109.37 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.525 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.1 m-20 -125.64 -27.14 3.42 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.533 -0.729 . . . . 0.0 109.261 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -140.16 97.63 7.73 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.339 -0.851 . . . . 0.0 108.846 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.532 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.72 127.12 15.73 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.79 2.327 . . . . 0.0 112.067 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.63 138.51 93.5 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.256 -0.902 . . . . 0.0 109.234 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.8 Cg_endo -70.45 153.66 65.6 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.603 2.202 . . . . 0.0 111.845 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.402 HD12 HG21 ' A' ' 108' ' ' VAL . 34.9 pt -127.55 161.08 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.452 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.458 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 43.7 m -71.79 150.56 44.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.348 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -56.93 -37.91 72.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.335 -0.853 . . . . 0.0 109.456 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -60.35 -34.02 73.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.441 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.458 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 76.5 mm-40 -59.12 -41.85 89.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.922 . . . . 0.0 109.384 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.463 HG23 ' CG ' ' A' ' 9' ' ' TRP . 90.0 t -63.33 -36.2 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.913 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -66.6 -38.71 87.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.69 -47.7 77.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.451 HD13 ' CD2' ' A' ' 70' ' ' LEU . 45.2 mt -50.49 -51.41 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.497 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 96.2 mmm . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.156 -0.965 . . . . 0.0 109.387 179.937 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 40.1 mttt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.474 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 23.1 mtm180 -122.26 154.85 37.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -93.56 137.69 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.549 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 46.0 m-85 -131.85 164.19 26.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.868 . . . . 0.0 109.567 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.452 HG12 ' CG1' ' A' ' 93' ' ' ILE . 40.9 t -99.2 139.89 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 109.53 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.9 t -122.74 119.54 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.501 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 49.8 tt0 -87.24 135.44 33.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.32 161.28 38.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.369 -0.832 . . . . 0.0 109.41 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.458 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 97.4 m-85 -57.75 149.99 20.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 35.0 t -71.9 145.94 48.18 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.51 -34.37 4.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.428 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 17.9 m-30 -108.48 6.61 26.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.261 -1.141 . . . . 0.0 109.502 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.505 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 22.8 pt-20 -51.62 -43.84 62.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.331 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -67.29 -54.35 20.76 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -58.68 -40.57 83.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.174 -1.192 . . . . 0.0 109.389 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 88' ' ' ARG . 76.6 t -50.75 -48.67 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.408 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.42 ' HB1' HG11 ' A' ' 42' ' ' VAL . . . -55.32 -40.73 71.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.243 -0.911 . . . . 0.0 109.336 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.2 m -65.83 -39.94 91.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.249 -0.907 . . . . 0.0 109.418 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 21.1 m -57.85 -46.35 84.93 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.254 -0.904 . . . . 0.0 109.398 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.464 ' O ' HG12 ' A' ' 30' ' ' ILE . 34.9 mt -52.27 -55.98 17.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.348 -0.845 . . . . 0.0 109.357 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.408 ' C ' ' O ' ' A' ' 26' ' ' LEU . 49.3 ttt-85 -42.58 -40.75 2.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.417 -0.802 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 25' ' ' SER . 89.7 mt-10 -58.85 -39.05 80.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.21 -0.931 . . . . 0.0 109.393 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.574 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 66.0 m-70 -82.18 -19.85 39.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.352 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' A' ' 39' ' ' PHE . 20.5 mm -75.34 -48.46 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.239 -0.913 . . . . 0.0 109.225 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -71.53 -41.22 69.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -0.851 . . . . 0.0 109.236 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.0 mt -63.9 -47.42 80.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.449 -0.782 . . . . 0.0 109.404 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.565 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 88.8 m-70 -84.05 9.25 12.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 49.08 48.47 20.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 0.0 109.394 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.544 ' HB3' ' CD1' ' A' ' 39' ' ' PHE . 41.4 mtt -102.79 -0.66 31.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 35' ' ' MET . 97.2 mt-10 -43.89 -36.04 2.23 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.243 -0.91 . . . . 0.0 109.647 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -56.96 -50.25 73.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.205 -0.934 . . . . 0.0 109.713 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.524 HD23 ' ND2' ' A' ' 76' ' ' ASN . 0.3 OUTLIER -71.31 -48.52 50.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.52 -179.691 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' A' ' 30' ' ' ILE . 66.1 m-85 -70.4 141.35 52.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 109.452 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.452 ' HA3' ' OE1' ' A' ' 72' ' ' GLN . . . -102.65 -70.12 0.84 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -158.66 147.21 18.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.187 -1.184 . . . . 0.0 109.495 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.459 HG22 HG11 ' A' ' 71' ' ' VAL . 60.1 t -95.79 138.45 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.499 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.451 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 65.1 mtm -121.32 150.09 41.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.368 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 93.4 t . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.576 179.992 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -128.61 115.3 17.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.196 -1.179 . . . . 0.0 109.375 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 43' ' ' MET . 87.3 t -132.9 144.85 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.262 -0.899 . . . . 0.0 109.609 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.58 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.1 mp -101.06 129.53 46.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.328 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.461 HG21 ' O ' ' A' ' 70' ' ' LEU . 91.0 t -140.75 115.36 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.76 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.452 ' OE1' ' HA3' ' A' ' 40' ' ' GLY . 36.9 tt0 -65.98 135.9 55.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.928 . . . . 0.0 109.171 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.575 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 10.9 ttp -173.78 152.1 1.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.16 -0.962 . . . . 0.0 109.587 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.512 ' N ' ' HG2' ' A' ' 73' ' ' MET . 38.7 t -81.67 141.2 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.281 179.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.528 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 15.1 tpp -78.1 100.12 6.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.212 -0.93 . . . . 0.0 109.74 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.524 ' ND2' HD23 ' A' ' 38' ' ' LEU . 51.4 p-10 -140.87 169.39 17.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.306 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -72.67 -26.39 61.61 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.5 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.58 -71.31 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 0.0 109.584 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.53 ' OG ' ' CE ' ' A' ' 73' ' ' MET . 11.4 p -53.47 -45.19 69.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.412 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.9 t90 -56.44 -59.01 5.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -54.92 -44.01 73.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.565 ' CD1' ' CD2' ' A' ' 33' ' ' HIS . 41.1 tp -56.13 -47.8 77.44 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 80.0 t -50.41 -48.05 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.245 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 16.5 ttt-85 -70.63 -28.17 64.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.383 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.4 m -58.82 -47.15 85.8 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.35 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.574 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 4.4 p -76.08 132.39 73.93 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.472 ' O ' HG23 ' A' ' 89' ' ' VAL . 47.7 Cg_endo -69.02 -174.03 0.7 Allowed 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.672 2.248 . . . . 0.0 111.892 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.462 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 70.1 mtt85 63.69 32.04 14.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.359 -0.838 . . . . 0.0 109.444 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 87' ' ' PRO . 6.4 t -131.89 117.26 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.501 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 83.2 mtp -73.73 -38.29 64.84 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 148.62 -176.26 27.5 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.573 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 15.7 m-85 -94.98 158.25 15.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.311 -1.111 . . . . 0.0 109.649 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.452 ' CG1' HG12 ' A' ' 11' ' ' VAL . 18.9 mm -118.55 114.24 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.301 -0.875 . . . . 0.0 109.378 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.01 -141.77 3.25 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.55 -29.12 60.2 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.463 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 21.0 p -136.33 169.32 17.85 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.199 -1.177 . . . . 0.0 109.655 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -91.72 19.61 6.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.356 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.463 ' OD1' ' OG1' ' A' ' 96' ' ' THR . 48.1 p30 -140.73 11.05 2.25 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.55 -0.718 . . . . 0.0 109.081 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -171.88 97.8 0.39 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.327 -0.858 . . . . 0.0 108.916 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.573 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 49.7 Cg_endo -68.94 113.75 3.34 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.752 2.301 . . . . 0.0 111.949 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.91 142.02 74.17 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.229 -0.92 . . . . 0.0 109.357 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.471 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 50.9 Cg_endo -70.22 153.98 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.715 2.277 . . . . 0.0 111.922 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.454 ' HB ' ' OE1' ' A' ' 107' ' ' GLU . 31.3 pt -129.23 152.73 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.9 m -67.0 145.29 55.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.617 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -53.75 -41.03 66.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.888 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -59.19 -44.57 92.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.454 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 83.2 tt0 -51.17 -46.32 62.04 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.443 HG11 ' HE1' ' A' ' 43' ' ' MET . 60.4 t -53.97 -41.56 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.229 -0.919 . . . . 0.0 109.282 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -59.77 -41.18 90.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.247 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.52 -52.62 64.77 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.278 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 54.1 mt -47.05 -51.91 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.299 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.322 179.897 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 54.7 mttp . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.297 0.57 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.2 mtt180 -126.14 158.95 34.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.466 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.489 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 58.8 m95 -99.82 121.09 40.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.955 . . . . 0.0 109.788 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.568 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 96.6 m-85 -114.77 157.59 23.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.31 -0.869 . . . . 0.0 109.229 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 88.6 t -105.89 143.48 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 109.599 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.0 t -120.99 127.96 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.314 -0.866 . . . . 0.0 109.472 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.524 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 68.2 tp60 -86.98 145.32 26.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -0.9 . . . . 0.0 109.48 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.09 153.87 34.8 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.54 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -58.72 144.27 44.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.517 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 26.2 t -61.9 141.09 58.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.43 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.94 -31.18 5.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.486 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 90.3 m-85 -105.01 7.33 33.99 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.267 -1.137 . . . . 0.0 109.585 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.576 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 85.5 tt0 -58.44 -42.59 87.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.117 -0.99 . . . . 0.0 109.382 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.82 -38.0 65.91 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.459 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 22.2 ttm180 -62.02 -50.63 71.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -1.15 . . . . 0.0 109.442 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 88' ' ' ARG . 37.4 t -49.45 -41.02 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.181 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 -42.39 99.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.234 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 41.5 m -67.38 -47.12 71.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.273 -0.892 . . . . 0.0 109.341 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.9 m -64.66 -34.41 78.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.253 -0.904 . . . . 0.0 109.375 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.537 HD21 ' CE2' ' A' ' 39' ' ' PHE . 5.4 tt -58.57 -53.54 57.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.304 -0.873 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.403 ' NE ' ' NZ ' ' A' ' 31' ' ' LYS . 23.0 tpt180 -45.14 -46.0 11.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.254 -0.904 . . . . 0.0 109.598 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -53.5 -50.88 64.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.558 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.454 ' HB3' HD13 ' A' ' 82' ' ' LEU . 94.7 m-70 -56.92 -29.1 62.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.286 -0.883 . . . . 0.0 109.533 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.639 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 10.2 mm -68.94 -53.72 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.227 -0.921 . . . . 0.0 109.567 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.51 ' CD ' ' OE2' ' A' ' 36' ' ' GLU . 24.8 mmtm -66.05 -44.18 85.3 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.658 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 49.0 mt -61.32 -55.95 25.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.277 -0.89 . . . . 0.0 109.611 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.627 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 90.8 m-70 -81.87 7.53 12.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 53.1 t30 48.83 45.76 22.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.585 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.495 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 35.2 mmm -99.55 20.57 13.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.374 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' OE2' ' CD ' ' A' ' 31' ' ' LYS . 83.9 mt-10 -53.83 -36.86 63.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -0.873 . . . . 0.0 109.482 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -59.16 -44.97 92.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.925 . . . . 0.0 109.486 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.496 HD21 ' CG1' ' A' ' 74' ' ' VAL . 35.2 mt -66.94 -56.66 9.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.918 . . . . 0.0 109.507 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.639 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 93.6 m-85 -72.01 141.08 49.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.902 . . . . 0.0 109.472 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -125.62 -61.99 0.17 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.55 149.34 43.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.189 -1.183 . . . . 0.0 109.698 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.454 HG11 HG23 ' A' ' 71' ' ' VAL . 45.3 t -117.48 151.86 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.344 -0.847 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.511 ' CE ' ' HE1' ' A' ' 112' ' ' MET . 80.8 mmm -117.11 137.41 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.231 -0.918 . . . . 0.0 109.676 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.459 HG21 ' O ' ' A' ' 43' ' ' MET . 43.2 t . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.313 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.429 ' O ' ' NE2' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.419 ' CE1' ' OE1' ' A' ' 13' ' ' GLN . 1.8 m-85 -119.71 117.21 27.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.2 -1.176 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 78.4 t -131.61 141.85 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.917 . . . . 0.0 109.657 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.568 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.7 mp -106.97 132.96 52.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -0.88 . . . . 0.0 109.271 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.454 HG23 HG11 ' A' ' 42' ' ' VAL . 86.5 t -137.94 121.67 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.178 -0.951 . . . . 0.0 109.639 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.467 ' O ' ' HB2' ' A' ' 73' ' ' MET . 38.0 tt0 -72.16 137.1 46.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.267 -0.895 . . . . 0.0 109.199 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.512 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 45.8 ttp 171.81 157.73 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.263 -0.898 . . . . 0.0 109.604 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.506 ' N ' ' HG2' ' A' ' 73' ' ' MET . 12.2 p -85.69 138.31 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.174 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.575 ' CE ' ' CG ' ' A' ' 100' ' ' PRO . 16.4 mmt -90.04 115.36 27.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.208 -0.932 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.489 ' OD1' ' N ' ' A' ' 79' ' ' SER . 48.8 p-10 -140.48 -176.59 4.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.351 -0.843 . . . . 0.0 109.425 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -73.37 -11.6 60.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.589 ' HA ' ' CE1' ' A' ' 81' ' ' HIS . . . -94.23 -71.1 0.68 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.466 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.489 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 68.9 p -50.69 -48.13 58.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.379 -0.826 . . . . 0.0 109.516 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.61 ' NE1' ' CE2' ' A' ' 92' ' ' PHE . 79.7 t90 -48.51 -58.92 3.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -0.928 . . . . 0.0 109.694 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.625 ' CD2' ' N ' ' A' ' 82' ' ' LEU . 1.5 p-80 -57.84 -30.84 66.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.085 -1.009 . . . . 0.0 109.213 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.627 ' CD1' ' CD2' ' A' ' 33' ' ' HIS . 19.0 tp -68.52 -36.34 78.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.384 -0.823 . . . . 0.0 109.328 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 77.5 t -62.04 -42.63 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.248 -0.908 . . . . 0.0 109.399 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -65.96 -33.25 75.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.377 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 35.8 m -60.07 -32.96 71.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.173 -0.954 . . . . 0.0 109.38 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.521 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 18.8 t -55.37 123.41 49.48 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.487 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.463 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.9 Cg_endo -70.83 156.48 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.618 2.212 . . . . 0.0 111.712 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.486 ' HD3' ' CD1' ' A' ' 18' ' ' PHE . 42.4 mtt-85 62.44 35.29 14.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.31 -0.869 . . . . 0.0 109.586 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.521 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 7.4 p -123.39 125.82 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.436 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.524 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 51.3 mtt -68.93 -62.01 1.56 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.459 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 171.13 -151.57 16.03 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.61 ' CE2' ' NE1' ' A' ' 80' ' ' TRP . 93.1 m-85 -96.27 162.96 13.29 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.327 -1.102 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.518 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 47.3 mm -110.97 152.7 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.223 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.82 -108.95 3.44 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.409 ' O ' ' C ' ' A' ' 96' ' ' THR . . . -57.06 -37.24 78.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 97' ' ' SER . 68.8 p 43.73 -148.66 0.05 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -1.167 . . . . 0.0 109.477 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.469 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 26.7 t 44.67 39.92 3.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.173 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 80' ' ' TRP . 22.8 m-20 67.09 38.2 3.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.347 -0.846 . . . . 0.0 109.313 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.404 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 4.2 mtp180 -161.48 88.41 1.57 Allowed Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.281 -0.887 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.575 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 48.2 Cg_endo -69.96 135.27 29.56 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.783 2.322 . . . . 0.0 111.952 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -99.14 143.48 26.47 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.451 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.45 155.51 63.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.823 2.349 . . . . 0.0 111.759 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.468 HD12 ' CG2' ' A' ' 108' ' ' VAL . 24.0 pt -125.5 156.32 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.401 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 48.3 m -69.8 150.22 47.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.303 -0.873 . . . . 0.0 109.531 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -59.68 -42.38 92.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -0.899 . . . . 0.0 109.442 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -53.94 -43.09 69.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.314 -0.866 . . . . 0.0 109.424 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.401 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.8 mt-10 -53.78 -44.69 70.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.468 ' CG2' HD12 ' A' ' 103' ' ' ILE . 98.0 t -55.91 -37.95 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.26 -0.9 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -70.44 -34.91 72.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.933 . . . . 0.0 109.381 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.28 -36.71 84.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.445 HG13 HD21 ' A' ' 70' ' ' LEU . 32.1 mm -49.6 -56.48 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.28 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.511 ' HE1' ' CE ' ' A' ' 43' ' ' MET . 54.2 mtt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.289 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.514 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 68.4 mttm . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.411 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 63.0 mtt180 -128.16 152.22 48.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.419 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -85.38 129.84 34.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.486 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CZ ' ' HB2' ' A' ' 75' ' ' MET . 81.2 m-85 -122.84 155.77 35.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.391 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.563 ' CG1' ' CE1' ' A' ' 68' ' ' TYR . 43.1 t -92.02 150.76 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.512 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.5 t -132.49 124.29 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.308 -0.87 . . . . 0.0 109.387 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.51 ' HB3' ' CE ' ' A' ' 90' ' ' MET . 96.3 mt-30 -85.18 147.22 26.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.282 -0.886 . . . . 0.0 109.528 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.2 155.27 34.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.382 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.514 ' CD1' ' HA ' ' A' ' 88' ' ' ARG . 97.0 m-85 -72.16 147.22 46.82 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.0 m -55.56 144.08 27.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.292 -0.88 . . . . 0.0 109.471 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.91 -33.67 4.36 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -106.45 15.34 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.49 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.427 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.5 tt0 -52.43 -39.27 60.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.408 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 23' ' ' ALA . . . -90.93 -35.61 7.09 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 22' ' ' VAL . 35.5 ttt-85 -51.72 -52.64 46.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -1.169 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.426 HG11 HG12 ' A' ' 86' ' ' VAL . 38.9 t -45.64 -38.04 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.175 -0.953 . . . . 0.0 109.314 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.446 ' HB3' ' O ' ' A' ' 20' ' ' GLY . . . -64.83 -43.04 94.36 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.297 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 58.2 m -67.03 -47.03 72.66 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.287 -0.883 . . . . 0.0 109.3 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.7 m -61.75 -40.59 95.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.36 -0.837 . . . . 0.0 109.435 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.523 ' CD1' ' CG2' ' A' ' 86' ' ' VAL . 11.5 tp -56.12 -40.98 74.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.9 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -53.32 -44.14 68.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.309 -0.87 . . . . 0.0 109.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.41 ' O ' ' CD1' ' A' ' 32' ' ' LEU . 97.4 mt-10 -60.68 -47.82 84.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.421 ' HB3' HD11 ' A' ' 82' ' ' LEU . 95.3 m-70 -63.46 -43.5 97.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.529 HG12 ' CE1' ' A' ' 39' ' ' PHE . 89.3 mt -67.83 -50.76 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.902 . . . . 0.0 109.482 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -59.6 -40.0 86.04 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.303 -0.873 . . . . 0.0 109.447 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.41 ' CD1' ' O ' ' A' ' 28' ' ' GLU . 16.0 mt -63.22 -53.98 44.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.47 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.466 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 97.4 m-70 -82.99 -0.6 49.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.56 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.508 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.2 m-20 62.56 47.11 5.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.18 -0.95 . . . . 0.0 109.356 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.505 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 57.8 mmm -90.35 0.57 57.2 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.586 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.451 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -47.83 -33.38 7.27 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.906 . . . . 0.0 109.489 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -60.4 -42.32 95.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.7 mt -70.42 -49.41 49.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.303 -0.873 . . . . 0.0 109.313 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.561 ' CE1' HD23 ' A' ' 82' ' ' LEU . 88.5 m-85 -74.74 140.73 44.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.05 -64.69 0.53 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -140.52 157.44 45.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 109.53 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.445 ' CG1' HG21 ' A' ' 71' ' ' VAL . 61.6 t -120.16 147.41 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.517 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.457 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 60.7 mtm -131.46 141.9 49.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.238 -0.914 . . . . 0.0 109.449 179.945 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.563 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 51.7 t80 -108.9 136.14 48.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.226 -1.161 . . . . 0.0 109.521 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.26 144.8 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.298 -0.876 . . . . 0.0 109.567 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 43' ' ' MET . 4.3 mp -113.91 130.9 56.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.293 -0.879 . . . . 0.0 109.144 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 42' ' ' VAL . 93.8 t -144.1 120.73 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.728 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.514 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 6.1 tt0 -75.07 129.65 37.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.507 ' HE1' ' CE2' ' A' ' 39' ' ' PHE . 9.8 tmm? -168.63 147.94 4.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.313 -0.867 . . . . 0.0 109.58 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -75.81 109.84 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.556 ' HB2' ' CZ ' ' A' ' 10' ' ' TYR . 22.3 tpp -59.43 120.33 9.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.285 -0.884 . . . . 0.0 109.504 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 31.2 p-10 -155.89 170.55 21.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -56.01 -36.54 68.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.557 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.45 ' HB1' ' HE3' ' A' ' 35' ' ' MET . . . -70.48 -71.7 0.23 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.623 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 76' ' ' ASN . 10.0 p -47.14 -48.04 23.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 109.56 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 77.6 t90 -51.65 -50.07 61.06 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -66.36 -39.6 89.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.951 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.561 HD23 ' CE1' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -59.13 -47.38 85.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.945 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.46 -48.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.87 . . . . 0.0 109.551 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -59.4 -36.77 76.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -60.59 -34.2 73.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.523 ' CG2' ' CD1' ' A' ' 26' ' ' LEU . 14.1 t -60.13 123.95 75.12 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.393 -0.817 . . . . 0.0 109.51 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.457 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.6 Cg_endo -70.75 163.21 39.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.545 2.163 . . . . 0.0 111.7 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.514 ' HA ' ' CD1' ' A' ' 15' ' ' PHE . 78.9 mmt-85 64.61 28.31 13.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.644 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 5.8 p -128.93 137.11 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.918 . . . . 0.0 109.597 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.51 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 69.4 mtm -89.97 -42.1 11.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.83 -149.73 20.31 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.482 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . 90.6 m-85 -102.73 157.21 17.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -1.163 . . . . 0.0 109.52 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.511 ' CD1' HG11 ' A' ' 11' ' ' VAL . 8.4 mt -109.3 130.69 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.229 -0.919 . . . . 0.0 109.398 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 148.6 -119.19 1.04 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . 0.401 ' C ' HG21 ' A' ' 96' ' ' THR . . . -66.4 -82.94 0.11 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.401 HG21 ' C ' ' A' ' 95' ' ' GLY . 17.4 p -130.43 -173.98 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -1.19 . . . . 0.0 109.662 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 42.2 p -97.22 17.66 16.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.434 ' O ' ' HG2' ' A' ' 99' ' ' ARG . 82.0 m-20 -120.98 -24.67 5.53 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.463 -0.773 . . . . 0.0 109.102 179.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.434 ' HG2' ' O ' ' A' ' 98' ' ' ASP . 7.6 mtt180 -147.87 87.79 5.75 Favored Pre-proline 0 C--N 1.304 -1.405 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.499 ' CG ' ' SD ' ' A' ' 75' ' ' MET . 42.9 Cg_endo -65.07 120.55 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.939 2.426 . . . . 0.0 112.416 -179.184 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 134.07 78.19 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.435 -0.791 . . . . 0.0 109.217 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.37 152.82 71.35 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.692 2.261 . . . . 0.0 111.904 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.484 HD11 HG21 ' A' ' 103' ' ' ILE . 30.7 pt -118.5 160.57 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.336 -0.853 . . . . 0.0 109.231 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.2 m -70.05 150.47 46.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -0.907 . . . . 0.0 109.431 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -62.74 -37.81 88.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -63.24 -37.7 88.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -0.85 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.439 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 85.5 tt0 -59.82 -39.7 85.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.464 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.475 HG22 ' CD1' ' A' ' 103' ' ' ILE . 73.3 t -62.9 -35.97 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.381 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -68.19 -34.19 75.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.247 -0.908 . . . . 0.0 109.489 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.78 -38.24 88.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.428 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.412 HD12 HG21 ' A' ' 111' ' ' ILE . 74.3 mt -55.73 -51.74 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.476 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 53.2 ttm . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.426 -179.987 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.0 mttt . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 80.7 mtt85 -117.76 158.27 25.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . 0.56 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 46.0 m95 -109.53 130.64 55.49 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.506 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CE2' ' O ' ' A' ' 73' ' ' MET . 23.9 m-85 -122.51 143.82 49.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.549 HG13 ' CE2' ' A' ' 68' ' ' TYR . 15.7 t -99.7 129.99 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.297 -0.877 . . . . 0.0 109.515 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 37.9 t -109.82 131.27 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.884 . . . . 0.0 109.458 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.549 ' CG ' ' CD1' ' A' ' 93' ' ' ILE . 91.8 mt-30 -78.73 150.07 32.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.322 -0.861 . . . . 0.0 109.462 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.53 151.74 31.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -68.42 143.75 54.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.446 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.3 m -59.3 142.92 50.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.12 -32.33 5.48 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.514 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 98.7 m-85 -106.53 7.95 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.297 -1.119 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.423 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 83.5 tt0 -53.74 -32.6 52.77 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.966 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -83.53 -55.27 2.9 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.3 ttt85 -57.94 -33.66 69.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.145 -1.209 . . . . 0.0 109.441 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.514 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 55.0 t -57.74 -40.89 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.402 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.86 -36.76 85.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.393 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 47.1 m -61.52 -37.31 83.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.3 m -60.45 -35.93 77.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.198 -0.939 . . . . 0.0 109.457 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.499 HD22 ' CG1' ' A' ' 86' ' ' VAL . 48.2 mt -60.27 -40.5 90.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.873 . . . . 0.0 109.393 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -58.35 -45.27 88.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.301 -0.874 . . . . 0.0 109.571 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -64.14 -60.8 2.78 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.228 -0.92 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.42 ' C ' HD11 ' A' ' 82' ' ' LEU . 98.7 m-70 -53.18 -50.78 63.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.256 -0.902 . . . . 0.0 109.378 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.53 HG12 ' CE2' ' A' ' 39' ' ' PHE . 96.9 mt -58.14 -54.19 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -53.81 -45.19 70.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.426 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 71.0 mt -64.29 -55.88 18.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.253 -0.904 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.458 ' HB3' ' HE2' ' A' ' 35' ' ' MET . 97.0 m-70 -68.34 -10.54 55.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.867 . . . . 0.0 109.384 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.457 ' N ' ' O ' ' A' ' 30' ' ' ILE . 76.1 m-20 61.58 46.63 7.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.331 -0.856 . . . . 0.0 109.389 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.472 ' O ' ' HG ' ' A' ' 38' ' ' LEU . 2.6 mtt -95.9 5.67 50.71 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.354 -0.841 . . . . 0.0 109.551 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -50.82 -22.95 2.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -63.38 -40.83 98.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.518 ' CD1' ' SD ' ' A' ' 73' ' ' MET . 0.4 OUTLIER -91.36 -32.02 15.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.414 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 58.2 m-85 -75.27 136.9 40.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.363 -0.836 . . . . 0.0 109.395 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.22 -79.94 0.7 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 41' ' ' GLU . 56.7 mp0 -129.38 163.96 24.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.135 . . . . 0.0 109.549 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.524 ' CG1' HG21 ' A' ' 71' ' ' VAL . 55.2 t -123.16 160.74 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.316 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.56 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 94.4 mmm -117.99 138.43 52.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.935 . . . . 0.0 109.573 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 57.2 t . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.964 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.549 ' CE2' HG13 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -114.89 123.29 48.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.189 -1.183 . . . . 0.0 109.502 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 70' ' ' LEU . 86.0 t -132.52 144.66 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.326 -0.859 . . . . 0.0 109.572 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.6 mp -115.91 138.48 51.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.278 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.524 HG21 ' CG1' ' A' ' 42' ' ' VAL . 59.5 t -132.46 120.89 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.179 -0.951 . . . . 0.0 109.777 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.443 ' O ' ' HB2' ' A' ' 73' ' ' MET . 35.8 tt0 -69.82 142.12 53.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.036 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.566 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.9 ttp 173.67 158.41 0.14 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.01 . . . . 0.0 109.578 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.513 ' N ' ' HG2' ' A' ' 73' ' ' MET . 9.1 p -82.84 142.74 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.225 -0.922 . . . . 0.0 109.406 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.532 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -72.66 116.1 12.73 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.657 -179.77 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.447 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 51.3 p-10 -143.93 175.48 9.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 109.33 179.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -84.6 -18.34 35.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.21 -0.931 . . . . 0.0 109.621 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.67 -57.54 3.92 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.242 -0.912 . . . . 0.0 109.319 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.501 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 53.4 p -59.34 -41.45 89.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.41 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.417 ' C ' ' O ' ' A' ' 79' ' ' SER . 47.1 t90 -43.98 -45.78 7.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.615 -179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -79.59 -25.84 41.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 109.43 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.575 HD22 ' CZ ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -64.03 -41.45 97.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.291 -0.881 . . . . 0.0 109.532 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.522 HG21 ' CE2' ' A' ' 92' ' ' PHE . 88.6 t -65.94 -48.28 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.257 -0.902 . . . . 0.0 109.521 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -59.56 -41.41 90.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.0 p -61.96 -27.88 69.16 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.208 -0.933 . . . . 0.0 109.54 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.499 ' CG1' HD22 ' A' ' 26' ' ' LEU . 43.9 t -67.77 126.04 92.09 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 109.515 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.421 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.6 Cg_endo -70.31 163.48 38.55 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 122.653 2.235 . . . . 0.0 111.727 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.1 mtt-85 61.54 44.63 8.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 99.0 t -131.21 118.9 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.271 -0.893 . . . . 0.0 109.539 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.502 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 74.8 mtm -70.57 -42.22 71.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.81 -162.41 35.06 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.522 ' CE2' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -104.82 171.26 7.42 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.235 -1.156 . . . . 0.0 109.453 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.549 ' CD1' ' CG ' ' A' ' 13' ' ' GLN . 32.6 mm -124.43 128.45 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.452 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 172.71 -148.96 10.95 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.45 -39.54 50.25 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.461 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 29.2 p -130.7 171.98 12.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.185 -1.185 . . . . 0.0 109.497 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 p -88.55 14.73 9.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.169 -0.957 . . . . 0.0 109.443 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.461 ' OD1' ' OG1' ' A' ' 96' ' ' THR . 17.8 p30 -130.21 -13.64 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.772 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.429 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 49.5 mtt180 -145.75 91.42 5.66 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.231 -0.918 . . . . 0.0 108.884 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.532 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.48 113.89 3.08 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.774 2.316 . . . . 0.0 112.007 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.21 136.84 93.89 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.263 -0.898 . . . . 0.0 109.395 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.498 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.41 154.67 65.0 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.654 2.236 . . . . 0.0 111.814 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.4 pt -124.03 159.7 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 38.5 m -66.04 148.41 51.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.258 -0.902 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 73.6 m-20 -57.41 -41.59 80.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -57.74 -39.81 78.19 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -51.43 -40.75 59.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.923 . . . . 0.0 109.417 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -63.02 -34.6 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.388 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -63.24 -38.11 89.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.61 -40.4 95.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.386 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 27.0 mm -51.55 -57.32 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.462 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.2 mtp . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.318 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.518 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 69.5 mttt . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.461 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 96.3 mtt180 -118.62 150.64 39.35 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.293 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 65.7 m95 -99.04 135.65 40.14 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 109.668 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.426 ' CE2' ' HE3' ' A' ' 75' ' ' MET . 55.5 m-85 -128.35 153.61 46.85 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.874 . . . . 0.0 109.398 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.522 ' HB ' ' CD1' ' A' ' 93' ' ' ILE . 3.1 t -100.16 137.46 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.906 . . . . 0.0 109.511 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.53 124.63 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.214 -0.929 . . . . 0.0 109.365 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.511 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 98.0 mt-30 -90.47 145.73 24.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.512 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -149.63 163.47 37.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.332 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -67.02 140.88 57.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.189 -0.944 . . . . 0.0 109.52 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.9 m -58.07 145.78 35.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.55 -31.07 5.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . 0.5 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 96.5 m-85 -111.21 9.82 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -1.183 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.449 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 81.6 tt0 -61.11 -29.9 70.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.253 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -81.45 -36.9 18.99 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -66.87 -49.05 66.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -1.129 . . . . 0.0 109.419 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 88' ' ' ARG . 21.8 t -48.33 -41.56 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -0.98 . . . . 0.0 109.038 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.7 -46.59 84.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -0.867 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 88.4 m -62.38 -37.13 84.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.557 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 98.6 p -65.99 -37.0 84.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.435 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.517 HD22 ' CG1' ' A' ' 86' ' ' VAL . 50.4 mt -52.44 -72.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.35 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.402 ' C ' ' O ' ' A' ' 26' ' ' LEU . 41.8 ttm180 -44.25 -41.48 5.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.351 -0.843 . . . . 0.0 109.534 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -56.1 -37.36 69.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.909 . . . . 0.0 109.479 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 25' ' ' SER . 89.8 m-70 -79.27 -29.24 42.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.892 . . . . 0.0 109.374 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.623 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 17.6 mm -66.79 -43.4 89.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.559 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -67.19 -36.87 82.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.525 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 38.4 mt -70.18 -53.51 16.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 0.0 109.545 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.408 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.6 m-70 -84.76 10.95 10.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 46.34 46.74 13.77 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.47 ' CE ' HD12 ' A' ' 38' ' ' LEU . 56.8 mmm -97.25 15.76 21.88 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.195 -0.941 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.515 ' N ' HG22 ' A' ' 30' ' ' ILE . 74.9 mm-40 -55.34 -33.21 63.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 109.447 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -65.43 -45.91 81.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.277 -0.889 . . . . 0.0 109.357 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.47 HD12 ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -68.04 -55.26 13.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.303 -0.873 . . . . 0.0 109.26 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.623 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 77.6 m-85 -67.37 141.6 57.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.323 -0.861 . . . . 0.0 109.435 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.99 -69.28 0.76 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -143.14 166.17 25.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -1.145 . . . . 0.0 109.542 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.423 HG23 HG12 ' A' ' 71' ' ' VAL . 83.3 t -117.4 138.38 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.412 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.48 ' CE ' ' HG3' ' A' ' 112' ' ' MET . 83.2 mtp -127.87 156.35 42.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.208 -0.933 . . . . 0.0 109.466 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.9 t . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.271 -0.893 . . . . 0.0 109.382 -179.987 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.504 ' CE2' HD12 ' A' ' 93' ' ' ILE . 2.7 m-85 -112.25 121.4 44.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.112 -1.228 . . . . 0.0 109.574 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.46 HG13 ' N ' ' A' ' 70' ' ' LEU . 57.8 t -129.41 144.12 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.217 -0.927 . . . . 0.0 109.571 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.549 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.3 mp -109.04 130.05 55.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.497 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.423 HG12 HG23 ' A' ' 42' ' ' VAL . 48.5 t -140.91 126.4 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.319 -0.863 . . . . 0.0 109.574 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.518 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 2.6 tt0 -69.54 138.95 53.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.932 . . . . 0.0 109.268 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.493 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 14.9 ttp 178.76 152.86 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.226 -0.922 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.455 ' N ' ' HG2' ' A' ' 73' ' ' MET . 23.6 m -99.2 160.48 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.376 -0.827 . . . . 0.0 109.557 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.531 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 14.6 mmt -94.24 120.5 34.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.295 -0.878 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.8 p-10 -146.21 -161.18 1.26 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.565 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -101.49 42.4 1.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -0.878 . . . . 0.0 109.452 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -159.33 -51.11 0.06 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.291 -0.881 . . . . 0.0 109.337 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.426 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 53.4 p -65.98 -30.19 70.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 109.31 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -66.52 -46.58 75.71 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.427 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -69.35 -33.15 72.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.34 -0.85 . . . . 0.0 109.35 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.558 HD23 ' CZ ' ' A' ' 39' ' ' PHE . 5.1 tt -65.79 -35.58 81.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.426 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 92' ' ' PHE . 72.3 t -69.38 -47.49 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.415 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 42.2 ttt-85 -61.15 -33.59 73.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.431 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.3 p -63.15 -22.89 67.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.424 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.528 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 12.7 t -60.93 120.33 52.82 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.343 -0.848 . . . . 0.0 109.51 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.422 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.1 Cg_endo -71.2 160.11 49.98 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.588 2.192 . . . . 0.0 111.862 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.527 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 50.0 mtt85 60.94 33.14 19.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -0.932 . . . . 0.0 109.683 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 7.3 p -122.28 132.4 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -0.941 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.511 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 95.4 mtp -72.51 -43.03 64.15 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.36 -153.86 25.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 0.6 OUTLIER -107.15 164.26 12.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.348 -1.09 . . . . 0.0 109.507 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.522 ' CD1' ' HB ' ' A' ' 11' ' ' VAL . 58.3 mt -116.39 139.6 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 113.76 134.77 5.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 48.51 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.525 ' OG1' ' N ' ' A' ' 97' ' ' SER . 0.8 OUTLIER -141.16 -172.08 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.346 -1.091 . . . . 0.0 109.421 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.525 ' N ' ' OG1' ' A' ' 96' ' ' THR . 35.4 p -91.32 20.97 4.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.201 -0.937 . . . . 0.0 109.633 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -121.29 -29.56 4.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.342 -0.849 . . . . 0.0 108.931 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -149.23 83.39 6.61 Favored Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.531 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 44.0 Cg_endo -65.6 128.32 19.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.948 2.432 . . . . 0.0 112.484 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.63 141.93 90.93 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.489 -0.757 . . . . 0.0 109.269 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.461 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.0 Cg_endo -69.41 153.59 70.32 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.693 2.262 . . . . 0.0 111.924 -179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.476 HD13 ' CG2' ' A' ' 108' ' ' VAL . 26.7 pt -116.22 158.65 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 109.35 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.431 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 45.4 m -71.66 147.91 47.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.493 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -58.94 -36.38 74.67 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.318 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -59.83 -39.19 84.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.4 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.431 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.5 mt-10 -57.57 -46.4 84.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.29 -0.881 . . . . 0.0 109.361 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.476 ' CG2' HD13 ' A' ' 103' ' ' ILE . 71.5 t -61.64 -39.63 83.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.388 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -66.82 -37.51 84.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.258 -0.901 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.9 63.62 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.353 -0.842 . . . . 0.0 109.426 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 55.0 mt -50.51 -56.41 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.325 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' MET . . . . . 0.48 ' HG3' ' CE ' ' A' ' 43' ' ' MET . 96.0 mmm . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.912 . . . . 0.0 109.418 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' LYS . . . . . 0.427 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 63.0 mttm . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 88.2 mtt-85 -121.88 157.89 30.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -88.01 133.92 33.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.2 -0.938 . . . . 0.0 109.536 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.1 m-85 -119.05 156.47 29.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 44.7 t -99.09 143.59 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.254 -0.904 . . . . 0.0 109.428 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.7 t -125.21 123.19 64.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.309 -0.87 . . . . 0.0 109.314 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 62.5 tt0 -94.57 135.16 36.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.661 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.419 ' HB1' HG23 ' A' ' 22' ' ' VAL . . . -152.88 155.8 37.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.315 -0.866 . . . . 0.0 109.317 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -56.41 140.74 44.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.259 -0.901 . . . . 0.0 109.576 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.0 p -65.45 151.97 45.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 109.487 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.56 -31.34 5.24 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -118.89 8.82 11.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -1.175 . . . . 0.0 109.466 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.514 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 23.4 pt-20 -55.41 -46.19 76.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.395 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -59.98 -38.6 94.43 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttm-85 -55.62 -49.37 73.0 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.3 -1.118 . . . . 0.0 109.38 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.525 ' CG1' HG11 ' A' ' 86' ' ' VAL . 39.2 t -47.24 -39.72 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.267 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.13 -44.57 95.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.882 . . . . 0.0 109.339 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 89.4 m -65.93 -51.34 59.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.309 -0.87 . . . . 0.0 109.391 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 83.1 p -59.65 -36.06 75.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.402 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.456 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 tp -56.57 -53.1 61.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.2 -0.937 . . . . 0.0 109.494 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.417 ' C ' ' O ' ' A' ' 26' ' ' LEU . 57.0 ttt180 -43.7 -49.82 7.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.41 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.414 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 96.3 mt-10 -54.04 -45.39 71.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.296 -0.878 . . . . 0.0 109.361 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' HIS . . . . . 0.451 ' HB3' HD11 ' A' ' 82' ' ' LEU . 76.3 m-70 -61.32 -34.34 75.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.306 -0.871 . . . . 0.0 109.297 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.638 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 20.2 mm -63.22 -54.5 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.443 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 36.0 mttt -66.96 -37.59 84.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.924 . . . . 0.0 109.389 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 66.4 mt -60.58 -55.32 34.81 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.371 -0.831 . . . . 0.0 109.433 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . 0.415 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 96.7 m-70 -89.46 0.09 57.11 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.315 -0.866 . . . . 0.0 109.56 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.49 ' N ' ' O ' ' A' ' 30' ' ' ILE . 79.3 m-20 60.18 49.5 7.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.898 . . . . 0.0 109.48 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.558 ' CE ' ' CD1' ' A' ' 38' ' ' LEU . 51.2 mmm -101.87 14.08 32.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.492 ' HA ' ' CG2' ' A' ' 30' ' ' ILE . 97.8 mt-10 -52.06 -36.81 51.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -60.86 -40.75 94.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.229 -0.919 . . . . 0.0 109.548 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.558 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 5.7 mt -70.48 -49.05 52.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.506 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 93.2 m-85 -75.76 138.03 40.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.1 -68.62 0.42 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.414 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 84.7 tt0 -129.96 155.93 45.28 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.525 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.453 ' CG1' HG22 ' A' ' 71' ' ' VAL . 39.2 t -123.74 145.37 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' MET . . . . . 0.452 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 92.9 mtp -124.44 150.48 45.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 43' ' ' MET . 66.6 t . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.383 -0.823 . . . . 0.0 109.235 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.406 ' HA2' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.42 ' OH ' ' CG2' ' A' ' 93' ' ' ILE . 1.7 m-85 -133.19 121.92 23.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.192 -1.181 . . . . 0.0 109.475 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.416 HG11 ' N ' ' A' ' 70' ' ' LEU . 60.7 t -131.02 147.03 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -0.853 . . . . 0.0 109.521 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.55 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.8 mp -111.82 128.01 55.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.351 -0.843 . . . . 0.0 109.42 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.453 HG22 ' CG1' ' A' ' 42' ' ' VAL . 98.6 t -139.85 124.58 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLN . . . . . 0.427 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 37.9 tt0 -77.74 132.3 38.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.26 -0.9 . . . . 0.0 109.363 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.6 ttp -165.39 164.31 19.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.2 -0.937 . . . . 0.0 109.493 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.506 ' N ' ' HG2' ' A' ' 73' ' ' MET . 42.2 t -82.47 142.76 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.504 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' MET . . . . . 0.491 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 1.2 tpt -81.15 111.38 17.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.901 . . . . 0.0 109.462 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.513 ' ND2' HD21 ' A' ' 38' ' ' LEU . 37.6 p-10 -150.46 164.04 36.91 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 109.393 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.442 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 85.2 m-20 -74.51 -26.81 60.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.158 -0.964 . . . . 0.0 109.405 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -65.44 -58.02 6.88 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.499 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.461 ' OG ' ' HE1' ' A' ' 73' ' ' MET . 11.2 p -56.62 -46.44 80.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.695 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' TRP . . . . . 0.573 ' CH2' ' HD2' ' A' ' 84' ' ' ARG . 37.9 t90 -43.63 -59.35 2.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.236 -0.915 . . . . 0.0 109.62 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.442 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 94.5 m-70 -57.24 -35.95 70.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.935 . . . . 0.0 109.614 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.526 HD22 ' CE1' ' A' ' 39' ' ' PHE . 1.0 OUTLIER -62.91 -41.32 99.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.919 . . . . 0.0 109.66 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.57 HG13 ' CZ ' ' A' ' 92' ' ' PHE . 50.5 t -60.55 -46.09 96.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.573 ' HD2' ' CH2' ' A' ' 80' ' ' TRP . 29.5 mtp180 -56.6 -36.0 68.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -61.12 -28.78 69.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.24 -0.913 . . . . 0.0 109.537 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.525 HG11 ' CG1' ' A' ' 22' ' ' VAL . 40.2 t -55.4 121.28 36.8 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.276 -0.89 . . . . 0.0 109.446 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.452 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.3 Cg_endo -70.5 149.94 62.95 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.684 2.256 . . . . 0.0 111.819 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.452 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.9 mtt85 61.3 40.19 14.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.339 -0.85 . . . . 0.0 109.521 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 9.9 p -122.33 128.19 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.338 -0.851 . . . . 0.0 109.316 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' MET . . . . . 0.473 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.0 mmm -71.66 -53.72 12.68 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.16 -0.962 . . . . 0.0 109.506 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.42 -150.69 20.92 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' PHE . . . . . 0.57 ' CZ ' HG13 ' A' ' 83' ' ' VAL . 82.7 m-85 -100.53 157.68 16.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -1.095 . . . . 0.0 109.56 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.52 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 38.8 mm -117.6 135.94 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 0.0 109.331 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 110.12 145.86 10.86 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 50.75 -95.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 94' ' ' GLY . 19.3 p -140.33 -173.04 3.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -1.19 . . . . 0.0 109.558 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 p -95.53 22.24 7.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.215 -0.928 . . . . 0.0 109.485 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.541 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 73.4 m-20 -120.51 -25.13 5.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.371 -0.831 . . . . 0.0 109.215 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.423 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 15.2 mtp180 -153.04 102.36 2.64 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.358 -0.839 . . . . 0.0 109.013 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.562 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 44.3 Cg_endo -66.46 114.58 3.13 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.769 2.313 . . . . 0.0 112.012 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.54 140.29 88.89 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.397 -0.814 . . . . 0.0 109.487 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.514 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.4 Cg_endo -70.42 153.4 65.95 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.669 2.246 . . . . 0.0 111.823 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.451 HD12 ' CG2' ' A' ' 108' ' ' VAL . 31.8 pt -126.96 157.4 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.887 . . . . 0.0 109.49 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 53.0 p -72.36 151.07 42.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.618 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -61.6 -35.03 76.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -61.84 -40.12 94.21 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . 0.452 ' O ' HG13 ' A' ' 111' ' ' ILE . 86.5 tt0 -59.52 -41.88 90.99 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.293 -0.88 . . . . 0.0 109.467 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.465 ' CG1' HD23 ' A' ' 70' ' ' LEU . 70.6 t -60.29 -37.51 74.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.315 -0.866 . . . . 0.0 109.471 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -64.7 -40.27 95.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.973 . . . . 0.0 109.378 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -66.04 -43.13 88.46 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.452 HG13 ' O ' ' A' ' 107' ' ' GLU . 70.8 mt -52.44 -49.53 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.213 -0.929 . . . . 0.0 109.468 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 94.9 mmm . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.431 179.993 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.2 mtp . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.4 m -56.38 -36.12 68.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -110.31 140.65 44.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.415 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.9 130.8 79.16 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.47 144.71 51.0 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.698 2.265 . . . . 0.0 111.833 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 31.2 tttm -116.4 129.47 56.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.323 -0.861 . . . . 0.0 109.404 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -95.52 135.29 37.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.451 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.456 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 61.9 mtt180 -122.67 152.94 40.03 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.228 -0.92 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.572 ' CE2' ' OE1' ' A' ' 72' ' ' GLN . 74.9 m95 -95.01 133.89 38.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CE2' ' O ' ' A' ' 73' ' ' MET . 28.3 m-85 -122.69 149.39 44.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -0.873 . . . . 0.0 109.308 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 25.0 t -97.68 142.62 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.491 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.75 130.81 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.478 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.451 ' HB3' ' HB2' ' A' ' 90' ' ' MET . 57.3 tt0 -96.96 128.1 43.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 109.464 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -142.08 164.23 30.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.214 -0.928 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -69.22 145.33 53.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.2 p -66.19 149.49 50.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.31 -33.03 4.69 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -109.53 1.6 19.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.3 -1.118 . . . . 0.0 109.623 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.459 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 85.6 tt0 -53.45 -40.07 64.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.44 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.57 -47.77 74.4 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -63.65 -39.36 94.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -1.171 . . . . 0.0 109.461 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 88' ' ' ARG . 60.6 t -52.18 -44.69 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.473 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.76 -42.79 98.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.333 -0.854 . . . . 0.0 109.465 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.1 m -61.2 -39.0 88.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.462 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 24.1 m -58.95 -39.18 80.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.505 ' CD2' HG23 ' A' ' 86' ' ' VAL . 48.3 mt -56.11 -46.61 79.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttt85 -56.15 -41.89 76.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -0.89 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -66.78 -58.73 4.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 25' ' ' SER . 73.4 m-70 -57.22 -48.63 78.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 0.0 109.498 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.555 HG12 ' CE1' ' A' ' 39' ' ' PHE . 89.7 mt -61.9 -49.52 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.251 -0.906 . . . . 0.0 109.446 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -57.87 -45.56 86.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.467 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 45.3 mt -63.26 -48.62 77.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.444 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -83.44 5.5 23.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.251 -0.906 . . . . 0.0 109.52 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 30' ' ' ILE . 38.1 t30 54.69 46.13 25.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.33 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.539 ' CG ' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -96.54 3.89 52.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.579 -179.914 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.1 mt-10 -53.4 -35.61 60.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -54.3 -40.46 67.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.22 -0.925 . . . . 0.0 109.463 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.539 ' CD1' ' CG ' ' A' ' 35' ' ' MET . 0.7 OUTLIER -73.9 -48.77 28.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.288 -0.883 . . . . 0.0 109.294 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.569 ' CE1' ' SD ' ' A' ' 73' ' ' MET . 89.4 m-85 -70.41 130.12 41.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.358 -0.839 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.14 -63.16 0.58 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -141.44 115.46 9.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -1.19 . . . . 0.0 109.66 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.476 HG23 ' CG2' ' A' ' 71' ' ' VAL . 8.2 p -89.5 147.08 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.39 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.563 ' HE3' ' CH2' ' A' ' 9' ' ' TRP . 46.3 mtt -112.88 148.98 33.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.496 ' CG1' ' O ' ' A' ' 46' ' ' THR . 35.3 t -135.32 95.66 14.55 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.342 -0.849 . . . . 0.0 109.274 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.02 -3.32 12.59 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.749 2.3 . . . . 0.0 111.995 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.496 ' O ' ' CG1' ' A' ' 44' ' ' VAL . 8.9 t -122.99 154.04 38.98 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.913 . . . . 0.0 109.515 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -103.87 149.16 25.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.273 -0.892 . . . . 0.0 109.521 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -60.09 -28.04 67.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.277 -0.89 . . . . 0.0 109.507 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.01 173.13 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.506 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.1 m -116.73 155.44 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.473 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -92.75 144.17 25.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.284 -0.885 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 89.5 mt -58.39 -39.32 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.249 -0.907 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -57.75 146.59 30.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.407 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.3 -176.2 19.94 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -54.45 141.59 34.62 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -61.64 -36.77 81.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.24 -1.153 . . . . 0.0 109.499 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 82.4 mtm180 -127.62 145.29 50.92 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.293 -0.879 . . . . 0.0 109.449 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 59.6 mtt-85 -61.33 -35.47 77.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -61.17 -32.39 72.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.904 . . . . 0.0 109.49 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.5 p -56.02 156.37 5.46 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -117.78 172.64 7.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.548 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.0 mtt180 -111.3 135.92 51.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.89 . . . . 0.0 109.49 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -88.27 4.97 43.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.21 -0.932 . . . . 0.0 109.554 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.415 ' CD1' HD13 ' A' ' 115' ' ' LEU . 24.1 m-85 -72.12 145.66 47.99 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.485 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -120.38 80.42 29.4 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.65 151.64 64.16 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 94.09 -8.41 72.9 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.459 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -117.59 128.51 55.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -1.14 . . . . 0.0 109.492 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.446 HG23 ' OE2' ' A' ' 19' ' ' GLU . 65.8 t -130.73 143.44 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.273 -0.892 . . . . 0.0 109.538 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.575 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.1 mp -107.32 133.04 52.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.322 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.476 ' CG2' HG23 ' A' ' 42' ' ' VAL . 43.1 t -139.51 131.15 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.684 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.572 ' OE1' ' CE2' ' A' ' 9' ' ' TRP . 23.2 tt0 -88.05 128.5 35.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.218 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 55.7 ttp -173.98 163.96 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.179 -0.951 . . . . 0.0 109.682 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.514 ' N ' ' HG2' ' A' ' 73' ' ' MET . 28.6 m -87.45 138.24 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.267 -0.896 . . . . 0.0 109.459 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.496 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 1.1 ttm -76.68 116.76 17.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.434 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 52.8 p-10 -145.01 170.71 15.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.428 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -67.88 -33.66 75.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -0.919 . . . . 0.0 109.915 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.521 ' CB ' ' HE2' ' A' ' 35' ' ' MET . . . -67.7 -69.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 0.0 109.7 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 80' ' ' TRP . 9.9 p -46.6 -59.52 2.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -0.892 . . . . 0.0 109.645 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.49 ' N ' ' OG ' ' A' ' 79' ' ' SER . 68.0 t90 -42.84 -58.09 2.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.638 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -58.34 -37.69 75.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.944 . . . . 0.0 109.493 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.511 ' CD1' ' HB3' ' A' ' 29' ' ' HIS . 67.4 tp -63.41 -39.7 95.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.568 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.533 ' CG1' ' CE2' ' A' ' 92' ' ' PHE . 85.4 t -59.93 -47.29 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 109.584 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.59 -37.69 76.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.543 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 82' ' ' LEU . 80.4 p -64.67 -26.28 68.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -0.914 . . . . 0.0 109.499 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.505 HG23 ' CD2' ' A' ' 26' ' ' LEU . 98.7 t -60.79 124.51 79.73 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.486 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.444 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.4 Cg_endo -70.35 156.41 61.88 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.696 2.264 . . . . 0.0 111.795 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.449 ' O ' HG23 ' A' ' 22' ' ' VAL . 68.2 mtt-85 61.28 46.07 8.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.395 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.462 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.4 t -132.85 118.65 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.593 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.451 ' HB2' ' HB3' ' A' ' 13' ' ' GLN . 64.2 mtt -69.03 -42.82 75.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.423 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.0 -152.81 24.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.533 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 3.4 m-85 -109.99 161.82 15.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.232 -1.158 . . . . 0.0 109.537 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.459 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 14.5 mm -115.9 116.35 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.507 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -172.88 -148.1 6.14 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.59 -35.01 67.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.6 t -138.9 175.6 9.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -1.189 . . . . 0.0 109.665 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 p -93.56 19.44 8.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.288 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -131.19 -0.83 4.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 109.429 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.403 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtt180 -168.28 96.39 0.58 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.88 . . . . 0.0 109.003 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.496 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.9 Cg_endo -67.52 116.88 4.46 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.798 2.332 . . . . 0.0 112.16 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -60.72 135.5 92.44 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.267 -0.896 . . . . 0.0 109.304 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.1 Cg_endo -69.92 153.32 68.32 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.674 2.25 . . . . 0.0 111.785 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.458 ' CD1' HG21 ' A' ' 108' ' ' VAL . 28.3 pt -126.42 157.6 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.386 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 38.7 m -63.27 147.81 49.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.4 -39.31 83.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.428 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.2 tttt -59.74 -39.28 84.23 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.456 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -59.95 -41.4 91.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.256 -0.903 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.526 HG23 ' CG ' ' A' ' 9' ' ' TRP . 97.7 t -61.89 -35.96 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.515 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -67.33 -33.82 76.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.274 -0.891 . . . . 0.0 109.485 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.73 96.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.226 -0.921 . . . . 0.0 109.422 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.409 HG22 HD13 ' A' ' 111' ' ' ILE . 70.2 mt -56.86 -51.93 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 109.482 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 89.1 mtp -64.95 -33.98 77.31 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -57.95 -37.94 75.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 52.5 mtt180 -61.75 -39.92 93.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.93 . . . . 0.0 109.434 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.415 HD13 ' CD1' ' A' ' 64' ' ' PHE . 3.9 tp -60.64 -39.48 88.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 63.9 tt0 -68.31 -31.93 71.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -56.26 138.57 50.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.488 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.9 m -132.26 160.76 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.492 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -90.23 58.63 3.51 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -55.13 -35.5 64.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.135 . . . . 0.0 109.48 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 29.6 mtpp -121.08 81.9 36.51 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.96 145.22 55.38 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.682 2.255 . . . . 0.0 111.818 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.0 mmt180 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.412 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.8 mtm . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.231 0.539 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.8 p -127.68 155.0 44.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.269 -0.894 . . . . 0.0 109.542 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -99.93 136.49 39.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -73.93 129.01 85.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.492 ' O ' ' NE ' ' A' ' 8' ' ' ARG . 51.0 Cg_endo -70.46 -10.75 28.66 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.722 2.282 . . . . 0.0 111.864 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.446 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 26.2 mttm -91.58 156.84 17.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.446 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 76.9 mttt 62.27 46.1 6.3 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.529 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 49.0 mtt180 -80.59 148.32 30.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.523 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.533 ' CH2' ' HG3' ' A' ' 43' ' ' MET . 77.2 m95 -78.01 135.68 37.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.947 . . . . 0.0 109.639 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.615 ' CZ ' ' CG ' ' A' ' 75' ' ' MET . 76.0 m-85 -132.21 139.02 48.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -0.92 . . . . 0.0 109.372 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.51 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.7 t -83.17 148.94 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.108 -0.995 . . . . 0.0 109.519 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.91 122.94 57.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.423 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.499 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 13.4 mt-30 -78.83 145.0 34.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.266 -0.896 . . . . 0.0 109.588 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -157.03 157.09 34.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.299 -0.876 . . . . 0.0 109.401 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -63.86 142.86 58.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.481 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.1 p -68.12 151.0 47.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.463 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.21 -34.08 4.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -112.08 9.22 20.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.453 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.52 ' OE2' ' CG2' ' A' ' 69' ' ' VAL . 85.6 tt0 -54.18 -41.0 68.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.87 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.53 -44.33 83.38 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.7 ttm-85 -62.44 -35.39 79.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -1.147 . . . . 0.0 109.498 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.447 HG21 ' O ' ' A' ' 88' ' ' ARG . 53.7 t -56.51 -38.21 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.65 -37.41 86.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -0.894 . . . . 0.0 109.445 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 54.8 m -73.54 -40.68 63.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 26.6 m -64.48 -33.48 75.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.552 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.523 HD11 ' CG2' ' A' ' 86' ' ' VAL . 20.2 tp -63.32 -49.92 72.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.439 ' HG2' ' NZ ' ' A' ' 31' ' ' LYS . 18.4 ttp180 -43.21 -51.86 5.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.334 -0.854 . . . . 0.0 109.52 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -51.38 -49.18 62.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.528 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.448 ' HB3' ' CD1' ' A' ' 82' ' ' LEU . 90.3 m-70 -57.76 -26.08 61.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.474 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.636 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 20.7 mm -72.22 -51.95 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.454 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 58.7 mttp -66.9 -39.66 87.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.304 -0.872 . . . . 0.0 109.435 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 41.4 mt -57.45 -57.85 10.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.491 ' CD2' HD11 ' A' ' 82' ' ' LEU . 85.1 m-70 -89.5 5.39 45.65 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 30' ' ' ILE . 69.9 m-20 55.18 48.4 19.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.551 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.523 ' CE ' ' CD1' ' A' ' 38' ' ' LEU . 49.0 mmm -98.17 15.06 25.5 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 98.0 mt-10 -55.01 -29.27 57.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.481 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -67.69 -38.3 83.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.338 -0.851 . . . . 0.0 109.508 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.523 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 6.3 mt -72.63 -52.85 13.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.425 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.636 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 93.2 m-85 -69.91 133.77 47.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 109.335 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.52 -64.06 0.61 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -146.6 153.07 39.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.168 -1.195 . . . . 0.0 109.556 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.509 ' CG1' HG23 ' A' ' 71' ' ' VAL . 38.9 t -114.44 149.72 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.455 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.533 ' HG3' ' CH2' ' A' ' 9' ' ' TRP . 58.4 mtm -132.08 140.36 48.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.167 -0.958 . . . . 0.0 109.562 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.3 t -131.01 76.72 76.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.47 58.44 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.705 2.27 . . . . 0.0 111.829 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.8 p -129.77 153.53 48.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.189 -0.944 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.426 ' HB2' ' O ' ' A' ' 62' ' ' ARG . 95.3 mt-10 -62.31 -19.48 63.34 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.244 -0.91 . . . . 0.0 109.362 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.451 ' HB2' ' HE2' ' A' ' 63' ' ' LYS . 84.4 tt0 -48.41 -34.97 11.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.7 p -127.02 136.19 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.4 m -137.78 162.08 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.316 -0.865 . . . . 0.0 109.384 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.7 tp10 -47.19 -56.34 6.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.433 HG23 ' O ' ' A' ' 52' ' ' ILE . 1.1 tt -126.36 101.24 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.429 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 75.0 mtm-85 -59.24 145.16 43.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.281 -0.887 . . . . 0.0 109.509 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -65.93 -30.01 76.21 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.449 ' O ' ' HG3' ' A' ' 57' ' ' ARG . . . 116.21 -97.47 0.77 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.411 ' O ' ' HB2' ' A' ' 57' ' ' ARG . 56.3 tp60 -57.94 -32.17 67.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -1.171 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.449 ' HG3' ' O ' ' A' ' 55' ' ' GLY . 59.8 mtt180 60.38 39.98 17.99 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.207 -0.933 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 69.7 mtt85 -58.84 -32.64 69.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.17 -0.956 . . . . 0.0 109.445 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 tttm -76.05 133.12 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.43 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.2 m -58.47 153.85 15.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -122.88 149.73 43.83 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.198 -0.939 . . . . 0.0 109.455 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.426 ' O ' ' HB2' ' A' ' 47' ' ' GLU . 97.5 mtt180 -126.98 146.09 50.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.511 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.451 ' HE2' ' HB2' ' A' ' 48' ' ' GLU . 21.3 mttt -102.45 118.2 36.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.682 ' CD1' ' CZ ' ' A' ' 65' ' ' PHE . 32.2 t80 -59.66 -45.17 92.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.293 -0.88 . . . . 0.0 109.313 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.682 ' CZ ' ' CD1' ' A' ' 64' ' ' PHE . 2.2 m-85 -114.8 83.81 9.64 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.251 -0.906 . . . . 0.0 109.335 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.38 115.29 3.97 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.726 2.284 . . . . 0.0 111.842 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.39 18.6 70.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.448 ' HB2' ' HB3' ' A' ' 65' ' ' PHE . 1.7 m-85 -117.89 109.49 16.59 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -1.141 . . . . 0.0 109.437 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.52 ' CG2' ' OE2' ' A' ' 19' ' ' GLU . 77.0 t -137.25 133.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.275 -0.891 . . . . 0.0 109.585 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.55 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 2.1 mp -101.26 147.1 26.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.285 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.509 HG23 ' CG1' ' A' ' 42' ' ' VAL . 65.0 t -145.49 113.78 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.246 -0.909 . . . . 0.0 109.638 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.452 ' NE2' ' CZ2' ' A' ' 9' ' ' TRP . 0.0 OUTLIER -54.06 124.35 15.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.209 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.564 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 38.1 ttp -177.21 155.22 1.12 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 0.0 109.533 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.483 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.1 t -91.52 140.45 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.302 -0.874 . . . . 0.0 109.402 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.615 ' CG ' ' CZ ' ' A' ' 10' ' ' TYR . 30.6 mmm -84.02 109.33 17.57 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.278 -0.889 . . . . 0.0 109.597 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.515 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 51.2 p-10 -138.27 173.89 11.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -64.18 -26.16 68.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.249 -0.907 . . . . 0.0 109.562 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -78.25 -70.14 0.51 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.51 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 25.1 p -54.67 -45.99 73.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -0.896 . . . . 0.0 109.736 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 73.1 t90 -51.15 -54.38 25.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.6 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -61.57 -39.09 89.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.925 . . . . 0.0 109.559 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.514 ' CD2' ' HG3' ' A' ' 35' ' ' MET . 58.4 tp -63.21 -41.64 99.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.152 -0.967 . . . . 0.0 109.503 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.555 ' CG1' ' CE2' ' A' ' 92' ' ' PHE . 55.6 t -56.32 -43.89 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.139 -0.976 . . . . 0.0 109.534 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -61.83 -35.65 78.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.175 -0.953 . . . . 0.0 109.481 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 29.8 t -66.76 -28.34 68.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.479 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.523 ' CG2' HD11 ' A' ' 26' ' ' LEU . 49.8 t -54.9 124.93 53.99 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.464 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.457 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.2 155.08 65.29 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.745 2.296 . . . . 0.0 111.789 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.457 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 82.6 mmt-85 63.36 43.43 6.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.254 -0.904 . . . . 0.0 109.526 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 86' ' ' VAL . 53.6 t -128.79 115.58 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.5 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.499 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.7 mtp -68.5 -40.16 80.98 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.907 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.59 -158.86 31.43 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.555 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 0.2 OUTLIER -112.69 166.68 11.13 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.218 -1.166 . . . . 0.0 109.514 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.51 HD12 ' CG1' ' A' ' 11' ' ' VAL . 67.4 mt -118.24 137.5 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.878 . . . . 0.0 109.379 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.456 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 161.18 -147.08 13.24 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -78.08 -44.09 12.46 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.3 p -127.73 173.38 9.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.156 -1.202 . . . . 0.0 109.53 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.1 m -89.89 18.09 6.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.274 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 87.6 m-20 -130.17 -33.24 1.74 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.574 -0.704 . . . . 0.0 109.134 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.55 88.58 38.46 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.264 -0.898 . . . . 0.0 108.836 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.562 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.46 128.76 18.8 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.71 2.274 . . . . 0.0 112.048 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 137.14 82.56 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.291 -0.88 . . . . 0.0 109.361 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.529 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.3 Cg_endo -69.7 153.23 69.47 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.699 2.266 . . . . 0.0 111.841 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.455 ' HB ' ' OE1' ' A' ' 107' ' ' GLU . 26.7 pt -112.65 154.96 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.369 -0.832 . . . . 0.0 109.481 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.9 m -65.38 146.26 55.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.152 -0.968 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -58.13 -41.01 82.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.278 -0.889 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 42.5 tttt -57.98 -43.42 86.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.449 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.455 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 86.5 tt0 -51.85 -43.75 63.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.902 . . . . 0.0 109.441 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.414 HG23 HD11 ' A' ' 103' ' ' ILE . 74.8 t -57.17 -38.69 62.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.303 -0.873 . . . . 0.0 109.375 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -68.41 -31.75 71.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.23 -0.919 . . . . 0.0 109.465 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -62.93 -42.28 99.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.435 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.534 HG22 ' CE2' ' A' ' 65' ' ' PHE . 50.9 mt -52.43 -53.69 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.211 -0.93 . . . . 0.0 109.395 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.4 mtt -62.58 -36.73 83.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.926 . . . . 0.0 109.377 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -60.94 -37.54 82.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.498 ' NH1' HG12 ' A' ' 111' ' ' ILE . 24.6 mtm180 -55.17 -40.77 71.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.479 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 87.1 mt -54.57 -40.43 68.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.414 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -65.25 -31.53 72.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -65.51 137.15 57.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.382 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.522 ' HB ' ' CB ' ' A' ' 121' ' ' LYS . 39.5 t -119.71 140.21 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -54.42 -35.15 55.62 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 60.5 t0 -144.39 88.77 1.96 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.306 -1.114 . . . . 0.0 109.4 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.522 ' CB ' ' HB ' ' A' ' 118' ' ' VAL . 1.3 tppp? -155.06 106.55 2.28 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.228 -0.92 . . . . 0.0 109.516 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.27 -17.81 35.01 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.654 2.236 . . . . 0.0 111.765 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 55.4 ttt180 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.064 -0.969 . . . . 0.0 109.398 179.944 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.1 mmm . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.4 p -67.36 -14.52 62.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.276 -0.89 . . . . 0.0 109.486 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -51.99 -37.4 53.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.541 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -168.93 148.65 3.83 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 109.492 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.97 147.94 62.61 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.713 2.275 . . . . 0.0 111.817 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 56.5 mttm -106.39 139.78 40.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.462 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 47.1 mttt -113.29 138.21 50.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.224 -0.922 . . . . 0.0 109.48 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.462 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 78.8 mtt-85 -128.92 156.48 43.66 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 67.4 m95 -91.55 128.15 37.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.177 -0.952 . . . . 0.0 109.617 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.561 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.9 m-85 -120.9 150.11 41.58 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.46 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.46 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 53.0 t -102.27 136.04 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.245 -0.909 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.79 126.68 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.508 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 69.9 tp60 -90.35 130.64 36.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.425 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.403 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -142.67 154.74 44.61 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.528 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -55.12 149.67 11.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.423 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.8 t -67.93 147.71 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.498 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 -33.94 4.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.511 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 93.5 m-85 -109.53 7.15 24.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -1.155 . . . . 0.0 109.592 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.483 ' OE2' ' CB ' ' A' ' 46' ' ' THR . 23.0 pt-20 -56.12 -39.31 72.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.441 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -75.44 -54.2 5.66 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -57.86 -39.21 77.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -1.136 . . . . 0.0 109.497 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 50.9 t -53.05 -40.75 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.29 96.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.894 . . . . 0.0 109.433 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.8 m -64.48 -43.51 93.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.524 ' CB ' HG22 ' A' ' 86' ' ' VAL . 58.1 m -58.41 -41.68 85.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.568 HD23 ' CE1' ' A' ' 39' ' ' PHE . 4.8 tp -59.14 -39.41 82.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 109.272 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -58.48 -26.03 62.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.321 -0.862 . . . . 0.0 109.392 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.471 ' HB2' ' O ' ' A' ' 25' ' ' SER . 71.2 mt-10 -68.66 -47.65 65.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.325 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.567 ' CD2' ' HB ' ' A' ' 86' ' ' VAL . 79.8 m-70 -68.06 -43.47 78.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.632 ' CD1' ' CD2' ' A' ' 39' ' ' PHE . 54.9 mt -57.94 -50.44 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.52 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 58.2 tttp -60.49 -41.48 94.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.611 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.459 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 32.3 mt -69.27 -50.88 42.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.547 ' CD2' HD12 ' A' ' 82' ' ' LEU . 97.3 m-70 -77.49 -6.89 55.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.217 -0.927 . . . . 0.0 109.528 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.487 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.1 t30 66.14 42.98 2.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.514 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.511 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 45.8 mmm -92.04 5.19 51.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.45 ' O ' ' O ' ' A' ' 39' ' ' PHE . 96.5 mt-10 -48.76 -37.79 19.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.461 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -53.26 -44.25 68.03 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.214 -0.929 . . . . 0.0 109.362 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.52 HD22 ' CG1' ' A' ' 74' ' ' VAL . 1.2 mt -72.19 -52.66 15.5 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.302 -0.874 . . . . 0.0 109.4 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.632 ' CD2' ' CD1' ' A' ' 30' ' ' ILE . 98.1 m-85 -70.97 129.09 38.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.187 -0.946 . . . . 0.0 109.441 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.32 -69.19 0.66 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -139.71 147.15 40.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -1.163 . . . . 0.0 109.583 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.456 HG11 ' O ' ' A' ' 70' ' ' LEU . 39.0 t -113.99 154.01 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.374 -0.829 . . . . 0.0 109.351 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.443 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 64.3 mtm -137.78 144.05 41.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.566 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.6 t -129.7 100.49 19.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.438 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.52 ' HD3' ' CD1' ' A' ' 70' ' ' LEU . 49.9 Cg_endo -70.44 -16.75 34.75 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.692 2.262 . . . . 0.0 111.857 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.483 ' CB ' ' OE2' ' A' ' 19' ' ' GLU . 12.0 p -64.95 -14.14 59.24 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.215 -0.928 . . . . 0.0 109.566 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.445 ' OE2' HG13 ' A' ' 52' ' ' ILE . 77.8 tt0 -100.51 130.99 46.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.15 -0.969 . . . . 0.0 109.441 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -65.89 -49.06 69.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.299 -0.876 . . . . 0.0 109.477 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.432 ' O ' ' OE2' ' A' ' 47' ' ' GLU . 44.8 t -129.4 158.04 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.436 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 8.8 p -46.89 -35.95 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.515 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -110.01 150.32 28.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.9 . . . . 0.0 109.55 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.445 HG13 ' OE2' ' A' ' 47' ' ' GLU . 55.6 mt -121.12 96.65 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 87.3 mtt180 -59.22 146.76 38.03 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.266 -0.896 . . . . 0.0 109.48 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -57.11 -39.94 90.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 46.03 -110.6 0.5 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.81 154.16 23.39 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.263 -1.139 . . . . 0.0 109.506 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.6 mtm-85 -50.26 -35.45 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.414 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 35.1 ttt180 -129.28 132.16 47.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.261 -0.9 . . . . 0.0 109.492 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 mttm -100.43 134.91 42.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.34 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 18.2 m -63.11 -23.63 67.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -52.36 147.8 7.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.5 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -130.19 151.02 51.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.307 -0.87 . . . . 0.0 109.426 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.456 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 28.9 mttp -88.92 114.09 25.16 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.5 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -63.78 -40.62 97.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.252 -0.905 . . . . 0.0 109.467 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -129.39 75.92 79.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.302 -0.874 . . . . 0.0 109.503 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 48.9 Cg_endo -69.94 144.6 53.58 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.743 2.295 . . . . 0.0 111.801 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . 83.46 19.64 61.76 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -118.64 124.25 46.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -1.199 . . . . 0.0 109.445 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 76.6 t -132.2 146.49 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.567 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.2 mp -106.85 130.09 54.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.408 HG23 HG23 ' A' ' 42' ' ' VAL . 99.1 t -136.63 124.77 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.176 -0.952 . . . . 0.0 109.642 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.462 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 7.5 tt0 -81.02 128.37 33.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.171 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.561 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 50.9 ttp -173.83 165.12 4.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.65 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.526 ' N ' ' CG ' ' A' ' 73' ' ' MET . 14.5 p -88.53 143.36 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.353 -0.842 . . . . 0.0 109.218 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.522 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 16.9 tpp -82.91 113.82 20.78 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.593 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.0 p30 -142.14 168.94 18.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.318 -0.864 . . . . 0.0 109.427 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.572 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.6 m-20 -68.61 -30.12 68.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.217 -0.927 . . . . 0.0 109.47 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.441 ' HB1' ' HE2' ' A' ' 35' ' ' MET . . . -70.02 -71.88 0.22 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.905 . . . . 0.0 109.55 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.472 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 7.5 m -48.27 -49.61 32.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 66.3 t90 -49.63 -52.3 31.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.873 . . . . 0.0 109.73 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 56.5 m-70 -66.6 -24.19 66.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.6 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.547 HD12 ' CD2' ' A' ' 33' ' ' HIS . 56.9 tp -68.74 -45.21 72.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.526 ' CG2' ' CZ ' ' A' ' 92' ' ' PHE . 70.0 t -50.92 -44.05 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.573 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 36.2 ttp180 -62.92 -23.02 67.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.139 -0.976 . . . . 0.0 109.368 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.5 t -61.6 -63.86 1.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 0.0 109.415 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.567 ' HB ' ' CD2' ' A' ' 29' ' ' HIS . 1.8 p -59.62 125.8 80.89 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.164 -0.96 . . . . 0.0 109.467 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.474 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.1 Cg_endo -69.65 -177.77 1.99 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.732 2.288 . . . . 0.0 111.834 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.474 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.1 mtt85 62.94 23.01 13.77 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.314 -0.866 . . . . 0.0 109.582 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.462 HG21 ' O ' ' A' ' 87' ' ' PRO . 22.2 t -116.88 116.48 52.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.482 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.508 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 44.8 mtt -65.93 -43.68 87.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.346 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.19 -150.86 22.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.526 ' CZ ' ' CG2' ' A' ' 83' ' ' VAL . 4.6 m-85 -111.8 161.4 16.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.4 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.46 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 15.8 mm -114.88 123.12 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.306 -0.871 . . . . 0.0 109.548 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.86 -152.76 11.57 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -64.95 -45.04 93.62 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.9 p -129.32 172.86 11.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.183 -1.187 . . . . 0.0 109.565 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 14.4 p -89.82 20.05 4.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.2 -0.937 . . . . 0.0 109.412 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -123.12 -22.65 5.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.449 -0.782 . . . . 0.0 109.37 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.53 103.18 3.27 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.328 -0.857 . . . . 0.0 108.94 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.522 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.4 Cg_endo -68.77 111.46 2.61 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.756 2.304 . . . . 0.0 111.996 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.98 140.7 81.95 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 109.427 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.462 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.9 Cg_endo -70.15 153.34 67.24 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.637 2.225 . . . . 0.0 111.81 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.62 155.11 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.255 -0.903 . . . . 0.0 109.408 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.7 m -71.74 151.34 43.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -52.29 -41.7 63.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -55.82 -41.52 74.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.921 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -52.88 -45.12 67.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.333 -0.854 . . . . 0.0 109.377 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.418 ' CG1' ' HE3' ' A' ' 43' ' ' MET . 98.1 t -56.78 -38.03 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -67.54 -34.2 76.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.229 -0.919 . . . . 0.0 109.445 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -56.48 -46.3 80.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.332 -0.855 . . . . 0.0 109.415 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 50.5 mt -49.69 -56.36 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.329 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.6 mtt -60.3 -35.17 74.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.276 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -61.27 -34.69 75.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 109.355 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.7 ttt180 -55.88 -36.97 68.21 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 72.8 mt -55.79 -43.46 76.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.428 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -64.68 -31.82 73.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.527 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -69.99 137.26 51.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.5 -39.44 81.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.291 -0.881 . . . . 0.0 109.483 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 96.81 10.4 55.29 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 121' ' ' LYS . 30.9 p-10 -58.03 -34.69 70.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.217 -1.167 . . . . 0.0 109.414 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.505 ' N ' ' OD1' ' A' ' 120' ' ' ASP . 12.8 tttm -124.11 81.05 57.67 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.364 -0.835 . . . . 0.0 109.509 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.12 -18.91 35.0 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.726 2.284 . . . . 0.0 111.685 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 38.6 ttt180 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.505 179.965 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.7 mtp . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.0 t -57.41 -35.87 70.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.294 -0.878 . . . . 0.0 109.506 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.94 -34.75 75.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.43 80.04 60.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.312 -0.867 . . . . 0.0 109.465 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.26 141.33 42.93 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.671 2.247 . . . . 0.0 111.759 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 26.9 mttp -110.22 150.14 29.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.309 -0.869 . . . . 0.0 109.401 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 77.5 mttt -99.02 133.27 43.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.323 -0.86 . . . . 0.0 109.561 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.514 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 44.9 mtm180 -132.72 159.55 39.35 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.493 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.54 ' CH2' ' SD ' ' A' ' 43' ' ' MET . 46.3 m95 -99.34 132.54 44.59 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.892 . . . . 0.0 109.556 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.582 ' CD2' ' HE3' ' A' ' 75' ' ' MET . 66.1 m-85 -130.93 155.23 47.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.443 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.471 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 10.7 t -96.18 145.93 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.226 -0.921 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.0 t -119.03 123.57 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 109.364 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.514 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 64.5 tt0 -93.1 131.67 37.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.923 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.4 ' HB3' HG22 ' A' ' 22' ' ' VAL . . . -138.72 -153.23 0.46 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 109.369 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 61.7 t80 -98.23 133.49 42.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.452 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 31.3 t -54.77 126.0 22.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.214 -0.929 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.11 -27.15 19.67 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 19.2 m-85 -105.09 7.52 33.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -1.116 . . . . 0.0 109.493 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -56.89 -34.72 68.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.915 . . . . 0.0 109.374 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -71.13 -37.87 63.68 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.458 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 17.9 ttm180 -63.81 -49.86 71.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.204 -1.174 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.442 HG13 HG13 ' A' ' 86' ' ' VAL . 39.1 t -50.37 -38.78 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.235 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.73 -39.72 91.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.929 . . . . 0.0 109.251 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.6 m -69.01 -46.6 67.55 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.388 -0.82 . . . . 0.0 109.376 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.479 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.4 m -65.72 -39.63 91.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.438 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.494 ' HG ' ' CD1' ' A' ' 30' ' ' ILE . 30.8 tp -54.34 -43.55 71.34 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.6 ttm-85 -57.83 -36.89 72.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -67.94 -52.58 34.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.203 -0.936 . . . . 0.0 109.474 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.517 ' HB3' ' CD1' ' A' ' 82' ' ' LEU . 68.1 m-70 -58.44 -48.06 81.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.93 . . . . 0.0 109.443 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.564 HG12 ' CE2' ' A' ' 39' ' ' PHE . 89.2 mt -57.69 -52.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.305 -0.872 . . . . 0.0 109.515 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.4 tttm -57.61 -43.39 84.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.29 -0.881 . . . . 0.0 109.497 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 40.2 mt -68.25 -49.48 60.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.229 -0.92 . . . . 0.0 109.416 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.466 ' CD2' HD11 ' A' ' 82' ' ' LEU . 98.5 m-70 -80.35 4.19 18.7 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 109.577 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 30' ' ' ILE . 40.5 t30 52.75 50.53 17.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.403 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.522 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 53.3 mmm -102.88 4.74 37.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.427 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.3 mt-10 -49.78 -34.93 20.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -57.77 -43.03 85.23 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.413 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.511 HD23 ' ND2' ' A' ' 76' ' ' ASN . 1.4 mt -72.84 -50.12 25.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.287 -0.883 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.564 ' CE2' HG12 ' A' ' 30' ' ' ILE . 96.4 m-85 -71.2 130.83 42.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.295 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.56 -65.4 0.55 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -137.19 122.68 19.6 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -1.204 . . . . 0.0 109.675 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.441 ' CG2' HG21 ' A' ' 71' ' ' VAL . 8.2 p -92.53 136.0 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.34 -0.85 . . . . 0.0 109.145 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.54 ' SD ' ' CH2' ' A' ' 9' ' ' TRP . 97.2 mtp -125.12 117.42 23.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.192 -0.942 . . . . 0.0 109.768 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.518 ' O ' ' CG1' ' A' ' 44' ' ' VAL . 12.0 p -135.06 81.83 44.07 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.323 -0.861 . . . . 0.0 109.099 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.13 130.52 20.26 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.79 2.327 . . . . 0.0 111.98 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 55.8 p -124.68 -0.52 8.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.494 ' HB2' ' CD2' ' A' ' 115' ' ' LEU . 85.4 tt0 50.83 86.0 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.244 -0.91 . . . . 0.0 109.639 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -58.99 137.45 57.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.258 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.4 p -131.43 137.93 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.162 -0.961 . . . . 0.0 109.733 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.69 154.11 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.343 -0.848 . . . . 0.0 109.327 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.465 ' OE2' ' HA2' ' A' ' 55' ' ' GLY . 83.4 tt0 -119.62 156.75 29.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.922 . . . . 0.0 109.601 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.463 HG22 ' HG3' ' A' ' 53' ' ' ARG . 56.5 mt -142.72 109.56 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.416 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.463 ' HG3' HG22 ' A' ' 52' ' ' ILE . 77.1 mtp180 64.07 135.4 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.267 -0.896 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 93.84 -175.42 35.38 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.465 ' HA2' ' OE2' ' A' ' 51' ' ' GLU . . . 167.16 178.97 39.85 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -126.24 149.17 49.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.193 -1.181 . . . . 0.0 109.449 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -57.46 -35.15 69.77 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -127.38 143.48 51.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.921 . . . . 0.0 109.494 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tptp -82.5 131.84 35.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.903 . . . . 0.0 109.499 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 32.1 t -127.55 139.09 52.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 109.505 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.503 ' OE1' ' CE ' ' A' ' 63' ' ' LYS . 98.9 mt-10 -117.15 135.99 53.35 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.245 -0.909 . . . . 0.0 109.376 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.484 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 75.3 mtm180 -71.78 -44.99 63.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.219 -0.925 . . . . 0.0 109.519 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.503 ' CE ' ' OE1' ' A' ' 61' ' ' GLU . 75.7 mmtt 46.7 63.33 1.95 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.484 ' CZ ' ' HD2' ' A' ' 62' ' ' ARG . 70.2 m-85 -60.68 -36.16 78.07 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.416 ' HB3' ' HB2' ' A' ' 68' ' ' TYR . 13.4 m-85 -105.73 106.66 57.27 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.35 70.96 1.86 Allowed 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.694 2.263 . . . . 0.0 111.839 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . 74.73 45.48 21.92 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.416 ' HB2' ' HB3' ' A' ' 65' ' ' PHE . 1.3 m-85 -111.95 120.79 43.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.485 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 43' ' ' MET . 96.5 t -133.34 146.88 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -0.888 . . . . 0.0 109.577 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.58 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 1.2 mm? -105.03 131.0 53.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.886 . . . . 0.0 109.341 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.441 HG21 ' CG2' ' A' ' 42' ' ' VAL . 64.3 t -138.55 125.74 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 109.709 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.449 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.7 tt0 -78.8 119.58 22.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.826 . . . . 0.0 109.299 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.552 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 48.6 ttp -165.99 163.46 18.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.602 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.51 ' N ' ' HG2' ' A' ' 73' ' ' MET . 32.3 t -91.48 147.61 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.582 ' HE3' ' CD2' ' A' ' 10' ' ' TYR . 10.2 mmt -86.5 114.14 23.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.935 . . . . 0.0 109.653 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.511 ' ND2' HD23 ' A' ' 38' ' ' LEU . 51.1 p-10 -143.25 167.92 21.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.305 -0.872 . . . . 0.0 109.324 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.6 m-20 -66.36 -24.29 66.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.257 -0.902 . . . . 0.0 109.696 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -75.57 -70.26 0.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.235 -0.916 . . . . 0.0 109.526 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.462 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 12.4 p -56.07 -49.72 73.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.168 -0.957 . . . . 0.0 109.682 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.451 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.8 t90 -43.97 -44.93 7.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 33.0 m-70 -73.54 -32.01 63.96 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 109.484 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.522 ' CD2' ' HG3' ' A' ' 35' ' ' MET . 54.9 tp -63.07 -45.88 90.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.549 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 82.8 t -55.4 -45.64 78.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -62.95 -36.39 83.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.638 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 41.0 m -61.48 -38.89 88.95 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.133 -0.979 . . . . 0.0 109.471 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.511 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 38.5 t -51.73 126.14 31.14 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.289 -0.882 . . . . 0.0 109.531 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.467 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -71.17 156.36 59.55 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.69 2.26 . . . . 0.0 111.714 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 82.0 mtt-85 62.06 35.86 15.68 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.857 . . . . 0.0 109.672 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.511 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 8.2 p -129.09 128.31 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.158 -0.964 . . . . 0.0 109.571 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.48 ' CG ' ' HG2' ' A' ' 13' ' ' GLN . 92.4 mmm -71.96 -54.59 9.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.285 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 162.03 -148.01 14.87 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.549 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 5.3 m-85 -104.62 160.6 14.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -1.162 . . . . 0.0 109.499 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.514 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 17.3 mm -118.14 119.11 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.453 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.476 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -171.63 -143.57 4.11 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -71.98 -35.42 61.36 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.0 t -140.93 176.16 9.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.211 -1.17 . . . . 0.0 109.633 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 13.1 p -92.96 21.57 5.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.43 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -137.05 8.79 2.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.46 -0.775 . . . . 0.0 109.133 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -176.69 92.51 0.25 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.343 -0.848 . . . . 0.0 108.948 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.516 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 46.0 Cg_endo -68.48 120.78 7.71 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.688 2.259 . . . . 0.0 111.988 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -64.37 148.61 95.95 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.285 -0.884 . . . . 0.0 109.317 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.469 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 49.5 Cg_endo -70.07 153.28 67.68 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.68 2.253 . . . . 0.0 111.82 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 9' ' ' TRP . 26.1 pt -125.21 157.91 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.336 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.452 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 39.0 m -75.64 148.71 38.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.554 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -56.51 -40.8 75.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -58.15 -40.37 81.17 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -0.882 . . . . 0.0 109.417 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.452 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 93.3 mt-10 -56.03 -43.78 78.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.197 -0.939 . . . . 0.0 109.389 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.413 HG22 ' CG ' ' A' ' 9' ' ' TRP . 54.1 t -57.35 -37.83 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -0.902 . . . . 0.0 109.343 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -73.81 -34.1 64.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.326 -0.859 . . . . 0.0 109.367 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.39 -43.41 81.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.388 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.423 HG13 ' O ' ' A' ' 107' ' ' GLU . 89.7 mt -50.05 -50.09 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.454 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.3 mtp -60.13 -39.94 88.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.414 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -59.96 -40.79 90.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.43 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.476 ' O ' ' N ' ' A' ' 117' ' ' GLN . 65.2 mtt180 -56.16 -46.34 79.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.4 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.494 ' CD2' ' HB2' ' A' ' 47' ' ' GLU . 5.2 tp -44.13 -48.56 9.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -0.922 . . . . 0.0 109.438 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -66.46 -25.49 66.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.875 . . . . 0.0 109.49 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.476 ' N ' ' O ' ' A' ' 114' ' ' ARG . 58.0 tp60 -86.02 141.16 29.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.265 -0.897 . . . . 0.0 109.379 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 39.6 t -125.65 151.27 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.446 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -53.38 -37.03 54.72 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.432 ' OD1' ' HG2' ' A' ' 122' ' ' PRO . 56.6 t0 -152.19 94.11 1.9 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -1.107 . . . . 0.0 109.449 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.508 ' N ' ' HD2' ' A' ' 122' ' ' PRO . 0.0 OUTLIER -46.59 -58.85 5.97 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.517 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 121' ' ' LYS . 49.7 Cg_endo -70.11 145.77 56.06 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.661 2.24 . . . . 0.0 111.815 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.452 ' HG2' ' OXT' ' A' ' 123' ' ' ARG . 67.1 ttt180 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.407 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.6 mtp . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.282 0.563 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.0 m -64.39 152.65 40.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.472 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -60.99 -33.45 73.25 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.493 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.44 144.76 61.83 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.29 -0.881 . . . . 0.0 109.428 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.56 147.27 63.77 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.751 2.3 . . . . 0.0 111.817 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -90.91 28.68 1.5 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.278 -0.889 . . . . 0.0 109.431 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.429 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 80.1 mttt -93.53 134.94 35.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.283 -0.885 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.531 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 51.3 mtt85 -117.27 156.01 28.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.19 -0.944 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.466 ' O ' HG12 ' A' ' 103' ' ' ILE . 83.7 m95 -87.78 128.06 35.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.587 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.618 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 91.2 m-85 -121.18 160.67 23.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.912 . . . . 0.0 109.542 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.489 HG11 ' CD1' ' A' ' 93' ' ' ILE . 21.1 t -95.13 154.64 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.207 -0.933 . . . . 0.0 109.588 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.44 115.94 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.302 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.519 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 78.4 mt-30 -81.01 150.47 28.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.692 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -157.56 158.42 35.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 109.405 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.452 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.7 m-85 -62.44 143.97 56.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 34.0 t -67.78 147.34 52.72 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.25 -33.52 4.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.451 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.5 m-85 -108.07 10.66 28.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -1.139 . . . . 0.0 109.476 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.517 ' OE2' ' CB ' ' A' ' 46' ' ' THR . 20.9 pt-20 -61.15 -36.78 80.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.433 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.81 -50.02 38.54 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.0 ttt85 -63.77 -37.48 87.51 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -1.144 . . . . 0.0 109.424 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 18' ' ' PHE . 50.3 t -52.21 -41.67 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -0.934 . . . . 0.0 109.271 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.16 -48.93 79.8 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.298 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 78.7 m -59.39 -46.39 88.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.39 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.421 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.9 m -51.3 -44.79 61.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.295 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.472 ' O ' HG12 ' A' ' 30' ' ' ILE . 47.5 mt -51.29 -69.68 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.36 -0.838 . . . . 0.0 109.388 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HA ' HG12 ' A' ' 30' ' ' ILE . 48.6 ttt85 -42.78 -42.81 3.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.386 -0.821 . . . . 0.0 109.72 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -55.78 -37.81 69.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.208 -0.932 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.432 ' N ' ' O ' ' A' ' 26' ' ' LEU . 93.3 m-70 -79.85 -27.28 40.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.274 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.643 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 11.8 mm -64.01 -43.45 97.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.302 -0.874 . . . . 0.0 109.321 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -70.38 -36.41 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 39.4 mt -70.61 -55.75 8.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.335 -0.853 . . . . 0.0 109.472 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.497 ' CG ' HD12 ' A' ' 82' ' ' LEU . 93.0 m-70 -81.18 4.82 18.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.195 -0.941 . . . . 0.0 109.559 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.6 t30 50.09 46.64 24.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.19 -0.944 . . . . 0.0 109.517 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.492 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 40.3 mmm -100.05 14.99 28.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.357 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.533 ' HA ' ' CG2' ' A' ' 30' ' ' ILE . 99.4 mt-10 -52.49 -31.31 34.5 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.276 -0.89 . . . . 0.0 109.492 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -60.34 -42.38 95.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.216 -0.927 . . . . 0.0 109.507 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.501 HD22 ' CG1' ' A' ' 74' ' ' VAL . 2.4 mt -74.06 -53.97 8.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.351 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.643 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 94.2 m-85 -69.99 130.0 41.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.29 -64.27 0.48 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -138.93 146.34 40.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.164 -1.198 . . . . 0.0 109.525 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.479 ' CG1' HG22 ' A' ' 71' ' ' VAL . 48.2 t -111.12 153.83 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.5 ' CE ' ' SD ' ' A' ' 112' ' ' MET . 89.5 mtp -123.62 143.81 50.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.499 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.41 ' CG1' HG21 ' A' ' 46' ' ' THR . 46.7 t -139.87 94.06 9.2 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.152 -0.967 . . . . 0.0 109.428 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.447 ' HB2' HD11 ' A' ' 115' ' ' LEU . 49.4 Cg_endo -70.03 -24.05 28.86 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.636 2.224 . . . . 0.0 111.699 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.517 ' CB ' ' OE2' ' A' ' 19' ' ' GLU . 9.3 t -71.68 64.15 0.45 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.506 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -61.82 -38.16 87.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.912 . . . . 0.0 109.371 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -108.31 151.78 25.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.406 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 39.6 t -118.07 137.02 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.162 -0.961 . . . . 0.0 109.556 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.446 ' O ' HG23 ' A' ' 50' ' ' VAL . 34.3 m -61.4 140.25 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.302 -0.874 . . . . 0.0 109.424 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 51.7 tt0 -95.41 145.29 25.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 109.447 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 22.9 pt -66.34 -17.07 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.397 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 16.5 ptt180 -152.44 169.53 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.448 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 96.44 175.55 35.74 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.56 147.01 10.39 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -122.96 147.2 46.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.288 -1.125 . . . . 0.0 109.489 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -56.65 -38.08 71.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.261 -0.899 . . . . 0.0 109.469 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 68.9 mtm-85 -58.6 -32.66 69.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.915 . . . . 0.0 109.489 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 8.7 tptp -65.81 130.88 44.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.152 -0.967 . . . . 0.0 109.471 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.4 m -65.12 154.23 38.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.513 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.0 mm-40 -120.4 155.27 33.78 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.571 ' HB2' ' CE2' ' A' ' 64' ' ' PHE . 9.3 mtt85 -118.57 147.45 43.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -80.8 128.24 33.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.198 -0.939 . . . . 0.0 109.42 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.571 ' CE2' ' HB2' ' A' ' 62' ' ' ARG . 98.6 m-85 -124.08 154.86 39.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.413 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.48 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 7.2 p90 -117.67 80.79 14.05 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 0.0 109.575 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.52 150.59 63.83 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.654 2.236 . . . . 0.0 111.625 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.08 4.59 61.27 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -115.36 119.18 35.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -1.174 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 93.4 t -133.27 138.39 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.219 -0.926 . . . . 0.0 109.591 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.576 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.1 mp -108.22 131.03 55.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.311 -0.868 . . . . 0.0 109.337 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.479 HG22 ' CG1' ' A' ' 42' ' ' VAL . 86.3 t -138.42 120.58 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.702 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.469 ' O ' ' HB2' ' A' ' 73' ' ' MET . 36.4 tt0 -69.15 135.55 50.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.228 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.571 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 52.8 ttp 172.94 156.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.99 . . . . 0.0 109.66 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.506 ' N ' ' HG2' ' A' ' 73' ' ' MET . 13.9 p -88.96 134.91 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.284 -0.885 . . . . 0.0 109.36 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.618 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 24.6 mmm -79.33 116.94 19.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.248 -0.907 . . . . 0.0 109.469 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.519 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 49.5 p-10 -143.43 171.03 14.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.227 -0.921 . . . . 0.0 109.468 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.556 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.1 m-20 -59.76 -33.3 71.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.462 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -72.02 -70.96 0.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.506 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 6.7 m -52.76 -51.82 59.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.422 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.519 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 29.8 t90 -44.57 -46.65 10.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.312 -0.868 . . . . 0.0 109.593 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.556 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 34.7 m-70 -70.39 -36.38 74.06 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.928 . . . . 0.0 109.422 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.497 HD12 ' CG ' ' A' ' 33' ' ' HIS . 3.0 tp -53.34 -45.01 68.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.952 . . . . 0.0 109.461 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.435 ' HA ' HG22 ' A' ' 86' ' ' VAL . 11.6 t -62.02 -31.77 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.405 -0.81 . . . . 0.0 109.591 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 80' ' ' TRP . 40.5 mtt-85 -70.98 -33.2 70.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.934 . . . . 0.0 109.407 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.9 p -79.7 -20.22 47.04 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.297 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 89' ' ' VAL . 88.5 t -67.29 127.33 93.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.343 -0.848 . . . . 0.0 109.326 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.21 153.06 67.22 Favored 'Trans proline' 0 C--O 1.214 -0.708 0 C-N-CA 122.687 2.258 . . . . 0.0 111.853 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 33.7 mtt85 63.09 47.34 4.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.605 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 86' ' ' VAL . 69.1 t -127.33 123.44 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 109.527 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.519 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 85.5 mtp -78.16 -50.72 11.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.41 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 164.07 -160.87 33.84 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.444 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 6.7 m-85 -109.57 160.52 16.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -1.154 . . . . 0.0 109.667 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.489 ' CD1' HG11 ' A' ' 11' ' ' VAL . 3.7 mt -117.51 134.16 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.339 -0.851 . . . . 0.0 109.251 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 168.22 -142.22 7.32 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.25 -50.75 42.9 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.0 p -126.77 179.13 5.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -1.163 . . . . 0.0 109.587 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.47 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 25.6 p -94.38 22.54 5.97 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.261 -0.899 . . . . 0.0 109.309 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 97' ' ' SER . 92.2 m-20 -137.0 6.42 2.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.476 -0.765 . . . . 0.0 109.459 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER -170.88 95.72 0.44 Allowed Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.292 -0.88 . . . . 0.0 109.019 -179.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.525 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.5 Cg_endo -68.5 116.78 4.57 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.79 2.327 . . . . 0.0 111.947 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.27 148.51 98.46 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.327 -0.858 . . . . 0.0 109.302 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.531 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.9 Cg_endo -69.43 153.15 70.82 Favored 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 122.688 2.259 . . . . 0.0 111.777 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.466 HG12 ' O ' ' A' ' 9' ' ' TRP . 29.3 pt -126.62 160.05 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.9 m -74.89 153.06 38.81 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.936 . . . . 0.0 109.348 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -62.4 -33.36 74.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 18.7 tttp -61.58 -35.65 78.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.868 . . . . 0.0 109.475 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 -63.28 -40.69 98.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.434 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.513 ' CG1' HD22 ' A' ' 70' ' ' LEU . 76.0 t -65.81 -36.62 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -0.94 . . . . 0.0 109.361 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -68.45 -31.16 70.27 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.301 -0.875 . . . . 0.0 109.515 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.57 -40.12 84.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.473 HG21 HD13 ' A' ' 111' ' ' ILE . 54.8 mt -55.41 -51.46 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 109.415 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.5 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 86.2 mtp -60.71 -35.76 77.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -0.912 . . . . 0.0 109.372 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -58.72 -31.75 68.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.435 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -58.56 -43.34 89.3 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.447 HD11 ' HB2' ' A' ' 45' ' ' PRO . 97.7 mt -56.02 -42.65 76.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.664 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -66.17 -28.41 68.75 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.15 -0.969 . . . . 0.0 109.549 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.401 ' C ' HG23 ' A' ' 118' ' ' VAL . 58.8 tt0 -71.07 135.74 47.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.515 ' CG1' ' HG2' ' A' ' 62' ' ' ARG . 6.7 t -129.9 151.53 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.42 -25.09 48.38 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -119.03 152.41 36.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.259 -1.142 . . . . 0.0 109.486 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.19 74.24 49.73 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.243 -0.911 . . . . 0.0 109.414 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.69 -17.63 37.76 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.69 2.26 . . . . 0.0 111.9 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.472 179.958 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.4 mtp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.3 m -58.56 -33.01 69.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.437 ' O ' ' O ' ' A' ' 4' ' ' ALA . 96.8 mt-10 46.44 25.77 0.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.437 ' O ' ' O ' ' A' ' 3' ' ' GLU . . . 62.06 139.96 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.25 140.46 40.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.659 2.24 . . . . 0.0 111.803 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -90.65 131.41 36.37 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.89 . . . . 0.0 109.377 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.404 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 36.3 mttm -92.95 140.17 29.76 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.193 -0.942 . . . . 0.0 109.497 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 79.1 mtt85 -125.95 154.17 43.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.259 -0.9 . . . . 0.0 109.467 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.428 ' CZ3' ' HG3' ' A' ' 43' ' ' MET . 90.1 m95 -91.0 130.11 36.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.211 -0.931 . . . . 0.0 109.502 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.459 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 93.3 m-85 -123.63 154.33 39.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.498 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 53.2 t -90.98 148.24 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.506 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -126.5 122.07 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.219 -0.926 . . . . 0.0 109.404 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.494 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 48.6 tt0 -84.9 133.71 34.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.211 -0.931 . . . . 0.0 109.432 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.39 161.88 36.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.481 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.4 m-85 -70.38 145.64 50.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.887 . . . . 0.0 109.544 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.9 t -60.32 139.31 57.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.458 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.67 -30.28 6.66 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.451 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 10.3 m-85 -103.69 8.52 37.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -1.129 . . . . 0.0 109.517 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.513 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 67.0 tt0 -53.08 -29.72 32.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.62 -55.44 2.04 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -55.91 -34.53 65.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.239 -1.153 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 54.9 t -58.82 -38.18 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.326 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.92 -34.32 77.86 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.483 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 42.5 m -63.38 -32.94 74.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.928 . . . . 0.0 109.426 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.405 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 28.6 m -65.17 -32.57 74.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.472 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.454 ' O ' HG13 ' A' ' 30' ' ' ILE . 59.3 mt -60.77 -44.93 96.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.462 ' O ' ' HB2' ' A' ' 31' ' ' LYS . 74.2 ttt180 -58.03 -41.46 83.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 109.654 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -69.01 -60.37 2.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.243 -0.911 . . . . 0.0 109.596 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.513 ' NE2' ' HD2' ' A' ' 87' ' ' PRO . 91.0 m-70 -54.77 -47.09 74.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.219 -0.925 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.58 HG12 ' CE1' ' A' ' 39' ' ' PHE . 87.4 mt -66.21 -44.67 91.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -0.876 . . . . 0.0 109.634 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 27' ' ' ARG . 15.3 ttpp -59.27 -41.47 88.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 45.8 mt -70.63 -52.67 19.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.324 -0.86 . . . . 0.0 109.41 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.448 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 99.0 m-70 -74.79 -6.97 51.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.9 . . . . 0.0 109.391 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.499 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.0 m-20 61.42 46.15 7.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.505 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 45.3 mmm -91.87 -2.32 56.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.605 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.443 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.2 mt-10 -44.28 -38.81 4.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -52.13 -43.11 63.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.347 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.463 ' CD2' ' ND2' ' A' ' 76' ' ' ASN . 1.1 mt -73.01 -43.98 61.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.37 -0.831 . . . . 0.0 109.336 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CE1' HG12 ' A' ' 30' ' ' ILE . 96.2 m-85 -73.19 137.32 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.282 -0.886 . . . . 0.0 109.427 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.78 -66.69 0.52 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.405 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 82.6 tt0 -136.68 152.04 49.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.567 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.521 ' CG1' HG21 ' A' ' 71' ' ' VAL . 48.1 t -117.51 147.61 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.29 -0.881 . . . . 0.0 109.359 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.512 ' CE ' ' HE2' ' A' ' 112' ' ' MET . 90.6 mtp -120.64 141.5 50.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.141 -0.974 . . . . 0.0 109.527 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.446 HG21 ' O ' ' A' ' 43' ' ' MET . 53.0 t -149.83 92.09 4.2 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.241 -0.912 . . . . 0.0 109.436 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.572 ' HG3' ' CE2' ' A' ' 65' ' ' PHE . 51.0 Cg_endo -70.25 -5.58 16.84 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.624 2.216 . . . . 0.0 111.792 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.469 ' HB ' ' NH1' ' A' ' 62' ' ' ARG . 3.7 p -82.12 156.72 24.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 47.72 64.46 1.61 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.54 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -59.48 -34.63 72.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 0.0 109.452 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 36.7 t -119.26 131.22 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.269 -0.894 . . . . 0.0 109.455 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 71.1 t -72.66 -28.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.218 -0.926 . . . . 0.0 109.349 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -65.31 -46.97 78.2 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 30.8 mm -121.46 96.96 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.277 -0.889 . . . . 0.0 109.436 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 74.4 mtp85 -46.54 -37.39 7.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.309 -0.87 . . . . 0.0 109.679 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 99.59 -169.68 22.56 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.84 51.01 4.4 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -56.46 -38.76 72.11 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -1.128 . . . . 0.0 109.646 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -63.73 146.63 53.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.917 . . . . 0.0 109.525 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 96.2 mtt-85 -58.41 -34.88 71.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.46 ' O ' ' HG3' ' A' ' 61' ' ' GLU . 97.5 mttt -57.35 -36.02 70.67 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.279 -0.888 . . . . 0.0 109.416 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.404 ' C ' ' O ' ' A' ' 59' ' ' LYS . 24.8 m 45.46 38.59 3.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.865 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.46 ' HG3' ' O ' ' A' ' 59' ' ' LYS . 94.9 mt-10 -102.48 157.54 16.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.211 -0.93 . . . . 0.0 109.403 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.469 ' NH1' ' HB ' ' A' ' 46' ' ' THR . 71.6 mtt85 -116.02 85.8 2.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -63.11 -27.44 69.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.298 -0.876 . . . . 0.0 109.454 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -66.99 -39.03 87.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.536 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 45' ' ' PRO . 81.4 m-85 -134.47 74.11 66.86 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.545 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -71.03 72.42 2.07 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.643 2.229 . . . . 0.0 111.902 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.36 26.19 59.92 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.507 ' OH ' ' CG2' ' A' ' 93' ' ' ILE . 1.7 m-85 -109.68 126.27 53.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -1.154 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.513 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 86.3 t -134.15 142.72 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.388 -0.82 . . . . 0.0 109.505 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.57 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.8 mp -103.91 132.53 50.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.471 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.521 HG21 ' CG1' ' A' ' 42' ' ' VAL . 88.0 t -143.77 122.06 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.263 -0.898 . . . . 0.0 109.557 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.404 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 43.1 tt0 -78.36 130.33 36.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.224 -0.923 . . . . 0.0 109.187 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.57 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 41.1 ttp -162.67 154.67 18.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.502 ' N ' ' HG2' ' A' ' 73' ' ' MET . 59.2 t -69.81 151.19 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -0.948 . . . . 0.0 109.224 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.534 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -94.33 112.97 24.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 109.496 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.463 ' ND2' ' CD2' ' A' ' 38' ' ' LEU . 42.0 p-10 -148.51 169.17 20.86 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.573 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 86.2 m-20 -72.38 -31.22 65.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -63.48 -61.45 2.33 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.513 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.462 ' CB ' ' OD1' ' A' ' 76' ' ' ASN . 17.4 p -53.36 -48.07 68.87 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.275 -0.891 . . . . 0.0 109.753 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.517 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 39.1 t90 -44.03 -49.32 8.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.888 . . . . 0.0 109.581 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 89.8 m-70 -67.87 -39.38 83.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.206 -0.934 . . . . 0.0 109.471 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.505 ' CD1' ' HG3' ' A' ' 35' ' ' MET . 0.4 OUTLIER -56.92 -45.2 82.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.726 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 78.0 t -62.48 -48.43 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.507 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 23.7 mtp85 -62.45 -37.24 85.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.57 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -66.63 -26.75 67.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -0.948 . . . . 0.0 109.491 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.44 HG13 HD22 ' A' ' 26' ' ' LEU . 56.5 t -65.4 129.66 94.46 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.513 ' HD2' ' NE2' ' A' ' 29' ' ' HIS . 49.7 Cg_endo -70.17 161.03 47.48 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.703 2.269 . . . . 0.0 111.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.481 ' HA ' ' CD2' ' A' ' 15' ' ' PHE . 93.0 mtt-85 61.51 35.76 17.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.432 HG21 ' HB ' ' A' ' 86' ' ' VAL . 91.5 t -129.39 115.51 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.288 -0.882 . . . . 0.0 109.566 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.494 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 84.3 mtp -69.97 -43.43 71.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.177 -0.952 . . . . 0.0 109.471 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.57 -146.99 14.03 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.454 ' HB3' ' HB3' ' A' ' 100' ' ' PRO . 51.6 m-85 -107.45 163.08 13.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.292 -1.122 . . . . 0.0 109.574 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.507 ' CG2' ' OH ' ' A' ' 68' ' ' TYR . 31.9 mm -119.4 124.22 72.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 109.337 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . . . 147.87 -141.12 8.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' GLY . . . -43.43 -89.36 0.01 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 18.9 p -123.7 -179.33 4.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.297 -1.12 . . . . 0.0 109.652 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 m -90.9 22.03 3.84 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.338 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.517 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 91.4 m-20 -118.49 -23.52 7.13 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.41 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 3.3 mtm180 -155.98 96.86 2.3 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.534 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 42.2 Cg_endo -65.13 119.99 7.13 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.865 2.376 . . . . 0.0 112.135 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.97 141.85 97.75 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.436 -0.79 . . . . 0.0 109.482 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.33 154.49 61.16 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.706 2.271 . . . . 0.0 111.854 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.483 ' CD1' ' CG2' ' A' ' 108' ' ' VAL . 34.0 pt -124.57 158.16 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.874 . . . . 0.0 109.378 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.454 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 42.2 m -69.51 148.18 49.83 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.916 . . . . 0.0 109.439 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.41 -37.74 78.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.399 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -61.3 -38.77 87.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.454 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 98.5 mt-10 -59.88 -42.21 93.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.483 ' CG2' ' CD1' ' A' ' 103' ' ' ILE . 78.3 t -61.61 -36.99 76.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.377 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -69.7 -33.24 72.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.405 ' HA ' ' OD1' ' A' ' 113' ' ' ASN . . . -65.69 -39.67 91.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.44 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.501 ' CD1' HD22 ' A' ' 70' ' ' LEU . 56.2 mt -56.84 -52.25 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.525 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.512 ' HE2' ' CE ' ' A' ' 43' ' ' MET . 53.7 ttm -61.45 -38.18 86.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.405 ' OD1' ' HA ' ' A' ' 110' ' ' ALA . 23.4 m120 -53.31 -37.72 62.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.42 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -51.33 -49.99 60.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.544 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 12.1 tp -47.78 -44.33 28.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.319 -0.863 . . . . 0.0 109.393 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -63.24 -26.99 69.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.384 -0.822 . . . . 0.0 109.525 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -77.44 128.34 34.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' A' ' 120' ' ' ASP . 37.0 t -118.69 133.1 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -0.92 . . . . 0.0 109.437 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -46.67 95.35 0.01 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 118' ' ' VAL . 51.6 p30 -89.2 9.46 25.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -1.164 . . . . 0.0 109.441 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -64.69 136.82 96.93 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.28 -19.69 38.06 Favored 'Trans proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.706 2.271 . . . . 0.0 111.917 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 54.9 mtt-85 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.482 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.9 mtp . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.299 0.571 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.5 t -121.29 138.67 54.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.19 -35.47 67.3 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 109.427 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.17 89.7 51.56 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.907 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.3 146.89 58.13 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.692 2.261 . . . . 0.0 111.774 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -79.81 136.7 36.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.169 -0.957 . . . . 0.0 109.5 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -103.76 146.89 27.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.443 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 63.4 mtt180 -116.99 153.08 33.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.454 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.538 ' CG ' HG23 ' A' ' 108' ' ' VAL . 82.5 m95 -99.69 131.97 45.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.47 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 62.5 m-85 -122.36 141.83 51.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.463 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.429 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.3 t -86.65 145.66 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.711 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -125.8 125.19 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 109.284 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.498 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 64.0 tp60 -87.58 131.96 34.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.609 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -139.33 164.82 28.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.324 -0.86 . . . . 0.0 109.418 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -68.61 140.34 55.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 109.448 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.8 m -66.57 149.42 50.49 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.307 -0.87 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.63 -33.28 4.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -109.45 8.46 25.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.18 -1.188 . . . . 0.0 109.506 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.76 -39.34 73.84 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.62 -52.29 44.21 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 56.7 ttt-85 -62.62 -38.74 91.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -1.149 . . . . 0.0 109.491 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 88' ' ' ARG . 79.7 t -56.01 -39.88 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.424 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.08 -37.88 89.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.267 -0.896 . . . . 0.0 109.413 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.5 m -65.16 -38.94 92.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.223 -0.923 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.565 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 97.1 p -60.02 -38.42 82.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.462 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.413 ' O ' HG13 ' A' ' 30' ' ' ILE . 44.4 mt -56.66 -49.45 75.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -0.871 . . . . 0.0 109.469 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttp85 -65.79 -37.06 85.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.515 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.457 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 80.1 tt0 -66.27 -44.76 82.68 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.26 -0.9 . . . . 0.0 109.499 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.565 ' CD2' ' O ' ' A' ' 25' ' ' SER . 94.9 m-70 -71.82 -51.5 22.2 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.457 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.55 HD11 ' CD2' ' A' ' 39' ' ' PHE . 83.4 mt -56.91 -45.3 83.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.917 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 39.8 tttt -56.59 -48.46 77.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -0.904 . . . . 0.0 109.465 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.457 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 48.6 mt -64.84 -51.24 63.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.934 . . . . 0.0 109.45 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.537 ' CD2' HD13 ' A' ' 82' ' ' LEU . 97.8 m-70 -74.86 -2.08 25.2 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.241 -0.912 . . . . 0.0 109.575 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.466 ' N ' ' O ' ' A' ' 30' ' ' ILE . 55.2 t30 55.0 45.44 26.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -0.927 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.492 ' CA ' HD22 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.66 5.17 47.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.521 179.982 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.507 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.9 mt-10 -61.02 -16.95 49.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 109.447 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -62.26 -40.57 96.64 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.292 -0.88 . . . . 0.0 109.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.492 HD22 ' CA ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -86.37 -31.39 21.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.353 179.887 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.55 ' CD2' HD11 ' A' ' 30' ' ' ILE . 42.6 m-85 -76.44 132.08 39.44 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -96.67 -78.12 1.39 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.8 tp10 -139.44 136.53 34.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.519 ' CG2' HG21 ' A' ' 71' ' ' VAL . 10.0 p -97.79 143.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.265 -0.897 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.454 ' HE2' HG11 ' A' ' 108' ' ' VAL . 58.3 mtt -108.53 141.21 40.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 47.8 t -137.35 83.83 25.37 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.39 57.27 1.75 Allowed 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 122.684 2.256 . . . . 0.0 111.779 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.2 p -132.97 162.45 31.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -90.98 138.75 31.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.18 -0.95 . . . . 0.0 109.494 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -65.11 -33.7 76.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.6 p -134.57 147.15 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 0.0 109.406 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 23.6 m -122.81 156.26 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.494 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.48 ' OE2' ' NE ' ' A' ' 53' ' ' ARG . 86.0 tt0 -106.68 130.81 54.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 0.0 109.48 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 80.4 mt -66.96 -38.01 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.477 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.48 ' NE ' ' OE2' ' A' ' 51' ' ' GLU . 71.9 mtm-85 -60.2 152.15 25.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -0.869 . . . . 0.0 109.474 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 102.74 -6.97 52.68 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 171.92 177.09 41.27 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.447 ' O ' ' O ' ' A' ' 59' ' ' LYS . 94.5 mm-40 -122.88 153.07 40.13 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.31 -1.112 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.7 mtp85 -60.8 -30.15 69.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.436 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.4 tpt85 -62.75 -38.15 89.4 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.447 ' O ' ' O ' ' A' ' 56' ' ' GLN . 40.4 tttt -127.9 131.52 49.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.5 t -106.54 137.23 44.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.224 -0.923 . . . . 0.0 109.523 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 85.9 mt-10 -122.15 47.2 1.95 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.393 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -120.49 142.14 49.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -0.851 . . . . 0.0 109.507 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -97.73 9.9 41.43 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.328 -0.857 . . . . 0.0 109.637 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.467 ' CE1' ' CD1' ' A' ' 115' ' ' LEU . 61.6 m-85 -66.65 155.7 37.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.423 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.505 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 9.7 p90 -117.49 81.52 14.29 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.83 155.85 64.66 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.682 2.255 . . . . 0.0 111.764 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.45 1.58 47.14 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.432 ' CZ ' ' OE1' ' A' ' 13' ' ' GLN . 7.2 m-85 -121.74 122.68 40.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.282 -1.128 . . . . 0.0 109.388 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.31 142.65 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.913 . . . . 0.0 109.514 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.565 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.6 mp -102.77 129.13 49.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.872 . . . . 0.0 109.428 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.519 HG21 ' CG2' ' A' ' 42' ' ' VAL . 56.7 t -137.43 127.35 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 41.6 tt0 -84.22 138.75 32.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.284 -0.885 . . . . 0.0 109.32 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.516 ' HB2' ' CD1' ' A' ' 39' ' ' PHE . 6.1 tmm? -177.89 149.09 0.56 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.485 ' CG1' ' HB2' ' A' ' 38' ' ' LEU . 7.4 p -75.03 122.87 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.186 -0.946 . . . . 0.0 109.458 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.511 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -52.82 112.97 0.94 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.682 -179.824 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.421 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 48.1 p-10 -146.2 161.79 39.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.371 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.488 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.2 m-20 -72.37 -27.48 62.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.185 -0.947 . . . . 0.0 109.466 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -62.52 -62.94 1.4 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.436 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 24.3 p -53.7 -51.43 63.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.263 -0.898 . . . . 0.0 109.56 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 30.7 t90 -44.31 -55.84 4.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.551 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.488 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 87.7 m-70 -59.7 -40.79 89.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.521 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.537 HD13 ' CD2' ' A' ' 33' ' ' HIS . 65.1 tp -60.3 -36.45 77.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.262 -0.899 . . . . 0.0 109.657 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.446 ' CG2' ' CE2' ' A' ' 92' ' ' PHE . 74.1 t -61.6 -44.69 99.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.525 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 48.5 tpt85 -57.92 -40.81 81.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.4 p -64.45 -27.53 69.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.459 ' HB ' HG22 ' A' ' 89' ' ' VAL . 79.1 t -61.84 123.18 76.29 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.4 150.42 64.28 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.602 2.202 . . . . 0.0 111.769 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.463 ' O ' HG23 ' A' ' 22' ' ' VAL . 31.8 mtt-85 62.05 51.11 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.184 -0.947 . . . . 0.0 109.434 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.459 HG22 ' HB ' ' A' ' 86' ' ' VAL . 66.9 t -126.3 116.84 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.488 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.498 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.9 mmm -65.57 -45.66 82.45 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.42 -148.32 18.67 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.446 ' CE2' ' CG2' ' A' ' 83' ' ' VAL . 3.6 m-85 -117.84 164.49 14.95 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.238 -1.154 . . . . 0.0 109.54 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.429 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 9.2 mm -121.76 120.89 62.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.355 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 177.88 -144.13 6.4 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.27 -43.84 37.16 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 p -129.39 174.34 9.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.264 -1.139 . . . . 0.0 109.549 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 72.3 m -89.86 17.89 6.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -0.964 . . . . 0.0 109.369 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.7 m-20 -127.84 -30.73 2.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.518 -0.739 . . . . 0.0 109.273 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -134.57 91.51 21.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.309 -0.869 . . . . 0.0 108.916 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.511 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.6 Cg_endo -67.86 116.66 4.41 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.634 2.223 . . . . 0.0 112.001 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.42 146.5 79.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.443 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 50.0 Cg_endo -70.14 154.58 66.1 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.7 2.267 . . . . 0.0 111.759 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.416 HD11 HG21 ' A' ' 108' ' ' VAL . 28.7 pt -118.02 158.36 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.46 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 44.2 m -70.66 152.27 44.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.33 -0.856 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -57.22 -38.67 74.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.212 -0.93 . . . . 0.0 109.359 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.62 -38.29 80.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.389 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -56.92 -45.77 82.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.315 -0.866 . . . . 0.0 109.408 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.538 HG23 ' CG ' ' A' ' 9' ' ' TRP . 96.4 t -60.07 -40.83 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.364 -0.835 . . . . 0.0 109.368 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -65.81 -36.76 84.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.399 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.88 -53.49 57.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 109.463 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.518 ' CD1' HD22 ' A' ' 70' ' ' LEU . 49.1 mt -48.03 -54.05 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.183 -0.948 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.2 mtp -60.7 -37.59 82.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.27 -0.894 . . . . 0.0 109.348 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -56.83 -41.93 78.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 109.401 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.405 ' O ' ' C ' ' A' ' 115' ' ' LEU . 51.9 mtt180 -53.34 -52.94 57.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.467 ' CD1' ' CE1' ' A' ' 64' ' ' PHE . 12.6 tp -45.44 -45.25 12.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.449 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 50.4 tt0 -60.82 -36.0 77.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.239 -0.913 . . . . 0.0 109.443 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -60.46 -34.6 74.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.469 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.9 t 58.21 16.93 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.385 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.49 -106.05 0.69 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 121' ' ' LYS . 61.9 t0 -144.23 152.72 41.23 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.296 -1.12 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.51 ' N ' ' OD1' ' A' ' 120' ' ' ASP . 7.0 ttmt -121.39 68.48 20.33 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.52 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.77 146.07 59.01 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.688 2.259 . . . . 0.0 111.782 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 47.4 ttt85 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.5 -179.919 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.3 mtt . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.3 m -57.05 -35.57 69.47 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -59.29 140.72 55.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.486 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.92 161.34 77.99 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.12 147.34 60.32 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.732 2.288 . . . . 0.0 111.738 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 70.7 tttt -122.28 138.06 54.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 23.4 mmtp -90.61 135.11 33.92 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.154 -0.966 . . . . 0.0 109.449 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.471 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 93.6 mtt180 -125.38 152.94 44.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.375 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.472 ' CB ' HG22 ' A' ' 108' ' ' VAL . 85.6 m95 -96.4 129.38 43.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.541 ' CE1' ' HA ' ' A' ' 102' ' ' PRO . 64.0 m-85 -129.07 154.19 46.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.264 -0.898 . . . . 0.0 109.408 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.422 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 22.3 t -99.54 143.59 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.326 -0.858 . . . . 0.0 109.57 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -117.62 125.87 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.379 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.447 ' HG2' ' HB2' ' A' ' 90' ' ' MET . 52.3 tt0 -88.79 135.35 33.57 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.158 -0.964 . . . . 0.0 109.521 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.439 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -140.04 -165.24 1.86 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -104.55 139.8 38.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.186 -0.946 . . . . 0.0 109.468 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.2 m -56.61 150.87 14.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.03 -34.48 4.25 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.556 ' CG ' ' HD3' ' A' ' 88' ' ' ARG . 77.5 m-85 -118.98 10.18 12.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.309 -1.113 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.458 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.8 tt0 -58.02 -29.31 65.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.213 -0.929 . . . . 0.0 109.534 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -77.62 -53.05 5.2 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -59.63 -39.43 84.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -1.181 . . . . 0.0 109.46 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.453 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 99.0 t -50.5 -43.84 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.373 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.32 -41.52 85.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.469 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.9 m -64.62 -36.36 83.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.538 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 37.5 m -64.65 -37.78 88.74 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.954 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.476 ' O ' HG12 ' A' ' 30' ' ' ILE . 51.2 mt -53.77 -59.71 4.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -0.928 . . . . 0.0 109.579 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' LEU . 71.9 ttt180 -42.98 -51.11 5.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.852 . . . . 0.0 109.788 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.431 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 94.9 mt-10 -54.1 -41.79 68.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.138 -0.976 . . . . 0.0 109.503 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' A' ' 25' ' ' SER . 98.9 m-70 -66.96 -31.1 71.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.419 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.601 ' CD1' ' CD2' ' A' ' 39' ' ' PHE . 13.1 mm -67.32 -52.65 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.537 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.8 mttt -64.21 -43.38 95.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.262 -0.899 . . . . 0.0 109.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.431 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 27.3 mt -60.46 -51.16 70.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.527 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.622 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 92.6 m-70 -87.27 10.25 17.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.264 -0.898 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 18.1 m120 49.37 49.45 19.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.189 -0.944 . . . . 0.0 109.434 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.452 ' SD ' ' HB3' ' A' ' 33' ' ' HIS . 0.0 OUTLIER -106.48 21.21 17.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.425 -179.926 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 70.7 mm-40 -66.22 -12.53 56.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.199 -0.938 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.38 -52.67 24.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.288 -0.882 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.575 HD13 ' CE2' ' A' ' 39' ' ' PHE . 0.6 OUTLIER -75.96 -37.77 58.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.33 -0.856 . . . . 0.0 109.781 -179.825 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.601 ' CD2' ' CD1' ' A' ' 30' ' ' ILE . 52.0 m-85 -76.68 139.91 40.7 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.177 -0.952 . . . . 0.0 109.253 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.22 0.62 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.518 ' HG3' ' N ' ' A' ' 42' ' ' VAL . 45.9 tp10 -131.49 152.74 50.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -1.13 . . . . 0.0 109.569 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.525 HG22 ' CG1' ' A' ' 71' ' ' VAL . 91.9 t -119.42 154.43 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.289 -0.882 . . . . 0.0 109.383 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.485 ' HE3' ' CG1' ' A' ' 108' ' ' VAL . 61.2 mtm -135.68 145.11 46.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.1 t -122.98 121.52 27.24 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.211 -0.931 . . . . 0.0 109.546 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -70.25 -14.68 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.679 2.252 . . . . 0.0 111.876 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 7.6 p -91.52 158.19 16.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.213 -0.929 . . . . 0.0 109.588 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.94 145.94 45.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.502 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -118.91 148.32 43.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.242 -0.911 . . . . 0.0 109.468 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 46.9 t -127.35 127.26 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.474 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.404 ' O ' ' O ' ' A' ' 51' ' ' GLU . 12.2 t 45.9 25.05 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.337 -0.852 . . . . 0.0 109.585 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 50' ' ' VAL . 82.8 tt0 57.19 104.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.428 ' O ' ' CG2' ' A' ' 52' ' ' ILE . 14.0 tt -132.37 103.86 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.38 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 92.5 mtt-85 -47.52 148.35 1.44 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.523 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -139.69 168.26 25.04 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.05 -7.78 64.77 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -57.19 -35.12 69.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.166 -1.197 . . . . 0.0 109.445 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -121.55 149.54 42.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.528 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.9 mtm-85 -57.07 -31.0 64.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.536 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 73.5 tttt -68.76 133.13 47.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.912 . . . . 0.0 109.44 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -111.15 137.69 48.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.255 -0.903 . . . . 0.0 109.462 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -65.85 -31.2 72.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.37 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 94.4 mtt180 -127.66 132.01 49.76 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -108.32 28.98 7.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.399 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -107.1 129.56 54.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -0.865 . . . . 0.0 109.506 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 56.7 62.71 6.0 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.526 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.52 94.66 0.6 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.657 2.238 . . . . 0.0 111.777 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 76.6 32.23 51.46 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.458 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -111.58 116.03 30.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -1.141 . . . . 0.0 109.536 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 48.7 t -126.98 151.91 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.57 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.58 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.3 mp -108.05 129.02 55.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -0.93 . . . . 0.0 109.417 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.525 ' CG1' HG22 ' A' ' 42' ' ' VAL . 90.6 t -138.76 125.21 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.722 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.419 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 43.3 tt0 -78.12 120.14 22.52 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.248 -0.907 . . . . 0.0 109.08 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.578 ' HB2' ' CD1' ' A' ' 39' ' ' PHE . 8.0 tmm? -167.97 149.24 5.24 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -0.918 . . . . 0.0 109.569 -179.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 45.3 t -85.43 128.56 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.923 . . . . 0.0 109.163 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.532 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 11.7 mmt -64.72 107.69 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.705 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.488 ' OD1' ' N ' ' A' ' 79' ' ' SER . 53.0 p-10 -128.77 -179.66 5.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -75.09 -23.2 57.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.852 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -82.27 -67.11 0.81 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.201 -0.937 . . . . 0.0 109.621 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.488 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 6.3 p -49.62 -49.78 45.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 48.4 t90 -51.66 -59.56 4.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.351 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -58.95 -37.91 77.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.296 -0.878 . . . . 0.0 109.459 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.622 ' CD1' ' CD2' ' A' ' 33' ' ' HIS . 39.6 tp -63.61 -37.62 88.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.933 . . . . 0.0 109.401 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.518 HG11 ' CE2' ' A' ' 92' ' ' PHE . 54.8 t -56.92 -50.13 76.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.468 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -55.01 -41.54 71.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.2 t -57.08 -33.15 66.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.885 . . . . 0.0 109.497 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.458 ' O ' HG22 ' A' ' 89' ' ' VAL . 22.6 t -61.08 121.91 65.85 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.269 -0.895 . . . . 0.0 109.387 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.455 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -70.32 158.29 56.69 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.691 2.261 . . . . 0.0 111.777 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.556 ' HD3' ' CG ' ' A' ' 18' ' ' PHE . 8.9 mtt85 63.11 45.77 5.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.932 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 86' ' ' VAL . 96.8 t -130.92 118.89 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.172 -0.955 . . . . 0.0 109.549 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.447 ' HB2' ' HG2' ' A' ' 13' ' ' GLN . 85.9 mtp -68.83 -44.57 73.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -0.937 . . . . 0.0 109.404 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.71 -151.8 22.35 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.518 ' CE2' HG11 ' A' ' 83' ' ' VAL . 2.3 m-85 -111.8 164.25 13.27 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -1.203 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.422 ' HB ' ' HB ' ' A' ' 11' ' ' VAL . 20.9 mm -118.46 120.3 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.647 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.64 -149.76 9.17 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.46 -38.8 91.16 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.3 t -140.53 176.57 8.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -1.186 . . . . 0.0 109.47 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.8 p -92.62 17.99 9.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 109.414 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -121.72 -14.35 8.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.515 -0.741 . . . . 0.0 109.264 179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.42 99.24 1.25 Allowed Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.349 -0.844 . . . . 0.0 109.008 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.532 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 46.4 Cg_endo -68.09 120.51 7.49 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.706 2.27 . . . . 0.0 112.015 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -63.27 138.31 97.31 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.88 . . . . 0.0 109.39 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.541 ' HA ' ' CE1' ' A' ' 10' ' ' TYR . 51.2 Cg_endo -70.51 153.74 65.28 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.649 2.233 . . . . 0.0 111.765 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 108' ' ' VAL . 35.1 pt -124.32 156.23 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.438 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 32.3 m -71.97 151.11 43.49 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.311 -0.868 . . . . 0.0 109.423 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -54.76 -40.99 69.94 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.358 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -59.31 -38.64 80.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -58.86 -44.36 91.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.276 -0.89 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.485 ' CG1' ' HE3' ' A' ' 43' ' ' MET . 58.1 t -57.93 -39.33 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -66.42 -40.95 89.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.261 -0.899 . . . . 0.0 109.416 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -63.43 -44.63 94.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.428 HG13 ' O ' ' A' ' 107' ' ' GLU . 68.8 mt -52.48 -51.39 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.332 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.6 mtp -58.85 -38.3 78.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -56.88 -35.58 69.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.5 ' O ' ' N ' ' A' ' 117' ' ' GLN . 99.4 mtt180 -53.92 -44.68 70.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.229 -0.919 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.402 ' C ' ' O ' ' A' ' 114' ' ' ARG . 8.5 tp -44.05 -46.85 8.67 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.384 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -60.29 -26.64 66.67 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.228 -0.92 . . . . 0.0 109.503 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 114' ' ' ARG . 52.6 tt0 -83.27 126.31 32.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.454 HG11 ' OD2' ' A' ' 120' ' ' ASP . 26.5 t -65.42 -32.0 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.315 -0.865 . . . . 0.0 109.506 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 89.9 -3.49 82.9 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.454 ' OD2' HG11 ' A' ' 118' ' ' VAL . 89.9 m-20 -55.76 -39.79 71.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -1.18 . . . . 0.0 109.502 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.51 142.49 70.87 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.264 -0.898 . . . . 0.0 109.554 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.01 145.6 56.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.745 2.297 . . . . 0.0 111.753 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.445 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.0 mtp . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.4 t -56.99 -37.94 72.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.638 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -54.65 -36.81 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.228 -0.92 . . . . 0.0 109.525 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -121.59 107.52 36.33 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.314 -0.867 . . . . 0.0 109.515 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.83 139.19 39.37 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.682 2.255 . . . . 0.0 111.777 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.46 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 29.5 mttt -122.87 155.26 37.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -0.892 . . . . 0.0 109.489 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 8.6 mmtp 64.45 53.81 1.59 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.404 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.406 ' HD3' ' HA ' ' A' ' 8' ' ' ARG . 17.1 mmt85 -110.48 153.13 25.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.334 -0.854 . . . . 0.0 109.455 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.486 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 56.5 m95 -103.81 129.24 51.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.928 . . . . 0.0 109.506 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.424 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 87.1 m-85 -124.18 163.83 20.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.407 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.507 HG13 ' CG1' ' A' ' 93' ' ' ILE . 24.5 t -98.7 147.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.6 t -124.83 123.64 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.329 -0.857 . . . . 0.0 109.331 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.523 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 6.1 tt0 -90.8 137.83 32.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -145.45 159.98 42.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.488 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -67.9 143.26 55.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.164 -0.96 . . . . 0.0 109.56 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 46.0 m -59.14 147.62 34.44 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.44 -33.54 4.31 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.524 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 99.1 m-85 -107.22 5.21 27.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -1.149 . . . . 0.0 109.562 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.442 ' OE2' ' HG3' ' A' ' 45' ' ' PRO . 85.1 tt0 -53.55 -36.23 61.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.361 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.36 -58.64 3.08 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 45.4 ttm105 -56.5 -42.43 78.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.415 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 53.2 t -49.14 -47.57 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.351 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.81 -44.66 82.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.265 -0.897 . . . . 0.0 109.411 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -64.09 -45.52 88.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.389 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 50.8 m -52.03 -56.45 14.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.46 HD12 HG13 ' A' ' 86' ' ' VAL . 16.9 tp -48.15 -55.52 10.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.307 -0.871 . . . . 0.0 109.365 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HA ' HD11 ' A' ' 30' ' ' ILE . 25.2 ttt85 -53.74 -30.65 45.16 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.946 . . . . 0.0 109.136 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.453 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.9 tt0 -63.1 -44.45 95.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.309 -0.87 . . . . 0.0 109.36 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.567 ' CD2' ' HB ' ' A' ' 86' ' ' VAL . 74.3 m-70 -75.79 -33.92 60.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.574 HG12 ' CE2' ' A' ' 39' ' ' PHE . 79.8 mt -54.93 -48.83 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.283 -0.885 . . . . 0.0 109.292 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -60.26 -43.15 96.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.531 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.5 mt -64.2 -50.81 66.62 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.45 ' CD2' HD11 ' A' ' 82' ' ' LEU . 91.5 m-70 -82.15 3.1 28.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.244 -0.91 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.409 ' N ' ' O ' ' A' ' 30' ' ' ILE . 21.4 m120 59.4 50.62 7.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.338 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.555 ' CE ' ' CD1' ' A' ' 38' ' ' LEU . 68.5 mmm -99.58 3.92 45.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.29 -0.881 . . . . 0.0 109.706 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.471 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.2 mt-10 -54.89 -34.33 62.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.173 -0.954 . . . . 0.0 109.451 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -60.88 -42.47 98.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.894 . . . . 0.0 109.358 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.555 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.1 mt -70.88 -50.33 36.27 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.311 -0.868 . . . . 0.0 109.347 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.574 ' CE2' HG12 ' A' ' 30' ' ' ILE . 98.9 m-85 -75.99 134.47 40.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.385 -0.822 . . . . 0.0 109.418 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.08 -68.77 0.59 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 83.3 tt0 -127.6 155.9 43.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -1.128 . . . . 0.0 109.533 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.424 ' N ' ' HG2' ' A' ' 41' ' ' GLU . 51.9 t -121.11 150.39 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.388 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.486 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 88.7 mmm -120.98 161.86 20.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.464 HG13 ' HD2' ' A' ' 45' ' ' PRO . 75.5 t -157.59 131.03 4.67 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.304 -0.873 . . . . 0.0 109.378 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.563 ' HB3' ' CE2' ' A' ' 65' ' ' PHE . 50.1 Cg_endo -69.69 0.27 5.83 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 122.717 2.278 . . . . 0.0 112.019 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.452 HG22 ' HE2' ' A' ' 63' ' ' LYS . 1.3 p -131.95 161.67 32.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.943 . . . . 0.0 109.424 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 54.7 mp0 -51.36 141.02 16.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.146 -0.971 . . . . 0.0 109.444 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -60.04 -34.78 73.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.439 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.72 142.9 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.31 -0.869 . . . . 0.0 109.384 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.4 t -119.74 137.49 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.205 -0.935 . . . . 0.0 109.533 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -116.37 130.26 56.68 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 81.5 mt -64.4 -36.28 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 24.6 mmt180 -56.05 -33.68 65.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.528 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -50.62 -32.4 24.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -164.79 105.58 0.25 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -57.6 -37.03 72.53 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.252 -1.146 . . . . 0.0 109.511 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 13.3 mtt-85 -68.13 148.72 50.53 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.266 -0.896 . . . . 0.0 109.476 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -101.39 140.36 35.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.341 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 20.6 mmtp -113.72 150.5 33.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.463 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.454 ' O ' ' HB2' ' A' ' 61' ' ' GLU . 21.1 t -55.09 -28.45 52.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 60' ' ' SER . 46.9 mt-10 61.13 125.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.89 . . . . 0.0 109.51 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 68.1 mtm180 -128.75 145.82 51.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.458 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 28.3 mttp -124.49 125.43 44.22 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.973 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.515 ' HB2' ' CE1' ' A' ' 65' ' ' PHE . 97.1 m-85 -57.53 -45.11 85.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.477 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 0.3 OUTLIER -136.16 79.58 43.31 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.317 -0.865 . . . . 0.0 109.512 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 50.4 Cg_endo -70.03 143.58 49.99 Favored 'Trans proline' 0 C--O 1.217 -0.574 0 C-N-CA 122.669 2.246 . . . . 0.0 111.855 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 81.03 10.09 85.39 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.438 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.7 m-85 -121.28 119.04 31.08 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -1.158 . . . . 0.0 109.511 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.434 HG13 ' N ' ' A' ' 70' ' ' LEU . 95.1 t -132.03 142.35 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.226 -0.921 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.566 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 2.4 mm? -106.37 129.55 54.35 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 70' ' ' LEU . 84.4 t -139.69 128.88 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.541 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.409 ' OE1' ' HA ' ' A' ' 7' ' ' LYS . 6.6 tt0 -76.94 137.7 39.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.256 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.522 ' HE2' ' CZ ' ' A' ' 39' ' ' PHE . 7.5 tmm? 177.83 151.19 0.23 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.454 ' O ' ' SD ' ' A' ' 73' ' ' MET . 40.4 t -85.22 124.03 39.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.915 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.515 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 10.4 mmt -66.43 120.48 13.43 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.298 -0.876 . . . . 0.0 109.439 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.495 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.7 p-10 -150.3 179.16 8.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.261 -0.9 . . . . 0.0 109.47 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.576 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 93.5 m-20 -65.58 -35.19 80.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.348 -0.845 . . . . 0.0 109.548 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.407 ' HB3' ' HE2' ' A' ' 35' ' ' MET . . . -74.02 -72.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.193 -0.942 . . . . 0.0 109.653 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.495 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 3.7 m -45.2 -52.81 8.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.608 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.452 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 80.2 t90 -55.53 -53.07 60.93 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.242 -0.911 . . . . 0.0 109.571 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.576 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 24.8 m-70 -62.81 -34.84 78.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.256 -0.903 . . . . 0.0 109.524 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.504 ' CD2' ' HG3' ' A' ' 35' ' ' MET . 52.5 tp -58.05 -42.34 85.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 86' ' ' VAL . 79.5 t -57.88 -45.53 87.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.214 -0.929 . . . . 0.0 109.537 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -67.36 -29.84 69.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.203 -0.936 . . . . 0.0 109.461 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 67.5 m -59.59 -50.76 72.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.334 -0.854 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.567 ' HB ' ' CD2' ' A' ' 29' ' ' HIS . 7.4 p -78.78 128.67 76.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.677 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.465 ' O ' HG23 ' A' ' 89' ' ' VAL . 50.3 Cg_endo -70.13 -171.06 0.46 Allowed 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.752 2.301 . . . . 0.0 111.664 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.46 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 31.6 mtt-85 61.38 21.7 12.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.877 . . . . 0.0 109.48 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.467 HG22 HG11 ' A' ' 86' ' ' VAL . 43.6 t -119.78 107.93 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.447 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.479 ' CE ' ' OE1' ' A' ' 13' ' ' GLN . 74.6 mtp -60.22 -43.43 96.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.177 -0.952 . . . . 0.0 109.468 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.07 -149.41 21.21 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.46 ' HB3' ' HB3' ' A' ' 100' ' ' PRO . 45.4 m-85 -110.36 160.65 16.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.277 -1.131 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.523 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 22.1 mm -115.29 129.95 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.385 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 95' ' ' GLY . . . 140.53 -141.47 11.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 94' ' ' GLY . . . -44.0 -89.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -125.16 -178.25 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.247 -1.149 . . . . 0.0 109.435 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.2 p -90.38 21.57 3.81 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -0.918 . . . . 0.0 109.351 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -117.55 -22.94 7.88 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.82 94.68 2.68 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.515 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 41.4 Cg_endo -63.85 118.4 5.34 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.922 2.414 . . . . 0.0 112.138 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.44 142.1 82.6 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.493 -0.754 . . . . 0.0 109.59 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.54 153.34 65.43 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.784 2.322 . . . . 0.0 111.814 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.488 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -126.13 156.78 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 49.8 m -70.46 143.55 51.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 109.586 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.46 -35.87 68.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.386 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 51.0 tttm -62.43 -40.36 96.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.191 -0.943 . . . . 0.0 109.448 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.453 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 87.4 tt0 -54.56 -44.76 73.19 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.488 ' CG2' HD11 ' A' ' 103' ' ' ILE . 68.8 t -57.91 -40.44 76.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.345 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -63.91 -37.24 86.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.454 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.11 -47.27 86.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.407 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.523 ' CG2' ' CE2' ' A' ' 65' ' ' PHE . 68.7 mt -51.9 -48.01 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.3 mmm -63.11 -33.34 75.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.357 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -60.44 -34.45 74.0 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.241 -0.912 . . . . 0.0 109.465 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -54.92 -39.85 69.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 87.0 mt -56.93 -40.75 76.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.203 -0.936 . . . . 0.0 109.465 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -65.4 -31.68 72.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.219 -0.926 . . . . 0.0 109.491 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -63.53 141.6 58.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.515 ' CG1' ' HB2' ' A' ' 121' ' ' LYS . 43.6 t -114.53 142.29 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.385 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.46 -36.48 38.47 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 59.9 t0 -171.49 -38.92 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -1.169 . . . . 0.0 109.526 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.515 ' HB2' ' CG1' ' A' ' 118' ' ' VAL . 0.7 OUTLIER 53.35 63.5 8.15 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 109.517 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.29 147.52 59.67 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.618 2.212 . . . . 0.0 111.796 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.53 179.946 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.7 mtp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.8 t -57.76 -33.02 68.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.509 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -107.36 157.14 18.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -54.64 150.53 17.59 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.933 . . . . 0.0 109.381 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.74 141.89 46.55 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.719 2.279 . . . . 0.0 111.95 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 85.7 mttt -93.06 30.21 1.68 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -93.79 128.02 39.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.571 ' HB2' ' CE1' ' A' ' 10' ' ' TYR . 41.7 mtt-85 -126.38 161.53 27.65 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.159 -0.963 . . . . 0.0 109.509 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.492 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 69.2 m95 -91.35 124.79 35.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.606 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 95.8 m-85 -120.85 147.46 45.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.528 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 55.2 t -87.04 159.4 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.393 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.447 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 64.4 t -144.56 103.94 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.237 -0.915 . . . . 0.0 109.173 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.451 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 50.0 tt0 -42.18 -47.4 4.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.54 -0.725 . . . . 0.0 109.657 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.464 ' O ' ' HG2' ' A' ' 90' ' ' MET . . . 53.62 -168.28 0.06 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.283 -0.885 . . . . 0.0 109.471 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 57.5 t80 -103.17 142.08 34.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.878 . . . . 0.0 109.341 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.416 ' HA ' ' OE2' ' A' ' 19' ' ' GLU . 28.3 p -66.96 131.07 45.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.62 -28.04 9.84 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 17.9 m-30 -103.29 18.26 22.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.223 -1.163 . . . . 0.0 109.506 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.517 ' OE2' ' N ' ' A' ' 67' ' ' GLY . 33.3 mp0 -51.64 -40.94 60.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.191 -0.943 . . . . 0.0 109.251 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.03 -58.39 3.21 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.1 ttm-85 -55.05 -47.48 74.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.155 -1.203 . . . . 0.0 109.426 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 46.8 t -46.7 -45.9 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 109.31 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.77 -45.01 66.92 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.386 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 86.0 m -62.03 -42.99 99.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.336 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.4 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 1.2 t -50.07 -54.97 16.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.215 -0.928 . . . . 0.0 109.289 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.439 ' O ' HG13 ' A' ' 30' ' ' ILE . 82.8 mt -47.68 -56.33 7.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.267 -0.895 . . . . 0.0 109.235 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.458 ' HA ' ' HB ' ' A' ' 30' ' ' ILE . 70.0 ttt-85 -52.72 -34.1 50.98 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.894 . . . . 0.0 109.127 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.4 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.7 tt0 -61.38 -46.09 91.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.183 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.57 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 69.3 m-70 -83.45 -30.1 27.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.249 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.57 HG12 ' CE1' ' A' ' 39' ' ' PHE . 86.5 mt -64.44 -45.09 96.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -60.18 -40.56 90.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.9 . . . . 0.0 109.271 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.8 mt -69.61 -51.77 32.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.299 -0.876 . . . . 0.0 109.354 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.406 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 97.4 m-70 -79.23 0.02 30.24 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.59 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 30' ' ' ILE . 83.9 m-20 59.57 49.03 8.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.521 ' HB2' ' CG2' ' A' ' 30' ' ' ILE . 65.7 mmm -95.38 1.37 54.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.327 -0.858 . . . . 0.0 109.554 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -48.8 -36.48 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.563 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -57.1 -45.2 83.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.441 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -70.88 -53.72 14.09 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -0.883 . . . . 0.0 109.443 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.576 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 91.7 m-85 -68.76 138.5 54.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.863 . . . . 0.0 109.422 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.03 -70.39 0.22 Allowed Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -128.63 157.48 41.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -1.16 . . . . 0.0 109.649 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.408 HG13 HG22 ' A' ' 71' ' ' VAL . 57.6 t -121.56 156.98 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.492 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 87.3 mmm -121.64 150.78 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.71 72.89 68.42 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.265 -0.897 . . . . 0.0 109.398 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.17 -0.64 7.56 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.799 2.333 . . . . 0.0 111.817 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.487 HG21 ' CG ' ' A' ' 19' ' ' GLU . 12.5 t -116.67 176.28 5.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.557 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 46' ' ' THR . 63.2 mm-40 62.05 126.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 109.557 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -61.77 -37.21 83.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.418 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.455 ' O ' HG23 ' A' ' 49' ' ' VAL . 23.2 m -129.44 147.18 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.356 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.5 p -64.31 -26.74 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.211 -0.93 . . . . 0.0 109.619 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.454 ' OE2' ' HD2' ' A' ' 53' ' ' ARG . 77.5 tt0 -80.63 139.79 36.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.933 . . . . 0.0 109.524 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 85.5 mt -59.2 -38.88 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.438 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.454 ' HD2' ' OE2' ' A' ' 51' ' ' GLU . 51.4 mtt180 -52.14 148.84 5.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.275 -0.89 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.5 35.84 18.73 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . -167.33 -161.99 18.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.441 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 93.3 mt-30 61.69 51.37 3.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.324 -1.103 . . . . 0.0 109.52 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 86.6 mtt180 -97.66 154.79 17.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.229 -0.919 . . . . 0.0 109.472 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -92.07 143.01 26.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.44 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.449 ' HG2' ' O ' ' A' ' 59' ' ' LYS . 20.6 ttpp 55.56 43.65 28.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.489 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 97.5 p -117.17 147.73 42.21 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -111.41 156.57 21.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.937 . . . . 0.0 109.455 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 94.8 mtt-85 -127.21 143.05 51.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.378 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -98.19 13.89 29.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.515 ' CD1' HD11 ' A' ' 115' ' ' LEU . 14.0 m-85 -111.86 163.02 14.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.266 -0.896 . . . . 0.0 109.427 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.479 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 5.3 p90 -105.85 89.24 3.43 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.607 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -70.67 155.19 63.4 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.641 2.227 . . . . 0.0 111.601 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.517 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . 107.47 -4.06 34.86 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -123.48 122.2 37.62 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -1.157 . . . . 0.0 109.41 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.444 HG12 ' N ' ' A' ' 70' ' ' LEU . 88.1 t -133.02 140.81 46.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 109.516 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.57 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.1 mp -105.66 134.99 47.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.38 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.408 HG22 HG13 ' A' ' 42' ' ' VAL . 77.2 t -139.98 117.86 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.303 -0.873 . . . . 0.0 109.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.441 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.2 tt0 -67.61 135.49 52.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.42 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 44.6 ttp 173.57 154.69 0.11 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.511 ' N ' ' HG2' ' A' ' 73' ' ' MET . 97.1 t -84.21 140.78 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.606 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 19.3 mmm -84.8 125.71 32.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.536 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 47.8 p-10 -152.65 173.54 15.09 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -64.84 -29.4 70.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.247 -0.908 . . . . 0.0 109.542 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.507 ' HB2' ' CE ' ' A' ' 35' ' ' MET . . . -74.87 -72.41 0.3 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.665 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.515 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 10.6 m -44.38 -56.82 3.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.257 -0.902 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.517 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 51.7 t90 -44.62 -54.04 6.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.278 -0.889 . . . . 0.0 109.385 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -61.1 -35.79 77.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.362 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.576 HD22 ' CZ ' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -57.25 -37.24 72.03 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.27 -0.894 . . . . 0.0 109.413 179.892 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.515 ' CG1' HG12 ' A' ' 89' ' ' VAL . 44.1 t -73.04 -45.96 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -68.94 -31.31 70.1 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 95.1 p -64.8 -45.6 85.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.906 . . . . 0.0 109.362 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.57 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 11.1 p -82.35 133.49 50.23 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.395 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.463 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.3 Cg_endo -69.12 -166.87 0.18 Allowed 'Trans proline' 0 C--O 1.214 -0.722 0 C-N-CA 122.697 2.265 . . . . 0.0 111.876 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.463 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 89.6 mtt-85 63.01 16.73 9.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.433 -0.792 . . . . 0.0 109.535 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.515 HG12 ' CG1' ' A' ' 83' ' ' VAL . 11.6 t -119.99 109.27 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.409 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.464 ' HG2' ' O ' ' A' ' 14' ' ' ALA . 90.9 mmm -65.3 -39.89 93.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 109.576 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.92 -169.59 35.23 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.452 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 15.3 m-85 -100.37 158.56 15.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.653 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.528 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 34.3 mm -117.7 115.69 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.298 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 179.8 -142.71 5.28 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.95 -37.55 50.14 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 p -132.39 169.89 15.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -1.156 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.0 p -88.84 14.93 9.22 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.251 -0.906 . . . . 0.0 109.336 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.517 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 88.5 m-20 -125.15 -22.49 4.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.566 -0.709 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -140.8 101.27 6.5 Favored Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.191 -0.943 . . . . 0.0 109.15 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.522 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.7 Cg_endo -69.02 109.69 2.23 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.744 2.296 . . . . 0.0 111.922 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.94 139.64 78.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 154.04 67.41 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.72 2.28 . . . . 0.0 111.842 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.417 HD13 HG21 ' A' ' 103' ' ' ILE . 34.5 pt -123.83 158.13 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 m -70.21 147.74 49.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -55.01 -38.86 68.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -58.62 -40.34 83.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -51.77 -48.67 63.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.281 -0.887 . . . . 0.0 109.403 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.456 HG23 ' CG ' ' A' ' 9' ' ' TRP . 74.2 t -57.67 -44.09 84.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -60.9 -41.38 95.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.184 -0.948 . . . . 0.0 109.344 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.436 ' O ' ' HB2' ' A' ' 113' ' ' ASN . . . -58.45 -52.82 64.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.326 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.443 HG23 HD12 ' A' ' 111' ' ' ILE . 69.0 mt -49.79 -53.98 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.378 -0.826 . . . . 0.0 109.373 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 95.3 mmm -59.57 -38.78 82.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.254 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 110' ' ' ALA . 97.4 m-20 -53.02 -46.89 68.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.362 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.509 ' O ' ' N ' ' A' ' 117' ' ' GLN . 56.8 mtt180 -55.53 -54.22 46.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.201 -0.937 . . . . 0.0 109.398 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.515 HD11 ' CD1' ' A' ' 64' ' ' PHE . 15.4 tp -45.74 -43.77 13.18 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.492 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -63.57 -21.36 66.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.509 ' N ' ' O ' ' A' ' 114' ' ' ARG . 50.4 tt0 -85.69 110.12 19.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.454 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 t -64.38 -19.27 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 86.76 10.31 72.97 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -63.1 156.27 25.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -1.173 . . . . 0.0 109.525 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.59 ' CB ' ' CD ' ' A' ' 122' ' ' PRO . 0.0 OUTLIER -160.26 -66.28 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 109.441 179.902 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . 0.59 ' CD ' ' CB ' ' A' ' 121' ' ' LYS . 52.1 Cg_endo -71.28 -14.03 31.11 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.615 2.21 . . . . 0.0 111.741 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.519 179.994 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.5 mtm . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.5 t -121.22 144.29 48.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.515 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -60.03 -33.87 72.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.42 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 53.08 68.49 2.94 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.503 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.421 ' O ' ' HB2' ' A' ' 6' ' ' LYS . 48.6 Cg_endo -69.76 -17.52 37.55 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 122.704 2.269 . . . . 0.0 111.71 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.457 ' O ' ' CG1' ' A' ' 74' ' ' VAL . 28.2 mttm 60.64 44.12 11.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.42 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 94.9 mttt -130.53 126.0 35.69 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.451 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 95.4 mtt-85 -139.51 150.27 44.93 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.396 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.431 ' O ' HG12 ' A' ' 103' ' ' ILE . 72.4 m95 -100.67 136.72 40.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.642 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -130.21 149.85 51.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.328 -0.857 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.42 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 12.8 t -98.93 139.16 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.188 -0.945 . . . . 0.0 109.524 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.423 HG23 ' CE1' ' A' ' 92' ' ' PHE . 46.3 t -119.18 130.0 74.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.872 . . . . 0.0 109.41 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.508 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 95.8 mt-30 -87.68 147.47 25.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.329 -0.857 . . . . 0.0 109.468 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.3 154.63 38.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.921 . . . . 0.0 109.462 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -66.38 146.47 54.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.286 -0.884 . . . . 0.0 109.457 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 42.0 m -58.08 135.97 57.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.73 -29.28 7.49 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -104.08 7.15 36.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.2 -1.176 . . . . 0.0 109.545 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.86 -37.33 71.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.432 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -79.7 -35.0 29.72 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 63.4 ttt-85 -63.18 -47.4 82.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.233 -1.157 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.463 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 45.6 t -50.71 -39.12 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.451 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.21 -39.55 94.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 67.9 m -67.43 -36.0 80.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.572 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.487 ' HB2' ' CG1' ' A' ' 86' ' ' VAL . 31.8 m -63.72 -41.38 98.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.157 -0.964 . . . . 0.0 109.484 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.522 HD22 ' CG2' ' A' ' 86' ' ' VAL . 61.9 mt -56.48 -43.78 79.98 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.539 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.519 ' CG ' ' HE3' ' A' ' 31' ' ' LYS . 41.4 ttm180 -57.19 -39.46 75.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -73.97 -59.82 2.54 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.514 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.453 ' CD2' ' O ' ' A' ' 25' ' ' SER . 93.6 m-70 -52.44 -45.81 66.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.564 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.563 HG12 ' CE1' ' A' ' 39' ' ' PHE . 96.5 mt -64.1 -55.58 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.477 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.519 ' HE3' ' CG ' ' A' ' 27' ' ' ARG . 82.6 mttt -53.89 -37.13 63.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 51.3 mt -73.06 -48.19 38.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.539 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -81.38 0.87 35.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.939 . . . . 0.0 109.615 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 30' ' ' ILE . 77.7 m-20 59.08 49.77 8.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.524 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 40.0 mmm -101.8 8.98 41.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.557 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.436 ' OE2' ' HG2' ' A' ' 31' ' ' LYS . 97.5 mt-10 -51.73 -37.02 49.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.461 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -60.35 -37.83 81.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.407 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.522 HD22 ' CG2' ' A' ' 74' ' ' VAL . 5.8 mt -73.61 -55.06 6.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.252 -0.905 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.568 ' CZ ' ' SD ' ' A' ' 73' ' ' MET . 92.0 m-85 -72.47 136.17 45.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 109.407 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.39 -66.49 0.5 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -137.94 152.76 49.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.203 -1.175 . . . . 0.0 109.562 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.507 ' CG1' HG21 ' A' ' 71' ' ' VAL . 42.8 t -116.81 155.3 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.481 ' CE ' ' HE1' ' A' ' 112' ' ' MET . 87.9 mtp -120.65 138.7 53.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.887 . . . . 0.0 109.568 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.3 t -145.99 90.24 5.86 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.02 -19.38 34.96 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.732 2.288 . . . . 0.0 111.919 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' GLU . 6.3 t -89.53 -4.28 57.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.65 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' A' ' 46' ' ' THR . 95.5 mt-10 51.25 177.36 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.443 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.57 -35.26 79.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.435 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 43.8 t -122.28 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 5.4 p -63.15 -44.3 99.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.241 -0.912 . . . . 0.0 109.494 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -139.79 137.33 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 81.5 mt -61.69 -41.78 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.566 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -56.87 -32.75 66.17 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.472 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.82 -137.0 15.11 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 24.52 36.08 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 77.4 mt-30 -59.7 -28.78 67.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -1.158 . . . . 0.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -59.2 -30.38 68.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.386 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.491 ' O ' ' CB ' ' A' ' 59' ' ' LYS . 83.0 mtm180 -118.2 160.74 21.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.193 -0.942 . . . . 0.0 109.422 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.491 ' CB ' ' O ' ' A' ' 58' ' ' ARG . 11.4 ttmm 73.77 66.87 0.1 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.249 -0.907 . . . . 0.0 109.434 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 37.4 m -58.37 -32.66 68.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.36 147.37 52.21 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.476 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 22.0 mmt85 -116.89 128.21 55.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.461 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 30.0 mttt -61.45 -30.83 70.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.557 ' CD1' HD12 ' A' ' 115' ' ' LEU . 9.3 m-30 -94.45 171.35 8.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.91 . . . . 0.0 109.469 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 13.0 p90 -109.59 80.67 1.64 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.08 164.08 36.16 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.631 2.221 . . . . 0.0 111.745 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 104.76 -11.69 49.76 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.98 125.84 49.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -1.178 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.418 HG12 ' O ' ' A' ' 43' ' ' MET . 91.0 t -132.06 143.25 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.575 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.3 mp -107.65 127.41 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.385 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.507 HG21 ' CG1' ' A' ' 42' ' ' VAL . 96.9 t -133.27 133.17 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.538 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.42 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.3 tt0 -84.49 133.94 34.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.377 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.568 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 28.5 ttp -175.04 162.71 3.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.475 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.522 ' CG2' HD22 ' A' ' 38' ' ' LEU . 33.3 m -103.51 145.66 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.364 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.521 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 11.7 mmt -79.42 122.44 26.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.454 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 36.0 p-10 -133.74 -143.76 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.29 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.2 p30 -117.91 0.85 12.0 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.025 -1.047 . . . . 0.0 110.067 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -122.8 -20.02 6.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.103 -0.998 . . . . 0.0 109.785 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.455 ' OG ' HD12 ' A' ' 38' ' ' LEU . 4.5 m -79.1 -36.66 40.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.24 -0.912 . . . . 0.0 109.581 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 85.6 t90 -56.24 -51.25 68.78 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.293 -0.879 . . . . 0.0 109.595 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -66.22 -32.21 73.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.689 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.563 HD22 ' CZ ' ' A' ' 39' ' ' PHE . 0.6 OUTLIER -62.86 -37.12 85.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.214 -0.929 . . . . 0.0 109.475 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.549 HG12 ' CE2' ' A' ' 92' ' ' PHE . 55.8 t -68.96 -50.02 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 23.1 ttp85 -60.98 -35.69 77.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.506 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.3 t -60.5 -30.83 69.96 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.93 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.523 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 22.0 t -61.84 117.9 33.25 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.413 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.13 167.71 24.15 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.584 2.189 . . . . 0.0 111.693 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 39.0 mmt180 60.91 29.85 19.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 7.7 p -122.79 130.09 74.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.212 -0.93 . . . . 0.0 109.407 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.508 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.5 mtp -70.12 -50.93 35.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.21 -0.931 . . . . 0.0 109.508 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 169.36 -151.24 16.96 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.549 ' CE2' HG12 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -115.63 170.21 8.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.27 -1.135 . . . . 0.0 109.516 179.998 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.5 HD12 ' NE2' ' A' ' 13' ' ' GLN . 39.6 mm -121.78 125.48 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.355 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 169.71 -163.23 36.73 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -54.57 -56.77 20.51 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 p -125.49 178.96 5.34 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -1.162 . . . . 0.0 109.593 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.3 p -93.76 16.91 12.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -120.11 -28.64 5.06 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 10.1 mtp85 -142.56 90.75 7.78 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.521 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.0 Cg_endo -66.43 120.26 7.37 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.92 2.413 . . . . 0.0 112.239 -179.307 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.28 146.93 97.1 Favored Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.451 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.2 Cg_endo -69.85 152.84 68.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.598 2.198 . . . . 0.0 111.903 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.505 ' CD1' HG21 ' A' ' 108' ' ' VAL . 30.2 pt -113.1 156.12 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.316 -0.865 . . . . 0.0 109.4 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.0 m -74.52 152.21 39.4 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -56.6 -37.83 71.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.35 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -58.14 -42.08 85.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.223 -0.923 . . . . 0.0 109.404 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.405 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 90.1 mt-10 -58.76 -45.06 90.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.485 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.522 ' CG1' HD22 ' A' ' 70' ' ' LEU . 73.4 t -59.43 -39.62 79.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.322 -0.861 . . . . 0.0 109.379 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.6 -34.21 73.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.267 -0.896 . . . . 0.0 109.388 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.27 -44.43 95.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.349 -0.844 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.51 ' CD1' HD23 ' A' ' 70' ' ' LEU . 73.9 mt -54.21 -54.16 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.474 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.481 ' HE1' ' CE ' ' A' ' 43' ' ' MET . 55.9 ttm -64.27 -36.73 85.03 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.515 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 46.8 t-20 -52.17 -44.21 64.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 27.2 mtp180 -49.08 -50.42 36.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.491 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.557 HD12 ' CD1' ' A' ' 64' ' ' PHE . 13.5 tp -53.64 -43.42 68.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.271 -0.893 . . . . 0.0 109.417 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -68.68 -29.58 68.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.3 tp60 -53.33 -30.92 41.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.306 -0.872 . . . . 0.0 109.396 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 28.6 t -100.28 134.21 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -77.83 107.18 2.39 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -52.78 -39.59 62.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -1.145 . . . . 0.0 109.427 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.6 mtpt -139.03 165.07 34.88 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.38 -20.51 36.54 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.72 2.28 . . . . 0.0 111.831 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.948 -1.025 . . . . 0.0 109.502 -179.992 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.8 mtt . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.9 t -55.59 -36.46 66.94 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.495 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 mp0 -62.55 -32.6 73.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.494 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.94 78.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.417 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.34 143.22 47.43 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.599 2.2 . . . . 0.0 111.793 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -90.38 149.28 22.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.373 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.511 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 46.9 mttt -121.1 143.1 49.27 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.898 . . . . 0.0 109.571 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.446 ' HD2' ' OH ' ' A' ' 10' ' ' TYR . 78.3 mtt180 -125.27 156.72 38.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.392 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.45 ' CZ2' ' HB2' ' A' ' 72' ' ' GLN . 59.4 m95 -104.42 126.8 51.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.184 -0.948 . . . . 0.0 109.591 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE1' ' HE2' ' A' ' 75' ' ' MET . 85.6 m-85 -125.15 148.13 48.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.417 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.482 HG21 ' CD1' ' A' ' 70' ' ' LEU . 22.8 t -92.06 143.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -0.926 . . . . 0.0 109.615 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.3 t -120.61 132.79 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.516 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 58.1 mt-30 -84.53 151.99 24.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.9 . . . . 0.0 109.483 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.436 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -163.96 150.47 11.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 0.0 109.506 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -61.14 143.67 55.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.224 -0.923 . . . . 0.0 109.509 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.9 t -61.62 136.45 58.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.82 -31.53 5.53 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.416 ' HB3' ' HD3' ' A' ' 88' ' ' ARG . 87.2 m-85 -105.08 -2.62 24.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.202 -1.175 . . . . 0.0 109.536 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.473 ' CD ' ' CG2' ' A' ' 46' ' ' THR . 15.7 pt-20 -56.52 -41.82 77.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.194 -0.941 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.466 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -63.15 -39.09 97.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.421 ' O ' ' C ' ' A' ' 22' ' ' VAL . 58.1 ttt85 -59.07 -48.73 80.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -1.129 . . . . 0.0 109.432 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.421 ' C ' ' O ' ' A' ' 21' ' ' ARG . 40.5 t -43.79 -39.18 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.881 . . . . 0.0 109.268 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -54.63 -56.01 23.57 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.252 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.9 m -63.45 -48.55 77.24 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.361 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.485 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 17.0 m -56.27 -49.04 75.37 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 0.0 109.328 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.572 HD23 ' CE2' ' A' ' 39' ' ' PHE . 5.1 tp -48.33 -56.46 8.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 43.1 ttt180 -55.08 -37.48 66.84 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.332 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 71.5 tt0 -56.88 -47.78 79.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.257 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' A' ' 25' ' ' SER . 62.0 m-70 -71.23 -41.62 69.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.243 -0.91 . . . . 0.0 109.344 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.623 ' CD1' ' CD1' ' A' ' 39' ' ' PHE . 76.1 mt -59.15 -52.2 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.394 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -54.23 -43.5 70.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.448 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.3 mt -65.44 -48.4 72.88 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -0.915 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.443 ' CB ' ' SD ' ' A' ' 35' ' ' MET . 96.2 m-70 -85.17 6.39 25.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.56 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.516 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.6 t30 51.97 47.14 25.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.566 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.517 ' HG2' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.36 6.12 47.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.252 -0.905 . . . . 0.0 109.419 179.921 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.573 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.24 -35.5 49.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.158 -0.964 . . . . 0.0 109.523 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -55.25 -42.47 73.51 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.517 ' CD1' ' HG2' ' A' ' 35' ' ' MET . 0.9 OUTLIER -71.1 -54.47 11.0 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.201 -0.937 . . . . 0.0 109.322 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.623 ' CD1' ' CD1' ' A' ' 30' ' ' ILE . 96.0 m-85 -64.46 137.79 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.9 -67.48 0.38 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -132.76 149.74 52.24 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.251 -1.147 . . . . 0.0 109.707 -179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.471 HG12 ' CG2' ' A' ' 71' ' ' VAL . 98.6 t -120.01 149.14 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.881 . . . . 0.0 109.289 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.521 ' HE3' ' CG1' ' A' ' 108' ' ' VAL . 73.4 mtm -130.37 146.14 51.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.144 -0.973 . . . . 0.0 109.578 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.472 ' CG1' HG22 ' A' ' 46' ' ' THR . 74.9 t -130.68 99.47 18.61 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.272 -0.893 . . . . 0.0 109.301 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.14 -10.05 27.38 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.696 2.264 . . . . 0.0 111.944 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.473 ' CG2' ' CD ' ' A' ' 19' ' ' GLU . 9.0 t -91.31 7.27 41.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.221 -0.925 . . . . 0.0 109.548 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.424 ' C ' ' O ' ' A' ' 46' ' ' THR . 92.5 mt-10 44.11 -163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.165 -0.959 . . . . 0.0 109.434 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 58.6 mp0 -83.42 157.58 22.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.393 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.2 t -60.57 -39.84 82.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.412 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.6 t -115.41 140.64 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.62 143.46 36.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.25 -0.906 . . . . 0.0 109.517 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 79.5 mt -51.46 -43.35 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -82.07 143.65 31.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.293 -0.879 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -57.71 -36.06 77.16 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.75 167.46 43.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -59.93 -40.4 88.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.16 . . . . 0.0 109.502 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -134.29 146.64 50.2 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.847 . . . . 0.0 109.423 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -65.59 -32.54 74.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.46 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.3 tttt -128.69 140.66 51.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.525 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.3 t -95.38 136.94 35.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -0.937 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -78.67 -21.29 48.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.519 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -122.71 142.38 50.75 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.164 -0.96 . . . . 0.0 109.463 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.5 mttp -114.76 147.74 39.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.411 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.563 ' CD2' HD12 ' A' ' 115' ' ' LEU . 98.4 m-85 -104.62 135.13 46.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.592 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.539 ' CE1' HG22 ' A' ' 111' ' ' ILE . 17.9 m-85 44.75 57.58 14.51 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.24 -0.912 . . . . 0.0 109.579 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.08 113.07 3.47 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.677 2.252 . . . . 0.0 111.781 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . 81.62 13.46 79.99 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -110.02 128.86 55.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.222 -1.164 . . . . 0.0 109.583 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.427 HG12 ' N ' ' A' ' 70' ' ' LEU . 99.9 t -133.55 141.58 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.576 ' CD2' ' N ' ' A' ' 70' ' ' LEU . 2.3 mm? -106.27 131.5 53.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.354 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.471 ' CG2' HG12 ' A' ' 42' ' ' VAL . 83.9 t -140.52 120.85 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.262 -0.899 . . . . 0.0 109.754 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 4.4 tt0 -76.62 124.74 28.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.567 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.2 ttp -162.82 155.97 19.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.683 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.495 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.7 t -86.14 130.11 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.551 ' HE2' ' CE1' ' A' ' 10' ' ' TYR . 18.9 ttm -75.26 135.49 40.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 44.7 p-10 -151.58 -161.0 1.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -102.99 34.35 2.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.417 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -149.88 -50.21 0.14 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.495 ' OG ' ' CD1' ' A' ' 38' ' ' LEU . 14.8 m -63.24 -44.06 96.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.51 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 70.3 t90 -50.78 -47.02 59.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -69.25 -34.05 74.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.412 ' CD1' ' HB3' ' A' ' 29' ' ' HIS . 53.9 tp -63.43 -38.69 92.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.28 -0.887 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.436 ' HA ' HG21 ' A' ' 86' ' ' VAL . 70.6 t -60.69 -49.57 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.383 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -58.8 -35.3 72.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.306 -0.871 . . . . 0.0 109.439 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 24.1 m -62.73 -33.96 76.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.426 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.525 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 49.0 t -49.18 127.71 15.8 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.467 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.7 Cg_endo -70.8 156.77 60.02 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.617 2.211 . . . . 0.0 111.803 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.9 mtt-85 63.51 34.19 12.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 109.678 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 8.4 p -128.52 134.41 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.516 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 73.2 mtm -79.56 -44.56 20.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.241 -0.912 . . . . 0.0 109.488 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.74 -147.04 12.25 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.436 ' CE2' HG23 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -113.25 167.07 10.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -1.114 . . . . 0.0 109.55 -179.976 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.486 HD13 ' CG ' ' A' ' 13' ' ' GLN . 33.5 mm -121.25 137.65 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.854 . . . . 0.0 109.438 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.471 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 163.09 -148.07 14.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.59 -46.55 14.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.2 p -121.64 171.2 9.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -1.192 . . . . 0.0 109.804 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 59.9 m -91.61 18.56 7.3 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.23 -0.919 . . . . 0.0 109.322 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.51 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 90.2 m-20 -124.82 -30.92 3.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.525 -0.734 . . . . 0.0 109.099 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 6.2 mtt180 -144.64 98.67 4.88 Favored Pre-proline 0 N--CA 1.488 1.464 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.509 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 44.3 Cg_endo -67.12 132.28 27.49 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.695 2.263 . . . . 0.0 112.101 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.07 137.02 96.93 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.387 -0.821 . . . . 0.0 109.36 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.19 152.69 72.26 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.645 2.23 . . . . 0.0 111.741 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.536 ' CD1' ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -123.53 164.46 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.407 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.6 p -83.52 155.32 23.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -0.928 . . . . 0.0 109.447 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -63.74 -30.39 71.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.257 -0.902 . . . . 0.0 109.494 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -65.43 -37.1 85.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -0.906 . . . . 0.0 109.4 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.444 ' O ' HG13 ' A' ' 111' ' ' ILE . 85.2 tt0 -65.0 -39.86 94.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.254 -0.904 . . . . 0.0 109.385 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.536 ' CG2' ' CD1' ' A' ' 103' ' ' ILE . 76.3 t -67.02 -34.08 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.354 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 92.2 m-20 -70.5 -34.11 71.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.88 . . . . 0.0 109.453 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -69.34 -39.51 78.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.334 -0.854 . . . . 0.0 109.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.539 HG22 ' CE1' ' A' ' 65' ' ' PHE . 71.9 mt -56.93 -51.37 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.234 -0.916 . . . . 0.0 109.541 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.5 mtp -63.39 -37.86 88.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.226 -0.921 . . . . 0.0 109.496 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.445 ' OD1' ' O ' ' A' ' 109' ' ' ASP . 18.7 m120 -54.13 -37.76 64.73 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.321 -0.862 . . . . 0.0 109.514 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.495 ' O ' ' N ' ' A' ' 117' ' ' GLN . 52.4 mtt85 -55.56 -52.69 62.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.617 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.563 HD12 ' CD2' ' A' ' 64' ' ' PHE . 18.5 tp -43.21 -47.79 6.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.319 -0.863 . . . . 0.0 109.626 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 -57.89 -27.09 62.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.317 -0.864 . . . . 0.0 109.495 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 114' ' ' ARG . 43.6 tt0 -83.07 134.11 35.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.49 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 42.9 t -63.76 -31.41 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.509 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.54 18.11 75.24 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 51.7 p30 -75.23 172.26 12.73 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.13 -1.217 . . . . 0.0 109.476 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.53 81.0 70.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.277 -0.889 . . . . 0.0 109.555 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.53 -18.36 38.12 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.744 2.296 . . . . 0.0 111.775 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 53.6 mtm180 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.511 179.946 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.8 mmm . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 26.4 t -60.0 -34.33 73.2 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.478 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.25 138.47 39.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.297 -0.877 . . . . 0.0 109.511 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -126.39 159.78 61.25 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.248 -0.907 . . . . 0.0 109.426 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -69.93 142.94 48.52 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.701 2.268 . . . . 0.0 111.782 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -88.4 148.43 24.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.441 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.433 ' HD2' ' NE2' ' A' ' 72' ' ' GLN . 16.0 pttt -132.16 128.34 37.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.281 -0.887 . . . . 0.0 109.516 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.0 mtt-85 -133.53 153.5 51.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.237 -0.914 . . . . 0.0 109.491 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 70.4 m95 -101.38 135.81 42.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.909 . . . . 0.0 109.415 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CE2' ' O ' ' A' ' 73' ' ' MET . 22.9 m-85 -124.58 151.62 44.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.468 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 18.4 t -101.1 137.89 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.333 -0.855 . . . . 0.0 109.489 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 30.6 t -115.11 128.7 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.306 -0.871 . . . . 0.0 109.234 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.519 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 60.4 tt0 -95.6 129.96 42.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.913 . . . . 0.0 109.617 -179.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.416 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -147.42 -178.2 6.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -75.03 134.26 41.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.448 ' OG ' ' HB2' ' A' ' 66' ' ' PRO . 19.7 m -57.79 140.6 51.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.39 -25.44 15.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.467 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.4 m-85 -112.05 13.57 20.71 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.23 -1.159 . . . . 0.0 109.39 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.499 ' OE1' ' CG ' ' A' ' 45' ' ' PRO . 87.2 mt-10 -54.07 -45.31 71.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.12 -42.25 91.85 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.423 ' HD3' ' NE ' ' A' ' 88' ' ' ARG . 52.7 ttt85 -52.16 -54.53 29.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.228 -1.16 . . . . 0.0 109.389 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.412 HG21 ' HB2' ' A' ' 14' ' ' ALA . 26.1 t -50.35 -37.23 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.203 -0.936 . . . . 0.0 109.119 179.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.72 -36.79 85.43 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.211 -0.931 . . . . 0.0 109.231 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -58.83 -43.03 90.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.397 -0.815 . . . . 0.0 109.158 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.46 ' HB3' ' NE2' ' A' ' 29' ' ' HIS . 20.3 m -58.77 -41.04 85.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 109.319 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.513 HD23 ' CG2' ' A' ' 86' ' ' VAL . 50.1 mt -53.45 -44.51 68.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.865 . . . . 0.0 109.409 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 31' ' ' LYS . 65.9 ttt180 -52.6 -42.49 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.34 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.409 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 64.6 mm-40 -75.02 -57.77 3.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.46 ' NE2' ' HB3' ' A' ' 25' ' ' SER . 87.2 m-70 -55.15 -38.03 67.73 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -0.942 . . . . 0.0 109.268 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.58 HG12 ' CE1' ' A' ' 39' ' ' PHE . 82.2 mt -77.17 -54.46 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.293 -0.879 . . . . 0.0 109.49 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 27' ' ' ARG . 42.2 tttm -59.97 -38.24 81.92 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.906 . . . . 0.0 109.286 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 25.2 mt -70.64 -52.05 23.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.194 -0.942 . . . . 0.0 109.388 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -81.17 0.84 34.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.536 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.509 ' N ' ' O ' ' A' ' 30' ' ' ILE . 20.2 m120 60.37 51.49 5.33 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.242 -0.911 . . . . 0.0 109.408 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.467 ' HG3' HD13 ' A' ' 82' ' ' LEU . 59.9 mmm -99.84 -0.15 40.3 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.291 -0.88 . . . . 0.0 109.599 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.516 ' N ' HG23 ' A' ' 30' ' ' ILE . 96.1 mt-10 -45.67 -37.94 6.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.402 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -53.45 -44.24 68.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.922 . . . . 0.0 109.436 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.475 HD21 ' CG1' ' A' ' 74' ' ' VAL . 1.0 OUTLIER -74.62 -46.92 35.19 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.376 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.58 ' CE1' HG12 ' A' ' 30' ' ' ILE . 92.0 m-85 -75.41 125.87 29.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.9 . . . . 0.0 109.497 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.69 -67.06 0.6 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -132.46 144.74 50.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -1.154 . . . . 0.0 109.524 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.421 HG13 HG22 ' A' ' 71' ' ' VAL . 19.5 t -109.06 147.65 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.247 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.458 ' O ' HG22 ' A' ' 44' ' ' VAL . 88.2 mtp -122.73 152.32 40.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.118 -0.988 . . . . 0.0 109.757 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.525 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 12.3 t -149.57 141.18 14.77 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.365 -0.835 . . . . 0.0 109.228 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.525 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 47.8 Cg_endo -68.59 -2.13 8.72 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.65 2.233 . . . . 0.0 111.815 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 11.3 t -145.98 137.19 24.7 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.339 -0.851 . . . . 0.0 109.291 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 48' ' ' GLU . 91.8 mt-10 -109.48 137.62 47.05 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.258 -0.901 . . . . 0.0 109.562 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.415 ' HA ' ' OE1' ' A' ' 48' ' ' GLU . 73.4 mm-40 43.41 81.43 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.339 -0.851 . . . . 0.0 109.638 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.438 HG11 ' O ' ' A' ' 49' ' ' VAL . 13.9 p -135.31 140.29 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.54 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.517 ' HB ' ' CB ' ' A' ' 53' ' ' ARG . 23.8 t -118.3 143.25 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.538 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -60.97 -68.65 0.29 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.509 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.416 ' O ' ' C ' ' A' ' 53' ' ' ARG . 77.8 mt -46.76 -52.94 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.318 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.517 ' CB ' ' HB ' ' A' ' 50' ' ' VAL . 59.4 ttp85 -44.56 -49.48 10.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.883 . . . . 0.0 109.514 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 68.47 -127.72 23.68 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -113.44 102.19 1.23 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -66.32 -35.81 81.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.264 -1.139 . . . . 0.0 109.487 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -57.4 -44.61 84.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.221 -0.924 . . . . 0.0 109.495 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -146.77 149.51 33.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.9 . . . . 0.0 109.458 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -50.83 -46.39 59.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.915 . . . . 0.0 109.541 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 53.1 p -58.43 164.01 2.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.525 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -133.58 140.27 47.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 60.9 mtt85 -122.78 145.26 48.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.325 -0.859 . . . . 0.0 109.381 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 20.4 mttt -135.42 137.03 41.85 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -0.926 . . . . 0.0 109.655 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.514 ' CB ' HD11 ' A' ' 115' ' ' LEU . 98.3 m-85 -109.75 142.33 41.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.361 -0.837 . . . . 0.0 109.263 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.422 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 39.3 m-85 51.13 66.39 5.45 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.125 -0.984 . . . . 0.0 109.384 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.448 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 48.9 Cg_endo -69.93 128.73 16.28 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.692 2.261 . . . . 0.0 111.778 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.485 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . 65.37 24.12 70.54 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.01 118.29 22.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -1.125 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 70' ' ' LEU . 79.0 t -130.64 148.82 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.559 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.564 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.0 mp -116.05 132.66 56.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.292 -0.88 . . . . 0.0 109.314 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.421 HG22 HG13 ' A' ' 42' ' ' VAL . 92.4 t -137.03 129.91 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.649 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.433 ' NE2' ' HD2' ' A' ' 7' ' ' LYS . 37.6 tt0 -79.87 132.74 36.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.225 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 50.3 ttp 174.07 165.19 0.2 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.162 -0.961 . . . . 0.0 109.621 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.524 ' N ' ' CG ' ' A' ' 73' ' ' MET . 15.0 p -94.6 138.57 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.286 -0.884 . . . . 0.0 109.237 179.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.514 ' HE1' ' CG ' ' A' ' 100' ' ' PRO . 34.3 tpp -79.15 119.52 22.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.3 p-10 -141.94 179.06 7.09 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.35 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -64.97 -36.7 85.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.464 ' CB ' ' HE1' ' A' ' 35' ' ' MET . . . -74.47 -72.78 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.173 -0.954 . . . . 0.0 109.827 -179.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.517 ' HB3' ' CE ' ' A' ' 73' ' ' MET . 3.6 m -42.24 -47.5 4.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.392 -0.818 . . . . 0.0 109.741 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.556 ' CZ2' ' HD2' ' A' ' 84' ' ' ARG . 63.7 t90 -50.63 -49.72 56.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.226 -0.921 . . . . 0.0 109.577 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -68.34 -25.16 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.527 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.553 HD22 ' CE1' ' A' ' 39' ' ' PHE . 0.9 OUTLIER -60.52 -54.75 41.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.297 -0.877 . . . . 0.0 109.562 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.52 ' CG2' ' CZ ' ' A' ' 92' ' ' PHE . 2.7 t -62.26 -49.09 85.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.504 -0.747 . . . . 0.0 109.896 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.556 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 58.2 mtp180 -62.77 -29.38 70.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.134 -0.979 . . . . 0.0 109.509 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.1 p -79.6 -17.8 53.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.408 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.528 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 71.8 t -73.01 125.9 90.79 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.449 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.01 160.34 49.65 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.626 2.218 . . . . 0.0 111.782 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.526 ' CZ ' ' HB2' ' A' ' 88' ' ' ARG . 13.0 ttm105 64.74 31.72 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 8.9 p -126.59 130.93 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.192 -0.942 . . . . 0.0 109.451 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.488 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 95.7 mmm -71.29 -46.85 59.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.09 -155.5 26.35 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.52 ' CZ ' ' CG2' ' A' ' 83' ' ' VAL . 2.0 m-85 -104.74 162.45 13.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -1.086 . . . . 0.0 109.588 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.519 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 10.7 mm -119.02 118.27 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.41 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.447 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -174.52 -145.57 5.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.93 -46.01 24.62 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.8 p -127.36 173.37 9.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.195 -1.179 . . . . 0.0 109.604 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.2 p -90.49 18.78 5.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.111 -0.993 . . . . 0.0 109.253 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -126.62 -6.3 6.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.579 -0.701 . . . . 0.0 109.428 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -164.73 99.57 0.85 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.252 -0.905 . . . . 0.0 109.07 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.514 ' CG ' ' HE1' ' A' ' 75' ' ' MET . 47.6 Cg_endo -68.55 114.21 3.41 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.678 2.252 . . . . 0.0 111.891 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.57 137.37 82.19 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.519 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.82 153.9 68.12 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.707 2.271 . . . . 0.0 111.813 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.461 ' CD1' HG21 ' A' ' 108' ' ' VAL . 32.1 pt -124.44 161.04 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.444 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.442 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 49.9 m -70.94 147.95 48.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -62.26 -36.28 81.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.197 -0.94 . . . . 0.0 109.34 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -61.59 -35.96 79.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.442 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 99.8 mt-10 -60.8 -43.15 98.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.887 . . . . 0.0 109.366 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.461 HG21 ' CD1' ' A' ' 103' ' ' ILE . 75.4 t -62.53 -35.14 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.455 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -66.99 -38.04 85.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.885 . . . . 0.0 109.412 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.6 -44.31 91.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.955 . . . . 0.0 109.441 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.5 HD12 HG22 ' A' ' 111' ' ' ILE . 67.9 mt -53.53 -52.54 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -0.922 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.428 ' CG ' ' HE1' ' A' ' 43' ' ' MET . 93.2 mmm -58.32 -38.79 77.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.498 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -52.75 -41.71 64.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 109.452 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.493 ' O ' ' N ' ' A' ' 117' ' ' GLN . 37.6 mtp85 -57.28 -43.89 83.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.514 HD11 ' CB ' ' A' ' 64' ' ' PHE . 6.7 tp -43.98 -49.42 8.58 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -0.876 . . . . 0.0 109.511 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -57.56 -26.32 61.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.299 -0.876 . . . . 0.0 109.474 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.493 ' N ' ' O ' ' A' ' 114' ' ' ARG . 44.5 tt0 -85.82 125.01 32.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.468 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -120.61 134.34 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.36 -21.49 6.24 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -95.34 139.45 31.63 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -1.116 . . . . 0.0 109.493 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 mmtp -119.86 74.64 19.48 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.514 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.08 144.16 51.51 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.665 2.244 . . . . 0.0 111.805 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 33.2 ttt-85 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.976 -1.012 . . . . 0.0 109.483 -179.997 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.3 mmm . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.3 t -60.38 -28.82 68.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -0.886 . . . . 0.0 109.421 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -62.04 141.62 57.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.227 -0.921 . . . . 0.0 109.372 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.52 81.52 31.72 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.13 -0.981 . . . . 0.0 109.597 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.85 145.91 58.05 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.753 2.302 . . . . 0.0 111.719 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.4 ' O ' ' HG2' ' A' ' 6' ' ' LYS . 48.1 tttp -91.3 27.82 1.82 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.533 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.39 133.13 44.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.246 -0.909 . . . . 0.0 109.509 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.461 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 54.3 mtt180 -123.42 153.96 39.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.427 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.549 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 73.8 m95 -96.16 123.74 39.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.227 -0.92 . . . . 0.0 109.581 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.57 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 88.1 m-85 -119.19 159.64 23.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -0.943 . . . . 0.0 109.473 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.458 ' O ' ' CD1' ' A' ' 92' ' ' PHE . 27.0 t -94.33 149.18 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.637 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.454 ' N ' HG12 ' A' ' 11' ' ' VAL . 57.3 t -124.64 118.74 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.246 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.519 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 59.3 tt0 -84.85 140.07 31.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.58 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.438 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -156.92 -153.39 0.41 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.934 . . . . 0.0 109.391 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.96 140.62 46.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.446 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 t -59.24 132.73 54.89 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.48 -16.92 60.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -109.48 0.19 19.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -1.143 . . . . 0.0 109.576 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.492 ' OE2' ' N ' ' A' ' 68' ' ' TYR . 99.0 mt-10 -56.35 -44.34 79.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.367 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.55 -50.15 67.11 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.512 ' NH2' ' HG3' ' A' ' 88' ' ' ARG . 12.4 ttp180 -57.3 -56.26 24.12 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -1.123 . . . . 0.0 109.416 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.403 ' C ' ' O ' ' A' ' 21' ' ' ARG . 40.7 t -45.46 -38.68 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.87 -44.85 96.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.342 -0.849 . . . . 0.0 109.266 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.4 m -69.44 -47.28 64.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.531 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 15.3 t -57.4 -56.21 24.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.338 -0.851 . . . . 0.0 109.489 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.427 HD13 ' CG2' ' A' ' 86' ' ' VAL . 14.0 tp -46.82 -49.71 19.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.377 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.465 ' CG ' ' HE2' ' A' ' 31' ' ' LYS . 46.7 ttm-85 -60.71 -34.59 74.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.186 -0.946 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -64.18 -48.07 77.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.225 -0.922 . . . . 0.0 109.322 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 25' ' ' SER . 60.1 m-70 -66.3 -37.29 85.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 109.341 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.588 ' CD1' ' CD2' ' A' ' 39' ' ' PHE . 90.8 mt -65.26 -49.03 81.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.256 -0.903 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.465 ' HE2' ' CG ' ' A' ' 27' ' ' ARG . 25.3 mttm -56.84 -40.05 75.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 29.8 mt -69.91 -52.02 28.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.45 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.7 m-70 -81.12 4.34 20.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.591 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' ILE . 78.8 m-20 54.76 47.65 21.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.248 -0.907 . . . . 0.0 109.511 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.523 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 61.1 mmm -94.2 6.54 48.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.932 . . . . 0.0 109.594 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.502 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.53 -31.19 34.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.394 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -61.85 -41.84 98.31 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.351 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.491 ' CD1' ' HE1' ' A' ' 35' ' ' MET . 10.3 mt -70.93 -53.68 14.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.588 ' CD2' ' CD1' ' A' ' 30' ' ' ILE . 73.9 m-85 -75.2 143.33 43.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.306 -0.871 . . . . 0.0 109.474 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.34 -58.84 0.24 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -136.29 156.48 48.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -1.223 . . . . 0.0 109.734 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.455 HG12 HG21 ' A' ' 71' ' ' VAL . 54.5 t -121.01 154.66 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.549 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 88.7 mmm -121.99 147.68 45.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.159 -0.963 . . . . 0.0 109.633 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -138.45 103.95 7.81 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.379 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.549 ' HB2' ' CG ' ' A' ' 65' ' ' PHE . 48.7 Cg_endo -70.03 -9.26 25.61 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.643 2.229 . . . . 0.0 111.853 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.4 p -76.04 142.39 41.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.127 -0.983 . . . . 0.0 109.53 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -63.23 -40.47 97.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.209 -0.932 . . . . 0.0 109.412 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -143.18 150.4 39.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.895 . . . . 0.0 109.374 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 70.3 t -63.66 -37.86 80.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.2 t -111.82 142.09 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.495 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 87.7 tt0 -82.05 143.62 31.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.908 . . . . 0.0 109.543 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 65.1 mt -137.05 107.92 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.255 -0.903 . . . . 0.0 109.379 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -48.32 -33.12 8.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.919 . . . . 0.0 109.497 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -80.13 -113.6 0.28 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 68.49 -120.35 11.36 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 91.8 mt-30 -103.99 152.29 22.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -1.104 . . . . 0.0 109.491 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -58.98 -34.4 71.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.443 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 44.8 mtp85 -54.5 145.06 19.44 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.286 -0.884 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 20.8 tttm -96.74 135.34 38.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 50.1 m -119.83 146.72 45.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -0.945 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -122.23 150.52 42.18 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.288 -0.882 . . . . 0.0 109.501 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 11.7 mtt85 -104.76 6.13 33.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . 0.446 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 62.4 mttm -62.06 -25.14 67.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -57.42 -36.62 71.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -0.902 . . . . 0.0 109.597 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.549 ' CG ' ' HB2' ' A' ' 45' ' ' PRO . 32.7 m-85 -130.26 80.62 70.28 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.524 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 50.9 Cg_endo -70.79 76.73 1.51 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.667 2.244 . . . . 0.0 111.964 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 75.31 33.73 52.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.492 ' N ' ' OE2' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -111.0 119.47 39.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 109.366 179.946 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.4 ' O ' ' N ' ' A' ' 12' ' ' VAL . 86.0 t -134.17 140.62 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.554 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.0 mp -104.3 141.76 35.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.382 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.455 HG21 HG12 ' A' ' 42' ' ' VAL . 68.9 t -145.26 123.67 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -0.951 . . . . 0.0 109.705 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -73.96 124.87 27.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.309 -0.869 . . . . 0.0 109.127 179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.458 ' SD ' ' OG ' ' A' ' 79' ' ' SER . 8.8 tmm? -169.22 151.52 4.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.293 -0.88 . . . . 0.0 109.398 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 28.6 m -77.59 118.97 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.585 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.57 ' HG2' ' CE2' ' A' ' 10' ' ' TYR . 8.5 mmt -61.72 115.84 4.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.172 -0.955 . . . . 0.0 109.585 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.2 p-10 -151.28 172.74 15.39 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.36 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -63.4 -33.78 76.29 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.645 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -71.5 -72.36 0.22 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 109.661 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.524 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 18.0 p -46.63 -57.59 4.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.525 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 44.0 t90 -43.65 -53.89 5.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.34 -0.85 . . . . 0.0 109.574 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.53 -43.41 98.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.61 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.57 HD23 ' CE2' ' A' ' 39' ' ' PHE . 0.8 OUTLIER -55.81 -43.1 76.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 0.0 109.491 -179.843 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 98.2 t -61.01 -52.11 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 57.4 ttt85 -55.63 -35.08 65.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.566 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 39.9 m -59.58 -37.22 77.93 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.187 -0.946 . . . . 0.0 109.555 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.518 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 91.8 t -54.99 125.56 56.92 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 109.516 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.462 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.7 Cg_endo -71.25 160.28 49.39 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.624 2.216 . . . . 0.0 111.769 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.512 ' HG3' ' NH2' ' A' ' 21' ' ' ARG . 50.1 mmt-85 63.66 30.79 14.79 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.695 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.518 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 6.1 p -129.24 130.63 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.157 -0.964 . . . . 0.0 109.375 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.492 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.1 mmm -76.46 -54.98 5.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 166.67 -150.12 16.74 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.569 ' CE1' ' HE1' ' A' ' 75' ' ' MET . 6.5 m-85 -105.5 161.86 13.98 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -1.131 . . . . 0.0 109.561 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.519 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 19.3 mm -120.3 122.13 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.415 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -179.66 -144.39 5.88 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.62 -45.25 95.04 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 p -130.76 171.01 13.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.219 -1.165 . . . . 0.0 109.463 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.9 p -89.02 16.61 6.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.144 -0.972 . . . . 0.0 109.37 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.525 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.1 m-20 -125.64 -27.14 3.42 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.533 -0.729 . . . . 0.0 109.261 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -140.16 97.63 7.73 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.339 -0.851 . . . . 0.0 108.846 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.532 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.72 127.12 15.73 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.79 2.327 . . . . 0.0 112.067 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.63 138.51 93.5 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.256 -0.902 . . . . 0.0 109.234 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.456 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.8 Cg_endo -70.45 153.66 65.6 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.603 2.202 . . . . 0.0 111.845 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.402 HD12 HG21 ' A' ' 108' ' ' VAL . 34.9 pt -127.55 161.08 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.452 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.458 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 43.7 m -71.79 150.56 44.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.348 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -56.93 -37.91 72.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.335 -0.853 . . . . 0.0 109.456 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -60.35 -34.02 73.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.441 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.458 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 76.5 mm-40 -59.12 -41.85 89.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.922 . . . . 0.0 109.384 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.463 HG23 ' CG ' ' A' ' 9' ' ' TRP . 90.0 t -63.33 -36.2 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.913 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -66.6 -38.71 87.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.69 -47.7 77.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.451 HD13 ' CD2' ' A' ' 70' ' ' LEU . 45.2 mt -50.49 -51.41 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.497 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 96.2 mmm -60.32 -35.87 76.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.156 -0.965 . . . . 0.0 109.387 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -61.82 -32.7 73.03 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.246 -0.909 . . . . 0.0 109.42 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 115' ' ' LEU . 59.2 mtt180 -56.23 -50.69 70.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.283 -0.885 . . . . 0.0 109.458 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.46 HD13 ' CE1' ' A' ' 65' ' ' PHE . 10.3 tp -44.88 -47.9 11.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.354 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -71.43 -29.66 65.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.208 -0.933 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -75.47 131.21 39.98 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.474 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.401 HG11 ' OD1' ' A' ' 120' ' ' ASP . 75.5 t -68.08 -35.74 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.296 -0.878 . . . . 0.0 109.516 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.56 45.7 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.401 ' OD1' HG11 ' A' ' 118' ' ' VAL . 95.3 m-20 -55.51 -36.7 67.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -1.171 . . . . 0.0 109.515 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.76 68.52 2.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.206 -0.934 . . . . 0.0 109.526 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.95 147.0 60.67 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 122.631 2.22 . . . . 0.0 111.825 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 66.0 mtp85 . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.48 -179.963 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.0 mtm . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.7 p -63.23 -22.72 67.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.21 -0.931 . . . . 0.0 109.499 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -91.92 150.7 20.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.167 -0.958 . . . . 0.0 109.453 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 58.12 62.07 5.16 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.09 -19.22 34.85 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.714 2.276 . . . . 0.0 111.782 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mmtm -90.43 155.87 18.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 40.1 mttt -82.61 139.89 33.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.399 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.474 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 23.1 mtm180 -122.26 154.85 37.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -93.56 137.69 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.549 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 46.0 m-85 -131.85 164.19 26.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.868 . . . . 0.0 109.567 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.452 HG12 ' CG1' ' A' ' 93' ' ' ILE . 40.9 t -99.2 139.89 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 109.53 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.9 t -122.74 119.54 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.501 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 49.8 tt0 -87.24 135.44 33.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -141.32 161.28 38.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.369 -0.832 . . . . 0.0 109.41 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.458 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 97.4 m-85 -57.75 149.99 20.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 35.0 t -71.9 145.94 48.18 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.51 -34.37 4.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.428 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 17.9 m-30 -108.48 6.61 26.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.261 -1.141 . . . . 0.0 109.502 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.505 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 22.8 pt-20 -51.62 -43.84 62.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.331 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -67.29 -54.35 20.76 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -58.68 -40.57 83.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.174 -1.192 . . . . 0.0 109.389 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 88' ' ' ARG . 76.6 t -50.75 -48.67 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.408 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.42 ' HB1' HG11 ' A' ' 42' ' ' VAL . . . -55.32 -40.73 71.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.243 -0.911 . . . . 0.0 109.336 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.2 m -65.83 -39.94 91.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.249 -0.907 . . . . 0.0 109.418 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 21.1 m -57.85 -46.35 84.93 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.254 -0.904 . . . . 0.0 109.398 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.464 ' O ' HG12 ' A' ' 30' ' ' ILE . 34.9 mt -52.27 -55.98 17.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.348 -0.845 . . . . 0.0 109.357 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.408 ' C ' ' O ' ' A' ' 26' ' ' LEU . 49.3 ttt-85 -42.58 -40.75 2.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.417 -0.802 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.464 ' HB2' ' O ' ' A' ' 25' ' ' SER . 89.7 mt-10 -58.85 -39.05 80.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.21 -0.931 . . . . 0.0 109.393 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.574 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 66.0 m-70 -82.18 -19.85 39.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.352 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' A' ' 39' ' ' PHE . 20.5 mm -75.34 -48.46 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.239 -0.913 . . . . 0.0 109.225 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -71.53 -41.22 69.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -0.851 . . . . 0.0 109.236 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 67.0 mt -63.9 -47.42 80.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.449 -0.782 . . . . 0.0 109.404 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.565 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 88.8 m-70 -84.05 9.25 12.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 49.08 48.47 20.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 0.0 109.394 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.544 ' HB3' ' CD1' ' A' ' 39' ' ' PHE . 41.4 mtt -102.79 -0.66 31.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 35' ' ' MET . 97.2 mt-10 -43.89 -36.04 2.23 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.243 -0.91 . . . . 0.0 109.647 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -56.96 -50.25 73.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.205 -0.934 . . . . 0.0 109.713 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.524 HD23 ' ND2' ' A' ' 76' ' ' ASN . 0.3 OUTLIER -71.31 -48.52 50.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.52 -179.691 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' A' ' 30' ' ' ILE . 66.1 m-85 -70.4 141.35 52.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 109.452 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.452 ' HA3' ' OE1' ' A' ' 72' ' ' GLN . . . -102.65 -70.12 0.84 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -158.66 147.21 18.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.187 -1.184 . . . . 0.0 109.495 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.459 HG22 HG11 ' A' ' 71' ' ' VAL . 60.1 t -95.79 138.45 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.499 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.451 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 65.1 mtm -121.32 150.09 41.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.368 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.427 HG11 ' HD2' ' A' ' 45' ' ' PRO . 93.4 t -144.58 127.02 8.3 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.576 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.457 ' O ' HD12 ' A' ' 115' ' ' LEU . 50.0 Cg_endo -70.47 -8.54 23.84 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.687 2.258 . . . . 0.0 111.684 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.482 ' CG2' ' OE2' ' A' ' 19' ' ' GLU . 16.2 p -104.81 37.96 2.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.908 . . . . 0.0 109.492 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -47.33 -34.66 7.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.214 -0.929 . . . . 0.0 109.379 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -101.8 131.98 47.81 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.419 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.8 t -121.88 136.45 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.307 -0.871 . . . . 0.0 109.426 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.21 148.65 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.229 -0.919 . . . . 0.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.44 ' OE2' ' HD3' ' A' ' 53' ' ' ARG . 65.3 tt0 -121.58 138.57 54.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 109.454 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.2 tt -57.23 -31.33 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . 0.456 ' O ' ' O ' ' A' ' 54' ' ' GLY . 72.5 mtp85 -57.93 -32.38 67.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.221 -0.924 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' A' ' 53' ' ' ARG . . . -54.78 -167.87 0.04 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 54' ' ' GLY . . . -45.01 103.92 0.06 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -61.13 -32.2 71.91 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -1.135 . . . . 0.0 109.47 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 20.9 ttp85 -53.44 -38.6 63.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.47 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 89.6 mtt-85 -83.56 131.66 34.97 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -139.65 125.23 19.28 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.869 . . . . 0.0 109.467 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 t -177.48 112.15 0.08 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.206 -0.934 . . . . 0.0 109.383 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -132.79 145.69 51.21 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.635 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.405 ' HB2' ' CE2' ' A' ' 64' ' ' PHE . 77.0 mtt180 -120.87 148.21 44.35 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.259 -0.901 . . . . 0.0 109.338 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -107.33 121.97 45.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.263 -0.898 . . . . 0.0 109.62 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.561 ' CE1' ' HA ' ' A' ' 115' ' ' LEU . 77.8 m-85 -127.5 156.94 41.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.352 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.425 ' C ' ' O ' ' A' ' 64' ' ' PHE . 1.4 p90 -42.19 101.08 0.24 Allowed Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.346 -0.846 . . . . 0.0 109.647 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 53.2 Cg_endo -72.81 152.09 52.13 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.637 2.225 . . . . 0.0 111.806 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.448 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . 67.75 29.84 74.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -128.61 115.3 17.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.196 -1.179 . . . . 0.0 109.375 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 43' ' ' MET . 87.3 t -132.9 144.85 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.262 -0.899 . . . . 0.0 109.609 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.58 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.1 mp -101.06 129.53 46.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.328 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.461 HG21 ' O ' ' A' ' 70' ' ' LEU . 91.0 t -140.75 115.36 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.76 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.452 ' OE1' ' HA3' ' A' ' 40' ' ' GLY . 36.9 tt0 -65.98 135.9 55.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.928 . . . . 0.0 109.171 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.575 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 10.9 ttp -173.78 152.1 1.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.16 -0.962 . . . . 0.0 109.587 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.512 ' N ' ' HG2' ' A' ' 73' ' ' MET . 38.7 t -81.67 141.2 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.281 179.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.528 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 15.1 tpp -78.1 100.12 6.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.212 -0.93 . . . . 0.0 109.74 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.524 ' ND2' HD23 ' A' ' 38' ' ' LEU . 51.4 p-10 -140.87 169.39 17.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.306 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -72.67 -26.39 61.61 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.5 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.58 -71.31 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 0.0 109.584 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.53 ' OG ' ' CE ' ' A' ' 73' ' ' MET . 11.4 p -53.47 -45.19 69.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.412 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.9 t90 -56.44 -59.01 5.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -54.92 -44.01 73.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.565 ' CD1' ' CD2' ' A' ' 33' ' ' HIS . 41.1 tp -56.13 -47.8 77.44 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 80.0 t -50.41 -48.05 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.245 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 16.5 ttt-85 -70.63 -28.17 64.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.383 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.4 m -58.82 -47.15 85.8 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.35 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.574 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 4.4 p -76.08 132.39 73.93 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.472 ' O ' HG23 ' A' ' 89' ' ' VAL . 47.7 Cg_endo -69.02 -174.03 0.7 Allowed 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.672 2.248 . . . . 0.0 111.892 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.462 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 70.1 mtt85 63.69 32.04 14.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.359 -0.838 . . . . 0.0 109.444 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 87' ' ' PRO . 6.4 t -131.89 117.26 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.501 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 83.2 mtp -73.73 -38.29 64.84 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 148.62 -176.26 27.5 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.573 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 15.7 m-85 -94.98 158.25 15.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.311 -1.111 . . . . 0.0 109.649 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.452 ' CG1' HG12 ' A' ' 11' ' ' VAL . 18.9 mm -118.55 114.24 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.301 -0.875 . . . . 0.0 109.378 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.01 -141.77 3.25 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.55 -29.12 60.2 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.463 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 21.0 p -136.33 169.32 17.85 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.199 -1.177 . . . . 0.0 109.655 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -91.72 19.61 6.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.356 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.463 ' OD1' ' OG1' ' A' ' 96' ' ' THR . 48.1 p30 -140.73 11.05 2.25 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.55 -0.718 . . . . 0.0 109.081 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -171.88 97.8 0.39 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.327 -0.858 . . . . 0.0 108.916 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.573 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 49.7 Cg_endo -68.94 113.75 3.34 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.752 2.301 . . . . 0.0 111.949 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.91 142.02 74.17 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.229 -0.92 . . . . 0.0 109.357 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.471 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 50.9 Cg_endo -70.22 153.98 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.715 2.277 . . . . 0.0 111.922 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.454 ' HB ' ' OE1' ' A' ' 107' ' ' GLU . 31.3 pt -129.23 152.73 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.9 m -67.0 145.29 55.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.617 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -53.75 -41.03 66.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.888 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -59.19 -44.57 92.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.454 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 83.2 tt0 -51.17 -46.32 62.04 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.443 HG11 ' HE1' ' A' ' 43' ' ' MET . 60.4 t -53.97 -41.56 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.229 -0.919 . . . . 0.0 109.282 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -59.77 -41.18 90.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.247 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.462 ' O ' ' HB2' ' A' ' 113' ' ' ASN . . . -59.52 -52.62 64.77 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.278 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 54.1 mt -47.05 -51.91 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.299 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.8 mtp -56.5 -37.02 69.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.322 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.462 ' HB2' ' O ' ' A' ' 110' ' ' ALA . 97.4 m-20 -58.13 -34.93 70.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 117' ' ' GLN . 59.2 mtt180 -50.54 -45.83 57.11 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.561 ' HA ' ' CE1' ' A' ' 64' ' ' PHE . 7.3 tp -44.08 -44.14 7.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -62.6 -29.84 70.9 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.885 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 114' ' ' ARG . 63.3 tt0 -69.14 139.29 54.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.325 -0.859 . . . . 0.0 109.51 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.514 ' CG1' ' OD1' ' A' ' 120' ' ' ASP . 86.2 t -54.76 -44.05 69.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 86.93 26.13 32.56 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.514 ' OD1' ' CG1' ' A' ' 118' ' ' VAL . 96.9 m-20 -55.76 -36.03 66.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.305 -1.115 . . . . 0.0 109.447 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -91.95 110.8 46.35 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.278 -0.889 . . . . 0.0 109.485 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.97 147.49 61.66 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.686 2.258 . . . . 0.0 111.83 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.45 -179.936 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.1 mtp . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.5 p -61.85 -30.78 71.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.536 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -61.11 -36.23 79.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.875 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -73.6 149.97 88.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.422 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.17 147.31 59.94 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.658 2.239 . . . . 0.0 111.768 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 23.3 mttp -89.99 143.45 26.77 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.431 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -89.44 134.66 33.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.92 . . . . 0.0 109.536 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.2 mtt180 -126.14 158.95 34.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.466 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.489 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 58.8 m95 -99.82 121.09 40.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.955 . . . . 0.0 109.788 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.568 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 96.6 m-85 -114.77 157.59 23.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.31 -0.869 . . . . 0.0 109.229 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 88.6 t -105.89 143.48 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 109.599 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.0 t -120.99 127.96 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.314 -0.866 . . . . 0.0 109.472 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.524 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 68.2 tp60 -86.98 145.32 26.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -0.9 . . . . 0.0 109.48 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.09 153.87 34.8 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.54 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -58.72 144.27 44.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.517 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 26.2 t -61.9 141.09 58.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.43 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.94 -31.18 5.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.486 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 90.3 m-85 -105.01 7.33 33.99 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.267 -1.137 . . . . 0.0 109.585 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.576 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 85.5 tt0 -58.44 -42.59 87.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.117 -0.99 . . . . 0.0 109.382 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.82 -38.0 65.91 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.459 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 22.2 ttm180 -62.02 -50.63 71.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -1.15 . . . . 0.0 109.442 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.451 ' CG2' ' O ' ' A' ' 88' ' ' ARG . 37.4 t -49.45 -41.02 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.181 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 -42.39 99.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.234 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 41.5 m -67.38 -47.12 71.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.273 -0.892 . . . . 0.0 109.341 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.9 m -64.66 -34.41 78.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.253 -0.904 . . . . 0.0 109.375 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.537 HD21 ' CE2' ' A' ' 39' ' ' PHE . 5.4 tt -58.57 -53.54 57.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.304 -0.873 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.403 ' NE ' ' NZ ' ' A' ' 31' ' ' LYS . 23.0 tpt180 -45.14 -46.0 11.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.254 -0.904 . . . . 0.0 109.598 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -53.5 -50.88 64.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.558 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.454 ' HB3' HD13 ' A' ' 82' ' ' LEU . 94.7 m-70 -56.92 -29.1 62.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.286 -0.883 . . . . 0.0 109.533 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.639 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 10.2 mm -68.94 -53.72 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.227 -0.921 . . . . 0.0 109.567 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.51 ' CD ' ' OE2' ' A' ' 36' ' ' GLU . 24.8 mmtm -66.05 -44.18 85.3 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.658 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 49.0 mt -61.32 -55.95 25.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.277 -0.89 . . . . 0.0 109.611 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.627 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 90.8 m-70 -81.87 7.53 12.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 53.1 t30 48.83 45.76 22.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.585 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.495 ' HG3' ' CD2' ' A' ' 82' ' ' LEU . 35.2 mmm -99.55 20.57 13.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.374 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' OE2' ' CD ' ' A' ' 31' ' ' LYS . 83.9 mt-10 -53.83 -36.86 63.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -0.873 . . . . 0.0 109.482 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -59.16 -44.97 92.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.925 . . . . 0.0 109.486 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.496 HD21 ' CG1' ' A' ' 74' ' ' VAL . 35.2 mt -66.94 -56.66 9.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.918 . . . . 0.0 109.507 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.639 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 93.6 m-85 -72.01 141.08 49.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.902 . . . . 0.0 109.472 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -125.62 -61.99 0.17 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.55 149.34 43.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.189 -1.183 . . . . 0.0 109.698 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.454 HG11 HG23 ' A' ' 71' ' ' VAL . 45.3 t -117.48 151.86 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.344 -0.847 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.511 ' CE ' ' HE1' ' A' ' 112' ' ' MET . 80.8 mmm -117.11 137.41 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.231 -0.918 . . . . 0.0 109.676 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.459 HG21 ' O ' ' A' ' 43' ' ' MET . 43.2 t -145.12 82.33 9.95 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.313 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.72 0.68 6.0 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.649 2.233 . . . . 0.0 111.988 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 14.5 t -125.96 144.08 50.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 47.59 50.27 15.25 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.296 -0.878 . . . . 0.0 109.484 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.436 ' HB2' ' O ' ' A' ' 44' ' ' VAL . 84.6 tt0 -103.16 129.47 50.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.314 -0.866 . . . . 0.0 109.515 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 80.8 t -63.41 -40.02 87.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.302 -0.874 . . . . 0.0 109.503 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 63.4 t -52.92 -39.01 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -77.89 154.28 31.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.219 -0.925 . . . . 0.0 109.474 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 65.0 mt -133.25 94.58 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.894 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 50.1 ttm-85 -82.49 149.02 27.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.305 -0.872 . . . . 0.0 109.426 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -178.84 36.82 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.83 38.64 41.41 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -83.08 139.76 33.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.218 -1.166 . . . . 0.0 109.526 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 15.2 mmt85 -115.74 161.25 18.99 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.261 -0.899 . . . . 0.0 109.446 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -51.52 -38.33 53.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.162 -0.961 . . . . 0.0 109.519 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 53.0 tttm -129.95 116.69 18.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.412 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.0 t -153.5 156.51 38.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -97.2 137.04 36.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.275 -0.89 . . . . 0.0 109.424 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.5 mtp180 -134.0 145.58 49.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.207 -0.933 . . . . 0.0 109.576 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -136.88 121.67 18.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.273 -0.892 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -131.92 156.05 46.83 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.916 . . . . 0.0 109.518 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.556 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 23.3 p90 -116.65 68.39 4.09 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.167 -0.958 . . . . 0.0 109.583 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.49 155.77 62.83 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.429 ' O ' ' NE2' ' A' ' 13' ' ' GLN . . . 101.21 -6.65 56.28 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.419 ' CE1' ' OE1' ' A' ' 13' ' ' GLN . 1.8 m-85 -119.71 117.21 27.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.2 -1.176 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 78.4 t -131.61 141.85 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.917 . . . . 0.0 109.657 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.568 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.7 mp -106.97 132.96 52.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -0.88 . . . . 0.0 109.271 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.454 HG23 HG11 ' A' ' 42' ' ' VAL . 86.5 t -137.94 121.67 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.178 -0.951 . . . . 0.0 109.639 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.467 ' O ' ' HB2' ' A' ' 73' ' ' MET . 38.0 tt0 -72.16 137.1 46.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.267 -0.895 . . . . 0.0 109.199 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.512 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 45.8 ttp 171.81 157.73 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.263 -0.898 . . . . 0.0 109.604 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.506 ' N ' ' HG2' ' A' ' 73' ' ' MET . 12.2 p -85.69 138.31 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.174 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.575 ' CE ' ' CG ' ' A' ' 100' ' ' PRO . 16.4 mmt -90.04 115.36 27.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.208 -0.932 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.489 ' OD1' ' N ' ' A' ' 79' ' ' SER . 48.8 p-10 -140.48 -176.59 4.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.351 -0.843 . . . . 0.0 109.425 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -73.37 -11.6 60.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.589 ' HA ' ' CE1' ' A' ' 81' ' ' HIS . . . -94.23 -71.1 0.68 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.466 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.489 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 68.9 p -50.69 -48.13 58.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.379 -0.826 . . . . 0.0 109.516 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.61 ' NE1' ' CE2' ' A' ' 92' ' ' PHE . 79.7 t90 -48.51 -58.92 3.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -0.928 . . . . 0.0 109.694 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.625 ' CD2' ' N ' ' A' ' 82' ' ' LEU . 1.5 p-80 -57.84 -30.84 66.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.085 -1.009 . . . . 0.0 109.213 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.627 ' CD1' ' CD2' ' A' ' 33' ' ' HIS . 19.0 tp -68.52 -36.34 78.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.384 -0.823 . . . . 0.0 109.328 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 77.5 t -62.04 -42.63 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.248 -0.908 . . . . 0.0 109.399 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -65.96 -33.25 75.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.377 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 35.8 m -60.07 -32.96 71.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.173 -0.954 . . . . 0.0 109.38 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.521 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 18.8 t -55.37 123.41 49.48 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.487 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.463 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.9 Cg_endo -70.83 156.48 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.618 2.212 . . . . 0.0 111.712 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.486 ' HD3' ' CD1' ' A' ' 18' ' ' PHE . 42.4 mtt-85 62.44 35.29 14.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.31 -0.869 . . . . 0.0 109.586 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.521 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 7.4 p -123.39 125.82 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.436 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.524 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 51.3 mtt -68.93 -62.01 1.56 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.459 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 171.13 -151.57 16.03 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.61 ' CE2' ' NE1' ' A' ' 80' ' ' TRP . 93.1 m-85 -96.27 162.96 13.29 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.327 -1.102 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.518 ' CD1' ' HB2' ' A' ' 13' ' ' GLN . 47.3 mm -110.97 152.7 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.223 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.82 -108.95 3.44 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.409 ' O ' ' C ' ' A' ' 96' ' ' THR . . . -57.06 -37.24 78.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.415 ' O ' ' C ' ' A' ' 97' ' ' SER . 68.8 p 43.73 -148.66 0.05 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -1.167 . . . . 0.0 109.477 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.469 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 26.7 t 44.67 39.92 3.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.173 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 80' ' ' TRP . 22.8 m-20 67.09 38.2 3.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.347 -0.846 . . . . 0.0 109.313 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.404 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 4.2 mtp180 -161.48 88.41 1.57 Allowed Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.281 -0.887 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.575 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 48.2 Cg_endo -69.96 135.27 29.56 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.783 2.322 . . . . 0.0 111.952 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -99.14 143.48 26.47 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.451 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.45 155.51 63.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.823 2.349 . . . . 0.0 111.759 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.468 HD12 ' CG2' ' A' ' 108' ' ' VAL . 24.0 pt -125.5 156.32 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.401 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 48.3 m -69.8 150.22 47.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.303 -0.873 . . . . 0.0 109.531 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -59.68 -42.38 92.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -0.899 . . . . 0.0 109.442 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -53.94 -43.09 69.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.314 -0.866 . . . . 0.0 109.424 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.401 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.8 mt-10 -53.78 -44.69 70.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.468 ' CG2' HD12 ' A' ' 103' ' ' ILE . 98.0 t -55.91 -37.95 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.26 -0.9 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -70.44 -34.91 72.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.933 . . . . 0.0 109.381 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.28 -36.71 84.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.445 HG13 HD21 ' A' ' 70' ' ' LEU . 32.1 mm -49.6 -56.48 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.28 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.511 ' HE1' ' CE ' ' A' ' 43' ' ' MET . 54.2 mtt -59.84 -31.48 69.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.289 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -61.6 -38.55 87.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.393 -0.817 . . . . 0.0 109.446 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 31.9 mtp85 -56.88 -46.33 81.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.249 -0.907 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.4 tp -54.3 -40.19 67.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -80.3 -4.19 52.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -78.32 144.72 35.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.184 -0.947 . . . . 0.0 109.451 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 t -99.59 146.71 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.347 -0.845 . . . . 0.0 109.507 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -48.12 -23.83 3.01 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -67.59 141.08 56.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.234 -1.156 . . . . 0.0 109.483 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.9 122.17 74.36 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.307 -0.87 . . . . 0.0 109.452 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.4 144.35 50.38 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.781 2.321 . . . . 0.0 111.759 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.489 179.962 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.4 m -122.05 146.51 47.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.296 -0.878 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -52.42 -36.02 53.35 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 58.7 99.78 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.449 ' O ' ' HB2' ' A' ' 6' ' ' LYS . 50.4 Cg_endo -70.68 -2.45 10.86 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.73 2.287 . . . . 0.0 111.811 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' A' ' 5' ' ' PRO . 57.5 mttp 61.72 42.49 10.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.274 -0.891 . . . . 0.0 109.471 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.514 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 68.4 mttm -87.27 137.54 32.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.219 -0.925 . . . . 0.0 109.54 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.411 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 63.0 mtt180 -128.16 152.22 48.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.419 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -85.38 129.84 34.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.486 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CZ ' ' HB2' ' A' ' 75' ' ' MET . 81.2 m-85 -122.84 155.77 35.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.391 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.563 ' CG1' ' CE1' ' A' ' 68' ' ' TYR . 43.1 t -92.02 150.76 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.512 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.5 t -132.49 124.29 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.308 -0.87 . . . . 0.0 109.387 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.51 ' HB3' ' CE ' ' A' ' 90' ' ' MET . 96.3 mt-30 -85.18 147.22 26.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.282 -0.886 . . . . 0.0 109.528 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.2 155.27 34.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.382 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.514 ' CD1' ' HA ' ' A' ' 88' ' ' ARG . 97.0 m-85 -72.16 147.22 46.82 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.0 m -55.56 144.08 27.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.292 -0.88 . . . . 0.0 109.471 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.425 ' HA2' ' OE1' ' A' ' 51' ' ' GLU . . . 89.91 -33.67 4.36 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -106.45 15.34 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.49 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.427 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.5 tt0 -52.43 -39.27 60.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.408 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 23' ' ' ALA . . . -90.93 -35.61 7.09 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 22' ' ' VAL . 35.5 ttt-85 -51.72 -52.64 46.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -1.169 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.426 HG11 HG12 ' A' ' 86' ' ' VAL . 38.9 t -45.64 -38.04 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.175 -0.953 . . . . 0.0 109.314 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.446 ' HB3' ' O ' ' A' ' 20' ' ' GLY . . . -64.83 -43.04 94.36 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.297 179.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 58.2 m -67.03 -47.03 72.66 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.287 -0.883 . . . . 0.0 109.3 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.7 m -61.75 -40.59 95.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.36 -0.837 . . . . 0.0 109.435 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.523 ' CD1' ' CG2' ' A' ' 86' ' ' VAL . 11.5 tp -56.12 -40.98 74.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.9 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -53.32 -44.14 68.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.309 -0.87 . . . . 0.0 109.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.41 ' O ' ' CD1' ' A' ' 32' ' ' LEU . 97.4 mt-10 -60.68 -47.82 84.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.421 ' HB3' HD11 ' A' ' 82' ' ' LEU . 95.3 m-70 -63.46 -43.5 97.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.529 HG12 ' CE1' ' A' ' 39' ' ' PHE . 89.3 mt -67.83 -50.76 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.902 . . . . 0.0 109.482 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -59.6 -40.0 86.04 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.303 -0.873 . . . . 0.0 109.447 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.41 ' CD1' ' O ' ' A' ' 28' ' ' GLU . 16.0 mt -63.22 -53.98 44.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.47 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.466 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 97.4 m-70 -82.99 -0.6 49.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.56 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.508 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.2 m-20 62.56 47.11 5.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.18 -0.95 . . . . 0.0 109.356 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.505 ' HG3' ' CD1' ' A' ' 82' ' ' LEU . 57.8 mmm -90.35 0.57 57.2 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.586 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.451 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -47.83 -33.38 7.27 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.906 . . . . 0.0 109.489 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -60.4 -42.32 95.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.7 mt -70.42 -49.41 49.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.303 -0.873 . . . . 0.0 109.313 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.561 ' CE1' HD23 ' A' ' 82' ' ' LEU . 88.5 m-85 -74.74 140.73 44.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.05 -64.69 0.53 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -140.52 157.44 45.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 109.53 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.445 ' CG1' HG21 ' A' ' 71' ' ' VAL . 61.6 t -120.16 147.41 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.517 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.457 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 60.7 mtm -131.46 141.9 49.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.411 HG12 ' OG1' ' A' ' 46' ' ' THR . 42.8 t -124.77 105.01 30.03 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.238 -0.914 . . . . 0.0 109.449 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.83 60.75 2.27 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.721 2.281 . . . . 0.0 111.803 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.411 ' OG1' HG12 ' A' ' 44' ' ' VAL . 29.2 p -137.19 147.61 45.99 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 109.447 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.438 ' HA ' ' OE1' ' A' ' 47' ' ' GLU . 70.8 mm-40 -63.63 -34.8 78.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.234 -0.916 . . . . 0.0 109.373 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 37.4 tp10 -131.63 145.92 51.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.298 -0.876 . . . . 0.0 109.365 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 18.3 m -63.53 -31.03 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 31.4 t -110.04 139.62 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.525 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.425 ' OE1' ' HA2' ' A' ' 17' ' ' GLY . 86.0 tt0 -85.34 125.55 33.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.411 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 24.9 pt -102.45 -7.87 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.313 -0.867 . . . . 0.0 109.597 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 84.3 mtm180 -110.97 153.8 25.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.137 -0.977 . . . . 0.0 109.511 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -136.62 169.02 23.99 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.429 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . 94.27 -0.17 65.95 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.429 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 52.8 mt-30 61.55 42.55 11.11 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -1.158 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -68.38 139.65 55.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 92.5 mtm-85 -134.77 145.08 48.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.25 -0.906 . . . . 0.0 109.477 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 77.7 mttt -105.36 128.92 53.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.179 -0.951 . . . . 0.0 109.464 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 15.7 m -62.93 -19.47 64.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.368 -0.832 . . . . 0.0 109.463 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 90.0 mt-10 -65.55 -32.24 73.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.269 -0.894 . . . . 0.0 109.514 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.444 ' HG2' HG12 ' A' ' 118' ' ' VAL . 65.1 mtt85 -140.32 139.95 35.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -97.9 125.73 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.215 -0.928 . . . . 0.0 109.541 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -119.11 155.66 31.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.46 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.523 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 0.9 OUTLIER -124.34 87.21 54.16 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.235 -0.916 . . . . 0.0 109.538 -179.983 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -70.85 153.65 63.8 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.73 2.287 . . . . 0.0 111.836 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.23 9.68 79.35 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.563 ' CE1' ' CG1' ' A' ' 11' ' ' VAL . 51.7 t80 -108.9 136.14 48.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.226 -1.161 . . . . 0.0 109.521 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.26 144.8 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.298 -0.876 . . . . 0.0 109.567 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.457 ' HB2' ' HB2' ' A' ' 43' ' ' MET . 4.3 mp -113.91 130.9 56.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.293 -0.879 . . . . 0.0 109.144 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.445 HG21 ' CG1' ' A' ' 42' ' ' VAL . 93.8 t -144.1 120.73 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.728 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.514 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 6.1 tt0 -75.07 129.65 37.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.507 ' HE1' ' CE2' ' A' ' 39' ' ' PHE . 9.8 tmm? -168.63 147.94 4.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.313 -0.867 . . . . 0.0 109.58 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -75.81 109.84 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.556 ' HB2' ' CZ ' ' A' ' 10' ' ' TYR . 22.3 tpp -59.43 120.33 9.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.285 -0.884 . . . . 0.0 109.504 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 31.2 p-10 -155.89 170.55 21.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -56.01 -36.54 68.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.557 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.45 ' HB1' ' HE3' ' A' ' 35' ' ' MET . . . -70.48 -71.7 0.23 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.623 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.532 ' CB ' ' OD1' ' A' ' 76' ' ' ASN . 10.0 p -47.14 -48.04 23.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 109.56 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 77.6 t90 -51.65 -50.07 61.06 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -66.36 -39.6 89.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.951 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.561 HD23 ' CE1' ' A' ' 39' ' ' PHE . 0.5 OUTLIER -59.13 -47.38 85.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.945 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.46 -48.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.87 . . . . 0.0 109.551 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -59.4 -36.77 76.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -60.59 -34.2 73.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.523 ' CG2' ' CD1' ' A' ' 26' ' ' LEU . 14.1 t -60.13 123.95 75.12 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.393 -0.817 . . . . 0.0 109.51 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.457 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.6 Cg_endo -70.75 163.21 39.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.545 2.163 . . . . 0.0 111.7 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.514 ' HA ' ' CD1' ' A' ' 15' ' ' PHE . 78.9 mmt-85 64.61 28.31 13.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.644 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 5.8 p -128.93 137.11 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.918 . . . . 0.0 109.597 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.51 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 69.4 mtm -89.97 -42.1 11.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.83 -149.73 20.31 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.482 ' CB ' ' HB3' ' A' ' 100' ' ' PRO . 90.6 m-85 -102.73 157.21 17.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -1.163 . . . . 0.0 109.52 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.511 ' CD1' HG11 ' A' ' 11' ' ' VAL . 8.4 mt -109.3 130.69 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.229 -0.919 . . . . 0.0 109.398 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 148.6 -119.19 1.04 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.401 ' C ' HG21 ' A' ' 96' ' ' THR . . . -66.4 -82.94 0.11 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.401 HG21 ' C ' ' A' ' 95' ' ' GLY . 17.4 p -130.43 -173.98 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -1.19 . . . . 0.0 109.662 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 42.2 p -97.22 17.66 16.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.434 ' O ' ' HG2' ' A' ' 99' ' ' ARG . 82.0 m-20 -120.98 -24.67 5.53 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.463 -0.773 . . . . 0.0 109.102 179.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.434 ' HG2' ' O ' ' A' ' 98' ' ' ASP . 7.6 mtt180 -147.87 87.79 5.75 Favored Pre-proline 0 C--N 1.304 -1.405 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.499 ' CG ' ' SD ' ' A' ' 75' ' ' MET . 42.9 Cg_endo -65.07 120.55 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.939 2.426 . . . . 0.0 112.416 -179.184 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 134.07 78.19 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.435 -0.791 . . . . 0.0 109.217 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.37 152.82 71.35 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.692 2.261 . . . . 0.0 111.904 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.484 HD11 HG21 ' A' ' 103' ' ' ILE . 30.7 pt -118.5 160.57 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.336 -0.853 . . . . 0.0 109.231 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.2 m -70.05 150.47 46.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -0.907 . . . . 0.0 109.431 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -62.74 -37.81 88.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -63.24 -37.7 88.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -0.85 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.439 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 85.5 tt0 -59.82 -39.7 85.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.464 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.475 HG22 ' CD1' ' A' ' 103' ' ' ILE . 73.3 t -62.9 -35.97 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.381 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -68.19 -34.19 75.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.247 -0.908 . . . . 0.0 109.489 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.78 -38.24 88.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.428 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.412 HD12 HG21 ' A' ' 111' ' ' ILE . 74.3 mt -55.73 -51.74 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.476 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 53.2 ttm -61.05 -35.52 77.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.426 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.0 m120 -59.59 -32.85 70.76 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -0.905 . . . . 0.0 109.494 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -55.91 -36.8 68.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -0.866 . . . . 0.0 109.583 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 69.2 mt -56.39 -37.69 70.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.56 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -88.34 7.36 32.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.9 . . . . 0.0 109.645 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -93.74 137.92 32.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.23 -0.919 . . . . 0.0 109.524 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.444 HG12 ' HG2' ' A' ' 62' ' ' ARG . 11.7 m -130.1 152.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.417 ' O ' ' HD3' ' A' ' 122' ' ' PRO . . . -104.83 30.74 9.51 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -56.99 -35.95 69.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.26 -1.141 . . . . 0.0 109.422 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 4.2 pttp -120.03 78.8 25.02 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.251 -0.906 . . . . 0.0 109.396 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 119' ' ' GLY . 49.1 Cg_endo -69.86 -20.42 34.39 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.725 2.283 . . . . 0.0 111.805 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 117.919 -1.039 . . . . 0.0 109.51 179.956 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.5 mtp . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.6 t -53.9 -38.83 65.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.514 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -102.71 156.9 17.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.92 . . . . 0.0 109.556 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 54.65 70.56 1.61 Allowed Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.507 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.22 149.81 64.5 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.651 2.234 . . . . 0.0 111.785 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.457 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 78.1 tttt -126.24 138.92 53.67 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 25.0 mttt 61.41 118.7 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.343 -0.848 . . . . 0.0 109.518 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 80.7 mtt85 -117.76 158.27 25.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . 0.56 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 46.0 m95 -109.53 130.64 55.49 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.506 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CE2' ' O ' ' A' ' 73' ' ' MET . 23.9 m-85 -122.51 143.82 49.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.549 HG13 ' CE2' ' A' ' 68' ' ' TYR . 15.7 t -99.7 129.99 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.297 -0.877 . . . . 0.0 109.515 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 37.9 t -109.82 131.27 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.884 . . . . 0.0 109.458 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.549 ' CG ' ' CD1' ' A' ' 93' ' ' ILE . 91.8 mt-30 -78.73 150.07 32.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.322 -0.861 . . . . 0.0 109.462 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.53 151.74 31.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -68.42 143.75 54.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.446 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.3 m -59.3 142.92 50.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.12 -32.33 5.48 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.514 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 98.7 m-85 -106.53 7.95 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.297 -1.119 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.423 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 83.5 tt0 -53.74 -32.6 52.77 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.966 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -83.53 -55.27 2.9 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.3 ttt85 -57.94 -33.66 69.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.145 -1.209 . . . . 0.0 109.441 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.514 ' CG2' ' O ' ' A' ' 18' ' ' PHE . 55.0 t -57.74 -40.89 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.402 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.86 -36.76 85.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.393 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 47.1 m -61.52 -37.31 83.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 24.3 m -60.45 -35.93 77.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.198 -0.939 . . . . 0.0 109.457 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.499 HD22 ' CG1' ' A' ' 86' ' ' VAL . 48.2 mt -60.27 -40.5 90.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.873 . . . . 0.0 109.393 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -58.35 -45.27 88.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.301 -0.874 . . . . 0.0 109.571 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -64.14 -60.8 2.78 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.228 -0.92 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.42 ' C ' HD11 ' A' ' 82' ' ' LEU . 98.7 m-70 -53.18 -50.78 63.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.256 -0.902 . . . . 0.0 109.378 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.53 HG12 ' CE2' ' A' ' 39' ' ' PHE . 96.9 mt -58.14 -54.19 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -53.81 -45.19 70.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.426 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 71.0 mt -64.29 -55.88 18.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.253 -0.904 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.458 ' HB3' ' HE2' ' A' ' 35' ' ' MET . 97.0 m-70 -68.34 -10.54 55.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.867 . . . . 0.0 109.384 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.457 ' N ' ' O ' ' A' ' 30' ' ' ILE . 76.1 m-20 61.58 46.63 7.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.331 -0.856 . . . . 0.0 109.389 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.472 ' O ' ' HG ' ' A' ' 38' ' ' LEU . 2.6 mtt -95.9 5.67 50.71 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.354 -0.841 . . . . 0.0 109.551 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -50.82 -22.95 2.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -63.38 -40.83 98.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.518 ' CD1' ' SD ' ' A' ' 73' ' ' MET . 0.4 OUTLIER -91.36 -32.02 15.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.414 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.575 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 58.2 m-85 -75.27 136.9 40.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.363 -0.836 . . . . 0.0 109.395 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.22 -79.94 0.7 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 41' ' ' GLU . 56.7 mp0 -129.38 163.96 24.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.135 . . . . 0.0 109.549 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.524 ' CG1' HG21 ' A' ' 71' ' ' VAL . 55.2 t -123.16 160.74 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.316 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.56 ' HG2' ' CZ3' ' A' ' 9' ' ' TRP . 94.4 mmm -117.99 138.43 52.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.935 . . . . 0.0 109.573 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 46' ' ' THR . 57.2 t -132.32 74.69 75.55 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.19 61.01 1.95 Allowed 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.673 2.248 . . . . 0.0 111.764 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.427 HG21 ' HB3' ' A' ' 48' ' ' GLU . 13.5 t -135.0 150.42 50.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.425 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -62.06 -27.43 68.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.312 -0.867 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . 0.427 ' HB3' HG21 ' A' ' 46' ' ' THR . 86.3 tt0 -49.93 -38.62 37.12 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.164 -0.96 . . . . 0.0 109.526 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.46 HG13 ' CG2' ' A' ' 50' ' ' VAL . 8.2 p -49.95 -35.8 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.46 ' CG2' HG13 ' A' ' 49' ' ' VAL . 22.4 t -112.61 141.82 26.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.182 -0.949 . . . . 0.0 109.559 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.437 ' O ' ' CG2' ' A' ' 52' ' ' ILE . 86.8 tt0 -99.19 138.11 36.76 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.498 ' CG1' ' O ' ' A' ' 52' ' ' ILE . 5.3 pt -155.49 117.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.412 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -47.15 143.93 2.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -56.95 100.4 0.12 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . -64.72 -30.19 77.27 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.441 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 97.4 mm-40 62.63 42.13 8.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.338 -1.095 . . . . 0.0 109.439 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -75.09 148.29 39.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.335 -0.853 . . . . 0.0 109.408 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -53.51 -34.86 59.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.429 ' HE3' ' HB2' ' A' ' 120' ' ' ASP . 63.6 tttm -88.19 135.89 33.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.188 -0.945 . . . . 0.0 109.392 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 94.2 p -112.77 152.8 28.71 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -106.35 153.21 22.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -126.22 149.63 48.92 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.939 . . . . 0.0 109.447 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.2 mttt -83.22 126.87 33.11 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.293 -0.88 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -66.37 -42.96 87.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.874 . . . . 0.0 109.521 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 1.9 p90 -139.74 80.6 21.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.547 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.01 146.18 57.91 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.733 2.288 . . . . 0.0 111.903 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 74.91 24.49 71.82 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.549 ' CE2' HG13 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -114.89 123.29 48.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.189 -1.183 . . . . 0.0 109.502 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 70' ' ' LEU . 86.0 t -132.52 144.66 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.326 -0.859 . . . . 0.0 109.572 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.571 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.6 mp -115.91 138.48 51.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.278 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.524 HG21 ' CG1' ' A' ' 42' ' ' VAL . 59.5 t -132.46 120.89 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.179 -0.951 . . . . 0.0 109.777 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.443 ' O ' ' HB2' ' A' ' 73' ' ' MET . 35.8 tt0 -69.82 142.12 53.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.036 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.566 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.9 ttp 173.67 158.41 0.14 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.01 . . . . 0.0 109.578 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.513 ' N ' ' HG2' ' A' ' 73' ' ' MET . 9.1 p -82.84 142.74 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.225 -0.922 . . . . 0.0 109.406 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.532 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -72.66 116.1 12.73 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.657 -179.77 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.447 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 51.3 p-10 -143.93 175.48 9.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 109.33 179.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -84.6 -18.34 35.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.21 -0.931 . . . . 0.0 109.621 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -73.67 -57.54 3.92 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.242 -0.912 . . . . 0.0 109.319 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.501 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 53.4 p -59.34 -41.45 89.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.41 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.417 ' C ' ' O ' ' A' ' 79' ' ' SER . 47.1 t90 -43.98 -45.78 7.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.615 -179.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -79.59 -25.84 41.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 109.43 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.575 HD22 ' CZ ' ' A' ' 39' ' ' PHE . 0.7 OUTLIER -64.03 -41.45 97.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.291 -0.881 . . . . 0.0 109.532 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.522 HG21 ' CE2' ' A' ' 92' ' ' PHE . 88.6 t -65.94 -48.28 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.257 -0.902 . . . . 0.0 109.521 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -59.56 -41.41 90.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.0 p -61.96 -27.88 69.16 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.208 -0.933 . . . . 0.0 109.54 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.499 ' CG1' HD22 ' A' ' 26' ' ' LEU . 43.9 t -67.77 126.04 92.09 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 109.515 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.421 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.6 Cg_endo -70.31 163.48 38.55 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 122.653 2.235 . . . . 0.0 111.727 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.421 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.1 mtt-85 61.54 44.63 8.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 99.0 t -131.21 118.9 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.271 -0.893 . . . . 0.0 109.539 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.502 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 74.8 mtm -70.57 -42.22 71.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.81 -162.41 35.06 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.522 ' CE2' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -104.82 171.26 7.42 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.235 -1.156 . . . . 0.0 109.453 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.549 ' CD1' ' CG ' ' A' ' 13' ' ' GLN . 32.6 mm -124.43 128.45 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.452 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 172.71 -148.96 10.95 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.45 -39.54 50.25 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.461 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 29.2 p -130.7 171.98 12.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.185 -1.185 . . . . 0.0 109.497 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 p -88.55 14.73 9.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.169 -0.957 . . . . 0.0 109.443 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.461 ' OD1' ' OG1' ' A' ' 96' ' ' THR . 17.8 p30 -130.21 -13.64 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.772 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.429 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 49.5 mtt180 -145.75 91.42 5.66 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.231 -0.918 . . . . 0.0 108.884 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.532 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.48 113.89 3.08 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.774 2.316 . . . . 0.0 112.007 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.21 136.84 93.89 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.263 -0.898 . . . . 0.0 109.395 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.498 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.41 154.67 65.0 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.654 2.236 . . . . 0.0 111.814 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.4 pt -124.03 159.7 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 38.5 m -66.04 148.41 51.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.258 -0.902 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 73.6 m-20 -57.41 -41.59 80.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -57.74 -39.81 78.19 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -51.43 -40.75 59.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.923 . . . . 0.0 109.417 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 73.8 t -63.02 -34.6 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.388 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -63.24 -38.11 89.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.61 -40.4 95.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.386 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 27.0 mm -51.55 -57.32 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.462 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.2 mtp -60.86 -35.71 77.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.318 179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 53.0 t-20 -55.17 -43.45 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -0.889 . . . . 0.0 109.38 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.43 ' O ' ' N ' ' A' ' 117' ' ' GLN . 90.5 mtt-85 -51.54 -54.29 28.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 11.8 tp -45.63 -46.67 14.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 109.388 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -61.31 -28.94 69.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.411 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 114' ' ' ARG . 56.0 tt0 -73.35 141.02 47.06 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.3 t -120.67 136.09 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.452 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -46.35 -26.83 2.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.429 ' HB2' ' HE3' ' A' ' 59' ' ' LYS . 83.7 m-20 -110.48 139.98 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.321 -1.105 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 6.8 mtpp -122.26 79.64 44.55 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.443 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.57 144.3 54.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.772 2.314 . . . . 0.0 111.801 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 23.2 mmt180 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 117.993 -1.004 . . . . 0.0 109.464 179.994 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.0 mtm . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.332 0.587 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.0 p -63.0 -25.84 68.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.935 . . . . 0.0 109.465 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.31 148.16 29.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.145 -0.972 . . . . 0.0 109.486 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.99 74.84 71.72 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.46 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.64 140.42 39.36 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.682 2.255 . . . . 0.0 111.822 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -105.45 139.37 40.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.239 -0.913 . . . . 0.0 109.404 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.518 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 69.5 mttt -127.52 139.35 52.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.468 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.461 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 96.3 mtt180 -118.62 150.64 39.35 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.293 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 65.7 m95 -99.04 135.65 40.14 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 109.668 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.426 ' CE2' ' HE3' ' A' ' 75' ' ' MET . 55.5 m-85 -128.35 153.61 46.85 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.874 . . . . 0.0 109.398 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.522 ' HB ' ' CD1' ' A' ' 93' ' ' ILE . 3.1 t -100.16 137.46 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.906 . . . . 0.0 109.511 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.53 124.63 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.214 -0.929 . . . . 0.0 109.365 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.511 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 98.0 mt-30 -90.47 145.73 24.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.512 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -149.63 163.47 37.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.332 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -67.02 140.88 57.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.189 -0.944 . . . . 0.0 109.52 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.9 m -58.07 145.78 35.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.55 -31.07 5.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . 0.5 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 96.5 m-85 -111.21 9.82 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -1.183 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.514 ' OE2' ' CG ' ' A' ' 45' ' ' PRO . 81.6 tt0 -61.11 -29.9 70.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.253 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -81.45 -36.9 18.99 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -66.87 -49.05 66.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -1.129 . . . . 0.0 109.419 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 88' ' ' ARG . 21.8 t -48.33 -41.56 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -0.98 . . . . 0.0 109.038 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.7 -46.59 84.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -0.867 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 88.4 m -62.38 -37.13 84.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.557 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 98.6 p -65.99 -37.0 84.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.435 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.517 HD22 ' CG1' ' A' ' 86' ' ' VAL . 50.4 mt -52.44 -72.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.35 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.402 ' C ' ' O ' ' A' ' 26' ' ' LEU . 41.8 ttm180 -44.25 -41.48 5.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.351 -0.843 . . . . 0.0 109.534 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -56.1 -37.36 69.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.909 . . . . 0.0 109.479 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 25' ' ' SER . 89.8 m-70 -79.27 -29.24 42.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.892 . . . . 0.0 109.374 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.623 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 17.6 mm -66.79 -43.4 89.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.559 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -67.19 -36.87 82.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.525 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 38.4 mt -70.18 -53.51 16.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 0.0 109.545 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.408 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.6 m-70 -84.76 10.95 10.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 46.34 46.74 13.77 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.47 ' CE ' HD12 ' A' ' 38' ' ' LEU . 56.8 mmm -97.25 15.76 21.88 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.195 -0.941 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.515 ' N ' HG22 ' A' ' 30' ' ' ILE . 74.9 mm-40 -55.34 -33.21 63.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 109.447 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -65.43 -45.91 81.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.277 -0.889 . . . . 0.0 109.357 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.47 HD12 ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -68.04 -55.26 13.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.303 -0.873 . . . . 0.0 109.26 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.623 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 77.6 m-85 -67.37 141.6 57.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.323 -0.861 . . . . 0.0 109.435 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.99 -69.28 0.76 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -143.14 166.17 25.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -1.145 . . . . 0.0 109.542 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.423 HG23 HG12 ' A' ' 71' ' ' VAL . 83.3 t -117.4 138.38 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.412 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.48 ' CE ' ' HG3' ' A' ' 112' ' ' MET . 83.2 mtp -127.87 156.35 42.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.208 -0.933 . . . . 0.0 109.466 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.46 HG12 ' HD2' ' A' ' 45' ' ' PRO . 31.9 t -146.79 132.34 9.25 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.271 -0.893 . . . . 0.0 109.382 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.514 ' CG ' ' OE2' ' A' ' 19' ' ' GLU . 49.1 Cg_endo -69.98 -0.65 7.41 Favored 'Trans proline' 0 C--O 1.215 -0.625 0 C-N-CA 122.605 2.203 . . . . 0.0 111.792 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 2.4 p -133.84 151.43 51.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.152 -0.967 . . . . 0.0 109.45 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -119.11 135.54 54.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.487 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -65.82 143.87 57.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 109.567 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.498 ' O ' ' CG1' ' A' ' 50' ' ' VAL . 21.7 m -127.13 155.76 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.243 -0.911 . . . . 0.0 109.485 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.498 ' CG1' ' O ' ' A' ' 49' ' ' VAL . 13.9 m -160.23 -41.4 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.251 -0.906 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 23.9 pt-20 -67.94 -26.55 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.473 ' O ' ' CG2' ' A' ' 52' ' ' ILE . 6.2 tp -133.46 101.49 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.58 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 30.1 mmm-85 -56.76 -35.58 68.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 92.03 -164.56 28.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 58' ' ' ARG . . . -140.43 178.05 20.26 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -60.82 -32.39 71.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.263 -1.139 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -56.42 -35.28 67.63 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . 0.461 ' O ' ' O ' ' A' ' 55' ' ' GLY . 90.9 mtt180 -118.97 146.91 44.61 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 109.46 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 34.0 tttp -132.77 132.05 41.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.287 -0.883 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 24.5 m -50.89 -43.32 59.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.204 -0.935 . . . . 0.0 109.458 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -68.66 144.28 54.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.47 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.52 ' CD ' HD11 ' A' ' 115' ' ' LEU . 92.6 mtt-85 -121.45 146.48 46.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.246 -0.909 . . . . 0.0 109.496 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 34.9 mttm -87.15 -8.38 57.02 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.512 ' C ' ' CG ' ' A' ' 65' ' ' PHE . 20.3 m-85 -48.43 -37.19 16.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.583 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.58 ' CE2' ' CG2' ' A' ' 111' ' ' ILE . 0.0 OUTLIER 169.96 76.14 0.03 OUTLIER Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.956 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -71.25 153.07 61.99 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.691 2.261 . . . . 0.0 111.802 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.464 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . 71.93 10.12 72.14 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.504 ' CE2' HD12 ' A' ' 93' ' ' ILE . 2.7 m-85 -112.25 121.4 44.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.112 -1.228 . . . . 0.0 109.574 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.46 HG13 ' N ' ' A' ' 70' ' ' LEU . 57.8 t -129.41 144.12 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.217 -0.927 . . . . 0.0 109.571 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.549 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 4.3 mp -109.04 130.05 55.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.497 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.423 HG12 HG23 ' A' ' 42' ' ' VAL . 48.5 t -140.91 126.4 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.319 -0.863 . . . . 0.0 109.574 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.518 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 2.6 tt0 -69.54 138.95 53.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.932 . . . . 0.0 109.268 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.493 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 14.9 ttp 178.76 152.86 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.226 -0.922 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.455 ' N ' ' HG2' ' A' ' 73' ' ' MET . 23.6 m -99.2 160.48 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.376 -0.827 . . . . 0.0 109.557 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.531 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 14.6 mmt -94.24 120.5 34.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.295 -0.878 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.8 p-10 -146.21 -161.18 1.26 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.565 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -101.49 42.4 1.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -0.878 . . . . 0.0 109.452 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -159.33 -51.11 0.06 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.291 -0.881 . . . . 0.0 109.337 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.426 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 53.4 p -65.98 -30.19 70.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 109.31 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -66.52 -46.58 75.71 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.427 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -69.35 -33.15 72.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.34 -0.85 . . . . 0.0 109.35 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.558 HD23 ' CZ ' ' A' ' 39' ' ' PHE . 5.1 tt -65.79 -35.58 81.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.426 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.568 ' CG1' ' CE2' ' A' ' 92' ' ' PHE . 72.3 t -69.38 -47.49 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.415 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 42.2 ttt-85 -61.15 -33.59 73.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.431 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.3 p -63.15 -22.89 67.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.424 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.528 ' O ' ' CG1' ' A' ' 89' ' ' VAL . 12.7 t -60.93 120.33 52.82 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.343 -0.848 . . . . 0.0 109.51 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.422 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.1 Cg_endo -71.2 160.11 49.98 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.588 2.192 . . . . 0.0 111.862 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.527 ' O ' ' CG2' ' A' ' 22' ' ' VAL . 50.0 mtt85 60.94 33.14 19.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -0.932 . . . . 0.0 109.683 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 7.3 p -122.28 132.4 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -0.941 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.511 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 95.4 mtp -72.51 -43.03 64.15 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.36 -153.86 25.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.568 ' CE2' ' CG1' ' A' ' 83' ' ' VAL . 0.6 OUTLIER -107.15 164.26 12.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.348 -1.09 . . . . 0.0 109.507 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.522 ' CD1' ' HB ' ' A' ' 11' ' ' VAL . 58.3 mt -116.39 139.6 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 113.76 134.77 5.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 48.51 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.525 ' OG1' ' N ' ' A' ' 97' ' ' SER . 0.8 OUTLIER -141.16 -172.08 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.346 -1.091 . . . . 0.0 109.421 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.525 ' N ' ' OG1' ' A' ' 96' ' ' THR . 35.4 p -91.32 20.97 4.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.201 -0.937 . . . . 0.0 109.633 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -121.29 -29.56 4.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.342 -0.849 . . . . 0.0 108.931 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -149.23 83.39 6.61 Favored Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.531 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 44.0 Cg_endo -65.6 128.32 19.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.948 2.432 . . . . 0.0 112.484 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.63 141.93 90.93 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.489 -0.757 . . . . 0.0 109.269 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.461 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.0 Cg_endo -69.41 153.59 70.32 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.693 2.262 . . . . 0.0 111.924 -179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.476 HD13 ' CG2' ' A' ' 108' ' ' VAL . 26.7 pt -116.22 158.65 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 109.35 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.431 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 45.4 m -71.66 147.91 47.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.493 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -58.94 -36.38 74.67 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.318 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -59.83 -39.19 84.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.4 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.431 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.5 mt-10 -57.57 -46.4 84.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.29 -0.881 . . . . 0.0 109.361 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.476 ' CG2' HD13 ' A' ' 103' ' ' ILE . 71.5 t -61.64 -39.63 83.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.388 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -66.82 -37.51 84.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.258 -0.901 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.9 63.62 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.353 -0.842 . . . . 0.0 109.426 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.58 ' CG2' ' CE2' ' A' ' 65' ' ' PHE . 55.0 mt -50.51 -56.41 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.325 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' MET . . . . . 0.48 ' HG3' ' CE ' ' A' ' 43' ' ' MET . 96.0 mmm -60.82 -39.26 88.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.912 . . . . 0.0 109.418 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -50.38 -49.24 54.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.362 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 62.9 mtt180 -55.7 -52.71 62.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.296 -0.878 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.52 HD11 ' CD ' ' A' ' 62' ' ' ARG . 9.5 tp -46.72 -45.19 19.39 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 109.442 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -62.21 -28.46 69.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.898 . . . . 0.0 109.534 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -73.2 129.66 38.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.215 -0.928 . . . . 0.0 109.443 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -122.52 139.47 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.212 -0.93 . . . . 0.0 109.432 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.96 -20.85 6.79 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -84.42 140.25 31.66 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -1.155 . . . . 0.0 109.506 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 ttpp -123.53 73.27 51.46 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.191 -0.943 . . . . 0.0 109.429 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . 0.436 ' O ' ' O ' ' A' ' 123' ' ' ARG . 49.4 Cg_endo -70.26 -20.24 32.72 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.723 2.282 . . . . 0.0 111.663 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 122' ' ' PRO . 60.6 mtt180 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.502 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtt . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.315 0.578 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 50.2 m -118.12 147.11 43.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.501 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -108.49 140.47 41.77 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.44 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -96.67 165.33 16.22 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.914 . . . . 0.0 109.449 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.8 144.6 54.35 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.727 2.284 . . . . 0.0 111.811 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 80.0 mttt -121.14 151.62 39.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.445 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.427 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 63.0 mttm -80.27 136.87 36.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.349 -0.845 . . . . 0.0 109.464 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 88.2 mtt-85 -121.88 157.89 30.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -88.01 133.92 33.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.2 -0.938 . . . . 0.0 109.536 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.1 m-85 -119.05 156.47 29.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 44.7 t -99.09 143.59 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.254 -0.904 . . . . 0.0 109.428 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.7 t -125.21 123.19 64.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.309 -0.87 . . . . 0.0 109.314 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 93' ' ' ILE . 62.5 tt0 -94.57 135.16 36.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.661 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.419 ' HB1' HG23 ' A' ' 22' ' ' VAL . . . -152.88 155.8 37.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.315 -0.866 . . . . 0.0 109.317 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -56.41 140.74 44.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.259 -0.901 . . . . 0.0 109.576 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.453 ' HB2' ' HB2' ' A' ' 66' ' ' PRO . 47.0 p -65.45 151.97 45.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 109.487 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.56 -31.34 5.24 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -118.89 8.82 11.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -1.175 . . . . 0.0 109.466 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.514 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 23.4 pt-20 -55.41 -46.19 76.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.395 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.514 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -59.98 -38.6 94.43 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttm-85 -55.62 -49.37 73.0 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.3 -1.118 . . . . 0.0 109.38 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.525 ' CG1' HG11 ' A' ' 86' ' ' VAL . 39.2 t -47.24 -39.72 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.267 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.13 -44.57 95.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.882 . . . . 0.0 109.339 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 89.4 m -65.93 -51.34 59.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.309 -0.87 . . . . 0.0 109.391 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 83.1 p -59.65 -36.06 75.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.402 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.456 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 tp -56.57 -53.1 61.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.2 -0.937 . . . . 0.0 109.494 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.417 ' C ' ' O ' ' A' ' 26' ' ' LEU . 57.0 ttt180 -43.7 -49.82 7.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.41 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.414 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 96.3 mt-10 -54.04 -45.39 71.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.296 -0.878 . . . . 0.0 109.361 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.451 ' HB3' HD11 ' A' ' 82' ' ' LEU . 76.3 m-70 -61.32 -34.34 75.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.306 -0.871 . . . . 0.0 109.297 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.638 ' CD1' ' CE1' ' A' ' 39' ' ' PHE . 20.2 mm -63.22 -54.5 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.443 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 36.0 mttt -66.96 -37.59 84.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.924 . . . . 0.0 109.389 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.414 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 66.4 mt -60.58 -55.32 34.81 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.371 -0.831 . . . . 0.0 109.433 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . 0.415 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 96.7 m-70 -89.46 0.09 57.11 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.315 -0.866 . . . . 0.0 109.56 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.49 ' N ' ' O ' ' A' ' 30' ' ' ILE . 79.3 m-20 60.18 49.5 7.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.898 . . . . 0.0 109.48 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.558 ' CE ' ' CD1' ' A' ' 38' ' ' LEU . 51.2 mmm -101.87 14.08 32.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.492 ' HA ' ' CG2' ' A' ' 30' ' ' ILE . 97.8 mt-10 -52.06 -36.81 51.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -60.86 -40.75 94.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.229 -0.919 . . . . 0.0 109.548 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.558 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 5.7 mt -70.48 -49.05 52.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.506 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 30' ' ' ILE . 93.2 m-85 -75.76 138.03 40.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.1 -68.62 0.42 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.414 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 84.7 tt0 -129.96 155.93 45.28 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.525 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.453 ' CG1' HG22 ' A' ' 71' ' ' VAL . 39.2 t -123.74 145.37 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' MET . . . . . 0.452 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 92.9 mtp -124.44 150.48 45.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.475 HG12 ' HD2' ' A' ' 45' ' ' PRO . 66.6 t -142.08 132.04 12.52 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.383 -0.823 . . . . 0.0 109.235 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.475 ' HD2' HG12 ' A' ' 44' ' ' VAL . 47.8 Cg_endo -68.76 -0.38 6.03 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.758 2.305 . . . . 0.0 112.105 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.577 HG22 ' CZ ' ' A' ' 64' ' ' PHE . 11.6 p -121.74 159.16 27.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 109.485 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -111.48 153.84 25.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.414 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -103.66 137.79 41.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.463 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.457 HG12 ' O ' ' A' ' 51' ' ' GLU . 42.1 t -118.31 134.85 60.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.199 -0.938 . . . . 0.0 109.475 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 17.2 m -68.29 -36.59 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.486 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.457 ' O ' HG12 ' A' ' 49' ' ' VAL . 85.1 tt0 -111.17 136.66 49.91 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.529 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 82.1 mt -58.77 -44.65 90.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -0.956 . . . . 0.0 109.479 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 50.8 mtp85 -60.27 -35.91 76.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.519 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 78.31 -166.23 52.4 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -81.11 6.24 63.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -114.54 155.1 27.08 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 83.8 mtt180 -61.3 -33.79 74.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.451 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -124.46 149.23 47.05 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.494 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -82.42 136.18 34.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.514 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.8 p -115.4 153.15 31.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.124 -0.985 . . . . 0.0 109.566 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.56 154.47 23.69 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.269 -0.894 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.445 ' HD2' ' OD2' ' A' ' 120' ' ' ASP . 25.2 mtm180 -128.51 146.66 50.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.175 -0.953 . . . . 0.0 109.54 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 23.1 mttm -97.24 131.79 43.62 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.913 . . . . 0.0 109.367 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.577 ' CZ ' HG22 ' A' ' 46' ' ' THR . 41.8 p90 -154.97 153.7 31.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.599 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.589 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 33.5 p90 -54.67 105.99 0.6 Allowed Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.21 -0.931 . . . . 0.0 109.461 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 52.9 Cg_endo -91.53 152.33 3.55 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.04 2.493 . . . . 0.0 111.9 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.406 ' HA2' ' O ' ' A' ' 14' ' ' ALA . . . 92.84 13.84 55.98 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.42 ' OH ' ' CG2' ' A' ' 93' ' ' ILE . 1.7 m-85 -133.19 121.92 23.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.192 -1.181 . . . . 0.0 109.475 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.416 HG11 ' N ' ' A' ' 70' ' ' LEU . 60.7 t -131.02 147.03 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -0.853 . . . . 0.0 109.521 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.55 ' N ' ' CD1' ' A' ' 70' ' ' LEU . 3.8 mp -111.82 128.01 55.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.351 -0.843 . . . . 0.0 109.42 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.453 HG22 ' CG1' ' A' ' 42' ' ' VAL . 98.6 t -139.85 124.58 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . 0.427 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 37.9 tt0 -77.74 132.3 38.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.26 -0.9 . . . . 0.0 109.363 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.6 ttp -165.39 164.31 19.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.2 -0.937 . . . . 0.0 109.493 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.506 ' N ' ' HG2' ' A' ' 73' ' ' MET . 42.2 t -82.47 142.76 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.504 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' MET . . . . . 0.491 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 1.2 tpt -81.15 111.38 17.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.901 . . . . 0.0 109.462 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.513 ' ND2' HD21 ' A' ' 38' ' ' LEU . 37.6 p-10 -150.46 164.04 36.91 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 109.393 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.442 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 85.2 m-20 -74.51 -26.81 60.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.158 -0.964 . . . . 0.0 109.405 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -65.44 -58.02 6.88 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.499 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.461 ' OG ' ' HE1' ' A' ' 73' ' ' MET . 11.2 p -56.62 -46.44 80.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.695 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' TRP . . . . . 0.573 ' CH2' ' HD2' ' A' ' 84' ' ' ARG . 37.9 t90 -43.63 -59.35 2.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.236 -0.915 . . . . 0.0 109.62 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.442 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 94.5 m-70 -57.24 -35.95 70.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.935 . . . . 0.0 109.614 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.526 HD22 ' CE1' ' A' ' 39' ' ' PHE . 1.0 OUTLIER -62.91 -41.32 99.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.919 . . . . 0.0 109.66 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.57 HG13 ' CZ ' ' A' ' 92' ' ' PHE . 50.5 t -60.55 -46.09 96.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.573 ' HD2' ' CH2' ' A' ' 80' ' ' TRP . 29.5 mtp180 -56.6 -36.0 68.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -61.12 -28.78 69.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.24 -0.913 . . . . 0.0 109.537 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.525 HG11 ' CG1' ' A' ' 22' ' ' VAL . 40.2 t -55.4 121.28 36.8 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.276 -0.89 . . . . 0.0 109.446 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.452 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.3 Cg_endo -70.5 149.94 62.95 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.684 2.256 . . . . 0.0 111.819 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.452 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.9 mtt85 61.3 40.19 14.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.339 -0.85 . . . . 0.0 109.521 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 86' ' ' VAL . 9.9 p -122.33 128.19 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.338 -0.851 . . . . 0.0 109.316 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' MET . . . . . 0.473 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.0 mmm -71.66 -53.72 12.68 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.16 -0.962 . . . . 0.0 109.506 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.42 -150.69 20.92 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.57 ' CZ ' HG13 ' A' ' 83' ' ' VAL . 82.7 m-85 -100.53 157.68 16.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -1.095 . . . . 0.0 109.56 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.52 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 38.8 mm -117.6 135.94 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 0.0 109.331 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 110.12 145.86 10.86 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 50.75 -95.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 94' ' ' GLY . 19.3 p -140.33 -173.04 3.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -1.19 . . . . 0.0 109.558 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 p -95.53 22.24 7.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.215 -0.928 . . . . 0.0 109.485 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.541 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 73.4 m-20 -120.51 -25.13 5.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.371 -0.831 . . . . 0.0 109.215 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.423 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 15.2 mtp180 -153.04 102.36 2.64 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.358 -0.839 . . . . 0.0 109.013 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.562 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 44.3 Cg_endo -66.46 114.58 3.13 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.769 2.313 . . . . 0.0 112.012 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.54 140.29 88.89 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.397 -0.814 . . . . 0.0 109.487 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.514 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.4 Cg_endo -70.42 153.4 65.95 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.669 2.246 . . . . 0.0 111.823 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.451 HD12 ' CG2' ' A' ' 108' ' ' VAL . 31.8 pt -126.96 157.4 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.887 . . . . 0.0 109.49 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 53.0 p -72.36 151.07 42.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.618 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -61.6 -35.03 76.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -61.84 -40.12 94.21 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.452 ' O ' HG13 ' A' ' 111' ' ' ILE . 86.5 tt0 -59.52 -41.88 90.99 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.293 -0.88 . . . . 0.0 109.467 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.465 ' CG1' HD23 ' A' ' 70' ' ' LEU . 70.6 t -60.29 -37.51 74.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.315 -0.866 . . . . 0.0 109.471 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -64.7 -40.27 95.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.973 . . . . 0.0 109.378 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -66.04 -43.13 88.46 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.452 HG13 ' O ' ' A' ' 107' ' ' GLU . 70.8 mt -52.44 -49.53 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.213 -0.929 . . . . 0.0 109.468 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 94.9 mmm -60.15 -36.67 78.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -58.13 -34.61 70.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.576 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.412 ' O ' ' N ' ' A' ' 117' ' ' GLN . 49.4 ttt85 -52.58 -46.23 66.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.42 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.48 HD13 ' CB ' ' A' ' 64' ' ' PHE . 3.1 tp -45.33 -45.36 12.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.584 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -69.26 -28.48 66.35 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.279 -0.888 . . . . 0.0 109.471 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.412 ' N ' ' O ' ' A' ' 114' ' ' ARG . 64.1 tt0 -50.57 -38.07 43.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.232 -0.918 . . . . 0.0 109.478 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.2 t -68.91 132.29 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.544 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.451 ' O ' ' HD3' ' A' ' 122' ' ' PRO . . . -83.43 98.26 2.07 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.445 ' OD2' ' HD2' ' A' ' 62' ' ' ARG . 87.8 m-20 -53.36 -41.33 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.232 -1.158 . . . . 0.0 109.563 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.82 83.43 66.2 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.495 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 119' ' ' GLY . 48.7 Cg_endo -69.43 -18.47 38.56 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.719 2.28 . . . . 0.0 111.848 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 27.3 mtm180 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.468 -179.997 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 89.7 mttt . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 61.9 mtt180 -122.67 152.94 40.03 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.228 -0.92 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.745 ' CG ' HG21 ' A' ' 108' ' ' VAL . 74.9 m95 -95.01 133.89 38.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CE2' ' O ' ' A' ' 73' ' ' MET . 28.3 m-85 -122.69 149.39 44.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -0.873 . . . . 0.0 109.308 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 25.0 t -97.68 142.62 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.491 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.75 130.81 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.478 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.818 ' HB2' HD11 ' A' ' 93' ' ' ILE . 57.3 tt0 -96.96 128.1 43.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 109.464 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.748 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.08 164.23 30.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.214 -0.928 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -69.22 145.33 53.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.2 p -66.19 149.49 50.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.31 -33.03 4.69 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.521 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.9 m-85 -109.53 1.6 19.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.3 -1.118 . . . . 0.0 109.623 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.554 ' OE2' HG22 ' A' ' 69' ' ' VAL . 85.6 tt0 -53.45 -40.07 64.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.44 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.57 -47.77 74.4 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -63.65 -39.36 94.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -1.171 . . . . 0.0 109.461 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.748 HG21 ' HB1' ' A' ' 14' ' ' ALA . 60.6 t -52.18 -44.69 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.473 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.76 -42.79 98.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.333 -0.854 . . . . 0.0 109.465 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.1 m -61.2 -39.0 88.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.462 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 24.1 m -58.95 -39.18 80.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.778 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.3 mt -56.11 -46.61 79.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttt85 -56.15 -41.89 76.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -0.89 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -66.78 -58.73 4.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.986 ' HB3' HD11 ' A' ' 82' ' ' LEU . 73.4 m-70 -57.22 -48.63 78.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 0.0 109.498 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.727 HG23 ' CB ' ' A' ' 35' ' ' MET . 89.7 mt -61.9 -49.52 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.251 -0.906 . . . . 0.0 109.446 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -57.87 -45.56 86.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.467 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.451 HD23 ' HA ' ' A' ' 32' ' ' LEU . 45.3 mt -63.26 -48.62 77.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 68.8 m80 -83.44 5.5 23.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.251 -0.906 . . . . 0.0 109.52 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 30' ' ' ILE . 38.1 t30 54.69 46.13 25.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.33 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.812 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -96.54 3.89 52.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.579 -179.914 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.1 mt-10 -53.4 -35.61 60.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -54.3 -40.46 67.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.22 -0.925 . . . . 0.0 109.463 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.539 ' CD1' ' CG ' ' A' ' 35' ' ' MET . 0.7 OUTLIER -73.9 -48.77 28.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.288 -0.883 . . . . 0.0 109.294 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.625 ' CD1' HD13 ' A' ' 30' ' ' ILE . 89.4 m-85 -70.41 130.12 41.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.358 -0.839 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.14 -63.16 0.58 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -141.44 115.46 9.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -1.19 . . . . 0.0 109.66 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.013 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -89.5 147.08 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.39 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.644 ' O ' HG13 ' A' ' 69' ' ' VAL . 46.3 mtt -112.88 148.98 33.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 44' ' ' VAL . 35.3 t . . . . . 0 N--CA 1.491 1.575 0 O-C-N 121.342 -0.849 . . . . 0.0 109.274 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.459 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -117.59 128.51 55.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -1.14 . . . . 0.0 109.492 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.644 HG13 ' O ' ' A' ' 43' ' ' MET . 65.8 t -130.73 143.44 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.273 -0.892 . . . . 0.0 109.538 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.846 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.1 mp -107.32 133.04 52.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.322 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.013 HG22 HG23 ' A' ' 42' ' ' VAL . 43.1 t -139.51 131.15 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.684 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.664 ' NE2' ' CE2' ' A' ' 9' ' ' TRP . 14.6 tt0 -88.05 128.5 35.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.218 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 55.7 ttp -173.98 163.96 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.179 -0.951 . . . . 0.0 109.682 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' A' ' 73' ' ' MET . 28.6 m -87.45 138.24 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.267 -0.896 . . . . 0.0 109.459 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.64 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 1.1 ttm -76.68 116.76 17.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.434 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 52.8 p-10 -145.01 170.71 15.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.428 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -67.88 -33.66 75.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -0.919 . . . . 0.0 109.915 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.561 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -67.7 -69.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 0.0 109.7 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 80' ' ' TRP . 9.9 p -46.6 -59.52 2.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -0.892 . . . . 0.0 109.645 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.49 ' N ' ' OG ' ' A' ' 79' ' ' SER . 68.0 t90 -42.84 -58.09 2.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.638 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -58.34 -37.69 75.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.944 . . . . 0.0 109.493 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.986 HD11 ' HB3' ' A' ' 29' ' ' HIS . 67.4 tp -63.41 -39.7 95.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.568 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.944 HG11 ' CE2' ' A' ' 92' ' ' PHE . 85.4 t -59.93 -47.29 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 109.584 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.59 -37.69 76.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.543 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.4 p -64.67 -26.28 68.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -0.914 . . . . 0.0 109.499 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.778 HG21 ' CD2' ' A' ' 26' ' ' LEU . 98.7 t -60.79 124.51 79.73 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.486 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.435 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.4 Cg_endo -70.35 156.41 61.88 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.696 2.264 . . . . 0.0 111.795 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 68.2 mtt-85 61.28 46.07 8.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.395 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.406 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.4 t -132.85 118.65 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.593 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' GLN . 64.2 mtt -69.03 -42.82 75.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.423 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.0 -152.81 24.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.944 ' CE2' HG11 ' A' ' 83' ' ' VAL . 3.4 m-85 -109.99 161.82 15.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.232 -1.158 . . . . 0.0 109.537 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.818 HD11 ' HB2' ' A' ' 13' ' ' GLN . 14.5 mm -115.9 116.35 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.507 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -172.88 -148.1 6.14 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.59 -35.01 67.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.78 HG23 ' H ' ' A' ' 98' ' ' ASP . 11.6 t -138.9 175.6 9.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -1.189 . . . . 0.0 109.665 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 p -93.56 19.44 8.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.288 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.78 ' H ' HG23 ' A' ' 96' ' ' THR . 86.0 m-20 -131.19 -0.83 4.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 109.429 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 98' ' ' ASP . 1.1 mtt180 -168.28 96.39 0.58 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.88 . . . . 0.0 109.003 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.64 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 45.9 Cg_endo -67.52 116.88 4.46 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.798 2.332 . . . . 0.0 112.16 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -60.72 135.5 92.44 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.267 -0.896 . . . . 0.0 109.304 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.1 Cg_endo -69.92 153.32 68.32 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.674 2.25 . . . . 0.0 111.785 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.831 HD11 HG22 ' A' ' 108' ' ' VAL . 28.3 pt -126.42 157.6 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.386 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.48 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 38.7 m -63.27 147.81 49.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.4 -39.31 83.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.428 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.2 tttt -59.74 -39.28 84.23 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.48 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -59.95 -41.4 91.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.256 -0.903 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.842 HG13 HD23 ' A' ' 70' ' ' LEU . 97.7 t -61.89 -35.96 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.515 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -67.33 -33.82 76.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.274 -0.891 . . . . 0.0 109.485 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.73 96.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.226 -0.921 . . . . 0.0 109.422 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.629 HD12 HD21 ' A' ' 70' ' ' LEU . 70.2 mt -56.86 -51.93 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 109.482 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 89.1 mtp . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.457 -179.983 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 76.9 mttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.552 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 49.0 mtt180 -80.59 148.32 30.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.523 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.536 ' CH2' ' HG3' ' A' ' 43' ' ' MET . 77.2 m95 -78.01 135.68 37.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.947 . . . . 0.0 109.639 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.615 ' CZ ' ' CG ' ' A' ' 75' ' ' MET . 76.0 m-85 -132.21 139.02 48.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -0.92 . . . . 0.0 109.372 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.899 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.7 t -83.17 148.94 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.108 -0.995 . . . . 0.0 109.519 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.91 122.94 57.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.423 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.51 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 13.4 mt-30 -78.83 145.0 34.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.266 -0.896 . . . . 0.0 109.588 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.764 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.03 157.09 34.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.299 -0.876 . . . . 0.0 109.401 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -63.86 142.86 58.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.481 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.1 p -68.12 151.0 47.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.463 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.21 -34.08 4.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.452 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -112.08 9.22 20.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.624 ' OE2' HG23 ' A' ' 69' ' ' VAL . 85.6 tt0 -54.18 -41.0 68.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.87 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.53 -44.33 83.38 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.7 ttm-85 -62.44 -35.39 79.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -1.147 . . . . 0.0 109.498 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.764 HG21 ' HB1' ' A' ' 14' ' ' ALA . 53.7 t -56.51 -38.21 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.65 -37.41 86.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -0.894 . . . . 0.0 109.445 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 54.8 m -73.54 -40.68 63.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 26.6 m -64.48 -33.48 75.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.552 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.76 HD13 HG21 ' A' ' 86' ' ' VAL . 20.2 tp -63.32 -49.92 72.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.449 ' HG2' ' NZ ' ' A' ' 31' ' ' LYS . 18.4 ttp180 -43.21 -51.86 5.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.334 -0.854 . . . . 0.0 109.52 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -51.38 -49.18 62.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.528 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.83 ' HB3' HD11 ' A' ' 82' ' ' LEU . 90.3 m-70 -57.76 -26.08 61.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.474 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.965 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.7 mm -72.22 -51.95 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.475 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 58.7 mttp -66.9 -39.66 87.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.304 -0.872 . . . . 0.0 109.435 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.428 HD23 ' HA ' ' A' ' 32' ' ' LEU . 41.4 mt -57.45 -57.85 10.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.469 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 76.1 m80 -89.5 5.39 45.65 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 30' ' ' ILE . 69.9 m-20 55.18 48.4 19.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.551 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.864 ' HG3' HD22 ' A' ' 82' ' ' LEU . 49.0 mmm -98.17 15.06 25.5 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.66 ' CG ' HG22 ' A' ' 30' ' ' ILE . 98.0 mt-10 -55.01 -29.27 57.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.481 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -67.69 -38.3 83.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.338 -0.851 . . . . 0.0 109.508 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.833 HD12 ' HB3' ' A' ' 35' ' ' MET . 6.3 mt -72.63 -52.85 13.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.425 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.965 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -69.91 133.77 47.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 109.335 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.52 -64.06 0.61 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -146.6 153.07 39.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.168 -1.195 . . . . 0.0 109.556 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.986 HG13 HG22 ' A' ' 71' ' ' VAL . 38.9 t -114.44 149.72 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.455 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.555 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.4 mtm -132.08 140.36 48.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.167 -0.958 . . . . 0.0 109.562 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.3 t . . . . . 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.969 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -117.89 109.49 16.59 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -1.141 . . . . 0.0 109.437 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.624 HG23 ' OE2' ' A' ' 19' ' ' GLU . 77.0 t -137.25 133.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.275 -0.891 . . . . 0.0 109.585 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.823 ' N ' HD12 ' A' ' 70' ' ' LEU . 2.1 mp -101.26 147.1 26.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.285 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.986 HG22 HG13 ' A' ' 42' ' ' VAL . 65.0 t -145.49 113.78 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.246 -0.909 . . . . 0.0 109.638 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -54.06 124.35 15.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.209 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.564 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 38.1 ttp -177.21 155.22 1.12 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 0.0 109.533 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.5 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.1 t -91.52 140.45 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.302 -0.874 . . . . 0.0 109.402 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.615 ' CG ' ' CZ ' ' A' ' 10' ' ' TYR . 30.6 mmm -84.02 109.33 17.57 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.278 -0.889 . . . . 0.0 109.597 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.515 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 51.2 p-10 -138.27 173.89 11.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -64.18 -26.16 68.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.249 -0.907 . . . . 0.0 109.562 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.48 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -78.25 -70.14 0.51 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.51 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 25.1 p -54.67 -45.99 73.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -0.896 . . . . 0.0 109.736 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.532 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 73.1 t90 -51.15 -54.38 25.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.6 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -61.57 -39.09 89.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.925 . . . . 0.0 109.559 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.864 HD22 ' HG3' ' A' ' 35' ' ' MET . 58.4 tp -63.21 -41.64 99.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.152 -0.967 . . . . 0.0 109.503 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.007 HG11 ' CE2' ' A' ' 92' ' ' PHE . 55.6 t -56.32 -43.89 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.139 -0.976 . . . . 0.0 109.534 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -61.83 -35.65 78.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.175 -0.953 . . . . 0.0 109.481 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 29.8 t -66.76 -28.34 68.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.479 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.76 HG21 HD13 ' A' ' 26' ' ' LEU . 49.8 t -54.9 124.93 53.99 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.464 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.445 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.2 155.08 65.29 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.745 2.296 . . . . 0.0 111.789 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.579 ' HB2' HG22 ' A' ' 22' ' ' VAL . 82.6 mmt-85 63.36 43.43 6.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.254 -0.904 . . . . 0.0 109.526 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.662 HG21 ' HB ' ' A' ' 86' ' ' VAL . 53.6 t -128.79 115.58 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.5 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.51 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.7 mtp -68.5 -40.16 80.98 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.907 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.59 -158.86 31.43 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 1.007 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.2 OUTLIER -112.69 166.68 11.13 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.218 -1.166 . . . . 0.0 109.514 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.899 HD12 ' CG1' ' A' ' 11' ' ' VAL . 67.4 mt -118.24 137.5 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.878 . . . . 0.0 109.379 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 161.18 -147.08 13.24 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -78.08 -44.09 12.46 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.3 p -127.73 173.38 9.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.156 -1.202 . . . . 0.0 109.53 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.1 m -89.89 18.09 6.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.274 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.532 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 87.6 m-20 -130.17 -33.24 1.74 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.574 -0.704 . . . . 0.0 109.134 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.55 88.58 38.46 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.264 -0.898 . . . . 0.0 108.836 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.46 128.76 18.8 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.71 2.274 . . . . 0.0 112.048 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 137.14 82.56 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.291 -0.88 . . . . 0.0 109.361 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.552 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.3 Cg_endo -69.7 153.23 69.47 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.699 2.266 . . . . 0.0 111.841 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.559 HD11 HG22 ' A' ' 108' ' ' VAL . 26.7 pt -112.65 154.96 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.369 -0.832 . . . . 0.0 109.481 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.9 m -65.38 146.26 55.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.152 -0.968 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -58.13 -41.01 82.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.278 -0.889 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 42.5 tttt -57.98 -43.42 86.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.449 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 86.5 tt0 -51.85 -43.75 63.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.902 . . . . 0.0 109.441 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.559 HG22 HD11 ' A' ' 103' ' ' ILE . 74.8 t -57.17 -38.69 62.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.303 -0.873 . . . . 0.0 109.375 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -68.41 -31.75 71.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.23 -0.919 . . . . 0.0 109.465 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -62.93 -42.28 99.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.435 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 50.9 mt -52.43 -53.69 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.211 -0.93 . . . . 0.0 109.395 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.4 mtt . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.926 . . . . 0.0 109.377 179.911 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.485 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 47.1 mttt . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 78.8 mtt-85 -128.92 156.48 43.66 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 67.4 m95 -91.55 128.15 37.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.177 -0.952 . . . . 0.0 109.617 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.561 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.9 m-85 -120.9 150.11 41.58 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.46 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.479 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 53.0 t -102.27 136.04 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.245 -0.909 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.79 126.68 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.717 ' HB2' HD11 ' A' ' 93' ' ' ILE . 69.9 tp60 -90.35 130.64 36.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.425 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.666 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.67 154.74 44.61 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.528 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -55.12 149.67 11.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.423 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.8 t -67.93 147.71 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.498 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 -33.94 4.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.826 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -109.53 7.15 24.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -1.155 . . . . 0.0 109.592 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.42 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 23.0 pt-20 -56.12 -39.31 72.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.441 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -75.44 -54.2 5.66 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -57.86 -39.21 77.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -1.136 . . . . 0.0 109.497 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.9 t -53.05 -40.75 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.29 96.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.894 . . . . 0.0 109.433 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.8 m -64.48 -43.51 93.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.468 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 58.1 m -58.41 -41.68 85.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.655 HD21 ' CE1' ' A' ' 39' ' ' PHE . 4.8 tp -59.14 -39.41 82.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 109.272 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -58.48 -26.03 62.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.321 -0.862 . . . . 0.0 109.392 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.469 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 71.2 mt-10 -68.66 -47.65 65.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.325 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 1.0 ' HB3' HD11 ' A' ' 82' ' ' LEU . 79.8 m-70 -68.06 -43.47 78.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.857 HD13 ' CD2' ' A' ' 39' ' ' PHE . 54.9 mt -57.94 -50.44 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.52 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 58.2 tttp -60.49 -41.48 94.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.611 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 32.3 mt -69.27 -50.88 42.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.481 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 64.0 m80 -77.49 -6.89 55.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.217 -0.927 . . . . 0.0 109.528 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.487 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.1 t30 66.14 42.98 2.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.514 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.908 ' HG3' HD22 ' A' ' 82' ' ' LEU . 45.8 mmm -92.04 5.19 51.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.45 ' O ' ' O ' ' A' ' 39' ' ' PHE . 96.5 mt-10 -48.76 -37.79 19.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.461 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -53.26 -44.25 68.03 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.214 -0.929 . . . . 0.0 109.362 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.904 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.2 mt -72.19 -52.66 15.5 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.302 -0.874 . . . . 0.0 109.4 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.857 ' CD2' HD13 ' A' ' 30' ' ' ILE . 98.1 m-85 -70.97 129.09 38.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.187 -0.946 . . . . 0.0 109.441 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.32 -69.19 0.66 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -139.71 147.15 40.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -1.163 . . . . 0.0 109.583 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.036 HG13 HG22 ' A' ' 71' ' ' VAL . 39.0 t -113.99 154.01 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.374 -0.829 . . . . 0.0 109.351 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.565 ' CE ' HG11 ' A' ' 108' ' ' VAL . 64.3 mtm -137.78 144.05 41.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.566 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.6 t . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.438 179.918 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -118.64 124.25 46.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -1.199 . . . . 0.0 109.445 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.434 ' C ' HD12 ' A' ' 70' ' ' LEU . 76.6 t -132.2 146.49 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.567 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.846 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.2 mp -106.85 130.09 54.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.036 HG22 HG13 ' A' ' 42' ' ' VAL . 99.1 t -136.63 124.77 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.176 -0.952 . . . . 0.0 109.642 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.485 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 7.5 tt0 -81.02 128.37 33.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.171 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.561 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 50.9 ttp -173.83 165.12 4.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.65 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.529 ' N ' ' HG2' ' A' ' 73' ' ' MET . 14.5 p -88.53 143.36 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.353 -0.842 . . . . 0.0 109.218 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.582 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 16.9 tpp -82.91 113.82 20.78 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.593 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.0 p30 -142.14 168.94 18.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.318 -0.864 . . . . 0.0 109.427 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.572 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.6 m-20 -68.61 -30.12 68.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.217 -0.927 . . . . 0.0 109.47 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.02 -71.88 0.22 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.905 . . . . 0.0 109.55 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.904 ' OG ' HD13 ' A' ' 38' ' ' LEU . 7.5 m -48.27 -49.61 32.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 66.3 t90 -49.63 -52.3 31.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.873 . . . . 0.0 109.73 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 56.5 m-70 -66.6 -24.19 66.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.6 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 1.0 HD11 ' HB3' ' A' ' 29' ' ' HIS . 56.9 tp -68.74 -45.21 72.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.075 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 70.0 t -50.92 -44.05 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.573 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 36.2 ttp180 -62.92 -23.02 67.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.139 -0.976 . . . . 0.0 109.368 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.5 t -61.6 -63.86 1.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 0.0 109.415 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.683 HG13 HG21 ' A' ' 89' ' ' VAL . 1.8 p -59.62 125.8 80.89 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.164 -0.96 . . . . 0.0 109.467 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.476 ' O ' HG23 ' A' ' 89' ' ' VAL . 48.1 Cg_endo -69.65 -177.77 1.99 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.732 2.288 . . . . 0.0 111.834 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.1 mtt85 62.94 23.01 13.77 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.314 -0.866 . . . . 0.0 109.582 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.683 HG21 HG13 ' A' ' 86' ' ' VAL . 22.2 t -116.88 116.48 52.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.482 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 44.8 mtt -65.93 -43.68 87.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.346 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.19 -150.86 22.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 1.075 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 4.6 m-85 -111.8 161.4 16.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.4 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.717 HD11 ' HB2' ' A' ' 13' ' ' GLN . 15.8 mm -114.88 123.12 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.306 -0.871 . . . . 0.0 109.548 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.86 -152.76 11.57 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -64.95 -45.04 93.62 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.9 p -129.32 172.86 11.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.183 -1.187 . . . . 0.0 109.565 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 14.4 p -89.82 20.05 4.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.2 -0.937 . . . . 0.0 109.412 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -123.12 -22.65 5.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.449 -0.782 . . . . 0.0 109.37 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.53 103.18 3.27 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.328 -0.857 . . . . 0.0 108.94 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 48.4 Cg_endo -68.77 111.46 2.61 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.756 2.304 . . . . 0.0 111.996 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.98 140.7 81.95 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 109.427 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.521 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.9 Cg_endo -70.15 153.34 67.24 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.637 2.225 . . . . 0.0 111.81 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.62 155.11 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.255 -0.903 . . . . 0.0 109.408 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.7 m -71.74 151.34 43.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -52.29 -41.7 63.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -55.82 -41.52 74.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.921 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -52.88 -45.12 67.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.333 -0.854 . . . . 0.0 109.377 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.835 HG13 ' CD2' ' A' ' 70' ' ' LEU . 98.1 t -56.78 -38.03 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -67.54 -34.2 76.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.229 -0.919 . . . . 0.0 109.445 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -56.48 -46.3 80.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.332 -0.855 . . . . 0.0 109.415 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.72 HD12 HD21 ' A' ' 70' ' ' LEU . 50.5 mt -49.69 -56.36 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.329 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.6 mtt . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.276 179.812 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 77.5 mttt . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.285 0.564 . . . . 0.0 109.561 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.514 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 44.9 mtm180 -132.72 159.55 39.35 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.493 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.546 ' CG ' HG21 ' A' ' 108' ' ' VAL . 46.3 m95 -99.34 132.54 44.59 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.892 . . . . 0.0 109.556 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.595 ' CD2' ' HE2' ' A' ' 75' ' ' MET . 66.1 m-85 -130.93 155.23 47.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.443 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.489 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 10.7 t -96.18 145.93 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.226 -0.921 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.0 t -119.03 123.57 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 109.364 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.993 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.5 tt0 -93.1 131.67 37.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.923 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.445 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -138.72 -153.23 0.46 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 109.369 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 61.7 t80 -98.23 133.49 42.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.452 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 31.3 t -54.77 126.0 22.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.214 -0.929 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.11 -27.15 19.67 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 19.2 m-85 -105.09 7.52 33.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -1.116 . . . . 0.0 109.493 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -56.89 -34.72 68.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.915 . . . . 0.0 109.374 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -71.13 -37.87 63.68 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 17.9 ttm180 -63.81 -49.86 71.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.204 -1.174 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.461 HG13 HG11 ' A' ' 86' ' ' VAL . 39.1 t -50.37 -38.78 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.235 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.73 -39.72 91.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.929 . . . . 0.0 109.251 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.6 m -69.01 -46.6 67.55 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.388 -0.82 . . . . 0.0 109.376 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.412 ' HB3' ' HE1' ' A' ' 29' ' ' HIS . 21.4 m -65.72 -39.63 91.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.438 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.5 ' HG ' ' CD1' ' A' ' 30' ' ' ILE . 30.8 tp -54.34 -43.55 71.34 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.6 ttm-85 -57.83 -36.89 72.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -67.94 -52.58 34.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.203 -0.936 . . . . 0.0 109.474 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.996 ' HB3' HD11 ' A' ' 82' ' ' LEU . 22.8 m80 -58.44 -48.06 81.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.93 . . . . 0.0 109.443 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.65 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.2 mt -57.69 -52.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.305 -0.872 . . . . 0.0 109.515 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.4 tttm -57.61 -43.39 84.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.29 -0.881 . . . . 0.0 109.497 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.427 ' HA ' HD23 ' A' ' 32' ' ' LEU . 40.2 mt -68.25 -49.48 60.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.229 -0.92 . . . . 0.0 109.416 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.506 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 63.9 m80 -80.35 4.19 18.7 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 109.577 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 30' ' ' ILE . 40.5 t30 52.75 50.53 17.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.403 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.937 ' HG3' HD22 ' A' ' 82' ' ' LEU . 53.3 mmm -102.88 4.74 37.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.427 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.3 mt-10 -49.78 -34.93 20.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -57.77 -43.03 85.23 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.413 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.586 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.4 mt -72.84 -50.12 25.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.287 -0.883 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.566 ' CE2' HG12 ' A' ' 30' ' ' ILE . 96.4 m-85 -71.2 130.83 42.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.295 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.56 -65.4 0.55 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -137.19 122.68 19.6 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -1.204 . . . . 0.0 109.675 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.983 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -92.53 136.0 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.34 -0.85 . . . . 0.0 109.145 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.766 ' O ' HG13 ' A' ' 69' ' ' VAL . 97.2 mtp -125.12 117.42 23.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.192 -0.942 . . . . 0.0 109.768 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 44' ' ' VAL . 12.0 p . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.323 -0.861 . . . . 0.0 109.099 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -111.95 120.79 43.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.485 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 43' ' ' MET . 96.5 t -133.34 146.88 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -0.888 . . . . 0.0 109.577 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.854 ' N ' HD22 ' A' ' 70' ' ' LEU . 1.2 mm? -105.03 131.0 53.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.886 . . . . 0.0 109.341 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.983 HG22 HG23 ' A' ' 42' ' ' VAL . 64.3 t -138.55 125.74 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 109.709 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.473 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.7 tt0 -78.8 119.58 22.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.826 . . . . 0.0 109.299 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.552 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 48.6 ttp -165.99 163.46 18.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.602 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' A' ' 73' ' ' MET . 32.3 t -91.48 147.61 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.595 ' HE2' ' CD2' ' A' ' 10' ' ' TYR . 10.2 mmt -86.5 114.14 23.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.935 . . . . 0.0 109.653 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.1 p-10 -143.25 167.92 21.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.305 -0.872 . . . . 0.0 109.324 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.6 m-20 -66.36 -24.29 66.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.257 -0.902 . . . . 0.0 109.696 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.533 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -75.57 -70.26 0.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.235 -0.916 . . . . 0.0 109.526 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.475 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 12.4 p -56.07 -49.72 73.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.168 -0.957 . . . . 0.0 109.682 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.476 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.8 t90 -43.97 -44.93 7.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 33.0 m-70 -73.54 -32.01 63.96 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 109.484 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.996 HD11 ' HB3' ' A' ' 29' ' ' HIS . 54.9 tp -63.07 -45.88 90.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.01 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 82.8 t -55.4 -45.64 78.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -62.95 -36.39 83.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.638 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 41.0 m -61.48 -38.89 88.95 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.133 -0.979 . . . . 0.0 109.471 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.644 ' O ' HG12 ' A' ' 89' ' ' VAL . 38.5 t -51.73 126.14 31.14 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.289 -0.882 . . . . 0.0 109.531 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.46 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -71.17 156.36 59.55 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.69 2.26 . . . . 0.0 111.714 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 21' ' ' ARG . 82.0 mtt-85 62.06 35.86 15.68 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.857 . . . . 0.0 109.672 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.2 p -129.09 128.31 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.158 -0.964 . . . . 0.0 109.571 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.486 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 92.4 mmm -71.96 -54.59 9.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.285 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 162.03 -148.01 14.87 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 1.01 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 5.3 m-85 -104.62 160.6 14.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -1.162 . . . . 0.0 109.499 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.993 HD11 ' HB2' ' A' ' 13' ' ' GLN . 17.3 mm -118.14 119.11 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.453 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -171.63 -143.57 4.11 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -71.98 -35.42 61.36 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.586 HG23 ' H ' ' A' ' 98' ' ' ASP . 7.0 t -140.93 176.16 9.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.211 -1.17 . . . . 0.0 109.633 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 13.1 p -92.96 21.57 5.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.43 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.586 ' H ' HG23 ' A' ' 96' ' ' THR . 2.6 p30 -137.05 8.79 2.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.46 -0.775 . . . . 0.0 109.133 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -176.69 92.51 0.25 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.343 -0.848 . . . . 0.0 108.948 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.525 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 46.0 Cg_endo -68.48 120.78 7.71 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.688 2.259 . . . . 0.0 111.988 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -64.37 148.61 95.95 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.285 -0.884 . . . . 0.0 109.317 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.507 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 49.5 Cg_endo -70.07 153.28 67.68 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.68 2.253 . . . . 0.0 111.82 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.533 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -125.21 157.91 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.336 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 39.0 m -75.64 148.71 38.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.554 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -56.51 -40.8 75.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -58.15 -40.37 81.17 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -0.882 . . . . 0.0 109.417 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 93.3 mt-10 -56.03 -43.78 78.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.197 -0.939 . . . . 0.0 109.389 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.546 HG21 ' CG ' ' A' ' 9' ' ' TRP . 54.1 t -57.35 -37.83 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -0.902 . . . . 0.0 109.343 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -73.81 -34.1 64.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.326 -0.859 . . . . 0.0 109.367 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.39 -43.41 81.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.388 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.422 HG13 ' O ' ' A' ' 107' ' ' GLU . 89.7 mt -50.05 -50.09 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.454 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.3 mtp . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.414 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 80.1 mttt . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.289 0.566 . . . . 0.0 109.493 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.556 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 51.3 mtt85 -117.27 156.01 28.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.19 -0.944 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 83.7 m95 -87.78 128.06 35.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.587 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.618 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 91.2 m-85 -121.18 160.67 23.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.912 . . . . 0.0 109.542 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 1.006 HG11 HD12 ' A' ' 93' ' ' ILE . 21.1 t -95.13 154.64 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.207 -0.933 . . . . 0.0 109.588 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.44 115.94 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.302 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.565 ' HG2' HD11 ' A' ' 93' ' ' ILE . 78.4 mt-30 -81.01 150.47 28.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.692 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.702 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.56 158.42 35.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 109.405 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.46 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.7 m-85 -62.44 143.97 56.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 34.0 t -67.78 147.34 52.72 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.25 -33.52 4.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.786 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.5 m-85 -108.07 10.66 28.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -1.139 . . . . 0.0 109.476 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -61.15 -36.78 80.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.433 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.81 -50.02 38.54 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.0 ttt85 -63.77 -37.48 87.51 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -1.144 . . . . 0.0 109.424 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.3 t -52.21 -41.67 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -0.934 . . . . 0.0 109.271 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.16 -48.93 79.8 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.298 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 78.7 m -59.39 -46.39 88.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.39 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.9 m -51.3 -44.79 61.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.295 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.473 ' O ' HG12 ' A' ' 30' ' ' ILE . 47.5 mt -51.29 -69.68 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.36 -0.838 . . . . 0.0 109.388 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.48 ' HA ' HG12 ' A' ' 30' ' ' ILE . 48.6 ttt85 -42.78 -42.81 3.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.386 -0.821 . . . . 0.0 109.72 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -55.78 -37.81 69.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.208 -0.932 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.465 ' HE1' ' HD2' ' A' ' 87' ' ' PRO . 40.2 m80 -79.85 -27.28 40.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.274 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.987 HD12 ' CD1' ' A' ' 39' ' ' PHE . 11.8 mm -64.01 -43.45 97.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.302 -0.874 . . . . 0.0 109.321 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -70.38 -36.41 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.434 HD23 ' HA ' ' A' ' 32' ' ' LEU . 39.4 mt -70.61 -55.75 8.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.335 -0.853 . . . . 0.0 109.472 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.93 ' CG ' HD11 ' A' ' 82' ' ' LEU . 62.7 m80 -81.18 4.82 18.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.195 -0.941 . . . . 0.0 109.559 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.6 t30 50.09 46.64 24.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.19 -0.944 . . . . 0.0 109.517 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.849 ' HB3' HD12 ' A' ' 38' ' ' LEU . 40.3 mmm -100.05 14.99 28.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.357 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.586 ' CG ' HG22 ' A' ' 30' ' ' ILE . 99.4 mt-10 -52.49 -31.31 34.5 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.276 -0.89 . . . . 0.0 109.492 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -60.34 -42.38 95.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.216 -0.927 . . . . 0.0 109.507 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 1.015 HD13 ' OG ' ' A' ' 79' ' ' SER . 2.4 mt -74.06 -53.97 8.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.351 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.987 ' CD1' HD12 ' A' ' 30' ' ' ILE . 94.2 m-85 -69.99 130.0 41.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.29 -64.27 0.48 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -138.93 146.34 40.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.164 -1.198 . . . . 0.0 109.525 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.991 HG13 HG22 ' A' ' 71' ' ' VAL . 48.2 t -111.12 153.83 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.516 ' SD ' HG11 ' A' ' 108' ' ' VAL . 89.5 mtp -123.62 143.81 50.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.499 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 N--CA 1.488 1.458 0 O-C-N 121.152 -0.967 . . . . 0.0 109.428 179.917 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -115.36 119.18 35.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -1.174 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.522 ' C ' HD12 ' A' ' 70' ' ' LEU . 93.4 t -133.27 138.39 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.219 -0.926 . . . . 0.0 109.591 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 1.11 HD21 HD12 ' A' ' 111' ' ' ILE . 4.1 mp -108.22 131.03 55.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.311 -0.868 . . . . 0.0 109.337 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.991 HG22 HG13 ' A' ' 42' ' ' VAL . 86.3 t -138.42 120.58 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.702 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.477 ' O ' ' HB2' ' A' ' 73' ' ' MET . 36.4 tt0 -69.15 135.55 50.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.228 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.571 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 52.8 ttp 172.94 156.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.99 . . . . 0.0 109.66 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.519 ' N ' ' HG2' ' A' ' 73' ' ' MET . 13.9 p -88.96 134.91 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.284 -0.885 . . . . 0.0 109.36 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.629 ' HE2' ' HG2' ' A' ' 100' ' ' PRO . 24.6 mmm -79.33 116.94 19.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.248 -0.907 . . . . 0.0 109.469 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.519 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 49.5 p-10 -143.43 171.03 14.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.227 -0.921 . . . . 0.0 109.468 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -59.76 -33.3 71.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.542 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -72.02 -70.96 0.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' SER . . . . . 1.015 ' OG ' HD13 ' A' ' 38' ' ' LEU . 6.7 m -52.76 -51.82 59.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.422 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.519 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 29.8 t90 -44.57 -46.65 10.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.312 -0.868 . . . . 0.0 109.593 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 19.5 m170 -70.39 -36.38 74.06 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.928 . . . . 0.0 109.422 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.93 HD11 ' CG ' ' A' ' 33' ' ' HIS . 3.0 tp -53.34 -45.01 68.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.952 . . . . 0.0 109.461 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.942 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 11.6 t -62.02 -31.77 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.405 -0.81 . . . . 0.0 109.591 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 80' ' ' TRP . 40.5 mtt-85 -70.98 -33.2 70.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.934 . . . . 0.0 109.407 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.9 p -79.7 -20.22 47.04 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.297 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 82' ' ' LEU . 88.5 t -67.29 127.33 93.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.343 -0.848 . . . . 0.0 109.326 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.465 ' HD2' ' HE1' ' A' ' 29' ' ' HIS . 49.2 Cg_endo -70.21 153.06 67.22 Favored 'Trans proline' 0 C--O 1.214 -0.708 0 C-N-CA 122.687 2.258 . . . . 0.0 111.853 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 18' ' ' PHE . 33.7 mtt85 63.09 47.34 4.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.605 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.608 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.1 t -127.33 123.44 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 109.527 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 85.5 mtp -78.16 -50.72 11.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.41 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 164.07 -160.87 33.84 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.942 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 6.7 m-85 -109.57 160.52 16.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -1.154 . . . . 0.0 109.667 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 1.006 HD12 HG11 ' A' ' 11' ' ' VAL . 3.7 mt -117.51 134.16 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.339 -0.851 . . . . 0.0 109.251 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 168.22 -142.22 7.32 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.25 -50.75 42.9 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.0 p -126.77 179.13 5.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -1.163 . . . . 0.0 109.587 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.47 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 25.6 p -94.38 22.54 5.97 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.261 -0.899 . . . . 0.0 109.309 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 97' ' ' SER . 92.2 m-20 -137.0 6.42 2.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.476 -0.765 . . . . 0.0 109.459 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER -170.88 95.72 0.44 Allowed Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.292 -0.88 . . . . 0.0 109.019 -179.966 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.629 ' HG2' ' HE2' ' A' ' 75' ' ' MET . 46.5 Cg_endo -68.5 116.78 4.57 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.79 2.327 . . . . 0.0 111.947 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.27 148.51 98.46 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.327 -0.858 . . . . 0.0 109.302 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.556 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.9 Cg_endo -69.43 153.15 70.82 Favored 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 122.688 2.259 . . . . 0.0 111.777 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.53 HD11 ' CG2' ' A' ' 108' ' ' VAL . 29.3 pt -126.62 160.05 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.9 m -74.89 153.06 38.81 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.936 . . . . 0.0 109.348 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -62.4 -33.36 74.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 18.7 tttp -61.58 -35.65 78.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.868 . . . . 0.0 109.475 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 -63.28 -40.69 98.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.434 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.723 HG13 HD22 ' A' ' 70' ' ' LEU . 76.0 t -65.81 -36.62 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -0.94 . . . . 0.0 109.361 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -68.45 -31.16 70.27 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.301 -0.875 . . . . 0.0 109.515 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.57 -40.12 84.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 1.11 HD12 HD21 ' A' ' 70' ' ' LEU . 54.8 mt -55.41 -51.46 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 109.415 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' MET . . . . . 0.5 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 86.2 mtp . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.24 -0.912 . . . . 0.0 109.372 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 36.3 mttm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.282 0.563 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 79.1 mtt85 -125.95 154.17 43.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.259 -0.9 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.427 ' CZ3' ' HG3' ' A' ' 43' ' ' MET . 90.1 m95 -91.0 130.11 36.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.211 -0.931 . . . . 0.0 109.502 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.476 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 93.3 m-85 -123.63 154.33 39.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 53.2 t -90.98 148.24 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.506 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -126.5 122.07 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.219 -0.926 . . . . 0.0 109.404 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.628 ' HB2' HD11 ' A' ' 93' ' ' ILE . 48.6 tt0 -84.9 133.71 34.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.211 -0.931 . . . . 0.0 109.432 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.741 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.39 161.88 36.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.488 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.4 m-85 -70.38 145.64 50.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.887 . . . . 0.0 109.544 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.9 t -60.32 139.31 57.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.458 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.67 -30.28 6.66 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 22' ' ' VAL . 10.3 m-85 -103.69 8.52 37.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -1.129 . . . . 0.0 109.517 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HG3' HG23 ' A' ' 69' ' ' VAL . 67.0 tt0 -53.08 -29.72 32.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.62 -55.44 2.04 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -55.91 -34.53 65.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.239 -1.153 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.741 HG21 ' HB1' ' A' ' 14' ' ' ALA . 54.9 t -58.82 -38.18 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.326 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.92 -34.32 77.86 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.483 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 42.5 m -63.38 -32.94 74.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.928 . . . . 0.0 109.426 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.405 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 28.6 m -65.17 -32.57 74.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.472 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.494 HD23 HG21 ' A' ' 86' ' ' VAL . 59.3 mt -60.77 -44.93 96.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.484 ' O ' ' HB2' ' A' ' 31' ' ' LYS . 74.2 ttt180 -58.03 -41.46 83.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 109.654 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -69.01 -60.37 2.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.243 -0.911 . . . . 0.0 109.596 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.644 ' CD2' HG22 ' A' ' 86' ' ' VAL . 91.0 m-70 -54.77 -47.09 74.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.219 -0.925 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.822 HG23 ' HB2' ' A' ' 35' ' ' MET . 87.4 mt -66.21 -44.67 91.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -0.876 . . . . 0.0 109.634 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 27' ' ' ARG . 15.3 ttpp -59.27 -41.47 88.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.457 HD23 ' HA ' ' A' ' 32' ' ' LEU . 45.8 mt -70.63 -52.67 19.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.324 -0.86 . . . . 0.0 109.41 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.469 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 48.5 m80 -74.79 -6.97 51.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.9 . . . . 0.0 109.391 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.499 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.0 m-20 61.42 46.15 7.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.997 ' HG3' HD13 ' A' ' 82' ' ' LEU . 45.3 mmm -91.87 -2.32 56.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.605 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.443 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.2 mt-10 -44.28 -38.81 4.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -52.13 -43.11 63.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.347 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.645 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.1 mt -73.01 -43.98 61.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.37 -0.831 . . . . 0.0 109.336 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.705 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.2 m-85 -73.19 137.32 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.282 -0.886 . . . . 0.0 109.427 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.78 -66.69 0.52 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.415 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 82.6 tt0 -136.68 152.04 49.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.567 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.045 HG13 HG22 ' A' ' 71' ' ' VAL . 48.1 t -117.51 147.61 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.29 -0.881 . . . . 0.0 109.359 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.478 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 90.6 mtp -120.64 141.5 50.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.141 -0.974 . . . . 0.0 109.527 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.241 -0.912 . . . . 0.0 109.436 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.606 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -109.68 126.27 53.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -1.154 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.546 HG23 ' HG3' ' A' ' 19' ' ' GLU . 86.3 t -134.15 142.72 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.388 -0.82 . . . . 0.0 109.505 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.85 HD21 HD12 ' A' ' 111' ' ' ILE . 3.8 mp -103.91 132.53 50.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.471 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.045 HG22 HG13 ' A' ' 42' ' ' VAL . 88.0 t -143.77 122.06 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.263 -0.898 . . . . 0.0 109.557 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.419 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 43.1 tt0 -78.36 130.33 36.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.224 -0.923 . . . . 0.0 109.187 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.57 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 41.1 ttp -162.67 154.67 18.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.514 ' N ' ' HG2' ' A' ' 73' ' ' MET . 59.2 t -69.81 151.19 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -0.948 . . . . 0.0 109.224 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.863 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -94.33 112.97 24.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 109.496 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.619 ' ND2' HD22 ' A' ' 38' ' ' LEU . 42.0 p-10 -148.51 169.17 20.86 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -72.38 -31.22 65.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.492 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -63.48 -61.45 2.33 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.513 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.467 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 17.4 p -53.36 -48.07 68.87 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.275 -0.891 . . . . 0.0 109.753 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.528 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 39.1 t90 -44.03 -49.32 8.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.888 . . . . 0.0 109.581 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 39.0 m80 -67.87 -39.38 83.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.206 -0.934 . . . . 0.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.997 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.4 OUTLIER -56.92 -45.2 82.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.726 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.579 HG21 ' HZ ' ' A' ' 92' ' ' PHE . 78.0 t -62.48 -48.43 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.525 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 23.7 mtp85 -62.45 -37.24 85.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.57 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -66.63 -26.75 67.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -0.948 . . . . 0.0 109.491 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.847 HG23 ' O ' ' A' ' 82' ' ' LEU . 56.5 t -65.4 129.66 94.46 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.537 ' HD2' ' NE2' ' A' ' 29' ' ' HIS . 49.7 Cg_endo -70.17 161.03 47.48 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.703 2.269 . . . . 0.0 111.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.488 ' HA ' ' CD2' ' A' ' 15' ' ' PHE . 93.0 mtt-85 61.51 35.76 17.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 86' ' ' VAL . 91.5 t -129.39 115.51 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.288 -0.882 . . . . 0.0 109.566 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.511 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 84.3 mtp -69.97 -43.43 71.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.177 -0.952 . . . . 0.0 109.471 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.57 -146.99 14.03 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.579 ' HZ ' HG21 ' A' ' 83' ' ' VAL . 51.6 m-85 -107.45 163.08 13.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.292 -1.122 . . . . 0.0 109.574 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.628 HD11 ' HB2' ' A' ' 13' ' ' GLN . 31.9 mm -119.4 124.22 72.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 109.337 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . . . 147.87 -141.12 8.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' GLY . . . -43.43 -89.36 0.01 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 18.9 p -123.7 -179.33 4.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.297 -1.12 . . . . 0.0 109.652 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 m -90.9 22.03 3.84 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.338 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.528 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 91.4 m-20 -118.49 -23.52 7.13 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -155.98 96.86 2.3 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.863 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 42.2 Cg_endo -65.13 119.99 7.13 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.865 2.376 . . . . 0.0 112.135 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.97 141.85 97.75 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.436 -0.79 . . . . 0.0 109.482 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.33 154.49 61.16 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.706 2.271 . . . . 0.0 111.854 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.873 HD11 HG22 ' A' ' 108' ' ' VAL . 34.0 pt -124.57 158.16 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.874 . . . . 0.0 109.378 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.453 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 42.2 m -69.51 148.18 49.83 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.916 . . . . 0.0 109.439 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.41 -37.74 78.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.399 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -61.3 -38.77 87.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.453 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 98.5 mt-10 -59.88 -42.21 93.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.873 HG22 HD11 ' A' ' 103' ' ' ILE . 78.3 t -61.61 -36.99 76.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.377 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -69.7 -33.24 72.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.69 -39.67 91.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.44 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.85 HD12 HD21 ' A' ' 70' ' ' LEU . 56.2 mt -56.84 -52.25 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.525 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' MET . . . . . 0.436 ' HE3' ' CE ' ' A' ' 43' ' ' MET . 53.7 ttm . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.403 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 46.0 mttp . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.323 0.582 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.502 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 63.4 mtt180 -116.99 153.08 33.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.454 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.55 ' CG ' HG21 ' A' ' 108' ' ' VAL . 82.5 m95 -99.69 131.97 45.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.48 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 62.5 m-85 -122.36 141.83 51.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.463 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.447 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.3 t -86.65 145.66 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.711 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -125.8 125.19 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 109.284 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.604 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.0 tp60 -87.58 131.96 34.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.609 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.517 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -139.33 164.82 28.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.324 -0.86 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -68.61 140.34 55.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 109.448 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.8 m -66.57 149.42 50.49 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.307 -0.87 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.63 -33.28 4.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.702 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.7 m-85 -109.45 8.46 25.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.18 -1.188 . . . . 0.0 109.506 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.47 ' OE2' HG22 ' A' ' 69' ' ' VAL . 84.4 tt0 -56.76 -39.34 73.84 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.62 -52.29 44.21 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 56.7 ttt-85 -62.62 -38.74 91.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -1.149 . . . . 0.0 109.491 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.702 HG23 ' O ' ' A' ' 18' ' ' PHE . 79.7 t -56.01 -39.88 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.424 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.08 -37.88 89.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.267 -0.896 . . . . 0.0 109.413 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.5 m -65.16 -38.94 92.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.223 -0.923 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.565 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 97.1 p -60.02 -38.42 82.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.462 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.403 ' CD2' HG21 ' A' ' 86' ' ' VAL . 44.4 mt -56.66 -49.45 75.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -0.871 . . . . 0.0 109.469 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttp85 -65.79 -37.06 85.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.515 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 80.1 tt0 -66.27 -44.76 82.68 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.26 -0.9 . . . . 0.0 109.499 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 1.067 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.9 m-70 -71.82 -51.5 22.2 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.457 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.779 HG22 ' HG3' ' A' ' 36' ' ' GLU . 83.4 mt -56.91 -45.3 83.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.917 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 39.8 tttt -56.59 -48.46 77.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -0.904 . . . . 0.0 109.465 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 48.6 mt -64.84 -51.24 63.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.934 . . . . 0.0 109.45 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB3' ' SD ' ' A' ' 35' ' ' MET . 70.2 m80 -74.86 -2.08 25.2 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.241 -0.912 . . . . 0.0 109.575 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.466 ' N ' ' O ' ' A' ' 30' ' ' ILE . 55.2 t30 55.0 45.44 26.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -0.927 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.73 ' HG3' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.66 5.17 47.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.521 179.982 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.779 ' HG3' HG22 ' A' ' 30' ' ' ILE . 97.9 mt-10 -61.02 -16.95 49.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 109.447 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -62.26 -40.57 96.64 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.292 -0.88 . . . . 0.0 109.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.896 ' HB2' HG12 ' A' ' 74' ' ' VAL . 0.3 OUTLIER -86.37 -31.39 21.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.353 179.887 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.524 ' CD1' ' HB2' ' A' ' 73' ' ' MET . 42.6 m-85 -76.44 132.08 39.44 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -96.67 -78.12 1.39 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.8 tp10 -139.44 136.53 34.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 71' ' ' VAL . 10.0 p -97.79 143.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.265 -0.897 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.627 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.3 mtt -108.53 141.21 40.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.54 ' O ' HG12 ' A' ' 44' ' ' VAL . 47.8 t . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.432 ' CZ ' ' OE1' ' A' ' 13' ' ' GLN . 7.2 m-85 -121.74 122.68 40.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.282 -1.128 . . . . 0.0 109.388 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 43' ' ' MET . 58.0 t -130.31 142.65 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.913 . . . . 0.0 109.514 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 1.035 HD21 HD12 ' A' ' 111' ' ' ILE . 3.6 mp -102.77 129.13 49.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.872 . . . . 0.0 109.428 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 42' ' ' VAL . 56.7 t -137.43 127.35 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.403 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 41.6 tt0 -84.22 138.75 32.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.284 -0.885 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.865 ' CG ' HD12 ' A' ' 38' ' ' LEU . 6.1 tmm? -177.89 149.09 0.56 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.896 HG12 ' HB2' ' A' ' 38' ' ' LEU . 7.4 p -75.03 122.87 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.186 -0.946 . . . . 0.0 109.458 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.641 ' HE3' ' HA ' ' A' ' 75' ' ' MET . 0.8 OUTLIER -52.82 112.97 0.94 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.682 -179.824 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 48.1 p-10 -146.2 161.79 39.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.371 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.37 -27.48 62.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.185 -0.947 . . . . 0.0 109.466 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.542 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -62.52 -62.94 1.4 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.456 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 24.3 p -53.7 -51.43 63.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.263 -0.898 . . . . 0.0 109.56 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 30.7 t90 -44.31 -55.84 4.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.551 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -59.7 -40.79 89.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.521 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 1.067 HD11 ' HB3' ' A' ' 29' ' ' HIS . 65.1 tp -60.3 -36.45 77.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.262 -0.899 . . . . 0.0 109.657 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.947 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 74.1 t -61.6 -44.69 99.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.525 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 48.5 tpt85 -57.92 -40.81 81.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.4 p -64.45 -27.53 69.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.752 ' HB ' HG21 ' A' ' 89' ' ' VAL . 79.1 t -61.84 123.18 76.29 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.447 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.4 150.42 64.28 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.602 2.202 . . . . 0.0 111.769 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.447 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 31.8 mtt-85 62.05 51.11 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.184 -0.947 . . . . 0.0 109.434 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.752 HG21 ' HB ' ' A' ' 86' ' ' VAL . 66.9 t -126.3 116.84 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.488 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.517 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.9 mmm -65.57 -45.66 82.45 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.42 -148.32 18.67 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.947 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 3.6 m-85 -117.84 164.49 14.95 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.238 -1.154 . . . . 0.0 109.54 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.604 HD11 ' HB2' ' A' ' 13' ' ' GLN . 9.2 mm -121.76 120.89 62.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.355 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 177.88 -144.13 6.4 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.27 -43.84 37.16 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 p -129.39 174.34 9.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.264 -1.139 . . . . 0.0 109.549 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 72.3 m -89.86 17.89 6.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -0.964 . . . . 0.0 109.369 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.7 m-20 -127.84 -30.73 2.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.518 -0.739 . . . . 0.0 109.273 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -134.57 91.51 21.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.309 -0.869 . . . . 0.0 108.916 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.6 Cg_endo -67.86 116.66 4.41 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.634 2.223 . . . . 0.0 112.001 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.42 146.5 79.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.502 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 50.0 Cg_endo -70.14 154.58 66.1 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.7 2.267 . . . . 0.0 111.759 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.682 HD11 HG22 ' A' ' 108' ' ' VAL . 28.7 pt -118.02 158.36 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.46 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 44.2 m -70.66 152.27 44.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.33 -0.856 . . . . 0.0 109.417 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -57.22 -38.67 74.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.212 -0.93 . . . . 0.0 109.359 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.62 -38.29 80.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.389 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 75.2 mm-40 -56.92 -45.77 82.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.315 -0.866 . . . . 0.0 109.408 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.72 HG13 ' CD2' ' A' ' 70' ' ' LEU . 96.4 t -60.07 -40.83 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.364 -0.835 . . . . 0.0 109.368 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -65.81 -36.76 84.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.399 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.88 -53.49 57.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 109.463 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 1.035 HD12 HD21 ' A' ' 70' ' ' LEU . 49.1 mt -48.03 -54.05 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.183 -0.948 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.2 mtp . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.27 -0.894 . . . . 0.0 109.348 179.885 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.446 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 23.4 mmtp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.531 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 93.6 mtt180 -125.38 152.94 44.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.375 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.48 ' CB ' HG21 ' A' ' 108' ' ' VAL . 85.6 m95 -96.4 129.38 43.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.495 ' CE1' ' HA ' ' A' ' 102' ' ' PRO . 64.0 m-85 -129.07 154.19 46.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.264 -0.898 . . . . 0.0 109.408 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 22.3 t -99.54 143.59 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.326 -0.858 . . . . 0.0 109.57 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -117.62 125.87 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.379 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.697 ' HB2' HD11 ' A' ' 93' ' ' ILE . 52.3 tt0 -88.79 135.35 33.57 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.158 -0.964 . . . . 0.0 109.521 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.654 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -140.04 -165.24 1.86 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -104.55 139.8 38.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.186 -0.946 . . . . 0.0 109.468 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.2 m -56.61 150.87 14.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.03 -34.48 4.25 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.889 ' O ' HG23 ' A' ' 22' ' ' VAL . 77.5 m-85 -118.98 10.18 12.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.309 -1.113 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.458 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.8 tt0 -58.02 -29.31 65.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.213 -0.929 . . . . 0.0 109.534 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -77.62 -53.05 5.2 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -59.63 -39.43 84.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -1.181 . . . . 0.0 109.46 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.889 HG23 ' O ' ' A' ' 18' ' ' PHE . 99.0 t -50.5 -43.84 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.373 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.32 -41.52 85.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.469 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.9 m -64.62 -36.36 83.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.5 m -64.65 -37.78 88.74 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.954 . . . . 0.0 109.525 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.707 ' CD2' HG21 ' A' ' 86' ' ' VAL . 51.2 mt -53.77 -59.71 4.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -0.928 . . . . 0.0 109.579 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' LEU . 71.9 ttt180 -42.98 -51.11 5.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.852 . . . . 0.0 109.788 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.437 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 94.9 mt-10 -54.1 -41.79 68.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.138 -0.976 . . . . 0.0 109.503 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.82 ' HB3' HD21 ' A' ' 82' ' ' LEU . 47.1 m80 -66.96 -31.1 71.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.419 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 1.025 HD12 ' CD2' ' A' ' 39' ' ' PHE . 13.1 mm -67.32 -52.65 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.537 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.8 mttt -64.21 -43.38 95.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.262 -0.899 . . . . 0.0 109.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.453 HD23 ' HA ' ' A' ' 32' ' ' LEU . 27.3 mt -60.46 -51.16 70.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.527 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.561 ' CE1' ' CD1' ' A' ' 82' ' ' LEU . 73.5 m80 -87.27 10.25 17.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.264 -0.898 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 18.1 m120 49.37 49.45 19.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.189 -0.944 . . . . 0.0 109.434 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.792 ' CG ' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -106.48 21.21 17.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.425 -179.926 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.49 ' N ' HG22 ' A' ' 30' ' ' ILE . 70.7 mm-40 -66.22 -12.53 56.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.199 -0.938 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.38 -52.67 24.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.288 -0.882 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.792 HD21 ' CG ' ' A' ' 35' ' ' MET . 0.6 OUTLIER -75.96 -37.77 58.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.33 -0.856 . . . . 0.0 109.781 -179.825 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 1.025 ' CD2' HD12 ' A' ' 30' ' ' ILE . 52.0 m-85 -76.68 139.91 40.7 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.177 -0.952 . . . . 0.0 109.253 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.22 0.62 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.508 ' HG3' ' N ' ' A' ' 42' ' ' VAL . 45.9 tp10 -131.49 152.74 50.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -1.13 . . . . 0.0 109.569 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.077 HG13 HG22 ' A' ' 71' ' ' VAL . 91.9 t -119.42 154.43 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.289 -0.882 . . . . 0.0 109.383 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.773 ' HE1' HG11 ' A' ' 108' ' ' VAL . 61.2 mtm -135.68 145.11 46.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.1 t . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.211 -0.931 . . . . 0.0 109.546 179.989 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.458 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -111.58 116.03 30.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -1.141 . . . . 0.0 109.536 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 70' ' ' LEU . 48.7 t -126.98 151.91 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.57 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.847 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.3 mp -108.05 129.02 55.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -0.93 . . . . 0.0 109.417 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.077 HG22 HG13 ' A' ' 42' ' ' VAL . 90.6 t -138.76 125.21 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.722 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.446 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 43.3 tt0 -78.12 120.14 22.52 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.248 -0.907 . . . . 0.0 109.08 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.682 ' CG ' HD12 ' A' ' 38' ' ' LEU . 8.0 tmm? -167.97 149.24 5.24 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -0.918 . . . . 0.0 109.569 -179.602 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 45.3 t -85.43 128.56 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.923 . . . . 0.0 109.163 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.519 ' SD ' ' CG ' ' A' ' 100' ' ' PRO . 11.7 mmt -64.72 107.69 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.705 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.604 ' ND2' HD22 ' A' ' 38' ' ' LEU . 53.0 p-10 -128.77 -179.66 5.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -75.09 -23.2 57.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.852 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.647 ' HB1' ' HE3' ' A' ' 35' ' ' MET . . . -82.27 -67.11 0.81 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.201 -0.937 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.533 ' HB3' HD13 ' A' ' 38' ' ' LEU . 6.3 p -49.62 -49.78 45.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.41 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 48.4 t90 -51.66 -59.56 4.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.351 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -58.95 -37.91 77.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.296 -0.878 . . . . 0.0 109.459 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.82 HD21 ' HB3' ' A' ' 29' ' ' HIS . 39.6 tp -63.61 -37.62 88.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.933 . . . . 0.0 109.401 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.94 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 54.8 t -56.92 -50.13 76.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.468 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -55.01 -41.54 71.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.2 t -57.08 -33.15 66.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.885 . . . . 0.0 109.497 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.707 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.6 t -61.08 121.91 65.85 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.269 -0.895 . . . . 0.0 109.387 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.443 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -70.32 158.29 56.69 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.691 2.261 . . . . 0.0 111.777 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.569 ' HD3' ' CG ' ' A' ' 18' ' ' PHE . 8.9 mtt85 63.11 45.77 5.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.932 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.512 HG21 ' HB ' ' A' ' 86' ' ' VAL . 96.8 t -130.92 118.89 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.172 -0.955 . . . . 0.0 109.549 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.45 ' SD ' ' HG2' ' A' ' 13' ' ' GLN . 85.9 mtp -68.83 -44.57 73.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -0.937 . . . . 0.0 109.404 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.71 -151.8 22.35 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.94 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.3 m-85 -111.8 164.25 13.27 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -1.203 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.697 HD11 ' HB2' ' A' ' 13' ' ' GLN . 20.9 mm -118.46 120.3 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.647 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.64 -149.76 9.17 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.46 -38.8 91.16 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.688 HG23 ' H ' ' A' ' 98' ' ' ASP . 10.3 t -140.53 176.57 8.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -1.186 . . . . 0.0 109.47 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.8 p -92.62 17.99 9.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 109.414 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.688 ' H ' HG23 ' A' ' 96' ' ' THR . 84.6 m-20 -121.72 -14.35 8.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.515 -0.741 . . . . 0.0 109.264 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.481 ' H ' HG23 ' A' ' 96' ' ' THR . 0.0 OUTLIER -161.42 99.24 1.25 Allowed Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.349 -0.844 . . . . 0.0 109.008 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.519 ' CG ' ' SD ' ' A' ' 75' ' ' MET . 46.4 Cg_endo -68.09 120.51 7.49 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.706 2.27 . . . . 0.0 112.015 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -63.27 138.31 97.31 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.88 . . . . 0.0 109.39 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.531 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.51 153.74 65.28 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.649 2.233 . . . . 0.0 111.765 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.774 HD11 HG22 ' A' ' 108' ' ' VAL . 35.1 pt -124.32 156.23 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 32.3 m -71.97 151.11 43.49 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.311 -0.868 . . . . 0.0 109.423 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -54.76 -40.99 69.94 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.358 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -59.31 -38.64 80.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.456 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -58.86 -44.36 91.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.276 -0.89 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.774 HG22 HD11 ' A' ' 103' ' ' ILE . 58.1 t -57.93 -39.33 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -66.42 -40.95 89.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.261 -0.899 . . . . 0.0 109.416 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -63.43 -44.63 94.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.427 HG13 ' O ' ' A' ' 107' ' ' GLU . 68.8 mt -52.48 -51.39 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.332 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.6 mtp . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.925 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.415 ' HA ' ' OE1' ' A' ' 72' ' ' GLN . 8.6 mmtp . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.418 ' HD3' ' HA ' ' A' ' 8' ' ' ARG . 17.1 mmt85 -110.48 153.13 25.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.334 -0.854 . . . . 0.0 109.455 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.511 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 56.5 m95 -103.81 129.24 51.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.928 . . . . 0.0 109.506 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.424 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 87.1 m-85 -124.18 163.83 20.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.407 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 24.5 t -98.7 147.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.6 t -124.83 123.64 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.329 -0.857 . . . . 0.0 109.331 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.821 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.1 tt0 -90.8 137.83 32.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.683 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -145.45 159.98 42.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -67.9 143.26 55.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.164 -0.96 . . . . 0.0 109.56 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 46.0 m -59.14 147.62 34.44 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.44 -33.54 4.31 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.756 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.1 m-85 -107.22 5.21 27.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -1.149 . . . . 0.0 109.562 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.438 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 85.1 tt0 -53.55 -36.23 61.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.361 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.36 -58.64 3.08 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 45.4 ttm105 -56.5 -42.43 78.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.415 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 18' ' ' PHE . 53.2 t -49.14 -47.57 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.351 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.81 -44.66 82.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.265 -0.897 . . . . 0.0 109.411 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -64.09 -45.52 88.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.389 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.467 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 50.8 m -52.03 -56.45 14.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 tp -48.15 -55.52 10.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.307 -0.871 . . . . 0.0 109.365 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.665 ' HA ' HD12 ' A' ' 30' ' ' ILE . 25.2 ttt85 -53.74 -30.65 45.16 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.946 . . . . 0.0 109.136 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.467 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.9 tt0 -63.1 -44.45 95.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.309 -0.87 . . . . 0.0 109.36 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.756 ' HB3' HD11 ' A' ' 82' ' ' LEU . 57.0 m80 -75.79 -33.92 60.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.919 HG23 ' HB2' ' A' ' 35' ' ' MET . 79.8 mt -54.93 -48.83 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.283 -0.885 . . . . 0.0 109.292 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -60.26 -43.15 96.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.531 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 32' ' ' LEU . 61.5 mt -64.2 -50.81 66.62 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.474 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 67.6 m80 -82.15 3.1 28.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.244 -0.91 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.409 ' N ' ' O ' ' A' ' 30' ' ' ILE . 21.4 m120 59.4 50.62 7.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.338 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.93 ' HG3' HD22 ' A' ' 82' ' ' LEU . 68.5 mmm -99.58 3.92 45.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.29 -0.881 . . . . 0.0 109.706 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.471 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.2 mt-10 -54.89 -34.33 62.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.173 -0.954 . . . . 0.0 109.451 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -60.88 -42.47 98.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.894 . . . . 0.0 109.358 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.555 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.1 mt -70.88 -50.33 36.27 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.311 -0.868 . . . . 0.0 109.347 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 30' ' ' ILE . 98.9 m-85 -75.99 134.47 40.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.385 -0.822 . . . . 0.0 109.418 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.08 -68.77 0.59 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.433 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 83.3 tt0 -127.6 155.9 43.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -1.128 . . . . 0.0 109.533 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.975 HG13 HG22 ' A' ' 71' ' ' VAL . 51.9 t -121.11 150.39 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.388 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.767 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -120.98 161.86 20.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 43' ' ' MET . 75.5 t . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.304 -0.873 . . . . 0.0 109.378 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.182 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.563 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -121.28 119.04 31.08 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -1.158 . . . . 0.0 109.511 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.767 HG13 ' O ' ' A' ' 43' ' ' MET . 95.1 t -132.03 142.35 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.226 -0.921 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.842 ' N ' HD22 ' A' ' 70' ' ' LEU . 2.4 mm? -106.37 129.55 54.35 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.975 HG22 HG13 ' A' ' 42' ' ' VAL . 84.4 t -139.69 128.88 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.541 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.415 ' OE1' ' HA ' ' A' ' 7' ' ' LYS . 6.6 tt0 -76.94 137.7 39.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.256 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.713 ' HE2' ' HB3' ' A' ' 79' ' ' SER . 7.5 tmm? 177.83 151.19 0.23 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.454 ' O ' ' SD ' ' A' ' 73' ' ' MET . 40.4 t -85.22 124.03 39.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.915 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.684 ' HE3' ' HG3' ' A' ' 100' ' ' PRO . 10.4 mmt -66.43 120.48 13.43 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.298 -0.876 . . . . 0.0 109.439 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.495 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.7 p-10 -150.3 179.16 8.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.261 -0.9 . . . . 0.0 109.47 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.576 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 93.5 m-20 -65.58 -35.19 80.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.348 -0.845 . . . . 0.0 109.548 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.412 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -74.02 -72.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.193 -0.942 . . . . 0.0 109.653 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.713 ' HB3' ' HE2' ' A' ' 73' ' ' MET . 3.7 m -45.2 -52.81 8.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.608 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.452 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 80.2 t90 -55.53 -53.07 60.93 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.242 -0.911 . . . . 0.0 109.571 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.576 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 24.8 m-70 -62.81 -34.84 78.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.256 -0.903 . . . . 0.0 109.524 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.93 HD22 ' HG3' ' A' ' 35' ' ' MET . 52.5 tp -58.05 -42.34 85.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.716 ' CG1' HG11 ' A' ' 89' ' ' VAL . 79.5 t -57.88 -45.53 87.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.214 -0.929 . . . . 0.0 109.537 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -67.36 -29.84 69.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.203 -0.936 . . . . 0.0 109.461 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 67.5 m -59.59 -50.76 72.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.334 -0.854 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.626 HG13 HG21 ' A' ' 89' ' ' VAL . 7.4 p -78.78 128.67 76.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.677 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.569 ' O ' HG23 ' A' ' 89' ' ' VAL . 50.3 Cg_endo -70.13 -171.06 0.46 Allowed 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.752 2.301 . . . . 0.0 111.664 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.499 ' HB3' HG22 ' A' ' 22' ' ' VAL . 31.6 mtt-85 61.38 21.7 12.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.877 . . . . 0.0 109.48 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.716 HG11 ' CG1' ' A' ' 83' ' ' VAL . 43.6 t -119.78 107.93 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.447 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.479 ' CE ' ' OE1' ' A' ' 13' ' ' GLN . 74.6 mtp -60.22 -43.43 96.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.177 -0.952 . . . . 0.0 109.468 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.07 -149.41 21.21 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.711 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 45.4 m-85 -110.36 160.65 16.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.277 -1.131 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.821 HD11 ' HB2' ' A' ' 13' ' ' GLN . 22.1 mm -115.29 129.95 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.385 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 95' ' ' GLY . . . 140.53 -141.47 11.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 94' ' ' GLY . . . -44.0 -89.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -125.16 -178.25 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.247 -1.149 . . . . 0.0 109.435 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.2 p -90.38 21.57 3.81 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -0.918 . . . . 0.0 109.351 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -117.55 -22.94 7.88 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.417 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -154.82 94.68 2.68 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.684 ' HG3' ' HE3' ' A' ' 75' ' ' MET . 41.4 Cg_endo -63.85 118.4 5.34 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.922 2.414 . . . . 0.0 112.138 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.44 142.1 82.6 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.493 -0.754 . . . . 0.0 109.59 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.54 153.34 65.43 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.784 2.322 . . . . 0.0 111.814 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.558 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -126.13 156.78 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 49.8 m -70.46 143.55 51.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 109.586 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.46 -35.87 68.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.386 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 51.0 tttm -62.43 -40.36 96.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.191 -0.943 . . . . 0.0 109.448 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 87.4 tt0 -54.56 -44.76 73.19 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.558 ' CG2' HD11 ' A' ' 103' ' ' ILE . 68.8 t -57.91 -40.44 76.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.345 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -63.91 -37.24 86.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.454 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.11 -47.27 86.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.407 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 68.7 mt -51.9 -48.01 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.3 mmm . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.357 -179.98 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 82.8 mttt . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.589 ' HB2' ' CE1' ' A' ' 10' ' ' TYR . 41.7 mtt-85 -126.38 161.53 27.65 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.159 -0.963 . . . . 0.0 109.509 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.514 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 69.2 m95 -91.35 124.79 35.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.606 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 95.8 m-85 -120.85 147.46 45.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 55.2 t -87.04 159.4 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.393 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.506 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.4 t -144.56 103.94 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.237 -0.915 . . . . 0.0 109.173 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.475 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 50.0 tt0 -42.18 -47.4 4.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.54 -0.725 . . . . 0.0 109.657 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.478 ' O ' ' HG2' ' A' ' 90' ' ' MET . . . 53.62 -168.28 0.06 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.283 -0.885 . . . . 0.0 109.471 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 57.5 t80 -103.17 142.08 34.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.878 . . . . 0.0 109.341 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.425 ' HA ' ' OE2' ' A' ' 19' ' ' GLU . 28.3 p -66.96 131.07 45.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.62 -28.04 9.84 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 17.9 m-30 -103.29 18.26 22.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.223 -1.163 . . . . 0.0 109.506 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.517 ' OE2' ' N ' ' A' ' 67' ' ' GLY . 33.3 mp0 -51.64 -40.94 60.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.191 -0.943 . . . . 0.0 109.251 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.03 -58.39 3.21 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.1 ttm-85 -55.05 -47.48 74.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.155 -1.203 . . . . 0.0 109.426 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.655 HG23 ' CB ' ' A' ' 18' ' ' PHE . 46.8 t -46.7 -45.9 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 109.31 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.77 -45.01 66.92 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.386 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 86.0 m -62.03 -42.99 99.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.336 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 1.2 t -50.07 -54.97 16.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.215 -0.928 . . . . 0.0 109.289 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.492 HD23 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -47.68 -56.33 7.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.267 -0.895 . . . . 0.0 109.235 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.471 ' HA ' ' HB ' ' A' ' 30' ' ' ILE . 70.0 ttt-85 -52.72 -34.1 50.98 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.894 . . . . 0.0 109.127 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.7 tt0 -61.38 -46.09 91.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.183 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.7 ' NE2' HG23 ' A' ' 86' ' ' VAL . 69.3 m-70 -83.45 -30.1 27.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.249 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.862 HG23 ' HB2' ' A' ' 35' ' ' MET . 86.5 mt -64.44 -45.09 96.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -60.18 -40.56 90.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.9 . . . . 0.0 109.271 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 32' ' ' LEU . 82.8 mt -69.61 -51.77 32.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.299 -0.876 . . . . 0.0 109.354 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.437 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 71.7 m80 -79.23 0.02 30.24 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.59 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 30' ' ' ILE . 83.9 m-20 59.57 49.03 8.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' MET . . . . . 1.04 ' HG3' HD13 ' A' ' 82' ' ' LEU . 65.7 mmm -95.38 1.37 54.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.327 -0.858 . . . . 0.0 109.554 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -48.8 -36.48 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.563 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -57.1 -45.2 83.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.783 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.5 mt -70.88 -53.72 14.09 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -0.883 . . . . 0.0 109.443 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.583 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 91.7 m-85 -68.76 138.5 54.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.863 . . . . 0.0 109.422 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.03 -70.39 0.22 Allowed Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -128.63 157.48 41.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -1.16 . . . . 0.0 109.649 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.856 HG13 HG22 ' A' ' 71' ' ' VAL . 57.6 t -121.56 156.98 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.624 ' O ' HG13 ' A' ' 69' ' ' VAL . 87.3 mmm -121.64 150.78 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.265 -0.897 . . . . 0.0 109.398 179.848 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.517 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -123.48 122.2 37.62 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -1.157 . . . . 0.0 109.41 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 43' ' ' MET . 88.1 t -133.02 140.81 46.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 109.516 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.832 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.1 mp -105.66 134.99 47.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.38 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 42' ' ' VAL . 77.2 t -139.98 117.86 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.303 -0.873 . . . . 0.0 109.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.448 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.2 tt0 -67.61 135.49 52.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.42 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 44.6 ttp 173.57 154.69 0.11 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 97.1 t -84.21 140.78 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.606 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 19.3 mmm -84.8 125.71 32.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.536 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.592 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 47.8 p-10 -152.65 173.54 15.09 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -64.84 -29.4 70.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.247 -0.908 . . . . 0.0 109.542 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.592 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -74.87 -72.41 0.3 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.665 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.783 ' OG ' HD13 ' A' ' 38' ' ' LEU . 10.6 m -44.38 -56.82 3.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.257 -0.902 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.517 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 51.7 t90 -44.62 -54.04 6.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.278 -0.889 . . . . 0.0 109.385 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -61.1 -35.79 77.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.362 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 1.04 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -57.25 -37.24 72.03 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.27 -0.894 . . . . 0.0 109.413 179.892 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.947 ' CG1' HG11 ' A' ' 89' ' ' VAL . 44.1 t -73.04 -45.96 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -68.94 -31.31 70.1 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 95.1 p -64.8 -45.6 85.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.906 . . . . 0.0 109.362 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.7 HG23 ' NE2' ' A' ' 29' ' ' HIS . 11.1 p -82.35 133.49 50.23 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.395 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.624 ' O ' HG23 ' A' ' 89' ' ' VAL . 49.3 Cg_endo -69.12 -166.87 0.18 Allowed 'Trans proline' 0 C--O 1.214 -0.722 0 C-N-CA 122.697 2.265 . . . . 0.0 111.876 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.502 ' HB3' HG22 ' A' ' 22' ' ' VAL . 89.6 mtt-85 63.01 16.73 9.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.433 -0.792 . . . . 0.0 109.535 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.947 HG11 ' CG1' ' A' ' 83' ' ' VAL . 11.6 t -119.99 109.27 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.409 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 14' ' ' ALA . 90.9 mmm -65.3 -39.89 93.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 109.576 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.92 -169.59 35.23 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.569 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 15.3 m-85 -100.37 158.56 15.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.653 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 34.3 mm -117.7 115.69 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.298 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 179.8 -142.71 5.28 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.95 -37.55 50.14 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 p -132.39 169.89 15.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -1.156 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.0 p -88.84 14.93 9.22 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.251 -0.906 . . . . 0.0 109.336 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.517 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 88.5 m-20 -125.15 -22.49 4.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.566 -0.709 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.411 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -140.8 101.27 6.5 Favored Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.191 -0.943 . . . . 0.0 109.15 179.814 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.7 Cg_endo -69.02 109.69 2.23 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.744 2.296 . . . . 0.0 111.922 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.94 139.64 78.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 154.04 67.41 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.72 2.28 . . . . 0.0 111.842 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 108' ' ' VAL . 34.5 pt -123.83 158.13 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 m -70.21 147.74 49.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -55.01 -38.86 68.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -58.62 -40.34 83.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -51.77 -48.67 63.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.281 -0.887 . . . . 0.0 109.403 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.68 HG22 HD23 ' A' ' 70' ' ' LEU . 74.2 t -57.67 -44.09 84.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -60.9 -41.38 95.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.184 -0.948 . . . . 0.0 109.344 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.45 -52.82 64.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.326 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.799 HD12 HD21 ' A' ' 70' ' ' LEU . 69.0 mt -49.79 -53.98 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.378 -0.826 . . . . 0.0 109.373 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 95.3 mmm . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.254 179.873 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.424 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 94.9 mttt . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 95.4 mtt-85 -139.51 150.27 44.93 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.396 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.443 ' O ' HG12 ' A' ' 103' ' ' ILE . 72.4 m95 -100.67 136.72 40.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.642 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -130.21 149.85 51.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.328 -0.857 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.436 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 12.8 t -98.93 139.16 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.188 -0.945 . . . . 0.0 109.524 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.53 HG22 ' CE1' ' A' ' 92' ' ' PHE . 46.3 t -119.18 130.0 74.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.872 . . . . 0.0 109.41 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.876 ' CG ' HD11 ' A' ' 93' ' ' ILE . 95.8 mt-30 -87.68 147.47 25.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.329 -0.857 . . . . 0.0 109.468 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.3 154.63 38.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.921 . . . . 0.0 109.462 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -66.38 146.47 54.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.286 -0.884 . . . . 0.0 109.457 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 42.0 m -58.08 135.97 57.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.73 -29.28 7.49 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -104.08 7.15 36.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.2 -1.176 . . . . 0.0 109.545 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.86 -37.33 71.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.432 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -79.7 -35.0 29.72 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 63.4 ttt-85 -63.18 -47.4 82.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.233 -1.157 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.474 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 45.6 t -50.71 -39.12 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.451 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.21 -39.55 94.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 67.9 m -67.43 -36.0 80.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.572 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.706 ' HB2' HG13 ' A' ' 86' ' ' VAL . 31.8 m -63.72 -41.38 98.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.157 -0.964 . . . . 0.0 109.484 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.925 ' CD2' HG21 ' A' ' 86' ' ' VAL . 61.9 mt -56.48 -43.78 79.98 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.539 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.509 ' CG ' ' HE3' ' A' ' 31' ' ' LYS . 41.4 ttm180 -57.19 -39.46 75.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -73.97 -59.82 2.54 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.514 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.432 ' CE1' ' HB3' ' A' ' 25' ' ' SER . 40.4 m80 -52.44 -45.81 66.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.564 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' A' ' 35' ' ' MET . 96.5 mt -64.1 -55.58 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.477 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.509 ' HE3' ' CG ' ' A' ' 27' ' ' ARG . 82.6 mttt -53.89 -37.13 63.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 32' ' ' LEU . 51.3 mt -73.06 -48.19 38.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.539 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.409 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 49.7 m80 -81.38 0.87 35.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.939 . . . . 0.0 109.615 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 30' ' ' ILE . 77.7 m-20 59.08 49.77 8.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' MET . . . . . 1.057 ' HG3' HD13 ' A' ' 82' ' ' LEU . 40.0 mmm -101.8 8.98 41.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.557 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.448 ' OE2' ' HG2' ' A' ' 31' ' ' LYS . 97.5 mt-10 -51.73 -37.02 49.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.461 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -60.35 -37.83 81.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.407 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.98 HD13 ' OG ' ' A' ' 79' ' ' SER . 5.8 mt -73.61 -55.06 6.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.252 -0.905 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.634 ' CE1' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -72.47 136.17 45.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 109.407 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.39 -66.49 0.5 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -137.94 152.76 49.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.203 -1.175 . . . . 0.0 109.562 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.055 HG13 HG22 ' A' ' 71' ' ' VAL . 42.8 t -116.81 155.3 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.466 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 87.9 mtp -120.65 138.7 53.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.887 . . . . 0.0 109.568 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 179.916 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.234 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.98 125.84 49.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -1.178 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.435 ' C ' HD12 ' A' ' 70' ' ' LEU . 91.0 t -132.06 143.25 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.954 HD21 HD12 ' A' ' 111' ' ' ILE . 3.3 mp -107.65 127.41 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.385 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.055 HG22 HG13 ' A' ' 42' ' ' VAL . 96.9 t -133.27 133.17 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.538 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.424 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.3 tt0 -84.49 133.94 34.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.377 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.568 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 28.5 ttp -175.04 162.71 3.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.475 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.537 ' N ' ' HG2' ' A' ' 73' ' ' MET . 33.3 m -103.51 145.66 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.364 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.548 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 11.7 mmt -79.42 122.44 26.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.454 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 36.0 p-10 -133.74 -143.76 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.29 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.2 p30 -117.91 0.85 12.0 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.025 -1.047 . . . . 0.0 110.067 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -122.8 -20.02 6.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.103 -0.998 . . . . 0.0 109.785 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.98 ' OG ' HD13 ' A' ' 38' ' ' LEU . 4.5 m -79.1 -36.66 40.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.24 -0.912 . . . . 0.0 109.581 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 85.6 t90 -56.24 -51.25 68.78 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.293 -0.879 . . . . 0.0 109.595 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -66.22 -32.21 73.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.689 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 1.057 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.6 OUTLIER -62.86 -37.12 85.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.214 -0.929 . . . . 0.0 109.475 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.832 HG21 ' CE2' ' A' ' 92' ' ' PHE . 55.8 t -68.96 -50.02 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 23.1 ttp85 -60.98 -35.69 77.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.506 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.3 t -60.5 -30.83 69.96 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.93 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.0 t -61.84 117.9 33.25 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.13 167.71 24.15 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.584 2.189 . . . . 0.0 111.693 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 39.0 mmt180 60.91 29.85 19.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.7 p -122.79 130.09 74.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.212 -0.93 . . . . 0.0 109.407 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.5 mtp -70.12 -50.93 35.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.21 -0.931 . . . . 0.0 109.508 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 169.36 -151.24 16.96 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.832 ' CE2' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -115.63 170.21 8.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.27 -1.135 . . . . 0.0 109.516 179.998 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.876 HD11 ' CG ' ' A' ' 13' ' ' GLN . 39.6 mm -121.78 125.48 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.355 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 169.71 -163.23 36.73 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -54.57 -56.77 20.51 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 p -125.49 178.96 5.34 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -1.162 . . . . 0.0 109.593 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.3 p -93.76 16.91 12.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -120.11 -28.64 5.06 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 10.1 mtp85 -142.56 90.75 7.78 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.548 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.0 Cg_endo -66.43 120.26 7.37 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.92 2.413 . . . . 0.0 112.239 -179.307 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.28 146.93 97.1 Favored Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.498 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.2 Cg_endo -69.85 152.84 68.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.598 2.198 . . . . 0.0 111.903 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.743 HD11 HG22 ' A' ' 108' ' ' VAL . 30.2 pt -113.1 156.12 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.316 -0.865 . . . . 0.0 109.4 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.0 m -74.52 152.21 39.4 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -56.6 -37.83 71.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.35 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -58.14 -42.08 85.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.223 -0.923 . . . . 0.0 109.404 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.413 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 90.1 mt-10 -58.76 -45.06 90.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.485 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 103' ' ' ILE . 73.4 t -59.43 -39.62 79.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.322 -0.861 . . . . 0.0 109.379 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.6 -34.21 73.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.267 -0.896 . . . . 0.0 109.388 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.27 -44.43 95.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.349 -0.844 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.954 HD12 HD21 ' A' ' 70' ' ' LEU . 73.9 mt -54.21 -54.16 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.474 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' MET . . . . . 0.429 ' HB2' ' HE3' ' A' ' 112' ' ' MET . 55.9 ttm . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.515 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.511 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 46.9 mttt . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.279 0.561 . . . . 0.0 109.571 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.472 ' HD2' ' OH ' ' A' ' 10' ' ' TYR . 78.3 mtt180 -125.27 156.72 38.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.392 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.456 ' CZ2' ' HB2' ' A' ' 72' ' ' GLN . 59.4 m95 -104.42 126.8 51.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.184 -0.948 . . . . 0.0 109.591 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.472 ' OH ' ' HD2' ' A' ' 8' ' ' ARG . 85.6 m-85 -125.15 148.13 48.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.417 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.548 HG22 ' CD1' ' A' ' 70' ' ' LEU . 22.8 t -92.06 143.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -0.926 . . . . 0.0 109.615 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.3 t -120.61 132.79 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.776 ' CG ' HD11 ' A' ' 93' ' ' ILE . 58.1 mt-30 -84.53 151.99 24.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.9 . . . . 0.0 109.483 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -163.96 150.47 11.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 0.0 109.506 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -61.14 143.67 55.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.224 -0.923 . . . . 0.0 109.509 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.9 t -61.62 136.45 58.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.82 -31.53 5.53 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.438 ' HB3' ' HD3' ' A' ' 88' ' ' ARG . 87.2 m-85 -105.08 -2.62 24.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.202 -1.175 . . . . 0.0 109.536 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.48 ' HG3' ' N ' ' A' ' 20' ' ' GLY . 15.7 pt-20 -56.52 -41.82 77.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.194 -0.941 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.48 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -63.15 -39.09 97.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.421 ' O ' ' C ' ' A' ' 22' ' ' VAL . 58.1 ttt85 -59.07 -48.73 80.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -1.129 . . . . 0.0 109.432 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.795 HG13 HG11 ' A' ' 86' ' ' VAL . 40.5 t -43.79 -39.18 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.881 . . . . 0.0 109.268 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -54.63 -56.01 23.57 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.252 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.9 m -63.45 -48.55 77.24 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.361 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.485 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 17.0 m -56.27 -49.04 75.37 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 0.0 109.328 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.673 HD12 HG21 ' A' ' 86' ' ' VAL . 5.1 tp -48.33 -56.46 8.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 43.1 ttt180 -55.08 -37.48 66.84 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.332 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.796 ' O ' HD12 ' A' ' 32' ' ' LEU . 71.5 tt0 -56.88 -47.78 79.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.257 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.885 ' HB3' HD11 ' A' ' 82' ' ' LEU . 62.0 m-70 -71.23 -41.62 69.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.243 -0.91 . . . . 0.0 109.344 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.769 HD13 ' CD1' ' A' ' 39' ' ' PHE . 76.1 mt -59.15 -52.2 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.394 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -54.23 -43.5 70.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.448 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.796 HD12 ' O ' ' A' ' 28' ' ' GLU . 4.3 mt -65.44 -48.4 72.88 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -0.915 . . . . 0.0 109.466 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB2' ' SD ' ' A' ' 35' ' ' MET . 65.1 m80 -85.17 6.39 25.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.56 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.516 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.6 t30 51.97 47.14 25.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.566 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.738 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -98.36 6.12 47.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.252 -0.905 . . . . 0.0 109.419 179.921 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.573 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.24 -35.5 49.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.158 -0.964 . . . . 0.0 109.523 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -55.25 -42.47 73.51 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 1.04 HD13 ' OG ' ' A' ' 79' ' ' SER . 0.9 OUTLIER -71.1 -54.47 11.0 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.201 -0.937 . . . . 0.0 109.322 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.769 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.0 m-85 -64.46 137.79 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.9 -67.48 0.38 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -132.76 149.74 52.24 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.251 -1.147 . . . . 0.0 109.707 -179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 71' ' ' VAL . 98.6 t -120.01 149.14 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.881 . . . . 0.0 109.289 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.822 ' HE1' HG11 ' A' ' 108' ' ' VAL . 73.4 mtm -130.37 146.14 51.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.144 -0.973 . . . . 0.0 109.578 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.9 t . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.272 -0.893 . . . . 0.0 109.301 179.882 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -110.02 128.86 55.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.222 -1.164 . . . . 0.0 109.583 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.485 ' C ' HD22 ' A' ' 70' ' ' LEU . 99.9 t -133.55 141.58 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.848 ' N ' HD22 ' A' ' 70' ' ' LEU . 2.3 mm? -106.27 131.5 53.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.354 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 42' ' ' VAL . 83.9 t -140.52 120.85 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.262 -0.899 . . . . 0.0 109.754 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 4.4 tt0 -76.62 124.74 28.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.567 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.2 ttp -162.82 155.97 19.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.683 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.513 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.7 t -86.14 130.11 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.7 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 18.9 ttm -75.26 135.49 40.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.469 HD21 ' HB3' ' A' ' 78' ' ' ALA . 44.7 p-10 -151.58 -161.0 1.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -102.99 34.35 2.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.417 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.469 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -149.88 -50.21 0.14 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' SER . . . . . 1.04 ' OG ' HD13 ' A' ' 38' ' ' LEU . 14.8 m -63.24 -44.06 96.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.51 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 70.3 t90 -50.78 -47.02 59.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -69.25 -34.05 74.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.885 HD11 ' HB3' ' A' ' 29' ' ' HIS . 53.9 tp -63.43 -38.69 92.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.28 -0.887 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 92' ' ' PHE . 70.6 t -60.69 -49.57 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.383 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -58.8 -35.3 72.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.306 -0.871 . . . . 0.0 109.439 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 24.1 m -62.73 -33.96 76.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.426 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.795 HG11 HG13 ' A' ' 22' ' ' VAL . 49.0 t -49.18 127.71 15.8 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.7 Cg_endo -70.8 156.77 60.02 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.617 2.211 . . . . 0.0 111.803 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.456 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.9 mtt-85 63.51 34.19 12.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 109.678 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.4 p -128.52 134.41 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 73.2 mtm -79.56 -44.56 20.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.241 -0.912 . . . . 0.0 109.488 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.74 -147.04 12.25 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -113.25 167.07 10.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -1.114 . . . . 0.0 109.55 -179.976 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.776 HD11 ' CG ' ' A' ' 13' ' ' GLN . 33.5 mm -121.25 137.65 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.854 . . . . 0.0 109.438 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 163.09 -148.07 14.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.59 -46.55 14.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.2 p -121.64 171.2 9.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -1.192 . . . . 0.0 109.804 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 59.9 m -91.61 18.56 7.3 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.23 -0.919 . . . . 0.0 109.322 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.51 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 90.2 m-20 -124.82 -30.92 3.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.525 -0.734 . . . . 0.0 109.099 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 6.2 mtt180 -144.64 98.67 4.88 Favored Pre-proline 0 N--CA 1.488 1.464 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.7 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 44.3 Cg_endo -67.12 132.28 27.49 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.695 2.263 . . . . 0.0 112.101 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.07 137.02 96.93 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.387 -0.821 . . . . 0.0 109.36 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.19 152.69 72.26 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.645 2.23 . . . . 0.0 111.741 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.801 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -123.53 164.46 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.407 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.6 p -83.52 155.32 23.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -0.928 . . . . 0.0 109.447 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -63.74 -30.39 71.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.257 -0.902 . . . . 0.0 109.494 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -65.43 -37.1 85.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -0.906 . . . . 0.0 109.4 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.447 ' O ' HG13 ' A' ' 111' ' ' ILE . 85.2 tt0 -65.0 -39.86 94.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.254 -0.904 . . . . 0.0 109.385 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.822 HG11 ' HE1' ' A' ' 43' ' ' MET . 76.3 t -67.02 -34.08 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.354 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -70.5 -34.11 71.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.88 . . . . 0.0 109.453 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -69.34 -39.51 78.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.334 -0.854 . . . . 0.0 109.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 107' ' ' GLU . 71.9 mt -56.93 -51.37 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.234 -0.916 . . . . 0.0 109.541 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.5 mtp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.226 -0.921 . . . . 0.0 109.496 -179.99 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.436 ' O ' ' HG3' ' A' ' 7' ' ' LYS . 16.0 pttt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.0 mtt-85 -133.53 153.5 51.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.237 -0.914 . . . . 0.0 109.491 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 70.4 m95 -101.38 135.81 42.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.909 . . . . 0.0 109.415 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CE2' ' O ' ' A' ' 73' ' ' MET . 22.9 m-85 -124.58 151.62 44.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 18.4 t -101.1 137.89 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.333 -0.855 . . . . 0.0 109.489 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 30.6 t -115.11 128.7 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.306 -0.871 . . . . 0.0 109.234 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.953 ' HB2' HD11 ' A' ' 93' ' ' ILE . 60.4 tt0 -95.6 129.96 42.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.913 . . . . 0.0 109.617 -179.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.44 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -147.42 -178.2 6.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -75.03 134.26 41.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.7 m -57.79 140.6 51.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.39 -25.44 15.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.49 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.4 m-85 -112.05 13.57 20.71 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.23 -1.159 . . . . 0.0 109.39 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.485 ' OE2' ' N ' ' A' ' 67' ' ' GLY . 87.2 mt-10 -54.07 -45.31 71.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.12 -42.25 91.85 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.425 ' HD3' ' NE ' ' A' ' 88' ' ' ARG . 52.7 ttt85 -52.16 -54.53 29.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.228 -1.16 . . . . 0.0 109.389 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.1 t -50.35 -37.23 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.203 -0.936 . . . . 0.0 109.119 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.72 -36.79 85.43 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.211 -0.931 . . . . 0.0 109.231 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -58.83 -43.03 90.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.397 -0.815 . . . . 0.0 109.158 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.67 ' HB3' ' CE1' ' A' ' 29' ' ' HIS . 20.3 m -58.77 -41.04 85.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 109.319 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.66 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.1 mt -53.45 -44.51 68.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.865 . . . . 0.0 109.409 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 31' ' ' LYS . 65.9 ttt180 -52.6 -42.49 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.34 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.413 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 64.6 mm-40 -75.02 -57.77 3.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.67 ' CE1' ' HB3' ' A' ' 25' ' ' SER . 32.9 m80 -55.15 -38.03 67.73 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -0.942 . . . . 0.0 109.268 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.792 HG23 ' HB2' ' A' ' 35' ' ' MET . 82.2 mt -77.17 -54.46 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.293 -0.879 . . . . 0.0 109.49 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 27' ' ' ARG . 42.2 tttm -59.97 -38.24 81.92 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.906 . . . . 0.0 109.286 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.467 HD23 ' HA ' ' A' ' 32' ' ' LEU . 25.2 mt -70.64 -52.05 23.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.194 -0.942 . . . . 0.0 109.388 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -81.17 0.84 34.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.536 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.509 ' N ' ' O ' ' A' ' 30' ' ' ILE . 20.2 m120 60.37 51.49 5.33 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.242 -0.911 . . . . 0.0 109.408 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.86 ' HG3' HD13 ' A' ' 82' ' ' LEU . 59.9 mmm -99.84 -0.15 40.3 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.291 -0.88 . . . . 0.0 109.599 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.515 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.1 mt-10 -45.67 -37.94 6.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.402 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -53.45 -44.24 68.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.922 . . . . 0.0 109.436 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.777 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.0 OUTLIER -74.62 -46.92 35.19 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.376 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.707 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -75.41 125.87 29.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.9 . . . . 0.0 109.497 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.69 -67.06 0.6 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -132.46 144.74 50.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -1.154 . . . . 0.0 109.524 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.875 HG13 HG22 ' A' ' 71' ' ' VAL . 19.5 t -109.06 147.65 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.247 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.495 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.2 mtp -122.73 152.32 40.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.118 -0.988 . . . . 0.0 109.757 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.3 t . . . . . 0 N--CA 1.49 1.525 0 O-C-N 121.365 -0.835 . . . . 0.0 109.228 179.949 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.485 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.01 118.29 22.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -1.125 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.572 ' C ' HD12 ' A' ' 70' ' ' LEU . 79.0 t -130.64 148.82 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.559 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.837 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.0 mp -116.05 132.66 56.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.292 -0.88 . . . . 0.0 109.314 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.875 HG22 HG13 ' A' ' 42' ' ' VAL . 92.4 t -137.03 129.91 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.649 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.6 tt0 -79.87 132.74 36.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.225 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 50.3 ttp 174.07 165.19 0.2 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.162 -0.961 . . . . 0.0 109.621 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 15.0 p -94.6 138.57 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.286 -0.884 . . . . 0.0 109.237 179.791 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.6 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 34.3 tpp -79.15 119.52 22.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.3 p-10 -141.94 179.06 7.09 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.35 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -64.97 -36.7 85.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.486 ' HB1' ' HE2' ' A' ' 35' ' ' MET . . . -74.47 -72.78 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.173 -0.954 . . . . 0.0 109.827 -179.693 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.777 ' OG ' HD13 ' A' ' 38' ' ' LEU . 3.6 m -42.24 -47.5 4.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.392 -0.818 . . . . 0.0 109.741 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.579 ' CZ2' ' HD2' ' A' ' 84' ' ' ARG . 63.7 t90 -50.63 -49.72 56.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.226 -0.921 . . . . 0.0 109.577 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -68.34 -25.16 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.527 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.86 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.9 OUTLIER -60.52 -54.75 41.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.297 -0.877 . . . . 0.0 109.562 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.033 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 2.7 t -62.26 -49.09 85.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.504 -0.747 . . . . 0.0 109.896 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.579 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 58.2 mtp180 -62.77 -29.38 70.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.134 -0.979 . . . . 0.0 109.509 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.1 p -79.6 -17.8 53.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.408 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.802 HG23 ' O ' ' A' ' 82' ' ' LEU . 71.8 t -73.01 125.9 90.79 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.449 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.01 160.34 49.65 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.626 2.218 . . . . 0.0 111.782 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.537 ' CZ ' ' HB2' ' A' ' 88' ' ' ARG . 13.0 ttm105 64.74 31.72 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.602 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.9 p -126.59 130.93 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.192 -0.942 . . . . 0.0 109.451 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.505 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 95.7 mmm -71.29 -46.85 59.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.09 -155.5 26.35 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 1.033 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.0 m-85 -104.74 162.45 13.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -1.086 . . . . 0.0 109.588 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.953 HD11 ' HB2' ' A' ' 13' ' ' GLN . 10.7 mm -119.02 118.27 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.41 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -174.52 -145.57 5.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.93 -46.01 24.62 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.8 p -127.36 173.37 9.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.195 -1.179 . . . . 0.0 109.604 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.2 p -90.49 18.78 5.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.111 -0.993 . . . . 0.0 109.253 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -126.62 -6.3 6.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.579 -0.701 . . . . 0.0 109.428 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.415 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -164.73 99.57 0.85 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.252 -0.905 . . . . 0.0 109.07 179.935 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.6 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 47.6 Cg_endo -68.55 114.21 3.41 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.678 2.252 . . . . 0.0 111.891 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.57 137.37 82.19 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.519 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.82 153.9 68.12 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.707 2.271 . . . . 0.0 111.813 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.615 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -124.44 161.04 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.444 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.441 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 49.9 m -70.94 147.95 48.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -62.26 -36.28 81.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.197 -0.94 . . . . 0.0 109.34 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -61.59 -35.96 79.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.441 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 99.8 mt-10 -60.8 -43.15 98.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.887 . . . . 0.0 109.366 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.615 ' CG2' HD11 ' A' ' 103' ' ' ILE . 75.4 t -62.53 -35.14 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.455 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -66.99 -38.04 85.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.885 . . . . 0.0 109.412 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.6 -44.31 91.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.955 . . . . 0.0 109.441 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 67.9 mt -53.53 -52.54 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -0.922 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.2 mmm . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.498 -179.992 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.421 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 98.6 mttt . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.312 0.577 . . . . 0.0 109.509 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 54.3 mtt180 -123.42 153.96 39.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.427 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.575 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 73.8 m95 -96.16 123.74 39.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.227 -0.92 . . . . 0.0 109.581 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.591 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 88.1 m-85 -119.19 159.64 23.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -0.943 . . . . 0.0 109.473 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.47 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 27.0 t -94.33 149.18 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.637 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.4 ' N ' ' O ' ' A' ' 69' ' ' VAL . 57.3 t -124.64 118.74 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.246 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.957 ' HB2' HD11 ' A' ' 93' ' ' ILE . 59.3 tt0 -84.85 140.07 31.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.58 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.438 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -156.92 -153.39 0.41 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.934 . . . . 0.0 109.391 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.96 140.62 46.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.446 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 t -59.24 132.73 54.89 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.48 -16.92 60.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -109.48 0.19 19.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -1.143 . . . . 0.0 109.576 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.51 ' OE2' ' N ' ' A' ' 68' ' ' TYR . 99.0 mt-10 -56.35 -44.34 79.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.367 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.55 -50.15 67.11 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.531 ' NH2' ' HG3' ' A' ' 88' ' ' ARG . 12.4 ttp180 -57.3 -56.26 24.12 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -1.123 . . . . 0.0 109.416 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.699 HG13 HG11 ' A' ' 86' ' ' VAL . 40.7 t -45.46 -38.68 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.87 -44.85 96.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.342 -0.849 . . . . 0.0 109.266 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.4 m -69.44 -47.28 64.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.677 ' HG ' ' HE2' ' A' ' 29' ' ' HIS . 15.3 t -57.4 -56.21 24.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.338 -0.851 . . . . 0.0 109.489 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.442 ' CD1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp -46.82 -49.71 19.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.377 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.487 ' CG ' ' HE2' ' A' ' 31' ' ' LYS . 46.7 ttm-85 -60.71 -34.59 74.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.186 -0.946 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -64.18 -48.07 77.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.225 -0.922 . . . . 0.0 109.322 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.677 ' HE2' ' HG ' ' A' ' 25' ' ' SER . 60.1 m-70 -66.3 -37.29 85.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 109.341 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.815 HG23 ' HB2' ' A' ' 35' ' ' MET . 90.8 mt -65.26 -49.03 81.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.256 -0.903 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.487 ' HE2' ' CG ' ' A' ' 27' ' ' ARG . 25.3 mttm -56.84 -40.05 75.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 32' ' ' LEU . 29.8 mt -69.91 -52.02 28.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.488 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 63.2 m80 -81.12 4.34 20.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.591 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' ILE . 78.8 m-20 54.76 47.65 21.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.248 -0.907 . . . . 0.0 109.511 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' MET . . . . . 1.008 ' HG3' HD13 ' A' ' 82' ' ' LEU . 61.1 mmm -94.2 6.54 48.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.932 . . . . 0.0 109.594 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.502 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.53 -31.19 34.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.394 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -61.85 -41.84 98.31 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.351 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.496 HD12 ' HB3' ' A' ' 35' ' ' MET . 10.3 mt -70.93 -53.68 14.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.699 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 73.9 m-85 -75.2 143.33 43.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.306 -0.871 . . . . 0.0 109.474 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.34 -58.84 0.24 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -136.29 156.48 48.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -1.223 . . . . 0.0 109.734 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.889 HG13 HG22 ' A' ' 71' ' ' VAL . 54.5 t -121.01 154.66 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.582 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -121.99 147.68 45.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.159 -0.963 . . . . 0.0 109.633 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.379 179.915 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.51 ' N ' ' OE2' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -111.0 119.47 39.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 109.366 179.946 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -134.17 140.62 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.554 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.851 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.0 mp -104.3 141.76 35.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.382 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.889 HG22 HG13 ' A' ' 42' ' ' VAL . 68.9 t -145.26 123.67 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -0.951 . . . . 0.0 109.705 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.421 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 38.5 tt0 -73.96 124.87 27.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.309 -0.869 . . . . 0.0 109.127 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.458 ' SD ' ' OG ' ' A' ' 79' ' ' SER . 8.8 tmm? -169.22 151.52 4.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.293 -0.88 . . . . 0.0 109.398 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 74' ' ' VAL . 28.6 m -77.59 118.97 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.585 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.596 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 8.5 mmt -61.72 115.84 4.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.172 -0.955 . . . . 0.0 109.585 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.2 p-10 -151.28 172.74 15.39 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.36 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -63.4 -33.78 76.29 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.645 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.535 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -71.5 -72.36 0.22 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 109.661 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.524 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 18.0 p -46.63 -57.59 4.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.525 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 44.0 t90 -43.65 -53.89 5.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.34 -0.85 . . . . 0.0 109.574 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.53 -43.41 98.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.61 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 1.008 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.8 OUTLIER -55.81 -43.1 76.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 0.0 109.491 -179.843 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 92' ' ' PHE . 98.2 t -61.01 -52.11 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 57.4 ttt85 -55.63 -35.08 65.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.566 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 39.9 m -59.58 -37.22 77.93 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.187 -0.946 . . . . 0.0 109.555 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.699 HG11 HG13 ' A' ' 22' ' ' VAL . 91.8 t -54.99 125.56 56.92 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 109.516 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.7 Cg_endo -71.25 160.28 49.39 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.624 2.216 . . . . 0.0 111.769 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.531 ' HG3' ' NH2' ' A' ' 21' ' ' ARG . 50.1 mmt-85 63.66 30.79 14.79 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.695 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 86' ' ' VAL . 6.1 p -129.24 130.63 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.157 -0.964 . . . . 0.0 109.375 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.509 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.1 mmm -76.46 -54.98 5.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 166.67 -150.12 16.74 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.684 ' CE2' HG11 ' A' ' 83' ' ' VAL . 6.5 m-85 -105.5 161.86 13.98 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -1.131 . . . . 0.0 109.561 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.957 HD11 ' HB2' ' A' ' 13' ' ' GLN . 19.3 mm -120.3 122.13 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.415 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -179.66 -144.39 5.88 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.62 -45.25 95.04 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 p -130.76 171.01 13.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.219 -1.165 . . . . 0.0 109.463 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.9 p -89.02 16.61 6.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.144 -0.972 . . . . 0.0 109.37 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.525 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.1 m-20 -125.64 -27.14 3.42 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.533 -0.729 . . . . 0.0 109.261 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -140.16 97.63 7.73 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.339 -0.851 . . . . 0.0 108.846 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.72 127.12 15.73 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.79 2.327 . . . . 0.0 112.067 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.63 138.51 93.5 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.256 -0.902 . . . . 0.0 109.234 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.514 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.8 Cg_endo -70.45 153.66 65.6 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.603 2.202 . . . . 0.0 111.845 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 34.9 pt -127.55 161.08 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.452 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.484 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 43.7 m -71.79 150.56 44.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.348 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -56.93 -37.91 72.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.335 -0.853 . . . . 0.0 109.456 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -60.35 -34.02 73.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.441 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.484 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 76.5 mm-40 -59.12 -41.85 89.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.922 . . . . 0.0 109.384 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.491 HG21 ' CG ' ' A' ' 9' ' ' TRP . 90.0 t -63.33 -36.2 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.913 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -66.6 -38.71 87.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.69 -47.7 77.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.586 HD12 HD21 ' A' ' 70' ' ' LEU . 45.2 mt -50.49 -51.41 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.497 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 96.2 mmm . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.156 -0.965 . . . . 0.0 109.387 179.937 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 40.1 mttt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.505 ' HD2' ' HB3' ' A' ' 102' ' ' PRO . 23.1 mtm180 -122.26 154.85 37.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -93.56 137.69 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.549 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 46.0 m-85 -131.85 164.19 26.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.868 . . . . 0.0 109.567 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.428 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.9 t -99.2 139.89 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 109.53 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.9 t -122.74 119.54 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.588 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.6 tt0 -87.24 135.44 33.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.887 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.32 161.28 38.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.369 -0.832 . . . . 0.0 109.41 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 97.4 m-85 -57.75 149.99 20.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 35.0 t -71.9 145.94 48.18 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.51 -34.37 4.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.843 ' O ' HG23 ' A' ' 22' ' ' VAL . 17.9 m-30 -108.48 6.61 26.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.261 -1.141 . . . . 0.0 109.502 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.505 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 22.8 pt-20 -51.62 -43.84 62.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.331 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -67.29 -54.35 20.76 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -58.68 -40.57 83.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.174 -1.192 . . . . 0.0 109.389 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.887 HG21 ' HB1' ' A' ' 14' ' ' ALA . 76.6 t -50.75 -48.67 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.408 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.029 ' HB1' HG11 ' A' ' 42' ' ' VAL . . . -55.32 -40.73 71.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.243 -0.911 . . . . 0.0 109.336 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.2 m -65.83 -39.94 91.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.249 -0.907 . . . . 0.0 109.418 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 21.1 m -57.85 -46.35 84.93 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.254 -0.904 . . . . 0.0 109.398 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.465 ' O ' HG12 ' A' ' 30' ' ' ILE . 34.9 mt -52.27 -55.98 17.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.348 -0.845 . . . . 0.0 109.357 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.408 ' C ' ' O ' ' A' ' 26' ' ' LEU . 49.3 ttt-85 -42.58 -40.75 2.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.417 -0.802 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 25' ' ' SER . 89.7 mt-10 -58.85 -39.05 80.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.21 -0.931 . . . . 0.0 109.393 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.574 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 66.0 m-70 -82.18 -19.85 39.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.352 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 39' ' ' PHE . 20.5 mm -75.34 -48.46 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.239 -0.913 . . . . 0.0 109.225 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -71.53 -41.22 69.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -0.851 . . . . 0.0 109.236 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.45 HD23 ' HA ' ' A' ' 32' ' ' LEU . 67.0 mt -63.9 -47.42 80.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.449 -0.782 . . . . 0.0 109.404 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.698 ' CE1' HD11 ' A' ' 82' ' ' LEU . 79.6 m80 -84.05 9.25 12.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 49.08 48.47 20.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 0.0 109.394 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.636 ' SD ' HD22 ' A' ' 82' ' ' LEU . 41.4 mtt -102.79 -0.66 31.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 35' ' ' MET . 97.2 mt-10 -43.89 -36.04 2.23 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.243 -0.91 . . . . 0.0 109.647 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -56.96 -50.25 73.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.205 -0.934 . . . . 0.0 109.713 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' CA ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -71.31 -48.52 50.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.52 -179.691 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 30' ' ' ILE . 66.1 m-85 -70.4 141.35 52.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 109.452 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.472 ' HA3' ' OE1' ' A' ' 72' ' ' GLN . . . -102.65 -70.12 0.84 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -158.66 147.21 18.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.187 -1.184 . . . . 0.0 109.495 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.029 HG11 ' HB1' ' A' ' 23' ' ' ALA . 60.1 t -95.79 138.45 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.499 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.623 ' HE1' HG11 ' A' ' 108' ' ' VAL . 65.1 mtm -121.32 150.09 41.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.368 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 93.4 t . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.576 179.992 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.722 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.2 m-85 -128.61 115.3 17.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.196 -1.179 . . . . 0.0 109.375 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 43' ' ' MET . 87.3 t -132.9 144.85 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.262 -0.899 . . . . 0.0 109.609 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.854 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.1 mp -101.06 129.53 46.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.328 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.745 HG22 HG13 ' A' ' 42' ' ' VAL . 91.0 t -140.75 115.36 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.76 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.472 ' OE1' ' HA3' ' A' ' 40' ' ' GLY . 36.9 tt0 -65.98 135.9 55.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.928 . . . . 0.0 109.171 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.575 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 10.9 ttp -173.78 152.1 1.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.16 -0.962 . . . . 0.0 109.587 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.526 ' N ' ' HG2' ' A' ' 73' ' ' MET . 38.7 t -81.67 141.2 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.281 179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.559 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 15.1 tpp -78.1 100.12 6.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.212 -0.93 . . . . 0.0 109.74 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.507 ' ND2' HD22 ' A' ' 38' ' ' LEU . 51.4 p-10 -140.87 169.39 17.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.306 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -72.67 -26.39 61.61 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.5 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.58 -71.31 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 0.0 109.584 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 83' ' ' VAL . 11.4 p -53.47 -45.19 69.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.433 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.9 t90 -56.44 -59.01 5.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -54.92 -44.01 73.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.698 HD11 ' CE1' ' A' ' 33' ' ' HIS . 41.1 tp -56.13 -47.8 77.44 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.813 HG11 ' CE2' ' A' ' 92' ' ' PHE . 80.0 t -50.41 -48.05 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.245 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 16.5 ttt-85 -70.63 -28.17 64.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.383 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.4 m -58.82 -47.15 85.8 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.35 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.574 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 4.4 p -76.08 132.39 73.93 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.532 ' O ' HG23 ' A' ' 89' ' ' VAL . 47.7 Cg_endo -69.02 -174.03 0.7 Allowed 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.672 2.248 . . . . 0.0 111.892 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.616 ' HB3' HG22 ' A' ' 22' ' ' VAL . 70.1 mtt85 63.69 32.04 14.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.359 -0.838 . . . . 0.0 109.444 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 87' ' ' PRO . 6.4 t -131.89 117.26 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 83.2 mtp -73.73 -38.29 64.84 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 148.62 -176.26 27.5 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.813 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.7 m-85 -94.98 158.25 15.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.311 -1.111 . . . . 0.0 109.649 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.722 HG21 ' OH ' ' A' ' 68' ' ' TYR . 18.9 mm -118.55 114.24 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.301 -0.875 . . . . 0.0 109.378 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.01 -141.77 3.25 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.55 -29.12 60.2 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -136.33 169.32 17.85 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.199 -1.177 . . . . 0.0 109.655 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -91.72 19.61 6.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.356 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 48.1 p30 -140.73 11.05 2.25 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.55 -0.718 . . . . 0.0 109.081 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.3 OUTLIER -171.88 97.8 0.39 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.327 -0.858 . . . . 0.0 108.916 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 49.7 Cg_endo -68.94 113.75 3.34 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.752 2.301 . . . . 0.0 111.949 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.91 142.02 74.17 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.229 -0.92 . . . . 0.0 109.357 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.505 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 50.9 Cg_endo -70.22 153.98 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.715 2.277 . . . . 0.0 111.922 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.632 HD11 HG22 ' A' ' 108' ' ' VAL . 31.3 pt -129.23 152.73 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.9 m -67.0 145.29 55.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.617 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -53.75 -41.03 66.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.888 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -59.19 -44.57 92.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.462 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 83.2 tt0 -51.17 -46.32 62.04 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.632 HG22 HD11 ' A' ' 103' ' ' ILE . 60.4 t -53.97 -41.56 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.229 -0.919 . . . . 0.0 109.282 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -59.77 -41.18 90.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.247 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.52 -52.62 64.77 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.278 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.4 HG21 HD13 ' A' ' 111' ' ' ILE . 54.1 mt -47.05 -51.91 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.299 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.322 179.897 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 54.7 mttp . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.297 0.57 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 96.2 mtt180 -126.14 158.95 34.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.466 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.51 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 58.8 m95 -99.82 121.09 40.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.955 . . . . 0.0 109.788 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.589 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 96.6 m-85 -114.77 157.59 23.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.31 -0.869 . . . . 0.0 109.229 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 88.6 t -105.89 143.48 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 109.599 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.0 t -120.99 127.96 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.314 -0.866 . . . . 0.0 109.472 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.915 ' HB2' HD11 ' A' ' 93' ' ' ILE . 68.2 tp60 -86.98 145.32 26.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -0.9 . . . . 0.0 109.48 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.09 153.87 34.8 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.54 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -58.72 144.27 44.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.517 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 26.2 t -61.9 141.09 58.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.43 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.94 -31.18 5.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.5 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 90.3 m-85 -105.01 7.33 33.99 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.267 -1.137 . . . . 0.0 109.585 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.576 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 85.5 tt0 -58.44 -42.59 87.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.117 -0.99 . . . . 0.0 109.382 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.82 -38.0 65.91 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 22.2 ttm180 -62.02 -50.63 71.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -1.15 . . . . 0.0 109.442 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.476 HG13 HG11 ' A' ' 86' ' ' VAL . 37.4 t -49.45 -41.02 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.181 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 -42.39 99.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.234 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 41.5 m -67.38 -47.12 71.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.273 -0.892 . . . . 0.0 109.341 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.9 m -64.66 -34.41 78.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.253 -0.904 . . . . 0.0 109.375 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.817 ' CD2' HD11 ' A' ' 30' ' ' ILE . 5.4 tt -58.57 -53.54 57.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.304 -0.873 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.403 ' NE ' ' NZ ' ' A' ' 31' ' ' LYS . 23.0 tpt180 -45.14 -46.0 11.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.254 -0.904 . . . . 0.0 109.598 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -53.5 -50.88 64.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.558 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.582 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.7 m-70 -56.92 -29.1 62.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.286 -0.883 . . . . 0.0 109.533 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 1.052 HD12 ' CD1' ' A' ' 39' ' ' PHE . 10.2 mm -68.94 -53.72 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.227 -0.921 . . . . 0.0 109.567 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.51 ' CD ' ' OE2' ' A' ' 36' ' ' GLU . 24.8 mmtm -66.05 -44.18 85.3 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.658 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.453 HD23 ' HA ' ' A' ' 32' ' ' LEU . 49.0 mt -61.32 -55.95 25.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.277 -0.89 . . . . 0.0 109.611 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.643 ' ND1' HD11 ' A' ' 82' ' ' LEU . 63.9 m80 -81.87 7.53 12.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 53.1 t30 48.83 45.76 22.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.585 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.933 ' HG3' HD22 ' A' ' 82' ' ' LEU . 35.2 mmm -99.55 20.57 13.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.374 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' OE2' ' CD ' ' A' ' 31' ' ' LYS . 83.9 mt-10 -53.83 -36.86 63.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -0.873 . . . . 0.0 109.482 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -59.16 -44.97 92.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.925 . . . . 0.0 109.486 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.882 HD13 ' HB3' ' A' ' 79' ' ' SER . 35.2 mt -66.94 -56.66 9.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.918 . . . . 0.0 109.507 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 1.052 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.6 m-85 -72.01 141.08 49.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.902 . . . . 0.0 109.472 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -125.62 -61.99 0.17 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.55 149.34 43.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.189 -1.183 . . . . 0.0 109.698 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.001 HG13 HG22 ' A' ' 71' ' ' VAL . 45.3 t -117.48 151.86 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.344 -0.847 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.516 ' O ' HG13 ' A' ' 69' ' ' VAL . 80.8 mmm -117.11 137.41 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.231 -0.918 . . . . 0.0 109.676 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 44' ' ' VAL . 43.2 t . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.313 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.429 ' O ' ' NE2' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.419 ' CE1' ' OE1' ' A' ' 13' ' ' GLN . 1.8 m-85 -119.71 117.21 27.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.2 -1.176 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 78.4 t -131.61 141.85 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.917 . . . . 0.0 109.657 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.843 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.7 mp -106.97 132.96 52.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -0.88 . . . . 0.0 109.271 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.001 HG22 HG13 ' A' ' 42' ' ' VAL . 86.5 t -137.94 121.67 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.178 -0.951 . . . . 0.0 109.639 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.475 ' O ' ' HB2' ' A' ' 73' ' ' MET . 38.0 tt0 -72.16 137.1 46.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.267 -0.895 . . . . 0.0 109.199 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.524 ' HG2' ' N ' ' A' ' 74' ' ' VAL . 45.8 ttp 171.81 157.73 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.263 -0.898 . . . . 0.0 109.604 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.59 ' CG1' HD22 ' A' ' 38' ' ' LEU . 12.2 p -85.69 138.31 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.174 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.589 ' HG2' ' CE2' ' A' ' 10' ' ' TYR . 16.4 mmt -90.04 115.36 27.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.208 -0.932 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.489 ' OD1' ' N ' ' A' ' 79' ' ' SER . 48.8 p-10 -140.48 -176.59 4.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.351 -0.843 . . . . 0.0 109.425 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -73.37 -11.6 60.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.598 ' HA ' ' CE1' ' A' ' 81' ' ' HIS . . . -94.23 -71.1 0.68 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.466 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.882 ' HB3' HD13 ' A' ' 38' ' ' LEU . 68.9 p -50.69 -48.13 58.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.379 -0.826 . . . . 0.0 109.516 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.61 ' NE1' ' CE2' ' A' ' 92' ' ' PHE . 79.7 t90 -48.51 -58.92 3.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -0.928 . . . . 0.0 109.694 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.625 ' CD2' ' N ' ' A' ' 82' ' ' LEU . 1.5 p-80 -57.84 -30.84 66.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.085 -1.009 . . . . 0.0 109.213 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.933 HD22 ' HG3' ' A' ' 35' ' ' MET . 19.0 tp -68.52 -36.34 78.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.384 -0.823 . . . . 0.0 109.328 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.545 HG11 ' CE1' ' A' ' 92' ' ' PHE . 77.5 t -62.04 -42.63 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.248 -0.908 . . . . 0.0 109.399 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -65.96 -33.25 75.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.377 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 35.8 m -60.07 -32.96 71.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.173 -0.954 . . . . 0.0 109.38 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 89' ' ' VAL . 18.8 t -55.37 123.41 49.48 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.487 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.9 Cg_endo -70.83 156.48 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.618 2.212 . . . . 0.0 111.712 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.5 ' HD3' ' CD1' ' A' ' 18' ' ' PHE . 42.4 mtt-85 62.44 35.29 14.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.31 -0.869 . . . . 0.0 109.586 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.588 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.4 p -123.39 125.82 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.436 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.539 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 51.3 mtt -68.93 -62.01 1.56 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.459 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 171.13 -151.57 16.03 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.704 ' O ' HG22 ' A' ' 96' ' ' THR . 93.1 m-85 -96.27 162.96 13.29 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.327 -1.102 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.915 HD11 ' HB2' ' A' ' 13' ' ' GLN . 47.3 mm -110.97 152.7 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.223 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.82 -108.95 3.44 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' GLY . . . . . 0.409 ' O ' ' C ' ' A' ' 96' ' ' THR . . . -57.06 -37.24 78.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.704 HG22 ' O ' ' A' ' 92' ' ' PHE . 68.8 p 43.73 -148.66 0.05 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -1.167 . . . . 0.0 109.477 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.456 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 26.7 t 44.67 39.92 3.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.173 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.565 ' HB3' ' CZ2' ' A' ' 80' ' ' TRP . 22.8 m-20 67.09 38.2 3.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.347 -0.846 . . . . 0.0 109.313 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.404 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 4.2 mtp180 -161.48 88.41 1.57 Allowed Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.281 -0.887 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.575 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 48.2 Cg_endo -69.96 135.27 29.56 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.783 2.322 . . . . 0.0 111.952 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -99.14 143.48 26.47 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.451 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.45 155.51 63.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.823 2.349 . . . . 0.0 111.759 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.431 HG12 ' O ' ' A' ' 9' ' ' TRP . 24.0 pt -125.5 156.32 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 48.3 m -69.8 150.22 47.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.303 -0.873 . . . . 0.0 109.531 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -59.68 -42.38 92.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -0.899 . . . . 0.0 109.442 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -53.94 -43.09 69.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.314 -0.866 . . . . 0.0 109.424 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.8 mt-10 -53.78 -44.69 70.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.421 HG22 HD23 ' A' ' 70' ' ' LEU . 98.0 t -55.91 -37.95 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.26 -0.9 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -70.44 -34.91 72.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.933 . . . . 0.0 109.381 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.28 -36.71 84.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.761 HG13 HD21 ' A' ' 70' ' ' LEU . 32.1 mm -49.6 -56.48 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.28 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' MET . . . . . 0.492 ' CE ' ' CE ' ' A' ' 43' ' ' MET . 54.2 mtt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.289 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.514 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 68.4 mttm . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.43 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 63.0 mtt180 -128.16 152.22 48.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.419 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.404 ' CZ3' ' HE2' ' A' ' 43' ' ' MET . 92.9 m95 -85.38 129.84 34.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.486 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 75' ' ' MET . 81.2 m-85 -122.84 155.77 35.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.391 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 93' ' ' ILE . 43.1 t -92.02 150.76 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.512 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.5 t -132.49 124.29 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.308 -0.87 . . . . 0.0 109.387 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.549 ' HB3' ' HE2' ' A' ' 90' ' ' MET . 96.3 mt-30 -85.18 147.22 26.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.282 -0.886 . . . . 0.0 109.528 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.2 155.27 34.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.382 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.519 ' CD1' ' HA ' ' A' ' 88' ' ' ARG . 97.0 m-85 -72.16 147.22 46.82 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.0 m -55.56 144.08 27.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.292 -0.88 . . . . 0.0 109.471 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.91 -33.67 4.36 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -106.45 15.34 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.49 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.427 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.5 tt0 -52.43 -39.27 60.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.408 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.61 7.09 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 22' ' ' VAL . 35.5 ttt-85 -51.72 -52.64 46.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -1.169 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 21' ' ' ARG . 38.9 t -45.64 -38.04 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.175 -0.953 . . . . 0.0 109.314 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.83 -43.04 94.36 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.297 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 58.2 m -67.03 -47.03 72.66 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.287 -0.883 . . . . 0.0 109.3 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.7 m -61.75 -40.59 95.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.36 -0.837 . . . . 0.0 109.435 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.898 ' CD1' HG21 ' A' ' 86' ' ' VAL . 11.5 tp -56.12 -40.98 74.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.9 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -53.32 -44.14 68.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.309 -0.87 . . . . 0.0 109.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.589 ' O ' HD12 ' A' ' 32' ' ' LEU . 97.4 mt-10 -60.68 -47.82 84.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.51 ' C ' HD11 ' A' ' 82' ' ' LEU . 54.9 m80 -63.46 -43.5 97.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.916 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.3 mt -67.83 -50.76 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.902 . . . . 0.0 109.482 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -59.6 -40.0 86.04 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.303 -0.873 . . . . 0.0 109.447 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 28' ' ' GLU . 16.0 mt -63.22 -53.98 44.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.47 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.458 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 59.6 m80 -82.99 -0.6 49.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.56 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.508 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.2 m-20 62.56 47.11 5.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.18 -0.95 . . . . 0.0 109.356 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.99 ' HG3' HD13 ' A' ' 82' ' ' LEU . 57.8 mmm -90.35 0.57 57.2 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.586 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.451 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -47.83 -33.38 7.27 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.906 . . . . 0.0 109.489 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -60.4 -42.32 95.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.617 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.42 -49.41 49.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.303 -0.873 . . . . 0.0 109.313 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 88.5 m-85 -74.74 140.73 44.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.05 -64.69 0.53 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -140.52 157.44 45.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 109.53 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.032 HG13 HG22 ' A' ' 71' ' ' VAL . 61.6 t -120.16 147.41 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.517 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.725 ' HE1' HG11 ' A' ' 108' ' ' VAL . 60.7 mtm -131.46 141.9 49.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.238 -0.914 . . . . 0.0 109.449 179.945 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.591 ' CE1' HG13 ' A' ' 11' ' ' VAL . 51.7 t80 -108.9 136.14 48.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.226 -1.161 . . . . 0.0 109.521 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.26 144.8 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.298 -0.876 . . . . 0.0 109.567 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.921 ' CD2' HG13 ' A' ' 108' ' ' VAL . 4.3 mp -113.91 130.9 56.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.293 -0.879 . . . . 0.0 109.144 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.032 HG22 HG13 ' A' ' 42' ' ' VAL . 93.8 t -144.1 120.73 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.728 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.514 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 6.1 tt0 -75.07 129.65 37.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.604 ' HE2' ' HB2' ' A' ' 79' ' ' SER . 9.8 tmm? -168.63 147.94 4.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.313 -0.867 . . . . 0.0 109.58 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -75.81 109.84 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.578 ' HB2' ' CZ ' ' A' ' 10' ' ' TYR . 22.3 tpp -59.43 120.33 9.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.285 -0.884 . . . . 0.0 109.504 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.659 HD21 ' HB3' ' A' ' 78' ' ' ALA . 31.2 p-10 -155.89 170.55 21.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -56.01 -36.54 68.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.557 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -70.48 -71.7 0.23 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.623 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.604 ' HB2' ' HE2' ' A' ' 73' ' ' MET . 10.0 p -47.14 -48.04 23.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 109.56 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 77.6 t90 -51.65 -50.07 61.06 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -66.36 -39.6 89.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.951 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.99 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -59.13 -47.38 85.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.945 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.565 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 55.9 t -56.46 -48.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.87 . . . . 0.0 109.551 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -59.4 -36.77 76.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -60.59 -34.2 73.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.898 HG21 ' CD1' ' A' ' 26' ' ' LEU . 14.1 t -60.13 123.95 75.12 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.393 -0.817 . . . . 0.0 109.51 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.442 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.6 Cg_endo -70.75 163.21 39.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.545 2.163 . . . . 0.0 111.7 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.519 ' HA ' ' CD1' ' A' ' 15' ' ' PHE . 78.9 mmt-85 64.61 28.31 13.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.644 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 86' ' ' VAL . 5.8 p -128.93 137.11 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.918 . . . . 0.0 109.597 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.549 ' HE2' ' HB3' ' A' ' 13' ' ' GLN . 69.4 mtm -89.97 -42.1 11.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.83 -149.73 20.31 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.565 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 90.6 m-85 -102.73 157.21 17.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -1.163 . . . . 0.0 109.52 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 11' ' ' VAL . 8.4 mt -109.3 130.69 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.229 -0.919 . . . . 0.0 109.398 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 148.6 -119.19 1.04 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -66.4 -82.94 0.11 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.4 p -130.43 -173.98 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -1.19 . . . . 0.0 109.662 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 42.2 p -97.22 17.66 16.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.447 ' O ' ' HG2' ' A' ' 99' ' ' ARG . 82.0 m-20 -120.98 -24.67 5.53 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.463 -0.773 . . . . 0.0 109.102 179.674 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 98' ' ' ASP . 7.6 mtt180 -147.87 87.79 5.75 Favored Pre-proline 0 C--N 1.304 -1.405 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.524 ' HB3' ' HB3' ' A' ' 92' ' ' PHE . 42.9 Cg_endo -65.07 120.55 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.939 2.426 . . . . 0.0 112.416 -179.184 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 134.07 78.19 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.435 -0.791 . . . . 0.0 109.217 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.411 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.7 Cg_endo -69.37 152.82 71.35 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.692 2.261 . . . . 0.0 111.904 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.819 HD11 HG22 ' A' ' 108' ' ' VAL . 30.7 pt -118.5 160.57 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.336 -0.853 . . . . 0.0 109.231 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.2 m -70.05 150.47 46.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -0.907 . . . . 0.0 109.431 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -62.74 -37.81 88.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -63.24 -37.7 88.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -0.85 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.448 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 85.5 tt0 -59.82 -39.7 85.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.464 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.921 HG13 ' CD2' ' A' ' 70' ' ' LEU . 73.3 t -62.9 -35.97 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.381 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -68.19 -34.19 75.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.247 -0.908 . . . . 0.0 109.489 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.78 -38.24 88.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.428 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 74.3 mt -55.73 -51.74 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.476 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 53.2 ttm . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.426 -179.987 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.0 mttt . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.537 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 80.7 mtt85 -117.76 158.27 25.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.582 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 46.0 m95 -109.53 130.64 55.49 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.506 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CE2' ' O ' ' A' ' 73' ' ' MET . 23.9 m-85 -122.51 143.82 49.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.524 HG11 ' CE2' ' A' ' 68' ' ' TYR . 15.7 t -99.7 129.99 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.297 -0.877 . . . . 0.0 109.515 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' CE1' ' A' ' 92' ' ' PHE . 37.9 t -109.82 131.27 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.884 . . . . 0.0 109.458 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.997 ' CG ' HD11 ' A' ' 93' ' ' ILE . 91.8 mt-30 -78.73 150.07 32.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.322 -0.861 . . . . 0.0 109.462 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -152.53 151.74 31.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -68.42 143.75 54.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.446 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.3 m -59.3 142.92 50.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.12 -32.33 5.48 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.828 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.7 m-85 -106.53 7.95 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.297 -1.119 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.528 ' HG3' HG23 ' A' ' 69' ' ' VAL . 83.5 tt0 -53.74 -32.6 52.77 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.966 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -83.53 -55.27 2.9 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.3 ttt85 -57.94 -33.66 69.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.145 -1.209 . . . . 0.0 109.441 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.828 HG23 ' O ' ' A' ' 18' ' ' PHE . 55.0 t -57.74 -40.89 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.402 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.86 -36.76 85.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.393 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 47.1 m -61.52 -37.31 83.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.477 ' CB ' HG13 ' A' ' 86' ' ' VAL . 24.3 m -60.45 -35.93 77.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.198 -0.939 . . . . 0.0 109.457 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.88 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.2 mt -60.27 -40.5 90.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.873 . . . . 0.0 109.393 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -58.35 -45.27 88.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.301 -0.874 . . . . 0.0 109.571 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -64.14 -60.8 2.78 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.228 -0.92 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.692 ' CD2' HG22 ' A' ' 86' ' ' VAL . 98.7 m-70 -53.18 -50.78 63.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.256 -0.902 . . . . 0.0 109.378 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 82' ' ' LEU . 96.9 mt -58.14 -54.19 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -53.81 -45.19 70.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.426 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 32' ' ' LEU . 71.0 mt -64.29 -55.88 18.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.253 -0.904 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.511 ' ND1' HD12 ' A' ' 82' ' ' LEU . 59.9 m80 -68.34 -10.54 55.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.867 . . . . 0.0 109.384 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.457 ' N ' ' O ' ' A' ' 30' ' ' ILE . 76.1 m-20 61.58 46.63 7.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.331 -0.856 . . . . 0.0 109.389 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.661 ' HB3' HD21 ' A' ' 38' ' ' LEU . 2.6 mtt -95.9 5.67 50.71 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.354 -0.841 . . . . 0.0 109.551 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -50.82 -22.95 2.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -63.38 -40.83 98.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.959 HD12 ' SD ' ' A' ' 73' ' ' MET . 0.4 OUTLIER -91.36 -32.02 15.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.414 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.721 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 58.2 m-85 -75.27 136.9 40.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.363 -0.836 . . . . 0.0 109.395 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.22 -79.94 0.7 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.439 ' OE1' ' N ' ' A' ' 41' ' ' GLU . 56.7 mp0 -129.38 163.96 24.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.135 . . . . 0.0 109.549 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 1.093 HG13 HG22 ' A' ' 71' ' ' VAL . 55.2 t -123.16 160.74 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.316 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.896 ' O ' HG13 ' A' ' 69' ' ' VAL . 94.4 mmm -117.99 138.43 52.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.935 . . . . 0.0 109.573 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.611 ' O ' HG12 ' A' ' 44' ' ' VAL . 57.2 t . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.524 ' CE2' HG11 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -114.89 123.29 48.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.189 -1.183 . . . . 0.0 109.502 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.896 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -132.52 144.66 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.326 -0.859 . . . . 0.0 109.572 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.853 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.6 mp -115.91 138.48 51.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.278 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 1.093 HG22 HG13 ' A' ' 42' ' ' VAL . 59.5 t -132.46 120.89 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.179 -0.951 . . . . 0.0 109.777 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.449 ' O ' ' HB2' ' A' ' 73' ' ' MET . 35.8 tt0 -69.82 142.12 53.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.036 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.959 ' SD ' HD12 ' A' ' 38' ' ' LEU . 46.9 ttp 173.67 158.41 0.14 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.01 . . . . 0.0 109.578 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.765 HG12 ' HB2' ' A' ' 38' ' ' LEU . 9.1 p -82.84 142.74 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.225 -0.922 . . . . 0.0 109.406 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.592 ' HE3' ' HA ' ' A' ' 75' ' ' MET . 0.0 OUTLIER -72.66 116.1 12.73 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.657 -179.77 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.546 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.3 p-10 -143.93 175.48 9.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 109.33 179.747 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -84.6 -18.34 35.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.21 -0.931 . . . . 0.0 109.621 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.546 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -73.67 -57.54 3.92 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.242 -0.912 . . . . 0.0 109.319 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.517 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 53.4 p -59.34 -41.45 89.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.41 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.417 ' C ' ' O ' ' A' ' 79' ' ' SER . 47.1 t90 -43.98 -45.78 7.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.615 -179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -79.59 -25.84 41.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 109.43 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.811 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.7 OUTLIER -64.03 -41.45 97.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.291 -0.881 . . . . 0.0 109.532 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.875 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 88.6 t -65.94 -48.28 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.257 -0.902 . . . . 0.0 109.521 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -59.56 -41.41 90.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.0 p -61.96 -27.88 69.16 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.208 -0.933 . . . . 0.0 109.54 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' CD2' ' A' ' 26' ' ' LEU . 43.9 t -67.77 126.04 92.09 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 109.515 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.407 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.6 Cg_endo -70.31 163.48 38.55 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 122.653 2.235 . . . . 0.0 111.727 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.443 ' HB2' HG22 ' A' ' 22' ' ' VAL . 63.1 mtt-85 61.54 44.63 8.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 99.0 t -131.21 118.9 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.271 -0.893 . . . . 0.0 109.539 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.51 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 74.8 mtm -70.57 -42.22 71.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.81 -162.41 35.06 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.875 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -104.82 171.26 7.42 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.235 -1.156 . . . . 0.0 109.453 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.997 HD11 ' CG ' ' A' ' 13' ' ' GLN . 32.6 mm -124.43 128.45 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.452 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 172.71 -148.96 10.95 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.45 -39.54 50.25 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.412 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 29.2 p -130.7 171.98 12.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.185 -1.185 . . . . 0.0 109.497 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 p -88.55 14.73 9.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.169 -0.957 . . . . 0.0 109.443 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 99' ' ' ARG . 17.8 p30 -130.21 -13.64 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.772 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.429 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 49.5 mtt180 -145.75 91.42 5.66 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.231 -0.918 . . . . 0.0 108.884 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.48 113.89 3.08 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.774 2.316 . . . . 0.0 112.007 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.21 136.84 93.89 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.263 -0.898 . . . . 0.0 109.395 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.537 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.41 154.67 65.0 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.654 2.236 . . . . 0.0 111.814 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.4 pt -124.03 159.7 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 38.5 m -66.04 148.41 51.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.258 -0.902 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 73.6 m-20 -57.41 -41.59 80.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -57.74 -39.81 78.19 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -51.43 -40.75 59.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.923 . . . . 0.0 109.417 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.517 HG21 ' CG ' ' A' ' 9' ' ' TRP . 73.8 t -63.02 -34.6 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.388 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -63.24 -38.11 89.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.61 -40.4 95.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.386 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 27.0 mm -51.55 -57.32 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' MET . . . . . 0.462 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.2 mtp . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.318 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.518 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 69.5 mttt . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 96.3 mtt180 -118.62 150.64 39.35 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.293 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.401 ' O ' HG12 ' A' ' 103' ' ' ILE . 65.7 m95 -99.04 135.65 40.14 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 109.668 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.417 ' CD2' ' CE ' ' A' ' 75' ' ' MET . 55.5 m-85 -128.35 153.61 46.85 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.874 . . . . 0.0 109.398 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.1 t -100.16 137.46 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.906 . . . . 0.0 109.511 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.53 124.63 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.214 -0.929 . . . . 0.0 109.365 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.526 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 98.0 mt-30 -90.47 145.73 24.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.512 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -149.63 163.47 37.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.332 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -67.02 140.88 57.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.189 -0.944 . . . . 0.0 109.52 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.9 m -58.07 145.78 35.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.55 -31.07 5.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PHE . . . . . 0.514 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 96.5 m-85 -111.21 9.82 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -1.183 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.449 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 81.6 tt0 -61.11 -29.9 70.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.253 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -81.45 -36.9 18.99 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -66.87 -49.05 66.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -1.129 . . . . 0.0 109.419 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.619 HG21 ' O ' ' A' ' 88' ' ' ARG . 21.8 t -48.33 -41.56 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -0.98 . . . . 0.0 109.038 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.7 -46.59 84.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -0.867 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 88.4 m -62.38 -37.13 84.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.557 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.523 ' OG ' HG13 ' A' ' 86' ' ' VAL . 98.6 p -65.99 -37.0 84.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.435 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.688 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.4 mt -52.44 -72.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.35 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.402 ' C ' ' O ' ' A' ' 26' ' ' LEU . 41.8 ttm180 -44.25 -41.48 5.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.351 -0.843 . . . . 0.0 109.534 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -56.1 -37.36 69.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.909 . . . . 0.0 109.479 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -79.27 -29.24 42.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.892 . . . . 0.0 109.374 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.958 HD12 ' CD1' ' A' ' 39' ' ' PHE . 17.6 mm -66.79 -43.4 89.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.559 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -67.19 -36.87 82.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.525 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.452 HD23 ' HA ' ' A' ' 32' ' ' LEU . 38.4 mt -70.18 -53.51 16.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 0.0 109.545 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.491 ' ND1' HD12 ' A' ' 82' ' ' LEU . 71.2 m80 -84.76 10.95 10.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 46.34 46.74 13.77 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.853 ' HG3' HD13 ' A' ' 82' ' ' LEU . 56.8 mmm -97.25 15.76 21.88 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.195 -0.941 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 74.9 mm-40 -55.34 -33.21 63.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 109.447 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -65.43 -45.91 81.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.277 -0.889 . . . . 0.0 109.357 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.477 HD13 ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -68.04 -55.26 13.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.303 -0.873 . . . . 0.0 109.26 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.958 ' CD1' HD12 ' A' ' 30' ' ' ILE . 77.6 m-85 -67.37 141.6 57.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.323 -0.861 . . . . 0.0 109.435 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.99 -69.28 0.76 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -143.14 166.17 25.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -1.145 . . . . 0.0 109.542 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 83.3 t -117.4 138.38 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.412 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.771 ' O ' HG13 ' A' ' 69' ' ' VAL . 83.2 mtp -127.87 156.35 42.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.208 -0.933 . . . . 0.0 109.466 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.9 t . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.271 -0.893 . . . . 0.0 109.382 -179.987 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.529 ' CE2' HD13 ' A' ' 93' ' ' ILE . 2.7 m-85 -112.25 121.4 44.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.112 -1.228 . . . . 0.0 109.574 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 43' ' ' MET . 57.8 t -129.41 144.12 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.217 -0.927 . . . . 0.0 109.571 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.992 HD21 HD12 ' A' ' 111' ' ' ILE . 4.3 mp -109.04 130.05 55.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.497 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -140.91 126.4 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.319 -0.863 . . . . 0.0 109.574 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.518 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 2.6 tt0 -69.54 138.95 53.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.932 . . . . 0.0 109.268 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.493 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 14.9 ttp 178.76 152.86 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.226 -0.922 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.471 ' N ' ' HG2' ' A' ' 73' ' ' MET . 23.6 m -99.2 160.48 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.376 -0.827 . . . . 0.0 109.557 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.566 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 14.6 mmt -94.24 120.5 34.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.295 -0.878 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.8 p-10 -146.21 -161.18 1.26 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.565 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -101.49 42.4 1.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -0.878 . . . . 0.0 109.452 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -159.33 -51.11 0.06 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.291 -0.881 . . . . 0.0 109.337 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 83' ' ' VAL . 53.4 p -65.98 -30.19 70.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 109.31 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -66.52 -46.58 75.71 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.427 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -69.35 -33.15 72.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.34 -0.85 . . . . 0.0 109.35 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.853 HD13 ' HG3' ' A' ' 35' ' ' MET . 5.1 tt -65.79 -35.58 81.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.426 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.937 HG11 ' CE2' ' A' ' 92' ' ' PHE . 72.3 t -69.38 -47.49 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.415 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 42.2 ttt-85 -61.15 -33.59 73.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.431 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.3 p -63.15 -22.89 67.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.424 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.688 HG21 ' CD2' ' A' ' 26' ' ' LEU . 12.7 t -60.93 120.33 52.82 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.343 -0.848 . . . . 0.0 109.51 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.413 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.1 Cg_endo -71.2 160.11 49.98 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.588 2.192 . . . . 0.0 111.862 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.619 ' O ' HG21 ' A' ' 22' ' ' VAL . 50.0 mtt85 60.94 33.14 19.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -0.932 . . . . 0.0 109.683 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.585 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.3 p -122.28 132.4 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -0.941 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 95.4 mtp -72.51 -43.03 64.15 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.36 -153.86 25.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.937 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.6 OUTLIER -107.15 164.26 12.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.348 -1.09 . . . . 0.0 109.507 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 11' ' ' VAL . 58.3 mt -116.39 139.6 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 113.76 134.77 5.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 48.51 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.525 ' OG1' ' N ' ' A' ' 97' ' ' SER . 0.8 OUTLIER -141.16 -172.08 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.346 -1.091 . . . . 0.0 109.421 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.525 ' N ' ' OG1' ' A' ' 96' ' ' THR . 35.4 p -91.32 20.97 4.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.201 -0.937 . . . . 0.0 109.633 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -121.29 -29.56 4.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.342 -0.849 . . . . 0.0 108.931 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -149.23 83.39 6.61 Favored Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 44.0 Cg_endo -65.6 128.32 19.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.948 2.432 . . . . 0.0 112.484 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.63 141.93 90.93 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.489 -0.757 . . . . 0.0 109.269 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.0 Cg_endo -69.41 153.59 70.32 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.693 2.262 . . . . 0.0 111.924 -179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.736 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.7 pt -116.22 158.65 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 109.35 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.436 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 45.4 m -71.66 147.91 47.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.493 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -58.94 -36.38 74.67 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.318 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -59.83 -39.19 84.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.4 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.436 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.5 mt-10 -57.57 -46.4 84.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.29 -0.881 . . . . 0.0 109.361 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.736 ' CG2' HD11 ' A' ' 103' ' ' ILE . 71.5 t -61.64 -39.63 83.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.388 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -66.82 -37.51 84.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.258 -0.901 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.9 63.62 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.353 -0.842 . . . . 0.0 109.426 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.992 HD12 HD21 ' A' ' 70' ' ' LEU . 55.0 mt -50.51 -56.41 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.325 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' MET . . . . . 0.498 ' HG3' ' CE ' ' A' ' 43' ' ' MET . 96.0 mmm . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.912 . . . . 0.0 109.418 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' LYS . . . . . 0.448 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 63.0 mttm . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.536 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 88.2 mtt-85 -121.88 157.89 30.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TRP . . . . . 0.489 ' CG ' HG21 ' A' ' 108' ' ' VAL . 90.3 m95 -88.01 133.92 33.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.2 -0.938 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.1 m-85 -119.05 156.47 29.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 44.7 t -99.09 143.59 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.254 -0.904 . . . . 0.0 109.428 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.7 t -125.21 123.19 64.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.309 -0.87 . . . . 0.0 109.314 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLN . . . . . 0.783 ' HB2' HD11 ' A' ' 93' ' ' ILE . 62.5 tt0 -94.57 135.16 36.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.661 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.427 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -152.88 155.8 37.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.315 -0.866 . . . . 0.0 109.317 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -56.41 140.74 44.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.259 -0.901 . . . . 0.0 109.576 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.0 p -65.45 151.97 45.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 109.487 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.56 -31.34 5.24 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -118.89 8.82 11.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -1.175 . . . . 0.0 109.466 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.534 ' HG3' ' N ' ' A' ' 20' ' ' GLY . 23.4 pt-20 -55.41 -46.19 76.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.395 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -59.98 -38.6 94.43 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttm-85 -55.62 -49.37 73.0 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.3 -1.118 . . . . 0.0 109.38 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.935 HG13 HG11 ' A' ' 86' ' ' VAL . 39.2 t -47.24 -39.72 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.267 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.13 -44.57 95.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.882 . . . . 0.0 109.339 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 89.4 m -65.93 -51.34 59.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.309 -0.87 . . . . 0.0 109.391 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 83.1 p -59.65 -36.06 75.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.402 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.459 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 tp -56.57 -53.1 61.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.2 -0.937 . . . . 0.0 109.494 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.417 ' C ' ' O ' ' A' ' 26' ' ' LEU . 57.0 ttt180 -43.7 -49.82 7.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.41 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.418 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 96.3 mt-10 -54.04 -45.39 71.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.296 -0.878 . . . . 0.0 109.361 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' HIS . . . . . 0.402 ' HD2' HG22 ' A' ' 86' ' ' VAL . 76.3 m-70 -61.32 -34.34 75.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.306 -0.871 . . . . 0.0 109.297 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.961 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.2 mm -63.22 -54.5 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' LYS . . . . . 0.465 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 36.0 mttt -66.96 -37.59 84.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.924 . . . . 0.0 109.389 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.418 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 66.4 mt -60.58 -55.32 34.81 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.371 -0.831 . . . . 0.0 109.433 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.436 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 73.0 m80 -89.46 0.09 57.11 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.315 -0.866 . . . . 0.0 109.56 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.49 ' N ' ' O ' ' A' ' 30' ' ' ILE . 79.3 m-20 60.18 49.5 7.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.898 . . . . 0.0 109.48 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.987 ' HG3' HD13 ' A' ' 82' ' ' LEU . 51.2 mmm -101.87 14.08 32.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.63 ' CG ' HG22 ' A' ' 30' ' ' ILE . 97.8 mt-10 -52.06 -36.81 51.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -60.86 -40.75 94.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.229 -0.919 . . . . 0.0 109.548 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.857 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.48 -49.05 52.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.506 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PHE . . . . . 0.961 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -75.76 138.03 40.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.1 -68.62 0.42 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.426 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 84.7 tt0 -129.96 155.93 45.28 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.525 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.969 HG13 HG22 ' A' ' 71' ' ' VAL . 39.2 t -123.74 145.37 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' MET . . . . . 0.524 ' O ' HG13 ' A' ' 69' ' ' VAL . 92.9 mtp -124.44 150.48 45.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.383 -0.823 . . . . 0.0 109.235 179.946 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.655 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -133.19 121.92 23.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.192 -1.181 . . . . 0.0 109.475 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 43' ' ' MET . 60.7 t -131.02 147.03 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -0.853 . . . . 0.0 109.521 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.813 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.8 mp -111.82 128.01 55.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.351 -0.843 . . . . 0.0 109.42 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.969 HG22 HG13 ' A' ' 42' ' ' VAL . 98.6 t -139.85 124.58 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLN . . . . . 0.448 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 37.9 tt0 -77.74 132.3 38.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.26 -0.9 . . . . 0.0 109.363 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.6 ttp -165.39 164.31 19.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.2 -0.937 . . . . 0.0 109.493 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.522 ' N ' ' HG2' ' A' ' 73' ' ' MET . 42.2 t -82.47 142.76 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.504 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' MET . . . . . 0.629 ' HE2' ' HA ' ' A' ' 75' ' ' MET . 1.2 tpt -81.15 111.38 17.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.901 . . . . 0.0 109.462 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.558 ' ND2' HD22 ' A' ' 38' ' ' LEU . 37.6 p-10 -150.46 164.04 36.91 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 109.393 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -74.51 -26.81 60.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.158 -0.964 . . . . 0.0 109.405 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -65.44 -58.02 6.88 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.499 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.461 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 11.2 p -56.62 -46.44 80.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.695 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' TRP . . . . . 0.59 ' CH2' ' HD2' ' A' ' 84' ' ' ARG . 37.9 t90 -43.63 -59.35 2.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.236 -0.915 . . . . 0.0 109.62 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -57.24 -35.95 70.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.935 . . . . 0.0 109.614 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.987 HD13 ' HG3' ' A' ' 35' ' ' MET . 1.0 OUTLIER -62.91 -41.32 99.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.919 . . . . 0.0 109.66 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.55 HG11 ' CZ ' ' A' ' 92' ' ' PHE . 50.5 t -60.55 -46.09 96.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.59 ' HD2' ' CH2' ' A' ' 80' ' ' TRP . 29.5 mtp180 -56.6 -36.0 68.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -61.12 -28.78 69.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.24 -0.913 . . . . 0.0 109.537 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.935 HG11 HG13 ' A' ' 22' ' ' VAL . 40.2 t -55.4 121.28 36.8 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.276 -0.89 . . . . 0.0 109.446 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.444 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.3 Cg_endo -70.5 149.94 62.95 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.684 2.256 . . . . 0.0 111.819 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.444 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.9 mtt85 61.3 40.19 14.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.339 -0.85 . . . . 0.0 109.521 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.587 HG12 ' O ' ' A' ' 86' ' ' VAL . 9.9 p -122.33 128.19 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.338 -0.851 . . . . 0.0 109.316 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' MET . . . . . 0.49 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.0 mmm -71.66 -53.72 12.68 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.16 -0.962 . . . . 0.0 109.506 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.42 -150.69 20.92 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' PHE . . . . . 0.554 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 82.7 m-85 -100.53 157.68 16.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -1.095 . . . . 0.0 109.56 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.783 HD11 ' HB2' ' A' ' 13' ' ' GLN . 38.8 mm -117.6 135.94 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 0.0 109.331 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 110.12 145.86 10.86 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 50.75 -95.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 94' ' ' GLY . 19.3 p -140.33 -173.04 3.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -1.19 . . . . 0.0 109.558 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 p -95.53 22.24 7.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.215 -0.928 . . . . 0.0 109.485 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.551 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 73.4 m-20 -120.51 -25.13 5.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.371 -0.831 . . . . 0.0 109.215 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.445 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 15.2 mtp180 -153.04 102.36 2.64 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.358 -0.839 . . . . 0.0 109.013 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.554 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 44.3 Cg_endo -66.46 114.58 3.13 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.769 2.313 . . . . 0.0 112.012 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.54 140.29 88.89 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.397 -0.814 . . . . 0.0 109.487 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.536 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.4 Cg_endo -70.42 153.4 65.95 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.669 2.246 . . . . 0.0 111.823 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.608 HD11 HG22 ' A' ' 108' ' ' VAL . 31.8 pt -126.96 157.4 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.887 . . . . 0.0 109.49 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 53.0 p -72.36 151.07 42.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.618 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -61.6 -35.03 76.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -61.84 -40.12 94.21 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG13 ' A' ' 111' ' ' ILE . 86.5 tt0 -59.52 -41.88 90.99 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.293 -0.88 . . . . 0.0 109.467 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.608 HG22 HD11 ' A' ' 103' ' ' ILE . 70.6 t -60.29 -37.51 74.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.315 -0.866 . . . . 0.0 109.471 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -64.7 -40.27 95.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.973 . . . . 0.0 109.378 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -66.04 -43.13 88.46 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 107' ' ' GLU . 70.8 mt -52.44 -49.53 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.213 -0.929 . . . . 0.0 109.468 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 94.9 mmm . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.431 179.993 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.2 mtp . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.4 m -56.38 -36.12 68.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -110.31 140.65 44.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.415 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.9 130.8 79.16 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.47 144.71 51.0 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.698 2.265 . . . . 0.0 111.833 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 31.2 tttm -116.4 129.47 56.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.323 -0.861 . . . . 0.0 109.404 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -95.52 135.29 37.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.451 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 61.9 mtt180 -122.67 152.94 40.03 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.228 -0.92 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.745 ' CG ' HG21 ' A' ' 108' ' ' VAL . 74.9 m95 -95.01 133.89 38.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CE2' ' O ' ' A' ' 73' ' ' MET . 28.3 m-85 -122.69 149.39 44.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -0.873 . . . . 0.0 109.308 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 25.0 t -97.68 142.62 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.491 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.75 130.81 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.478 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.818 ' HB2' HD11 ' A' ' 93' ' ' ILE . 57.3 tt0 -96.96 128.1 43.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 109.464 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.748 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.08 164.23 30.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.214 -0.928 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -69.22 145.33 53.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.2 p -66.19 149.49 50.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.31 -33.03 4.69 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.521 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.9 m-85 -109.53 1.6 19.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.3 -1.118 . . . . 0.0 109.623 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.776 ' HB3' HG21 ' A' ' 46' ' ' THR . 85.6 tt0 -53.45 -40.07 64.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.44 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.57 -47.77 74.4 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -63.65 -39.36 94.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -1.171 . . . . 0.0 109.461 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.748 HG21 ' HB1' ' A' ' 14' ' ' ALA . 60.6 t -52.18 -44.69 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.473 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.76 -42.79 98.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.333 -0.854 . . . . 0.0 109.465 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.1 m -61.2 -39.0 88.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.462 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 24.1 m -58.95 -39.18 80.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.778 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.3 mt -56.11 -46.61 79.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttt85 -56.15 -41.89 76.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -0.89 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -66.78 -58.73 4.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.986 ' HB3' HD11 ' A' ' 82' ' ' LEU . 73.4 m-70 -57.22 -48.63 78.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 0.0 109.498 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.727 HG23 ' CB ' ' A' ' 35' ' ' MET . 89.7 mt -61.9 -49.52 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.251 -0.906 . . . . 0.0 109.446 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -57.87 -45.56 86.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.467 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.451 HD23 ' HA ' ' A' ' 32' ' ' LEU . 45.3 mt -63.26 -48.62 77.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 68.8 m80 -83.44 5.5 23.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.251 -0.906 . . . . 0.0 109.52 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 30' ' ' ILE . 38.1 t30 54.69 46.13 25.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.33 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.812 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -96.54 3.89 52.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.579 -179.914 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.1 mt-10 -53.4 -35.61 60.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -54.3 -40.46 67.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.22 -0.925 . . . . 0.0 109.463 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.539 ' CD1' ' CG ' ' A' ' 35' ' ' MET . 0.7 OUTLIER -73.9 -48.77 28.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.288 -0.883 . . . . 0.0 109.294 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.625 ' CD1' HD13 ' A' ' 30' ' ' ILE . 89.4 m-85 -70.41 130.12 41.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.358 -0.839 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.14 -63.16 0.58 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -141.44 115.46 9.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -1.19 . . . . 0.0 109.66 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.013 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -89.5 147.08 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.39 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.644 ' O ' HG13 ' A' ' 69' ' ' VAL . 46.3 mtt -112.88 148.98 33.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.618 HG12 ' O ' ' A' ' 46' ' ' THR . 35.3 t -135.32 95.66 14.55 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.342 -0.849 . . . . 0.0 109.274 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.02 -3.32 12.59 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.749 2.3 . . . . 0.0 111.995 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.776 HG21 ' HB3' ' A' ' 19' ' ' GLU . 8.9 t -122.99 154.04 38.98 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.913 . . . . 0.0 109.515 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -103.87 149.16 25.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.273 -0.892 . . . . 0.0 109.521 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -60.09 -28.04 67.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.277 -0.89 . . . . 0.0 109.507 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.01 173.13 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.506 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.1 m -116.73 155.44 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.473 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -92.75 144.17 25.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.284 -0.885 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 89.5 mt -58.39 -39.32 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.249 -0.907 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -57.75 146.59 30.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.407 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.3 -176.2 19.94 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -54.45 141.59 34.62 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -61.64 -36.77 81.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.24 -1.153 . . . . 0.0 109.499 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 82.4 mtm180 -127.62 145.29 50.92 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.293 -0.879 . . . . 0.0 109.449 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 59.6 mtt-85 -61.33 -35.47 77.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -61.17 -32.39 72.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.904 . . . . 0.0 109.49 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.5 p -56.02 156.37 5.46 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -117.78 172.64 7.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.548 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.0 mtt180 -111.3 135.92 51.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.89 . . . . 0.0 109.49 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -88.27 4.97 43.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.21 -0.932 . . . . 0.0 109.554 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.634 ' HD1' HD12 ' A' ' 115' ' ' LEU . 24.1 m-85 -72.12 145.66 47.99 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.485 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -120.38 80.42 29.4 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.65 151.64 64.16 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 94.09 -8.41 72.9 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.459 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -117.59 128.51 55.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -1.14 . . . . 0.0 109.492 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.644 HG13 ' O ' ' A' ' 43' ' ' MET . 65.8 t -130.73 143.44 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.273 -0.892 . . . . 0.0 109.538 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.846 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.1 mp -107.32 133.04 52.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.322 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.013 HG22 HG23 ' A' ' 42' ' ' VAL . 43.1 t -139.51 131.15 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.684 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.664 ' NE2' ' CE2' ' A' ' 9' ' ' TRP . 14.6 tt0 -88.05 128.5 35.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.218 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 55.7 ttp -173.98 163.96 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.179 -0.951 . . . . 0.0 109.682 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' A' ' 73' ' ' MET . 28.6 m -87.45 138.24 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.267 -0.896 . . . . 0.0 109.459 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.64 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 1.1 ttm -76.68 116.76 17.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.434 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 52.8 p-10 -145.01 170.71 15.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.428 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -67.88 -33.66 75.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -0.919 . . . . 0.0 109.915 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.561 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -67.7 -69.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 0.0 109.7 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 80' ' ' TRP . 9.9 p -46.6 -59.52 2.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -0.892 . . . . 0.0 109.645 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.49 ' N ' ' OG ' ' A' ' 79' ' ' SER . 68.0 t90 -42.84 -58.09 2.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.638 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -58.34 -37.69 75.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.944 . . . . 0.0 109.493 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.986 HD11 ' HB3' ' A' ' 29' ' ' HIS . 67.4 tp -63.41 -39.7 95.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.568 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.944 HG11 ' CE2' ' A' ' 92' ' ' PHE . 85.4 t -59.93 -47.29 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 109.584 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.59 -37.69 76.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.543 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.4 p -64.67 -26.28 68.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -0.914 . . . . 0.0 109.499 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.778 HG21 ' CD2' ' A' ' 26' ' ' LEU . 98.7 t -60.79 124.51 79.73 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.486 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.435 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.4 Cg_endo -70.35 156.41 61.88 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.696 2.264 . . . . 0.0 111.795 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 68.2 mtt-85 61.28 46.07 8.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.395 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.406 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.4 t -132.85 118.65 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.593 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' GLN . 64.2 mtt -69.03 -42.82 75.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.423 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.0 -152.81 24.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.944 ' CE2' HG11 ' A' ' 83' ' ' VAL . 3.4 m-85 -109.99 161.82 15.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.232 -1.158 . . . . 0.0 109.537 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.818 HD11 ' HB2' ' A' ' 13' ' ' GLN . 14.5 mm -115.9 116.35 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.507 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -172.88 -148.1 6.14 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.59 -35.01 67.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.78 HG23 ' H ' ' A' ' 98' ' ' ASP . 11.6 t -138.9 175.6 9.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -1.189 . . . . 0.0 109.665 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 p -93.56 19.44 8.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.288 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.78 ' H ' HG23 ' A' ' 96' ' ' THR . 86.0 m-20 -131.19 -0.83 4.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 109.429 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 98' ' ' ASP . 1.1 mtt180 -168.28 96.39 0.58 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.88 . . . . 0.0 109.003 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.64 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 45.9 Cg_endo -67.52 116.88 4.46 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.798 2.332 . . . . 0.0 112.16 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -60.72 135.5 92.44 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.267 -0.896 . . . . 0.0 109.304 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.1 Cg_endo -69.92 153.32 68.32 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.674 2.25 . . . . 0.0 111.785 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.831 HD11 HG22 ' A' ' 108' ' ' VAL . 28.3 pt -126.42 157.6 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.386 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.48 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 38.7 m -63.27 147.81 49.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.4 -39.31 83.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.428 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.2 tttt -59.74 -39.28 84.23 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.48 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -59.95 -41.4 91.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.256 -0.903 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.842 HG13 HD23 ' A' ' 70' ' ' LEU . 97.7 t -61.89 -35.96 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.515 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -67.33 -33.82 76.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.274 -0.891 . . . . 0.0 109.485 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.73 96.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.226 -0.921 . . . . 0.0 109.422 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.629 HD12 HD21 ' A' ' 70' ' ' LEU . 70.2 mt -56.86 -51.93 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 109.482 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 89.1 mtp -64.95 -33.98 77.31 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -57.95 -37.94 75.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 52.5 mtt180 -61.75 -39.92 93.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.93 . . . . 0.0 109.434 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.634 HD12 ' HD1' ' A' ' 64' ' ' PHE . 3.9 tp -60.64 -39.48 88.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLN . . . . . 0.472 ' O ' HG13 ' A' ' 118' ' ' VAL . 63.9 tt0 -68.31 -31.93 71.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -56.26 138.57 50.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.488 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.472 HG13 ' O ' ' A' ' 116' ' ' GLN . 23.9 m -132.26 160.76 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -90.23 58.63 3.51 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -55.13 -35.5 64.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.135 . . . . 0.0 109.48 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 29.6 mtpp -121.08 81.9 36.51 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.96 145.22 55.38 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.682 2.255 . . . . 0.0 111.818 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.0 mmt180 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.412 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.8 mtm . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.231 0.539 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.8 p -127.68 155.0 44.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.269 -0.894 . . . . 0.0 109.542 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -99.93 136.49 39.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -73.93 129.01 85.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.492 ' O ' ' NE ' ' A' ' 8' ' ' ARG . 51.0 Cg_endo -70.46 -10.75 28.66 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.722 2.282 . . . . 0.0 111.864 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.432 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 26.2 mttm -91.58 156.84 17.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 76.9 mttt 62.27 46.1 6.3 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.552 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 49.0 mtt180 -80.59 148.32 30.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.523 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.536 ' CH2' ' HG3' ' A' ' 43' ' ' MET . 77.2 m95 -78.01 135.68 37.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.947 . . . . 0.0 109.639 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.615 ' CZ ' ' CG ' ' A' ' 75' ' ' MET . 76.0 m-85 -132.21 139.02 48.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -0.92 . . . . 0.0 109.372 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.899 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.7 t -83.17 148.94 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.108 -0.995 . . . . 0.0 109.519 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.91 122.94 57.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.423 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.51 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 13.4 mt-30 -78.83 145.0 34.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.266 -0.896 . . . . 0.0 109.588 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.764 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.03 157.09 34.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.299 -0.876 . . . . 0.0 109.401 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -63.86 142.86 58.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.481 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.1 p -68.12 151.0 47.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.463 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.21 -34.08 4.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.452 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -112.08 9.22 20.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.624 ' OE2' HG23 ' A' ' 69' ' ' VAL . 85.6 tt0 -54.18 -41.0 68.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.87 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.53 -44.33 83.38 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.7 ttm-85 -62.44 -35.39 79.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -1.147 . . . . 0.0 109.498 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.764 HG21 ' HB1' ' A' ' 14' ' ' ALA . 53.7 t -56.51 -38.21 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.65 -37.41 86.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -0.894 . . . . 0.0 109.445 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 54.8 m -73.54 -40.68 63.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 26.6 m -64.48 -33.48 75.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.552 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.76 HD13 HG21 ' A' ' 86' ' ' VAL . 20.2 tp -63.32 -49.92 72.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.449 ' HG2' ' NZ ' ' A' ' 31' ' ' LYS . 18.4 ttp180 -43.21 -51.86 5.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.334 -0.854 . . . . 0.0 109.52 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -51.38 -49.18 62.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.528 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.83 ' HB3' HD11 ' A' ' 82' ' ' LEU . 90.3 m-70 -57.76 -26.08 61.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.474 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.965 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.7 mm -72.22 -51.95 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.475 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 58.7 mttp -66.9 -39.66 87.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.304 -0.872 . . . . 0.0 109.435 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.428 HD23 ' HA ' ' A' ' 32' ' ' LEU . 41.4 mt -57.45 -57.85 10.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.469 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 76.1 m80 -89.5 5.39 45.65 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 30' ' ' ILE . 69.9 m-20 55.18 48.4 19.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.551 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.864 ' HG3' HD22 ' A' ' 82' ' ' LEU . 49.0 mmm -98.17 15.06 25.5 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.66 ' CG ' HG22 ' A' ' 30' ' ' ILE . 98.0 mt-10 -55.01 -29.27 57.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.481 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -67.69 -38.3 83.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.338 -0.851 . . . . 0.0 109.508 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.833 HD12 ' HB3' ' A' ' 35' ' ' MET . 6.3 mt -72.63 -52.85 13.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.425 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.965 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -69.91 133.77 47.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 109.335 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.52 -64.06 0.61 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -146.6 153.07 39.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.168 -1.195 . . . . 0.0 109.556 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.986 HG13 HG22 ' A' ' 71' ' ' VAL . 38.9 t -114.44 149.72 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.455 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.555 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.4 mtm -132.08 140.36 48.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.167 -0.958 . . . . 0.0 109.562 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.3 t -131.01 76.72 76.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.47 58.44 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.705 2.27 . . . . 0.0 111.829 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.8 p -129.77 153.53 48.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.189 -0.944 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.427 ' HB2' ' O ' ' A' ' 62' ' ' ARG . 95.3 mt-10 -62.31 -19.48 63.34 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.244 -0.91 . . . . 0.0 109.362 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.489 ' HB2' ' HE2' ' A' ' 63' ' ' LYS . 84.4 tt0 -48.41 -34.97 11.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.7 p -127.02 136.19 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.4 m -137.78 162.08 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.316 -0.865 . . . . 0.0 109.384 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.7 tp10 -47.19 -56.34 6.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.657 ' O ' HG23 ' A' ' 52' ' ' ILE . 1.1 tt -126.36 101.24 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.429 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 75.0 mtm-85 -59.24 145.16 43.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.281 -0.887 . . . . 0.0 109.509 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -65.93 -30.01 76.21 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.455 ' O ' ' HG3' ' A' ' 57' ' ' ARG . . . 116.21 -97.47 0.77 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.4 ' O ' ' HB2' ' A' ' 57' ' ' ARG . 56.3 tp60 -57.94 -32.17 67.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -1.171 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.455 ' HG3' ' O ' ' A' ' 55' ' ' GLY . 59.8 mtt180 60.38 39.98 17.99 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.207 -0.933 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 69.7 mtt85 -58.84 -32.64 69.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.17 -0.956 . . . . 0.0 109.445 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 tttm -76.05 133.12 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.43 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.2 m -58.47 153.85 15.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -122.88 149.73 43.83 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.198 -0.939 . . . . 0.0 109.455 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.427 ' O ' ' HB2' ' A' ' 47' ' ' GLU . 97.5 mtt180 -126.98 146.09 50.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.511 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.489 ' HE2' ' HB2' ' A' ' 48' ' ' GLU . 21.3 mttt -102.45 118.2 36.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.682 ' CD1' ' CZ ' ' A' ' 65' ' ' PHE . 32.2 t80 -59.66 -45.17 92.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.293 -0.88 . . . . 0.0 109.313 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.743 ' HE1' HD21 ' A' ' 115' ' ' LEU . 2.2 m-85 -114.8 83.81 9.64 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.251 -0.906 . . . . 0.0 109.335 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.38 115.29 3.97 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.726 2.284 . . . . 0.0 111.842 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.39 18.6 70.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.491 ' HB2' ' HB3' ' A' ' 65' ' ' PHE . 1.7 m-85 -117.89 109.49 16.59 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -1.141 . . . . 0.0 109.437 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.624 HG23 ' OE2' ' A' ' 19' ' ' GLU . 77.0 t -137.25 133.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.275 -0.891 . . . . 0.0 109.585 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.823 ' N ' HD12 ' A' ' 70' ' ' LEU . 2.1 mp -101.26 147.1 26.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.285 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.986 HG22 HG13 ' A' ' 42' ' ' VAL . 65.0 t -145.49 113.78 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.246 -0.909 . . . . 0.0 109.638 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -54.06 124.35 15.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.209 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.564 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 38.1 ttp -177.21 155.22 1.12 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 0.0 109.533 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.5 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.1 t -91.52 140.45 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.302 -0.874 . . . . 0.0 109.402 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.615 ' CG ' ' CZ ' ' A' ' 10' ' ' TYR . 30.6 mmm -84.02 109.33 17.57 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.278 -0.889 . . . . 0.0 109.597 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.515 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 51.2 p-10 -138.27 173.89 11.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -64.18 -26.16 68.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.249 -0.907 . . . . 0.0 109.562 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.48 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -78.25 -70.14 0.51 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.51 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 25.1 p -54.67 -45.99 73.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -0.896 . . . . 0.0 109.736 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.532 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 73.1 t90 -51.15 -54.38 25.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.6 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -61.57 -39.09 89.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.925 . . . . 0.0 109.559 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.864 HD22 ' HG3' ' A' ' 35' ' ' MET . 58.4 tp -63.21 -41.64 99.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.152 -0.967 . . . . 0.0 109.503 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.007 HG11 ' CE2' ' A' ' 92' ' ' PHE . 55.6 t -56.32 -43.89 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.139 -0.976 . . . . 0.0 109.534 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -61.83 -35.65 78.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.175 -0.953 . . . . 0.0 109.481 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 29.8 t -66.76 -28.34 68.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.479 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.76 HG21 HD13 ' A' ' 26' ' ' LEU . 49.8 t -54.9 124.93 53.99 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.464 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.445 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.2 155.08 65.29 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.745 2.296 . . . . 0.0 111.789 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.579 ' HB2' HG22 ' A' ' 22' ' ' VAL . 82.6 mmt-85 63.36 43.43 6.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.254 -0.904 . . . . 0.0 109.526 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.662 HG21 ' HB ' ' A' ' 86' ' ' VAL . 53.6 t -128.79 115.58 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.5 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.51 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.7 mtp -68.5 -40.16 80.98 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.907 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.59 -158.86 31.43 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 1.007 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.2 OUTLIER -112.69 166.68 11.13 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.218 -1.166 . . . . 0.0 109.514 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.899 HD12 ' CG1' ' A' ' 11' ' ' VAL . 67.4 mt -118.24 137.5 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.878 . . . . 0.0 109.379 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 161.18 -147.08 13.24 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -78.08 -44.09 12.46 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.3 p -127.73 173.38 9.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.156 -1.202 . . . . 0.0 109.53 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.1 m -89.89 18.09 6.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.274 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.532 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 87.6 m-20 -130.17 -33.24 1.74 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.574 -0.704 . . . . 0.0 109.134 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.55 88.58 38.46 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.264 -0.898 . . . . 0.0 108.836 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.46 128.76 18.8 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.71 2.274 . . . . 0.0 112.048 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 137.14 82.56 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.291 -0.88 . . . . 0.0 109.361 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.552 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.3 Cg_endo -69.7 153.23 69.47 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.699 2.266 . . . . 0.0 111.841 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.559 HD11 HG22 ' A' ' 108' ' ' VAL . 26.7 pt -112.65 154.96 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.369 -0.832 . . . . 0.0 109.481 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.9 m -65.38 146.26 55.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.152 -0.968 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -58.13 -41.01 82.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.278 -0.889 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 42.5 tttt -57.98 -43.42 86.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.449 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 86.5 tt0 -51.85 -43.75 63.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.902 . . . . 0.0 109.441 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.559 HG22 HD11 ' A' ' 103' ' ' ILE . 74.8 t -57.17 -38.69 62.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.303 -0.873 . . . . 0.0 109.375 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -68.41 -31.75 71.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.23 -0.919 . . . . 0.0 109.465 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -62.93 -42.28 99.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.435 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.51 HG12 ' NH1' ' A' ' 114' ' ' ARG . 50.9 mt -52.43 -53.69 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.211 -0.93 . . . . 0.0 109.395 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.4 mtt -62.58 -36.73 83.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.926 . . . . 0.0 109.377 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -60.94 -37.54 82.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.51 ' NH1' HG12 ' A' ' 111' ' ' ILE . 24.6 mtm180 -55.17 -40.77 71.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.479 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.743 HD21 ' HE1' ' A' ' 65' ' ' PHE . 87.1 mt -54.57 -40.43 68.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -65.25 -31.53 72.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -65.51 137.15 57.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.382 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.682 HG11 ' HE3' ' A' ' 121' ' ' LYS . 39.5 t -119.71 140.21 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -54.42 -35.15 55.62 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.537 ' H ' HG12 ' A' ' 118' ' ' VAL . 60.5 t0 -144.39 88.77 1.96 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.306 -1.114 . . . . 0.0 109.4 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.682 ' HE3' HG11 ' A' ' 118' ' ' VAL . 1.3 tppp? -155.06 106.55 2.28 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.228 -0.92 . . . . 0.0 109.516 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.27 -17.81 35.01 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.654 2.236 . . . . 0.0 111.765 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 55.4 ttt180 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.064 -0.969 . . . . 0.0 109.398 179.944 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.1 mmm . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.4 p -67.36 -14.52 62.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.276 -0.89 . . . . 0.0 109.486 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -51.99 -37.4 53.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.541 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -168.93 148.65 3.83 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 109.492 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.97 147.94 62.61 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.713 2.275 . . . . 0.0 111.817 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 56.5 mttm -106.39 139.78 40.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.485 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 47.1 mttt -113.29 138.21 50.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.224 -0.922 . . . . 0.0 109.48 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 78.8 mtt-85 -128.92 156.48 43.66 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 67.4 m95 -91.55 128.15 37.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.177 -0.952 . . . . 0.0 109.617 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.561 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.9 m-85 -120.9 150.11 41.58 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.46 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.479 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 53.0 t -102.27 136.04 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.245 -0.909 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.79 126.68 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.717 ' HB2' HD11 ' A' ' 93' ' ' ILE . 69.9 tp60 -90.35 130.64 36.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.425 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.666 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.67 154.74 44.61 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.528 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -55.12 149.67 11.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.423 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.8 t -67.93 147.71 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.498 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 -33.94 4.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.826 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -109.53 7.15 24.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -1.155 . . . . 0.0 109.592 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.846 ' OE1' HG21 ' A' ' 46' ' ' THR . 23.0 pt-20 -56.12 -39.31 72.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.441 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -75.44 -54.2 5.66 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -57.86 -39.21 77.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -1.136 . . . . 0.0 109.497 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.9 t -53.05 -40.75 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.29 96.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.894 . . . . 0.0 109.433 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.8 m -64.48 -43.51 93.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.468 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 58.1 m -58.41 -41.68 85.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.655 HD21 ' CE1' ' A' ' 39' ' ' PHE . 4.8 tp -59.14 -39.41 82.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 109.272 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -58.48 -26.03 62.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.321 -0.862 . . . . 0.0 109.392 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.469 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 71.2 mt-10 -68.66 -47.65 65.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.325 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 1.0 ' HB3' HD11 ' A' ' 82' ' ' LEU . 79.8 m-70 -68.06 -43.47 78.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.857 HD13 ' CD2' ' A' ' 39' ' ' PHE . 54.9 mt -57.94 -50.44 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.52 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 58.2 tttp -60.49 -41.48 94.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.611 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 32.3 mt -69.27 -50.88 42.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.481 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 64.0 m80 -77.49 -6.89 55.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.217 -0.927 . . . . 0.0 109.528 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.487 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.1 t30 66.14 42.98 2.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.514 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.908 ' HG3' HD22 ' A' ' 82' ' ' LEU . 45.8 mmm -92.04 5.19 51.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.45 ' O ' ' O ' ' A' ' 39' ' ' PHE . 96.5 mt-10 -48.76 -37.79 19.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.461 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -53.26 -44.25 68.03 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.214 -0.929 . . . . 0.0 109.362 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.904 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.2 mt -72.19 -52.66 15.5 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.302 -0.874 . . . . 0.0 109.4 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.857 ' CD2' HD13 ' A' ' 30' ' ' ILE . 98.1 m-85 -70.97 129.09 38.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.187 -0.946 . . . . 0.0 109.441 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.32 -69.19 0.66 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -139.71 147.15 40.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -1.163 . . . . 0.0 109.583 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.036 HG13 HG22 ' A' ' 71' ' ' VAL . 39.0 t -113.99 154.01 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.374 -0.829 . . . . 0.0 109.351 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.565 ' CE ' HG11 ' A' ' 108' ' ' VAL . 64.3 mtm -137.78 144.05 41.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.566 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.6 t -129.7 100.49 19.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.438 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.683 ' HD3' HD13 ' A' ' 70' ' ' LEU . 49.9 Cg_endo -70.44 -16.75 34.75 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.692 2.262 . . . . 0.0 111.857 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.846 HG21 ' OE1' ' A' ' 19' ' ' GLU . 12.0 p -64.95 -14.14 59.24 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.215 -0.928 . . . . 0.0 109.566 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.501 ' HG3' HD11 ' A' ' 52' ' ' ILE . 77.8 tt0 -100.51 130.99 46.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.15 -0.969 . . . . 0.0 109.441 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -65.89 -49.06 69.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.299 -0.876 . . . . 0.0 109.477 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.439 HG12 ' N ' ' A' ' 50' ' ' VAL . 44.8 t -129.4 158.04 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.436 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.439 ' N ' HG12 ' A' ' 49' ' ' VAL . 8.8 p -46.89 -35.95 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.415 ' N ' HG13 ' A' ' 50' ' ' VAL . 86.2 tt0 -110.01 150.32 28.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.9 . . . . 0.0 109.55 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.501 HD11 ' HG3' ' A' ' 47' ' ' GLU . 55.6 mt -121.12 96.65 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 87.3 mtt180 -59.22 146.76 38.03 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.266 -0.896 . . . . 0.0 109.48 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -57.11 -39.94 90.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 46.03 -110.6 0.5 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.81 154.16 23.39 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.263 -1.139 . . . . 0.0 109.506 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.6 mtm-85 -50.26 -35.45 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.414 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 35.1 ttt180 -129.28 132.16 47.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.261 -0.9 . . . . 0.0 109.492 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 mttm -100.43 134.91 42.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.34 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 18.2 m -63.11 -23.63 67.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -52.36 147.8 7.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.5 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -130.19 151.02 51.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.307 -0.87 . . . . 0.0 109.426 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.46 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 28.9 mttp -88.92 114.09 25.16 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.5 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -63.78 -40.62 97.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.252 -0.905 . . . . 0.0 109.467 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.573 ' CZ ' HD21 ' A' ' 115' ' ' LEU . 1.5 p90 -129.39 75.92 79.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.302 -0.874 . . . . 0.0 109.503 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 48.9 Cg_endo -69.94 144.6 53.58 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.743 2.295 . . . . 0.0 111.801 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . 83.46 19.64 61.76 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -118.64 124.25 46.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -1.199 . . . . 0.0 109.445 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.434 ' C ' HD12 ' A' ' 70' ' ' LEU . 76.6 t -132.2 146.49 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.567 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.846 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.2 mp -106.85 130.09 54.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.036 HG22 HG13 ' A' ' 42' ' ' VAL . 99.1 t -136.63 124.77 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.176 -0.952 . . . . 0.0 109.642 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.485 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 7.5 tt0 -81.02 128.37 33.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.171 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.561 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 50.9 ttp -173.83 165.12 4.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.65 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.529 ' N ' ' HG2' ' A' ' 73' ' ' MET . 14.5 p -88.53 143.36 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.353 -0.842 . . . . 0.0 109.218 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.582 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 16.9 tpp -82.91 113.82 20.78 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.593 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.0 p30 -142.14 168.94 18.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.318 -0.864 . . . . 0.0 109.427 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.572 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.6 m-20 -68.61 -30.12 68.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.217 -0.927 . . . . 0.0 109.47 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.02 -71.88 0.22 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.905 . . . . 0.0 109.55 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.904 ' OG ' HD13 ' A' ' 38' ' ' LEU . 7.5 m -48.27 -49.61 32.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 66.3 t90 -49.63 -52.3 31.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.873 . . . . 0.0 109.73 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 56.5 m-70 -66.6 -24.19 66.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.6 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 1.0 HD11 ' HB3' ' A' ' 29' ' ' HIS . 56.9 tp -68.74 -45.21 72.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.075 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 70.0 t -50.92 -44.05 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.573 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 36.2 ttp180 -62.92 -23.02 67.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.139 -0.976 . . . . 0.0 109.368 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.5 t -61.6 -63.86 1.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 0.0 109.415 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.683 HG13 HG21 ' A' ' 89' ' ' VAL . 1.8 p -59.62 125.8 80.89 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.164 -0.96 . . . . 0.0 109.467 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.476 ' O ' HG23 ' A' ' 89' ' ' VAL . 48.1 Cg_endo -69.65 -177.77 1.99 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.732 2.288 . . . . 0.0 111.834 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.1 mtt85 62.94 23.01 13.77 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.314 -0.866 . . . . 0.0 109.582 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.683 HG21 HG13 ' A' ' 86' ' ' VAL . 22.2 t -116.88 116.48 52.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.482 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 44.8 mtt -65.93 -43.68 87.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.346 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.19 -150.86 22.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 1.075 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 4.6 m-85 -111.8 161.4 16.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.4 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.717 HD11 ' HB2' ' A' ' 13' ' ' GLN . 15.8 mm -114.88 123.12 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.306 -0.871 . . . . 0.0 109.548 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.86 -152.76 11.57 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -64.95 -45.04 93.62 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.9 p -129.32 172.86 11.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.183 -1.187 . . . . 0.0 109.565 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 14.4 p -89.82 20.05 4.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.2 -0.937 . . . . 0.0 109.412 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -123.12 -22.65 5.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.449 -0.782 . . . . 0.0 109.37 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.53 103.18 3.27 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.328 -0.857 . . . . 0.0 108.94 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 48.4 Cg_endo -68.77 111.46 2.61 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.756 2.304 . . . . 0.0 111.996 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.98 140.7 81.95 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 109.427 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.521 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.9 Cg_endo -70.15 153.34 67.24 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.637 2.225 . . . . 0.0 111.81 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.62 155.11 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.255 -0.903 . . . . 0.0 109.408 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.7 m -71.74 151.34 43.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -52.29 -41.7 63.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -55.82 -41.52 74.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.921 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -52.88 -45.12 67.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.333 -0.854 . . . . 0.0 109.377 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.835 HG13 ' CD2' ' A' ' 70' ' ' LEU . 98.1 t -56.78 -38.03 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -67.54 -34.2 76.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.229 -0.919 . . . . 0.0 109.445 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -56.48 -46.3 80.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.332 -0.855 . . . . 0.0 109.415 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.72 HD12 HD21 ' A' ' 70' ' ' LEU . 50.5 mt -49.69 -56.36 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.329 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.6 mtt -60.3 -35.17 74.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.276 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -61.27 -34.69 75.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 109.355 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.7 ttt180 -55.88 -36.97 68.21 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.573 HD21 ' CZ ' ' A' ' 65' ' ' PHE . 72.8 mt -55.79 -43.46 76.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.428 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -64.68 -31.82 73.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.527 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -69.99 137.26 51.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.5 -39.44 81.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.291 -0.881 . . . . 0.0 109.483 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 96.81 10.4 55.29 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 121' ' ' LYS . 30.9 p-10 -58.03 -34.69 70.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.217 -1.167 . . . . 0.0 109.414 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.505 ' N ' ' OD1' ' A' ' 120' ' ' ASP . 12.8 tttm -124.11 81.05 57.67 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.364 -0.835 . . . . 0.0 109.509 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.12 -18.91 35.0 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.726 2.284 . . . . 0.0 111.685 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 38.6 ttt180 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.505 179.965 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.7 mtp . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.0 t -57.41 -35.87 70.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.294 -0.878 . . . . 0.0 109.506 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.94 -34.75 75.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.43 80.04 60.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.312 -0.867 . . . . 0.0 109.465 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.26 141.33 42.93 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.671 2.247 . . . . 0.0 111.759 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.738 ' O ' HG22 ' A' ' 74' ' ' VAL . 26.9 mttp -110.22 150.14 29.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.309 -0.869 . . . . 0.0 109.401 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 77.5 mttt -99.02 133.27 43.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.323 -0.86 . . . . 0.0 109.561 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.514 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 44.9 mtm180 -132.72 159.55 39.35 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.493 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.546 ' CG ' HG21 ' A' ' 108' ' ' VAL . 46.3 m95 -99.34 132.54 44.59 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.892 . . . . 0.0 109.556 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.595 ' CD2' ' HE2' ' A' ' 75' ' ' MET . 66.1 m-85 -130.93 155.23 47.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.443 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.489 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 10.7 t -96.18 145.93 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.226 -0.921 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.0 t -119.03 123.57 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 109.364 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.993 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.5 tt0 -93.1 131.67 37.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.923 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.445 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -138.72 -153.23 0.46 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 109.369 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 61.7 t80 -98.23 133.49 42.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.452 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 31.3 t -54.77 126.0 22.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.214 -0.929 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.11 -27.15 19.67 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 19.2 m-85 -105.09 7.52 33.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -1.116 . . . . 0.0 109.493 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.671 ' OE2' HG22 ' A' ' 46' ' ' THR . 23.6 pt-20 -56.89 -34.72 68.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.915 . . . . 0.0 109.374 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -71.13 -37.87 63.68 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 17.9 ttm180 -63.81 -49.86 71.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.204 -1.174 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.461 HG13 HG11 ' A' ' 86' ' ' VAL . 39.1 t -50.37 -38.78 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.235 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.73 -39.72 91.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.929 . . . . 0.0 109.251 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.6 m -69.01 -46.6 67.55 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.388 -0.82 . . . . 0.0 109.376 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.412 ' HB3' ' HE1' ' A' ' 29' ' ' HIS . 21.4 m -65.72 -39.63 91.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.438 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.5 ' HG ' ' CD1' ' A' ' 30' ' ' ILE . 30.8 tp -54.34 -43.55 71.34 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.6 ttm-85 -57.83 -36.89 72.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -67.94 -52.58 34.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.203 -0.936 . . . . 0.0 109.474 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.996 ' HB3' HD11 ' A' ' 82' ' ' LEU . 22.8 m80 -58.44 -48.06 81.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.93 . . . . 0.0 109.443 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.65 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.2 mt -57.69 -52.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.305 -0.872 . . . . 0.0 109.515 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.4 tttm -57.61 -43.39 84.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.29 -0.881 . . . . 0.0 109.497 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.427 ' HA ' HD23 ' A' ' 32' ' ' LEU . 40.2 mt -68.25 -49.48 60.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.229 -0.92 . . . . 0.0 109.416 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.506 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 63.9 m80 -80.35 4.19 18.7 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 109.577 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 30' ' ' ILE . 40.5 t30 52.75 50.53 17.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.403 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.937 ' HG3' HD22 ' A' ' 82' ' ' LEU . 53.3 mmm -102.88 4.74 37.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.427 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.3 mt-10 -49.78 -34.93 20.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -57.77 -43.03 85.23 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.413 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.586 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.4 mt -72.84 -50.12 25.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.287 -0.883 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.566 ' CE2' HG12 ' A' ' 30' ' ' ILE . 96.4 m-85 -71.2 130.83 42.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.295 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.56 -65.4 0.55 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -137.19 122.68 19.6 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -1.204 . . . . 0.0 109.675 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.983 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -92.53 136.0 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.34 -0.85 . . . . 0.0 109.145 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.766 ' O ' HG13 ' A' ' 69' ' ' VAL . 97.2 mtp -125.12 117.42 23.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.192 -0.942 . . . . 0.0 109.768 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 44' ' ' VAL . 12.0 p -135.06 81.83 44.07 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.323 -0.861 . . . . 0.0 109.099 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.13 130.52 20.26 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.79 2.327 . . . . 0.0 111.98 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.671 HG22 ' OE2' ' A' ' 19' ' ' GLU . 55.8 p -124.68 -0.52 8.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.784 ' HB2' HD21 ' A' ' 115' ' ' LEU . 85.4 tt0 50.83 86.0 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.244 -0.91 . . . . 0.0 109.639 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -58.99 137.45 57.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.258 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.4 p -131.43 137.93 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.162 -0.961 . . . . 0.0 109.733 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.69 154.11 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.343 -0.848 . . . . 0.0 109.327 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.467 ' OE2' ' HA2' ' A' ' 55' ' ' GLY . 83.4 tt0 -119.62 156.75 29.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.922 . . . . 0.0 109.601 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.448 ' O ' ' HB2' ' A' ' 53' ' ' ARG . 56.5 mt -142.72 109.56 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.416 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.448 ' HB2' ' O ' ' A' ' 52' ' ' ILE . 77.1 mtp180 64.07 135.4 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.267 -0.896 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 93.84 -175.42 35.38 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.467 ' HA2' ' OE2' ' A' ' 51' ' ' GLU . . . 167.16 178.97 39.85 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -126.24 149.17 49.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.193 -1.181 . . . . 0.0 109.449 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -57.46 -35.15 69.77 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -127.38 143.48 51.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.921 . . . . 0.0 109.494 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tptp -82.5 131.84 35.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.903 . . . . 0.0 109.499 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 32.1 t -127.55 139.09 52.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 109.505 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.503 ' OE1' ' CE ' ' A' ' 63' ' ' LYS . 98.9 mt-10 -117.15 135.99 53.35 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.245 -0.909 . . . . 0.0 109.376 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.483 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 75.3 mtm180 -71.78 -44.99 63.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.219 -0.925 . . . . 0.0 109.519 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.503 ' CE ' ' OE1' ' A' ' 61' ' ' GLU . 75.7 mmtt 46.7 63.33 1.95 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.506 ' HE1' HG13 ' A' ' 118' ' ' VAL . 70.2 m-85 -60.68 -36.16 78.07 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.429 ' HB3' ' HB2' ' A' ' 68' ' ' TYR . 13.4 m-85 -105.73 106.66 57.27 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.35 70.96 1.86 Allowed 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.694 2.263 . . . . 0.0 111.839 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 74.73 45.48 21.92 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.429 ' HB2' ' HB3' ' A' ' 65' ' ' PHE . 1.3 m-85 -111.95 120.79 43.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.485 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 43' ' ' MET . 96.5 t -133.34 146.88 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -0.888 . . . . 0.0 109.577 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.854 ' N ' HD22 ' A' ' 70' ' ' LEU . 1.2 mm? -105.03 131.0 53.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.886 . . . . 0.0 109.341 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.983 HG22 HG23 ' A' ' 42' ' ' VAL . 64.3 t -138.55 125.74 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 109.709 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.473 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.7 tt0 -78.8 119.58 22.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.826 . . . . 0.0 109.299 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.552 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 48.6 ttp -165.99 163.46 18.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.602 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.738 HG22 ' O ' ' A' ' 6' ' ' LYS . 32.3 t -91.48 147.61 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.595 ' HE2' ' CD2' ' A' ' 10' ' ' TYR . 10.2 mmt -86.5 114.14 23.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.935 . . . . 0.0 109.653 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.1 p-10 -143.25 167.92 21.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.305 -0.872 . . . . 0.0 109.324 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.6 m-20 -66.36 -24.29 66.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.257 -0.902 . . . . 0.0 109.696 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.533 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -75.57 -70.26 0.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.235 -0.916 . . . . 0.0 109.526 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.475 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 12.4 p -56.07 -49.72 73.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.168 -0.957 . . . . 0.0 109.682 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.476 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.8 t90 -43.97 -44.93 7.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 33.0 m-70 -73.54 -32.01 63.96 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 109.484 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.996 HD11 ' HB3' ' A' ' 29' ' ' HIS . 54.9 tp -63.07 -45.88 90.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.01 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 82.8 t -55.4 -45.64 78.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -62.95 -36.39 83.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.638 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 41.0 m -61.48 -38.89 88.95 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.133 -0.979 . . . . 0.0 109.471 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.644 ' O ' HG12 ' A' ' 89' ' ' VAL . 38.5 t -51.73 126.14 31.14 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.289 -0.882 . . . . 0.0 109.531 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.46 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -71.17 156.36 59.55 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.69 2.26 . . . . 0.0 111.714 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 21' ' ' ARG . 82.0 mtt-85 62.06 35.86 15.68 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.857 . . . . 0.0 109.672 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.2 p -129.09 128.31 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.158 -0.964 . . . . 0.0 109.571 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.486 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 92.4 mmm -71.96 -54.59 9.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.285 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 162.03 -148.01 14.87 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 1.01 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 5.3 m-85 -104.62 160.6 14.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -1.162 . . . . 0.0 109.499 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.993 HD11 ' HB2' ' A' ' 13' ' ' GLN . 17.3 mm -118.14 119.11 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.453 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -171.63 -143.57 4.11 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -71.98 -35.42 61.36 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.586 HG23 ' H ' ' A' ' 98' ' ' ASP . 7.0 t -140.93 176.16 9.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.211 -1.17 . . . . 0.0 109.633 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 13.1 p -92.96 21.57 5.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.43 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.586 ' H ' HG23 ' A' ' 96' ' ' THR . 2.6 p30 -137.05 8.79 2.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.46 -0.775 . . . . 0.0 109.133 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -176.69 92.51 0.25 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.343 -0.848 . . . . 0.0 108.948 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.525 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 46.0 Cg_endo -68.48 120.78 7.71 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.688 2.259 . . . . 0.0 111.988 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -64.37 148.61 95.95 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.285 -0.884 . . . . 0.0 109.317 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.507 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 49.5 Cg_endo -70.07 153.28 67.68 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.68 2.253 . . . . 0.0 111.82 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.533 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -125.21 157.91 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.336 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 39.0 m -75.64 148.71 38.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.554 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -56.51 -40.8 75.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -58.15 -40.37 81.17 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -0.882 . . . . 0.0 109.417 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 93.3 mt-10 -56.03 -43.78 78.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.197 -0.939 . . . . 0.0 109.389 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.546 HG21 ' CG ' ' A' ' 9' ' ' TRP . 54.1 t -57.35 -37.83 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -0.902 . . . . 0.0 109.343 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -73.81 -34.1 64.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.326 -0.859 . . . . 0.0 109.367 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.39 -43.41 81.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.388 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.422 HG13 ' O ' ' A' ' 107' ' ' GLU . 89.7 mt -50.05 -50.09 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.454 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.3 mtp -60.13 -39.94 88.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.414 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -59.96 -40.79 90.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.43 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.476 ' O ' ' N ' ' A' ' 117' ' ' GLN . 65.2 mtt180 -56.16 -46.34 79.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.4 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.784 HD21 ' HB2' ' A' ' 47' ' ' GLU . 5.2 tp -44.13 -48.56 9.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -0.922 . . . . 0.0 109.438 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -66.46 -25.49 66.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.875 . . . . 0.0 109.49 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.476 ' N ' ' O ' ' A' ' 114' ' ' ARG . 58.0 tp60 -86.02 141.16 29.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.265 -0.897 . . . . 0.0 109.379 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.506 HG13 ' HE1' ' A' ' 64' ' ' PHE . 39.6 t -125.65 151.27 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -53.38 -37.03 54.72 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' OD1' ' HG2' ' A' ' 122' ' ' PRO . 56.6 t0 -152.19 94.11 1.9 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -1.107 . . . . 0.0 109.449 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.525 ' N ' ' HD2' ' A' ' 122' ' ' PRO . 0.0 OUTLIER -46.59 -58.85 5.97 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.517 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 122' ' ' PRO . . . . . 0.525 ' HD2' ' N ' ' A' ' 121' ' ' LYS . 49.7 Cg_endo -70.11 145.77 56.06 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.661 2.24 . . . . 0.0 111.815 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.463 ' HG2' ' OXT' ' A' ' 123' ' ' ARG . 67.1 ttt180 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.407 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.6 mtp . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.282 0.563 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.0 m -64.39 152.65 40.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.472 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -60.99 -33.45 73.25 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.493 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.44 144.76 61.83 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.29 -0.881 . . . . 0.0 109.428 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.56 147.27 63.77 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.751 2.3 . . . . 0.0 111.817 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -90.91 28.68 1.5 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.278 -0.889 . . . . 0.0 109.431 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 80.1 mttt -93.53 134.94 35.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.283 -0.885 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.556 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 51.3 mtt85 -117.27 156.01 28.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.19 -0.944 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 83.7 m95 -87.78 128.06 35.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.587 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.618 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 91.2 m-85 -121.18 160.67 23.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.912 . . . . 0.0 109.542 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 1.006 HG11 HD12 ' A' ' 93' ' ' ILE . 21.1 t -95.13 154.64 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.207 -0.933 . . . . 0.0 109.588 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.44 115.94 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.302 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.565 ' HG2' HD11 ' A' ' 93' ' ' ILE . 78.4 mt-30 -81.01 150.47 28.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.692 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.702 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.56 158.42 35.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 109.405 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.46 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.7 m-85 -62.44 143.97 56.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 34.0 t -67.78 147.34 52.72 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.25 -33.52 4.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.786 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.5 m-85 -108.07 10.66 28.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -1.139 . . . . 0.0 109.476 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.517 ' OE2' ' CB ' ' A' ' 46' ' ' THR . 20.9 pt-20 -61.15 -36.78 80.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.433 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.81 -50.02 38.54 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.0 ttt85 -63.77 -37.48 87.51 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -1.144 . . . . 0.0 109.424 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.3 t -52.21 -41.67 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -0.934 . . . . 0.0 109.271 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.16 -48.93 79.8 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.298 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 78.7 m -59.39 -46.39 88.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.39 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 21.9 m -51.3 -44.79 61.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.295 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.473 ' O ' HG12 ' A' ' 30' ' ' ILE . 47.5 mt -51.29 -69.68 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.36 -0.838 . . . . 0.0 109.388 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.48 ' HA ' HG12 ' A' ' 30' ' ' ILE . 48.6 ttt85 -42.78 -42.81 3.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.386 -0.821 . . . . 0.0 109.72 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -55.78 -37.81 69.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.208 -0.932 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.465 ' HE1' ' HD2' ' A' ' 87' ' ' PRO . 40.2 m80 -79.85 -27.28 40.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.274 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.987 HD12 ' CD1' ' A' ' 39' ' ' PHE . 11.8 mm -64.01 -43.45 97.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.302 -0.874 . . . . 0.0 109.321 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -70.38 -36.41 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.434 HD23 ' HA ' ' A' ' 32' ' ' LEU . 39.4 mt -70.61 -55.75 8.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.335 -0.853 . . . . 0.0 109.472 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.93 ' CG ' HD11 ' A' ' 82' ' ' LEU . 62.7 m80 -81.18 4.82 18.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.195 -0.941 . . . . 0.0 109.559 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.6 t30 50.09 46.64 24.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.19 -0.944 . . . . 0.0 109.517 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.849 ' HB3' HD12 ' A' ' 38' ' ' LEU . 40.3 mmm -100.05 14.99 28.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.357 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.586 ' CG ' HG22 ' A' ' 30' ' ' ILE . 99.4 mt-10 -52.49 -31.31 34.5 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.276 -0.89 . . . . 0.0 109.492 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -60.34 -42.38 95.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.216 -0.927 . . . . 0.0 109.507 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 1.015 HD13 ' OG ' ' A' ' 79' ' ' SER . 2.4 mt -74.06 -53.97 8.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.351 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.987 ' CD1' HD12 ' A' ' 30' ' ' ILE . 94.2 m-85 -69.99 130.0 41.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.29 -64.27 0.48 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -138.93 146.34 40.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.164 -1.198 . . . . 0.0 109.525 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.991 HG13 HG22 ' A' ' 71' ' ' VAL . 48.2 t -111.12 153.83 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.516 ' SD ' HG11 ' A' ' 108' ' ' VAL . 89.5 mtp -123.62 143.81 50.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.499 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.609 HG13 HG22 ' A' ' 46' ' ' THR . 46.7 t -139.87 94.06 9.2 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.152 -0.967 . . . . 0.0 109.428 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.867 ' HB2' HD11 ' A' ' 115' ' ' LEU . 49.4 Cg_endo -70.03 -24.05 28.86 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.636 2.224 . . . . 0.0 111.699 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.702 ' O ' HG23 ' A' ' 46' ' ' THR . 9.3 t -71.68 64.15 0.45 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.506 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -61.82 -38.16 87.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.912 . . . . 0.0 109.371 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -108.31 151.78 25.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.406 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 39.6 t -118.07 137.02 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.162 -0.961 . . . . 0.0 109.556 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.3 m -61.4 140.25 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.302 -0.874 . . . . 0.0 109.424 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 51.7 tt0 -95.41 145.29 25.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 109.447 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 22.9 pt -66.34 -17.07 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.397 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 16.5 ptt180 -152.44 169.53 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.448 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 96.44 175.55 35.74 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.56 147.01 10.39 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -122.96 147.2 46.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.288 -1.125 . . . . 0.0 109.489 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -56.65 -38.08 71.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.261 -0.899 . . . . 0.0 109.469 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 68.9 mtm-85 -58.6 -32.66 69.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.915 . . . . 0.0 109.489 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 8.7 tptp -65.81 130.88 44.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.152 -0.967 . . . . 0.0 109.471 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.4 m -65.12 154.23 38.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.513 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.0 mm-40 -120.4 155.27 33.78 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.886 ' HG2' HG13 ' A' ' 118' ' ' VAL . 9.3 mtt85 -118.57 147.45 43.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -80.8 128.24 33.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.198 -0.939 . . . . 0.0 109.42 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.587 ' CE2' ' HB2' ' A' ' 62' ' ' ARG . 98.6 m-85 -124.08 154.86 39.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.413 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.48 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 7.2 p90 -117.67 80.79 14.05 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 0.0 109.575 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.52 150.59 63.83 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.654 2.236 . . . . 0.0 111.625 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.08 4.59 61.27 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -115.36 119.18 35.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -1.174 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.522 ' C ' HD12 ' A' ' 70' ' ' LEU . 93.4 t -133.27 138.39 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.219 -0.926 . . . . 0.0 109.591 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 1.11 HD21 HD12 ' A' ' 111' ' ' ILE . 4.1 mp -108.22 131.03 55.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.311 -0.868 . . . . 0.0 109.337 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.991 HG22 HG13 ' A' ' 42' ' ' VAL . 86.3 t -138.42 120.58 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.702 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.477 ' O ' ' HB2' ' A' ' 73' ' ' MET . 36.4 tt0 -69.15 135.55 50.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.228 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.571 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 52.8 ttp 172.94 156.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.99 . . . . 0.0 109.66 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.519 ' N ' ' HG2' ' A' ' 73' ' ' MET . 13.9 p -88.96 134.91 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.284 -0.885 . . . . 0.0 109.36 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.629 ' HE2' ' HG2' ' A' ' 100' ' ' PRO . 24.6 mmm -79.33 116.94 19.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.248 -0.907 . . . . 0.0 109.469 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.519 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 49.5 p-10 -143.43 171.03 14.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.227 -0.921 . . . . 0.0 109.468 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -59.76 -33.3 71.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.542 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -72.02 -70.96 0.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . 1.015 ' OG ' HD13 ' A' ' 38' ' ' LEU . 6.7 m -52.76 -51.82 59.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.422 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.519 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 29.8 t90 -44.57 -46.65 10.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.312 -0.868 . . . . 0.0 109.593 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 19.5 m170 -70.39 -36.38 74.06 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.928 . . . . 0.0 109.422 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.93 HD11 ' CG ' ' A' ' 33' ' ' HIS . 3.0 tp -53.34 -45.01 68.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.952 . . . . 0.0 109.461 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.942 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 11.6 t -62.02 -31.77 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.405 -0.81 . . . . 0.0 109.591 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 80' ' ' TRP . 40.5 mtt-85 -70.98 -33.2 70.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.934 . . . . 0.0 109.407 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.9 p -79.7 -20.22 47.04 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.297 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 82' ' ' LEU . 88.5 t -67.29 127.33 93.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.343 -0.848 . . . . 0.0 109.326 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.465 ' HD2' ' HE1' ' A' ' 29' ' ' HIS . 49.2 Cg_endo -70.21 153.06 67.22 Favored 'Trans proline' 0 C--O 1.214 -0.708 0 C-N-CA 122.687 2.258 . . . . 0.0 111.853 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 18' ' ' PHE . 33.7 mtt85 63.09 47.34 4.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.605 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.608 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.1 t -127.33 123.44 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 109.527 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 85.5 mtp -78.16 -50.72 11.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.41 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 164.07 -160.87 33.84 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.942 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 6.7 m-85 -109.57 160.52 16.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -1.154 . . . . 0.0 109.667 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 1.006 HD12 HG11 ' A' ' 11' ' ' VAL . 3.7 mt -117.51 134.16 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.339 -0.851 . . . . 0.0 109.251 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 168.22 -142.22 7.32 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.25 -50.75 42.9 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.0 p -126.77 179.13 5.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -1.163 . . . . 0.0 109.587 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.47 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 25.6 p -94.38 22.54 5.97 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.261 -0.899 . . . . 0.0 109.309 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 97' ' ' SER . 92.2 m-20 -137.0 6.42 2.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.476 -0.765 . . . . 0.0 109.459 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER -170.88 95.72 0.44 Allowed Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.292 -0.88 . . . . 0.0 109.019 -179.966 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.629 ' HG2' ' HE2' ' A' ' 75' ' ' MET . 46.5 Cg_endo -68.5 116.78 4.57 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.79 2.327 . . . . 0.0 111.947 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.27 148.51 98.46 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.327 -0.858 . . . . 0.0 109.302 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.556 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.9 Cg_endo -69.43 153.15 70.82 Favored 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 122.688 2.259 . . . . 0.0 111.777 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.53 HD11 ' CG2' ' A' ' 108' ' ' VAL . 29.3 pt -126.62 160.05 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.9 m -74.89 153.06 38.81 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.936 . . . . 0.0 109.348 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -62.4 -33.36 74.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 18.7 tttp -61.58 -35.65 78.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.868 . . . . 0.0 109.475 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 -63.28 -40.69 98.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.434 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.723 HG13 HD22 ' A' ' 70' ' ' LEU . 76.0 t -65.81 -36.62 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -0.94 . . . . 0.0 109.361 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -68.45 -31.16 70.27 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.301 -0.875 . . . . 0.0 109.515 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.57 -40.12 84.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 1.11 HD12 HD21 ' A' ' 70' ' ' LEU . 54.8 mt -55.41 -51.46 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 109.415 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' MET . . . . . 0.5 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 86.2 mtp -60.71 -35.76 77.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -0.912 . . . . 0.0 109.372 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.5 m-20 -58.72 -31.75 68.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.435 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -58.56 -43.34 89.3 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.867 HD11 ' HB2' ' A' ' 45' ' ' PRO . 97.7 mt -56.02 -42.65 76.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.664 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -66.17 -28.41 68.75 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.15 -0.969 . . . . 0.0 109.549 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -71.07 135.74 47.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.886 HG13 ' HG2' ' A' ' 62' ' ' ARG . 6.7 t -129.9 151.53 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.42 -25.09 48.38 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -119.03 152.41 36.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.259 -1.142 . . . . 0.0 109.486 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.19 74.24 49.73 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.243 -0.911 . . . . 0.0 109.414 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.69 -17.63 37.76 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.69 2.26 . . . . 0.0 111.9 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.472 179.958 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.4 mtp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.3 m -58.56 -33.01 69.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.456 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 96.8 mt-10 46.44 25.77 0.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 3' ' ' GLU . . . 62.06 139.96 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.25 140.46 40.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.659 2.24 . . . . 0.0 111.803 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -90.65 131.41 36.37 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.89 . . . . 0.0 109.377 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 36.3 mttm -92.95 140.17 29.76 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.193 -0.942 . . . . 0.0 109.497 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 79.1 mtt85 -125.95 154.17 43.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.259 -0.9 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.427 ' CZ3' ' HG3' ' A' ' 43' ' ' MET . 90.1 m95 -91.0 130.11 36.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.211 -0.931 . . . . 0.0 109.502 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.476 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 93.3 m-85 -123.63 154.33 39.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 53.2 t -90.98 148.24 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.506 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -126.5 122.07 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.219 -0.926 . . . . 0.0 109.404 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.628 ' HB2' HD11 ' A' ' 93' ' ' ILE . 48.6 tt0 -84.9 133.71 34.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.211 -0.931 . . . . 0.0 109.432 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.741 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.39 161.88 36.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.488 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.4 m-85 -70.38 145.64 50.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.887 . . . . 0.0 109.544 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.9 t -60.32 139.31 57.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.458 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.67 -30.28 6.66 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 22' ' ' VAL . 10.3 m-85 -103.69 8.52 37.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -1.129 . . . . 0.0 109.517 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HG3' HG23 ' A' ' 69' ' ' VAL . 67.0 tt0 -53.08 -29.72 32.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.62 -55.44 2.04 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -55.91 -34.53 65.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.239 -1.153 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.741 HG21 ' HB1' ' A' ' 14' ' ' ALA . 54.9 t -58.82 -38.18 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.326 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.92 -34.32 77.86 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.483 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 42.5 m -63.38 -32.94 74.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.928 . . . . 0.0 109.426 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.405 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 28.6 m -65.17 -32.57 74.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.472 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.494 HD23 HG21 ' A' ' 86' ' ' VAL . 59.3 mt -60.77 -44.93 96.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.484 ' O ' ' HB2' ' A' ' 31' ' ' LYS . 74.2 ttt180 -58.03 -41.46 83.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 109.654 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -69.01 -60.37 2.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.243 -0.911 . . . . 0.0 109.596 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.644 ' CD2' HG22 ' A' ' 86' ' ' VAL . 91.0 m-70 -54.77 -47.09 74.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.219 -0.925 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.822 HG23 ' HB2' ' A' ' 35' ' ' MET . 87.4 mt -66.21 -44.67 91.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -0.876 . . . . 0.0 109.634 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 27' ' ' ARG . 15.3 ttpp -59.27 -41.47 88.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.457 HD23 ' HA ' ' A' ' 32' ' ' LEU . 45.8 mt -70.63 -52.67 19.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.324 -0.86 . . . . 0.0 109.41 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.469 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 48.5 m80 -74.79 -6.97 51.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.9 . . . . 0.0 109.391 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.499 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.0 m-20 61.42 46.15 7.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.997 ' HG3' HD13 ' A' ' 82' ' ' LEU . 45.3 mmm -91.87 -2.32 56.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.605 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.443 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.2 mt-10 -44.28 -38.81 4.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -52.13 -43.11 63.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.347 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.645 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.1 mt -73.01 -43.98 61.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.37 -0.831 . . . . 0.0 109.336 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.705 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.2 m-85 -73.19 137.32 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.282 -0.886 . . . . 0.0 109.427 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.78 -66.69 0.52 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.415 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 82.6 tt0 -136.68 152.04 49.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.567 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.045 HG13 HG22 ' A' ' 71' ' ' VAL . 48.1 t -117.51 147.61 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.29 -0.881 . . . . 0.0 109.359 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.478 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 90.6 mtp -120.64 141.5 50.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.141 -0.974 . . . . 0.0 109.527 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -149.83 92.09 4.2 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.241 -0.912 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.594 ' HG3' ' CE2' ' A' ' 65' ' ' PHE . 51.0 Cg_endo -70.25 -5.58 16.84 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.624 2.216 . . . . 0.0 111.792 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.477 ' HB ' ' NH1' ' A' ' 62' ' ' ARG . 3.7 p -82.12 156.72 24.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 47.72 64.46 1.61 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.54 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -59.48 -34.63 72.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 0.0 109.452 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.482 HG12 ' H ' ' A' ' 51' ' ' GLU . 36.7 t -119.26 131.22 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.269 -0.894 . . . . 0.0 109.455 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 71.1 t -72.66 -28.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.218 -0.926 . . . . 0.0 109.349 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.619 ' O ' HD13 ' A' ' 52' ' ' ILE . 5.5 tt0 -65.31 -46.97 78.2 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.619 HD13 ' O ' ' A' ' 51' ' ' GLU . 30.8 mm -121.46 96.96 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.277 -0.889 . . . . 0.0 109.436 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 74.4 mtp85 -46.54 -37.39 7.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.309 -0.87 . . . . 0.0 109.679 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 99.59 -169.68 22.56 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.84 51.01 4.4 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -56.46 -38.76 72.11 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -1.128 . . . . 0.0 109.646 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -63.73 146.63 53.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.917 . . . . 0.0 109.525 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 96.2 mtt-85 -58.41 -34.88 71.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.482 ' O ' ' HG3' ' A' ' 61' ' ' GLU . 97.5 mttt -57.35 -36.02 70.67 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.279 -0.888 . . . . 0.0 109.416 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.404 ' C ' ' O ' ' A' ' 59' ' ' LYS . 24.8 m 45.46 38.59 3.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.865 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.482 ' HG3' ' O ' ' A' ' 59' ' ' LYS . 94.9 mt-10 -102.48 157.54 16.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.211 -0.93 . . . . 0.0 109.403 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.477 ' NH1' ' HB ' ' A' ' 46' ' ' THR . 71.6 mtt85 -116.02 85.8 2.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -63.11 -27.44 69.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.298 -0.876 . . . . 0.0 109.454 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -66.99 -39.03 87.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.536 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.611 ' HE2' HG22 ' A' ' 111' ' ' ILE . 81.4 m-85 -134.47 74.11 66.86 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.545 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -71.03 72.42 2.07 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.643 2.229 . . . . 0.0 111.902 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.36 26.19 59.92 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.606 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -109.68 126.27 53.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -1.154 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.546 HG23 ' HG3' ' A' ' 19' ' ' GLU . 86.3 t -134.15 142.72 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.388 -0.82 . . . . 0.0 109.505 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.85 HD21 HD12 ' A' ' 111' ' ' ILE . 3.8 mp -103.91 132.53 50.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.471 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.045 HG22 HG13 ' A' ' 42' ' ' VAL . 88.0 t -143.77 122.06 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.263 -0.898 . . . . 0.0 109.557 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.419 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 43.1 tt0 -78.36 130.33 36.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.224 -0.923 . . . . 0.0 109.187 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.57 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 41.1 ttp -162.67 154.67 18.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.514 ' N ' ' HG2' ' A' ' 73' ' ' MET . 59.2 t -69.81 151.19 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -0.948 . . . . 0.0 109.224 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.863 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -94.33 112.97 24.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 109.496 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.619 ' ND2' HD22 ' A' ' 38' ' ' LEU . 42.0 p-10 -148.51 169.17 20.86 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -72.38 -31.22 65.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.492 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -63.48 -61.45 2.33 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.513 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.467 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 17.4 p -53.36 -48.07 68.87 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.275 -0.891 . . . . 0.0 109.753 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.528 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 39.1 t90 -44.03 -49.32 8.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.888 . . . . 0.0 109.581 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 39.0 m80 -67.87 -39.38 83.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.206 -0.934 . . . . 0.0 109.471 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.997 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.4 OUTLIER -56.92 -45.2 82.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.726 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.579 HG21 ' HZ ' ' A' ' 92' ' ' PHE . 78.0 t -62.48 -48.43 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.525 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 23.7 mtp85 -62.45 -37.24 85.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.57 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -66.63 -26.75 67.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -0.948 . . . . 0.0 109.491 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.847 HG23 ' O ' ' A' ' 82' ' ' LEU . 56.5 t -65.4 129.66 94.46 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.537 ' HD2' ' NE2' ' A' ' 29' ' ' HIS . 49.7 Cg_endo -70.17 161.03 47.48 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.703 2.269 . . . . 0.0 111.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.488 ' HA ' ' CD2' ' A' ' 15' ' ' PHE . 93.0 mtt-85 61.51 35.76 17.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 86' ' ' VAL . 91.5 t -129.39 115.51 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.288 -0.882 . . . . 0.0 109.566 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.511 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 84.3 mtp -69.97 -43.43 71.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.177 -0.952 . . . . 0.0 109.471 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.57 -146.99 14.03 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.579 ' HZ ' HG21 ' A' ' 83' ' ' VAL . 51.6 m-85 -107.45 163.08 13.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.292 -1.122 . . . . 0.0 109.574 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.628 HD11 ' HB2' ' A' ' 13' ' ' GLN . 31.9 mm -119.4 124.22 72.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 109.337 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . . . 147.87 -141.12 8.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' GLY . . . -43.43 -89.36 0.01 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 18.9 p -123.7 -179.33 4.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.297 -1.12 . . . . 0.0 109.652 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 m -90.9 22.03 3.84 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.338 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.528 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 91.4 m-20 -118.49 -23.52 7.13 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -155.98 96.86 2.3 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.863 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 42.2 Cg_endo -65.13 119.99 7.13 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.865 2.376 . . . . 0.0 112.135 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.97 141.85 97.75 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.436 -0.79 . . . . 0.0 109.482 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.33 154.49 61.16 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.706 2.271 . . . . 0.0 111.854 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.873 HD11 HG22 ' A' ' 108' ' ' VAL . 34.0 pt -124.57 158.16 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.874 . . . . 0.0 109.378 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.453 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 42.2 m -69.51 148.18 49.83 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.916 . . . . 0.0 109.439 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.41 -37.74 78.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.399 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -61.3 -38.77 87.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.453 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 98.5 mt-10 -59.88 -42.21 93.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.873 HG22 HD11 ' A' ' 103' ' ' ILE . 78.3 t -61.61 -36.99 76.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.377 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -69.7 -33.24 72.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.413 ' HA ' ' OD1' ' A' ' 113' ' ' ASN . . . -65.69 -39.67 91.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.44 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.85 HD12 HD21 ' A' ' 70' ' ' LEU . 56.2 mt -56.84 -52.25 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.525 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' MET . . . . . 0.436 ' HE3' ' CE ' ' A' ' 43' ' ' MET . 53.7 ttm -61.45 -38.18 86.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.413 ' OD1' ' HA ' ' A' ' 110' ' ' ALA . 23.4 m120 -53.31 -37.72 62.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.42 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -51.33 -49.99 60.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.544 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 12.1 tp -47.78 -44.33 28.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.319 -0.863 . . . . 0.0 109.393 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -63.24 -26.99 69.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.384 -0.822 . . . . 0.0 109.525 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -77.44 128.34 34.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' A' ' 120' ' ' ASP . 37.0 t -118.69 133.1 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -0.92 . . . . 0.0 109.437 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -46.67 95.35 0.01 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 118' ' ' VAL . 51.6 p30 -89.2 9.46 25.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -1.164 . . . . 0.0 109.441 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -64.69 136.82 96.93 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.28 -19.69 38.06 Favored 'Trans proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.706 2.271 . . . . 0.0 111.917 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 54.9 mtt-85 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.482 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.9 mtp . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.299 0.571 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.5 t -121.29 138.67 54.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.19 -35.47 67.3 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 109.427 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.17 89.7 51.56 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.907 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.3 146.89 58.13 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.692 2.261 . . . . 0.0 111.774 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -79.81 136.7 36.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.169 -0.957 . . . . 0.0 109.5 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.403 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 46.0 mttp -103.76 146.89 27.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.502 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 63.4 mtt180 -116.99 153.08 33.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.454 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.55 ' CG ' HG21 ' A' ' 108' ' ' VAL . 82.5 m95 -99.69 131.97 45.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.48 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 62.5 m-85 -122.36 141.83 51.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.463 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.447 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.3 t -86.65 145.66 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.711 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -125.8 125.19 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 109.284 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.604 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.0 tp60 -87.58 131.96 34.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.609 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.517 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -139.33 164.82 28.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.324 -0.86 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -68.61 140.34 55.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 109.448 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.8 m -66.57 149.42 50.49 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.307 -0.87 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.63 -33.28 4.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.702 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.7 m-85 -109.45 8.46 25.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.18 -1.188 . . . . 0.0 109.506 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.47 ' OE2' HG22 ' A' ' 69' ' ' VAL . 84.4 tt0 -56.76 -39.34 73.84 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.62 -52.29 44.21 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 56.7 ttt-85 -62.62 -38.74 91.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -1.149 . . . . 0.0 109.491 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.702 HG23 ' O ' ' A' ' 18' ' ' PHE . 79.7 t -56.01 -39.88 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.424 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.08 -37.88 89.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.267 -0.896 . . . . 0.0 109.413 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.5 m -65.16 -38.94 92.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.223 -0.923 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.565 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 97.1 p -60.02 -38.42 82.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.462 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.403 ' CD2' HG21 ' A' ' 86' ' ' VAL . 44.4 mt -56.66 -49.45 75.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -0.871 . . . . 0.0 109.469 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttp85 -65.79 -37.06 85.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.515 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 80.1 tt0 -66.27 -44.76 82.68 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.26 -0.9 . . . . 0.0 109.499 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 1.067 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.9 m-70 -71.82 -51.5 22.2 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.457 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.779 HG22 ' HG3' ' A' ' 36' ' ' GLU . 83.4 mt -56.91 -45.3 83.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.917 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 39.8 tttt -56.59 -48.46 77.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -0.904 . . . . 0.0 109.465 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 48.6 mt -64.84 -51.24 63.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.934 . . . . 0.0 109.45 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB3' ' SD ' ' A' ' 35' ' ' MET . 70.2 m80 -74.86 -2.08 25.2 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.241 -0.912 . . . . 0.0 109.575 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.466 ' N ' ' O ' ' A' ' 30' ' ' ILE . 55.2 t30 55.0 45.44 26.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -0.927 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.73 ' HG3' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.66 5.17 47.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.521 179.982 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.779 ' HG3' HG22 ' A' ' 30' ' ' ILE . 97.9 mt-10 -61.02 -16.95 49.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 109.447 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -62.26 -40.57 96.64 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.292 -0.88 . . . . 0.0 109.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.896 ' HB2' HG12 ' A' ' 74' ' ' VAL . 0.3 OUTLIER -86.37 -31.39 21.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.353 179.887 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.524 ' CD1' ' HB2' ' A' ' 73' ' ' MET . 42.6 m-85 -76.44 132.08 39.44 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -96.67 -78.12 1.39 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.8 tp10 -139.44 136.53 34.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 71' ' ' VAL . 10.0 p -97.79 143.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.265 -0.897 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.627 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.3 mtt -108.53 141.21 40.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.54 ' O ' HG12 ' A' ' 44' ' ' VAL . 47.8 t -137.35 83.83 25.37 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.39 57.27 1.75 Allowed 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 122.684 2.256 . . . . 0.0 111.779 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.2 p -132.97 162.45 31.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -90.98 138.75 31.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.18 -0.95 . . . . 0.0 109.494 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -65.11 -33.7 76.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.6 p -134.57 147.15 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 0.0 109.406 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 23.6 m -122.81 156.26 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.494 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.48 ' OE2' ' NE ' ' A' ' 53' ' ' ARG . 86.0 tt0 -106.68 130.81 54.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 0.0 109.48 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 80.4 mt -66.96 -38.01 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.477 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.48 ' NE ' ' OE2' ' A' ' 51' ' ' GLU . 71.9 mtm-85 -60.2 152.15 25.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -0.869 . . . . 0.0 109.474 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 102.74 -6.97 52.68 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 171.92 177.09 41.27 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.447 ' O ' ' O ' ' A' ' 59' ' ' LYS . 94.5 mm-40 -122.88 153.07 40.13 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.31 -1.112 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.7 mtp85 -60.8 -30.15 69.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.436 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.4 tpt85 -62.75 -38.15 89.4 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.447 ' O ' ' O ' ' A' ' 56' ' ' GLN . 40.4 tttt -127.9 131.52 49.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.5 t -106.54 137.23 44.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.224 -0.923 . . . . 0.0 109.523 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 85.9 mt-10 -122.15 47.2 1.95 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.393 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -120.49 142.14 49.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -0.851 . . . . 0.0 109.507 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -97.73 9.9 41.43 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.328 -0.857 . . . . 0.0 109.637 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.731 ' CE1' HD12 ' A' ' 115' ' ' LEU . 61.6 m-85 -66.65 155.7 37.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.423 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.505 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 9.7 p90 -117.49 81.52 14.29 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.83 155.85 64.66 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.682 2.255 . . . . 0.0 111.764 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.45 1.58 47.14 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.432 ' CZ ' ' OE1' ' A' ' 13' ' ' GLN . 7.2 m-85 -121.74 122.68 40.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.282 -1.128 . . . . 0.0 109.388 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 43' ' ' MET . 58.0 t -130.31 142.65 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.913 . . . . 0.0 109.514 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 1.035 HD21 HD12 ' A' ' 111' ' ' ILE . 3.6 mp -102.77 129.13 49.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.872 . . . . 0.0 109.428 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 42' ' ' VAL . 56.7 t -137.43 127.35 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.403 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 41.6 tt0 -84.22 138.75 32.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.284 -0.885 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.865 ' CG ' HD12 ' A' ' 38' ' ' LEU . 6.1 tmm? -177.89 149.09 0.56 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.896 HG12 ' HB2' ' A' ' 38' ' ' LEU . 7.4 p -75.03 122.87 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.186 -0.946 . . . . 0.0 109.458 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.641 ' HE3' ' HA ' ' A' ' 75' ' ' MET . 0.8 OUTLIER -52.82 112.97 0.94 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.682 -179.824 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 48.1 p-10 -146.2 161.79 39.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.371 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -72.37 -27.48 62.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.185 -0.947 . . . . 0.0 109.466 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.542 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -62.52 -62.94 1.4 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.456 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 24.3 p -53.7 -51.43 63.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.263 -0.898 . . . . 0.0 109.56 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 30.7 t90 -44.31 -55.84 4.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.551 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -59.7 -40.79 89.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.521 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 1.067 HD11 ' HB3' ' A' ' 29' ' ' HIS . 65.1 tp -60.3 -36.45 77.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.262 -0.899 . . . . 0.0 109.657 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.947 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 74.1 t -61.6 -44.69 99.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.525 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 48.5 tpt85 -57.92 -40.81 81.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.4 p -64.45 -27.53 69.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.752 ' HB ' HG21 ' A' ' 89' ' ' VAL . 79.1 t -61.84 123.18 76.29 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.447 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.4 150.42 64.28 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.602 2.202 . . . . 0.0 111.769 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.447 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 31.8 mtt-85 62.05 51.11 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.184 -0.947 . . . . 0.0 109.434 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.752 HG21 ' HB ' ' A' ' 86' ' ' VAL . 66.9 t -126.3 116.84 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.488 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.517 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.9 mmm -65.57 -45.66 82.45 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.42 -148.32 18.67 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.947 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 3.6 m-85 -117.84 164.49 14.95 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.238 -1.154 . . . . 0.0 109.54 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.604 HD11 ' HB2' ' A' ' 13' ' ' GLN . 9.2 mm -121.76 120.89 62.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.355 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 177.88 -144.13 6.4 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.27 -43.84 37.16 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 p -129.39 174.34 9.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.264 -1.139 . . . . 0.0 109.549 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 72.3 m -89.86 17.89 6.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -0.964 . . . . 0.0 109.369 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.7 m-20 -127.84 -30.73 2.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.518 -0.739 . . . . 0.0 109.273 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -134.57 91.51 21.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.309 -0.869 . . . . 0.0 108.916 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.6 Cg_endo -67.86 116.66 4.41 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.634 2.223 . . . . 0.0 112.001 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.42 146.5 79.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.502 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 50.0 Cg_endo -70.14 154.58 66.1 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.7 2.267 . . . . 0.0 111.759 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.682 HD11 HG22 ' A' ' 108' ' ' VAL . 28.7 pt -118.02 158.36 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.46 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 44.2 m -70.66 152.27 44.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.33 -0.856 . . . . 0.0 109.417 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -57.22 -38.67 74.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.212 -0.93 . . . . 0.0 109.359 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.62 -38.29 80.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.389 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 75.2 mm-40 -56.92 -45.77 82.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.315 -0.866 . . . . 0.0 109.408 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.72 HG13 ' CD2' ' A' ' 70' ' ' LEU . 96.4 t -60.07 -40.83 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.364 -0.835 . . . . 0.0 109.368 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -65.81 -36.76 84.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.399 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.88 -53.49 57.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 109.463 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 1.035 HD12 HD21 ' A' ' 70' ' ' LEU . 49.1 mt -48.03 -54.05 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.183 -0.948 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.2 mtp -60.7 -37.59 82.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.27 -0.894 . . . . 0.0 109.348 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -56.83 -41.93 78.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 109.401 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.405 ' O ' ' C ' ' A' ' 115' ' ' LEU . 51.9 mtt180 -53.34 -52.94 57.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.731 HD12 ' CE1' ' A' ' 64' ' ' PHE . 12.6 tp -45.44 -45.25 12.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.449 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLN . . . . . 0.794 ' O ' HG23 ' A' ' 118' ' ' VAL . 50.4 tt0 -60.82 -36.0 77.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.239 -0.913 . . . . 0.0 109.443 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.427 ' C ' HG23 ' A' ' 118' ' ' VAL . 64.4 tt0 -60.46 -34.6 74.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.469 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 116' ' ' GLN . 1.9 t 58.21 16.93 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.385 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.49 -106.05 0.69 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 121' ' ' LYS . 61.9 t0 -144.23 152.72 41.23 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.296 -1.12 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.51 ' N ' ' OD1' ' A' ' 120' ' ' ASP . 7.0 ttmt -121.39 68.48 20.33 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.52 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.77 146.07 59.01 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.688 2.259 . . . . 0.0 111.782 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 47.4 ttt85 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.5 -179.919 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.3 mtt . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.3 m -57.05 -35.57 69.47 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -59.29 140.72 55.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.486 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB1' ' HD2' ' A' ' 5' ' ' PRO . . . -74.92 161.34 77.99 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.517 ' HD2' ' HB1' ' A' ' 4' ' ' ALA . 48.8 Cg_endo -70.12 147.34 60.32 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.732 2.288 . . . . 0.0 111.738 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 70.7 tttt -122.28 138.06 54.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.446 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 23.4 mmtp -90.61 135.11 33.92 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.154 -0.966 . . . . 0.0 109.449 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.531 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 93.6 mtt180 -125.38 152.94 44.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.375 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.48 ' CB ' HG21 ' A' ' 108' ' ' VAL . 85.6 m95 -96.4 129.38 43.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.495 ' CE1' ' HA ' ' A' ' 102' ' ' PRO . 64.0 m-85 -129.07 154.19 46.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.264 -0.898 . . . . 0.0 109.408 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 22.3 t -99.54 143.59 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.326 -0.858 . . . . 0.0 109.57 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -117.62 125.87 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.379 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.697 ' HB2' HD11 ' A' ' 93' ' ' ILE . 52.3 tt0 -88.79 135.35 33.57 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.158 -0.964 . . . . 0.0 109.521 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.654 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -140.04 -165.24 1.86 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -104.55 139.8 38.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.186 -0.946 . . . . 0.0 109.468 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.2 m -56.61 150.87 14.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.03 -34.48 4.25 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.889 ' O ' HG23 ' A' ' 22' ' ' VAL . 77.5 m-85 -118.98 10.18 12.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.309 -1.113 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.458 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.8 tt0 -58.02 -29.31 65.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.213 -0.929 . . . . 0.0 109.534 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -77.62 -53.05 5.2 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -59.63 -39.43 84.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -1.181 . . . . 0.0 109.46 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.889 HG23 ' O ' ' A' ' 18' ' ' PHE . 99.0 t -50.5 -43.84 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.373 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.32 -41.52 85.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.469 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.9 m -64.62 -36.36 83.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 37.5 m -64.65 -37.78 88.74 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.954 . . . . 0.0 109.525 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.707 ' CD2' HG21 ' A' ' 86' ' ' VAL . 51.2 mt -53.77 -59.71 4.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -0.928 . . . . 0.0 109.579 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' LEU . 71.9 ttt180 -42.98 -51.11 5.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.852 . . . . 0.0 109.788 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.437 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 94.9 mt-10 -54.1 -41.79 68.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.138 -0.976 . . . . 0.0 109.503 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.82 ' HB3' HD21 ' A' ' 82' ' ' LEU . 47.1 m80 -66.96 -31.1 71.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.419 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 1.025 HD12 ' CD2' ' A' ' 39' ' ' PHE . 13.1 mm -67.32 -52.65 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.537 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.8 mttt -64.21 -43.38 95.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.262 -0.899 . . . . 0.0 109.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.453 HD23 ' HA ' ' A' ' 32' ' ' LEU . 27.3 mt -60.46 -51.16 70.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.527 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.561 ' CE1' ' CD1' ' A' ' 82' ' ' LEU . 73.5 m80 -87.27 10.25 17.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.264 -0.898 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 18.1 m120 49.37 49.45 19.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.189 -0.944 . . . . 0.0 109.434 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.792 ' CG ' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -106.48 21.21 17.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.425 -179.926 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.49 ' N ' HG22 ' A' ' 30' ' ' ILE . 70.7 mm-40 -66.22 -12.53 56.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.199 -0.938 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.38 -52.67 24.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.288 -0.882 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.792 HD21 ' CG ' ' A' ' 35' ' ' MET . 0.6 OUTLIER -75.96 -37.77 58.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.33 -0.856 . . . . 0.0 109.781 -179.825 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 1.025 ' CD2' HD12 ' A' ' 30' ' ' ILE . 52.0 m-85 -76.68 139.91 40.7 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.177 -0.952 . . . . 0.0 109.253 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.22 0.62 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.508 ' HG3' ' N ' ' A' ' 42' ' ' VAL . 45.9 tp10 -131.49 152.74 50.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -1.13 . . . . 0.0 109.569 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.077 HG13 HG22 ' A' ' 71' ' ' VAL . 91.9 t -119.42 154.43 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.289 -0.882 . . . . 0.0 109.383 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.773 ' HE1' HG11 ' A' ' 108' ' ' VAL . 61.2 mtm -135.68 145.11 46.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.566 HG12 ' H ' ' A' ' 46' ' ' THR . 99.1 t -122.98 121.52 27.24 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.211 -0.931 . . . . 0.0 109.546 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -70.25 -14.68 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.679 2.252 . . . . 0.0 111.876 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.566 ' H ' HG12 ' A' ' 44' ' ' VAL . 7.6 p -91.52 158.19 16.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.213 -0.929 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.94 145.94 45.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.502 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -118.91 148.32 43.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.242 -0.911 . . . . 0.0 109.468 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.688 HG12 HG23 ' A' ' 50' ' ' VAL . 46.9 t -127.35 127.26 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.474 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.688 HG23 HG12 ' A' ' 49' ' ' VAL . 12.2 t 45.9 25.05 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.337 -0.852 . . . . 0.0 109.585 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 50' ' ' VAL . 82.8 tt0 57.19 104.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.687 ' O ' HG23 ' A' ' 52' ' ' ILE . 14.0 tt -132.37 103.86 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.38 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 92.5 mtt-85 -47.52 148.35 1.44 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.523 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -139.69 168.26 25.04 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.05 -7.78 64.77 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -57.19 -35.12 69.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.166 -1.197 . . . . 0.0 109.445 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -121.55 149.54 42.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.528 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.9 mtm-85 -57.07 -31.0 64.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.536 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 73.5 tttt -68.76 133.13 47.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.912 . . . . 0.0 109.44 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -111.15 137.69 48.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.255 -0.903 . . . . 0.0 109.462 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -65.85 -31.2 72.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.37 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 94.4 mtt180 -127.66 132.01 49.76 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -108.32 28.98 7.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.399 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -107.1 129.56 54.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -0.865 . . . . 0.0 109.506 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 56.7 62.71 6.0 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.526 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.52 94.66 0.6 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.657 2.238 . . . . 0.0 111.777 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 76.6 32.23 51.46 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.458 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -111.58 116.03 30.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -1.141 . . . . 0.0 109.536 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 70' ' ' LEU . 48.7 t -126.98 151.91 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.57 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.847 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.3 mp -108.05 129.02 55.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -0.93 . . . . 0.0 109.417 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.077 HG22 HG13 ' A' ' 42' ' ' VAL . 90.6 t -138.76 125.21 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.722 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.446 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 43.3 tt0 -78.12 120.14 22.52 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.248 -0.907 . . . . 0.0 109.08 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.682 ' CG ' HD12 ' A' ' 38' ' ' LEU . 8.0 tmm? -167.97 149.24 5.24 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -0.918 . . . . 0.0 109.569 -179.602 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 45.3 t -85.43 128.56 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.923 . . . . 0.0 109.163 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.519 ' SD ' ' CG ' ' A' ' 100' ' ' PRO . 11.7 mmt -64.72 107.69 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.705 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.604 ' ND2' HD22 ' A' ' 38' ' ' LEU . 53.0 p-10 -128.77 -179.66 5.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -75.09 -23.2 57.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.852 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.647 ' HB1' ' HE3' ' A' ' 35' ' ' MET . . . -82.27 -67.11 0.81 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.201 -0.937 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.533 ' HB3' HD13 ' A' ' 38' ' ' LEU . 6.3 p -49.62 -49.78 45.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.41 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 48.4 t90 -51.66 -59.56 4.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.351 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -58.95 -37.91 77.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.296 -0.878 . . . . 0.0 109.459 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.82 HD21 ' HB3' ' A' ' 29' ' ' HIS . 39.6 tp -63.61 -37.62 88.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.933 . . . . 0.0 109.401 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.94 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 54.8 t -56.92 -50.13 76.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.468 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -55.01 -41.54 71.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.2 t -57.08 -33.15 66.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.885 . . . . 0.0 109.497 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.707 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.6 t -61.08 121.91 65.85 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.269 -0.895 . . . . 0.0 109.387 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.443 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -70.32 158.29 56.69 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.691 2.261 . . . . 0.0 111.777 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.569 ' HD3' ' CG ' ' A' ' 18' ' ' PHE . 8.9 mtt85 63.11 45.77 5.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.932 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.512 HG21 ' HB ' ' A' ' 86' ' ' VAL . 96.8 t -130.92 118.89 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.172 -0.955 . . . . 0.0 109.549 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.45 ' SD ' ' HG2' ' A' ' 13' ' ' GLN . 85.9 mtp -68.83 -44.57 73.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -0.937 . . . . 0.0 109.404 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.71 -151.8 22.35 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.94 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.3 m-85 -111.8 164.25 13.27 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -1.203 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.697 HD11 ' HB2' ' A' ' 13' ' ' GLN . 20.9 mm -118.46 120.3 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.647 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.64 -149.76 9.17 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.46 -38.8 91.16 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.688 HG23 ' H ' ' A' ' 98' ' ' ASP . 10.3 t -140.53 176.57 8.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -1.186 . . . . 0.0 109.47 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.8 p -92.62 17.99 9.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 109.414 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.688 ' H ' HG23 ' A' ' 96' ' ' THR . 84.6 m-20 -121.72 -14.35 8.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.515 -0.741 . . . . 0.0 109.264 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.481 ' H ' HG23 ' A' ' 96' ' ' THR . 0.0 OUTLIER -161.42 99.24 1.25 Allowed Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.349 -0.844 . . . . 0.0 109.008 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.519 ' CG ' ' SD ' ' A' ' 75' ' ' MET . 46.4 Cg_endo -68.09 120.51 7.49 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.706 2.27 . . . . 0.0 112.015 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -63.27 138.31 97.31 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.88 . . . . 0.0 109.39 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.531 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.51 153.74 65.28 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.649 2.233 . . . . 0.0 111.765 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.774 HD11 HG22 ' A' ' 108' ' ' VAL . 35.1 pt -124.32 156.23 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 32.3 m -71.97 151.11 43.49 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.311 -0.868 . . . . 0.0 109.423 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -54.76 -40.99 69.94 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.358 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -59.31 -38.64 80.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.456 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -58.86 -44.36 91.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.276 -0.89 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.774 HG22 HD11 ' A' ' 103' ' ' ILE . 58.1 t -57.93 -39.33 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -66.42 -40.95 89.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.261 -0.899 . . . . 0.0 109.416 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -63.43 -44.63 94.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.427 HG13 ' O ' ' A' ' 107' ' ' GLU . 68.8 mt -52.48 -51.39 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.332 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.6 mtp -58.85 -38.3 78.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -56.88 -35.58 69.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.5 ' O ' ' N ' ' A' ' 117' ' ' GLN . 99.4 mtt180 -53.92 -44.68 70.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.229 -0.919 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.402 ' C ' ' O ' ' A' ' 114' ' ' ARG . 8.5 tp -44.05 -46.85 8.67 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.384 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -60.29 -26.64 66.67 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.228 -0.92 . . . . 0.0 109.503 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 114' ' ' ARG . 52.6 tt0 -83.27 126.31 32.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.5 t -65.42 -32.0 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.315 -0.865 . . . . 0.0 109.506 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 89.9 -3.49 82.9 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -55.76 -39.79 71.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -1.18 . . . . 0.0 109.502 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.51 142.49 70.87 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.264 -0.898 . . . . 0.0 109.554 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.01 145.6 56.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.745 2.297 . . . . 0.0 111.753 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.445 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.0 mtp . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.4 t -56.99 -37.94 72.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.638 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -54.65 -36.81 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.228 -0.92 . . . . 0.0 109.525 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -121.59 107.52 36.33 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.314 -0.867 . . . . 0.0 109.515 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.83 139.19 39.37 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.682 2.255 . . . . 0.0 111.777 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 29.5 mttt -122.87 155.26 37.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -0.892 . . . . 0.0 109.489 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 8.6 mmtp 64.45 53.81 1.59 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.404 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.418 ' HD3' ' HA ' ' A' ' 8' ' ' ARG . 17.1 mmt85 -110.48 153.13 25.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.334 -0.854 . . . . 0.0 109.455 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.511 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 56.5 m95 -103.81 129.24 51.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.928 . . . . 0.0 109.506 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.424 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 87.1 m-85 -124.18 163.83 20.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.407 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 24.5 t -98.7 147.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.6 t -124.83 123.64 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.329 -0.857 . . . . 0.0 109.331 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.821 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.1 tt0 -90.8 137.83 32.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.683 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -145.45 159.98 42.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -67.9 143.26 55.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.164 -0.96 . . . . 0.0 109.56 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 46.0 m -59.14 147.62 34.44 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.44 -33.54 4.31 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.756 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.1 m-85 -107.22 5.21 27.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -1.149 . . . . 0.0 109.562 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.467 ' OE2' ' HG3' ' A' ' 45' ' ' PRO . 85.1 tt0 -53.55 -36.23 61.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.361 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.36 -58.64 3.08 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 45.4 ttm105 -56.5 -42.43 78.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.415 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 18' ' ' PHE . 53.2 t -49.14 -47.57 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.351 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.81 -44.66 82.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.265 -0.897 . . . . 0.0 109.411 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -64.09 -45.52 88.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.389 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.467 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 50.8 m -52.03 -56.45 14.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 tp -48.15 -55.52 10.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.307 -0.871 . . . . 0.0 109.365 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.665 ' HA ' HD12 ' A' ' 30' ' ' ILE . 25.2 ttt85 -53.74 -30.65 45.16 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.946 . . . . 0.0 109.136 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.467 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.9 tt0 -63.1 -44.45 95.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.309 -0.87 . . . . 0.0 109.36 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.756 ' HB3' HD11 ' A' ' 82' ' ' LEU . 57.0 m80 -75.79 -33.92 60.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.919 HG23 ' HB2' ' A' ' 35' ' ' MET . 79.8 mt -54.93 -48.83 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.283 -0.885 . . . . 0.0 109.292 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -60.26 -43.15 96.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.531 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 32' ' ' LEU . 61.5 mt -64.2 -50.81 66.62 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.474 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 67.6 m80 -82.15 3.1 28.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.244 -0.91 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.409 ' N ' ' O ' ' A' ' 30' ' ' ILE . 21.4 m120 59.4 50.62 7.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.338 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.93 ' HG3' HD22 ' A' ' 82' ' ' LEU . 68.5 mmm -99.58 3.92 45.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.29 -0.881 . . . . 0.0 109.706 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.471 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.2 mt-10 -54.89 -34.33 62.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.173 -0.954 . . . . 0.0 109.451 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -60.88 -42.47 98.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.894 . . . . 0.0 109.358 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.555 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.1 mt -70.88 -50.33 36.27 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.311 -0.868 . . . . 0.0 109.347 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 30' ' ' ILE . 98.9 m-85 -75.99 134.47 40.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.385 -0.822 . . . . 0.0 109.418 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.08 -68.77 0.59 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.433 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 83.3 tt0 -127.6 155.9 43.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -1.128 . . . . 0.0 109.533 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.975 HG13 HG22 ' A' ' 71' ' ' VAL . 51.9 t -121.11 150.39 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.388 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.767 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -120.98 161.86 20.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.898 HG12 ' H ' ' A' ' 46' ' ' THR . 75.5 t -157.59 131.03 4.67 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.304 -0.873 . . . . 0.0 109.378 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.574 ' HB3' ' CE2' ' A' ' 65' ' ' PHE . 50.1 Cg_endo -69.69 0.27 5.83 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 122.717 2.278 . . . . 0.0 112.019 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.898 ' H ' HG12 ' A' ' 44' ' ' VAL . 1.3 p -131.95 161.67 32.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.943 . . . . 0.0 109.424 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 54.7 mp0 -51.36 141.02 16.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.146 -0.971 . . . . 0.0 109.444 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -60.04 -34.78 73.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.439 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.72 142.9 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.31 -0.869 . . . . 0.0 109.384 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.4 t -119.74 137.49 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.205 -0.935 . . . . 0.0 109.533 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -116.37 130.26 56.68 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 81.5 mt -64.4 -36.28 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 24.6 mmt180 -56.05 -33.68 65.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.528 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -50.62 -32.4 24.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -164.79 105.58 0.25 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -57.6 -37.03 72.53 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.252 -1.146 . . . . 0.0 109.511 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 13.3 mtt-85 -68.13 148.72 50.53 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.266 -0.896 . . . . 0.0 109.476 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -101.39 140.36 35.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.341 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 20.6 mmtp -113.72 150.5 33.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.463 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.452 ' O ' ' O ' ' A' ' 61' ' ' GLU . 21.1 t -55.09 -28.45 52.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.452 ' O ' ' O ' ' A' ' 60' ' ' SER . 46.9 mt-10 61.13 125.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.89 . . . . 0.0 109.51 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 68.1 mtm180 -128.75 145.82 51.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.458 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.476 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 28.3 mttp -124.49 125.43 44.22 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.973 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.537 ' HB2' ' CE1' ' A' ' 65' ' ' PHE . 97.1 m-85 -57.53 -45.11 85.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.477 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.621 ' N ' ' CD1' ' A' ' 65' ' ' PHE . 0.3 OUTLIER -136.16 79.58 43.31 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.317 -0.865 . . . . 0.0 109.512 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.476 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 50.4 Cg_endo -70.03 143.58 49.99 Favored 'Trans proline' 0 C--O 1.217 -0.574 0 C-N-CA 122.669 2.246 . . . . 0.0 111.855 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 81.03 10.09 85.39 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.563 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -121.28 119.04 31.08 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -1.158 . . . . 0.0 109.511 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.767 HG13 ' O ' ' A' ' 43' ' ' MET . 95.1 t -132.03 142.35 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.226 -0.921 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.842 ' N ' HD22 ' A' ' 70' ' ' LEU . 2.4 mm? -106.37 129.55 54.35 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.975 HG22 HG13 ' A' ' 42' ' ' VAL . 84.4 t -139.69 128.88 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.541 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.415 ' OE1' ' HA ' ' A' ' 7' ' ' LYS . 6.6 tt0 -76.94 137.7 39.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.256 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.713 ' HE2' ' HB3' ' A' ' 79' ' ' SER . 7.5 tmm? 177.83 151.19 0.23 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.454 ' O ' ' SD ' ' A' ' 73' ' ' MET . 40.4 t -85.22 124.03 39.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.915 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.684 ' HE3' ' HG3' ' A' ' 100' ' ' PRO . 10.4 mmt -66.43 120.48 13.43 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.298 -0.876 . . . . 0.0 109.439 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.495 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.7 p-10 -150.3 179.16 8.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.261 -0.9 . . . . 0.0 109.47 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.576 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 93.5 m-20 -65.58 -35.19 80.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.348 -0.845 . . . . 0.0 109.548 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.412 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -74.02 -72.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.193 -0.942 . . . . 0.0 109.653 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.713 ' HB3' ' HE2' ' A' ' 73' ' ' MET . 3.7 m -45.2 -52.81 8.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.608 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.452 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 80.2 t90 -55.53 -53.07 60.93 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.242 -0.911 . . . . 0.0 109.571 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.576 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 24.8 m-70 -62.81 -34.84 78.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.256 -0.903 . . . . 0.0 109.524 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.93 HD22 ' HG3' ' A' ' 35' ' ' MET . 52.5 tp -58.05 -42.34 85.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.716 ' CG1' HG11 ' A' ' 89' ' ' VAL . 79.5 t -57.88 -45.53 87.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.214 -0.929 . . . . 0.0 109.537 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -67.36 -29.84 69.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.203 -0.936 . . . . 0.0 109.461 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 67.5 m -59.59 -50.76 72.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.334 -0.854 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.626 HG13 HG21 ' A' ' 89' ' ' VAL . 7.4 p -78.78 128.67 76.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.677 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.569 ' O ' HG23 ' A' ' 89' ' ' VAL . 50.3 Cg_endo -70.13 -171.06 0.46 Allowed 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.752 2.301 . . . . 0.0 111.664 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.499 ' HB3' HG22 ' A' ' 22' ' ' VAL . 31.6 mtt-85 61.38 21.7 12.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.877 . . . . 0.0 109.48 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.716 HG11 ' CG1' ' A' ' 83' ' ' VAL . 43.6 t -119.78 107.93 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.447 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.479 ' CE ' ' OE1' ' A' ' 13' ' ' GLN . 74.6 mtp -60.22 -43.43 96.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.177 -0.952 . . . . 0.0 109.468 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.07 -149.41 21.21 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.711 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 45.4 m-85 -110.36 160.65 16.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.277 -1.131 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.821 HD11 ' HB2' ' A' ' 13' ' ' GLN . 22.1 mm -115.29 129.95 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.385 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 95' ' ' GLY . . . 140.53 -141.47 11.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 94' ' ' GLY . . . -44.0 -89.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -125.16 -178.25 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.247 -1.149 . . . . 0.0 109.435 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.2 p -90.38 21.57 3.81 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -0.918 . . . . 0.0 109.351 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -117.55 -22.94 7.88 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.417 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -154.82 94.68 2.68 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.684 ' HG3' ' HE3' ' A' ' 75' ' ' MET . 41.4 Cg_endo -63.85 118.4 5.34 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.922 2.414 . . . . 0.0 112.138 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.44 142.1 82.6 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.493 -0.754 . . . . 0.0 109.59 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.54 153.34 65.43 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.784 2.322 . . . . 0.0 111.814 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.558 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -126.13 156.78 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 49.8 m -70.46 143.55 51.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 109.586 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.46 -35.87 68.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.386 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 51.0 tttm -62.43 -40.36 96.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.191 -0.943 . . . . 0.0 109.448 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 87.4 tt0 -54.56 -44.76 73.19 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.558 ' CG2' HD11 ' A' ' 103' ' ' ILE . 68.8 t -57.91 -40.44 76.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.345 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -63.91 -37.24 86.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.454 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.11 -47.27 86.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.407 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.523 ' CG2' ' CE2' ' A' ' 65' ' ' PHE . 68.7 mt -51.9 -48.01 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.3 mmm -63.11 -33.34 75.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.357 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -60.44 -34.45 74.0 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.241 -0.912 . . . . 0.0 109.465 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -54.92 -39.85 69.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.538 HD11 ' HA ' ' A' ' 45' ' ' PRO . 87.0 mt -56.93 -40.75 76.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.203 -0.936 . . . . 0.0 109.465 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -65.4 -31.68 72.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.219 -0.926 . . . . 0.0 109.491 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -63.53 141.6 58.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.804 HG11 ' HB2' ' A' ' 121' ' ' LYS . 43.6 t -114.53 142.29 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.385 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.46 -36.48 38.47 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.502 ' H ' HG12 ' A' ' 118' ' ' VAL . 59.9 t0 -171.49 -38.92 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -1.169 . . . . 0.0 109.526 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.804 ' HB2' HG11 ' A' ' 118' ' ' VAL . 0.7 OUTLIER 53.35 63.5 8.15 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 109.517 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.29 147.52 59.67 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.618 2.212 . . . . 0.0 111.796 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.53 179.946 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.7 mtp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.8 t -57.76 -33.02 68.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.509 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -107.36 157.14 18.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -54.64 150.53 17.59 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.933 . . . . 0.0 109.381 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.74 141.89 46.55 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.719 2.279 . . . . 0.0 111.95 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 85.7 mttt -93.06 30.21 1.68 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -93.79 128.02 39.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.589 ' HB2' ' CE1' ' A' ' 10' ' ' TYR . 41.7 mtt-85 -126.38 161.53 27.65 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.159 -0.963 . . . . 0.0 109.509 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.514 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 69.2 m95 -91.35 124.79 35.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.606 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 95.8 m-85 -120.85 147.46 45.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 55.2 t -87.04 159.4 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.393 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.506 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.4 t -144.56 103.94 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.237 -0.915 . . . . 0.0 109.173 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.475 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 50.0 tt0 -42.18 -47.4 4.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.54 -0.725 . . . . 0.0 109.657 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.478 ' O ' ' HG2' ' A' ' 90' ' ' MET . . . 53.62 -168.28 0.06 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.283 -0.885 . . . . 0.0 109.471 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 57.5 t80 -103.17 142.08 34.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.878 . . . . 0.0 109.341 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.425 ' HA ' ' OE2' ' A' ' 19' ' ' GLU . 28.3 p -66.96 131.07 45.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.62 -28.04 9.84 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 17.9 m-30 -103.29 18.26 22.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.223 -1.163 . . . . 0.0 109.506 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.546 ' CG ' HG21 ' A' ' 46' ' ' THR . 33.3 mp0 -51.64 -40.94 60.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.191 -0.943 . . . . 0.0 109.251 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.03 -58.39 3.21 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.1 ttm-85 -55.05 -47.48 74.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.155 -1.203 . . . . 0.0 109.426 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.655 HG23 ' CB ' ' A' ' 18' ' ' PHE . 46.8 t -46.7 -45.9 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 109.31 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.77 -45.01 66.92 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.386 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 86.0 m -62.03 -42.99 99.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.336 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 1.2 t -50.07 -54.97 16.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.215 -0.928 . . . . 0.0 109.289 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.492 HD23 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -47.68 -56.33 7.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.267 -0.895 . . . . 0.0 109.235 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.471 ' HA ' ' HB ' ' A' ' 30' ' ' ILE . 70.0 ttt-85 -52.72 -34.1 50.98 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.894 . . . . 0.0 109.127 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.7 tt0 -61.38 -46.09 91.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.183 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.7 ' NE2' HG23 ' A' ' 86' ' ' VAL . 69.3 m-70 -83.45 -30.1 27.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.249 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.862 HG23 ' HB2' ' A' ' 35' ' ' MET . 86.5 mt -64.44 -45.09 96.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -60.18 -40.56 90.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.9 . . . . 0.0 109.271 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 32' ' ' LEU . 82.8 mt -69.61 -51.77 32.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.299 -0.876 . . . . 0.0 109.354 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.437 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 71.7 m80 -79.23 0.02 30.24 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.59 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 30' ' ' ILE . 83.9 m-20 59.57 49.03 8.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' MET . . . . . 1.04 ' HG3' HD13 ' A' ' 82' ' ' LEU . 65.7 mmm -95.38 1.37 54.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.327 -0.858 . . . . 0.0 109.554 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -48.8 -36.48 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.563 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -57.1 -45.2 83.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.783 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.5 mt -70.88 -53.72 14.09 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -0.883 . . . . 0.0 109.443 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.583 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 91.7 m-85 -68.76 138.5 54.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.863 . . . . 0.0 109.422 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.03 -70.39 0.22 Allowed Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -128.63 157.48 41.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -1.16 . . . . 0.0 109.649 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.856 HG13 HG22 ' A' ' 71' ' ' VAL . 57.6 t -121.56 156.98 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.624 ' O ' HG13 ' A' ' 69' ' ' VAL . 87.3 mmm -121.64 150.78 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.71 72.89 68.42 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.265 -0.897 . . . . 0.0 109.398 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.424 ' O ' HD13 ' A' ' 115' ' ' LEU . 50.7 Cg_endo -70.17 -0.64 7.56 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.799 2.333 . . . . 0.0 111.817 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.546 HG21 ' CG ' ' A' ' 19' ' ' GLU . 12.5 t -116.67 176.28 5.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.557 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.456 ' HG2' HG23 ' A' ' 46' ' ' THR . 63.2 mm-40 62.05 126.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 109.557 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -61.77 -37.21 83.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.418 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 51' ' ' GLU . 23.2 m -129.44 147.18 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.356 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.5 p -64.31 -26.74 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.211 -0.93 . . . . 0.0 109.619 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.588 ' O ' HG23 ' A' ' 49' ' ' VAL . 77.5 tt0 -80.63 139.79 36.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.933 . . . . 0.0 109.524 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 85.5 mt -59.2 -38.88 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.438 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.442 ' HD2' ' OE2' ' A' ' 51' ' ' GLU . 51.4 mtt180 -52.14 148.84 5.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.275 -0.89 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.5 35.84 18.73 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . -167.33 -161.99 18.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.43 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 93.3 mt-30 61.69 51.37 3.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.324 -1.103 . . . . 0.0 109.52 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 86.6 mtt180 -97.66 154.79 17.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.229 -0.919 . . . . 0.0 109.472 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -92.07 143.01 26.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.44 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.444 ' HG2' ' O ' ' A' ' 59' ' ' LYS . 20.6 ttpp 55.56 43.65 28.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.489 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 97.5 p -117.17 147.73 42.21 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -111.41 156.57 21.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.937 . . . . 0.0 109.455 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 94.8 mtt-85 -127.21 143.05 51.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.378 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -98.19 13.89 29.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.422 ' CG ' HD11 ' A' ' 115' ' ' LEU . 14.0 m-85 -111.86 163.02 14.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.266 -0.896 . . . . 0.0 109.427 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.479 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 5.3 p90 -105.85 89.24 3.43 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.607 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 48.5 Cg_endo -70.67 155.19 63.4 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.641 2.227 . . . . 0.0 111.601 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.517 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . 107.47 -4.06 34.86 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -123.48 122.2 37.62 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -1.157 . . . . 0.0 109.41 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 43' ' ' MET . 88.1 t -133.02 140.81 46.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 109.516 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.832 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.1 mp -105.66 134.99 47.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.38 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 42' ' ' VAL . 77.2 t -139.98 117.86 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.303 -0.873 . . . . 0.0 109.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.448 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.2 tt0 -67.61 135.49 52.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.42 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 44.6 ttp 173.57 154.69 0.11 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 97.1 t -84.21 140.78 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.606 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 19.3 mmm -84.8 125.71 32.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.536 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.592 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 47.8 p-10 -152.65 173.54 15.09 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -64.84 -29.4 70.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.247 -0.908 . . . . 0.0 109.542 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.592 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -74.87 -72.41 0.3 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.665 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.783 ' OG ' HD13 ' A' ' 38' ' ' LEU . 10.6 m -44.38 -56.82 3.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.257 -0.902 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.517 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 51.7 t90 -44.62 -54.04 6.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.278 -0.889 . . . . 0.0 109.385 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -61.1 -35.79 77.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.362 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 1.04 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -57.25 -37.24 72.03 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.27 -0.894 . . . . 0.0 109.413 179.892 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.947 ' CG1' HG11 ' A' ' 89' ' ' VAL . 44.1 t -73.04 -45.96 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -68.94 -31.31 70.1 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 95.1 p -64.8 -45.6 85.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.906 . . . . 0.0 109.362 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.7 HG23 ' NE2' ' A' ' 29' ' ' HIS . 11.1 p -82.35 133.49 50.23 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.395 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.624 ' O ' HG23 ' A' ' 89' ' ' VAL . 49.3 Cg_endo -69.12 -166.87 0.18 Allowed 'Trans proline' 0 C--O 1.214 -0.722 0 C-N-CA 122.697 2.265 . . . . 0.0 111.876 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.502 ' HB3' HG22 ' A' ' 22' ' ' VAL . 89.6 mtt-85 63.01 16.73 9.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.433 -0.792 . . . . 0.0 109.535 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.947 HG11 ' CG1' ' A' ' 83' ' ' VAL . 11.6 t -119.99 109.27 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.409 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 14' ' ' ALA . 90.9 mmm -65.3 -39.89 93.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 109.576 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.92 -169.59 35.23 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.569 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 15.3 m-85 -100.37 158.56 15.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.653 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 34.3 mm -117.7 115.69 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.298 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 179.8 -142.71 5.28 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.95 -37.55 50.14 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 p -132.39 169.89 15.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -1.156 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.0 p -88.84 14.93 9.22 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.251 -0.906 . . . . 0.0 109.336 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.517 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 88.5 m-20 -125.15 -22.49 4.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.566 -0.709 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.411 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -140.8 101.27 6.5 Favored Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.191 -0.943 . . . . 0.0 109.15 179.814 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.7 Cg_endo -69.02 109.69 2.23 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.744 2.296 . . . . 0.0 111.922 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.94 139.64 78.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 154.04 67.41 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.72 2.28 . . . . 0.0 111.842 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 108' ' ' VAL . 34.5 pt -123.83 158.13 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 m -70.21 147.74 49.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -55.01 -38.86 68.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -58.62 -40.34 83.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -51.77 -48.67 63.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.281 -0.887 . . . . 0.0 109.403 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.68 HG22 HD23 ' A' ' 70' ' ' LEU . 74.2 t -57.67 -44.09 84.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -60.9 -41.38 95.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.184 -0.948 . . . . 0.0 109.344 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.432 ' O ' ' HB2' ' A' ' 113' ' ' ASN . . . -58.45 -52.82 64.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.326 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.799 HD12 HD21 ' A' ' 70' ' ' LEU . 69.0 mt -49.79 -53.98 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.378 -0.826 . . . . 0.0 109.373 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 95.3 mmm -59.57 -38.78 82.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.254 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.432 ' HB2' ' O ' ' A' ' 110' ' ' ALA . 97.4 m-20 -53.02 -46.89 68.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.362 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.459 ' O ' ' N ' ' A' ' 117' ' ' GLN . 56.8 mtt180 -55.53 -54.22 46.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.201 -0.937 . . . . 0.0 109.398 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.424 HD13 ' O ' ' A' ' 45' ' ' PRO . 15.4 tp -45.74 -43.77 13.18 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.492 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -63.57 -21.36 66.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.459 ' N ' ' O ' ' A' ' 114' ' ' ARG . 50.4 tt0 -85.69 110.12 19.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.454 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 t -64.38 -19.27 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 86.76 10.31 72.97 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -63.1 156.27 25.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -1.173 . . . . 0.0 109.525 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.59 ' CB ' ' CD ' ' A' ' 122' ' ' PRO . 0.0 OUTLIER -160.26 -66.28 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 109.441 179.902 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 122' ' ' PRO . . . . . 0.59 ' CD ' ' CB ' ' A' ' 121' ' ' LYS . 52.1 Cg_endo -71.28 -14.03 31.11 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.615 2.21 . . . . 0.0 111.741 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.519 179.994 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.5 mtm . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.5 t -121.22 144.29 48.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.515 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -60.03 -33.87 72.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.42 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 53.08 68.49 2.94 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.503 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.41 ' O ' ' HB2' ' A' ' 6' ' ' LYS . 48.6 Cg_endo -69.76 -17.52 37.55 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 122.704 2.269 . . . . 0.0 111.71 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.457 ' O ' ' CG1' ' A' ' 74' ' ' VAL . 28.2 mttm 60.64 44.12 11.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.424 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 94.9 mttt -130.53 126.0 35.69 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 95.4 mtt-85 -139.51 150.27 44.93 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.396 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.443 ' O ' HG12 ' A' ' 103' ' ' ILE . 72.4 m95 -100.67 136.72 40.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.642 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -130.21 149.85 51.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.328 -0.857 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.436 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 12.8 t -98.93 139.16 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.188 -0.945 . . . . 0.0 109.524 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.53 HG22 ' CE1' ' A' ' 92' ' ' PHE . 46.3 t -119.18 130.0 74.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.872 . . . . 0.0 109.41 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.876 ' CG ' HD11 ' A' ' 93' ' ' ILE . 95.8 mt-30 -87.68 147.47 25.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.329 -0.857 . . . . 0.0 109.468 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.3 154.63 38.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.921 . . . . 0.0 109.462 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -66.38 146.47 54.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.286 -0.884 . . . . 0.0 109.457 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 42.0 m -58.08 135.97 57.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.73 -29.28 7.49 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -104.08 7.15 36.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.2 -1.176 . . . . 0.0 109.545 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.86 -37.33 71.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.432 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -79.7 -35.0 29.72 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 63.4 ttt-85 -63.18 -47.4 82.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.233 -1.157 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.474 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 45.6 t -50.71 -39.12 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.451 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.21 -39.55 94.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 67.9 m -67.43 -36.0 80.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.572 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.706 ' HB2' HG13 ' A' ' 86' ' ' VAL . 31.8 m -63.72 -41.38 98.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.157 -0.964 . . . . 0.0 109.484 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.925 ' CD2' HG21 ' A' ' 86' ' ' VAL . 61.9 mt -56.48 -43.78 79.98 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.539 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.509 ' CG ' ' HE3' ' A' ' 31' ' ' LYS . 41.4 ttm180 -57.19 -39.46 75.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -73.97 -59.82 2.54 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.514 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.432 ' CE1' ' HB3' ' A' ' 25' ' ' SER . 40.4 m80 -52.44 -45.81 66.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.564 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' A' ' 35' ' ' MET . 96.5 mt -64.1 -55.58 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.477 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.509 ' HE3' ' CG ' ' A' ' 27' ' ' ARG . 82.6 mttt -53.89 -37.13 63.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 32' ' ' LEU . 51.3 mt -73.06 -48.19 38.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.539 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.409 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 49.7 m80 -81.38 0.87 35.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.939 . . . . 0.0 109.615 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 30' ' ' ILE . 77.7 m-20 59.08 49.77 8.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' MET . . . . . 1.057 ' HG3' HD13 ' A' ' 82' ' ' LEU . 40.0 mmm -101.8 8.98 41.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.557 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.448 ' OE2' ' HG2' ' A' ' 31' ' ' LYS . 97.5 mt-10 -51.73 -37.02 49.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.461 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -60.35 -37.83 81.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.407 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.98 HD13 ' OG ' ' A' ' 79' ' ' SER . 5.8 mt -73.61 -55.06 6.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.252 -0.905 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.634 ' CE1' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -72.47 136.17 45.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 109.407 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.39 -66.49 0.5 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -137.94 152.76 49.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.203 -1.175 . . . . 0.0 109.562 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.055 HG13 HG22 ' A' ' 71' ' ' VAL . 42.8 t -116.81 155.3 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.466 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 87.9 mtp -120.65 138.7 53.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.887 . . . . 0.0 109.568 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.513 HG12 ' H ' ' A' ' 47' ' ' GLU . 66.3 t -145.99 90.24 5.86 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.02 -19.38 34.96 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.732 2.288 . . . . 0.0 111.919 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' GLU . 6.3 t -89.53 -4.28 57.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.65 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.513 ' H ' HG12 ' A' ' 44' ' ' VAL . 95.5 mt-10 51.25 177.36 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.443 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.57 -35.26 79.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.435 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 43.8 t -122.28 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.516 HG13 ' N ' ' A' ' 51' ' ' GLU . 5.4 p -63.15 -44.3 99.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.241 -0.912 . . . . 0.0 109.494 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.516 ' N ' HG13 ' A' ' 50' ' ' VAL . 83.1 tt0 -139.79 137.33 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 81.5 mt -61.69 -41.78 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.566 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -56.87 -32.75 66.17 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.472 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.82 -137.0 15.11 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 24.52 36.08 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 77.4 mt-30 -59.7 -28.78 67.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -1.158 . . . . 0.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -59.2 -30.38 68.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.386 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.491 ' O ' ' CB ' ' A' ' 59' ' ' LYS . 83.0 mtm180 -118.2 160.74 21.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.193 -0.942 . . . . 0.0 109.422 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.491 ' CB ' ' O ' ' A' ' 58' ' ' ARG . 11.4 ttmm 73.77 66.87 0.1 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.249 -0.907 . . . . 0.0 109.434 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 37.4 m -58.37 -32.66 68.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.36 147.37 52.21 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.476 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 22.0 mmt85 -116.89 128.21 55.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.461 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 30.0 mttt -61.45 -30.83 70.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.503 ' CD1' HD11 ' A' ' 115' ' ' LEU . 9.3 m-30 -94.45 171.35 8.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.91 . . . . 0.0 109.469 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 13.0 p90 -109.59 80.67 1.64 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.08 164.08 36.16 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.631 2.221 . . . . 0.0 111.745 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 104.76 -11.69 49.76 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.98 125.84 49.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -1.178 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.435 ' C ' HD12 ' A' ' 70' ' ' LEU . 91.0 t -132.06 143.25 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.954 HD21 HD12 ' A' ' 111' ' ' ILE . 3.3 mp -107.65 127.41 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.385 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.055 HG22 HG13 ' A' ' 42' ' ' VAL . 96.9 t -133.27 133.17 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.538 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.424 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.3 tt0 -84.49 133.94 34.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.377 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.568 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 28.5 ttp -175.04 162.71 3.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.475 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.537 ' N ' ' HG2' ' A' ' 73' ' ' MET . 33.3 m -103.51 145.66 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.364 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.548 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 11.7 mmt -79.42 122.44 26.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.454 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 36.0 p-10 -133.74 -143.76 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.29 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.2 p30 -117.91 0.85 12.0 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.025 -1.047 . . . . 0.0 110.067 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -122.8 -20.02 6.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.103 -0.998 . . . . 0.0 109.785 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.98 ' OG ' HD13 ' A' ' 38' ' ' LEU . 4.5 m -79.1 -36.66 40.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.24 -0.912 . . . . 0.0 109.581 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 85.6 t90 -56.24 -51.25 68.78 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.293 -0.879 . . . . 0.0 109.595 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -66.22 -32.21 73.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.689 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 1.057 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.6 OUTLIER -62.86 -37.12 85.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.214 -0.929 . . . . 0.0 109.475 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.832 HG21 ' CE2' ' A' ' 92' ' ' PHE . 55.8 t -68.96 -50.02 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 23.1 ttp85 -60.98 -35.69 77.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.506 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.3 t -60.5 -30.83 69.96 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.93 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.0 t -61.84 117.9 33.25 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.13 167.71 24.15 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.584 2.189 . . . . 0.0 111.693 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 39.0 mmt180 60.91 29.85 19.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.7 p -122.79 130.09 74.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.212 -0.93 . . . . 0.0 109.407 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.5 mtp -70.12 -50.93 35.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.21 -0.931 . . . . 0.0 109.508 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 169.36 -151.24 16.96 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.832 ' CE2' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -115.63 170.21 8.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.27 -1.135 . . . . 0.0 109.516 179.998 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.876 HD11 ' CG ' ' A' ' 13' ' ' GLN . 39.6 mm -121.78 125.48 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.355 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 169.71 -163.23 36.73 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -54.57 -56.77 20.51 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 p -125.49 178.96 5.34 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -1.162 . . . . 0.0 109.593 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.3 p -93.76 16.91 12.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -120.11 -28.64 5.06 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 10.1 mtp85 -142.56 90.75 7.78 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.548 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.0 Cg_endo -66.43 120.26 7.37 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.92 2.413 . . . . 0.0 112.239 -179.307 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.28 146.93 97.1 Favored Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.498 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.2 Cg_endo -69.85 152.84 68.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.598 2.198 . . . . 0.0 111.903 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.743 HD11 HG22 ' A' ' 108' ' ' VAL . 30.2 pt -113.1 156.12 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.316 -0.865 . . . . 0.0 109.4 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.0 m -74.52 152.21 39.4 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -56.6 -37.83 71.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.35 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -58.14 -42.08 85.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.223 -0.923 . . . . 0.0 109.404 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.413 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 90.1 mt-10 -58.76 -45.06 90.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.485 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 103' ' ' ILE . 73.4 t -59.43 -39.62 79.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.322 -0.861 . . . . 0.0 109.379 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.6 -34.21 73.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.267 -0.896 . . . . 0.0 109.388 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.27 -44.43 95.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.349 -0.844 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.954 HD12 HD21 ' A' ' 70' ' ' LEU . 73.9 mt -54.21 -54.16 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.474 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' MET . . . . . 0.429 ' HB2' ' HE3' ' A' ' 112' ' ' MET . 55.9 ttm -64.27 -36.73 85.03 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.515 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 46.8 t-20 -52.17 -44.21 64.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 27.2 mtp180 -49.08 -50.42 36.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.491 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.503 HD11 ' CD1' ' A' ' 64' ' ' PHE . 13.5 tp -53.64 -43.42 68.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.271 -0.893 . . . . 0.0 109.417 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -68.68 -29.58 68.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.3 tp60 -53.33 -30.92 41.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.306 -0.872 . . . . 0.0 109.396 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 28.6 t -100.28 134.21 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -77.83 107.18 2.39 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -52.78 -39.59 62.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -1.145 . . . . 0.0 109.427 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.6 mtpt -139.03 165.07 34.88 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.38 -20.51 36.54 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.72 2.28 . . . . 0.0 111.831 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.948 -1.025 . . . . 0.0 109.502 -179.992 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.8 mtt . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.9 t -55.59 -36.46 66.94 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.495 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 mp0 -62.55 -32.6 73.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.494 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.94 78.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.417 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.34 143.22 47.43 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.599 2.2 . . . . 0.0 111.793 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -90.38 149.28 22.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.373 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.511 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 46.9 mttt -121.1 143.1 49.27 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.898 . . . . 0.0 109.571 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.472 ' HD2' ' OH ' ' A' ' 10' ' ' TYR . 78.3 mtt180 -125.27 156.72 38.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.392 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.456 ' CZ2' ' HB2' ' A' ' 72' ' ' GLN . 59.4 m95 -104.42 126.8 51.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.184 -0.948 . . . . 0.0 109.591 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.472 ' OH ' ' HD2' ' A' ' 8' ' ' ARG . 85.6 m-85 -125.15 148.13 48.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.417 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.548 HG22 ' CD1' ' A' ' 70' ' ' LEU . 22.8 t -92.06 143.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -0.926 . . . . 0.0 109.615 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.3 t -120.61 132.79 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.776 ' CG ' HD11 ' A' ' 93' ' ' ILE . 58.1 mt-30 -84.53 151.99 24.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.9 . . . . 0.0 109.483 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -163.96 150.47 11.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 0.0 109.506 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -61.14 143.67 55.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.224 -0.923 . . . . 0.0 109.509 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.9 t -61.62 136.45 58.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.82 -31.53 5.53 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.438 ' HB3' ' HD3' ' A' ' 88' ' ' ARG . 87.2 m-85 -105.08 -2.62 24.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.202 -1.175 . . . . 0.0 109.536 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.602 ' CD ' HG21 ' A' ' 46' ' ' THR . 15.7 pt-20 -56.52 -41.82 77.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.194 -0.941 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.48 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -63.15 -39.09 97.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.421 ' O ' ' C ' ' A' ' 22' ' ' VAL . 58.1 ttt85 -59.07 -48.73 80.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -1.129 . . . . 0.0 109.432 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.795 HG13 HG11 ' A' ' 86' ' ' VAL . 40.5 t -43.79 -39.18 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.881 . . . . 0.0 109.268 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -54.63 -56.01 23.57 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.252 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.9 m -63.45 -48.55 77.24 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.361 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.485 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 17.0 m -56.27 -49.04 75.37 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 0.0 109.328 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.673 HD12 HG21 ' A' ' 86' ' ' VAL . 5.1 tp -48.33 -56.46 8.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 43.1 ttt180 -55.08 -37.48 66.84 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.332 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.796 ' O ' HD12 ' A' ' 32' ' ' LEU . 71.5 tt0 -56.88 -47.78 79.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.257 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.885 ' HB3' HD11 ' A' ' 82' ' ' LEU . 62.0 m-70 -71.23 -41.62 69.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.243 -0.91 . . . . 0.0 109.344 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.769 HD13 ' CD1' ' A' ' 39' ' ' PHE . 76.1 mt -59.15 -52.2 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.394 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -54.23 -43.5 70.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.448 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.796 HD12 ' O ' ' A' ' 28' ' ' GLU . 4.3 mt -65.44 -48.4 72.88 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -0.915 . . . . 0.0 109.466 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB2' ' SD ' ' A' ' 35' ' ' MET . 65.1 m80 -85.17 6.39 25.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.56 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.516 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.6 t30 51.97 47.14 25.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.566 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.738 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -98.36 6.12 47.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.252 -0.905 . . . . 0.0 109.419 179.921 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.573 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.24 -35.5 49.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.158 -0.964 . . . . 0.0 109.523 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -55.25 -42.47 73.51 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 1.04 HD13 ' OG ' ' A' ' 79' ' ' SER . 0.9 OUTLIER -71.1 -54.47 11.0 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.201 -0.937 . . . . 0.0 109.322 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.769 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.0 m-85 -64.46 137.79 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.9 -67.48 0.38 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -132.76 149.74 52.24 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.251 -1.147 . . . . 0.0 109.707 -179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 71' ' ' VAL . 98.6 t -120.01 149.14 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.881 . . . . 0.0 109.289 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.822 ' HE1' HG11 ' A' ' 108' ' ' VAL . 73.4 mtm -130.37 146.14 51.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.144 -0.973 . . . . 0.0 109.578 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.611 HG13 HG22 ' A' ' 46' ' ' THR . 74.9 t -130.68 99.47 18.61 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.272 -0.893 . . . . 0.0 109.301 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.14 -10.05 27.38 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.696 2.264 . . . . 0.0 111.944 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.611 HG22 HG13 ' A' ' 44' ' ' VAL . 9.0 t -91.31 7.27 41.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.221 -0.925 . . . . 0.0 109.548 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.424 ' C ' ' O ' ' A' ' 46' ' ' THR . 92.5 mt-10 44.11 -163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.165 -0.959 . . . . 0.0 109.434 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 58.6 mp0 -83.42 157.58 22.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.393 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.2 t -60.57 -39.84 82.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.412 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.6 t -115.41 140.64 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.62 143.46 36.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.25 -0.906 . . . . 0.0 109.517 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 79.5 mt -51.46 -43.35 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -82.07 143.65 31.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.293 -0.879 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -57.71 -36.06 77.16 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.75 167.46 43.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -59.93 -40.4 88.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.16 . . . . 0.0 109.502 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -134.29 146.64 50.2 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.847 . . . . 0.0 109.423 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -65.59 -32.54 74.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.46 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.3 tttt -128.69 140.66 51.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.525 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.3 t -95.38 136.94 35.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -0.937 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -78.67 -21.29 48.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.519 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -122.71 142.38 50.75 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.164 -0.96 . . . . 0.0 109.463 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.5 mttp -114.76 147.74 39.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.411 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.569 ' CG ' HD12 ' A' ' 115' ' ' LEU . 98.4 m-85 -104.62 135.13 46.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.592 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.542 ' CE1' HG23 ' A' ' 111' ' ' ILE . 17.9 m-85 44.75 57.58 14.51 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.24 -0.912 . . . . 0.0 109.579 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.08 113.07 3.47 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.677 2.252 . . . . 0.0 111.781 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . 81.62 13.46 79.99 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -110.02 128.86 55.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.222 -1.164 . . . . 0.0 109.583 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.485 ' C ' HD22 ' A' ' 70' ' ' LEU . 99.9 t -133.55 141.58 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.848 ' N ' HD22 ' A' ' 70' ' ' LEU . 2.3 mm? -106.27 131.5 53.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.354 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 42' ' ' VAL . 83.9 t -140.52 120.85 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.262 -0.899 . . . . 0.0 109.754 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 4.4 tt0 -76.62 124.74 28.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.567 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.2 ttp -162.82 155.97 19.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.683 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.513 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.7 t -86.14 130.11 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.7 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 18.9 ttm -75.26 135.49 40.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.469 HD21 ' HB3' ' A' ' 78' ' ' ALA . 44.7 p-10 -151.58 -161.0 1.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -102.99 34.35 2.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.417 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.469 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -149.88 -50.21 0.14 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . 1.04 ' OG ' HD13 ' A' ' 38' ' ' LEU . 14.8 m -63.24 -44.06 96.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.51 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 70.3 t90 -50.78 -47.02 59.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -69.25 -34.05 74.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.885 HD11 ' HB3' ' A' ' 29' ' ' HIS . 53.9 tp -63.43 -38.69 92.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.28 -0.887 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 92' ' ' PHE . 70.6 t -60.69 -49.57 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.383 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -58.8 -35.3 72.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.306 -0.871 . . . . 0.0 109.439 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 24.1 m -62.73 -33.96 76.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.426 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.795 HG11 HG13 ' A' ' 22' ' ' VAL . 49.0 t -49.18 127.71 15.8 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.7 Cg_endo -70.8 156.77 60.02 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.617 2.211 . . . . 0.0 111.803 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.456 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.9 mtt-85 63.51 34.19 12.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 109.678 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.4 p -128.52 134.41 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 73.2 mtm -79.56 -44.56 20.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.241 -0.912 . . . . 0.0 109.488 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.74 -147.04 12.25 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -113.25 167.07 10.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -1.114 . . . . 0.0 109.55 -179.976 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.776 HD11 ' CG ' ' A' ' 13' ' ' GLN . 33.5 mm -121.25 137.65 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.854 . . . . 0.0 109.438 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 163.09 -148.07 14.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.59 -46.55 14.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.2 p -121.64 171.2 9.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -1.192 . . . . 0.0 109.804 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 59.9 m -91.61 18.56 7.3 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.23 -0.919 . . . . 0.0 109.322 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.51 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 90.2 m-20 -124.82 -30.92 3.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.525 -0.734 . . . . 0.0 109.099 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 6.2 mtt180 -144.64 98.67 4.88 Favored Pre-proline 0 N--CA 1.488 1.464 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.7 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 44.3 Cg_endo -67.12 132.28 27.49 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.695 2.263 . . . . 0.0 112.101 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.07 137.02 96.93 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.387 -0.821 . . . . 0.0 109.36 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.19 152.69 72.26 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.645 2.23 . . . . 0.0 111.741 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.801 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -123.53 164.46 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.407 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.6 p -83.52 155.32 23.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -0.928 . . . . 0.0 109.447 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -63.74 -30.39 71.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.257 -0.902 . . . . 0.0 109.494 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -65.43 -37.1 85.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -0.906 . . . . 0.0 109.4 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.447 ' O ' HG13 ' A' ' 111' ' ' ILE . 85.2 tt0 -65.0 -39.86 94.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.254 -0.904 . . . . 0.0 109.385 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.822 HG11 ' HE1' ' A' ' 43' ' ' MET . 76.3 t -67.02 -34.08 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.354 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 92.2 m-20 -70.5 -34.11 71.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.88 . . . . 0.0 109.453 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -69.34 -39.51 78.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.334 -0.854 . . . . 0.0 109.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.542 HG23 ' CE1' ' A' ' 65' ' ' PHE . 71.9 mt -56.93 -51.37 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.234 -0.916 . . . . 0.0 109.541 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.5 mtp -63.39 -37.86 88.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.226 -0.921 . . . . 0.0 109.496 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.445 ' OD1' ' O ' ' A' ' 109' ' ' ASP . 18.7 m120 -54.13 -37.76 64.73 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.321 -0.862 . . . . 0.0 109.514 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.497 ' NH1' ' HA ' ' A' ' 111' ' ' ILE . 52.4 mtt85 -55.56 -52.69 62.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.617 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.569 HD12 ' CG ' ' A' ' 64' ' ' PHE . 18.5 tp -43.21 -47.79 6.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.319 -0.863 . . . . 0.0 109.626 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 -57.89 -27.09 62.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.317 -0.864 . . . . 0.0 109.495 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 114' ' ' ARG . 43.6 tt0 -83.07 134.11 35.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.49 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 42.9 t -63.76 -31.41 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.509 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.54 18.11 75.24 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 51.7 p30 -75.23 172.26 12.73 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.13 -1.217 . . . . 0.0 109.476 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.53 81.0 70.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.277 -0.889 . . . . 0.0 109.555 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.53 -18.36 38.12 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.744 2.296 . . . . 0.0 111.775 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 53.6 mtm180 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.511 179.946 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.8 mmm . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 26.4 t -60.0 -34.33 73.2 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.478 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.25 138.47 39.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.297 -0.877 . . . . 0.0 109.511 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.469 ' HB1' ' HD2' ' A' ' 5' ' ' PRO . . . -126.39 159.78 61.25 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.248 -0.907 . . . . 0.0 109.426 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.469 ' HD2' ' HB1' ' A' ' 4' ' ' ALA . 49.7 Cg_endo -69.93 142.94 48.52 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.701 2.268 . . . . 0.0 111.782 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -88.4 148.43 24.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.441 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.436 ' O ' ' HG3' ' A' ' 7' ' ' LYS . 16.0 pttt -132.16 128.34 37.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.281 -0.887 . . . . 0.0 109.516 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.0 mtt-85 -133.53 153.5 51.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.237 -0.914 . . . . 0.0 109.491 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 70.4 m95 -101.38 135.81 42.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.909 . . . . 0.0 109.415 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CE2' ' O ' ' A' ' 73' ' ' MET . 22.9 m-85 -124.58 151.62 44.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 18.4 t -101.1 137.89 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.333 -0.855 . . . . 0.0 109.489 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 30.6 t -115.11 128.7 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.306 -0.871 . . . . 0.0 109.234 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.953 ' HB2' HD11 ' A' ' 93' ' ' ILE . 60.4 tt0 -95.6 129.96 42.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.913 . . . . 0.0 109.617 -179.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.44 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -147.42 -178.2 6.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -75.03 134.26 41.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.451 ' OG ' ' HB2' ' A' ' 66' ' ' PRO . 19.7 m -57.79 140.6 51.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.39 -25.44 15.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.49 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.4 m-85 -112.05 13.57 20.71 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.23 -1.159 . . . . 0.0 109.39 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.499 ' OE1' ' CG ' ' A' ' 45' ' ' PRO . 87.2 mt-10 -54.07 -45.31 71.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.12 -42.25 91.85 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.425 ' HD3' ' NE ' ' A' ' 88' ' ' ARG . 52.7 ttt85 -52.16 -54.53 29.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.228 -1.16 . . . . 0.0 109.389 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.1 t -50.35 -37.23 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.203 -0.936 . . . . 0.0 109.119 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.72 -36.79 85.43 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.211 -0.931 . . . . 0.0 109.231 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -58.83 -43.03 90.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.397 -0.815 . . . . 0.0 109.158 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.67 ' HB3' ' CE1' ' A' ' 29' ' ' HIS . 20.3 m -58.77 -41.04 85.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 109.319 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.66 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.1 mt -53.45 -44.51 68.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.865 . . . . 0.0 109.409 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 31' ' ' LYS . 65.9 ttt180 -52.6 -42.49 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.34 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.413 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 64.6 mm-40 -75.02 -57.77 3.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.67 ' CE1' ' HB3' ' A' ' 25' ' ' SER . 32.9 m80 -55.15 -38.03 67.73 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -0.942 . . . . 0.0 109.268 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.792 HG23 ' HB2' ' A' ' 35' ' ' MET . 82.2 mt -77.17 -54.46 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.293 -0.879 . . . . 0.0 109.49 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 27' ' ' ARG . 42.2 tttm -59.97 -38.24 81.92 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.906 . . . . 0.0 109.286 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.467 HD23 ' HA ' ' A' ' 32' ' ' LEU . 25.2 mt -70.64 -52.05 23.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.194 -0.942 . . . . 0.0 109.388 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -81.17 0.84 34.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.536 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.509 ' N ' ' O ' ' A' ' 30' ' ' ILE . 20.2 m120 60.37 51.49 5.33 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.242 -0.911 . . . . 0.0 109.408 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.86 ' HG3' HD13 ' A' ' 82' ' ' LEU . 59.9 mmm -99.84 -0.15 40.3 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.291 -0.88 . . . . 0.0 109.599 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.515 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.1 mt-10 -45.67 -37.94 6.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.402 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -53.45 -44.24 68.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.922 . . . . 0.0 109.436 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.777 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.0 OUTLIER -74.62 -46.92 35.19 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.376 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.707 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -75.41 125.87 29.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.9 . . . . 0.0 109.497 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.69 -67.06 0.6 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -132.46 144.74 50.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -1.154 . . . . 0.0 109.524 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.875 HG13 HG22 ' A' ' 71' ' ' VAL . 19.5 t -109.06 147.65 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.247 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.495 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.2 mtp -122.73 152.32 40.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.118 -0.988 . . . . 0.0 109.757 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 12.3 t -149.57 141.18 14.77 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.365 -0.835 . . . . 0.0 109.228 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.529 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 47.8 Cg_endo -68.59 -2.13 8.72 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.65 2.233 . . . . 0.0 111.815 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 49' ' ' VAL . 11.3 t -145.98 137.19 24.7 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.339 -0.851 . . . . 0.0 109.291 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 48' ' ' GLU . 91.8 mt-10 -109.48 137.62 47.05 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.258 -0.901 . . . . 0.0 109.562 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.418 ' OE1' ' HA ' ' A' ' 48' ' ' GLU . 73.4 mm-40 43.41 81.43 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.339 -0.851 . . . . 0.0 109.638 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.525 HG11 HG21 ' A' ' 46' ' ' THR . 13.9 p -135.31 140.29 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.54 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.528 ' HB ' ' CB ' ' A' ' 53' ' ' ARG . 23.8 t -118.3 143.25 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.538 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -60.97 -68.65 0.29 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.509 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.416 ' O ' ' C ' ' A' ' 53' ' ' ARG . 77.8 mt -46.76 -52.94 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.318 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.528 ' CB ' ' HB ' ' A' ' 50' ' ' VAL . 59.4 ttp85 -44.56 -49.48 10.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.883 . . . . 0.0 109.514 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 68.47 -127.72 23.68 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -113.44 102.19 1.23 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -66.32 -35.81 81.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.264 -1.139 . . . . 0.0 109.487 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -57.4 -44.61 84.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.221 -0.924 . . . . 0.0 109.495 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -146.77 149.51 33.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.9 . . . . 0.0 109.458 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -50.83 -46.39 59.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.915 . . . . 0.0 109.541 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 53.1 p -58.43 164.01 2.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.525 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -133.58 140.27 47.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 60.9 mtt85 -122.78 145.26 48.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.325 -0.859 . . . . 0.0 109.381 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 20.4 mttt -135.42 137.03 41.85 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -0.926 . . . . 0.0 109.655 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.587 ' HZ ' HG13 ' A' ' 118' ' ' VAL . 98.3 m-85 -109.75 142.33 41.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.361 -0.837 . . . . 0.0 109.263 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.422 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 39.3 m-85 51.13 66.39 5.45 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.125 -0.984 . . . . 0.0 109.384 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.451 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 48.9 Cg_endo -69.93 128.73 16.28 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.692 2.261 . . . . 0.0 111.778 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.485 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . 65.37 24.12 70.54 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.01 118.29 22.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -1.125 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.572 ' C ' HD12 ' A' ' 70' ' ' LEU . 79.0 t -130.64 148.82 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.559 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.837 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.0 mp -116.05 132.66 56.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.292 -0.88 . . . . 0.0 109.314 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.875 HG22 HG13 ' A' ' 42' ' ' VAL . 92.4 t -137.03 129.91 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.649 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.6 tt0 -79.87 132.74 36.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.225 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 50.3 ttp 174.07 165.19 0.2 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.162 -0.961 . . . . 0.0 109.621 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 15.0 p -94.6 138.57 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.286 -0.884 . . . . 0.0 109.237 179.791 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.6 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 34.3 tpp -79.15 119.52 22.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.3 p-10 -141.94 179.06 7.09 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.35 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -64.97 -36.7 85.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.486 ' HB1' ' HE2' ' A' ' 35' ' ' MET . . . -74.47 -72.78 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.173 -0.954 . . . . 0.0 109.827 -179.693 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.777 ' OG ' HD13 ' A' ' 38' ' ' LEU . 3.6 m -42.24 -47.5 4.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.392 -0.818 . . . . 0.0 109.741 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.579 ' CZ2' ' HD2' ' A' ' 84' ' ' ARG . 63.7 t90 -50.63 -49.72 56.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.226 -0.921 . . . . 0.0 109.577 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -68.34 -25.16 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.527 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.86 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.9 OUTLIER -60.52 -54.75 41.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.297 -0.877 . . . . 0.0 109.562 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.033 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 2.7 t -62.26 -49.09 85.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.504 -0.747 . . . . 0.0 109.896 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.579 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 58.2 mtp180 -62.77 -29.38 70.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.134 -0.979 . . . . 0.0 109.509 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.1 p -79.6 -17.8 53.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.408 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.802 HG23 ' O ' ' A' ' 82' ' ' LEU . 71.8 t -73.01 125.9 90.79 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.449 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.01 160.34 49.65 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.626 2.218 . . . . 0.0 111.782 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.537 ' CZ ' ' HB2' ' A' ' 88' ' ' ARG . 13.0 ttm105 64.74 31.72 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.602 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.9 p -126.59 130.93 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.192 -0.942 . . . . 0.0 109.451 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.505 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 95.7 mmm -71.29 -46.85 59.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.09 -155.5 26.35 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 1.033 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.0 m-85 -104.74 162.45 13.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -1.086 . . . . 0.0 109.588 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.953 HD11 ' HB2' ' A' ' 13' ' ' GLN . 10.7 mm -119.02 118.27 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.41 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -174.52 -145.57 5.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.93 -46.01 24.62 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.8 p -127.36 173.37 9.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.195 -1.179 . . . . 0.0 109.604 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.2 p -90.49 18.78 5.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.111 -0.993 . . . . 0.0 109.253 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -126.62 -6.3 6.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.579 -0.701 . . . . 0.0 109.428 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.415 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -164.73 99.57 0.85 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.252 -0.905 . . . . 0.0 109.07 179.935 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.6 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 47.6 Cg_endo -68.55 114.21 3.41 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.678 2.252 . . . . 0.0 111.891 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.57 137.37 82.19 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.519 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.82 153.9 68.12 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.707 2.271 . . . . 0.0 111.813 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.615 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -124.44 161.04 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.444 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.441 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 49.9 m -70.94 147.95 48.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -62.26 -36.28 81.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.197 -0.94 . . . . 0.0 109.34 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -61.59 -35.96 79.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.441 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 99.8 mt-10 -60.8 -43.15 98.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.887 . . . . 0.0 109.366 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.615 ' CG2' HD11 ' A' ' 103' ' ' ILE . 75.4 t -62.53 -35.14 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.455 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -66.99 -38.04 85.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.885 . . . . 0.0 109.412 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.6 -44.31 91.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.955 . . . . 0.0 109.441 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 67.9 mt -53.53 -52.54 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -0.922 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.2 mmm -58.32 -38.79 77.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.498 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -52.75 -41.71 64.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 109.452 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.493 ' O ' ' N ' ' A' ' 117' ' ' GLN . 37.6 mtp85 -57.28 -43.89 83.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.488 HD12 ' CB ' ' A' ' 64' ' ' PHE . 6.7 tp -43.98 -49.42 8.58 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -0.876 . . . . 0.0 109.511 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -57.56 -26.32 61.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.299 -0.876 . . . . 0.0 109.474 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.493 ' N ' ' O ' ' A' ' 114' ' ' ARG . 44.5 tt0 -85.82 125.01 32.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.468 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.587 HG13 ' HZ ' ' A' ' 64' ' ' PHE . 1.6 t -120.61 134.34 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.36 -21.49 6.24 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -95.34 139.45 31.63 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -1.116 . . . . 0.0 109.493 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 mmtp -119.86 74.64 19.48 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.514 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.08 144.16 51.51 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.665 2.244 . . . . 0.0 111.805 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 33.2 ttt-85 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.976 -1.012 . . . . 0.0 109.483 -179.997 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.3 mmm . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.3 t -60.38 -28.82 68.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -0.886 . . . . 0.0 109.421 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -62.04 141.62 57.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.227 -0.921 . . . . 0.0 109.372 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.52 81.52 31.72 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.13 -0.981 . . . . 0.0 109.597 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.85 145.91 58.05 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.753 2.302 . . . . 0.0 111.719 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -91.3 27.82 1.82 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.533 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.421 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 98.6 mttt -99.39 133.13 44.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.246 -0.909 . . . . 0.0 109.509 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 54.3 mtt180 -123.42 153.96 39.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.427 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.575 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 73.8 m95 -96.16 123.74 39.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.227 -0.92 . . . . 0.0 109.581 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.591 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 88.1 m-85 -119.19 159.64 23.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -0.943 . . . . 0.0 109.473 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.47 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 27.0 t -94.33 149.18 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.637 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.4 ' N ' ' O ' ' A' ' 69' ' ' VAL . 57.3 t -124.64 118.74 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.246 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.957 ' HB2' HD11 ' A' ' 93' ' ' ILE . 59.3 tt0 -84.85 140.07 31.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.58 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.438 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -156.92 -153.39 0.41 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.934 . . . . 0.0 109.391 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.96 140.62 46.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.446 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 t -59.24 132.73 54.89 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.48 -16.92 60.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -109.48 0.19 19.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -1.143 . . . . 0.0 109.576 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.51 ' OE2' ' N ' ' A' ' 68' ' ' TYR . 99.0 mt-10 -56.35 -44.34 79.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.367 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.55 -50.15 67.11 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.531 ' NH2' ' HG3' ' A' ' 88' ' ' ARG . 12.4 ttp180 -57.3 -56.26 24.12 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -1.123 . . . . 0.0 109.416 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.699 HG13 HG11 ' A' ' 86' ' ' VAL . 40.7 t -45.46 -38.68 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.87 -44.85 96.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.342 -0.849 . . . . 0.0 109.266 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.4 m -69.44 -47.28 64.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.677 ' HG ' ' HE2' ' A' ' 29' ' ' HIS . 15.3 t -57.4 -56.21 24.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.338 -0.851 . . . . 0.0 109.489 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.442 ' CD1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp -46.82 -49.71 19.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.377 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.487 ' CG ' ' HE2' ' A' ' 31' ' ' LYS . 46.7 ttm-85 -60.71 -34.59 74.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.186 -0.946 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -64.18 -48.07 77.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.225 -0.922 . . . . 0.0 109.322 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.677 ' HE2' ' HG ' ' A' ' 25' ' ' SER . 60.1 m-70 -66.3 -37.29 85.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 109.341 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.815 HG23 ' HB2' ' A' ' 35' ' ' MET . 90.8 mt -65.26 -49.03 81.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.256 -0.903 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.487 ' HE2' ' CG ' ' A' ' 27' ' ' ARG . 25.3 mttm -56.84 -40.05 75.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 32' ' ' LEU . 29.8 mt -69.91 -52.02 28.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.488 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 63.2 m80 -81.12 4.34 20.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.591 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' ILE . 78.8 m-20 54.76 47.65 21.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.248 -0.907 . . . . 0.0 109.511 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' MET . . . . . 1.008 ' HG3' HD13 ' A' ' 82' ' ' LEU . 61.1 mmm -94.2 6.54 48.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.932 . . . . 0.0 109.594 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.502 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.53 -31.19 34.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.394 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -61.85 -41.84 98.31 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.351 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.496 HD12 ' HB3' ' A' ' 35' ' ' MET . 10.3 mt -70.93 -53.68 14.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.699 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 73.9 m-85 -75.2 143.33 43.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.306 -0.871 . . . . 0.0 109.474 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.34 -58.84 0.24 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -136.29 156.48 48.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -1.223 . . . . 0.0 109.734 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.889 HG13 HG22 ' A' ' 71' ' ' VAL . 54.5 t -121.01 154.66 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.582 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -121.99 147.68 45.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.159 -0.963 . . . . 0.0 109.633 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -138.45 103.95 7.81 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.379 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.584 ' HB2' ' CG ' ' A' ' 65' ' ' PHE . 48.7 Cg_endo -70.03 -9.26 25.61 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.643 2.229 . . . . 0.0 111.853 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.4 p -76.04 142.39 41.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.127 -0.983 . . . . 0.0 109.53 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -63.23 -40.47 97.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.209 -0.932 . . . . 0.0 109.412 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -143.18 150.4 39.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.895 . . . . 0.0 109.374 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 70.3 t -63.66 -37.86 80.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.2 t -111.82 142.09 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.495 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 87.7 tt0 -82.05 143.62 31.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.908 . . . . 0.0 109.543 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 65.1 mt -137.05 107.92 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.255 -0.903 . . . . 0.0 109.379 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -48.32 -33.12 8.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.919 . . . . 0.0 109.497 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -80.13 -113.6 0.28 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 68.49 -120.35 11.36 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 91.8 mt-30 -103.99 152.29 22.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -1.104 . . . . 0.0 109.491 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -58.98 -34.4 71.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.443 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 44.8 mtp85 -54.5 145.06 19.44 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.286 -0.884 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 20.8 tttm -96.74 135.34 38.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 50.1 m -119.83 146.72 45.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -0.945 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -122.23 150.52 42.18 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.288 -0.882 . . . . 0.0 109.501 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 11.7 mtt85 -104.76 6.13 33.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LYS . . . . . 0.453 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 62.4 mttm -62.06 -25.14 67.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -57.42 -36.62 71.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -0.902 . . . . 0.0 109.597 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.584 ' CG ' ' HB2' ' A' ' 45' ' ' PRO . 32.7 m-85 -130.26 80.62 70.28 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.524 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 50.9 Cg_endo -70.79 76.73 1.51 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.667 2.244 . . . . 0.0 111.964 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 75.31 33.73 52.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.51 ' N ' ' OE2' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -111.0 119.47 39.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 109.366 179.946 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -134.17 140.62 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.554 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.851 ' N ' HD12 ' A' ' 70' ' ' LEU . 4.0 mp -104.3 141.76 35.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.382 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.889 HG22 HG13 ' A' ' 42' ' ' VAL . 68.9 t -145.26 123.67 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -0.951 . . . . 0.0 109.705 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.421 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 38.5 tt0 -73.96 124.87 27.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.309 -0.869 . . . . 0.0 109.127 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.458 ' SD ' ' OG ' ' A' ' 79' ' ' SER . 8.8 tmm? -169.22 151.52 4.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.293 -0.88 . . . . 0.0 109.398 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 74' ' ' VAL . 28.6 m -77.59 118.97 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.585 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.596 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 8.5 mmt -61.72 115.84 4.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.172 -0.955 . . . . 0.0 109.585 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.2 p-10 -151.28 172.74 15.39 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.36 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -63.4 -33.78 76.29 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.645 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.535 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -71.5 -72.36 0.22 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 109.661 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.524 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 18.0 p -46.63 -57.59 4.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.525 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 44.0 t90 -43.65 -53.89 5.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.34 -0.85 . . . . 0.0 109.574 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.53 -43.41 98.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.61 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 1.008 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.8 OUTLIER -55.81 -43.1 76.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 0.0 109.491 -179.843 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 92' ' ' PHE . 98.2 t -61.01 -52.11 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 57.4 ttt85 -55.63 -35.08 65.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.566 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 39.9 m -59.58 -37.22 77.93 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.187 -0.946 . . . . 0.0 109.555 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.699 HG11 HG13 ' A' ' 22' ' ' VAL . 91.8 t -54.99 125.56 56.92 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 109.516 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.7 Cg_endo -71.25 160.28 49.39 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.624 2.216 . . . . 0.0 111.769 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.531 ' HG3' ' NH2' ' A' ' 21' ' ' ARG . 50.1 mmt-85 63.66 30.79 14.79 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.695 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 86' ' ' VAL . 6.1 p -129.24 130.63 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.157 -0.964 . . . . 0.0 109.375 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.509 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.1 mmm -76.46 -54.98 5.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 166.67 -150.12 16.74 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.684 ' CE2' HG11 ' A' ' 83' ' ' VAL . 6.5 m-85 -105.5 161.86 13.98 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -1.131 . . . . 0.0 109.561 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.957 HD11 ' HB2' ' A' ' 13' ' ' GLN . 19.3 mm -120.3 122.13 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.415 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -179.66 -144.39 5.88 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.62 -45.25 95.04 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 p -130.76 171.01 13.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.219 -1.165 . . . . 0.0 109.463 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.9 p -89.02 16.61 6.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.144 -0.972 . . . . 0.0 109.37 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.525 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.1 m-20 -125.64 -27.14 3.42 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.533 -0.729 . . . . 0.0 109.261 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -140.16 97.63 7.73 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.339 -0.851 . . . . 0.0 108.846 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.72 127.12 15.73 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.79 2.327 . . . . 0.0 112.067 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.63 138.51 93.5 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.256 -0.902 . . . . 0.0 109.234 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.514 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.8 Cg_endo -70.45 153.66 65.6 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.603 2.202 . . . . 0.0 111.845 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 34.9 pt -127.55 161.08 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.452 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.484 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 43.7 m -71.79 150.56 44.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.348 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -56.93 -37.91 72.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.335 -0.853 . . . . 0.0 109.456 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -60.35 -34.02 73.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.441 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.484 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 76.5 mm-40 -59.12 -41.85 89.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.922 . . . . 0.0 109.384 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.491 HG21 ' CG ' ' A' ' 9' ' ' TRP . 90.0 t -63.33 -36.2 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.913 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -66.6 -38.71 87.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.69 -47.7 77.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.586 HD12 HD21 ' A' ' 70' ' ' LEU . 45.2 mt -50.49 -51.41 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.497 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 96.2 mmm -60.32 -35.87 76.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.156 -0.965 . . . . 0.0 109.387 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -61.82 -32.7 73.03 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.246 -0.909 . . . . 0.0 109.42 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 115' ' ' LEU . 59.2 mtt180 -56.23 -50.69 70.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.283 -0.885 . . . . 0.0 109.458 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.415 ' C ' ' O ' ' A' ' 114' ' ' ARG . 10.3 tp -44.88 -47.9 11.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.354 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -71.43 -29.66 65.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.208 -0.933 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -75.47 131.21 39.98 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.474 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 75.5 t -68.08 -35.74 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.296 -0.878 . . . . 0.0 109.516 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.56 45.7 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.51 -36.7 67.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -1.171 . . . . 0.0 109.515 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.76 68.52 2.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.206 -0.934 . . . . 0.0 109.526 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.95 147.0 60.67 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 122.631 2.22 . . . . 0.0 111.825 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 66.0 mtp85 . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.48 -179.963 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.0 mtm . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.7 p -63.23 -22.72 67.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.21 -0.931 . . . . 0.0 109.499 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -91.92 150.7 20.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.167 -0.958 . . . . 0.0 109.453 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 58.12 62.07 5.16 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.09 -19.22 34.85 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.714 2.276 . . . . 0.0 111.782 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mmtm -90.43 155.87 18.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 40.1 mttt -82.61 139.89 33.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.399 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.505 ' HD2' ' HB3' ' A' ' 102' ' ' PRO . 23.1 mtm180 -122.26 154.85 37.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -93.56 137.69 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.549 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 46.0 m-85 -131.85 164.19 26.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.868 . . . . 0.0 109.567 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.428 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.9 t -99.2 139.89 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 109.53 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.9 t -122.74 119.54 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.588 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.6 tt0 -87.24 135.44 33.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.887 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.32 161.28 38.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.369 -0.832 . . . . 0.0 109.41 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 97.4 m-85 -57.75 149.99 20.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 35.0 t -71.9 145.94 48.18 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.51 -34.37 4.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.843 ' O ' HG23 ' A' ' 22' ' ' VAL . 17.9 m-30 -108.48 6.61 26.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.261 -1.141 . . . . 0.0 109.502 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.866 ' OE2' HG21 ' A' ' 46' ' ' THR . 22.8 pt-20 -51.62 -43.84 62.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.331 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -67.29 -54.35 20.76 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -58.68 -40.57 83.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.174 -1.192 . . . . 0.0 109.389 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.887 HG21 ' HB1' ' A' ' 14' ' ' ALA . 76.6 t -50.75 -48.67 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.408 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.029 ' HB1' HG11 ' A' ' 42' ' ' VAL . . . -55.32 -40.73 71.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.243 -0.911 . . . . 0.0 109.336 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.2 m -65.83 -39.94 91.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.249 -0.907 . . . . 0.0 109.418 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 21.1 m -57.85 -46.35 84.93 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.254 -0.904 . . . . 0.0 109.398 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.465 ' O ' HG12 ' A' ' 30' ' ' ILE . 34.9 mt -52.27 -55.98 17.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.348 -0.845 . . . . 0.0 109.357 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.408 ' C ' ' O ' ' A' ' 26' ' ' LEU . 49.3 ttt-85 -42.58 -40.75 2.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.417 -0.802 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 25' ' ' SER . 89.7 mt-10 -58.85 -39.05 80.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.21 -0.931 . . . . 0.0 109.393 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.574 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 66.0 m-70 -82.18 -19.85 39.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.352 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 39' ' ' PHE . 20.5 mm -75.34 -48.46 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.239 -0.913 . . . . 0.0 109.225 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -71.53 -41.22 69.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -0.851 . . . . 0.0 109.236 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.45 HD23 ' HA ' ' A' ' 32' ' ' LEU . 67.0 mt -63.9 -47.42 80.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.449 -0.782 . . . . 0.0 109.404 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.698 ' CE1' HD11 ' A' ' 82' ' ' LEU . 79.6 m80 -84.05 9.25 12.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 49.08 48.47 20.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 0.0 109.394 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.636 ' SD ' HD22 ' A' ' 82' ' ' LEU . 41.4 mtt -102.79 -0.66 31.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 35' ' ' MET . 97.2 mt-10 -43.89 -36.04 2.23 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.243 -0.91 . . . . 0.0 109.647 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -56.96 -50.25 73.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.205 -0.934 . . . . 0.0 109.713 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' CA ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -71.31 -48.52 50.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.52 -179.691 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 30' ' ' ILE . 66.1 m-85 -70.4 141.35 52.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 109.452 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.472 ' HA3' ' OE1' ' A' ' 72' ' ' GLN . . . -102.65 -70.12 0.84 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -158.66 147.21 18.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.187 -1.184 . . . . 0.0 109.495 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.029 HG11 ' HB1' ' A' ' 23' ' ' ALA . 60.1 t -95.79 138.45 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.499 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.623 ' HE1' HG11 ' A' ' 108' ' ' VAL . 65.1 mtm -121.32 150.09 41.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.368 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.82 HG12 ' H ' ' A' ' 46' ' ' THR . 93.4 t -144.58 127.02 8.3 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.576 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.5 ' HB2' HD13 ' A' ' 115' ' ' LEU . 50.0 Cg_endo -70.47 -8.54 23.84 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.687 2.258 . . . . 0.0 111.684 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.866 HG21 ' OE2' ' A' ' 19' ' ' GLU . 16.2 p -104.81 37.96 2.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.908 . . . . 0.0 109.492 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -47.33 -34.66 7.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.214 -0.929 . . . . 0.0 109.379 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -101.8 131.98 47.81 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.419 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.8 t -121.88 136.45 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.307 -0.871 . . . . 0.0 109.426 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.21 148.65 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.229 -0.919 . . . . 0.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.461 ' OE2' ' HD3' ' A' ' 53' ' ' ARG . 65.3 tt0 -121.58 138.57 54.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 109.454 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.2 tt -57.23 -31.33 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.461 ' HD3' ' OE2' ' A' ' 51' ' ' GLU . 72.5 mtp85 -57.93 -32.38 67.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.221 -0.924 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' A' ' 53' ' ' ARG . . . -54.78 -167.87 0.04 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 54' ' ' GLY . . . -45.01 103.92 0.06 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -61.13 -32.2 71.91 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -1.135 . . . . 0.0 109.47 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 20.9 ttp85 -53.44 -38.6 63.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.47 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 89.6 mtt-85 -83.56 131.66 34.97 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -139.65 125.23 19.28 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.869 . . . . 0.0 109.467 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 t -177.48 112.15 0.08 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.206 -0.934 . . . . 0.0 109.383 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -132.79 145.69 51.21 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.635 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.43 ' HB2' ' CE2' ' A' ' 64' ' ' PHE . 77.0 mtt180 -120.87 148.21 44.35 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.259 -0.901 . . . . 0.0 109.338 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -107.33 121.97 45.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.263 -0.898 . . . . 0.0 109.62 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.569 ' CE1' ' HA ' ' A' ' 115' ' ' LEU . 77.8 m-85 -127.5 156.94 41.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.352 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.425 ' C ' ' O ' ' A' ' 64' ' ' PHE . 1.4 p90 -42.19 101.08 0.24 Allowed Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.346 -0.846 . . . . 0.0 109.647 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 53.2 Cg_endo -72.81 152.09 52.13 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.637 2.225 . . . . 0.0 111.806 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . 67.75 29.84 74.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.722 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.2 m-85 -128.61 115.3 17.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.196 -1.179 . . . . 0.0 109.375 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 43' ' ' MET . 87.3 t -132.9 144.85 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.262 -0.899 . . . . 0.0 109.609 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.854 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.1 mp -101.06 129.53 46.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.328 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.745 HG22 HG13 ' A' ' 42' ' ' VAL . 91.0 t -140.75 115.36 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.76 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.472 ' OE1' ' HA3' ' A' ' 40' ' ' GLY . 36.9 tt0 -65.98 135.9 55.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.928 . . . . 0.0 109.171 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.575 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 10.9 ttp -173.78 152.1 1.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.16 -0.962 . . . . 0.0 109.587 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.526 ' N ' ' HG2' ' A' ' 73' ' ' MET . 38.7 t -81.67 141.2 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.281 179.692 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.559 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 15.1 tpp -78.1 100.12 6.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.212 -0.93 . . . . 0.0 109.74 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.507 ' ND2' HD22 ' A' ' 38' ' ' LEU . 51.4 p-10 -140.87 169.39 17.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.306 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -72.67 -26.39 61.61 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.5 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.58 -71.31 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 0.0 109.584 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 83' ' ' VAL . 11.4 p -53.47 -45.19 69.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.433 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.9 t90 -56.44 -59.01 5.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -54.92 -44.01 73.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.698 HD11 ' CE1' ' A' ' 33' ' ' HIS . 41.1 tp -56.13 -47.8 77.44 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.813 HG11 ' CE2' ' A' ' 92' ' ' PHE . 80.0 t -50.41 -48.05 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.245 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 16.5 ttt-85 -70.63 -28.17 64.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.383 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.4 m -58.82 -47.15 85.8 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.35 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.574 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 4.4 p -76.08 132.39 73.93 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.532 ' O ' HG23 ' A' ' 89' ' ' VAL . 47.7 Cg_endo -69.02 -174.03 0.7 Allowed 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.672 2.248 . . . . 0.0 111.892 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.616 ' HB3' HG22 ' A' ' 22' ' ' VAL . 70.1 mtt85 63.69 32.04 14.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.359 -0.838 . . . . 0.0 109.444 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 87' ' ' PRO . 6.4 t -131.89 117.26 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 83.2 mtp -73.73 -38.29 64.84 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 148.62 -176.26 27.5 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.813 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.7 m-85 -94.98 158.25 15.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.311 -1.111 . . . . 0.0 109.649 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.722 HG21 ' OH ' ' A' ' 68' ' ' TYR . 18.9 mm -118.55 114.24 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.301 -0.875 . . . . 0.0 109.378 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.01 -141.77 3.25 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.55 -29.12 60.2 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -136.33 169.32 17.85 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.199 -1.177 . . . . 0.0 109.655 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -91.72 19.61 6.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.356 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' OD1' ' A' ' 98' ' ' ASP . 48.1 p30 -140.73 11.05 2.25 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.55 -0.718 . . . . 0.0 109.081 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.3 OUTLIER -171.88 97.8 0.39 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.327 -0.858 . . . . 0.0 108.916 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 49.7 Cg_endo -68.94 113.75 3.34 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.752 2.301 . . . . 0.0 111.949 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.91 142.02 74.17 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.229 -0.92 . . . . 0.0 109.357 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.505 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 50.9 Cg_endo -70.22 153.98 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.715 2.277 . . . . 0.0 111.922 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.632 HD11 HG22 ' A' ' 108' ' ' VAL . 31.3 pt -129.23 152.73 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.9 m -67.0 145.29 55.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.617 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -53.75 -41.03 66.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.888 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -59.19 -44.57 92.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.462 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 83.2 tt0 -51.17 -46.32 62.04 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.632 HG22 HD11 ' A' ' 103' ' ' ILE . 60.4 t -53.97 -41.56 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.229 -0.919 . . . . 0.0 109.282 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -59.77 -41.18 90.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.247 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 113' ' ' ASN . . . -59.52 -52.62 64.77 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.278 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.4 HG21 HD13 ' A' ' 111' ' ' ILE . 54.1 mt -47.05 -51.91 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.299 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.8 mtp -56.5 -37.02 69.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.322 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.453 ' HB2' ' O ' ' A' ' 110' ' ' ALA . 97.4 m-20 -58.13 -34.93 70.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 117' ' ' GLN . 59.2 mtt180 -50.54 -45.83 57.11 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.569 ' HA ' ' CE1' ' A' ' 64' ' ' PHE . 7.3 tp -44.08 -44.14 7.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -62.6 -29.84 70.9 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.885 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 114' ' ' ARG . 63.3 tt0 -69.14 139.29 54.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.325 -0.859 . . . . 0.0 109.51 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.514 ' CG1' ' OD1' ' A' ' 120' ' ' ASP . 86.2 t -54.76 -44.05 69.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 86.93 26.13 32.56 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.514 ' OD1' ' CG1' ' A' ' 118' ' ' VAL . 96.9 m-20 -55.76 -36.03 66.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.305 -1.115 . . . . 0.0 109.447 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -91.95 110.8 46.35 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.278 -0.889 . . . . 0.0 109.485 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.97 147.49 61.66 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.686 2.258 . . . . 0.0 111.83 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.45 -179.936 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.1 mtp . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.5 p -61.85 -30.78 71.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.536 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -61.11 -36.23 79.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.875 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -73.6 149.97 88.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.422 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.17 147.31 59.94 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.658 2.239 . . . . 0.0 111.768 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 23.3 mttp -89.99 143.45 26.77 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.431 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -89.44 134.66 33.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.92 . . . . 0.0 109.536 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 96.2 mtt180 -126.14 158.95 34.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.466 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.51 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 58.8 m95 -99.82 121.09 40.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.955 . . . . 0.0 109.788 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.589 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 96.6 m-85 -114.77 157.59 23.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.31 -0.869 . . . . 0.0 109.229 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 88.6 t -105.89 143.48 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 109.599 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.0 t -120.99 127.96 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.314 -0.866 . . . . 0.0 109.472 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.915 ' HB2' HD11 ' A' ' 93' ' ' ILE . 68.2 tp60 -86.98 145.32 26.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -0.9 . . . . 0.0 109.48 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.09 153.87 34.8 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.54 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -58.72 144.27 44.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.517 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 26.2 t -61.9 141.09 58.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.43 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.94 -31.18 5.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.5 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 90.3 m-85 -105.01 7.33 33.99 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.267 -1.137 . . . . 0.0 109.585 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.576 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 85.5 tt0 -58.44 -42.59 87.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.117 -0.99 . . . . 0.0 109.382 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.82 -38.0 65.91 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 22.2 ttm180 -62.02 -50.63 71.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -1.15 . . . . 0.0 109.442 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.476 HG13 HG11 ' A' ' 86' ' ' VAL . 37.4 t -49.45 -41.02 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.181 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 -42.39 99.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.234 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 41.5 m -67.38 -47.12 71.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.273 -0.892 . . . . 0.0 109.341 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.9 m -64.66 -34.41 78.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.253 -0.904 . . . . 0.0 109.375 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.817 ' CD2' HD11 ' A' ' 30' ' ' ILE . 5.4 tt -58.57 -53.54 57.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.304 -0.873 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.403 ' NE ' ' NZ ' ' A' ' 31' ' ' LYS . 23.0 tpt180 -45.14 -46.0 11.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.254 -0.904 . . . . 0.0 109.598 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -53.5 -50.88 64.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.558 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.582 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.7 m-70 -56.92 -29.1 62.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.286 -0.883 . . . . 0.0 109.533 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 1.052 HD12 ' CD1' ' A' ' 39' ' ' PHE . 10.2 mm -68.94 -53.72 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.227 -0.921 . . . . 0.0 109.567 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.51 ' CD ' ' OE2' ' A' ' 36' ' ' GLU . 24.8 mmtm -66.05 -44.18 85.3 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.658 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.453 HD23 ' HA ' ' A' ' 32' ' ' LEU . 49.0 mt -61.32 -55.95 25.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.277 -0.89 . . . . 0.0 109.611 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.643 ' ND1' HD11 ' A' ' 82' ' ' LEU . 63.9 m80 -81.87 7.53 12.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 53.1 t30 48.83 45.76 22.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.585 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.933 ' HG3' HD22 ' A' ' 82' ' ' LEU . 35.2 mmm -99.55 20.57 13.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.374 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' OE2' ' CD ' ' A' ' 31' ' ' LYS . 83.9 mt-10 -53.83 -36.86 63.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -0.873 . . . . 0.0 109.482 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -59.16 -44.97 92.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.925 . . . . 0.0 109.486 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.882 HD13 ' HB3' ' A' ' 79' ' ' SER . 35.2 mt -66.94 -56.66 9.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.918 . . . . 0.0 109.507 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 1.052 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.6 m-85 -72.01 141.08 49.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.902 . . . . 0.0 109.472 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -125.62 -61.99 0.17 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.55 149.34 43.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.189 -1.183 . . . . 0.0 109.698 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.001 HG13 HG22 ' A' ' 71' ' ' VAL . 45.3 t -117.48 151.86 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.344 -0.847 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.516 ' O ' HG13 ' A' ' 69' ' ' VAL . 80.8 mmm -117.11 137.41 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.231 -0.918 . . . . 0.0 109.676 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 44' ' ' VAL . 43.2 t -145.12 82.33 9.95 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.313 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.72 0.68 6.0 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.649 2.233 . . . . 0.0 111.988 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 14.5 t -125.96 144.08 50.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 47.59 50.27 15.25 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.296 -0.878 . . . . 0.0 109.484 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 44' ' ' VAL . 84.6 tt0 -103.16 129.47 50.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.314 -0.866 . . . . 0.0 109.515 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 80.8 t -63.41 -40.02 87.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.302 -0.874 . . . . 0.0 109.503 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 63.4 t -52.92 -39.01 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -77.89 154.28 31.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.219 -0.925 . . . . 0.0 109.474 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 65.0 mt -133.25 94.58 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.894 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 50.1 ttm-85 -82.49 149.02 27.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.305 -0.872 . . . . 0.0 109.426 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -178.84 36.82 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.83 38.64 41.41 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -83.08 139.76 33.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.218 -1.166 . . . . 0.0 109.526 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 15.2 mmt85 -115.74 161.25 18.99 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.261 -0.899 . . . . 0.0 109.446 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -51.52 -38.33 53.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.162 -0.961 . . . . 0.0 109.519 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 53.0 tttm -129.95 116.69 18.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.412 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.0 t -153.5 156.51 38.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -97.2 137.04 36.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.275 -0.89 . . . . 0.0 109.424 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.5 mtp180 -134.0 145.58 49.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.207 -0.933 . . . . 0.0 109.576 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -136.88 121.67 18.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.273 -0.892 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -131.92 156.05 46.83 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.916 . . . . 0.0 109.518 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.556 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 23.3 p90 -116.65 68.39 4.09 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.167 -0.958 . . . . 0.0 109.583 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.49 155.77 62.83 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.429 ' O ' ' NE2' ' A' ' 13' ' ' GLN . . . 101.21 -6.65 56.28 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.419 ' CE1' ' OE1' ' A' ' 13' ' ' GLN . 1.8 m-85 -119.71 117.21 27.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.2 -1.176 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 78.4 t -131.61 141.85 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.917 . . . . 0.0 109.657 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.843 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.7 mp -106.97 132.96 52.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -0.88 . . . . 0.0 109.271 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.001 HG22 HG13 ' A' ' 42' ' ' VAL . 86.5 t -137.94 121.67 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.178 -0.951 . . . . 0.0 109.639 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.475 ' O ' ' HB2' ' A' ' 73' ' ' MET . 38.0 tt0 -72.16 137.1 46.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.267 -0.895 . . . . 0.0 109.199 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.524 ' HG2' ' N ' ' A' ' 74' ' ' VAL . 45.8 ttp 171.81 157.73 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.263 -0.898 . . . . 0.0 109.604 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.59 ' CG1' HD22 ' A' ' 38' ' ' LEU . 12.2 p -85.69 138.31 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.174 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.589 ' HG2' ' CE2' ' A' ' 10' ' ' TYR . 16.4 mmt -90.04 115.36 27.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.208 -0.932 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.489 ' OD1' ' N ' ' A' ' 79' ' ' SER . 48.8 p-10 -140.48 -176.59 4.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.351 -0.843 . . . . 0.0 109.425 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -73.37 -11.6 60.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.598 ' HA ' ' CE1' ' A' ' 81' ' ' HIS . . . -94.23 -71.1 0.68 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.466 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.882 ' HB3' HD13 ' A' ' 38' ' ' LEU . 68.9 p -50.69 -48.13 58.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.379 -0.826 . . . . 0.0 109.516 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.61 ' NE1' ' CE2' ' A' ' 92' ' ' PHE . 79.7 t90 -48.51 -58.92 3.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -0.928 . . . . 0.0 109.694 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.625 ' CD2' ' N ' ' A' ' 82' ' ' LEU . 1.5 p-80 -57.84 -30.84 66.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.085 -1.009 . . . . 0.0 109.213 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.933 HD22 ' HG3' ' A' ' 35' ' ' MET . 19.0 tp -68.52 -36.34 78.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.384 -0.823 . . . . 0.0 109.328 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.545 HG11 ' CE1' ' A' ' 92' ' ' PHE . 77.5 t -62.04 -42.63 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.248 -0.908 . . . . 0.0 109.399 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -65.96 -33.25 75.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.377 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 35.8 m -60.07 -32.96 71.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.173 -0.954 . . . . 0.0 109.38 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 89' ' ' VAL . 18.8 t -55.37 123.41 49.48 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.487 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.9 Cg_endo -70.83 156.48 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.618 2.212 . . . . 0.0 111.712 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.5 ' HD3' ' CD1' ' A' ' 18' ' ' PHE . 42.4 mtt-85 62.44 35.29 14.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.31 -0.869 . . . . 0.0 109.586 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.588 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.4 p -123.39 125.82 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.436 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.539 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 51.3 mtt -68.93 -62.01 1.56 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.459 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 171.13 -151.57 16.03 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.704 ' O ' HG22 ' A' ' 96' ' ' THR . 93.1 m-85 -96.27 162.96 13.29 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.327 -1.102 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.915 HD11 ' HB2' ' A' ' 13' ' ' GLN . 47.3 mm -110.97 152.7 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.223 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.82 -108.95 3.44 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.409 ' O ' ' C ' ' A' ' 96' ' ' THR . . . -57.06 -37.24 78.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.704 HG22 ' O ' ' A' ' 92' ' ' PHE . 68.8 p 43.73 -148.66 0.05 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -1.167 . . . . 0.0 109.477 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.456 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 26.7 t 44.67 39.92 3.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.173 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.565 ' HB3' ' CZ2' ' A' ' 80' ' ' TRP . 22.8 m-20 67.09 38.2 3.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.347 -0.846 . . . . 0.0 109.313 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.404 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 4.2 mtp180 -161.48 88.41 1.57 Allowed Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.281 -0.887 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.575 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 48.2 Cg_endo -69.96 135.27 29.56 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.783 2.322 . . . . 0.0 111.952 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -99.14 143.48 26.47 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.451 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.45 155.51 63.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.823 2.349 . . . . 0.0 111.759 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.431 HG12 ' O ' ' A' ' 9' ' ' TRP . 24.0 pt -125.5 156.32 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 48.3 m -69.8 150.22 47.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.303 -0.873 . . . . 0.0 109.531 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -59.68 -42.38 92.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -0.899 . . . . 0.0 109.442 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -53.94 -43.09 69.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.314 -0.866 . . . . 0.0 109.424 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.8 mt-10 -53.78 -44.69 70.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.421 HG22 HD23 ' A' ' 70' ' ' LEU . 98.0 t -55.91 -37.95 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.26 -0.9 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -70.44 -34.91 72.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.933 . . . . 0.0 109.381 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.28 -36.71 84.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.761 HG13 HD21 ' A' ' 70' ' ' LEU . 32.1 mm -49.6 -56.48 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.28 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' MET . . . . . 0.492 ' CE ' ' CE ' ' A' ' 43' ' ' MET . 54.2 mtt -59.84 -31.48 69.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.289 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -61.6 -38.55 87.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.393 -0.817 . . . . 0.0 109.446 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 31.9 mtp85 -56.88 -46.33 81.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.249 -0.907 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.4 tp -54.3 -40.19 67.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -80.3 -4.19 52.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -78.32 144.72 35.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.184 -0.947 . . . . 0.0 109.451 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 t -99.59 146.71 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.347 -0.845 . . . . 0.0 109.507 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -48.12 -23.83 3.01 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -67.59 141.08 56.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.234 -1.156 . . . . 0.0 109.483 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.9 122.17 74.36 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.307 -0.87 . . . . 0.0 109.452 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.4 144.35 50.38 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.781 2.321 . . . . 0.0 111.759 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.489 179.962 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.4 m -122.05 146.51 47.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.296 -0.878 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -52.42 -36.02 53.35 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 58.7 99.78 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.438 ' O ' ' HB2' ' A' ' 6' ' ' LYS . 50.4 Cg_endo -70.68 -2.45 10.86 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.73 2.287 . . . . 0.0 111.811 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.438 ' HB2' ' O ' ' A' ' 5' ' ' PRO . 57.5 mttp 61.72 42.49 10.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.274 -0.891 . . . . 0.0 109.471 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.514 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 68.4 mttm -87.27 137.54 32.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.219 -0.925 . . . . 0.0 109.54 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.43 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 63.0 mtt180 -128.16 152.22 48.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.419 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.404 ' CZ3' ' HE2' ' A' ' 43' ' ' MET . 92.9 m95 -85.38 129.84 34.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.486 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 75' ' ' MET . 81.2 m-85 -122.84 155.77 35.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.391 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 93' ' ' ILE . 43.1 t -92.02 150.76 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.512 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.5 t -132.49 124.29 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.308 -0.87 . . . . 0.0 109.387 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.549 ' HB3' ' HE2' ' A' ' 90' ' ' MET . 96.3 mt-30 -85.18 147.22 26.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.282 -0.886 . . . . 0.0 109.528 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.2 155.27 34.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.382 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.519 ' CD1' ' HA ' ' A' ' 88' ' ' ARG . 97.0 m-85 -72.16 147.22 46.82 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.0 m -55.56 144.08 27.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.292 -0.88 . . . . 0.0 109.471 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.436 ' HA2' ' OE1' ' A' ' 51' ' ' GLU . . . 89.91 -33.67 4.36 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -106.45 15.34 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.49 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.427 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.5 tt0 -52.43 -39.27 60.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.408 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.61 7.09 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 22' ' ' VAL . 35.5 ttt-85 -51.72 -52.64 46.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -1.169 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 21' ' ' ARG . 38.9 t -45.64 -38.04 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.175 -0.953 . . . . 0.0 109.314 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.83 -43.04 94.36 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.297 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 58.2 m -67.03 -47.03 72.66 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.287 -0.883 . . . . 0.0 109.3 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.7 m -61.75 -40.59 95.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.36 -0.837 . . . . 0.0 109.435 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.898 ' CD1' HG21 ' A' ' 86' ' ' VAL . 11.5 tp -56.12 -40.98 74.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.9 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -53.32 -44.14 68.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.309 -0.87 . . . . 0.0 109.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.589 ' O ' HD12 ' A' ' 32' ' ' LEU . 97.4 mt-10 -60.68 -47.82 84.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.51 ' C ' HD11 ' A' ' 82' ' ' LEU . 54.9 m80 -63.46 -43.5 97.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.916 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.3 mt -67.83 -50.76 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.902 . . . . 0.0 109.482 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -59.6 -40.0 86.04 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.303 -0.873 . . . . 0.0 109.447 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 28' ' ' GLU . 16.0 mt -63.22 -53.98 44.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.47 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.458 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 59.6 m80 -82.99 -0.6 49.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.56 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.508 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.2 m-20 62.56 47.11 5.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.18 -0.95 . . . . 0.0 109.356 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.99 ' HG3' HD13 ' A' ' 82' ' ' LEU . 57.8 mmm -90.35 0.57 57.2 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.586 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.451 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -47.83 -33.38 7.27 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.906 . . . . 0.0 109.489 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -60.4 -42.32 95.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.617 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.42 -49.41 49.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.303 -0.873 . . . . 0.0 109.313 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 88.5 m-85 -74.74 140.73 44.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.05 -64.69 0.53 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -140.52 157.44 45.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 109.53 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.032 HG13 HG22 ' A' ' 71' ' ' VAL . 61.6 t -120.16 147.41 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.517 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.725 ' HE1' HG11 ' A' ' 108' ' ' VAL . 60.7 mtm -131.46 141.9 49.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.8 t -124.77 105.01 30.03 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.238 -0.914 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.83 60.75 2.27 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.721 2.281 . . . . 0.0 111.803 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 29.2 p -137.19 147.61 45.99 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 109.447 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.444 ' OE1' ' HA ' ' A' ' 47' ' ' GLU . 70.8 mm-40 -63.63 -34.8 78.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.234 -0.916 . . . . 0.0 109.373 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 37.4 tp10 -131.63 145.92 51.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.298 -0.876 . . . . 0.0 109.365 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.92 HG23 HG23 ' A' ' 50' ' ' VAL . 18.3 m -63.53 -31.03 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.92 HG23 HG23 ' A' ' 49' ' ' VAL . 31.4 t -110.04 139.62 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.525 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.436 ' OE1' ' HA2' ' A' ' 17' ' ' GLY . 86.0 tt0 -85.34 125.55 33.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.411 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.435 HG13 ' HG3' ' A' ' 53' ' ' ARG . 24.9 pt -102.45 -7.87 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.313 -0.867 . . . . 0.0 109.597 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ARG . . . . . 0.435 ' HG3' HG13 ' A' ' 52' ' ' ILE . 84.3 mtm180 -110.97 153.8 25.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.137 -0.977 . . . . 0.0 109.511 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -136.62 169.02 23.99 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . 94.27 -0.17 65.95 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.418 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 52.8 mt-30 61.55 42.55 11.11 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -1.158 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -68.38 139.65 55.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 92.5 mtm-85 -134.77 145.08 48.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.25 -0.906 . . . . 0.0 109.477 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 77.7 mttt -105.36 128.92 53.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.179 -0.951 . . . . 0.0 109.464 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 15.7 m -62.93 -19.47 64.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.368 -0.832 . . . . 0.0 109.463 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 90.0 mt-10 -65.55 -32.24 73.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.269 -0.894 . . . . 0.0 109.514 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.576 ' HG2' HG12 ' A' ' 118' ' ' VAL . 65.1 mtt85 -140.32 139.95 35.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -97.9 125.73 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.215 -0.928 . . . . 0.0 109.541 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -119.11 155.66 31.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.46 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.523 ' N ' ' CD1' ' A' ' 65' ' ' PHE . 0.9 OUTLIER -124.34 87.21 54.16 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.235 -0.916 . . . . 0.0 109.538 -179.983 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -70.85 153.65 63.8 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.73 2.287 . . . . 0.0 111.836 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.23 9.68 79.35 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.591 ' CE1' HG13 ' A' ' 11' ' ' VAL . 51.7 t80 -108.9 136.14 48.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.226 -1.161 . . . . 0.0 109.521 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.26 144.8 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.298 -0.876 . . . . 0.0 109.567 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.921 ' CD2' HG13 ' A' ' 108' ' ' VAL . 4.3 mp -113.91 130.9 56.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.293 -0.879 . . . . 0.0 109.144 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.032 HG22 HG13 ' A' ' 42' ' ' VAL . 93.8 t -144.1 120.73 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.728 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.514 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 6.1 tt0 -75.07 129.65 37.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.604 ' HE2' ' HB2' ' A' ' 79' ' ' SER . 9.8 tmm? -168.63 147.94 4.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.313 -0.867 . . . . 0.0 109.58 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -75.81 109.84 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.578 ' HB2' ' CZ ' ' A' ' 10' ' ' TYR . 22.3 tpp -59.43 120.33 9.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.285 -0.884 . . . . 0.0 109.504 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.659 HD21 ' HB3' ' A' ' 78' ' ' ALA . 31.2 p-10 -155.89 170.55 21.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -56.01 -36.54 68.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.557 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -70.48 -71.7 0.23 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.623 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.604 ' HB2' ' HE2' ' A' ' 73' ' ' MET . 10.0 p -47.14 -48.04 23.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 109.56 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 77.6 t90 -51.65 -50.07 61.06 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -66.36 -39.6 89.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.951 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.99 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -59.13 -47.38 85.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.945 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.565 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 55.9 t -56.46 -48.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.87 . . . . 0.0 109.551 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -59.4 -36.77 76.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -60.59 -34.2 73.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.898 HG21 ' CD1' ' A' ' 26' ' ' LEU . 14.1 t -60.13 123.95 75.12 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.393 -0.817 . . . . 0.0 109.51 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.442 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.6 Cg_endo -70.75 163.21 39.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.545 2.163 . . . . 0.0 111.7 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.519 ' HA ' ' CD1' ' A' ' 15' ' ' PHE . 78.9 mmt-85 64.61 28.31 13.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.644 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 86' ' ' VAL . 5.8 p -128.93 137.11 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.918 . . . . 0.0 109.597 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.549 ' HE2' ' HB3' ' A' ' 13' ' ' GLN . 69.4 mtm -89.97 -42.1 11.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.83 -149.73 20.31 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.565 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 90.6 m-85 -102.73 157.21 17.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -1.163 . . . . 0.0 109.52 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 11' ' ' VAL . 8.4 mt -109.3 130.69 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.229 -0.919 . . . . 0.0 109.398 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 148.6 -119.19 1.04 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -66.4 -82.94 0.11 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.4 p -130.43 -173.98 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -1.19 . . . . 0.0 109.662 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 42.2 p -97.22 17.66 16.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.447 ' O ' ' HG2' ' A' ' 99' ' ' ARG . 82.0 m-20 -120.98 -24.67 5.53 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.463 -0.773 . . . . 0.0 109.102 179.674 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 98' ' ' ASP . 7.6 mtt180 -147.87 87.79 5.75 Favored Pre-proline 0 C--N 1.304 -1.405 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.524 ' HB3' ' HB3' ' A' ' 92' ' ' PHE . 42.9 Cg_endo -65.07 120.55 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.939 2.426 . . . . 0.0 112.416 -179.184 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 134.07 78.19 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.435 -0.791 . . . . 0.0 109.217 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.411 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.7 Cg_endo -69.37 152.82 71.35 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.692 2.261 . . . . 0.0 111.904 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.819 HD11 HG22 ' A' ' 108' ' ' VAL . 30.7 pt -118.5 160.57 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.336 -0.853 . . . . 0.0 109.231 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.2 m -70.05 150.47 46.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -0.907 . . . . 0.0 109.431 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -62.74 -37.81 88.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -63.24 -37.7 88.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -0.85 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.448 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 85.5 tt0 -59.82 -39.7 85.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.464 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.921 HG13 ' CD2' ' A' ' 70' ' ' LEU . 73.3 t -62.9 -35.97 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.381 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -68.19 -34.19 75.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.247 -0.908 . . . . 0.0 109.489 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.78 -38.24 88.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.428 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 74.3 mt -55.73 -51.74 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.476 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 53.2 ttm -61.05 -35.52 77.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.426 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.0 m120 -59.59 -32.85 70.76 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -0.905 . . . . 0.0 109.494 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -55.91 -36.8 68.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -0.866 . . . . 0.0 109.583 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 69.2 mt -56.39 -37.69 70.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.56 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -88.34 7.36 32.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.9 . . . . 0.0 109.645 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -93.74 137.92 32.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.23 -0.919 . . . . 0.0 109.524 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.576 HG12 ' HG2' ' A' ' 62' ' ' ARG . 11.7 m -130.1 152.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.422 ' O ' ' HD3' ' A' ' 122' ' ' PRO . . . -104.83 30.74 9.51 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -56.99 -35.95 69.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.26 -1.141 . . . . 0.0 109.422 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 4.2 pttp -120.03 78.8 25.02 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.251 -0.906 . . . . 0.0 109.396 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 119' ' ' GLY . 49.1 Cg_endo -69.86 -20.42 34.39 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.725 2.283 . . . . 0.0 111.805 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 117.919 -1.039 . . . . 0.0 109.51 179.956 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.5 mtp . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.6 t -53.9 -38.83 65.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.514 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -102.71 156.9 17.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.92 . . . . 0.0 109.556 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 54.65 70.56 1.61 Allowed Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.507 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.22 149.81 64.5 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.651 2.234 . . . . 0.0 111.785 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.447 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 78.1 tttt -126.24 138.92 53.67 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 25.0 mttt 61.41 118.7 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.343 -0.848 . . . . 0.0 109.518 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.537 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 80.7 mtt85 -117.76 158.27 25.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.582 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 46.0 m95 -109.53 130.64 55.49 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.506 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CE2' ' O ' ' A' ' 73' ' ' MET . 23.9 m-85 -122.51 143.82 49.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.524 HG11 ' CE2' ' A' ' 68' ' ' TYR . 15.7 t -99.7 129.99 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.297 -0.877 . . . . 0.0 109.515 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' CE1' ' A' ' 92' ' ' PHE . 37.9 t -109.82 131.27 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.884 . . . . 0.0 109.458 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.997 ' CG ' HD11 ' A' ' 93' ' ' ILE . 91.8 mt-30 -78.73 150.07 32.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.322 -0.861 . . . . 0.0 109.462 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -152.53 151.74 31.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -68.42 143.75 54.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.446 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.3 m -59.3 142.92 50.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.12 -32.33 5.48 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.828 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.7 m-85 -106.53 7.95 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.297 -1.119 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.528 ' HG3' HG23 ' A' ' 69' ' ' VAL . 83.5 tt0 -53.74 -32.6 52.77 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.966 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -83.53 -55.27 2.9 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.3 ttt85 -57.94 -33.66 69.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.145 -1.209 . . . . 0.0 109.441 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.828 HG23 ' O ' ' A' ' 18' ' ' PHE . 55.0 t -57.74 -40.89 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.402 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.86 -36.76 85.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.393 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 47.1 m -61.52 -37.31 83.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.477 ' CB ' HG13 ' A' ' 86' ' ' VAL . 24.3 m -60.45 -35.93 77.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.198 -0.939 . . . . 0.0 109.457 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.88 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.2 mt -60.27 -40.5 90.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.873 . . . . 0.0 109.393 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -58.35 -45.27 88.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.301 -0.874 . . . . 0.0 109.571 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -64.14 -60.8 2.78 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.228 -0.92 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.692 ' CD2' HG22 ' A' ' 86' ' ' VAL . 98.7 m-70 -53.18 -50.78 63.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.256 -0.902 . . . . 0.0 109.378 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 82' ' ' LEU . 96.9 mt -58.14 -54.19 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -53.81 -45.19 70.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.426 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 32' ' ' LEU . 71.0 mt -64.29 -55.88 18.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.253 -0.904 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.511 ' ND1' HD12 ' A' ' 82' ' ' LEU . 59.9 m80 -68.34 -10.54 55.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.867 . . . . 0.0 109.384 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.457 ' N ' ' O ' ' A' ' 30' ' ' ILE . 76.1 m-20 61.58 46.63 7.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.331 -0.856 . . . . 0.0 109.389 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.661 ' HB3' HD21 ' A' ' 38' ' ' LEU . 2.6 mtt -95.9 5.67 50.71 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.354 -0.841 . . . . 0.0 109.551 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -50.82 -22.95 2.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -63.38 -40.83 98.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.959 HD12 ' SD ' ' A' ' 73' ' ' MET . 0.4 OUTLIER -91.36 -32.02 15.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.414 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.721 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 58.2 m-85 -75.27 136.9 40.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.363 -0.836 . . . . 0.0 109.395 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.22 -79.94 0.7 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.439 ' OE1' ' N ' ' A' ' 41' ' ' GLU . 56.7 mp0 -129.38 163.96 24.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.135 . . . . 0.0 109.549 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 1.093 HG13 HG22 ' A' ' 71' ' ' VAL . 55.2 t -123.16 160.74 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.316 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.896 ' O ' HG13 ' A' ' 69' ' ' VAL . 94.4 mmm -117.99 138.43 52.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.935 . . . . 0.0 109.573 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.812 HG12 HG22 ' A' ' 46' ' ' THR . 57.2 t -132.32 74.69 75.55 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.19 61.01 1.95 Allowed 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.673 2.248 . . . . 0.0 111.764 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.812 HG22 HG12 ' A' ' 44' ' ' VAL . 13.5 t -135.0 150.42 50.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.425 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -62.06 -27.43 68.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.312 -0.867 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -49.93 -38.62 37.12 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.164 -0.96 . . . . 0.0 109.526 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 1.059 HG13 HG23 ' A' ' 50' ' ' VAL . 8.2 p -49.95 -35.8 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 1.059 HG23 HG13 ' A' ' 49' ' ' VAL . 22.4 t -112.61 141.82 26.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.182 -0.949 . . . . 0.0 109.559 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.462 ' C ' HG23 ' A' ' 52' ' ' ILE . 86.8 tt0 -99.19 138.11 36.76 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.498 ' O ' ' CG1' ' A' ' 52' ' ' ILE . 5.3 pt -155.49 117.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.412 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -47.15 143.93 2.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -56.95 100.4 0.12 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.427 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . -64.72 -30.19 77.27 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.427 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 97.4 mm-40 62.63 42.13 8.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.338 -1.095 . . . . 0.0 109.439 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -75.09 148.29 39.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.335 -0.853 . . . . 0.0 109.408 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -53.51 -34.86 59.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.467 ' HE3' ' HB2' ' A' ' 120' ' ' ASP . 63.6 tttm -88.19 135.89 33.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.188 -0.945 . . . . 0.0 109.392 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 94.2 p -112.77 152.8 28.71 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -106.35 153.21 22.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -126.22 149.63 48.92 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.939 . . . . 0.0 109.447 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.2 mttt -83.22 126.87 33.11 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.293 -0.88 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.402 ' HB2' ' CD1' ' A' ' 65' ' ' PHE . 97.7 m-85 -66.37 -42.96 87.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.874 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 1.9 p90 -139.74 80.6 21.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.547 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.01 146.18 57.91 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.733 2.288 . . . . 0.0 111.903 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 74.91 24.49 71.82 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.524 ' CE2' HG11 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -114.89 123.29 48.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.189 -1.183 . . . . 0.0 109.502 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.896 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -132.52 144.66 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.326 -0.859 . . . . 0.0 109.572 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.853 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.6 mp -115.91 138.48 51.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.278 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 1.093 HG22 HG13 ' A' ' 42' ' ' VAL . 59.5 t -132.46 120.89 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.179 -0.951 . . . . 0.0 109.777 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.449 ' O ' ' HB2' ' A' ' 73' ' ' MET . 35.8 tt0 -69.82 142.12 53.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.036 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.959 ' SD ' HD12 ' A' ' 38' ' ' LEU . 46.9 ttp 173.67 158.41 0.14 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.01 . . . . 0.0 109.578 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.765 HG12 ' HB2' ' A' ' 38' ' ' LEU . 9.1 p -82.84 142.74 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.225 -0.922 . . . . 0.0 109.406 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.592 ' HE3' ' HA ' ' A' ' 75' ' ' MET . 0.0 OUTLIER -72.66 116.1 12.73 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.657 -179.77 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.546 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.3 p-10 -143.93 175.48 9.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 109.33 179.747 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -84.6 -18.34 35.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.21 -0.931 . . . . 0.0 109.621 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.546 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -73.67 -57.54 3.92 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.242 -0.912 . . . . 0.0 109.319 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.517 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 53.4 p -59.34 -41.45 89.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.41 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.417 ' C ' ' O ' ' A' ' 79' ' ' SER . 47.1 t90 -43.98 -45.78 7.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.615 -179.794 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -79.59 -25.84 41.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 109.43 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.811 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.7 OUTLIER -64.03 -41.45 97.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.291 -0.881 . . . . 0.0 109.532 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.875 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 88.6 t -65.94 -48.28 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.257 -0.902 . . . . 0.0 109.521 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -59.56 -41.41 90.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.0 p -61.96 -27.88 69.16 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.208 -0.933 . . . . 0.0 109.54 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' CD2' ' A' ' 26' ' ' LEU . 43.9 t -67.77 126.04 92.09 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 109.515 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.407 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.6 Cg_endo -70.31 163.48 38.55 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 122.653 2.235 . . . . 0.0 111.727 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.443 ' HB2' HG22 ' A' ' 22' ' ' VAL . 63.1 mtt-85 61.54 44.63 8.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 99.0 t -131.21 118.9 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.271 -0.893 . . . . 0.0 109.539 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.51 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 74.8 mtm -70.57 -42.22 71.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.81 -162.41 35.06 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.875 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -104.82 171.26 7.42 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.235 -1.156 . . . . 0.0 109.453 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.997 HD11 ' CG ' ' A' ' 13' ' ' GLN . 32.6 mm -124.43 128.45 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.452 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 172.71 -148.96 10.95 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.45 -39.54 50.25 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.412 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 29.2 p -130.7 171.98 12.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.185 -1.185 . . . . 0.0 109.497 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 p -88.55 14.73 9.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.169 -0.957 . . . . 0.0 109.443 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 99' ' ' ARG . 17.8 p30 -130.21 -13.64 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.772 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.429 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 49.5 mtt180 -145.75 91.42 5.66 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.231 -0.918 . . . . 0.0 108.884 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.48 113.89 3.08 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.774 2.316 . . . . 0.0 112.007 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.21 136.84 93.89 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.263 -0.898 . . . . 0.0 109.395 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.537 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.41 154.67 65.0 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.654 2.236 . . . . 0.0 111.814 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.4 pt -124.03 159.7 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 38.5 m -66.04 148.41 51.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.258 -0.902 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 73.6 m-20 -57.41 -41.59 80.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -57.74 -39.81 78.19 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -51.43 -40.75 59.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.923 . . . . 0.0 109.417 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.517 HG21 ' CG ' ' A' ' 9' ' ' TRP . 73.8 t -63.02 -34.6 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.388 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -63.24 -38.11 89.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.61 -40.4 95.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.386 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 27.0 mm -51.55 -57.32 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' MET . . . . . 0.462 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.2 mtp -60.86 -35.71 77.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.318 179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 53.0 t-20 -55.17 -43.45 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -0.889 . . . . 0.0 109.38 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.43 ' O ' ' N ' ' A' ' 117' ' ' GLN . 90.5 mtt-85 -51.54 -54.29 28.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 11.8 tp -45.63 -46.67 14.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 109.388 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -61.31 -28.94 69.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.411 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 114' ' ' ARG . 56.0 tt0 -73.35 141.02 47.06 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.3 t -120.67 136.09 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.452 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -46.35 -26.83 2.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.467 ' HB2' ' HE3' ' A' ' 59' ' ' LYS . 83.7 m-20 -110.48 139.98 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.321 -1.105 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 6.8 mtpp -122.26 79.64 44.55 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.443 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.57 144.3 54.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.772 2.314 . . . . 0.0 111.801 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 23.2 mmt180 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 117.993 -1.004 . . . . 0.0 109.464 179.994 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.0 mtm . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.332 0.587 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.0 p -63.0 -25.84 68.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.935 . . . . 0.0 109.465 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.31 148.16 29.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.145 -0.972 . . . . 0.0 109.486 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.99 74.84 71.72 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.46 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.64 140.42 39.36 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.682 2.255 . . . . 0.0 111.822 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -105.45 139.37 40.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.239 -0.913 . . . . 0.0 109.404 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.518 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 69.5 mttt -127.52 139.35 52.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.468 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 96.3 mtt180 -118.62 150.64 39.35 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.293 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.401 ' O ' HG12 ' A' ' 103' ' ' ILE . 65.7 m95 -99.04 135.65 40.14 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 109.668 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.417 ' CD2' ' CE ' ' A' ' 75' ' ' MET . 55.5 m-85 -128.35 153.61 46.85 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.874 . . . . 0.0 109.398 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.1 t -100.16 137.46 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.906 . . . . 0.0 109.511 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.53 124.63 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.214 -0.929 . . . . 0.0 109.365 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.526 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 98.0 mt-30 -90.47 145.73 24.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.512 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -149.63 163.47 37.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.332 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -67.02 140.88 57.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.189 -0.944 . . . . 0.0 109.52 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.9 m -58.07 145.78 35.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.55 -31.07 5.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PHE . . . . . 0.514 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 96.5 m-85 -111.21 9.82 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -1.183 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.514 ' OE2' ' CG ' ' A' ' 45' ' ' PRO . 81.6 tt0 -61.11 -29.9 70.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.253 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -81.45 -36.9 18.99 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -66.87 -49.05 66.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -1.129 . . . . 0.0 109.419 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.619 HG21 ' O ' ' A' ' 88' ' ' ARG . 21.8 t -48.33 -41.56 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -0.98 . . . . 0.0 109.038 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.7 -46.59 84.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -0.867 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 88.4 m -62.38 -37.13 84.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.557 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.523 ' OG ' HG13 ' A' ' 86' ' ' VAL . 98.6 p -65.99 -37.0 84.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.435 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.688 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.4 mt -52.44 -72.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.35 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.402 ' C ' ' O ' ' A' ' 26' ' ' LEU . 41.8 ttm180 -44.25 -41.48 5.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.351 -0.843 . . . . 0.0 109.534 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -56.1 -37.36 69.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.909 . . . . 0.0 109.479 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' HIS . . . . . . . . . . . . . 37.9 m80 -79.27 -29.24 42.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.892 . . . . 0.0 109.374 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.958 HD12 ' CD1' ' A' ' 39' ' ' PHE . 17.6 mm -66.79 -43.4 89.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.559 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -67.19 -36.87 82.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.525 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.452 HD23 ' HA ' ' A' ' 32' ' ' LEU . 38.4 mt -70.18 -53.51 16.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 0.0 109.545 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.491 ' ND1' HD12 ' A' ' 82' ' ' LEU . 71.2 m80 -84.76 10.95 10.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 46.34 46.74 13.77 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.853 ' HG3' HD13 ' A' ' 82' ' ' LEU . 56.8 mmm -97.25 15.76 21.88 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.195 -0.941 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 74.9 mm-40 -55.34 -33.21 63.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 109.447 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -65.43 -45.91 81.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.277 -0.889 . . . . 0.0 109.357 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.477 HD13 ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -68.04 -55.26 13.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.303 -0.873 . . . . 0.0 109.26 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.958 ' CD1' HD12 ' A' ' 30' ' ' ILE . 77.6 m-85 -67.37 141.6 57.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.323 -0.861 . . . . 0.0 109.435 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.99 -69.28 0.76 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -143.14 166.17 25.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -1.145 . . . . 0.0 109.542 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 83.3 t -117.4 138.38 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.412 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.771 ' O ' HG13 ' A' ' 69' ' ' VAL . 83.2 mtp -127.87 156.35 42.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.208 -0.933 . . . . 0.0 109.466 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.69 HG12 ' H ' ' A' ' 46' ' ' THR . 31.9 t -146.79 132.34 9.25 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.271 -0.893 . . . . 0.0 109.382 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.514 ' CG ' ' OE2' ' A' ' 19' ' ' GLU . 49.1 Cg_endo -69.98 -0.65 7.41 Favored 'Trans proline' 0 C--O 1.215 -0.625 0 C-N-CA 122.605 2.203 . . . . 0.0 111.792 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.69 ' H ' HG12 ' A' ' 44' ' ' VAL . 2.4 p -133.84 151.43 51.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.152 -0.967 . . . . 0.0 109.45 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -119.11 135.54 54.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.487 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -65.82 143.87 57.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 109.567 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.626 ' O ' HG13 ' A' ' 50' ' ' VAL . 21.7 m -127.13 155.76 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.243 -0.911 . . . . 0.0 109.485 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 49' ' ' VAL . 13.9 m -160.23 -41.4 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.251 -0.906 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.42 ' N ' HG23 ' A' ' 50' ' ' VAL . 23.9 pt-20 -67.94 -26.55 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.741 ' O ' HG23 ' A' ' 52' ' ' ILE . 6.2 tp -133.46 101.49 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.58 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 30.1 mmm-85 -56.76 -35.58 68.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 92.03 -164.56 28.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 58' ' ' ARG . . . -140.43 178.05 20.26 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -60.82 -32.39 71.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.263 -1.139 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -56.42 -35.28 67.63 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ARG . . . . . 0.461 ' O ' ' O ' ' A' ' 55' ' ' GLY . 90.9 mtt180 -118.97 146.91 44.61 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 109.46 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 34.0 tttp -132.77 132.05 41.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.287 -0.883 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 24.5 m -50.89 -43.32 59.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.204 -0.935 . . . . 0.0 109.458 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -68.66 144.28 54.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.47 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.443 ' NE ' HD11 ' A' ' 115' ' ' LEU . 92.6 mtt-85 -121.45 146.48 46.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.246 -0.909 . . . . 0.0 109.496 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 34.9 mttm -87.15 -8.38 57.02 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.512 ' C ' ' CG ' ' A' ' 65' ' ' PHE . 20.3 m-85 -48.43 -37.19 16.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.583 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.946 ' CE2' HG23 ' A' ' 111' ' ' ILE . 0.0 OUTLIER 169.96 76.14 0.03 OUTLIER Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.956 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -71.25 153.07 61.99 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.691 2.261 . . . . 0.0 111.802 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . 71.93 10.12 72.14 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.529 ' CE2' HD13 ' A' ' 93' ' ' ILE . 2.7 m-85 -112.25 121.4 44.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.112 -1.228 . . . . 0.0 109.574 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 43' ' ' MET . 57.8 t -129.41 144.12 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.217 -0.927 . . . . 0.0 109.571 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.992 HD21 HD12 ' A' ' 111' ' ' ILE . 4.3 mp -109.04 130.05 55.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.497 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -140.91 126.4 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.319 -0.863 . . . . 0.0 109.574 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.518 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 2.6 tt0 -69.54 138.95 53.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.932 . . . . 0.0 109.268 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.493 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 14.9 ttp 178.76 152.86 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.226 -0.922 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.471 ' N ' ' HG2' ' A' ' 73' ' ' MET . 23.6 m -99.2 160.48 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.376 -0.827 . . . . 0.0 109.557 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.566 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 14.6 mmt -94.24 120.5 34.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.295 -0.878 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.8 p-10 -146.21 -161.18 1.26 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.565 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -101.49 42.4 1.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -0.878 . . . . 0.0 109.452 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -159.33 -51.11 0.06 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.291 -0.881 . . . . 0.0 109.337 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 83' ' ' VAL . 53.4 p -65.98 -30.19 70.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 109.31 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -66.52 -46.58 75.71 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.427 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -69.35 -33.15 72.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.34 -0.85 . . . . 0.0 109.35 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.853 HD13 ' HG3' ' A' ' 35' ' ' MET . 5.1 tt -65.79 -35.58 81.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.426 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.937 HG11 ' CE2' ' A' ' 92' ' ' PHE . 72.3 t -69.38 -47.49 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.415 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 42.2 ttt-85 -61.15 -33.59 73.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.431 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.3 p -63.15 -22.89 67.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.424 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.688 HG21 ' CD2' ' A' ' 26' ' ' LEU . 12.7 t -60.93 120.33 52.82 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.343 -0.848 . . . . 0.0 109.51 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.413 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.1 Cg_endo -71.2 160.11 49.98 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.588 2.192 . . . . 0.0 111.862 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.619 ' O ' HG21 ' A' ' 22' ' ' VAL . 50.0 mtt85 60.94 33.14 19.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -0.932 . . . . 0.0 109.683 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.585 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.3 p -122.28 132.4 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -0.941 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 95.4 mtp -72.51 -43.03 64.15 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.36 -153.86 25.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.937 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.6 OUTLIER -107.15 164.26 12.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.348 -1.09 . . . . 0.0 109.507 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 11' ' ' VAL . 58.3 mt -116.39 139.6 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 113.76 134.77 5.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 48.51 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.525 ' OG1' ' N ' ' A' ' 97' ' ' SER . 0.8 OUTLIER -141.16 -172.08 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.346 -1.091 . . . . 0.0 109.421 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.525 ' N ' ' OG1' ' A' ' 96' ' ' THR . 35.4 p -91.32 20.97 4.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.201 -0.937 . . . . 0.0 109.633 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -121.29 -29.56 4.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.342 -0.849 . . . . 0.0 108.931 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -149.23 83.39 6.61 Favored Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 44.0 Cg_endo -65.6 128.32 19.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.948 2.432 . . . . 0.0 112.484 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.63 141.93 90.93 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.489 -0.757 . . . . 0.0 109.269 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.0 Cg_endo -69.41 153.59 70.32 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.693 2.262 . . . . 0.0 111.924 -179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.736 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.7 pt -116.22 158.65 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 109.35 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.436 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 45.4 m -71.66 147.91 47.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.493 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -58.94 -36.38 74.67 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.318 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -59.83 -39.19 84.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.4 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.436 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.5 mt-10 -57.57 -46.4 84.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.29 -0.881 . . . . 0.0 109.361 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.736 ' CG2' HD11 ' A' ' 103' ' ' ILE . 71.5 t -61.64 -39.63 83.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.388 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -66.82 -37.51 84.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.258 -0.901 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.9 63.62 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.353 -0.842 . . . . 0.0 109.426 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.992 HD12 HD21 ' A' ' 70' ' ' LEU . 55.0 mt -50.51 -56.41 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.325 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' MET . . . . . 0.498 ' HG3' ' CE ' ' A' ' 43' ' ' MET . 96.0 mmm -60.82 -39.26 88.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.912 . . . . 0.0 109.418 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -50.38 -49.24 54.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.362 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 62.9 mtt180 -55.7 -52.71 62.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.296 -0.878 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.443 HD11 ' NE ' ' A' ' 62' ' ' ARG . 9.5 tp -46.72 -45.19 19.39 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 109.442 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -62.21 -28.46 69.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.898 . . . . 0.0 109.534 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -73.2 129.66 38.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.215 -0.928 . . . . 0.0 109.443 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -122.52 139.47 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.212 -0.93 . . . . 0.0 109.432 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.96 -20.85 6.79 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -84.42 140.25 31.66 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -1.155 . . . . 0.0 109.506 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 ttpp -123.53 73.27 51.46 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.191 -0.943 . . . . 0.0 109.429 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' PRO . . . . . 0.436 ' O ' ' O ' ' A' ' 123' ' ' ARG . 49.4 Cg_endo -70.26 -20.24 32.72 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.723 2.282 . . . . 0.0 111.663 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 122' ' ' PRO . 60.6 mtt180 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.502 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtt . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.315 0.578 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 50.2 m -118.12 147.11 43.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.501 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -108.49 140.47 41.77 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.44 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 5' ' ' PRO . . . -96.67 165.33 16.22 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.914 . . . . 0.0 109.449 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 4' ' ' ALA . 50.2 Cg_endo -69.8 144.6 54.35 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.727 2.284 . . . . 0.0 111.811 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 80.0 mttt -121.14 151.62 39.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.445 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.448 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 63.0 mttm -80.27 136.87 36.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.349 -0.845 . . . . 0.0 109.464 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.536 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 88.2 mtt-85 -121.88 157.89 30.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TRP . . . . . 0.489 ' CG ' HG21 ' A' ' 108' ' ' VAL . 90.3 m95 -88.01 133.92 33.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.2 -0.938 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.1 m-85 -119.05 156.47 29.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 44.7 t -99.09 143.59 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.254 -0.904 . . . . 0.0 109.428 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.7 t -125.21 123.19 64.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.309 -0.87 . . . . 0.0 109.314 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLN . . . . . 0.783 ' HB2' HD11 ' A' ' 93' ' ' ILE . 62.5 tt0 -94.57 135.16 36.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.661 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.427 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -152.88 155.8 37.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.315 -0.866 . . . . 0.0 109.317 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -56.41 140.74 44.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.259 -0.901 . . . . 0.0 109.576 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.507 ' HB2' ' HB2' ' A' ' 66' ' ' PRO . 47.0 p -65.45 151.97 45.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 109.487 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.56 -31.34 5.24 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -118.89 8.82 11.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -1.175 . . . . 0.0 109.466 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.534 ' HG3' ' N ' ' A' ' 20' ' ' GLY . 23.4 pt-20 -55.41 -46.19 76.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.395 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -59.98 -38.6 94.43 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttm-85 -55.62 -49.37 73.0 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.3 -1.118 . . . . 0.0 109.38 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.935 HG13 HG11 ' A' ' 86' ' ' VAL . 39.2 t -47.24 -39.72 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.267 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.13 -44.57 95.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.882 . . . . 0.0 109.339 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 89.4 m -65.93 -51.34 59.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.309 -0.87 . . . . 0.0 109.391 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 83.1 p -59.65 -36.06 75.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.402 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.459 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 tp -56.57 -53.1 61.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.2 -0.937 . . . . 0.0 109.494 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.417 ' C ' ' O ' ' A' ' 26' ' ' LEU . 57.0 ttt180 -43.7 -49.82 7.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.41 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.418 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 96.3 mt-10 -54.04 -45.39 71.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.296 -0.878 . . . . 0.0 109.361 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.402 ' HD2' HG22 ' A' ' 86' ' ' VAL . 76.3 m-70 -61.32 -34.34 75.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.306 -0.871 . . . . 0.0 109.297 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.961 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.2 mm -63.22 -54.5 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.465 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 36.0 mttt -66.96 -37.59 84.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.924 . . . . 0.0 109.389 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.418 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 66.4 mt -60.58 -55.32 34.81 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.371 -0.831 . . . . 0.0 109.433 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.436 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 73.0 m80 -89.46 0.09 57.11 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.315 -0.866 . . . . 0.0 109.56 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.49 ' N ' ' O ' ' A' ' 30' ' ' ILE . 79.3 m-20 60.18 49.5 7.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.898 . . . . 0.0 109.48 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.987 ' HG3' HD13 ' A' ' 82' ' ' LEU . 51.2 mmm -101.87 14.08 32.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.63 ' CG ' HG22 ' A' ' 30' ' ' ILE . 97.8 mt-10 -52.06 -36.81 51.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -60.86 -40.75 94.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.229 -0.919 . . . . 0.0 109.548 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.857 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.48 -49.05 52.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.506 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PHE . . . . . 0.961 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -75.76 138.03 40.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.1 -68.62 0.42 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.426 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 84.7 tt0 -129.96 155.93 45.28 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.525 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.969 HG13 HG22 ' A' ' 71' ' ' VAL . 39.2 t -123.74 145.37 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' MET . . . . . 0.524 ' O ' HG13 ' A' ' 69' ' ' VAL . 92.9 mtp -124.44 150.48 45.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.936 HG12 ' H ' ' A' ' 46' ' ' THR . 66.6 t -142.08 132.04 12.52 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.383 -0.823 . . . . 0.0 109.235 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.405 ' HB2' ' CD2' ' A' ' 64' ' ' PHE . 47.8 Cg_endo -68.76 -0.38 6.03 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.758 2.305 . . . . 0.0 112.105 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.936 ' H ' HG12 ' A' ' 44' ' ' VAL . 11.6 p -121.74 159.16 27.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 109.485 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -111.48 153.84 25.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.414 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -103.66 137.79 41.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.463 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 42.1 t -118.31 134.85 60.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.199 -0.938 . . . . 0.0 109.475 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.445 HG23 ' N ' ' A' ' 51' ' ' GLU . 17.2 m -68.29 -36.59 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.486 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.445 ' N ' HG23 ' A' ' 50' ' ' VAL . 85.1 tt0 -111.17 136.66 49.91 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.529 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 82.1 mt -58.77 -44.65 90.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -0.956 . . . . 0.0 109.479 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 50.8 mtp85 -60.27 -35.91 76.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.519 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 78.31 -166.23 52.4 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -81.11 6.24 63.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -114.54 155.1 27.08 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 83.8 mtt180 -61.3 -33.79 74.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.451 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -124.46 149.23 47.05 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.494 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -82.42 136.18 34.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.514 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.8 p -115.4 153.15 31.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.124 -0.985 . . . . 0.0 109.566 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.56 154.47 23.69 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.269 -0.894 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.467 ' HD2' ' OD2' ' A' ' 120' ' ' ASP . 25.2 mtm180 -128.51 146.66 50.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.175 -0.953 . . . . 0.0 109.54 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 23.1 mttm -97.24 131.79 43.62 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.913 . . . . 0.0 109.367 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.763 ' HB2' HD12 ' A' ' 115' ' ' LEU . 41.8 p90 -154.97 153.7 31.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.599 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.589 ' CD2' ' O ' ' A' ' 65' ' ' PHE . 33.5 p90 -54.67 105.99 0.6 Allowed Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.21 -0.931 . . . . 0.0 109.461 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.507 ' HB2' ' HB2' ' A' ' 16' ' ' SER . 52.9 Cg_endo -91.53 152.33 3.55 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.04 2.493 . . . . 0.0 111.9 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 14' ' ' ALA . . . 92.84 13.84 55.98 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.655 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -133.19 121.92 23.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.192 -1.181 . . . . 0.0 109.475 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 43' ' ' MET . 60.7 t -131.02 147.03 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -0.853 . . . . 0.0 109.521 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.813 ' N ' HD12 ' A' ' 70' ' ' LEU . 3.8 mp -111.82 128.01 55.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.351 -0.843 . . . . 0.0 109.42 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.969 HG22 HG13 ' A' ' 42' ' ' VAL . 98.6 t -139.85 124.58 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLN . . . . . 0.448 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 37.9 tt0 -77.74 132.3 38.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.26 -0.9 . . . . 0.0 109.363 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.6 ttp -165.39 164.31 19.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.2 -0.937 . . . . 0.0 109.493 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.522 ' N ' ' HG2' ' A' ' 73' ' ' MET . 42.2 t -82.47 142.76 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.504 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' MET . . . . . 0.629 ' HE2' ' HA ' ' A' ' 75' ' ' MET . 1.2 tpt -81.15 111.38 17.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.901 . . . . 0.0 109.462 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.558 ' ND2' HD22 ' A' ' 38' ' ' LEU . 37.6 p-10 -150.46 164.04 36.91 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 109.393 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 85.2 m-20 -74.51 -26.81 60.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.158 -0.964 . . . . 0.0 109.405 179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -65.44 -58.02 6.88 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.499 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.461 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 11.2 p -56.62 -46.44 80.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.695 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' TRP . . . . . 0.59 ' CH2' ' HD2' ' A' ' 84' ' ' ARG . 37.9 t90 -43.63 -59.35 2.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.236 -0.915 . . . . 0.0 109.62 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 41.5 m80 -57.24 -35.95 70.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.935 . . . . 0.0 109.614 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.987 HD13 ' HG3' ' A' ' 35' ' ' MET . 1.0 OUTLIER -62.91 -41.32 99.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.919 . . . . 0.0 109.66 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.55 HG11 ' CZ ' ' A' ' 92' ' ' PHE . 50.5 t -60.55 -46.09 96.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.59 ' HD2' ' CH2' ' A' ' 80' ' ' TRP . 29.5 mtp180 -56.6 -36.0 68.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -61.12 -28.78 69.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.24 -0.913 . . . . 0.0 109.537 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.935 HG11 HG13 ' A' ' 22' ' ' VAL . 40.2 t -55.4 121.28 36.8 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.276 -0.89 . . . . 0.0 109.446 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.444 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.3 Cg_endo -70.5 149.94 62.95 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.684 2.256 . . . . 0.0 111.819 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.444 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.9 mtt85 61.3 40.19 14.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.339 -0.85 . . . . 0.0 109.521 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.587 HG12 ' O ' ' A' ' 86' ' ' VAL . 9.9 p -122.33 128.19 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.338 -0.851 . . . . 0.0 109.316 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' MET . . . . . 0.49 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.0 mmm -71.66 -53.72 12.68 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.16 -0.962 . . . . 0.0 109.506 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.42 -150.69 20.92 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.554 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 82.7 m-85 -100.53 157.68 16.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -1.095 . . . . 0.0 109.56 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.783 HD11 ' HB2' ' A' ' 13' ' ' GLN . 38.8 mm -117.6 135.94 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 0.0 109.331 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 110.12 145.86 10.86 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 50.75 -95.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 94' ' ' GLY . 19.3 p -140.33 -173.04 3.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -1.19 . . . . 0.0 109.558 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 p -95.53 22.24 7.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.215 -0.928 . . . . 0.0 109.485 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.551 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 73.4 m-20 -120.51 -25.13 5.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.371 -0.831 . . . . 0.0 109.215 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.445 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 15.2 mtp180 -153.04 102.36 2.64 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.358 -0.839 . . . . 0.0 109.013 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.554 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 44.3 Cg_endo -66.46 114.58 3.13 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.769 2.313 . . . . 0.0 112.012 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.54 140.29 88.89 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.397 -0.814 . . . . 0.0 109.487 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.536 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.4 Cg_endo -70.42 153.4 65.95 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.669 2.246 . . . . 0.0 111.823 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.608 HD11 HG22 ' A' ' 108' ' ' VAL . 31.8 pt -126.96 157.4 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.887 . . . . 0.0 109.49 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 53.0 p -72.36 151.07 42.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.618 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -61.6 -35.03 76.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -61.84 -40.12 94.21 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG13 ' A' ' 111' ' ' ILE . 86.5 tt0 -59.52 -41.88 90.99 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.293 -0.88 . . . . 0.0 109.467 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.608 HG22 HD11 ' A' ' 103' ' ' ILE . 70.6 t -60.29 -37.51 74.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.315 -0.866 . . . . 0.0 109.471 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -64.7 -40.27 95.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.973 . . . . 0.0 109.378 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -66.04 -43.13 88.46 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 107' ' ' GLU . 70.8 mt -52.44 -49.53 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.213 -0.929 . . . . 0.0 109.468 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 94.9 mmm -60.15 -36.67 78.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -58.13 -34.61 70.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.576 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.412 ' O ' ' N ' ' A' ' 117' ' ' GLN . 49.4 ttt85 -52.58 -46.23 66.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.42 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.763 HD12 ' HB2' ' A' ' 64' ' ' PHE . 3.1 tp -45.33 -45.36 12.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.584 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -69.26 -28.48 66.35 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.279 -0.888 . . . . 0.0 109.471 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.412 ' N ' ' O ' ' A' ' 114' ' ' ARG . 64.1 tt0 -50.57 -38.07 43.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.232 -0.918 . . . . 0.0 109.478 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.2 t -68.91 132.29 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.544 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.458 ' O ' ' HD3' ' A' ' 122' ' ' PRO . . . -83.43 98.26 2.07 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.467 ' OD2' ' HD2' ' A' ' 62' ' ' ARG . 87.8 m-20 -53.36 -41.33 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.232 -1.158 . . . . 0.0 109.563 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.82 83.43 66.2 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.495 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 119' ' ' GLY . 48.7 Cg_endo -69.43 -18.47 38.56 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.719 2.28 . . . . 0.0 111.848 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 27.3 mtm180 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.468 -179.997 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 89.7 mttt . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 61.9 mtt180 -122.67 152.94 40.03 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.228 -0.92 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.745 ' CG ' HG21 ' A' ' 108' ' ' VAL . 74.9 m95 -95.01 133.89 38.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CE2' ' O ' ' A' ' 73' ' ' MET . 28.3 m-85 -122.69 149.39 44.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -0.873 . . . . 0.0 109.308 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 25.0 t -97.68 142.62 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.491 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.75 130.81 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.478 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.818 ' HB2' HD11 ' A' ' 93' ' ' ILE . 57.3 tt0 -96.96 128.1 43.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 109.464 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.748 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.08 164.23 30.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.214 -0.928 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -69.22 145.33 53.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.2 p -66.19 149.49 50.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.31 -33.03 4.69 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.521 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.9 m-85 -109.53 1.6 19.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.3 -1.118 . . . . 0.0 109.623 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.554 ' OE2' HG22 ' A' ' 69' ' ' VAL . 85.6 tt0 -53.45 -40.07 64.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.44 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.57 -47.77 74.4 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -63.65 -39.36 94.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -1.171 . . . . 0.0 109.461 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.748 HG21 ' HB1' ' A' ' 14' ' ' ALA . 60.6 t -52.18 -44.69 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.473 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.76 -42.79 98.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.333 -0.854 . . . . 0.0 109.465 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.1 m -61.2 -39.0 88.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.462 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 24.1 m -58.95 -39.18 80.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.778 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.3 mt -56.11 -46.61 79.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttt85 -56.15 -41.89 76.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -0.89 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -66.78 -58.73 4.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.986 ' HB3' HD11 ' A' ' 82' ' ' LEU . 73.4 m-70 -57.22 -48.63 78.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 0.0 109.498 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.727 HG23 ' CB ' ' A' ' 35' ' ' MET . 89.7 mt -61.9 -49.52 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.251 -0.906 . . . . 0.0 109.446 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -57.87 -45.56 86.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.467 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.451 ' HA ' HD23 ' A' ' 32' ' ' LEU . 45.3 mt -63.26 -48.62 77.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -83.44 5.5 23.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.251 -0.906 . . . . 0.0 109.52 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 30' ' ' ILE . 38.1 t30 54.69 46.13 25.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.33 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.812 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -96.54 3.89 52.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.579 -179.914 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.1 mt-10 -53.4 -35.61 60.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -54.3 -40.46 67.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.22 -0.925 . . . . 0.0 109.463 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.539 ' CD1' ' CG ' ' A' ' 35' ' ' MET . 0.7 OUTLIER -73.9 -48.77 28.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.288 -0.883 . . . . 0.0 109.294 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.625 ' CD1' HD13 ' A' ' 30' ' ' ILE . 89.4 m-85 -70.41 130.12 41.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.358 -0.839 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.14 -63.16 0.58 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -141.44 115.46 9.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -1.19 . . . . 0.0 109.66 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.013 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -89.5 147.08 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.39 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.644 ' O ' HG13 ' A' ' 69' ' ' VAL . 46.3 mtt -112.88 148.98 33.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 44' ' ' VAL . 35.3 t . . . . . 0 N--CA 1.491 1.575 0 O-C-N 121.342 -0.849 . . . . 0.0 109.274 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.459 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -117.59 128.51 55.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -1.14 . . . . 0.0 109.492 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.644 HG13 ' O ' ' A' ' 43' ' ' MET . 65.8 t -130.73 143.44 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.273 -0.892 . . . . 0.0 109.538 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.846 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.1 mp -107.32 133.04 52.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.322 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.013 HG22 HG23 ' A' ' 42' ' ' VAL . 43.1 t -139.51 131.15 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.684 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.572 ' OE1' ' CE2' ' A' ' 9' ' ' TRP . 23.2 tt0 -88.05 128.5 35.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.218 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 55.7 ttp -173.98 163.96 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.179 -0.951 . . . . 0.0 109.682 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' A' ' 73' ' ' MET . 28.6 m -87.45 138.24 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.267 -0.896 . . . . 0.0 109.459 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.64 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 1.1 ttm -76.68 116.76 17.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.434 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 52.8 p-10 -145.01 170.71 15.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.428 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -67.88 -33.66 75.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -0.919 . . . . 0.0 109.915 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.561 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -67.7 -69.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 0.0 109.7 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 80' ' ' TRP . 9.9 p -46.6 -59.52 2.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -0.892 . . . . 0.0 109.645 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.49 ' N ' ' OG ' ' A' ' 79' ' ' SER . 68.0 t90 -42.84 -58.09 2.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.638 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -58.34 -37.69 75.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.944 . . . . 0.0 109.493 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.986 HD11 ' HB3' ' A' ' 29' ' ' HIS . 67.4 tp -63.41 -39.7 95.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.568 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.944 HG11 ' CE2' ' A' ' 92' ' ' PHE . 85.4 t -59.93 -47.29 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 109.584 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.59 -37.69 76.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.543 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.4 p -64.67 -26.28 68.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -0.914 . . . . 0.0 109.499 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.778 HG21 ' CD2' ' A' ' 26' ' ' LEU . 98.7 t -60.79 124.51 79.73 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.486 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.435 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.4 Cg_endo -70.35 156.41 61.88 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.696 2.264 . . . . 0.0 111.795 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 68.2 mtt-85 61.28 46.07 8.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.395 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.406 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.4 t -132.85 118.65 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.593 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' GLN . 64.2 mtt -69.03 -42.82 75.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.423 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.0 -152.81 24.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.944 ' CE2' HG11 ' A' ' 83' ' ' VAL . 3.4 m-85 -109.99 161.82 15.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.232 -1.158 . . . . 0.0 109.537 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.818 HD11 ' HB2' ' A' ' 13' ' ' GLN . 14.5 mm -115.9 116.35 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.507 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -172.88 -148.1 6.14 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.59 -35.01 67.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.78 HG23 ' H ' ' A' ' 98' ' ' ASP . 11.6 t -138.9 175.6 9.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -1.189 . . . . 0.0 109.665 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 p -93.56 19.44 8.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.288 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.78 ' H ' HG23 ' A' ' 96' ' ' THR . 86.0 m-20 -131.19 -0.83 4.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 109.429 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 98' ' ' ASP . 1.1 mtt180 -168.28 96.39 0.58 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.88 . . . . 0.0 109.003 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.64 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 45.9 Cg_endo -67.52 116.88 4.46 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.798 2.332 . . . . 0.0 112.16 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -60.72 135.5 92.44 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.267 -0.896 . . . . 0.0 109.304 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.1 Cg_endo -69.92 153.32 68.32 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.674 2.25 . . . . 0.0 111.785 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.831 HD11 HG22 ' A' ' 108' ' ' VAL . 28.3 pt -126.42 157.6 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.386 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.48 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 38.7 m -63.27 147.81 49.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.4 -39.31 83.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.428 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.2 tttt -59.74 -39.28 84.23 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.48 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -59.95 -41.4 91.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.256 -0.903 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.842 HG13 HD23 ' A' ' 70' ' ' LEU . 97.7 t -61.89 -35.96 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.515 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -67.33 -33.82 76.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.274 -0.891 . . . . 0.0 109.485 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.73 96.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.226 -0.921 . . . . 0.0 109.422 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.629 HD12 HD21 ' A' ' 70' ' ' LEU . 70.2 mt -56.86 -51.93 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 109.482 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 89.1 mtp . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.457 -179.983 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 76.9 mttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.552 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 49.0 mtt180 -80.59 148.32 30.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.523 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.536 ' CH2' ' HG3' ' A' ' 43' ' ' MET . 77.2 m95 -78.01 135.68 37.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.947 . . . . 0.0 109.639 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.615 ' CZ ' ' CG ' ' A' ' 75' ' ' MET . 76.0 m-85 -132.21 139.02 48.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -0.92 . . . . 0.0 109.372 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.899 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.7 t -83.17 148.94 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.108 -0.995 . . . . 0.0 109.519 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.91 122.94 57.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.423 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.51 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 13.4 mt-30 -78.83 145.0 34.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.266 -0.896 . . . . 0.0 109.588 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.764 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.03 157.09 34.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.299 -0.876 . . . . 0.0 109.401 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -63.86 142.86 58.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.481 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.1 p -68.12 151.0 47.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.463 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.21 -34.08 4.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.452 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -112.08 9.22 20.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.624 ' OE2' HG23 ' A' ' 69' ' ' VAL . 85.6 tt0 -54.18 -41.0 68.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.87 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.53 -44.33 83.38 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.7 ttm-85 -62.44 -35.39 79.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -1.147 . . . . 0.0 109.498 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.764 HG21 ' HB1' ' A' ' 14' ' ' ALA . 53.7 t -56.51 -38.21 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.65 -37.41 86.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -0.894 . . . . 0.0 109.445 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 54.8 m -73.54 -40.68 63.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 26.6 m -64.48 -33.48 75.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.552 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.76 HD13 HG21 ' A' ' 86' ' ' VAL . 20.2 tp -63.32 -49.92 72.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.449 ' HG2' ' NZ ' ' A' ' 31' ' ' LYS . 18.4 ttp180 -43.21 -51.86 5.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.334 -0.854 . . . . 0.0 109.52 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -51.38 -49.18 62.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.528 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.83 ' HB3' HD11 ' A' ' 82' ' ' LEU . 90.3 m-70 -57.76 -26.08 61.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.474 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.965 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.7 mm -72.22 -51.95 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.475 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 58.7 mttp -66.9 -39.66 87.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.304 -0.872 . . . . 0.0 109.435 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.428 HD23 ' HA ' ' A' ' 32' ' ' LEU . 41.4 mt -57.45 -57.85 10.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.615 ' CD2' HD13 ' A' ' 82' ' ' LEU . 85.1 m-70 -89.5 5.39 45.65 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 30' ' ' ILE . 69.9 m-20 55.18 48.4 19.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.551 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.864 ' HG3' HD22 ' A' ' 82' ' ' LEU . 49.0 mmm -98.17 15.06 25.5 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.66 ' CG ' HG22 ' A' ' 30' ' ' ILE . 98.0 mt-10 -55.01 -29.27 57.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.481 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -67.69 -38.3 83.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.338 -0.851 . . . . 0.0 109.508 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.833 HD12 ' HB3' ' A' ' 35' ' ' MET . 6.3 mt -72.63 -52.85 13.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.425 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.965 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -69.91 133.77 47.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 109.335 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.52 -64.06 0.61 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -146.6 153.07 39.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.168 -1.195 . . . . 0.0 109.556 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.986 HG13 HG22 ' A' ' 71' ' ' VAL . 38.9 t -114.44 149.72 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.455 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.555 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.4 mtm -132.08 140.36 48.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.167 -0.958 . . . . 0.0 109.562 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.3 t . . . . . 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.969 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.187 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -117.89 109.49 16.59 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -1.141 . . . . 0.0 109.437 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.624 HG23 ' OE2' ' A' ' 19' ' ' GLU . 77.0 t -137.25 133.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.275 -0.891 . . . . 0.0 109.585 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.823 HD12 ' N ' ' A' ' 70' ' ' LEU . 2.1 mp -101.26 147.1 26.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.285 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.986 HG22 HG13 ' A' ' 42' ' ' VAL . 65.0 t -145.49 113.78 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.246 -0.909 . . . . 0.0 109.638 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.452 ' NE2' ' CZ2' ' A' ' 9' ' ' TRP . 0.0 OUTLIER -54.06 124.35 15.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.209 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.564 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 38.1 ttp -177.21 155.22 1.12 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 0.0 109.533 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.5 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.1 t -91.52 140.45 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.302 -0.874 . . . . 0.0 109.402 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.615 ' CG ' ' CZ ' ' A' ' 10' ' ' TYR . 30.6 mmm -84.02 109.33 17.57 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.278 -0.889 . . . . 0.0 109.597 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.515 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 51.2 p-10 -138.27 173.89 11.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -64.18 -26.16 68.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.249 -0.907 . . . . 0.0 109.562 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.48 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -78.25 -70.14 0.51 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.51 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 25.1 p -54.67 -45.99 73.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -0.896 . . . . 0.0 109.736 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.532 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 73.1 t90 -51.15 -54.38 25.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.6 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -61.57 -39.09 89.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.925 . . . . 0.0 109.559 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.864 HD22 ' HG3' ' A' ' 35' ' ' MET . 58.4 tp -63.21 -41.64 99.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.152 -0.967 . . . . 0.0 109.503 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.007 HG11 ' CE2' ' A' ' 92' ' ' PHE . 55.6 t -56.32 -43.89 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.139 -0.976 . . . . 0.0 109.534 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -61.83 -35.65 78.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.175 -0.953 . . . . 0.0 109.481 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 29.8 t -66.76 -28.34 68.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.479 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.76 HG21 HD13 ' A' ' 26' ' ' LEU . 49.8 t -54.9 124.93 53.99 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.464 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.445 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.2 155.08 65.29 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.745 2.296 . . . . 0.0 111.789 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.579 ' HB2' HG22 ' A' ' 22' ' ' VAL . 82.6 mmt-85 63.36 43.43 6.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.254 -0.904 . . . . 0.0 109.526 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.662 HG21 ' HB ' ' A' ' 86' ' ' VAL . 53.6 t -128.79 115.58 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.5 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.51 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.7 mtp -68.5 -40.16 80.98 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.907 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.59 -158.86 31.43 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 1.007 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.2 OUTLIER -112.69 166.68 11.13 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.218 -1.166 . . . . 0.0 109.514 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.899 HD12 ' CG1' ' A' ' 11' ' ' VAL . 67.4 mt -118.24 137.5 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.878 . . . . 0.0 109.379 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 161.18 -147.08 13.24 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -78.08 -44.09 12.46 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.3 p -127.73 173.38 9.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.156 -1.202 . . . . 0.0 109.53 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.1 m -89.89 18.09 6.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.274 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.532 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 87.6 m-20 -130.17 -33.24 1.74 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.574 -0.704 . . . . 0.0 109.134 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.55 88.58 38.46 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.264 -0.898 . . . . 0.0 108.836 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.46 128.76 18.8 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.71 2.274 . . . . 0.0 112.048 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 137.14 82.56 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.291 -0.88 . . . . 0.0 109.361 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.552 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.3 Cg_endo -69.7 153.23 69.47 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.699 2.266 . . . . 0.0 111.841 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.559 HD11 HG22 ' A' ' 108' ' ' VAL . 26.7 pt -112.65 154.96 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.369 -0.832 . . . . 0.0 109.481 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.9 m -65.38 146.26 55.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.152 -0.968 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -58.13 -41.01 82.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.278 -0.889 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 42.5 tttt -57.98 -43.42 86.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.449 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 86.5 tt0 -51.85 -43.75 63.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.902 . . . . 0.0 109.441 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.559 HG22 HD11 ' A' ' 103' ' ' ILE . 74.8 t -57.17 -38.69 62.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.303 -0.873 . . . . 0.0 109.375 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -68.41 -31.75 71.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.23 -0.919 . . . . 0.0 109.465 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -62.93 -42.28 99.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.435 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 50.9 mt -52.43 -53.69 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.211 -0.93 . . . . 0.0 109.395 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.4 mtt . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.926 . . . . 0.0 109.377 179.911 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.485 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 47.1 mttt . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 78.8 mtt-85 -128.92 156.48 43.66 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 67.4 m95 -91.55 128.15 37.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.177 -0.952 . . . . 0.0 109.617 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.561 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.9 m-85 -120.9 150.11 41.58 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.46 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.479 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 53.0 t -102.27 136.04 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.245 -0.909 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.79 126.68 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.717 ' HB2' HD11 ' A' ' 93' ' ' ILE . 69.9 tp60 -90.35 130.64 36.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.425 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.666 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.67 154.74 44.61 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.528 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -55.12 149.67 11.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.423 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.8 t -67.93 147.71 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.498 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 -33.94 4.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.826 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -109.53 7.15 24.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -1.155 . . . . 0.0 109.592 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.42 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 23.0 pt-20 -56.12 -39.31 72.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.441 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -75.44 -54.2 5.66 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -57.86 -39.21 77.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -1.136 . . . . 0.0 109.497 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.9 t -53.05 -40.75 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.29 96.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.894 . . . . 0.0 109.433 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.8 m -64.48 -43.51 93.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.468 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 58.1 m -58.41 -41.68 85.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.655 HD21 ' CE1' ' A' ' 39' ' ' PHE . 4.8 tp -59.14 -39.41 82.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 109.272 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -58.48 -26.03 62.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.321 -0.862 . . . . 0.0 109.392 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.469 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 71.2 mt-10 -68.66 -47.65 65.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.325 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 1.0 ' HB3' HD11 ' A' ' 82' ' ' LEU . 79.8 m-70 -68.06 -43.47 78.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.857 HD13 ' CD2' ' A' ' 39' ' ' PHE . 54.9 mt -57.94 -50.44 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.52 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 58.2 tttp -60.49 -41.48 94.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.611 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 32.3 mt -69.27 -50.88 42.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.481 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.3 m-70 -77.49 -6.89 55.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.217 -0.927 . . . . 0.0 109.528 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.487 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.1 t30 66.14 42.98 2.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.514 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.908 ' HG3' HD22 ' A' ' 82' ' ' LEU . 45.8 mmm -92.04 5.19 51.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.45 ' O ' ' O ' ' A' ' 39' ' ' PHE . 96.5 mt-10 -48.76 -37.79 19.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.461 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -53.26 -44.25 68.03 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.214 -0.929 . . . . 0.0 109.362 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.904 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.2 mt -72.19 -52.66 15.5 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.302 -0.874 . . . . 0.0 109.4 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.857 ' CD2' HD13 ' A' ' 30' ' ' ILE . 98.1 m-85 -70.97 129.09 38.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.187 -0.946 . . . . 0.0 109.441 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.32 -69.19 0.66 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -139.71 147.15 40.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -1.163 . . . . 0.0 109.583 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.036 HG13 HG22 ' A' ' 71' ' ' VAL . 39.0 t -113.99 154.01 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.374 -0.829 . . . . 0.0 109.351 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.565 ' CE ' HG11 ' A' ' 108' ' ' VAL . 64.3 mtm -137.78 144.05 41.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.566 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.6 t . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.438 179.918 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -118.64 124.25 46.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -1.199 . . . . 0.0 109.445 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.434 ' C ' HD12 ' A' ' 70' ' ' LEU . 76.6 t -132.2 146.49 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.567 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.846 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.2 mp -106.85 130.09 54.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.036 HG22 HG13 ' A' ' 42' ' ' VAL . 99.1 t -136.63 124.77 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.176 -0.952 . . . . 0.0 109.642 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.485 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 7.5 tt0 -81.02 128.37 33.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.171 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.561 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 50.9 ttp -173.83 165.12 4.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.65 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.529 ' N ' ' HG2' ' A' ' 73' ' ' MET . 14.5 p -88.53 143.36 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.353 -0.842 . . . . 0.0 109.218 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.582 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 16.9 tpp -82.91 113.82 20.78 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.593 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.0 p30 -142.14 168.94 18.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.318 -0.864 . . . . 0.0 109.427 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.572 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.6 m-20 -68.61 -30.12 68.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.217 -0.927 . . . . 0.0 109.47 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.02 -71.88 0.22 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.905 . . . . 0.0 109.55 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.904 ' OG ' HD13 ' A' ' 38' ' ' LEU . 7.5 m -48.27 -49.61 32.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 66.3 t90 -49.63 -52.3 31.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.873 . . . . 0.0 109.73 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 56.5 m-70 -66.6 -24.19 66.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.6 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 1.0 HD11 ' HB3' ' A' ' 29' ' ' HIS . 56.9 tp -68.74 -45.21 72.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.075 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 70.0 t -50.92 -44.05 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.573 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 36.2 ttp180 -62.92 -23.02 67.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.139 -0.976 . . . . 0.0 109.368 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.5 t -61.6 -63.86 1.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 0.0 109.415 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.683 HG13 HG21 ' A' ' 89' ' ' VAL . 1.8 p -59.62 125.8 80.89 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.164 -0.96 . . . . 0.0 109.467 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.476 ' O ' HG23 ' A' ' 89' ' ' VAL . 48.1 Cg_endo -69.65 -177.77 1.99 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.732 2.288 . . . . 0.0 111.834 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.1 mtt85 62.94 23.01 13.77 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.314 -0.866 . . . . 0.0 109.582 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.683 HG21 HG13 ' A' ' 86' ' ' VAL . 22.2 t -116.88 116.48 52.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.482 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 44.8 mtt -65.93 -43.68 87.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.346 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.19 -150.86 22.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 1.075 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 4.6 m-85 -111.8 161.4 16.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.4 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.717 HD11 ' HB2' ' A' ' 13' ' ' GLN . 15.8 mm -114.88 123.12 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.306 -0.871 . . . . 0.0 109.548 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.86 -152.76 11.57 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -64.95 -45.04 93.62 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.9 p -129.32 172.86 11.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.183 -1.187 . . . . 0.0 109.565 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 14.4 p -89.82 20.05 4.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.2 -0.937 . . . . 0.0 109.412 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -123.12 -22.65 5.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.449 -0.782 . . . . 0.0 109.37 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.53 103.18 3.27 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.328 -0.857 . . . . 0.0 108.94 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 48.4 Cg_endo -68.77 111.46 2.61 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.756 2.304 . . . . 0.0 111.996 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.98 140.7 81.95 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 109.427 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.521 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.9 Cg_endo -70.15 153.34 67.24 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.637 2.225 . . . . 0.0 111.81 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.62 155.11 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.255 -0.903 . . . . 0.0 109.408 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.7 m -71.74 151.34 43.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -52.29 -41.7 63.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -55.82 -41.52 74.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.921 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -52.88 -45.12 67.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.333 -0.854 . . . . 0.0 109.377 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.835 HG13 ' CD2' ' A' ' 70' ' ' LEU . 98.1 t -56.78 -38.03 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -67.54 -34.2 76.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.229 -0.919 . . . . 0.0 109.445 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -56.48 -46.3 80.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.332 -0.855 . . . . 0.0 109.415 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.72 HD12 HD21 ' A' ' 70' ' ' LEU . 50.5 mt -49.69 -56.36 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.329 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.6 mtt . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.276 179.812 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 77.5 mttt . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.285 0.564 . . . . 0.0 109.561 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.514 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 44.9 mtm180 -132.72 159.55 39.35 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.493 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.546 ' CG ' HG21 ' A' ' 108' ' ' VAL . 46.3 m95 -99.34 132.54 44.59 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.892 . . . . 0.0 109.556 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.595 ' CD2' ' HE2' ' A' ' 75' ' ' MET . 66.1 m-85 -130.93 155.23 47.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.443 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.489 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 10.7 t -96.18 145.93 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.226 -0.921 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.0 t -119.03 123.57 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 109.364 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.993 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.5 tt0 -93.1 131.67 37.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.923 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.445 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -138.72 -153.23 0.46 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 109.369 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 61.7 t80 -98.23 133.49 42.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.452 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 31.3 t -54.77 126.0 22.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.214 -0.929 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.11 -27.15 19.67 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 19.2 m-85 -105.09 7.52 33.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -1.116 . . . . 0.0 109.493 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -56.89 -34.72 68.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.915 . . . . 0.0 109.374 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -71.13 -37.87 63.68 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 17.9 ttm180 -63.81 -49.86 71.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.204 -1.174 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.461 HG13 HG11 ' A' ' 86' ' ' VAL . 39.1 t -50.37 -38.78 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.235 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.73 -39.72 91.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.929 . . . . 0.0 109.251 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.6 m -69.01 -46.6 67.55 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.388 -0.82 . . . . 0.0 109.376 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.479 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.4 m -65.72 -39.63 91.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.438 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.5 ' HG ' ' CD1' ' A' ' 30' ' ' ILE . 30.8 tp -54.34 -43.55 71.34 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.6 ttm-85 -57.83 -36.89 72.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -67.94 -52.58 34.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.203 -0.936 . . . . 0.0 109.474 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.996 ' HB3' HD11 ' A' ' 82' ' ' LEU . 68.1 m-70 -58.44 -48.06 81.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.93 . . . . 0.0 109.443 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.65 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.2 mt -57.69 -52.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.305 -0.872 . . . . 0.0 109.515 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.4 tttm -57.61 -43.39 84.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.29 -0.881 . . . . 0.0 109.497 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.427 ' HA ' HD23 ' A' ' 32' ' ' LEU . 40.2 mt -68.25 -49.48 60.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.229 -0.92 . . . . 0.0 109.416 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.506 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 98.5 m-70 -80.35 4.19 18.7 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 109.577 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 30' ' ' ILE . 40.5 t30 52.75 50.53 17.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.403 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.937 ' HG3' HD22 ' A' ' 82' ' ' LEU . 53.3 mmm -102.88 4.74 37.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.427 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.3 mt-10 -49.78 -34.93 20.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -57.77 -43.03 85.23 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.413 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.586 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.4 mt -72.84 -50.12 25.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.287 -0.883 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.566 ' CE2' HG12 ' A' ' 30' ' ' ILE . 96.4 m-85 -71.2 130.83 42.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.295 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.56 -65.4 0.55 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -137.19 122.68 19.6 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -1.204 . . . . 0.0 109.675 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.983 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -92.53 136.0 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.34 -0.85 . . . . 0.0 109.145 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.766 ' O ' HG13 ' A' ' 69' ' ' VAL . 97.2 mtp -125.12 117.42 23.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.192 -0.942 . . . . 0.0 109.768 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 44' ' ' VAL . 12.0 p . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.323 -0.861 . . . . 0.0 109.099 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -111.95 120.79 43.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.485 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 43' ' ' MET . 96.5 t -133.34 146.88 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -0.888 . . . . 0.0 109.577 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.854 HD22 ' N ' ' A' ' 70' ' ' LEU . 1.2 mm? -105.03 131.0 53.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.886 . . . . 0.0 109.341 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.983 HG22 HG23 ' A' ' 42' ' ' VAL . 64.3 t -138.55 125.74 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 109.709 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.473 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.7 tt0 -78.8 119.58 22.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.826 . . . . 0.0 109.299 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.552 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 48.6 ttp -165.99 163.46 18.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.602 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' A' ' 73' ' ' MET . 32.3 t -91.48 147.61 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.595 ' HE2' ' CD2' ' A' ' 10' ' ' TYR . 10.2 mmt -86.5 114.14 23.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.935 . . . . 0.0 109.653 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.1 p-10 -143.25 167.92 21.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.305 -0.872 . . . . 0.0 109.324 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.6 m-20 -66.36 -24.29 66.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.257 -0.902 . . . . 0.0 109.696 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.533 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -75.57 -70.26 0.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.235 -0.916 . . . . 0.0 109.526 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.475 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 12.4 p -56.07 -49.72 73.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.168 -0.957 . . . . 0.0 109.682 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.476 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.8 t90 -43.97 -44.93 7.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 33.0 m-70 -73.54 -32.01 63.96 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 109.484 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.996 HD11 ' HB3' ' A' ' 29' ' ' HIS . 54.9 tp -63.07 -45.88 90.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.01 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 82.8 t -55.4 -45.64 78.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -62.95 -36.39 83.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.638 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 41.0 m -61.48 -38.89 88.95 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.133 -0.979 . . . . 0.0 109.471 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.644 ' O ' HG12 ' A' ' 89' ' ' VAL . 38.5 t -51.73 126.14 31.14 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.289 -0.882 . . . . 0.0 109.531 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.46 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -71.17 156.36 59.55 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.69 2.26 . . . . 0.0 111.714 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 21' ' ' ARG . 82.0 mtt-85 62.06 35.86 15.68 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.857 . . . . 0.0 109.672 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.2 p -129.09 128.31 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.158 -0.964 . . . . 0.0 109.571 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.486 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 92.4 mmm -71.96 -54.59 9.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.285 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 162.03 -148.01 14.87 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 1.01 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 5.3 m-85 -104.62 160.6 14.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -1.162 . . . . 0.0 109.499 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.993 HD11 ' HB2' ' A' ' 13' ' ' GLN . 17.3 mm -118.14 119.11 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.453 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -171.63 -143.57 4.11 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -71.98 -35.42 61.36 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.586 HG23 ' H ' ' A' ' 98' ' ' ASP . 7.0 t -140.93 176.16 9.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.211 -1.17 . . . . 0.0 109.633 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 13.1 p -92.96 21.57 5.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.43 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.586 ' H ' HG23 ' A' ' 96' ' ' THR . 2.6 p30 -137.05 8.79 2.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.46 -0.775 . . . . 0.0 109.133 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -176.69 92.51 0.25 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.343 -0.848 . . . . 0.0 108.948 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.525 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 46.0 Cg_endo -68.48 120.78 7.71 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.688 2.259 . . . . 0.0 111.988 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -64.37 148.61 95.95 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.285 -0.884 . . . . 0.0 109.317 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.507 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 49.5 Cg_endo -70.07 153.28 67.68 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.68 2.253 . . . . 0.0 111.82 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.533 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -125.21 157.91 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.336 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 39.0 m -75.64 148.71 38.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.554 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -56.51 -40.8 75.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -58.15 -40.37 81.17 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -0.882 . . . . 0.0 109.417 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 93.3 mt-10 -56.03 -43.78 78.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.197 -0.939 . . . . 0.0 109.389 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.546 HG21 ' CG ' ' A' ' 9' ' ' TRP . 54.1 t -57.35 -37.83 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -0.902 . . . . 0.0 109.343 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -73.81 -34.1 64.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.326 -0.859 . . . . 0.0 109.367 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.39 -43.41 81.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.388 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.422 HG13 ' O ' ' A' ' 107' ' ' GLU . 89.7 mt -50.05 -50.09 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.454 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.3 mtp . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.414 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 80.1 mttt . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.289 0.566 . . . . 0.0 109.493 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.556 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 51.3 mtt85 -117.27 156.01 28.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.19 -0.944 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 83.7 m95 -87.78 128.06 35.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.587 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.618 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 91.2 m-85 -121.18 160.67 23.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.912 . . . . 0.0 109.542 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 1.006 HG11 HD12 ' A' ' 93' ' ' ILE . 21.1 t -95.13 154.64 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.207 -0.933 . . . . 0.0 109.588 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.44 115.94 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.302 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.565 ' HG2' HD11 ' A' ' 93' ' ' ILE . 78.4 mt-30 -81.01 150.47 28.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.692 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.702 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.56 158.42 35.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 109.405 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.46 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.7 m-85 -62.44 143.97 56.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 34.0 t -67.78 147.34 52.72 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.25 -33.52 4.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.786 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.5 m-85 -108.07 10.66 28.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -1.139 . . . . 0.0 109.476 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -61.15 -36.78 80.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.433 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.81 -50.02 38.54 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.0 ttt85 -63.77 -37.48 87.51 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -1.144 . . . . 0.0 109.424 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.3 t -52.21 -41.67 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -0.934 . . . . 0.0 109.271 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.16 -48.93 79.8 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.298 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 78.7 m -59.39 -46.39 88.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.39 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.421 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.9 m -51.3 -44.79 61.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.295 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.473 ' O ' HG12 ' A' ' 30' ' ' ILE . 47.5 mt -51.29 -69.68 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.36 -0.838 . . . . 0.0 109.388 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.48 ' HA ' HG12 ' A' ' 30' ' ' ILE . 48.6 ttt85 -42.78 -42.81 3.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.386 -0.821 . . . . 0.0 109.72 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -55.78 -37.81 69.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.208 -0.932 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.626 ' CD2' HG22 ' A' ' 86' ' ' VAL . 93.3 m-70 -79.85 -27.28 40.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.274 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.987 HD12 ' CD1' ' A' ' 39' ' ' PHE . 11.8 mm -64.01 -43.45 97.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.302 -0.874 . . . . 0.0 109.321 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -70.38 -36.41 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.434 HD23 ' HA ' ' A' ' 32' ' ' LEU . 39.4 mt -70.61 -55.75 8.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.335 -0.853 . . . . 0.0 109.472 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.937 ' CD2' HD11 ' A' ' 82' ' ' LEU . 93.0 m-70 -81.18 4.82 18.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.195 -0.941 . . . . 0.0 109.559 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.6 t30 50.09 46.64 24.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.19 -0.944 . . . . 0.0 109.517 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.849 ' HB3' HD12 ' A' ' 38' ' ' LEU . 40.3 mmm -100.05 14.99 28.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.357 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.586 ' CG ' HG22 ' A' ' 30' ' ' ILE . 99.4 mt-10 -52.49 -31.31 34.5 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.276 -0.89 . . . . 0.0 109.492 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -60.34 -42.38 95.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.216 -0.927 . . . . 0.0 109.507 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 1.015 HD13 ' OG ' ' A' ' 79' ' ' SER . 2.4 mt -74.06 -53.97 8.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.351 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.987 ' CD1' HD12 ' A' ' 30' ' ' ILE . 94.2 m-85 -69.99 130.0 41.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.29 -64.27 0.48 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -138.93 146.34 40.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.164 -1.198 . . . . 0.0 109.525 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.991 HG13 HG22 ' A' ' 71' ' ' VAL . 48.2 t -111.12 153.83 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.516 ' SD ' HG11 ' A' ' 108' ' ' VAL . 89.5 mtp -123.62 143.81 50.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.499 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 N--CA 1.488 1.458 0 O-C-N 121.152 -0.967 . . . . 0.0 109.428 179.917 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -115.36 119.18 35.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -1.174 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.522 ' C ' HD12 ' A' ' 70' ' ' LEU . 93.4 t -133.27 138.39 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.219 -0.926 . . . . 0.0 109.591 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 1.11 HD21 HD12 ' A' ' 111' ' ' ILE . 4.1 mp -108.22 131.03 55.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.311 -0.868 . . . . 0.0 109.337 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.991 HG22 HG13 ' A' ' 42' ' ' VAL . 86.3 t -138.42 120.58 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.702 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.477 ' O ' ' HB2' ' A' ' 73' ' ' MET . 36.4 tt0 -69.15 135.55 50.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.228 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.571 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 52.8 ttp 172.94 156.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.99 . . . . 0.0 109.66 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.519 ' N ' ' HG2' ' A' ' 73' ' ' MET . 13.9 p -88.96 134.91 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.284 -0.885 . . . . 0.0 109.36 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.629 ' HE2' ' HG2' ' A' ' 100' ' ' PRO . 24.6 mmm -79.33 116.94 19.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.248 -0.907 . . . . 0.0 109.469 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.519 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 49.5 p-10 -143.43 171.03 14.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.227 -0.921 . . . . 0.0 109.468 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.556 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.1 m-20 -59.76 -33.3 71.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -72.02 -70.96 0.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 1.015 ' OG ' HD13 ' A' ' 38' ' ' LEU . 6.7 m -52.76 -51.82 59.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.422 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.519 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 29.8 t90 -44.57 -46.65 10.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.312 -0.868 . . . . 0.0 109.593 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.556 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 34.7 m-70 -70.39 -36.38 74.06 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.928 . . . . 0.0 109.422 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.937 HD11 ' CD2' ' A' ' 33' ' ' HIS . 3.0 tp -53.34 -45.01 68.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.952 . . . . 0.0 109.461 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.942 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 11.6 t -62.02 -31.77 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.405 -0.81 . . . . 0.0 109.591 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 80' ' ' TRP . 40.5 mtt-85 -70.98 -33.2 70.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.934 . . . . 0.0 109.407 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.9 p -79.7 -20.22 47.04 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.297 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 82' ' ' LEU . 88.5 t -67.29 127.33 93.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.343 -0.848 . . . . 0.0 109.326 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.455 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.21 153.06 67.22 Favored 'Trans proline' 0 C--O 1.214 -0.708 0 C-N-CA 122.687 2.258 . . . . 0.0 111.853 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 18' ' ' PHE . 33.7 mtt85 63.09 47.34 4.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.605 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.608 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.1 t -127.33 123.44 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 109.527 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 85.5 mtp -78.16 -50.72 11.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.41 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 164.07 -160.87 33.84 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.942 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 6.7 m-85 -109.57 160.52 16.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -1.154 . . . . 0.0 109.667 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 1.006 HD12 HG11 ' A' ' 11' ' ' VAL . 3.7 mt -117.51 134.16 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.339 -0.851 . . . . 0.0 109.251 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 168.22 -142.22 7.32 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.25 -50.75 42.9 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.0 p -126.77 179.13 5.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -1.163 . . . . 0.0 109.587 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.47 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 25.6 p -94.38 22.54 5.97 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.261 -0.899 . . . . 0.0 109.309 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 97' ' ' SER . 92.2 m-20 -137.0 6.42 2.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.476 -0.765 . . . . 0.0 109.459 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER -170.88 95.72 0.44 Allowed Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.292 -0.88 . . . . 0.0 109.019 -179.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.629 ' HG2' ' HE2' ' A' ' 75' ' ' MET . 46.5 Cg_endo -68.5 116.78 4.57 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.79 2.327 . . . . 0.0 111.947 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.27 148.51 98.46 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.327 -0.858 . . . . 0.0 109.302 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.556 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.9 Cg_endo -69.43 153.15 70.82 Favored 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 122.688 2.259 . . . . 0.0 111.777 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.53 HD11 ' CG2' ' A' ' 108' ' ' VAL . 29.3 pt -126.62 160.05 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.9 m -74.89 153.06 38.81 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.936 . . . . 0.0 109.348 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -62.4 -33.36 74.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 18.7 tttp -61.58 -35.65 78.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.868 . . . . 0.0 109.475 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 -63.28 -40.69 98.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.434 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.723 HG13 HD22 ' A' ' 70' ' ' LEU . 76.0 t -65.81 -36.62 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -0.94 . . . . 0.0 109.361 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -68.45 -31.16 70.27 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.301 -0.875 . . . . 0.0 109.515 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.57 -40.12 84.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 1.11 HD12 HD21 ' A' ' 70' ' ' LEU . 54.8 mt -55.41 -51.46 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 109.415 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . 0.5 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 86.2 mtp . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.24 -0.912 . . . . 0.0 109.372 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 36.3 mttm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.282 0.563 . . . . 0.0 109.497 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 79.1 mtt85 -125.95 154.17 43.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.259 -0.9 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.427 ' CZ3' ' HG3' ' A' ' 43' ' ' MET . 90.1 m95 -91.0 130.11 36.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.211 -0.931 . . . . 0.0 109.502 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.476 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 93.3 m-85 -123.63 154.33 39.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 53.2 t -90.98 148.24 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.506 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -126.5 122.07 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.219 -0.926 . . . . 0.0 109.404 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.628 ' HB2' HD11 ' A' ' 93' ' ' ILE . 48.6 tt0 -84.9 133.71 34.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.211 -0.931 . . . . 0.0 109.432 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.741 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.39 161.88 36.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.488 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.4 m-85 -70.38 145.64 50.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.887 . . . . 0.0 109.544 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.9 t -60.32 139.31 57.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.458 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.67 -30.28 6.66 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 22' ' ' VAL . 10.3 m-85 -103.69 8.52 37.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -1.129 . . . . 0.0 109.517 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HG3' HG23 ' A' ' 69' ' ' VAL . 67.0 tt0 -53.08 -29.72 32.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.62 -55.44 2.04 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -55.91 -34.53 65.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.239 -1.153 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.741 HG21 ' HB1' ' A' ' 14' ' ' ALA . 54.9 t -58.82 -38.18 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.326 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.92 -34.32 77.86 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.483 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 42.5 m -63.38 -32.94 74.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.928 . . . . 0.0 109.426 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.405 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 28.6 m -65.17 -32.57 74.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.472 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.494 HD23 HG21 ' A' ' 86' ' ' VAL . 59.3 mt -60.77 -44.93 96.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.484 ' O ' ' HB2' ' A' ' 31' ' ' LYS . 74.2 ttt180 -58.03 -41.46 83.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 109.654 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -69.01 -60.37 2.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.243 -0.911 . . . . 0.0 109.596 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.644 ' CD2' HG22 ' A' ' 86' ' ' VAL . 91.0 m-70 -54.77 -47.09 74.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.219 -0.925 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.822 HG23 ' HB2' ' A' ' 35' ' ' MET . 87.4 mt -66.21 -44.67 91.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -0.876 . . . . 0.0 109.634 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 27' ' ' ARG . 15.3 ttpp -59.27 -41.47 88.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.457 ' HA ' HD23 ' A' ' 32' ' ' LEU . 45.8 mt -70.63 -52.67 19.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.324 -0.86 . . . . 0.0 109.41 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.469 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 99.0 m-70 -74.79 -6.97 51.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.9 . . . . 0.0 109.391 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.499 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.0 m-20 61.42 46.15 7.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.997 ' HG3' HD13 ' A' ' 82' ' ' LEU . 45.3 mmm -91.87 -2.32 56.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.605 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.443 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.2 mt-10 -44.28 -38.81 4.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -52.13 -43.11 63.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.347 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.645 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.1 mt -73.01 -43.98 61.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.37 -0.831 . . . . 0.0 109.336 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.705 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.2 m-85 -73.19 137.32 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.282 -0.886 . . . . 0.0 109.427 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.78 -66.69 0.52 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.415 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 82.6 tt0 -136.68 152.04 49.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.567 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.045 HG13 HG22 ' A' ' 71' ' ' VAL . 48.1 t -117.51 147.61 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.29 -0.881 . . . . 0.0 109.359 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.478 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 90.6 mtp -120.64 141.5 50.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.141 -0.974 . . . . 0.0 109.527 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.241 -0.912 . . . . 0.0 109.436 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.606 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -109.68 126.27 53.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -1.154 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.546 HG23 ' HG3' ' A' ' 19' ' ' GLU . 86.3 t -134.15 142.72 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.388 -0.82 . . . . 0.0 109.505 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.85 HD21 HD12 ' A' ' 111' ' ' ILE . 3.8 mp -103.91 132.53 50.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.471 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.045 HG22 HG13 ' A' ' 42' ' ' VAL . 88.0 t -143.77 122.06 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.263 -0.898 . . . . 0.0 109.557 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.419 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 43.1 tt0 -78.36 130.33 36.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.224 -0.923 . . . . 0.0 109.187 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.57 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 41.1 ttp -162.67 154.67 18.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.514 ' N ' ' HG2' ' A' ' 73' ' ' MET . 59.2 t -69.81 151.19 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -0.948 . . . . 0.0 109.224 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.863 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -94.33 112.97 24.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 109.496 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.619 ' ND2' HD22 ' A' ' 38' ' ' LEU . 42.0 p-10 -148.51 169.17 20.86 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.573 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 86.2 m-20 -72.38 -31.22 65.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -63.48 -61.45 2.33 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.513 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.467 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 17.4 p -53.36 -48.07 68.87 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.275 -0.891 . . . . 0.0 109.753 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.528 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 39.1 t90 -44.03 -49.32 8.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.888 . . . . 0.0 109.581 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 89.8 m-70 -67.87 -39.38 83.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.206 -0.934 . . . . 0.0 109.471 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.997 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.4 OUTLIER -56.92 -45.2 82.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.726 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.579 HG21 ' HZ ' ' A' ' 92' ' ' PHE . 78.0 t -62.48 -48.43 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.525 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 23.7 mtp85 -62.45 -37.24 85.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.57 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -66.63 -26.75 67.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -0.948 . . . . 0.0 109.491 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.847 HG23 ' O ' ' A' ' 82' ' ' LEU . 56.5 t -65.4 129.66 94.46 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.537 ' HD2' ' NE2' ' A' ' 29' ' ' HIS . 49.7 Cg_endo -70.17 161.03 47.48 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.703 2.269 . . . . 0.0 111.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.488 ' HA ' ' CD2' ' A' ' 15' ' ' PHE . 93.0 mtt-85 61.51 35.76 17.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 86' ' ' VAL . 91.5 t -129.39 115.51 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.288 -0.882 . . . . 0.0 109.566 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.511 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 84.3 mtp -69.97 -43.43 71.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.177 -0.952 . . . . 0.0 109.471 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.57 -146.99 14.03 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.579 ' HZ ' HG21 ' A' ' 83' ' ' VAL . 51.6 m-85 -107.45 163.08 13.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.292 -1.122 . . . . 0.0 109.574 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.628 HD11 ' HB2' ' A' ' 13' ' ' GLN . 31.9 mm -119.4 124.22 72.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 109.337 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . . . 147.87 -141.12 8.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' GLY . . . -43.43 -89.36 0.01 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 18.9 p -123.7 -179.33 4.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.297 -1.12 . . . . 0.0 109.652 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 m -90.9 22.03 3.84 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.338 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.528 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 91.4 m-20 -118.49 -23.52 7.13 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -155.98 96.86 2.3 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.863 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 42.2 Cg_endo -65.13 119.99 7.13 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.865 2.376 . . . . 0.0 112.135 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.97 141.85 97.75 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.436 -0.79 . . . . 0.0 109.482 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.33 154.49 61.16 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.706 2.271 . . . . 0.0 111.854 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.873 HD11 HG22 ' A' ' 108' ' ' VAL . 34.0 pt -124.57 158.16 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.874 . . . . 0.0 109.378 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.453 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 42.2 m -69.51 148.18 49.83 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.916 . . . . 0.0 109.439 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.41 -37.74 78.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.399 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -61.3 -38.77 87.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.453 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 98.5 mt-10 -59.88 -42.21 93.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.873 HG22 HD11 ' A' ' 103' ' ' ILE . 78.3 t -61.61 -36.99 76.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.377 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -69.7 -33.24 72.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.69 -39.67 91.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.44 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.85 HD12 HD21 ' A' ' 70' ' ' LEU . 56.2 mt -56.84 -52.25 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.525 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . 0.436 ' HE3' ' CE ' ' A' ' 43' ' ' MET . 53.7 ttm . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.403 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 46.0 mttp . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.323 0.582 . . . . 0.0 109.569 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.502 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 63.4 mtt180 -116.99 153.08 33.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.454 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.55 ' CG ' HG21 ' A' ' 108' ' ' VAL . 82.5 m95 -99.69 131.97 45.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.48 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 62.5 m-85 -122.36 141.83 51.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.463 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.447 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.3 t -86.65 145.66 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.711 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -125.8 125.19 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 109.284 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.604 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.0 tp60 -87.58 131.96 34.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.609 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.517 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -139.33 164.82 28.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.324 -0.86 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -68.61 140.34 55.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 109.448 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.8 m -66.57 149.42 50.49 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.307 -0.87 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.63 -33.28 4.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.702 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.7 m-85 -109.45 8.46 25.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.18 -1.188 . . . . 0.0 109.506 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.47 ' OE2' HG22 ' A' ' 69' ' ' VAL . 84.4 tt0 -56.76 -39.34 73.84 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.62 -52.29 44.21 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 56.7 ttt-85 -62.62 -38.74 91.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -1.149 . . . . 0.0 109.491 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.702 HG23 ' O ' ' A' ' 18' ' ' PHE . 79.7 t -56.01 -39.88 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.424 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.08 -37.88 89.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.267 -0.896 . . . . 0.0 109.413 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.5 m -65.16 -38.94 92.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.223 -0.923 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.565 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 97.1 p -60.02 -38.42 82.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.462 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.403 ' CD2' HG21 ' A' ' 86' ' ' VAL . 44.4 mt -56.66 -49.45 75.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -0.871 . . . . 0.0 109.469 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttp85 -65.79 -37.06 85.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.515 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 80.1 tt0 -66.27 -44.76 82.68 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.26 -0.9 . . . . 0.0 109.499 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 1.067 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.9 m-70 -71.82 -51.5 22.2 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.457 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.779 HG22 ' HG3' ' A' ' 36' ' ' GLU . 83.4 mt -56.91 -45.3 83.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.917 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 39.8 tttt -56.59 -48.46 77.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -0.904 . . . . 0.0 109.465 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 48.6 mt -64.84 -51.24 63.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.934 . . . . 0.0 109.45 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB3' ' SD ' ' A' ' 35' ' ' MET . 97.8 m-70 -74.86 -2.08 25.2 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.241 -0.912 . . . . 0.0 109.575 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.466 ' N ' ' O ' ' A' ' 30' ' ' ILE . 55.2 t30 55.0 45.44 26.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -0.927 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.73 ' HG3' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.66 5.17 47.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.521 179.982 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.779 ' HG3' HG22 ' A' ' 30' ' ' ILE . 97.9 mt-10 -61.02 -16.95 49.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 109.447 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -62.26 -40.57 96.64 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.292 -0.88 . . . . 0.0 109.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.896 ' HB2' HG12 ' A' ' 74' ' ' VAL . 0.3 OUTLIER -86.37 -31.39 21.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.353 179.887 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.524 ' CD1' ' HB2' ' A' ' 73' ' ' MET . 42.6 m-85 -76.44 132.08 39.44 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -96.67 -78.12 1.39 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.8 tp10 -139.44 136.53 34.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 71' ' ' VAL . 10.0 p -97.79 143.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.265 -0.897 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.627 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.3 mtt -108.53 141.21 40.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.54 ' O ' HG12 ' A' ' 44' ' ' VAL . 47.8 t . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.432 ' CZ ' ' OE1' ' A' ' 13' ' ' GLN . 7.2 m-85 -121.74 122.68 40.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.282 -1.128 . . . . 0.0 109.388 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 43' ' ' MET . 58.0 t -130.31 142.65 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.913 . . . . 0.0 109.514 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 1.035 HD21 HD12 ' A' ' 111' ' ' ILE . 3.6 mp -102.77 129.13 49.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.872 . . . . 0.0 109.428 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 42' ' ' VAL . 56.7 t -137.43 127.35 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.403 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 41.6 tt0 -84.22 138.75 32.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.284 -0.885 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.865 ' CG ' HD12 ' A' ' 38' ' ' LEU . 6.1 tmm? -177.89 149.09 0.56 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.896 HG12 ' HB2' ' A' ' 38' ' ' LEU . 7.4 p -75.03 122.87 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.186 -0.946 . . . . 0.0 109.458 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.641 ' HA ' ' HE3' ' A' ' 75' ' ' MET . 0.8 OUTLIER -52.82 112.97 0.94 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.682 -179.824 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 48.1 p-10 -146.2 161.79 39.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.371 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.488 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.2 m-20 -72.37 -27.48 62.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.185 -0.947 . . . . 0.0 109.466 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.542 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -62.52 -62.94 1.4 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.456 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 24.3 p -53.7 -51.43 63.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.263 -0.898 . . . . 0.0 109.56 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 30.7 t90 -44.31 -55.84 4.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.551 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.488 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 87.7 m-70 -59.7 -40.79 89.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.521 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 1.067 HD11 ' HB3' ' A' ' 29' ' ' HIS . 65.1 tp -60.3 -36.45 77.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.262 -0.899 . . . . 0.0 109.657 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.947 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 74.1 t -61.6 -44.69 99.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.525 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 48.5 tpt85 -57.92 -40.81 81.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.4 p -64.45 -27.53 69.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.752 ' HB ' HG21 ' A' ' 89' ' ' VAL . 79.1 t -61.84 123.18 76.29 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.447 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.4 150.42 64.28 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.602 2.202 . . . . 0.0 111.769 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.447 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 31.8 mtt-85 62.05 51.11 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.184 -0.947 . . . . 0.0 109.434 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.752 HG21 ' HB ' ' A' ' 86' ' ' VAL . 66.9 t -126.3 116.84 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.488 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.517 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.9 mmm -65.57 -45.66 82.45 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.42 -148.32 18.67 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.947 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 3.6 m-85 -117.84 164.49 14.95 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.238 -1.154 . . . . 0.0 109.54 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.604 HD11 ' HB2' ' A' ' 13' ' ' GLN . 9.2 mm -121.76 120.89 62.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.355 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 177.88 -144.13 6.4 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.27 -43.84 37.16 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 p -129.39 174.34 9.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.264 -1.139 . . . . 0.0 109.549 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 72.3 m -89.86 17.89 6.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -0.964 . . . . 0.0 109.369 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.7 m-20 -127.84 -30.73 2.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.518 -0.739 . . . . 0.0 109.273 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -134.57 91.51 21.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.309 -0.869 . . . . 0.0 108.916 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.6 Cg_endo -67.86 116.66 4.41 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.634 2.223 . . . . 0.0 112.001 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.42 146.5 79.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.502 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 50.0 Cg_endo -70.14 154.58 66.1 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.7 2.267 . . . . 0.0 111.759 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.682 HD11 HG22 ' A' ' 108' ' ' VAL . 28.7 pt -118.02 158.36 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.46 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 44.2 m -70.66 152.27 44.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.33 -0.856 . . . . 0.0 109.417 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -57.22 -38.67 74.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.212 -0.93 . . . . 0.0 109.359 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.62 -38.29 80.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.389 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 75.2 mm-40 -56.92 -45.77 82.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.315 -0.866 . . . . 0.0 109.408 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.72 HG13 ' CD2' ' A' ' 70' ' ' LEU . 96.4 t -60.07 -40.83 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.364 -0.835 . . . . 0.0 109.368 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -65.81 -36.76 84.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.399 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.88 -53.49 57.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 109.463 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 1.035 HD12 HD21 ' A' ' 70' ' ' LEU . 49.1 mt -48.03 -54.05 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.183 -0.948 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.2 mtp . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.27 -0.894 . . . . 0.0 109.348 179.885 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.446 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 23.4 mmtp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.531 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 93.6 mtt180 -125.38 152.94 44.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.375 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.48 ' CB ' HG21 ' A' ' 108' ' ' VAL . 85.6 m95 -96.4 129.38 43.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.495 ' CE1' ' HA ' ' A' ' 102' ' ' PRO . 64.0 m-85 -129.07 154.19 46.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.264 -0.898 . . . . 0.0 109.408 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 22.3 t -99.54 143.59 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.326 -0.858 . . . . 0.0 109.57 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -117.62 125.87 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.379 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.697 ' HB2' HD11 ' A' ' 93' ' ' ILE . 52.3 tt0 -88.79 135.35 33.57 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.158 -0.964 . . . . 0.0 109.521 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.654 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -140.04 -165.24 1.86 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -104.55 139.8 38.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.186 -0.946 . . . . 0.0 109.468 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.2 m -56.61 150.87 14.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.03 -34.48 4.25 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.889 ' O ' HG23 ' A' ' 22' ' ' VAL . 77.5 m-85 -118.98 10.18 12.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.309 -1.113 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.458 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.8 tt0 -58.02 -29.31 65.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.213 -0.929 . . . . 0.0 109.534 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -77.62 -53.05 5.2 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -59.63 -39.43 84.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -1.181 . . . . 0.0 109.46 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.889 HG23 ' O ' ' A' ' 18' ' ' PHE . 99.0 t -50.5 -43.84 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.373 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.32 -41.52 85.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.469 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.9 m -64.62 -36.36 83.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.538 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 37.5 m -64.65 -37.78 88.74 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.954 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.707 ' CD2' HG21 ' A' ' 86' ' ' VAL . 51.2 mt -53.77 -59.71 4.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -0.928 . . . . 0.0 109.579 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' LEU . 71.9 ttt180 -42.98 -51.11 5.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.852 . . . . 0.0 109.788 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.437 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 94.9 mt-10 -54.1 -41.79 68.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.138 -0.976 . . . . 0.0 109.503 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.82 ' HB3' HD21 ' A' ' 82' ' ' LEU . 98.9 m-70 -66.96 -31.1 71.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.419 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 1.025 HD12 ' CD2' ' A' ' 39' ' ' PHE . 13.1 mm -67.32 -52.65 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.537 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.8 mttt -64.21 -43.38 95.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.262 -0.899 . . . . 0.0 109.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.453 ' HA ' HD23 ' A' ' 32' ' ' LEU . 27.3 mt -60.46 -51.16 70.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.527 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.622 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 92.6 m-70 -87.27 10.25 17.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.264 -0.898 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 18.1 m120 49.37 49.45 19.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.189 -0.944 . . . . 0.0 109.434 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.792 ' CG ' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -106.48 21.21 17.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.425 -179.926 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.49 ' N ' HG22 ' A' ' 30' ' ' ILE . 70.7 mm-40 -66.22 -12.53 56.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.199 -0.938 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.38 -52.67 24.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.288 -0.882 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.792 HD21 ' CG ' ' A' ' 35' ' ' MET . 0.6 OUTLIER -75.96 -37.77 58.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.33 -0.856 . . . . 0.0 109.781 -179.825 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 1.025 ' CD2' HD12 ' A' ' 30' ' ' ILE . 52.0 m-85 -76.68 139.91 40.7 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.177 -0.952 . . . . 0.0 109.253 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.22 0.62 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.508 ' HG3' ' N ' ' A' ' 42' ' ' VAL . 45.9 tp10 -131.49 152.74 50.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -1.13 . . . . 0.0 109.569 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.077 HG13 HG22 ' A' ' 71' ' ' VAL . 91.9 t -119.42 154.43 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.289 -0.882 . . . . 0.0 109.383 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.773 ' HE1' HG11 ' A' ' 108' ' ' VAL . 61.2 mtm -135.68 145.11 46.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 99.1 t . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.211 -0.931 . . . . 0.0 109.546 179.989 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.458 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -111.58 116.03 30.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -1.141 . . . . 0.0 109.536 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 70' ' ' LEU . 48.7 t -126.98 151.91 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.57 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.847 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.3 mp -108.05 129.02 55.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -0.93 . . . . 0.0 109.417 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.077 HG22 HG13 ' A' ' 42' ' ' VAL . 90.6 t -138.76 125.21 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.722 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.446 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 43.3 tt0 -78.12 120.14 22.52 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.248 -0.907 . . . . 0.0 109.08 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.682 ' CG ' HD12 ' A' ' 38' ' ' LEU . 8.0 tmm? -167.97 149.24 5.24 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -0.918 . . . . 0.0 109.569 -179.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 45.3 t -85.43 128.56 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.923 . . . . 0.0 109.163 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.519 ' SD ' ' CG ' ' A' ' 100' ' ' PRO . 11.7 mmt -64.72 107.69 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.705 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.604 ' ND2' HD22 ' A' ' 38' ' ' LEU . 53.0 p-10 -128.77 -179.66 5.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -75.09 -23.2 57.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.852 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.647 ' HB1' ' HE3' ' A' ' 35' ' ' MET . . . -82.27 -67.11 0.81 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.201 -0.937 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.533 ' HB3' HD13 ' A' ' 38' ' ' LEU . 6.3 p -49.62 -49.78 45.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.41 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 48.4 t90 -51.66 -59.56 4.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.351 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -58.95 -37.91 77.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.296 -0.878 . . . . 0.0 109.459 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.82 HD21 ' HB3' ' A' ' 29' ' ' HIS . 39.6 tp -63.61 -37.62 88.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.933 . . . . 0.0 109.401 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.94 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 54.8 t -56.92 -50.13 76.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.468 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -55.01 -41.54 71.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.2 t -57.08 -33.15 66.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.885 . . . . 0.0 109.497 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.707 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.6 t -61.08 121.91 65.85 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.269 -0.895 . . . . 0.0 109.387 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.443 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -70.32 158.29 56.69 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.691 2.261 . . . . 0.0 111.777 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.569 ' HD3' ' CG ' ' A' ' 18' ' ' PHE . 8.9 mtt85 63.11 45.77 5.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.932 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.512 HG21 ' HB ' ' A' ' 86' ' ' VAL . 96.8 t -130.92 118.89 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.172 -0.955 . . . . 0.0 109.549 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.45 ' SD ' ' HG2' ' A' ' 13' ' ' GLN . 85.9 mtp -68.83 -44.57 73.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -0.937 . . . . 0.0 109.404 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.71 -151.8 22.35 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.94 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.3 m-85 -111.8 164.25 13.27 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -1.203 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.697 HD11 ' HB2' ' A' ' 13' ' ' GLN . 20.9 mm -118.46 120.3 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.647 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.64 -149.76 9.17 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.46 -38.8 91.16 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.688 HG23 ' H ' ' A' ' 98' ' ' ASP . 10.3 t -140.53 176.57 8.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -1.186 . . . . 0.0 109.47 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.8 p -92.62 17.99 9.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 109.414 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.688 ' H ' HG23 ' A' ' 96' ' ' THR . 84.6 m-20 -121.72 -14.35 8.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.515 -0.741 . . . . 0.0 109.264 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.481 ' H ' HG23 ' A' ' 96' ' ' THR . 0.0 OUTLIER -161.42 99.24 1.25 Allowed Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.349 -0.844 . . . . 0.0 109.008 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.519 ' CG ' ' SD ' ' A' ' 75' ' ' MET . 46.4 Cg_endo -68.09 120.51 7.49 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.706 2.27 . . . . 0.0 112.015 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -63.27 138.31 97.31 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.88 . . . . 0.0 109.39 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.531 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.51 153.74 65.28 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.649 2.233 . . . . 0.0 111.765 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.774 HD11 HG22 ' A' ' 108' ' ' VAL . 35.1 pt -124.32 156.23 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 32.3 m -71.97 151.11 43.49 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.311 -0.868 . . . . 0.0 109.423 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -54.76 -40.99 69.94 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.358 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -59.31 -38.64 80.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.456 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -58.86 -44.36 91.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.276 -0.89 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.774 HG22 HD11 ' A' ' 103' ' ' ILE . 58.1 t -57.93 -39.33 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -66.42 -40.95 89.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.261 -0.899 . . . . 0.0 109.416 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -63.43 -44.63 94.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.427 HG13 ' O ' ' A' ' 107' ' ' GLU . 68.8 mt -52.48 -51.39 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.332 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.6 mtp . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.925 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.415 ' HA ' ' OE1' ' A' ' 72' ' ' GLN . 8.6 mmtp . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.418 ' HD3' ' HA ' ' A' ' 8' ' ' ARG . 17.1 mmt85 -110.48 153.13 25.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.334 -0.854 . . . . 0.0 109.455 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.511 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 56.5 m95 -103.81 129.24 51.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.928 . . . . 0.0 109.506 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.424 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 87.1 m-85 -124.18 163.83 20.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.407 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 24.5 t -98.7 147.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.6 t -124.83 123.64 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.329 -0.857 . . . . 0.0 109.331 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.821 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.1 tt0 -90.8 137.83 32.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.683 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -145.45 159.98 42.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -67.9 143.26 55.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.164 -0.96 . . . . 0.0 109.56 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 46.0 m -59.14 147.62 34.44 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.44 -33.54 4.31 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.756 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.1 m-85 -107.22 5.21 27.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -1.149 . . . . 0.0 109.562 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.438 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 85.1 tt0 -53.55 -36.23 61.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.361 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.36 -58.64 3.08 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 45.4 ttm105 -56.5 -42.43 78.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.415 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 18' ' ' PHE . 53.2 t -49.14 -47.57 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.351 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.81 -44.66 82.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.265 -0.897 . . . . 0.0 109.411 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -64.09 -45.52 88.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.389 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.467 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 50.8 m -52.03 -56.45 14.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 tp -48.15 -55.52 10.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.307 -0.871 . . . . 0.0 109.365 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.665 ' HA ' HD12 ' A' ' 30' ' ' ILE . 25.2 ttt85 -53.74 -30.65 45.16 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.946 . . . . 0.0 109.136 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.467 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.9 tt0 -63.1 -44.45 95.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.309 -0.87 . . . . 0.0 109.36 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.756 ' HB3' HD11 ' A' ' 82' ' ' LEU . 74.3 m-70 -75.79 -33.92 60.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.919 HG23 ' HB2' ' A' ' 35' ' ' MET . 79.8 mt -54.93 -48.83 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.283 -0.885 . . . . 0.0 109.292 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -60.26 -43.15 96.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.531 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.426 ' HA ' HD23 ' A' ' 32' ' ' LEU . 61.5 mt -64.2 -50.81 66.62 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.474 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 91.5 m-70 -82.15 3.1 28.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.244 -0.91 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.409 ' N ' ' O ' ' A' ' 30' ' ' ILE . 21.4 m120 59.4 50.62 7.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.338 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.93 ' HG3' HD22 ' A' ' 82' ' ' LEU . 68.5 mmm -99.58 3.92 45.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.29 -0.881 . . . . 0.0 109.706 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.471 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.2 mt-10 -54.89 -34.33 62.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.173 -0.954 . . . . 0.0 109.451 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -60.88 -42.47 98.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.894 . . . . 0.0 109.358 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.555 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.1 mt -70.88 -50.33 36.27 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.311 -0.868 . . . . 0.0 109.347 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 30' ' ' ILE . 98.9 m-85 -75.99 134.47 40.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.385 -0.822 . . . . 0.0 109.418 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.08 -68.77 0.59 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.433 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 83.3 tt0 -127.6 155.9 43.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -1.128 . . . . 0.0 109.533 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.975 HG13 HG22 ' A' ' 71' ' ' VAL . 51.9 t -121.11 150.39 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.388 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.767 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -120.98 161.86 20.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 43' ' ' MET . 75.5 t . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.304 -0.873 . . . . 0.0 109.378 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.182 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.563 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -121.28 119.04 31.08 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -1.158 . . . . 0.0 109.511 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.767 HG13 ' O ' ' A' ' 43' ' ' MET . 95.1 t -132.03 142.35 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.226 -0.921 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.842 HD22 ' N ' ' A' ' 70' ' ' LEU . 2.4 mm? -106.37 129.55 54.35 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.975 HG22 HG13 ' A' ' 42' ' ' VAL . 84.4 t -139.69 128.88 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.541 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.415 ' OE1' ' HA ' ' A' ' 7' ' ' LYS . 6.6 tt0 -76.94 137.7 39.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.256 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.713 ' HE2' ' HB3' ' A' ' 79' ' ' SER . 7.5 tmm? 177.83 151.19 0.23 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.454 ' O ' ' SD ' ' A' ' 73' ' ' MET . 40.4 t -85.22 124.03 39.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.915 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.684 ' HE3' ' HG3' ' A' ' 100' ' ' PRO . 10.4 mmt -66.43 120.48 13.43 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.298 -0.876 . . . . 0.0 109.439 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.495 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.7 p-10 -150.3 179.16 8.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.261 -0.9 . . . . 0.0 109.47 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.576 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 93.5 m-20 -65.58 -35.19 80.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.348 -0.845 . . . . 0.0 109.548 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.412 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -74.02 -72.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.193 -0.942 . . . . 0.0 109.653 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.713 ' HB3' ' HE2' ' A' ' 73' ' ' MET . 3.7 m -45.2 -52.81 8.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.608 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.452 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 80.2 t90 -55.53 -53.07 60.93 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.242 -0.911 . . . . 0.0 109.571 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.576 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 24.8 m-70 -62.81 -34.84 78.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.256 -0.903 . . . . 0.0 109.524 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.93 HD22 ' HG3' ' A' ' 35' ' ' MET . 52.5 tp -58.05 -42.34 85.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.716 ' CG1' HG11 ' A' ' 89' ' ' VAL . 79.5 t -57.88 -45.53 87.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.214 -0.929 . . . . 0.0 109.537 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -67.36 -29.84 69.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.203 -0.936 . . . . 0.0 109.461 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 67.5 m -59.59 -50.76 72.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.334 -0.854 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.626 HG13 HG21 ' A' ' 89' ' ' VAL . 7.4 p -78.78 128.67 76.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.677 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.569 ' O ' HG23 ' A' ' 89' ' ' VAL . 50.3 Cg_endo -70.13 -171.06 0.46 Allowed 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.752 2.301 . . . . 0.0 111.664 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.499 ' HB3' HG22 ' A' ' 22' ' ' VAL . 31.6 mtt-85 61.38 21.7 12.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.877 . . . . 0.0 109.48 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.716 HG11 ' CG1' ' A' ' 83' ' ' VAL . 43.6 t -119.78 107.93 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.447 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.479 ' CE ' ' OE1' ' A' ' 13' ' ' GLN . 74.6 mtp -60.22 -43.43 96.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.177 -0.952 . . . . 0.0 109.468 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.07 -149.41 21.21 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.711 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 45.4 m-85 -110.36 160.65 16.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.277 -1.131 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.821 HD11 ' HB2' ' A' ' 13' ' ' GLN . 22.1 mm -115.29 129.95 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.385 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 95' ' ' GLY . . . 140.53 -141.47 11.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 94' ' ' GLY . . . -44.0 -89.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -125.16 -178.25 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.247 -1.149 . . . . 0.0 109.435 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.2 p -90.38 21.57 3.81 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -0.918 . . . . 0.0 109.351 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -117.55 -22.94 7.88 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.417 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -154.82 94.68 2.68 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.684 ' HG3' ' HE3' ' A' ' 75' ' ' MET . 41.4 Cg_endo -63.85 118.4 5.34 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.922 2.414 . . . . 0.0 112.138 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.44 142.1 82.6 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.493 -0.754 . . . . 0.0 109.59 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.54 153.34 65.43 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.784 2.322 . . . . 0.0 111.814 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.558 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -126.13 156.78 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 49.8 m -70.46 143.55 51.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 109.586 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.46 -35.87 68.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.386 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 51.0 tttm -62.43 -40.36 96.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.191 -0.943 . . . . 0.0 109.448 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 87.4 tt0 -54.56 -44.76 73.19 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.558 ' CG2' HD11 ' A' ' 103' ' ' ILE . 68.8 t -57.91 -40.44 76.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.345 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -63.91 -37.24 86.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.454 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.11 -47.27 86.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.407 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 68.7 mt -51.9 -48.01 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.3 mmm . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.357 -179.98 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 82.8 mttt . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.589 ' HB2' ' CE1' ' A' ' 10' ' ' TYR . 41.7 mtt-85 -126.38 161.53 27.65 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.159 -0.963 . . . . 0.0 109.509 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.514 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 69.2 m95 -91.35 124.79 35.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.606 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 95.8 m-85 -120.85 147.46 45.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 55.2 t -87.04 159.4 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.393 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.506 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.4 t -144.56 103.94 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.237 -0.915 . . . . 0.0 109.173 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.475 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 50.0 tt0 -42.18 -47.4 4.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.54 -0.725 . . . . 0.0 109.657 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.478 ' O ' ' HG2' ' A' ' 90' ' ' MET . . . 53.62 -168.28 0.06 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.283 -0.885 . . . . 0.0 109.471 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 57.5 t80 -103.17 142.08 34.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.878 . . . . 0.0 109.341 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.425 ' HA ' ' OE2' ' A' ' 19' ' ' GLU . 28.3 p -66.96 131.07 45.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.62 -28.04 9.84 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 17.9 m-30 -103.29 18.26 22.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.223 -1.163 . . . . 0.0 109.506 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.517 ' OE2' ' N ' ' A' ' 67' ' ' GLY . 33.3 mp0 -51.64 -40.94 60.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.191 -0.943 . . . . 0.0 109.251 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.03 -58.39 3.21 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.1 ttm-85 -55.05 -47.48 74.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.155 -1.203 . . . . 0.0 109.426 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.655 HG23 ' CB ' ' A' ' 18' ' ' PHE . 46.8 t -46.7 -45.9 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 109.31 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.77 -45.01 66.92 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.386 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 86.0 m -62.03 -42.99 99.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.336 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 1.2 t -50.07 -54.97 16.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.215 -0.928 . . . . 0.0 109.289 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.492 HD23 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -47.68 -56.33 7.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.267 -0.895 . . . . 0.0 109.235 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.471 ' HA ' ' HB ' ' A' ' 30' ' ' ILE . 70.0 ttt-85 -52.72 -34.1 50.98 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.894 . . . . 0.0 109.127 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.7 tt0 -61.38 -46.09 91.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.183 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.7 ' NE2' HG23 ' A' ' 86' ' ' VAL . 69.3 m-70 -83.45 -30.1 27.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.249 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.862 HG23 ' HB2' ' A' ' 35' ' ' MET . 86.5 mt -64.44 -45.09 96.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -60.18 -40.56 90.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.9 . . . . 0.0 109.271 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 32' ' ' LEU . 82.8 mt -69.61 -51.77 32.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.299 -0.876 . . . . 0.0 109.354 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.437 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.4 m-70 -79.23 0.02 30.24 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.59 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 30' ' ' ILE . 83.9 m-20 59.57 49.03 8.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 1.04 ' HG3' HD13 ' A' ' 82' ' ' LEU . 65.7 mmm -95.38 1.37 54.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.327 -0.858 . . . . 0.0 109.554 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -48.8 -36.48 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.563 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -57.1 -45.2 83.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.783 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.5 mt -70.88 -53.72 14.09 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -0.883 . . . . 0.0 109.443 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.583 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 91.7 m-85 -68.76 138.5 54.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.863 . . . . 0.0 109.422 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.03 -70.39 0.22 Allowed Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -128.63 157.48 41.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -1.16 . . . . 0.0 109.649 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.856 HG13 HG22 ' A' ' 71' ' ' VAL . 57.6 t -121.56 156.98 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.624 ' O ' HG13 ' A' ' 69' ' ' VAL . 87.3 mmm -121.64 150.78 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.265 -0.897 . . . . 0.0 109.398 179.848 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.517 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -123.48 122.2 37.62 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -1.157 . . . . 0.0 109.41 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 43' ' ' MET . 88.1 t -133.02 140.81 46.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 109.516 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.832 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.1 mp -105.66 134.99 47.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.38 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 42' ' ' VAL . 77.2 t -139.98 117.86 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.303 -0.873 . . . . 0.0 109.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.448 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.2 tt0 -67.61 135.49 52.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.42 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 44.6 ttp 173.57 154.69 0.11 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 97.1 t -84.21 140.78 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.606 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 19.3 mmm -84.8 125.71 32.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.536 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.592 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 47.8 p-10 -152.65 173.54 15.09 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -64.84 -29.4 70.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.247 -0.908 . . . . 0.0 109.542 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.592 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -74.87 -72.41 0.3 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.665 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.783 ' OG ' HD13 ' A' ' 38' ' ' LEU . 10.6 m -44.38 -56.82 3.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.257 -0.902 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.517 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 51.7 t90 -44.62 -54.04 6.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.278 -0.889 . . . . 0.0 109.385 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -61.1 -35.79 77.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.362 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 1.04 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -57.25 -37.24 72.03 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.27 -0.894 . . . . 0.0 109.413 179.892 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.947 ' CG1' HG11 ' A' ' 89' ' ' VAL . 44.1 t -73.04 -45.96 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -68.94 -31.31 70.1 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 95.1 p -64.8 -45.6 85.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.906 . . . . 0.0 109.362 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.7 HG23 ' NE2' ' A' ' 29' ' ' HIS . 11.1 p -82.35 133.49 50.23 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.395 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.624 ' O ' HG23 ' A' ' 89' ' ' VAL . 49.3 Cg_endo -69.12 -166.87 0.18 Allowed 'Trans proline' 0 C--O 1.214 -0.722 0 C-N-CA 122.697 2.265 . . . . 0.0 111.876 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.502 ' HB3' HG22 ' A' ' 22' ' ' VAL . 89.6 mtt-85 63.01 16.73 9.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.433 -0.792 . . . . 0.0 109.535 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.947 HG11 ' CG1' ' A' ' 83' ' ' VAL . 11.6 t -119.99 109.27 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.409 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 14' ' ' ALA . 90.9 mmm -65.3 -39.89 93.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 109.576 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.92 -169.59 35.23 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.569 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 15.3 m-85 -100.37 158.56 15.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.653 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 34.3 mm -117.7 115.69 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.298 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 179.8 -142.71 5.28 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.95 -37.55 50.14 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 p -132.39 169.89 15.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -1.156 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.0 p -88.84 14.93 9.22 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.251 -0.906 . . . . 0.0 109.336 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.517 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 88.5 m-20 -125.15 -22.49 4.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.566 -0.709 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.411 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -140.8 101.27 6.5 Favored Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.191 -0.943 . . . . 0.0 109.15 179.814 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.7 Cg_endo -69.02 109.69 2.23 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.744 2.296 . . . . 0.0 111.922 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.94 139.64 78.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 154.04 67.41 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.72 2.28 . . . . 0.0 111.842 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 108' ' ' VAL . 34.5 pt -123.83 158.13 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 m -70.21 147.74 49.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -55.01 -38.86 68.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -58.62 -40.34 83.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -51.77 -48.67 63.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.281 -0.887 . . . . 0.0 109.403 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.68 HG22 HD23 ' A' ' 70' ' ' LEU . 74.2 t -57.67 -44.09 84.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -60.9 -41.38 95.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.184 -0.948 . . . . 0.0 109.344 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.45 -52.82 64.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.326 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.799 HD12 HD21 ' A' ' 70' ' ' LEU . 69.0 mt -49.79 -53.98 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.378 -0.826 . . . . 0.0 109.373 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 95.3 mmm . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.254 179.873 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.424 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 94.9 mttt . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 95.4 mtt-85 -139.51 150.27 44.93 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.396 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.443 ' O ' HG12 ' A' ' 103' ' ' ILE . 72.4 m95 -100.67 136.72 40.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.642 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -130.21 149.85 51.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.328 -0.857 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.436 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 12.8 t -98.93 139.16 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.188 -0.945 . . . . 0.0 109.524 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.53 HG22 ' CE1' ' A' ' 92' ' ' PHE . 46.3 t -119.18 130.0 74.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.872 . . . . 0.0 109.41 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.876 ' CG ' HD11 ' A' ' 93' ' ' ILE . 95.8 mt-30 -87.68 147.47 25.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.329 -0.857 . . . . 0.0 109.468 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.3 154.63 38.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.921 . . . . 0.0 109.462 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -66.38 146.47 54.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.286 -0.884 . . . . 0.0 109.457 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 42.0 m -58.08 135.97 57.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.73 -29.28 7.49 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -104.08 7.15 36.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.2 -1.176 . . . . 0.0 109.545 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.86 -37.33 71.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.432 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -79.7 -35.0 29.72 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 63.4 ttt-85 -63.18 -47.4 82.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.233 -1.157 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.474 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 45.6 t -50.71 -39.12 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.451 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.21 -39.55 94.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 67.9 m -67.43 -36.0 80.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.572 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.706 ' HB2' HG13 ' A' ' 86' ' ' VAL . 31.8 m -63.72 -41.38 98.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.157 -0.964 . . . . 0.0 109.484 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.925 ' CD2' HG21 ' A' ' 86' ' ' VAL . 61.9 mt -56.48 -43.78 79.98 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.539 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.509 ' CG ' ' HE3' ' A' ' 31' ' ' LYS . 41.4 ttm180 -57.19 -39.46 75.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -73.97 -59.82 2.54 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.514 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.453 ' CD2' ' O ' ' A' ' 25' ' ' SER . 93.6 m-70 -52.44 -45.81 66.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.564 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' A' ' 35' ' ' MET . 96.5 mt -64.1 -55.58 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.477 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.509 ' HE3' ' CG ' ' A' ' 27' ' ' ARG . 82.6 mttt -53.89 -37.13 63.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 32' ' ' LEU . 51.3 mt -73.06 -48.19 38.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.539 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.456 ' CD2' HD12 ' A' ' 82' ' ' LEU . 98.1 m-70 -81.38 0.87 35.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.939 . . . . 0.0 109.615 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 30' ' ' ILE . 77.7 m-20 59.08 49.77 8.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 1.057 ' HG3' HD13 ' A' ' 82' ' ' LEU . 40.0 mmm -101.8 8.98 41.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.557 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.448 ' OE2' ' HG2' ' A' ' 31' ' ' LYS . 97.5 mt-10 -51.73 -37.02 49.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.461 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -60.35 -37.83 81.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.407 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.98 HD13 ' OG ' ' A' ' 79' ' ' SER . 5.8 mt -73.61 -55.06 6.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.252 -0.905 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.634 ' CE1' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -72.47 136.17 45.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 109.407 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.39 -66.49 0.5 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -137.94 152.76 49.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.203 -1.175 . . . . 0.0 109.562 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.055 HG13 HG22 ' A' ' 71' ' ' VAL . 42.8 t -116.81 155.3 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.466 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 87.9 mtp -120.65 138.7 53.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.887 . . . . 0.0 109.568 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.3 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 179.916 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.234 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.98 125.84 49.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -1.178 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.435 ' C ' HD12 ' A' ' 70' ' ' LEU . 91.0 t -132.06 143.25 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.954 HD21 HD12 ' A' ' 111' ' ' ILE . 3.3 mp -107.65 127.41 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.385 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.055 HG22 HG13 ' A' ' 42' ' ' VAL . 96.9 t -133.27 133.17 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.538 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.424 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.3 tt0 -84.49 133.94 34.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.377 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.568 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 28.5 ttp -175.04 162.71 3.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.475 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.537 ' N ' ' HG2' ' A' ' 73' ' ' MET . 33.3 m -103.51 145.66 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.364 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.548 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 11.7 mmt -79.42 122.44 26.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.454 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 36.0 p-10 -133.74 -143.76 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.29 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.2 p30 -117.91 0.85 12.0 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.025 -1.047 . . . . 0.0 110.067 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -122.8 -20.02 6.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.103 -0.998 . . . . 0.0 109.785 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.98 ' OG ' HD13 ' A' ' 38' ' ' LEU . 4.5 m -79.1 -36.66 40.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.24 -0.912 . . . . 0.0 109.581 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 85.6 t90 -56.24 -51.25 68.78 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.293 -0.879 . . . . 0.0 109.595 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -66.22 -32.21 73.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.689 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 1.057 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.6 OUTLIER -62.86 -37.12 85.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.214 -0.929 . . . . 0.0 109.475 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.832 HG21 ' CE2' ' A' ' 92' ' ' PHE . 55.8 t -68.96 -50.02 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 23.1 ttp85 -60.98 -35.69 77.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.506 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.3 t -60.5 -30.83 69.96 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.93 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.0 t -61.84 117.9 33.25 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.13 167.71 24.15 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.584 2.189 . . . . 0.0 111.693 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 39.0 mmt180 60.91 29.85 19.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.7 p -122.79 130.09 74.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.212 -0.93 . . . . 0.0 109.407 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.5 mtp -70.12 -50.93 35.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.21 -0.931 . . . . 0.0 109.508 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 169.36 -151.24 16.96 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.832 ' CE2' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -115.63 170.21 8.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.27 -1.135 . . . . 0.0 109.516 179.998 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.876 HD11 ' CG ' ' A' ' 13' ' ' GLN . 39.6 mm -121.78 125.48 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.355 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 169.71 -163.23 36.73 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -54.57 -56.77 20.51 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 p -125.49 178.96 5.34 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -1.162 . . . . 0.0 109.593 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.3 p -93.76 16.91 12.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -120.11 -28.64 5.06 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 10.1 mtp85 -142.56 90.75 7.78 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.548 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.0 Cg_endo -66.43 120.26 7.37 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.92 2.413 . . . . 0.0 112.239 -179.307 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.28 146.93 97.1 Favored Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.498 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.2 Cg_endo -69.85 152.84 68.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.598 2.198 . . . . 0.0 111.903 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.743 HD11 HG22 ' A' ' 108' ' ' VAL . 30.2 pt -113.1 156.12 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.316 -0.865 . . . . 0.0 109.4 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.0 m -74.52 152.21 39.4 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -56.6 -37.83 71.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.35 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -58.14 -42.08 85.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.223 -0.923 . . . . 0.0 109.404 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.413 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 90.1 mt-10 -58.76 -45.06 90.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.485 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 103' ' ' ILE . 73.4 t -59.43 -39.62 79.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.322 -0.861 . . . . 0.0 109.379 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.6 -34.21 73.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.267 -0.896 . . . . 0.0 109.388 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.27 -44.43 95.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.349 -0.844 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.954 HD12 HD21 ' A' ' 70' ' ' LEU . 73.9 mt -54.21 -54.16 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.474 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . 0.429 ' HB2' ' HE3' ' A' ' 112' ' ' MET . 55.9 ttm . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.515 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.511 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 46.9 mttt . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.279 0.561 . . . . 0.0 109.571 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.472 ' HD2' ' OH ' ' A' ' 10' ' ' TYR . 78.3 mtt180 -125.27 156.72 38.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.392 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.456 ' CZ2' ' HB2' ' A' ' 72' ' ' GLN . 59.4 m95 -104.42 126.8 51.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.184 -0.948 . . . . 0.0 109.591 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.472 ' OH ' ' HD2' ' A' ' 8' ' ' ARG . 85.6 m-85 -125.15 148.13 48.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.417 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.548 HG22 ' CD1' ' A' ' 70' ' ' LEU . 22.8 t -92.06 143.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -0.926 . . . . 0.0 109.615 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.3 t -120.61 132.79 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.776 ' CG ' HD11 ' A' ' 93' ' ' ILE . 58.1 mt-30 -84.53 151.99 24.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.9 . . . . 0.0 109.483 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -163.96 150.47 11.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 0.0 109.506 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -61.14 143.67 55.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.224 -0.923 . . . . 0.0 109.509 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.9 t -61.62 136.45 58.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.82 -31.53 5.53 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.438 ' HB3' ' HD3' ' A' ' 88' ' ' ARG . 87.2 m-85 -105.08 -2.62 24.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.202 -1.175 . . . . 0.0 109.536 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.48 ' HG3' ' N ' ' A' ' 20' ' ' GLY . 15.7 pt-20 -56.52 -41.82 77.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.194 -0.941 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.48 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -63.15 -39.09 97.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.421 ' O ' ' C ' ' A' ' 22' ' ' VAL . 58.1 ttt85 -59.07 -48.73 80.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -1.129 . . . . 0.0 109.432 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.795 HG13 HG11 ' A' ' 86' ' ' VAL . 40.5 t -43.79 -39.18 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.881 . . . . 0.0 109.268 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -54.63 -56.01 23.57 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.252 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.9 m -63.45 -48.55 77.24 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.361 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.485 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 17.0 m -56.27 -49.04 75.37 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 0.0 109.328 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.673 HD12 HG21 ' A' ' 86' ' ' VAL . 5.1 tp -48.33 -56.46 8.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 43.1 ttt180 -55.08 -37.48 66.84 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.332 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.796 ' O ' HD12 ' A' ' 32' ' ' LEU . 71.5 tt0 -56.88 -47.78 79.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.257 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.885 ' HB3' HD11 ' A' ' 82' ' ' LEU . 62.0 m-70 -71.23 -41.62 69.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.243 -0.91 . . . . 0.0 109.344 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.769 HD13 ' CD1' ' A' ' 39' ' ' PHE . 76.1 mt -59.15 -52.2 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.394 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -54.23 -43.5 70.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.448 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.796 HD12 ' O ' ' A' ' 28' ' ' GLU . 4.3 mt -65.44 -48.4 72.88 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -0.915 . . . . 0.0 109.466 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB2' ' SD ' ' A' ' 35' ' ' MET . 96.2 m-70 -85.17 6.39 25.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.56 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.516 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.6 t30 51.97 47.14 25.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.566 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.738 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -98.36 6.12 47.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.252 -0.905 . . . . 0.0 109.419 179.921 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.573 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.24 -35.5 49.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.158 -0.964 . . . . 0.0 109.523 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -55.25 -42.47 73.51 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 1.04 HD13 ' OG ' ' A' ' 79' ' ' SER . 0.9 OUTLIER -71.1 -54.47 11.0 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.201 -0.937 . . . . 0.0 109.322 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.769 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.0 m-85 -64.46 137.79 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.9 -67.48 0.38 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -132.76 149.74 52.24 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.251 -1.147 . . . . 0.0 109.707 -179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 71' ' ' VAL . 98.6 t -120.01 149.14 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.881 . . . . 0.0 109.289 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.822 ' HE1' HG11 ' A' ' 108' ' ' VAL . 73.4 mtm -130.37 146.14 51.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.144 -0.973 . . . . 0.0 109.578 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.9 t . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.272 -0.893 . . . . 0.0 109.301 179.882 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -110.02 128.86 55.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.222 -1.164 . . . . 0.0 109.583 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.485 ' C ' HD22 ' A' ' 70' ' ' LEU . 99.9 t -133.55 141.58 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.848 HD22 ' N ' ' A' ' 70' ' ' LEU . 2.3 mm? -106.27 131.5 53.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.354 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 42' ' ' VAL . 83.9 t -140.52 120.85 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.262 -0.899 . . . . 0.0 109.754 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 4.4 tt0 -76.62 124.74 28.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.567 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.2 ttp -162.82 155.97 19.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.683 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.513 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.7 t -86.14 130.11 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.7 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 18.9 ttm -75.26 135.49 40.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.469 HD21 ' HB3' ' A' ' 78' ' ' ALA . 44.7 p-10 -151.58 -161.0 1.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -102.99 34.35 2.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.417 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.469 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -149.88 -50.21 0.14 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 1.04 ' OG ' HD13 ' A' ' 38' ' ' LEU . 14.8 m -63.24 -44.06 96.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.51 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 70.3 t90 -50.78 -47.02 59.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -69.25 -34.05 74.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.885 HD11 ' HB3' ' A' ' 29' ' ' HIS . 53.9 tp -63.43 -38.69 92.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.28 -0.887 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 92' ' ' PHE . 70.6 t -60.69 -49.57 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.383 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -58.8 -35.3 72.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.306 -0.871 . . . . 0.0 109.439 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 24.1 m -62.73 -33.96 76.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.426 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.795 HG11 HG13 ' A' ' 22' ' ' VAL . 49.0 t -49.18 127.71 15.8 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.7 Cg_endo -70.8 156.77 60.02 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.617 2.211 . . . . 0.0 111.803 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.456 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.9 mtt-85 63.51 34.19 12.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 109.678 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.4 p -128.52 134.41 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 73.2 mtm -79.56 -44.56 20.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.241 -0.912 . . . . 0.0 109.488 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.74 -147.04 12.25 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -113.25 167.07 10.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -1.114 . . . . 0.0 109.55 -179.976 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.776 HD11 ' CG ' ' A' ' 13' ' ' GLN . 33.5 mm -121.25 137.65 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.854 . . . . 0.0 109.438 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 163.09 -148.07 14.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.59 -46.55 14.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.2 p -121.64 171.2 9.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -1.192 . . . . 0.0 109.804 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 59.9 m -91.61 18.56 7.3 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.23 -0.919 . . . . 0.0 109.322 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.51 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 90.2 m-20 -124.82 -30.92 3.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.525 -0.734 . . . . 0.0 109.099 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 6.2 mtt180 -144.64 98.67 4.88 Favored Pre-proline 0 N--CA 1.488 1.464 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.7 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 44.3 Cg_endo -67.12 132.28 27.49 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.695 2.263 . . . . 0.0 112.101 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.07 137.02 96.93 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.387 -0.821 . . . . 0.0 109.36 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.19 152.69 72.26 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.645 2.23 . . . . 0.0 111.741 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.801 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -123.53 164.46 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.407 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.6 p -83.52 155.32 23.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -0.928 . . . . 0.0 109.447 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -63.74 -30.39 71.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.257 -0.902 . . . . 0.0 109.494 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -65.43 -37.1 85.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -0.906 . . . . 0.0 109.4 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.447 ' O ' HG13 ' A' ' 111' ' ' ILE . 85.2 tt0 -65.0 -39.86 94.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.254 -0.904 . . . . 0.0 109.385 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.822 HG11 ' HE1' ' A' ' 43' ' ' MET . 76.3 t -67.02 -34.08 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.354 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -70.5 -34.11 71.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.88 . . . . 0.0 109.453 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -69.34 -39.51 78.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.334 -0.854 . . . . 0.0 109.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 107' ' ' GLU . 71.9 mt -56.93 -51.37 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.234 -0.916 . . . . 0.0 109.541 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.5 mtp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.226 -0.921 . . . . 0.0 109.496 -179.99 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.436 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 16.0 pttt . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.516 -0.549 . . . . 0.0 109.516 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.0 mtt-85 -133.53 153.5 51.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.237 -0.914 . . . . 0.0 109.491 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 70.4 m95 -101.38 135.81 42.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.909 . . . . 0.0 109.415 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CE2' ' O ' ' A' ' 73' ' ' MET . 22.9 m-85 -124.58 151.62 44.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 18.4 t -101.1 137.89 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.333 -0.855 . . . . 0.0 109.489 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 30.6 t -115.11 128.7 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.306 -0.871 . . . . 0.0 109.234 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.953 ' HB2' HD11 ' A' ' 93' ' ' ILE . 60.4 tt0 -95.6 129.96 42.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.913 . . . . 0.0 109.617 -179.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.44 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -147.42 -178.2 6.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -75.03 134.26 41.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.7 m -57.79 140.6 51.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.39 -25.44 15.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.49 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.4 m-85 -112.05 13.57 20.71 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.23 -1.159 . . . . 0.0 109.39 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.485 ' OE2' ' N ' ' A' ' 67' ' ' GLY . 87.2 mt-10 -54.07 -45.31 71.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.12 -42.25 91.85 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.425 ' HD3' ' NE ' ' A' ' 88' ' ' ARG . 52.7 ttt85 -52.16 -54.53 29.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.228 -1.16 . . . . 0.0 109.389 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.1 t -50.35 -37.23 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.203 -0.936 . . . . 0.0 109.119 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.72 -36.79 85.43 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.211 -0.931 . . . . 0.0 109.231 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -58.83 -43.03 90.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.397 -0.815 . . . . 0.0 109.158 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.47 ' HB3' ' NE2' ' A' ' 29' ' ' HIS . 20.3 m -58.77 -41.04 85.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 109.319 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.66 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.1 mt -53.45 -44.51 68.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.865 . . . . 0.0 109.409 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 31' ' ' LYS . 65.9 ttt180 -52.6 -42.49 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.34 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.413 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 64.6 mm-40 -75.02 -57.77 3.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.631 ' CD2' HG22 ' A' ' 86' ' ' VAL . 87.2 m-70 -55.15 -38.03 67.73 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -0.942 . . . . 0.0 109.268 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.792 HG23 ' HB2' ' A' ' 35' ' ' MET . 82.2 mt -77.17 -54.46 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.293 -0.879 . . . . 0.0 109.49 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 27' ' ' ARG . 42.2 tttm -59.97 -38.24 81.92 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.906 . . . . 0.0 109.286 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.467 HD23 ' HA ' ' A' ' 32' ' ' LEU . 25.2 mt -70.64 -52.05 23.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.194 -0.942 . . . . 0.0 109.388 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -81.17 0.84 34.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.536 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.509 ' N ' ' O ' ' A' ' 30' ' ' ILE . 20.2 m120 60.37 51.49 5.33 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.242 -0.911 . . . . 0.0 109.408 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.86 ' HG3' HD13 ' A' ' 82' ' ' LEU . 59.9 mmm -99.84 -0.15 40.3 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.291 -0.88 . . . . 0.0 109.599 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.515 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.1 mt-10 -45.67 -37.94 6.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.402 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -53.45 -44.24 68.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.922 . . . . 0.0 109.436 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.777 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.0 OUTLIER -74.62 -46.92 35.19 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.376 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.707 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -75.41 125.87 29.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.9 . . . . 0.0 109.497 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.69 -67.06 0.6 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -132.46 144.74 50.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -1.154 . . . . 0.0 109.524 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.875 HG13 HG22 ' A' ' 71' ' ' VAL . 19.5 t -109.06 147.65 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.247 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.495 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.2 mtp -122.73 152.32 40.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.118 -0.988 . . . . 0.0 109.757 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.3 t . . . . . 0 N--CA 1.49 1.525 0 O-C-N 121.365 -0.835 . . . . 0.0 109.228 179.949 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.485 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.01 118.29 22.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -1.125 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.572 ' C ' HD12 ' A' ' 70' ' ' LEU . 79.0 t -130.64 148.82 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.559 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.837 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.0 mp -116.05 132.66 56.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.292 -0.88 . . . . 0.0 109.314 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.875 HG22 HG13 ' A' ' 42' ' ' VAL . 92.4 t -137.03 129.91 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.649 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.6 tt0 -79.87 132.74 36.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.225 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 50.3 ttp 174.07 165.19 0.2 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.162 -0.961 . . . . 0.0 109.621 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 15.0 p -94.6 138.57 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.286 -0.884 . . . . 0.0 109.237 179.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.6 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 34.3 tpp -79.15 119.52 22.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.3 p-10 -141.94 179.06 7.09 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.35 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -64.97 -36.7 85.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.486 ' HB1' ' HE2' ' A' ' 35' ' ' MET . . . -74.47 -72.78 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.173 -0.954 . . . . 0.0 109.827 -179.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.777 ' OG ' HD13 ' A' ' 38' ' ' LEU . 3.6 m -42.24 -47.5 4.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.392 -0.818 . . . . 0.0 109.741 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.579 ' CZ2' ' HD2' ' A' ' 84' ' ' ARG . 63.7 t90 -50.63 -49.72 56.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.226 -0.921 . . . . 0.0 109.577 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -68.34 -25.16 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.527 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.86 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.9 OUTLIER -60.52 -54.75 41.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.297 -0.877 . . . . 0.0 109.562 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.033 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 2.7 t -62.26 -49.09 85.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.504 -0.747 . . . . 0.0 109.896 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.579 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 58.2 mtp180 -62.77 -29.38 70.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.134 -0.979 . . . . 0.0 109.509 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.1 p -79.6 -17.8 53.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.408 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.802 HG23 ' O ' ' A' ' 82' ' ' LEU . 71.8 t -73.01 125.9 90.79 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.449 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.01 160.34 49.65 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.626 2.218 . . . . 0.0 111.782 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.537 ' CZ ' ' HB2' ' A' ' 88' ' ' ARG . 13.0 ttm105 64.74 31.72 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.602 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.9 p -126.59 130.93 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.192 -0.942 . . . . 0.0 109.451 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.505 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 95.7 mmm -71.29 -46.85 59.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.09 -155.5 26.35 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 1.033 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.0 m-85 -104.74 162.45 13.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -1.086 . . . . 0.0 109.588 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.953 HD11 ' HB2' ' A' ' 13' ' ' GLN . 10.7 mm -119.02 118.27 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.41 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -174.52 -145.57 5.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.93 -46.01 24.62 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.8 p -127.36 173.37 9.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.195 -1.179 . . . . 0.0 109.604 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.2 p -90.49 18.78 5.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.111 -0.993 . . . . 0.0 109.253 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -126.62 -6.3 6.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.579 -0.701 . . . . 0.0 109.428 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.415 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -164.73 99.57 0.85 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.252 -0.905 . . . . 0.0 109.07 179.935 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.6 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 47.6 Cg_endo -68.55 114.21 3.41 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.678 2.252 . . . . 0.0 111.891 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.57 137.37 82.19 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.519 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.82 153.9 68.12 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.707 2.271 . . . . 0.0 111.813 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.615 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -124.44 161.04 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.444 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.441 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 49.9 m -70.94 147.95 48.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -62.26 -36.28 81.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.197 -0.94 . . . . 0.0 109.34 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -61.59 -35.96 79.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.441 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 99.8 mt-10 -60.8 -43.15 98.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.887 . . . . 0.0 109.366 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.615 ' CG2' HD11 ' A' ' 103' ' ' ILE . 75.4 t -62.53 -35.14 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.455 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -66.99 -38.04 85.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.885 . . . . 0.0 109.412 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.6 -44.31 91.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.955 . . . . 0.0 109.441 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 67.9 mt -53.53 -52.54 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -0.922 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.2 mmm . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.498 -179.992 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.421 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 98.6 mttt . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.312 0.577 . . . . 0.0 109.509 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 54.3 mtt180 -123.42 153.96 39.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.427 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.575 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 73.8 m95 -96.16 123.74 39.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.227 -0.92 . . . . 0.0 109.581 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.591 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 88.1 m-85 -119.19 159.64 23.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -0.943 . . . . 0.0 109.473 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.47 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 27.0 t -94.33 149.18 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.637 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.4 ' N ' ' O ' ' A' ' 69' ' ' VAL . 57.3 t -124.64 118.74 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.246 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.957 ' HB2' HD11 ' A' ' 93' ' ' ILE . 59.3 tt0 -84.85 140.07 31.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.58 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.438 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -156.92 -153.39 0.41 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.934 . . . . 0.0 109.391 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.96 140.62 46.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.446 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 t -59.24 132.73 54.89 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.48 -16.92 60.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -109.48 0.19 19.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -1.143 . . . . 0.0 109.576 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.51 ' OE2' ' N ' ' A' ' 68' ' ' TYR . 99.0 mt-10 -56.35 -44.34 79.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.367 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.55 -50.15 67.11 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.531 ' NH2' ' HG3' ' A' ' 88' ' ' ARG . 12.4 ttp180 -57.3 -56.26 24.12 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -1.123 . . . . 0.0 109.416 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.699 HG13 HG11 ' A' ' 86' ' ' VAL . 40.7 t -45.46 -38.68 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.87 -44.85 96.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.342 -0.849 . . . . 0.0 109.266 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.4 m -69.44 -47.28 64.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.677 ' HG ' ' HE2' ' A' ' 29' ' ' HIS . 15.3 t -57.4 -56.21 24.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.338 -0.851 . . . . 0.0 109.489 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.442 ' CD1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp -46.82 -49.71 19.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.377 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.487 ' CG ' ' HE2' ' A' ' 31' ' ' LYS . 46.7 ttm-85 -60.71 -34.59 74.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.186 -0.946 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -64.18 -48.07 77.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.225 -0.922 . . . . 0.0 109.322 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.677 ' HE2' ' HG ' ' A' ' 25' ' ' SER . 60.1 m-70 -66.3 -37.29 85.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 109.341 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.815 HG23 ' HB2' ' A' ' 35' ' ' MET . 90.8 mt -65.26 -49.03 81.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.256 -0.903 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.487 ' HE2' ' CG ' ' A' ' 27' ' ' ARG . 25.3 mttm -56.84 -40.05 75.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 32' ' ' LEU . 29.8 mt -69.91 -52.02 28.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.488 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.7 m-70 -81.12 4.34 20.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.591 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' ILE . 78.8 m-20 54.76 47.65 21.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.248 -0.907 . . . . 0.0 109.511 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 1.008 ' HG3' HD13 ' A' ' 82' ' ' LEU . 61.1 mmm -94.2 6.54 48.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.932 . . . . 0.0 109.594 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.502 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.53 -31.19 34.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.394 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -61.85 -41.84 98.31 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.351 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.496 HD12 ' HB3' ' A' ' 35' ' ' MET . 10.3 mt -70.93 -53.68 14.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.699 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 73.9 m-85 -75.2 143.33 43.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.306 -0.871 . . . . 0.0 109.474 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.34 -58.84 0.24 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -136.29 156.48 48.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -1.223 . . . . 0.0 109.734 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.889 HG13 HG22 ' A' ' 71' ' ' VAL . 54.5 t -121.01 154.66 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.582 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -121.99 147.68 45.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.159 -0.963 . . . . 0.0 109.633 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.379 179.915 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.51 ' N ' ' OE2' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -111.0 119.47 39.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 109.366 179.946 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -134.17 140.62 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.554 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.851 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.0 mp -104.3 141.76 35.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.382 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.889 HG22 HG13 ' A' ' 42' ' ' VAL . 68.9 t -145.26 123.67 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -0.951 . . . . 0.0 109.705 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.421 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 38.5 tt0 -73.96 124.87 27.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.309 -0.869 . . . . 0.0 109.127 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.458 ' SD ' ' OG ' ' A' ' 79' ' ' SER . 8.8 tmm? -169.22 151.52 4.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.293 -0.88 . . . . 0.0 109.398 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.582 ' O ' HG23 ' A' ' 74' ' ' VAL . 28.6 m -77.59 118.97 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.585 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.596 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 8.5 mmt -61.72 115.84 4.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.172 -0.955 . . . . 0.0 109.585 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.2 p-10 -151.28 172.74 15.39 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.36 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -63.4 -33.78 76.29 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.645 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.535 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -71.5 -72.36 0.22 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 109.661 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.524 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 18.0 p -46.63 -57.59 4.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.525 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 44.0 t90 -43.65 -53.89 5.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.34 -0.85 . . . . 0.0 109.574 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.53 -43.41 98.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.61 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 1.008 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.8 OUTLIER -55.81 -43.1 76.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 0.0 109.491 -179.843 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 92' ' ' PHE . 98.2 t -61.01 -52.11 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 57.4 ttt85 -55.63 -35.08 65.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.566 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 39.9 m -59.58 -37.22 77.93 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.187 -0.946 . . . . 0.0 109.555 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.699 HG11 HG13 ' A' ' 22' ' ' VAL . 91.8 t -54.99 125.56 56.92 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 109.516 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.7 Cg_endo -71.25 160.28 49.39 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.624 2.216 . . . . 0.0 111.769 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.531 ' HG3' ' NH2' ' A' ' 21' ' ' ARG . 50.1 mmt-85 63.66 30.79 14.79 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.695 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 86' ' ' VAL . 6.1 p -129.24 130.63 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.157 -0.964 . . . . 0.0 109.375 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.509 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.1 mmm -76.46 -54.98 5.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 166.67 -150.12 16.74 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.684 ' CE2' HG11 ' A' ' 83' ' ' VAL . 6.5 m-85 -105.5 161.86 13.98 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -1.131 . . . . 0.0 109.561 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.957 HD11 ' HB2' ' A' ' 13' ' ' GLN . 19.3 mm -120.3 122.13 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.415 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -179.66 -144.39 5.88 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.62 -45.25 95.04 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 p -130.76 171.01 13.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.219 -1.165 . . . . 0.0 109.463 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.9 p -89.02 16.61 6.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.144 -0.972 . . . . 0.0 109.37 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.525 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.1 m-20 -125.64 -27.14 3.42 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.533 -0.729 . . . . 0.0 109.261 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -140.16 97.63 7.73 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.339 -0.851 . . . . 0.0 108.846 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.72 127.12 15.73 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.79 2.327 . . . . 0.0 112.067 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.63 138.51 93.5 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.256 -0.902 . . . . 0.0 109.234 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.514 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.8 Cg_endo -70.45 153.66 65.6 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.603 2.202 . . . . 0.0 111.845 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 34.9 pt -127.55 161.08 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.452 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.484 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 43.7 m -71.79 150.56 44.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.348 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -56.93 -37.91 72.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.335 -0.853 . . . . 0.0 109.456 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -60.35 -34.02 73.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.441 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.484 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 76.5 mm-40 -59.12 -41.85 89.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.922 . . . . 0.0 109.384 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.491 HG21 ' CG ' ' A' ' 9' ' ' TRP . 90.0 t -63.33 -36.2 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.913 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -66.6 -38.71 87.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.69 -47.7 77.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.586 HD12 HD21 ' A' ' 70' ' ' LEU . 45.2 mt -50.49 -51.41 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.497 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 96.2 mmm . . . . . 0 N--CA 1.49 1.529 0 O-C-N 121.156 -0.965 . . . . 0.0 109.387 179.937 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 40.1 mttt . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.505 ' HD2' ' HB3' ' A' ' 102' ' ' PRO . 23.1 mtm180 -122.26 154.85 37.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -93.56 137.69 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.549 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 46.0 m-85 -131.85 164.19 26.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.868 . . . . 0.0 109.567 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.428 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.9 t -99.2 139.89 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 109.53 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.9 t -122.74 119.54 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.588 ' HB2' HD11 ' A' ' 93' ' ' ILE . 49.8 tt0 -87.24 135.44 33.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.887 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.32 161.28 38.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.369 -0.832 . . . . 0.0 109.41 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 97.4 m-85 -57.75 149.99 20.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 35.0 t -71.9 145.94 48.18 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.51 -34.37 4.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.843 ' O ' HG23 ' A' ' 22' ' ' VAL . 17.9 m-30 -108.48 6.61 26.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.261 -1.141 . . . . 0.0 109.502 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.505 ' CG ' ' N ' ' A' ' 20' ' ' GLY . 22.8 pt-20 -51.62 -43.84 62.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.331 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -67.29 -54.35 20.76 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -58.68 -40.57 83.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.174 -1.192 . . . . 0.0 109.389 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.887 HG21 ' HB1' ' A' ' 14' ' ' ALA . 76.6 t -50.75 -48.67 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.408 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.029 ' HB1' HG11 ' A' ' 42' ' ' VAL . . . -55.32 -40.73 71.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.243 -0.911 . . . . 0.0 109.336 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.2 m -65.83 -39.94 91.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.249 -0.907 . . . . 0.0 109.418 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 21.1 m -57.85 -46.35 84.93 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.254 -0.904 . . . . 0.0 109.398 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.465 ' O ' HG12 ' A' ' 30' ' ' ILE . 34.9 mt -52.27 -55.98 17.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.348 -0.845 . . . . 0.0 109.357 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.408 ' C ' ' O ' ' A' ' 26' ' ' LEU . 49.3 ttt-85 -42.58 -40.75 2.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.417 -0.802 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 25' ' ' SER . 89.7 mt-10 -58.85 -39.05 80.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.21 -0.931 . . . . 0.0 109.393 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.574 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 66.0 m-70 -82.18 -19.85 39.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.352 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 39' ' ' PHE . 20.5 mm -75.34 -48.46 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.239 -0.913 . . . . 0.0 109.225 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -71.53 -41.22 69.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -0.851 . . . . 0.0 109.236 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.45 HD23 ' HA ' ' A' ' 32' ' ' LEU . 67.0 mt -63.9 -47.42 80.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.449 -0.782 . . . . 0.0 109.404 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.633 ' CD2' HD11 ' A' ' 82' ' ' LEU . 88.8 m-70 -84.05 9.25 12.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 49.08 48.47 20.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 0.0 109.394 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.636 ' SD ' HD22 ' A' ' 82' ' ' LEU . 41.4 mtt -102.79 -0.66 31.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 35' ' ' MET . 97.2 mt-10 -43.89 -36.04 2.23 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.243 -0.91 . . . . 0.0 109.647 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -56.96 -50.25 73.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.205 -0.934 . . . . 0.0 109.713 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' CA ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -71.31 -48.52 50.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.52 -179.691 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 30' ' ' ILE . 66.1 m-85 -70.4 141.35 52.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 109.452 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.472 ' HA3' ' OE1' ' A' ' 72' ' ' GLN . . . -102.65 -70.12 0.84 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -158.66 147.21 18.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.187 -1.184 . . . . 0.0 109.495 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.029 HG11 ' HB1' ' A' ' 23' ' ' ALA . 60.1 t -95.79 138.45 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.499 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.623 ' HE1' HG11 ' A' ' 108' ' ' VAL . 65.1 mtm -121.32 150.09 41.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.368 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 93.4 t . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.576 179.992 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.722 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.2 m-85 -128.61 115.3 17.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.196 -1.179 . . . . 0.0 109.375 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 43' ' ' MET . 87.3 t -132.9 144.85 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.262 -0.899 . . . . 0.0 109.609 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.854 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.1 mp -101.06 129.53 46.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.328 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.745 HG22 HG13 ' A' ' 42' ' ' VAL . 91.0 t -140.75 115.36 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.76 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.472 ' OE1' ' HA3' ' A' ' 40' ' ' GLY . 36.9 tt0 -65.98 135.9 55.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.928 . . . . 0.0 109.171 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.575 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 10.9 ttp -173.78 152.1 1.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.16 -0.962 . . . . 0.0 109.587 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.526 ' N ' ' HG2' ' A' ' 73' ' ' MET . 38.7 t -81.67 141.2 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.281 179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.559 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 15.1 tpp -78.1 100.12 6.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.212 -0.93 . . . . 0.0 109.74 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.507 ' ND2' HD22 ' A' ' 38' ' ' LEU . 51.4 p-10 -140.87 169.39 17.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.306 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -72.67 -26.39 61.61 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.5 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.58 -71.31 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 0.0 109.584 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 83' ' ' VAL . 11.4 p -53.47 -45.19 69.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.433 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.9 t90 -56.44 -59.01 5.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -54.92 -44.01 73.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.636 HD22 ' SD ' ' A' ' 35' ' ' MET . 41.1 tp -56.13 -47.8 77.44 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.813 HG11 ' CE2' ' A' ' 92' ' ' PHE . 80.0 t -50.41 -48.05 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.245 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 16.5 ttt-85 -70.63 -28.17 64.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.383 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.4 m -58.82 -47.15 85.8 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.35 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.574 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 4.4 p -76.08 132.39 73.93 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.532 ' O ' HG23 ' A' ' 89' ' ' VAL . 47.7 Cg_endo -69.02 -174.03 0.7 Allowed 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.672 2.248 . . . . 0.0 111.892 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.616 ' HB3' HG22 ' A' ' 22' ' ' VAL . 70.1 mtt85 63.69 32.04 14.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.359 -0.838 . . . . 0.0 109.444 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 87' ' ' PRO . 6.4 t -131.89 117.26 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 83.2 mtp -73.73 -38.29 64.84 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 148.62 -176.26 27.5 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.813 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.7 m-85 -94.98 158.25 15.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.311 -1.111 . . . . 0.0 109.649 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.722 HG21 ' OH ' ' A' ' 68' ' ' TYR . 18.9 mm -118.55 114.24 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.301 -0.875 . . . . 0.0 109.378 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.01 -141.77 3.25 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.55 -29.12 60.2 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -136.33 169.32 17.85 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.199 -1.177 . . . . 0.0 109.655 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -91.72 19.61 6.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.356 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.432 ' OD1' ' C ' ' A' ' 98' ' ' ASP . 48.1 p30 -140.73 11.05 2.25 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.55 -0.718 . . . . 0.0 109.081 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.3 OUTLIER -171.88 97.8 0.39 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.327 -0.858 . . . . 0.0 108.916 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 49.7 Cg_endo -68.94 113.75 3.34 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.752 2.301 . . . . 0.0 111.949 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.91 142.02 74.17 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.229 -0.92 . . . . 0.0 109.357 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.505 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 50.9 Cg_endo -70.22 153.98 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.715 2.277 . . . . 0.0 111.922 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.632 HD11 HG22 ' A' ' 108' ' ' VAL . 31.3 pt -129.23 152.73 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.9 m -67.0 145.29 55.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.617 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -53.75 -41.03 66.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.888 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -59.19 -44.57 92.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.462 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 83.2 tt0 -51.17 -46.32 62.04 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.632 HG22 HD11 ' A' ' 103' ' ' ILE . 60.4 t -53.97 -41.56 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.229 -0.919 . . . . 0.0 109.282 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -59.77 -41.18 90.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.247 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.52 -52.62 64.77 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.278 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.4 HG21 HD13 ' A' ' 111' ' ' ILE . 54.1 mt -47.05 -51.91 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.299 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.322 179.897 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 54.7 mttp . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.297 0.57 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 96.2 mtt180 -126.14 158.95 34.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.466 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.51 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 58.8 m95 -99.82 121.09 40.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.955 . . . . 0.0 109.788 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.589 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 96.6 m-85 -114.77 157.59 23.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.31 -0.869 . . . . 0.0 109.229 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 88.6 t -105.89 143.48 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 109.599 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.0 t -120.99 127.96 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.314 -0.866 . . . . 0.0 109.472 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.915 ' HB2' HD11 ' A' ' 93' ' ' ILE . 68.2 tp60 -86.98 145.32 26.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -0.9 . . . . 0.0 109.48 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.09 153.87 34.8 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.54 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -58.72 144.27 44.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.517 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 26.2 t -61.9 141.09 58.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.43 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.94 -31.18 5.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.5 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 90.3 m-85 -105.01 7.33 33.99 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.267 -1.137 . . . . 0.0 109.585 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.576 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 85.5 tt0 -58.44 -42.59 87.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.117 -0.99 . . . . 0.0 109.382 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.82 -38.0 65.91 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 22.2 ttm180 -62.02 -50.63 71.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -1.15 . . . . 0.0 109.442 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.476 HG13 HG11 ' A' ' 86' ' ' VAL . 37.4 t -49.45 -41.02 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.181 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 -42.39 99.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.234 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 41.5 m -67.38 -47.12 71.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.273 -0.892 . . . . 0.0 109.341 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.9 m -64.66 -34.41 78.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.253 -0.904 . . . . 0.0 109.375 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.817 ' CD2' HD11 ' A' ' 30' ' ' ILE . 5.4 tt -58.57 -53.54 57.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.304 -0.873 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.403 ' NE ' ' NZ ' ' A' ' 31' ' ' LYS . 23.0 tpt180 -45.14 -46.0 11.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.254 -0.904 . . . . 0.0 109.598 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -53.5 -50.88 64.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.558 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.582 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.7 m-70 -56.92 -29.1 62.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.286 -0.883 . . . . 0.0 109.533 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 1.052 HD12 ' CD1' ' A' ' 39' ' ' PHE . 10.2 mm -68.94 -53.72 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.227 -0.921 . . . . 0.0 109.567 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.51 ' CD ' ' OE2' ' A' ' 36' ' ' GLU . 24.8 mmtm -66.05 -44.18 85.3 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.658 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.453 ' HA ' HD23 ' A' ' 32' ' ' LEU . 49.0 mt -61.32 -55.95 25.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.277 -0.89 . . . . 0.0 109.611 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.843 ' CD2' HD11 ' A' ' 82' ' ' LEU . 90.8 m-70 -81.87 7.53 12.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 53.1 t30 48.83 45.76 22.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.585 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.933 ' HG3' HD22 ' A' ' 82' ' ' LEU . 35.2 mmm -99.55 20.57 13.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.374 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' OE2' ' CD ' ' A' ' 31' ' ' LYS . 83.9 mt-10 -53.83 -36.86 63.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -0.873 . . . . 0.0 109.482 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -59.16 -44.97 92.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.925 . . . . 0.0 109.486 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.882 HD13 ' HB3' ' A' ' 79' ' ' SER . 35.2 mt -66.94 -56.66 9.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.918 . . . . 0.0 109.507 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 1.052 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.6 m-85 -72.01 141.08 49.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.902 . . . . 0.0 109.472 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -125.62 -61.99 0.17 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.55 149.34 43.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.189 -1.183 . . . . 0.0 109.698 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.001 HG13 HG22 ' A' ' 71' ' ' VAL . 45.3 t -117.48 151.86 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.344 -0.847 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.516 ' O ' HG13 ' A' ' 69' ' ' VAL . 80.8 mmm -117.11 137.41 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.231 -0.918 . . . . 0.0 109.676 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 44' ' ' VAL . 43.2 t . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.313 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.429 ' O ' ' NE2' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.419 ' CE1' ' OE1' ' A' ' 13' ' ' GLN . 1.8 m-85 -119.71 117.21 27.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.2 -1.176 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 78.4 t -131.61 141.85 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.917 . . . . 0.0 109.657 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.843 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.7 mp -106.97 132.96 52.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -0.88 . . . . 0.0 109.271 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.001 HG22 HG13 ' A' ' 42' ' ' VAL . 86.5 t -137.94 121.67 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.178 -0.951 . . . . 0.0 109.639 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.475 ' O ' ' HB2' ' A' ' 73' ' ' MET . 38.0 tt0 -72.16 137.1 46.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.267 -0.895 . . . . 0.0 109.199 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.524 ' HG2' ' N ' ' A' ' 74' ' ' VAL . 45.8 ttp 171.81 157.73 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.263 -0.898 . . . . 0.0 109.604 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.59 ' CG1' HD22 ' A' ' 38' ' ' LEU . 12.2 p -85.69 138.31 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.174 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.589 ' HG2' ' CE2' ' A' ' 10' ' ' TYR . 16.4 mmt -90.04 115.36 27.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.208 -0.932 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.489 ' OD1' ' N ' ' A' ' 79' ' ' SER . 48.8 p-10 -140.48 -176.59 4.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.351 -0.843 . . . . 0.0 109.425 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -73.37 -11.6 60.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.598 ' HA ' ' CE1' ' A' ' 81' ' ' HIS . . . -94.23 -71.1 0.68 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.466 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.882 ' HB3' HD13 ' A' ' 38' ' ' LEU . 68.9 p -50.69 -48.13 58.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.379 -0.826 . . . . 0.0 109.516 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.61 ' NE1' ' CE2' ' A' ' 92' ' ' PHE . 79.7 t90 -48.51 -58.92 3.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -0.928 . . . . 0.0 109.694 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.625 ' CD2' ' N ' ' A' ' 82' ' ' LEU . 1.5 p-80 -57.84 -30.84 66.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.085 -1.009 . . . . 0.0 109.213 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.933 HD22 ' HG3' ' A' ' 35' ' ' MET . 19.0 tp -68.52 -36.34 78.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.384 -0.823 . . . . 0.0 109.328 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.545 HG11 ' CE1' ' A' ' 92' ' ' PHE . 77.5 t -62.04 -42.63 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.248 -0.908 . . . . 0.0 109.399 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -65.96 -33.25 75.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.377 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 35.8 m -60.07 -32.96 71.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.173 -0.954 . . . . 0.0 109.38 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 89' ' ' VAL . 18.8 t -55.37 123.41 49.48 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.487 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.9 Cg_endo -70.83 156.48 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.618 2.212 . . . . 0.0 111.712 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.5 ' HD3' ' CD1' ' A' ' 18' ' ' PHE . 42.4 mtt-85 62.44 35.29 14.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.31 -0.869 . . . . 0.0 109.586 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.588 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.4 p -123.39 125.82 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.436 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.539 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 51.3 mtt -68.93 -62.01 1.56 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.459 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 171.13 -151.57 16.03 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.704 ' O ' HG22 ' A' ' 96' ' ' THR . 93.1 m-85 -96.27 162.96 13.29 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.327 -1.102 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.915 HD11 ' HB2' ' A' ' 13' ' ' GLN . 47.3 mm -110.97 152.7 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.223 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.82 -108.95 3.44 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . 0.409 ' O ' ' C ' ' A' ' 96' ' ' THR . . . -57.06 -37.24 78.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.704 HG22 ' O ' ' A' ' 92' ' ' PHE . 68.8 p 43.73 -148.66 0.05 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -1.167 . . . . 0.0 109.477 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.456 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 26.7 t 44.67 39.92 3.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.173 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.565 ' HB3' ' CZ2' ' A' ' 80' ' ' TRP . 22.8 m-20 67.09 38.2 3.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.347 -0.846 . . . . 0.0 109.313 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.404 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 4.2 mtp180 -161.48 88.41 1.57 Allowed Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.281 -0.887 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.575 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 48.2 Cg_endo -69.96 135.27 29.56 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.783 2.322 . . . . 0.0 111.952 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -99.14 143.48 26.47 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.451 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.45 155.51 63.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.823 2.349 . . . . 0.0 111.759 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.431 HG12 ' O ' ' A' ' 9' ' ' TRP . 24.0 pt -125.5 156.32 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 48.3 m -69.8 150.22 47.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.303 -0.873 . . . . 0.0 109.531 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -59.68 -42.38 92.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -0.899 . . . . 0.0 109.442 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -53.94 -43.09 69.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.314 -0.866 . . . . 0.0 109.424 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.8 mt-10 -53.78 -44.69 70.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.421 HG22 HD23 ' A' ' 70' ' ' LEU . 98.0 t -55.91 -37.95 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.26 -0.9 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -70.44 -34.91 72.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.933 . . . . 0.0 109.381 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.28 -36.71 84.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.761 HG13 HD21 ' A' ' 70' ' ' LEU . 32.1 mm -49.6 -56.48 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.28 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . 0.492 ' CE ' ' CE ' ' A' ' 43' ' ' MET . 54.2 mtt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.289 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.514 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 68.4 mttm . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.43 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 63.0 mtt180 -128.16 152.22 48.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.419 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.404 ' CZ3' ' HE2' ' A' ' 43' ' ' MET . 92.9 m95 -85.38 129.84 34.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.486 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 75' ' ' MET . 81.2 m-85 -122.84 155.77 35.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.391 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 93' ' ' ILE . 43.1 t -92.02 150.76 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.512 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.5 t -132.49 124.29 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.308 -0.87 . . . . 0.0 109.387 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.549 ' HB3' ' HE2' ' A' ' 90' ' ' MET . 96.3 mt-30 -85.18 147.22 26.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.282 -0.886 . . . . 0.0 109.528 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.2 155.27 34.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.382 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.519 ' CD1' ' HA ' ' A' ' 88' ' ' ARG . 97.0 m-85 -72.16 147.22 46.82 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.0 m -55.56 144.08 27.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.292 -0.88 . . . . 0.0 109.471 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.91 -33.67 4.36 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -106.45 15.34 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.49 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.427 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.5 tt0 -52.43 -39.27 60.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.408 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.61 7.09 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 22' ' ' VAL . 35.5 ttt-85 -51.72 -52.64 46.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -1.169 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 21' ' ' ARG . 38.9 t -45.64 -38.04 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.175 -0.953 . . . . 0.0 109.314 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.83 -43.04 94.36 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.297 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 58.2 m -67.03 -47.03 72.66 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.287 -0.883 . . . . 0.0 109.3 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.7 m -61.75 -40.59 95.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.36 -0.837 . . . . 0.0 109.435 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.898 ' CD1' HG21 ' A' ' 86' ' ' VAL . 11.5 tp -56.12 -40.98 74.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.9 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -53.32 -44.14 68.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.309 -0.87 . . . . 0.0 109.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.589 ' O ' HD12 ' A' ' 32' ' ' LEU . 97.4 mt-10 -60.68 -47.82 84.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.51 ' C ' HD11 ' A' ' 82' ' ' LEU . 95.3 m-70 -63.46 -43.5 97.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.916 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.3 mt -67.83 -50.76 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.902 . . . . 0.0 109.482 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -59.6 -40.0 86.04 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.303 -0.873 . . . . 0.0 109.447 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 28' ' ' GLU . 16.0 mt -63.22 -53.98 44.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.47 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.458 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 97.4 m-70 -82.99 -0.6 49.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.56 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.508 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.2 m-20 62.56 47.11 5.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.18 -0.95 . . . . 0.0 109.356 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.99 ' HG3' HD13 ' A' ' 82' ' ' LEU . 57.8 mmm -90.35 0.57 57.2 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.586 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.451 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -47.83 -33.38 7.27 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.906 . . . . 0.0 109.489 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -60.4 -42.32 95.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.617 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.42 -49.41 49.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.303 -0.873 . . . . 0.0 109.313 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 88.5 m-85 -74.74 140.73 44.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.05 -64.69 0.53 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -140.52 157.44 45.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 109.53 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.032 HG13 HG22 ' A' ' 71' ' ' VAL . 61.6 t -120.16 147.41 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.517 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.725 ' HE1' HG11 ' A' ' 108' ' ' VAL . 60.7 mtm -131.46 141.9 49.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.238 -0.914 . . . . 0.0 109.449 179.945 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.591 ' CE1' HG13 ' A' ' 11' ' ' VAL . 51.7 t80 -108.9 136.14 48.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.226 -1.161 . . . . 0.0 109.521 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.26 144.8 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.298 -0.876 . . . . 0.0 109.567 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.921 ' CD2' HG13 ' A' ' 108' ' ' VAL . 4.3 mp -113.91 130.9 56.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.293 -0.879 . . . . 0.0 109.144 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.032 HG22 HG13 ' A' ' 42' ' ' VAL . 93.8 t -144.1 120.73 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.728 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.514 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 6.1 tt0 -75.07 129.65 37.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.604 ' HE2' ' HB2' ' A' ' 79' ' ' SER . 9.8 tmm? -168.63 147.94 4.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.313 -0.867 . . . . 0.0 109.58 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -75.81 109.84 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.578 ' HB2' ' CZ ' ' A' ' 10' ' ' TYR . 22.3 tpp -59.43 120.33 9.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.285 -0.884 . . . . 0.0 109.504 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.659 HD21 ' HB3' ' A' ' 78' ' ' ALA . 31.2 p-10 -155.89 170.55 21.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -56.01 -36.54 68.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.557 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -70.48 -71.7 0.23 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.623 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.604 ' HB2' ' HE2' ' A' ' 73' ' ' MET . 10.0 p -47.14 -48.04 23.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 109.56 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 77.6 t90 -51.65 -50.07 61.06 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -66.36 -39.6 89.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.951 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.99 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -59.13 -47.38 85.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.945 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.565 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 55.9 t -56.46 -48.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.87 . . . . 0.0 109.551 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -59.4 -36.77 76.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -60.59 -34.2 73.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.898 HG21 ' CD1' ' A' ' 26' ' ' LEU . 14.1 t -60.13 123.95 75.12 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.393 -0.817 . . . . 0.0 109.51 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.442 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.6 Cg_endo -70.75 163.21 39.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.545 2.163 . . . . 0.0 111.7 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.519 ' HA ' ' CD1' ' A' ' 15' ' ' PHE . 78.9 mmt-85 64.61 28.31 13.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.644 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 86' ' ' VAL . 5.8 p -128.93 137.11 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.918 . . . . 0.0 109.597 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.549 ' HE2' ' HB3' ' A' ' 13' ' ' GLN . 69.4 mtm -89.97 -42.1 11.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.83 -149.73 20.31 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.565 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 90.6 m-85 -102.73 157.21 17.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -1.163 . . . . 0.0 109.52 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 11' ' ' VAL . 8.4 mt -109.3 130.69 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.229 -0.919 . . . . 0.0 109.398 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 148.6 -119.19 1.04 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -66.4 -82.94 0.11 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.4 p -130.43 -173.98 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -1.19 . . . . 0.0 109.662 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 42.2 p -97.22 17.66 16.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.447 ' O ' ' HG2' ' A' ' 99' ' ' ARG . 82.0 m-20 -120.98 -24.67 5.53 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.463 -0.773 . . . . 0.0 109.102 179.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 98' ' ' ASP . 7.6 mtt180 -147.87 87.79 5.75 Favored Pre-proline 0 C--N 1.304 -1.405 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.524 ' HB3' ' HB3' ' A' ' 92' ' ' PHE . 42.9 Cg_endo -65.07 120.55 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.939 2.426 . . . . 0.0 112.416 -179.184 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 134.07 78.19 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.435 -0.791 . . . . 0.0 109.217 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.411 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.7 Cg_endo -69.37 152.82 71.35 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.692 2.261 . . . . 0.0 111.904 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.819 HD11 HG22 ' A' ' 108' ' ' VAL . 30.7 pt -118.5 160.57 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.336 -0.853 . . . . 0.0 109.231 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.2 m -70.05 150.47 46.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -0.907 . . . . 0.0 109.431 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -62.74 -37.81 88.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -63.24 -37.7 88.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -0.85 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.448 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 85.5 tt0 -59.82 -39.7 85.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.464 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.921 HG13 ' CD2' ' A' ' 70' ' ' LEU . 73.3 t -62.9 -35.97 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.381 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -68.19 -34.19 75.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.247 -0.908 . . . . 0.0 109.489 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.78 -38.24 88.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.428 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 74.3 mt -55.73 -51.74 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.476 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 53.2 ttm . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.426 -179.987 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 25.0 mttt . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.537 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 80.7 mtt85 -117.76 158.27 25.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.582 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 46.0 m95 -109.53 130.64 55.49 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.506 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CE2' ' O ' ' A' ' 73' ' ' MET . 23.9 m-85 -122.51 143.82 49.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.524 HG11 ' CE2' ' A' ' 68' ' ' TYR . 15.7 t -99.7 129.99 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.297 -0.877 . . . . 0.0 109.515 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' CE1' ' A' ' 92' ' ' PHE . 37.9 t -109.82 131.27 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.884 . . . . 0.0 109.458 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.997 ' CG ' HD11 ' A' ' 93' ' ' ILE . 91.8 mt-30 -78.73 150.07 32.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.322 -0.861 . . . . 0.0 109.462 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -152.53 151.74 31.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -68.42 143.75 54.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.446 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.3 m -59.3 142.92 50.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.12 -32.33 5.48 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.828 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.7 m-85 -106.53 7.95 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.297 -1.119 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.528 ' HG3' HG23 ' A' ' 69' ' ' VAL . 83.5 tt0 -53.74 -32.6 52.77 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.966 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -83.53 -55.27 2.9 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.3 ttt85 -57.94 -33.66 69.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.145 -1.209 . . . . 0.0 109.441 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.828 HG23 ' O ' ' A' ' 18' ' ' PHE . 55.0 t -57.74 -40.89 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.402 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.86 -36.76 85.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.393 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 47.1 m -61.52 -37.31 83.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.477 ' CB ' HG13 ' A' ' 86' ' ' VAL . 24.3 m -60.45 -35.93 77.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.198 -0.939 . . . . 0.0 109.457 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.88 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.2 mt -60.27 -40.5 90.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.873 . . . . 0.0 109.393 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -58.35 -45.27 88.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.301 -0.874 . . . . 0.0 109.571 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -64.14 -60.8 2.78 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.228 -0.92 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.692 ' CD2' HG22 ' A' ' 86' ' ' VAL . 98.7 m-70 -53.18 -50.78 63.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.256 -0.902 . . . . 0.0 109.378 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 82' ' ' LEU . 96.9 mt -58.14 -54.19 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -53.81 -45.19 70.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.426 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.441 ' HA ' HD23 ' A' ' 32' ' ' LEU . 71.0 mt -64.29 -55.88 18.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.253 -0.904 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.711 ' CD2' HD12 ' A' ' 82' ' ' LEU . 97.0 m-70 -68.34 -10.54 55.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.867 . . . . 0.0 109.384 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.457 ' N ' ' O ' ' A' ' 30' ' ' ILE . 76.1 m-20 61.58 46.63 7.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.331 -0.856 . . . . 0.0 109.389 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.661 ' HB3' HD21 ' A' ' 38' ' ' LEU . 2.6 mtt -95.9 5.67 50.71 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.354 -0.841 . . . . 0.0 109.551 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -50.82 -22.95 2.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -63.38 -40.83 98.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.959 HD12 ' SD ' ' A' ' 73' ' ' MET . 0.4 OUTLIER -91.36 -32.02 15.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.414 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.721 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 58.2 m-85 -75.27 136.9 40.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.363 -0.836 . . . . 0.0 109.395 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.22 -79.94 0.7 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 41' ' ' GLU . 56.7 mp0 -129.38 163.96 24.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.135 . . . . 0.0 109.549 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 1.093 HG13 HG22 ' A' ' 71' ' ' VAL . 55.2 t -123.16 160.74 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.316 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.896 ' O ' HG13 ' A' ' 69' ' ' VAL . 94.4 mmm -117.99 138.43 52.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.935 . . . . 0.0 109.573 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.611 ' O ' HG12 ' A' ' 44' ' ' VAL . 57.2 t . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.524 ' CE2' HG11 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -114.89 123.29 48.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.189 -1.183 . . . . 0.0 109.502 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.896 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -132.52 144.66 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.326 -0.859 . . . . 0.0 109.572 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.853 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.6 mp -115.91 138.48 51.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.278 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 1.093 HG22 HG13 ' A' ' 42' ' ' VAL . 59.5 t -132.46 120.89 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.179 -0.951 . . . . 0.0 109.777 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.449 ' O ' ' HB2' ' A' ' 73' ' ' MET . 35.8 tt0 -69.82 142.12 53.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.036 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.959 ' SD ' HD12 ' A' ' 38' ' ' LEU . 46.9 ttp 173.67 158.41 0.14 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.01 . . . . 0.0 109.578 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.765 HG12 ' HB2' ' A' ' 38' ' ' LEU . 9.1 p -82.84 142.74 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.225 -0.922 . . . . 0.0 109.406 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.592 ' HA ' ' HE3' ' A' ' 75' ' ' MET . 0.0 OUTLIER -72.66 116.1 12.73 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.657 -179.77 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.546 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.3 p-10 -143.93 175.48 9.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 109.33 179.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -84.6 -18.34 35.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.21 -0.931 . . . . 0.0 109.621 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.546 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -73.67 -57.54 3.92 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.242 -0.912 . . . . 0.0 109.319 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.517 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 53.4 p -59.34 -41.45 89.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.41 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.417 ' C ' ' O ' ' A' ' 79' ' ' SER . 47.1 t90 -43.98 -45.78 7.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.615 -179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -79.59 -25.84 41.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 109.43 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.811 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.7 OUTLIER -64.03 -41.45 97.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.291 -0.881 . . . . 0.0 109.532 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.875 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 88.6 t -65.94 -48.28 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.257 -0.902 . . . . 0.0 109.521 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -59.56 -41.41 90.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.0 p -61.96 -27.88 69.16 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.208 -0.933 . . . . 0.0 109.54 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' CD2' ' A' ' 26' ' ' LEU . 43.9 t -67.77 126.04 92.09 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 109.515 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.407 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.6 Cg_endo -70.31 163.48 38.55 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 122.653 2.235 . . . . 0.0 111.727 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.443 ' HB2' HG22 ' A' ' 22' ' ' VAL . 63.1 mtt-85 61.54 44.63 8.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 99.0 t -131.21 118.9 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.271 -0.893 . . . . 0.0 109.539 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.51 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 74.8 mtm -70.57 -42.22 71.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.81 -162.41 35.06 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.875 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -104.82 171.26 7.42 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.235 -1.156 . . . . 0.0 109.453 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.997 HD11 ' CG ' ' A' ' 13' ' ' GLN . 32.6 mm -124.43 128.45 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.452 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 172.71 -148.96 10.95 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.45 -39.54 50.25 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.412 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 29.2 p -130.7 171.98 12.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.185 -1.185 . . . . 0.0 109.497 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 p -88.55 14.73 9.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.169 -0.957 . . . . 0.0 109.443 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 99' ' ' ARG . 17.8 p30 -130.21 -13.64 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.772 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.429 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 49.5 mtt180 -145.75 91.42 5.66 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.231 -0.918 . . . . 0.0 108.884 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.48 113.89 3.08 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.774 2.316 . . . . 0.0 112.007 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.21 136.84 93.89 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.263 -0.898 . . . . 0.0 109.395 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.537 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.41 154.67 65.0 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.654 2.236 . . . . 0.0 111.814 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.4 pt -124.03 159.7 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 38.5 m -66.04 148.41 51.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.258 -0.902 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 73.6 m-20 -57.41 -41.59 80.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -57.74 -39.81 78.19 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -51.43 -40.75 59.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.923 . . . . 0.0 109.417 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.517 HG21 ' CG ' ' A' ' 9' ' ' TRP . 73.8 t -63.02 -34.6 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.388 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -63.24 -38.11 89.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.61 -40.4 95.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.386 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 27.0 mm -51.55 -57.32 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . 0.462 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.2 mtp . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.318 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.518 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 69.5 mttt . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 96.3 mtt180 -118.62 150.64 39.35 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.293 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.401 ' O ' HG12 ' A' ' 103' ' ' ILE . 65.7 m95 -99.04 135.65 40.14 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 109.668 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.417 ' CD2' ' CE ' ' A' ' 75' ' ' MET . 55.5 m-85 -128.35 153.61 46.85 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.874 . . . . 0.0 109.398 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.1 t -100.16 137.46 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.906 . . . . 0.0 109.511 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.53 124.63 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.214 -0.929 . . . . 0.0 109.365 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.526 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 98.0 mt-30 -90.47 145.73 24.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.512 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -149.63 163.47 37.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.332 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -67.02 140.88 57.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.189 -0.944 . . . . 0.0 109.52 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.9 m -58.07 145.78 35.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.55 -31.07 5.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . 0.514 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 96.5 m-85 -111.21 9.82 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -1.183 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.449 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 81.6 tt0 -61.11 -29.9 70.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.253 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -81.45 -36.9 18.99 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -66.87 -49.05 66.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -1.129 . . . . 0.0 109.419 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.619 HG21 ' O ' ' A' ' 88' ' ' ARG . 21.8 t -48.33 -41.56 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -0.98 . . . . 0.0 109.038 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.7 -46.59 84.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -0.867 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 88.4 m -62.38 -37.13 84.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.557 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 98.6 p -65.99 -37.0 84.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.435 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.688 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.4 mt -52.44 -72.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.35 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.402 ' C ' ' O ' ' A' ' 26' ' ' LEU . 41.8 ttm180 -44.25 -41.48 5.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.351 -0.843 . . . . 0.0 109.534 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -56.1 -37.36 69.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.909 . . . . 0.0 109.479 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 25' ' ' SER . 89.8 m-70 -79.27 -29.24 42.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.892 . . . . 0.0 109.374 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.958 HD12 ' CD1' ' A' ' 39' ' ' PHE . 17.6 mm -66.79 -43.4 89.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.559 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -67.19 -36.87 82.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.525 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.452 ' HA ' HD23 ' A' ' 32' ' ' LEU . 38.4 mt -70.18 -53.51 16.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 0.0 109.545 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.691 ' CD2' HD12 ' A' ' 82' ' ' LEU . 97.6 m-70 -84.76 10.95 10.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 46.34 46.74 13.77 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.853 ' HG3' HD13 ' A' ' 82' ' ' LEU . 56.8 mmm -97.25 15.76 21.88 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.195 -0.941 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 74.9 mm-40 -55.34 -33.21 63.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 109.447 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -65.43 -45.91 81.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.277 -0.889 . . . . 0.0 109.357 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.477 HD13 ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -68.04 -55.26 13.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.303 -0.873 . . . . 0.0 109.26 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.958 ' CD1' HD12 ' A' ' 30' ' ' ILE . 77.6 m-85 -67.37 141.6 57.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.323 -0.861 . . . . 0.0 109.435 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.99 -69.28 0.76 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -143.14 166.17 25.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -1.145 . . . . 0.0 109.542 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 83.3 t -117.4 138.38 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.412 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.771 ' O ' HG13 ' A' ' 69' ' ' VAL . 83.2 mtp -127.87 156.35 42.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.208 -0.933 . . . . 0.0 109.466 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 31.9 t . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.271 -0.893 . . . . 0.0 109.382 -179.987 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.529 ' CE2' HD13 ' A' ' 93' ' ' ILE . 2.7 m-85 -112.25 121.4 44.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.112 -1.228 . . . . 0.0 109.574 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 43' ' ' MET . 57.8 t -129.41 144.12 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.217 -0.927 . . . . 0.0 109.571 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.992 HD21 HD12 ' A' ' 111' ' ' ILE . 4.3 mp -109.04 130.05 55.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.497 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -140.91 126.4 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.319 -0.863 . . . . 0.0 109.574 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.518 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 2.6 tt0 -69.54 138.95 53.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.932 . . . . 0.0 109.268 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.493 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 14.9 ttp 178.76 152.86 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.226 -0.922 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.471 ' N ' ' HG2' ' A' ' 73' ' ' MET . 23.6 m -99.2 160.48 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.376 -0.827 . . . . 0.0 109.557 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.566 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 14.6 mmt -94.24 120.5 34.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.295 -0.878 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.8 p-10 -146.21 -161.18 1.26 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.565 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -101.49 42.4 1.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -0.878 . . . . 0.0 109.452 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -159.33 -51.11 0.06 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.291 -0.881 . . . . 0.0 109.337 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 83' ' ' VAL . 53.4 p -65.98 -30.19 70.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 109.31 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -66.52 -46.58 75.71 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.427 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -69.35 -33.15 72.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.34 -0.85 . . . . 0.0 109.35 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.853 HD13 ' HG3' ' A' ' 35' ' ' MET . 5.1 tt -65.79 -35.58 81.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.426 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.937 HG11 ' CE2' ' A' ' 92' ' ' PHE . 72.3 t -69.38 -47.49 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.415 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 42.2 ttt-85 -61.15 -33.59 73.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.431 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.3 p -63.15 -22.89 67.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.424 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.688 HG21 ' CD2' ' A' ' 26' ' ' LEU . 12.7 t -60.93 120.33 52.82 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.343 -0.848 . . . . 0.0 109.51 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.413 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.1 Cg_endo -71.2 160.11 49.98 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.588 2.192 . . . . 0.0 111.862 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.619 ' O ' HG21 ' A' ' 22' ' ' VAL . 50.0 mtt85 60.94 33.14 19.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -0.932 . . . . 0.0 109.683 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.585 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.3 p -122.28 132.4 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -0.941 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 95.4 mtp -72.51 -43.03 64.15 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.36 -153.86 25.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.937 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.6 OUTLIER -107.15 164.26 12.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.348 -1.09 . . . . 0.0 109.507 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 11' ' ' VAL . 58.3 mt -116.39 139.6 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 113.76 134.77 5.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 48.51 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.525 ' OG1' ' N ' ' A' ' 97' ' ' SER . 0.8 OUTLIER -141.16 -172.08 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.346 -1.091 . . . . 0.0 109.421 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.525 ' N ' ' OG1' ' A' ' 96' ' ' THR . 35.4 p -91.32 20.97 4.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.201 -0.937 . . . . 0.0 109.633 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -121.29 -29.56 4.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.342 -0.849 . . . . 0.0 108.931 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -149.23 83.39 6.61 Favored Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 44.0 Cg_endo -65.6 128.32 19.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.948 2.432 . . . . 0.0 112.484 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.63 141.93 90.93 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.489 -0.757 . . . . 0.0 109.269 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.0 Cg_endo -69.41 153.59 70.32 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.693 2.262 . . . . 0.0 111.924 -179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.736 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.7 pt -116.22 158.65 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 109.35 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.436 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 45.4 m -71.66 147.91 47.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.493 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -58.94 -36.38 74.67 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.318 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -59.83 -39.19 84.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.4 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.436 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.5 mt-10 -57.57 -46.4 84.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.29 -0.881 . . . . 0.0 109.361 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.736 ' CG2' HD11 ' A' ' 103' ' ' ILE . 71.5 t -61.64 -39.63 83.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.388 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -66.82 -37.51 84.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.258 -0.901 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.9 63.62 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.353 -0.842 . . . . 0.0 109.426 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.992 HD12 HD21 ' A' ' 70' ' ' LEU . 55.0 mt -50.51 -56.41 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.325 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . 0.498 ' HG3' ' CE ' ' A' ' 43' ' ' MET . 96.0 mmm . . . . . 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.912 . . . . 0.0 109.418 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' LYS . . . . . 0.448 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 63.0 mttm . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.536 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 88.2 mtt-85 -121.88 157.89 30.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TRP . . . . . 0.489 ' CG ' HG21 ' A' ' 108' ' ' VAL . 90.3 m95 -88.01 133.92 33.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.2 -0.938 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.1 m-85 -119.05 156.47 29.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 44.7 t -99.09 143.59 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.254 -0.904 . . . . 0.0 109.428 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.7 t -125.21 123.19 64.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.309 -0.87 . . . . 0.0 109.314 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLN . . . . . 0.783 ' HB2' HD11 ' A' ' 93' ' ' ILE . 62.5 tt0 -94.57 135.16 36.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.661 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.427 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -152.88 155.8 37.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.315 -0.866 . . . . 0.0 109.317 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -56.41 140.74 44.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.259 -0.901 . . . . 0.0 109.576 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.0 p -65.45 151.97 45.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 109.487 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.56 -31.34 5.24 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -118.89 8.82 11.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -1.175 . . . . 0.0 109.466 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.534 ' HG3' ' N ' ' A' ' 20' ' ' GLY . 23.4 pt-20 -55.41 -46.19 76.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.395 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -59.98 -38.6 94.43 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttm-85 -55.62 -49.37 73.0 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.3 -1.118 . . . . 0.0 109.38 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.935 HG13 HG11 ' A' ' 86' ' ' VAL . 39.2 t -47.24 -39.72 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.267 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.13 -44.57 95.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.882 . . . . 0.0 109.339 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 89.4 m -65.93 -51.34 59.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.309 -0.87 . . . . 0.0 109.391 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 83.1 p -59.65 -36.06 75.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.402 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.459 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 tp -56.57 -53.1 61.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.2 -0.937 . . . . 0.0 109.494 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.417 ' C ' ' O ' ' A' ' 26' ' ' LEU . 57.0 ttt180 -43.7 -49.82 7.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.41 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.418 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 96.3 mt-10 -54.04 -45.39 71.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.296 -0.878 . . . . 0.0 109.361 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' HIS . . . . . 0.402 ' HD2' HG22 ' A' ' 86' ' ' VAL . 76.3 m-70 -61.32 -34.34 75.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.306 -0.871 . . . . 0.0 109.297 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.961 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.2 mm -63.22 -54.5 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . 0.465 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 36.0 mttt -66.96 -37.59 84.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.924 . . . . 0.0 109.389 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.418 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 66.4 mt -60.58 -55.32 34.81 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.371 -0.831 . . . . 0.0 109.433 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.455 ' CD2' HD12 ' A' ' 82' ' ' LEU . 96.7 m-70 -89.46 0.09 57.11 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.315 -0.866 . . . . 0.0 109.56 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.49 ' N ' ' O ' ' A' ' 30' ' ' ILE . 79.3 m-20 60.18 49.5 7.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.898 . . . . 0.0 109.48 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.987 ' HG3' HD13 ' A' ' 82' ' ' LEU . 51.2 mmm -101.87 14.08 32.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.63 ' CG ' HG22 ' A' ' 30' ' ' ILE . 97.8 mt-10 -52.06 -36.81 51.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -60.86 -40.75 94.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.229 -0.919 . . . . 0.0 109.548 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.857 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.48 -49.05 52.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.506 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PHE . . . . . 0.961 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -75.76 138.03 40.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.1 -68.62 0.42 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.426 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 84.7 tt0 -129.96 155.93 45.28 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.525 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.969 HG13 HG22 ' A' ' 71' ' ' VAL . 39.2 t -123.74 145.37 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' MET . . . . . 0.524 ' O ' HG13 ' A' ' 69' ' ' VAL . 92.9 mtp -124.44 150.48 45.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.383 -0.823 . . . . 0.0 109.235 179.946 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 14' ' ' ALA . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.655 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -133.19 121.92 23.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.192 -1.181 . . . . 0.0 109.475 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 43' ' ' MET . 60.7 t -131.02 147.03 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -0.853 . . . . 0.0 109.521 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.813 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.8 mp -111.82 128.01 55.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.351 -0.843 . . . . 0.0 109.42 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.969 HG22 HG13 ' A' ' 42' ' ' VAL . 98.6 t -139.85 124.58 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLN . . . . . 0.448 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 37.9 tt0 -77.74 132.3 38.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.26 -0.9 . . . . 0.0 109.363 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.6 ttp -165.39 164.31 19.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.2 -0.937 . . . . 0.0 109.493 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.522 ' N ' ' HG2' ' A' ' 73' ' ' MET . 42.2 t -82.47 142.76 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.504 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' MET . . . . . 0.629 ' HA ' ' HE2' ' A' ' 75' ' ' MET . 1.2 tpt -81.15 111.38 17.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.901 . . . . 0.0 109.462 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.558 ' ND2' HD22 ' A' ' 38' ' ' LEU . 37.6 p-10 -150.46 164.04 36.91 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 109.393 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.442 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 85.2 m-20 -74.51 -26.81 60.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.158 -0.964 . . . . 0.0 109.405 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -65.44 -58.02 6.88 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.499 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.461 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 11.2 p -56.62 -46.44 80.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.695 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' TRP . . . . . 0.59 ' CH2' ' HD2' ' A' ' 84' ' ' ARG . 37.9 t90 -43.63 -59.35 2.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.236 -0.915 . . . . 0.0 109.62 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.442 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 94.5 m-70 -57.24 -35.95 70.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.935 . . . . 0.0 109.614 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.987 HD13 ' HG3' ' A' ' 35' ' ' MET . 1.0 OUTLIER -62.91 -41.32 99.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.919 . . . . 0.0 109.66 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.55 HG11 ' CZ ' ' A' ' 92' ' ' PHE . 50.5 t -60.55 -46.09 96.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.59 ' HD2' ' CH2' ' A' ' 80' ' ' TRP . 29.5 mtp180 -56.6 -36.0 68.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -61.12 -28.78 69.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.24 -0.913 . . . . 0.0 109.537 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.935 HG11 HG13 ' A' ' 22' ' ' VAL . 40.2 t -55.4 121.28 36.8 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.276 -0.89 . . . . 0.0 109.446 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.444 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.3 Cg_endo -70.5 149.94 62.95 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.684 2.256 . . . . 0.0 111.819 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.444 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.9 mtt85 61.3 40.19 14.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.339 -0.85 . . . . 0.0 109.521 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.587 HG12 ' O ' ' A' ' 86' ' ' VAL . 9.9 p -122.33 128.19 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.338 -0.851 . . . . 0.0 109.316 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . 0.49 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.0 mmm -71.66 -53.72 12.68 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.16 -0.962 . . . . 0.0 109.506 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.42 -150.69 20.92 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' PHE . . . . . 0.554 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 82.7 m-85 -100.53 157.68 16.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -1.095 . . . . 0.0 109.56 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.783 HD11 ' HB2' ' A' ' 13' ' ' GLN . 38.8 mm -117.6 135.94 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 0.0 109.331 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 110.12 145.86 10.86 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 50.75 -95.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 94' ' ' GLY . 19.3 p -140.33 -173.04 3.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -1.19 . . . . 0.0 109.558 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 p -95.53 22.24 7.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.215 -0.928 . . . . 0.0 109.485 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.551 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 73.4 m-20 -120.51 -25.13 5.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.371 -0.831 . . . . 0.0 109.215 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.445 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 15.2 mtp180 -153.04 102.36 2.64 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.358 -0.839 . . . . 0.0 109.013 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.554 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 44.3 Cg_endo -66.46 114.58 3.13 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.769 2.313 . . . . 0.0 112.012 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.54 140.29 88.89 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.397 -0.814 . . . . 0.0 109.487 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.536 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.4 Cg_endo -70.42 153.4 65.95 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.669 2.246 . . . . 0.0 111.823 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.608 HD11 HG22 ' A' ' 108' ' ' VAL . 31.8 pt -126.96 157.4 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.887 . . . . 0.0 109.49 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 53.0 p -72.36 151.07 42.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.618 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -61.6 -35.03 76.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -61.84 -40.12 94.21 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG13 ' A' ' 111' ' ' ILE . 86.5 tt0 -59.52 -41.88 90.99 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.293 -0.88 . . . . 0.0 109.467 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.608 HG22 HD11 ' A' ' 103' ' ' ILE . 70.6 t -60.29 -37.51 74.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.315 -0.866 . . . . 0.0 109.471 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -64.7 -40.27 95.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.973 . . . . 0.0 109.378 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -66.04 -43.13 88.46 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 107' ' ' GLU . 70.8 mt -52.44 -49.53 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.213 -0.929 . . . . 0.0 109.468 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 94.9 mmm . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.431 179.993 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.2 mtp . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.4 m -56.38 -36.12 68.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -110.31 140.65 44.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.288 -0.882 . . . . 0.0 109.415 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.9 130.8 79.16 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.454 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.47 144.71 51.0 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.698 2.265 . . . . 0.0 111.833 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 31.2 tttm -116.4 129.47 56.25 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.323 -0.861 . . . . 0.0 109.404 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -95.52 135.29 37.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.451 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 61.9 mtt180 -122.67 152.94 40.03 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.228 -0.92 . . . . 0.0 109.495 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.745 ' CG ' HG21 ' A' ' 108' ' ' VAL . 74.9 m95 -95.01 133.89 38.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.437 ' CE2' ' O ' ' A' ' 73' ' ' MET . 28.3 m-85 -122.69 149.39 44.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.303 -0.873 . . . . 0.0 109.308 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 25.0 t -97.68 142.62 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.491 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.6 t -118.75 130.81 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.478 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.818 ' HB2' HD11 ' A' ' 93' ' ' ILE . 57.3 tt0 -96.96 128.1 43.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 109.464 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.748 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.08 164.23 30.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.214 -0.928 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -69.22 145.33 53.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.254 -0.904 . . . . 0.0 109.494 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.2 p -66.19 149.49 50.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.31 -33.03 4.69 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.521 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.9 m-85 -109.53 1.6 19.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.3 -1.118 . . . . 0.0 109.623 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.776 ' HB3' HG21 ' A' ' 46' ' ' THR . 85.6 tt0 -53.45 -40.07 64.94 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.182 -0.949 . . . . 0.0 109.44 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -65.57 -47.77 74.4 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.421 -1.471 . . . . 0.0 109.421 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 62.6 ttt180 -63.65 -39.36 94.15 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -1.171 . . . . 0.0 109.461 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.748 HG21 ' HB1' ' A' ' 14' ' ' ALA . 60.6 t -52.18 -44.69 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.473 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.76 -42.79 98.16 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.333 -0.854 . . . . 0.0 109.465 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.1 m -61.2 -39.0 88.58 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.462 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 24.1 m -58.95 -39.18 80.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.423 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.778 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.3 mt -56.11 -46.61 79.07 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttt85 -56.15 -41.89 76.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.277 -0.89 . . . . 0.0 109.474 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -66.78 -58.73 4.47 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.986 ' HB3' HD11 ' A' ' 82' ' ' LEU . 73.4 m-70 -57.22 -48.63 78.33 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.206 -0.934 . . . . 0.0 109.498 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.727 HG23 ' CB ' ' A' ' 35' ' ' MET . 89.7 mt -61.9 -49.52 83.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.251 -0.906 . . . . 0.0 109.446 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 26.2 tttt -57.87 -45.56 86.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.467 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.451 ' HA ' HD23 ' A' ' 32' ' ' LEU . 45.3 mt -63.26 -48.62 77.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.25 -0.906 . . . . 0.0 109.444 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -83.44 5.5 23.5 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.251 -0.906 . . . . 0.0 109.52 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.444 ' N ' ' O ' ' A' ' 30' ' ' ILE . 38.1 t30 54.69 46.13 25.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.216 -0.927 . . . . 0.0 109.33 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.812 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -96.54 3.89 52.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.579 -179.914 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.543 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.1 mt-10 -53.4 -35.61 60.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -54.3 -40.46 67.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.22 -0.925 . . . . 0.0 109.463 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.539 ' CD1' ' CG ' ' A' ' 35' ' ' MET . 0.7 OUTLIER -73.9 -48.77 28.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.288 -0.883 . . . . 0.0 109.294 179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.625 ' CD1' HD13 ' A' ' 30' ' ' ILE . 89.4 m-85 -70.41 130.12 41.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.358 -0.839 . . . . 0.0 109.499 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -107.14 -63.16 0.58 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 47.3 tp10 -141.44 115.46 9.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.177 -1.19 . . . . 0.0 109.66 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.013 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -89.5 147.08 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.223 -0.923 . . . . 0.0 109.39 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.644 ' O ' HG13 ' A' ' 69' ' ' VAL . 46.3 mtt -112.88 148.98 33.78 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.618 HG12 ' O ' ' A' ' 46' ' ' THR . 35.3 t -135.32 95.66 14.55 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.342 -0.849 . . . . 0.0 109.274 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.02 -3.32 12.59 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.749 2.3 . . . . 0.0 111.995 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.776 HG21 ' HB3' ' A' ' 19' ' ' GLU . 8.9 t -122.99 154.04 38.98 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.24 -0.913 . . . . 0.0 109.515 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -103.87 149.16 25.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.273 -0.892 . . . . 0.0 109.521 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -60.09 -28.04 67.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.277 -0.89 . . . . 0.0 109.507 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 25.4 m -120.01 173.13 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.281 -0.887 . . . . 0.0 109.506 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.1 m -116.73 155.44 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.292 -0.88 . . . . 0.0 109.473 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -92.75 144.17 25.56 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.284 -0.885 . . . . 0.0 109.456 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 89.5 mt -58.39 -39.32 74.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.249 -0.907 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 37.1 ttm180 -57.75 146.59 30.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.241 -0.912 . . . . 0.0 109.407 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -146.3 -176.2 19.94 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -54.45 141.59 34.62 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -61.64 -36.77 81.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.24 -1.153 . . . . 0.0 109.499 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 82.4 mtm180 -127.62 145.29 50.92 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.293 -0.879 . . . . 0.0 109.449 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 59.6 mtt-85 -61.33 -35.47 77.48 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.265 -0.897 . . . . 0.0 109.495 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 30.5 tttt -61.17 -32.39 72.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.253 -0.904 . . . . 0.0 109.49 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.5 p -56.02 156.37 5.46 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -117.78 172.64 7.24 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.548 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.0 mtt180 -111.3 135.92 51.14 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.89 . . . . 0.0 109.49 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mttm -88.27 4.97 43.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.21 -0.932 . . . . 0.0 109.554 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.634 ' HD1' HD12 ' A' ' 115' ' ' LEU . 24.1 m-85 -72.12 145.66 47.99 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.485 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -120.38 80.42 29.4 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.65 151.64 64.16 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 94.09 -8.41 72.9 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.459 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -117.59 128.51 55.01 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -1.14 . . . . 0.0 109.492 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.644 HG13 ' O ' ' A' ' 43' ' ' MET . 65.8 t -130.73 143.44 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.273 -0.892 . . . . 0.0 109.538 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.846 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.1 mp -107.32 133.04 52.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.322 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.013 HG22 HG23 ' A' ' 42' ' ' VAL . 43.1 t -139.51 131.15 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.684 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.572 ' OE1' ' CE2' ' A' ' 9' ' ' TRP . 23.2 tt0 -88.05 128.5 35.41 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.218 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CE1' ' A' ' 39' ' ' PHE . 55.7 ttp -173.98 163.96 4.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.179 -0.951 . . . . 0.0 109.682 -179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.528 ' N ' ' HG2' ' A' ' 73' ' ' MET . 28.6 m -87.45 138.24 19.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.267 -0.896 . . . . 0.0 109.459 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.64 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 1.1 ttm -76.68 116.76 17.64 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.434 ' OD1' ' CB ' ' A' ' 79' ' ' SER . 52.8 p-10 -145.01 170.71 15.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.924 . . . . 0.0 109.428 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -67.88 -33.66 75.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.23 -0.919 . . . . 0.0 109.915 -179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.561 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -67.7 -69.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.181 -0.95 . . . . 0.0 109.7 -179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.49 ' OG ' ' N ' ' A' ' 80' ' ' TRP . 9.9 p -46.6 -59.52 2.95 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -0.892 . . . . 0.0 109.645 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.49 ' N ' ' OG ' ' A' ' 79' ' ' SER . 68.0 t90 -42.84 -58.09 2.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.275 -0.89 . . . . 0.0 109.638 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -58.34 -37.69 75.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.944 . . . . 0.0 109.493 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.986 HD11 ' HB3' ' A' ' 29' ' ' HIS . 67.4 tp -63.41 -39.7 95.2 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.275 -0.891 . . . . 0.0 109.568 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.944 HG11 ' CE2' ' A' ' 92' ' ' PHE . 85.4 t -59.93 -47.29 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.18 -0.95 . . . . 0.0 109.584 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.59 -37.69 76.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.543 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.4 p -64.67 -26.28 68.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.238 -0.914 . . . . 0.0 109.499 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.778 HG21 ' CD2' ' A' ' 26' ' ' LEU . 98.7 t -60.79 124.51 79.73 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.486 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.435 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.4 Cg_endo -70.35 156.41 61.88 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.696 2.264 . . . . 0.0 111.795 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 68.2 mtt-85 61.28 46.07 8.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.395 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.406 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.4 t -132.85 118.65 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.593 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.455 ' HB2' ' HB3' ' A' ' 13' ' ' GLN . 64.2 mtt -69.03 -42.82 75.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.423 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.0 -152.81 24.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.944 ' CE2' HG11 ' A' ' 83' ' ' VAL . 3.4 m-85 -109.99 161.82 15.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.232 -1.158 . . . . 0.0 109.537 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.818 HD11 ' HB2' ' A' ' 13' ' ' GLN . 14.5 mm -115.9 116.35 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.507 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -172.88 -148.1 6.14 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -70.59 -35.01 67.45 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.78 HG23 ' H ' ' A' ' 98' ' ' ASP . 11.6 t -138.9 175.6 9.41 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -1.189 . . . . 0.0 109.665 -179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 p -93.56 19.44 8.53 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.288 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.78 ' H ' HG23 ' A' ' 96' ' ' THR . 86.0 m-20 -131.19 -0.83 4.07 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 109.429 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 98' ' ' ASP . 1.1 mtt180 -168.28 96.39 0.58 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.291 -0.88 . . . . 0.0 109.003 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.64 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 45.9 Cg_endo -67.52 116.88 4.46 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.798 2.332 . . . . 0.0 112.16 -179.54 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -60.72 135.5 92.44 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.267 -0.896 . . . . 0.0 109.304 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.1 Cg_endo -69.92 153.32 68.32 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.674 2.25 . . . . 0.0 111.785 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.831 HD11 HG22 ' A' ' 108' ' ' VAL . 28.3 pt -126.42 157.6 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.386 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.48 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 38.7 m -63.27 147.81 49.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -0.915 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -59.4 -39.31 83.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.428 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.2 tttt -59.74 -39.28 84.23 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.418 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.48 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -59.95 -41.4 91.78 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.256 -0.903 . . . . 0.0 109.432 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.842 HG13 HD23 ' A' ' 70' ' ' LEU . 97.7 t -61.89 -35.96 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -0.91 . . . . 0.0 109.515 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -67.33 -33.82 76.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.274 -0.891 . . . . 0.0 109.485 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.73 96.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.226 -0.921 . . . . 0.0 109.422 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.629 HD12 HD21 ' A' ' 70' ' ' LEU . 70.2 mt -56.86 -51.93 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 109.482 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 89.1 mtp -64.95 -33.98 77.31 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -57.95 -37.94 75.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.25 -0.906 . . . . 0.0 109.448 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 52.5 mtt180 -61.75 -39.92 93.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.93 . . . . 0.0 109.434 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.634 HD12 ' HD1' ' A' ' 64' ' ' PHE . 3.9 tp -60.64 -39.48 88.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.259 -0.901 . . . . 0.0 109.448 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . 0.472 ' O ' HG13 ' A' ' 118' ' ' VAL . 63.9 tt0 -68.31 -31.93 71.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.25 -0.906 . . . . 0.0 109.472 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -56.26 138.57 50.21 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.219 -0.926 . . . . 0.0 109.488 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.472 HG13 ' O ' ' A' ' 116' ' ' GLN . 23.9 m -132.26 160.76 42.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.268 -0.895 . . . . 0.0 109.492 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -90.23 58.63 3.51 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 54.9 t0 -55.13 -35.5 64.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.135 . . . . 0.0 109.48 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 29.6 mtpp -121.08 81.9 36.51 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.483 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.96 145.22 55.38 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.682 2.255 . . . . 0.0 111.818 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.0 mmt180 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.412 -179.994 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.8 mtm . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.231 0.539 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 92.8 p -127.68 155.0 44.63 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.269 -0.894 . . . . 0.0 109.542 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -99.93 136.49 39.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -73.93 129.01 85.65 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.284 -0.885 . . . . 0.0 109.43 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.492 ' O ' ' NE ' ' A' ' 8' ' ' ARG . 51.0 Cg_endo -70.46 -10.75 28.66 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.722 2.282 . . . . 0.0 111.864 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.432 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 26.2 mttm -91.58 156.84 17.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.497 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 76.9 mttt 62.27 46.1 6.3 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.397 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.552 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 49.0 mtt180 -80.59 148.32 30.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.258 -0.901 . . . . 0.0 109.523 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.536 ' CH2' ' HG3' ' A' ' 43' ' ' MET . 77.2 m95 -78.01 135.68 37.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.186 -0.947 . . . . 0.0 109.639 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.615 ' CZ ' ' CG ' ' A' ' 75' ' ' MET . 76.0 m-85 -132.21 139.02 48.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.229 -0.92 . . . . 0.0 109.372 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.899 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.7 t -83.17 148.94 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.108 -0.995 . . . . 0.0 109.519 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.91 122.94 57.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.423 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.51 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 13.4 mt-30 -78.83 145.0 34.5 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.266 -0.896 . . . . 0.0 109.588 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.764 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.03 157.09 34.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.299 -0.876 . . . . 0.0 109.401 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -63.86 142.86 58.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.885 . . . . 0.0 109.481 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.1 p -68.12 151.0 47.68 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.235 -0.915 . . . . 0.0 109.463 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.21 -34.08 4.27 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.452 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -112.08 9.22 20.27 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.253 -1.145 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.624 ' OE2' HG23 ' A' ' 69' ' ' VAL . 85.6 tt0 -54.18 -41.0 68.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.87 . . . . 0.0 109.462 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.53 -44.33 83.38 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 54.7 ttm-85 -62.44 -35.39 79.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.25 -1.147 . . . . 0.0 109.498 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.764 HG21 ' HB1' ' A' ' 14' ' ' ALA . 53.7 t -56.51 -38.21 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.65 -37.41 86.46 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.27 -0.894 . . . . 0.0 109.445 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 54.8 m -73.54 -40.68 63.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.247 -0.908 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 26.6 m -64.48 -33.48 75.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.296 -0.877 . . . . 0.0 109.552 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.76 HD13 HG21 ' A' ' 86' ' ' VAL . 20.2 tp -63.32 -49.92 72.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.24 -0.912 . . . . 0.0 109.516 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.449 ' HG2' ' NZ ' ' A' ' 31' ' ' LYS . 18.4 ttp180 -43.21 -51.86 5.89 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.334 -0.854 . . . . 0.0 109.52 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -51.38 -49.18 62.04 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.29 -0.882 . . . . 0.0 109.528 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.83 ' HB3' HD11 ' A' ' 82' ' ' LEU . 90.3 m-70 -57.76 -26.08 61.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.261 -0.899 . . . . 0.0 109.474 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.965 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.7 mm -72.22 -51.95 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.448 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.475 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 58.7 mttp -66.9 -39.66 87.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.304 -0.872 . . . . 0.0 109.435 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.428 HD23 ' HA ' ' A' ' 32' ' ' LEU . 41.4 mt -57.45 -57.85 10.86 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.615 ' CD2' HD13 ' A' ' 82' ' ' LEU . 85.1 m-70 -89.5 5.39 45.65 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.566 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.449 ' N ' ' O ' ' A' ' 30' ' ' ILE . 69.9 m-20 55.18 48.4 19.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.551 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.864 ' HG3' HD22 ' A' ' 82' ' ' LEU . 49.0 mmm -98.17 15.06 25.5 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.267 -0.896 . . . . 0.0 109.429 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.66 ' CG ' HG22 ' A' ' 30' ' ' ILE . 98.0 mt-10 -55.01 -29.27 57.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.481 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -67.69 -38.3 83.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.338 -0.851 . . . . 0.0 109.508 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.833 HD12 ' HB3' ' A' ' 35' ' ' MET . 6.3 mt -72.63 -52.85 13.67 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -0.936 . . . . 0.0 109.425 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.965 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -69.91 133.77 47.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 109.335 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -106.52 -64.06 0.61 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -146.6 153.07 39.91 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.168 -1.195 . . . . 0.0 109.556 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.986 HG13 HG22 ' A' ' 71' ' ' VAL . 38.9 t -114.44 149.72 16.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.309 -0.869 . . . . 0.0 109.455 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.555 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.4 mtm -132.08 140.36 48.82 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.167 -0.958 . . . . 0.0 109.562 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.3 t -131.01 76.72 76.46 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.449 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.47 58.44 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.705 2.27 . . . . 0.0 111.829 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 21.8 p -129.77 153.53 48.12 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.189 -0.944 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.427 ' HB2' ' O ' ' A' ' 62' ' ' ARG . 95.3 mt-10 -62.31 -19.48 63.34 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.244 -0.91 . . . . 0.0 109.362 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.489 ' HB2' ' HE2' ' A' ' 63' ' ' LYS . 84.4 tt0 -48.41 -34.97 11.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.7 p -127.02 136.19 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.439 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.4 m -137.78 162.08 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.316 -0.865 . . . . 0.0 109.384 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 31.7 tp10 -47.19 -56.34 6.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 52' ' ' ILE . 1.1 tt -126.36 101.24 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.287 -0.883 . . . . 0.0 109.429 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 75.0 mtm-85 -59.24 145.16 43.93 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.281 -0.887 . . . . 0.0 109.509 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -65.93 -30.01 76.21 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.455 ' O ' ' HG3' ' A' ' 57' ' ' ARG . . . 116.21 -97.47 0.77 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.4 ' O ' ' HB2' ' A' ' 57' ' ' ARG . 56.3 tp60 -57.94 -32.17 67.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -1.171 . . . . 0.0 109.477 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.455 ' HG3' ' O ' ' A' ' 55' ' ' GLY . 59.8 mtt180 60.38 39.98 17.99 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.207 -0.933 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 69.7 mtt85 -58.84 -32.64 69.61 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.17 -0.956 . . . . 0.0 109.445 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 44.2 tttm -76.05 133.12 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.43 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.2 m -58.47 153.85 15.09 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.251 -0.906 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -122.88 149.73 43.83 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.198 -0.939 . . . . 0.0 109.455 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.427 ' O ' ' HB2' ' A' ' 47' ' ' GLU . 97.5 mtt180 -126.98 146.09 50.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.286 -0.884 . . . . 0.0 109.511 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.489 ' HE2' ' HB2' ' A' ' 48' ' ' GLU . 21.3 mttt -102.45 118.2 36.36 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.242 -0.911 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.682 ' CD1' ' CZ ' ' A' ' 65' ' ' PHE . 32.2 t80 -59.66 -45.17 92.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.293 -0.88 . . . . 0.0 109.313 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.743 ' HE1' HD21 ' A' ' 115' ' ' LEU . 2.2 m-85 -114.8 83.81 9.64 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.251 -0.906 . . . . 0.0 109.335 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.38 115.29 3.97 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.726 2.284 . . . . 0.0 111.842 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 80.39 18.6 70.9 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.491 ' HB2' ' HB3' ' A' ' 65' ' ' PHE . 1.7 m-85 -117.89 109.49 16.59 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -1.141 . . . . 0.0 109.437 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.624 HG23 ' OE2' ' A' ' 19' ' ' GLU . 77.0 t -137.25 133.97 47.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.275 -0.891 . . . . 0.0 109.585 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.823 HD12 ' N ' ' A' ' 70' ' ' LEU . 2.1 mp -101.26 147.1 26.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.194 -0.941 . . . . 0.0 109.285 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.986 HG22 HG13 ' A' ' 42' ' ' VAL . 65.0 t -145.49 113.78 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.246 -0.909 . . . . 0.0 109.638 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.452 ' NE2' ' CZ2' ' A' ' 9' ' ' TRP . 0.0 OUTLIER -54.06 124.35 15.34 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.209 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.564 ' SD ' ' CE2' ' A' ' 39' ' ' PHE . 38.1 ttp -177.21 155.22 1.12 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.901 . . . . 0.0 109.533 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.5 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.1 t -91.52 140.45 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.302 -0.874 . . . . 0.0 109.402 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.615 ' CG ' ' CZ ' ' A' ' 10' ' ' TYR . 30.6 mmm -84.02 109.33 17.57 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.278 -0.889 . . . . 0.0 109.597 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.515 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 51.2 p-10 -138.27 173.89 11.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.294 -0.879 . . . . 0.0 109.505 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -64.18 -26.16 68.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.249 -0.907 . . . . 0.0 109.562 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.48 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -78.25 -70.14 0.51 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.259 -0.901 . . . . 0.0 109.59 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.51 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 25.1 p -54.67 -45.99 73.98 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.266 -0.896 . . . . 0.0 109.736 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.532 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 73.1 t90 -51.15 -54.38 25.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.6 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -61.57 -39.09 89.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.219 -0.925 . . . . 0.0 109.559 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.864 HD22 ' HG3' ' A' ' 35' ' ' MET . 58.4 tp -63.21 -41.64 99.17 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.152 -0.967 . . . . 0.0 109.503 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.007 HG11 ' CE2' ' A' ' 92' ' ' PHE . 55.6 t -56.32 -43.89 78.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.139 -0.976 . . . . 0.0 109.534 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 43.3 ttt180 -61.83 -35.65 78.87 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.175 -0.953 . . . . 0.0 109.481 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 29.8 t -66.76 -28.34 68.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.888 . . . . 0.0 109.479 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.76 HG21 HD13 ' A' ' 26' ' ' LEU . 49.8 t -54.9 124.93 53.99 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.464 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.445 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.2 155.08 65.29 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.745 2.296 . . . . 0.0 111.789 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.579 ' HB2' HG22 ' A' ' 22' ' ' VAL . 82.6 mmt-85 63.36 43.43 6.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.254 -0.904 . . . . 0.0 109.526 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.662 HG21 ' HB ' ' A' ' 86' ' ' VAL . 53.6 t -128.79 115.58 37.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.259 -0.901 . . . . 0.0 109.5 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.51 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.7 mtp -68.5 -40.16 80.98 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.907 . . . . 0.0 109.513 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.59 -158.86 31.43 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 1.007 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.2 OUTLIER -112.69 166.68 11.13 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.218 -1.166 . . . . 0.0 109.514 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.899 HD12 ' CG1' ' A' ' 11' ' ' VAL . 67.4 mt -118.24 137.5 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.878 . . . . 0.0 109.379 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 161.18 -147.08 13.24 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -78.08 -44.09 12.46 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.3 p -127.73 173.38 9.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.156 -1.202 . . . . 0.0 109.53 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.1 m -89.89 18.09 6.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.274 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.532 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 87.6 m-20 -130.17 -33.24 1.74 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.574 -0.704 . . . . 0.0 109.134 179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -132.55 88.58 38.46 Favored Pre-proline 0 N--CA 1.487 1.408 0 O-C-N 121.264 -0.898 . . . . 0.0 108.836 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE2' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.46 128.76 18.8 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.71 2.274 . . . . 0.0 112.048 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -71.84 137.14 82.56 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.291 -0.88 . . . . 0.0 109.361 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.552 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.3 Cg_endo -69.7 153.23 69.47 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.699 2.266 . . . . 0.0 111.841 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.559 HD11 HG22 ' A' ' 108' ' ' VAL . 26.7 pt -112.65 154.96 14.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.369 -0.832 . . . . 0.0 109.481 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 43.9 m -65.38 146.26 55.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.152 -0.968 . . . . 0.0 109.523 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -58.13 -41.01 82.75 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.278 -0.889 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 42.5 tttt -57.98 -43.42 86.52 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.449 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 86.5 tt0 -51.85 -43.75 63.36 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.256 -0.902 . . . . 0.0 109.441 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.559 HG22 HD11 ' A' ' 103' ' ' ILE . 74.8 t -57.17 -38.69 62.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.303 -0.873 . . . . 0.0 109.375 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -68.41 -31.75 71.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.23 -0.919 . . . . 0.0 109.465 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -62.93 -42.28 99.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.274 -0.891 . . . . 0.0 109.435 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.51 HG12 ' NH1' ' A' ' 114' ' ' ARG . 50.9 mt -52.43 -53.69 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.211 -0.93 . . . . 0.0 109.395 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.4 mtt -62.58 -36.73 83.62 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.219 -0.926 . . . . 0.0 109.377 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -60.94 -37.54 82.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.51 ' NH1' HG12 ' A' ' 111' ' ' ILE . 24.6 mtm180 -55.17 -40.77 71.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.281 -0.887 . . . . 0.0 109.479 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.743 HD21 ' HE1' ' A' ' 65' ' ' PHE . 87.1 mt -54.57 -40.43 68.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 109.414 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 -65.25 -31.53 72.73 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -65.51 137.15 57.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.382 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.682 HG11 ' HE3' ' A' ' 121' ' ' LYS . 39.5 t -119.71 140.21 44.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -54.42 -35.15 55.62 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.537 ' H ' HG12 ' A' ' 118' ' ' VAL . 60.5 t0 -144.39 88.77 1.96 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.306 -1.114 . . . . 0.0 109.4 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.682 ' HE3' HG11 ' A' ' 118' ' ' VAL . 1.3 tppp? -155.06 106.55 2.28 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.228 -0.92 . . . . 0.0 109.516 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.27 -17.81 35.01 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.654 2.236 . . . . 0.0 111.765 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 55.4 ttt180 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.064 -0.969 . . . . 0.0 109.398 179.944 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.1 mmm . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.4 p -67.36 -14.52 62.99 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.276 -0.89 . . . . 0.0 109.486 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -51.99 -37.4 53.04 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.227 -0.921 . . . . 0.0 109.541 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -168.93 148.65 3.83 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.355 -0.841 . . . . 0.0 109.492 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.97 147.94 62.61 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.713 2.275 . . . . 0.0 111.817 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 56.5 mttm -106.39 139.78 40.33 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.212 -0.93 . . . . 0.0 109.455 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.485 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 47.1 mttt -113.29 138.21 50.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.224 -0.922 . . . . 0.0 109.48 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.521 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 78.8 mtt-85 -128.92 156.48 43.66 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.447 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 67.4 m95 -91.55 128.15 37.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.177 -0.952 . . . . 0.0 109.617 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.561 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.9 m-85 -120.9 150.11 41.58 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.899 . . . . 0.0 109.46 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.479 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 53.0 t -102.27 136.04 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.245 -0.909 . . . . 0.0 109.45 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.0 t -112.79 126.68 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.528 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.717 ' HB2' HD11 ' A' ' 93' ' ' ILE . 69.9 tp60 -90.35 130.64 36.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.425 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.666 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -142.67 154.74 44.61 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.263 -0.898 . . . . 0.0 109.528 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -55.12 149.67 11.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.312 -0.867 . . . . 0.0 109.423 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 33.8 t -67.93 147.71 52.1 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -0.915 . . . . 0.0 109.498 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.99 -33.94 4.28 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.826 ' O ' HG23 ' A' ' 22' ' ' VAL . 93.5 m-85 -109.53 7.15 24.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -1.155 . . . . 0.0 109.592 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.846 ' OE1' HG21 ' A' ' 46' ' ' THR . 23.0 pt-20 -56.12 -39.31 72.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.441 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.42 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -75.44 -54.2 5.66 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -57.86 -39.21 77.21 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -1.136 . . . . 0.0 109.497 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.9 t -53.05 -40.75 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.299 -0.876 . . . . 0.0 109.525 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.78 -40.29 96.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.269 -0.894 . . . . 0.0 109.433 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.8 m -64.48 -43.51 93.96 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.468 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 58.1 m -58.41 -41.68 85.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.187 -0.945 . . . . 0.0 109.453 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.655 HD21 ' CE1' ' A' ' 39' ' ' PHE . 4.8 tp -59.14 -39.41 82.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.247 -0.908 . . . . 0.0 109.272 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 18.0 ttt180 -58.48 -26.03 62.97 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.321 -0.862 . . . . 0.0 109.392 179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.469 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 71.2 mt-10 -68.66 -47.65 65.99 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.325 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 1.0 ' HB3' HD11 ' A' ' 82' ' ' LEU . 79.8 m-70 -68.06 -43.47 78.58 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.857 HD13 ' CD2' ' A' ' 39' ' ' PHE . 54.9 mt -57.94 -50.44 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.295 -0.878 . . . . 0.0 109.52 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 58.2 tttp -60.49 -41.48 94.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.268 -0.895 . . . . 0.0 109.611 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 32.3 mt -69.27 -50.88 42.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.492 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.481 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.3 m-70 -77.49 -6.89 55.17 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.217 -0.927 . . . . 0.0 109.528 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.487 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.1 t30 66.14 42.98 2.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.255 -0.903 . . . . 0.0 109.514 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.908 ' HG3' HD22 ' A' ' 82' ' ' LEU . 45.8 mmm -92.04 5.19 51.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.189 -0.944 . . . . 0.0 109.542 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.45 ' O ' ' O ' ' A' ' 39' ' ' PHE . 96.5 mt-10 -48.76 -37.79 19.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.461 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -53.26 -44.25 68.03 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.214 -0.929 . . . . 0.0 109.362 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.904 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.2 mt -72.19 -52.66 15.5 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.302 -0.874 . . . . 0.0 109.4 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.857 ' CD2' HD13 ' A' ' 30' ' ' ILE . 98.1 m-85 -70.97 129.09 38.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.187 -0.946 . . . . 0.0 109.441 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.32 -69.19 0.66 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -139.71 147.15 40.51 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.223 -1.163 . . . . 0.0 109.583 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.036 HG13 HG22 ' A' ' 71' ' ' VAL . 39.0 t -113.99 154.01 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.374 -0.829 . . . . 0.0 109.351 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.565 ' CE ' HG11 ' A' ' 108' ' ' VAL . 64.3 mtm -137.78 144.05 41.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.195 -0.94 . . . . 0.0 109.566 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 45.6 t -129.7 100.49 19.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.316 -0.865 . . . . 0.0 109.438 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.683 ' HD3' HD13 ' A' ' 70' ' ' LEU . 49.9 Cg_endo -70.44 -16.75 34.75 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.692 2.262 . . . . 0.0 111.857 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.846 HG21 ' OE1' ' A' ' 19' ' ' GLU . 12.0 p -64.95 -14.14 59.24 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.215 -0.928 . . . . 0.0 109.566 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.501 ' HG3' HD11 ' A' ' 52' ' ' ILE . 77.8 tt0 -100.51 130.99 46.65 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.15 -0.969 . . . . 0.0 109.441 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -65.89 -49.06 69.39 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.299 -0.876 . . . . 0.0 109.477 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.439 HG12 ' N ' ' A' ' 50' ' ' VAL . 44.8 t -129.4 158.04 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.436 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.439 ' N ' HG12 ' A' ' 49' ' ' VAL . 8.8 p -46.89 -35.95 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.415 ' N ' HG13 ' A' ' 50' ' ' VAL . 86.2 tt0 -110.01 150.32 28.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.261 -0.9 . . . . 0.0 109.55 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.501 HD11 ' HG3' ' A' ' 47' ' ' GLU . 55.6 mt -121.12 96.65 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.443 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 87.3 mtt180 -59.22 146.76 38.03 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.266 -0.896 . . . . 0.0 109.48 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -57.11 -39.94 90.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 46.03 -110.6 0.5 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -109.81 154.16 23.39 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.263 -1.139 . . . . 0.0 109.506 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.6 mtm-85 -50.26 -35.45 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.272 -0.892 . . . . 0.0 109.414 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 35.1 ttt180 -129.28 132.16 47.12 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.261 -0.9 . . . . 0.0 109.492 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 mttm -100.43 134.91 42.68 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.34 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 18.2 m -63.11 -23.63 67.53 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -52.36 147.8 7.51 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.5 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.3 mtt-85 -130.19 151.02 51.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.307 -0.87 . . . . 0.0 109.426 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.46 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 28.9 mttp -88.92 114.09 25.16 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.167 -0.958 . . . . 0.0 109.5 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -63.78 -40.62 97.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.252 -0.905 . . . . 0.0 109.467 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.573 ' CZ ' HD21 ' A' ' 115' ' ' LEU . 1.5 p90 -129.39 75.92 79.44 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.302 -0.874 . . . . 0.0 109.503 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.46 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 48.9 Cg_endo -69.94 144.6 53.58 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.743 2.295 . . . . 0.0 111.801 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . 83.46 19.64 61.76 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -118.64 124.25 46.93 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -1.199 . . . . 0.0 109.445 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.434 ' C ' HD12 ' A' ' 70' ' ' LEU . 76.6 t -132.2 146.49 33.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.567 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.846 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.2 mp -106.85 130.09 54.59 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.272 -0.892 . . . . 0.0 109.421 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.036 HG22 HG13 ' A' ' 42' ' ' VAL . 99.1 t -136.63 124.77 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.176 -0.952 . . . . 0.0 109.642 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.485 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 7.5 tt0 -81.02 128.37 33.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.269 -0.894 . . . . 0.0 109.171 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.561 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 50.9 ttp -173.83 165.12 4.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.223 -0.923 . . . . 0.0 109.65 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.529 ' N ' ' HG2' ' A' ' 73' ' ' MET . 14.5 p -88.53 143.36 11.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.353 -0.842 . . . . 0.0 109.218 179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.582 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 16.9 tpp -82.91 113.82 20.78 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.228 -0.92 . . . . 0.0 109.593 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.0 p30 -142.14 168.94 18.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.318 -0.864 . . . . 0.0 109.427 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.572 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.6 m-20 -68.61 -30.12 68.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.217 -0.927 . . . . 0.0 109.47 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.02 -71.88 0.22 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.251 -0.905 . . . . 0.0 109.55 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.904 ' OG ' HD13 ' A' ' 38' ' ' LEU . 7.5 m -48.27 -49.61 32.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.266 -0.896 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 66.3 t90 -49.63 -52.3 31.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.304 -0.873 . . . . 0.0 109.73 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 56.5 m-70 -66.6 -24.19 66.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.6 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 1.0 HD11 ' HB3' ' A' ' 29' ' ' HIS . 56.9 tp -68.74 -45.21 72.06 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.598 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.075 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 70.0 t -50.92 -44.05 26.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.573 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 36.2 ttp180 -62.92 -23.02 67.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.139 -0.976 . . . . 0.0 109.368 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 13.5 t -61.6 -63.86 1.13 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -0.896 . . . . 0.0 109.415 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.683 HG13 HG21 ' A' ' 89' ' ' VAL . 1.8 p -59.62 125.8 80.89 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.164 -0.96 . . . . 0.0 109.467 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.476 ' O ' HG23 ' A' ' 89' ' ' VAL . 48.1 Cg_endo -69.65 -177.77 1.99 Allowed 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.732 2.288 . . . . 0.0 111.834 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.1 mtt85 62.94 23.01 13.77 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.314 -0.866 . . . . 0.0 109.582 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.683 HG21 HG13 ' A' ' 86' ' ' VAL . 22.2 t -116.88 116.48 52.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.482 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 44.8 mtt -65.93 -43.68 87.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.346 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.19 -150.86 22.3 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 1.075 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 4.6 m-85 -111.8 161.4 16.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.243 -1.151 . . . . 0.0 109.4 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.717 HD11 ' HB2' ' A' ' 13' ' ' GLN . 15.8 mm -114.88 123.12 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.306 -0.871 . . . . 0.0 109.548 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.482 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.86 -152.76 11.57 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -64.95 -45.04 93.62 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.9 p -129.32 172.86 11.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.183 -1.187 . . . . 0.0 109.565 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 14.4 p -89.82 20.05 4.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.2 -0.937 . . . . 0.0 109.412 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -123.12 -22.65 5.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.449 -0.782 . . . . 0.0 109.37 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.53 103.18 3.27 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.328 -0.857 . . . . 0.0 108.94 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.582 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 48.4 Cg_endo -68.77 111.46 2.61 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.756 2.304 . . . . 0.0 111.996 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.98 140.7 81.95 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.291 -0.881 . . . . 0.0 109.427 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.521 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.9 Cg_endo -70.15 153.34 67.24 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.637 2.225 . . . . 0.0 111.81 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.6 pt -125.62 155.11 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.255 -0.903 . . . . 0.0 109.408 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.7 m -71.74 151.34 43.65 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.43 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -52.29 -41.7 63.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.224 -0.923 . . . . 0.0 109.479 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -55.82 -41.52 74.34 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.227 -0.921 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -52.88 -45.12 67.33 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.333 -0.854 . . . . 0.0 109.377 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.835 HG13 ' CD2' ' A' ' 70' ' ' LEU . 98.1 t -56.78 -38.03 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -67.54 -34.2 76.6 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.229 -0.919 . . . . 0.0 109.445 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -56.48 -46.3 80.5 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.332 -0.855 . . . . 0.0 109.415 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.72 HD12 HD21 ' A' ' 70' ' ' LEU . 50.5 mt -49.69 -56.36 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.329 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 64.6 mtt -60.3 -35.17 74.96 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.276 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 50.0 t-20 -61.27 -34.69 75.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.302 -0.874 . . . . 0.0 109.355 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 45.7 ttt180 -55.88 -36.97 68.21 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.319 -0.863 . . . . 0.0 109.47 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.573 HD21 ' CZ ' ' A' ' 65' ' ' PHE . 72.8 mt -55.79 -43.46 76.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.322 -0.861 . . . . 0.0 109.428 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -64.68 -31.82 73.22 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.271 -0.893 . . . . 0.0 109.527 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -69.99 137.26 51.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.281 -0.887 . . . . 0.0 109.512 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 69.0 t -60.5 -39.44 81.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.291 -0.881 . . . . 0.0 109.483 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 96.81 10.4 55.29 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 121' ' ' LYS . 30.9 p-10 -58.03 -34.69 70.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.217 -1.167 . . . . 0.0 109.414 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.505 ' N ' ' OD1' ' A' ' 120' ' ' ASP . 12.8 tttm -124.11 81.05 57.67 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.364 -0.835 . . . . 0.0 109.509 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -70.12 -18.91 35.0 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.726 2.284 . . . . 0.0 111.685 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 38.6 ttt180 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.006 -0.997 . . . . 0.0 109.505 179.965 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.7 mtp . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.0 t -57.41 -35.87 70.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.294 -0.878 . . . . 0.0 109.506 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.94 -34.75 75.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.512 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.43 80.04 60.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.312 -0.867 . . . . 0.0 109.465 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.26 141.33 42.93 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.671 2.247 . . . . 0.0 111.759 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.738 ' O ' HG22 ' A' ' 74' ' ' VAL . 26.9 mttp -110.22 150.14 29.11 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.309 -0.869 . . . . 0.0 109.401 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.473 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 77.5 mttt -99.02 133.27 43.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.323 -0.86 . . . . 0.0 109.561 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.514 ' NE ' ' OH ' ' A' ' 10' ' ' TYR . 44.9 mtm180 -132.72 159.55 39.35 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.274 -0.891 . . . . 0.0 109.493 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.546 ' CG ' HG21 ' A' ' 108' ' ' VAL . 46.3 m95 -99.34 132.54 44.59 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.892 . . . . 0.0 109.556 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.595 ' CD2' ' HE2' ' A' ' 75' ' ' MET . 66.1 m-85 -130.93 155.23 47.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -0.906 . . . . 0.0 109.443 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.489 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 10.7 t -96.18 145.93 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.226 -0.921 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.0 t -119.03 123.57 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.33 -0.856 . . . . 0.0 109.364 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.993 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.5 tt0 -93.1 131.67 37.92 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.222 -0.923 . . . . 0.0 109.556 -179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.445 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -138.72 -153.23 0.46 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 109.369 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 61.7 t80 -98.23 133.49 42.58 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.452 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 31.3 t -54.77 126.0 22.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.214 -0.929 . . . . 0.0 109.527 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.11 -27.15 19.67 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.653 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 19.2 m-85 -105.09 7.52 33.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -1.116 . . . . 0.0 109.493 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.671 ' OE2' HG22 ' A' ' 46' ' ' THR . 23.6 pt-20 -56.89 -34.72 68.16 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.915 . . . . 0.0 109.374 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -71.13 -37.87 63.68 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 17.9 ttm180 -63.81 -49.86 71.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.204 -1.174 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.461 HG13 HG11 ' A' ' 86' ' ' VAL . 39.1 t -50.37 -38.78 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.235 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.73 -39.72 91.44 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -0.929 . . . . 0.0 109.251 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 59.6 m -69.01 -46.6 67.55 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.388 -0.82 . . . . 0.0 109.376 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.479 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.4 m -65.72 -39.63 91.39 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.321 -0.862 . . . . 0.0 109.438 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.5 ' HG ' ' CD1' ' A' ' 30' ' ' ILE . 30.8 tp -54.34 -43.55 71.34 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.233 -0.917 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.6 ttm-85 -57.83 -36.89 72.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.242 -0.911 . . . . 0.0 109.51 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -67.94 -52.58 34.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.203 -0.936 . . . . 0.0 109.474 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.996 ' HB3' HD11 ' A' ' 82' ' ' LEU . 68.1 m-70 -58.44 -48.06 81.94 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.93 . . . . 0.0 109.443 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.65 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.2 mt -57.69 -52.91 51.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.305 -0.872 . . . . 0.0 109.515 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.4 tttm -57.61 -43.39 84.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.29 -0.881 . . . . 0.0 109.497 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.427 ' HA ' HD23 ' A' ' 32' ' ' LEU . 40.2 mt -68.25 -49.48 60.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.229 -0.92 . . . . 0.0 109.416 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.506 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 98.5 m-70 -80.35 4.19 18.7 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 109.577 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.44 ' N ' ' O ' ' A' ' 30' ' ' ILE . 40.5 t30 52.75 50.53 17.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.137 -0.977 . . . . 0.0 109.403 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.937 ' HG3' HD22 ' A' ' 82' ' ' LEU . 53.3 mmm -102.88 4.74 37.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.236 -0.915 . . . . 0.0 109.581 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.427 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.3 mt-10 -49.78 -34.93 20.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.553 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -57.77 -43.03 85.23 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.413 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.586 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.4 mt -72.84 -50.12 25.97 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.287 -0.883 . . . . 0.0 109.316 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.566 ' CE2' HG12 ' A' ' 30' ' ' ILE . 96.4 m-85 -71.2 130.83 42.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.295 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -109.56 -65.4 0.55 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -137.19 122.68 19.6 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -1.204 . . . . 0.0 109.675 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.983 HG23 HG22 ' A' ' 71' ' ' VAL . 8.2 p -92.53 136.0 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.34 -0.85 . . . . 0.0 109.145 179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.766 ' O ' HG13 ' A' ' 69' ' ' VAL . 97.2 mtp -125.12 117.42 23.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.192 -0.942 . . . . 0.0 109.768 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.785 ' O ' HG13 ' A' ' 44' ' ' VAL . 12.0 p -135.06 81.83 44.07 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.323 -0.861 . . . . 0.0 109.099 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -69.13 130.52 20.26 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.79 2.327 . . . . 0.0 111.98 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.671 HG22 ' OE2' ' A' ' 19' ' ' GLU . 55.8 p -124.68 -0.52 8.03 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.784 ' HB2' HD21 ' A' ' 115' ' ' LEU . 85.4 tt0 50.83 86.0 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.244 -0.91 . . . . 0.0 109.639 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 73.1 mm-40 -58.99 137.45 57.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.258 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.4 p -131.43 137.93 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.162 -0.961 . . . . 0.0 109.733 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.3 p -128.69 154.11 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.343 -0.848 . . . . 0.0 109.327 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.467 ' OE2' ' HA2' ' A' ' 55' ' ' GLY . 83.4 tt0 -119.62 156.75 29.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.224 -0.922 . . . . 0.0 109.601 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.448 ' O ' ' HB2' ' A' ' 53' ' ' ARG . 56.5 mt -142.72 109.56 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.416 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.448 ' HB2' ' O ' ' A' ' 52' ' ' ILE . 77.1 mtp180 64.07 135.4 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.267 -0.896 . . . . 0.0 109.439 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 93.84 -175.42 35.38 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.467 ' HA2' ' OE2' ' A' ' 51' ' ' GLU . . . 167.16 178.97 39.85 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -126.24 149.17 49.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.193 -1.181 . . . . 0.0 109.449 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -57.46 -35.15 69.77 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.196 -0.94 . . . . 0.0 109.541 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 -127.38 143.48 51.21 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.227 -0.921 . . . . 0.0 109.494 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 26.9 tptp -82.5 131.84 35.21 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.254 -0.903 . . . . 0.0 109.499 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 32.1 t -127.55 139.09 52.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 109.505 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.503 ' OE1' ' CE ' ' A' ' 63' ' ' LYS . 98.9 mt-10 -117.15 135.99 53.35 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.245 -0.909 . . . . 0.0 109.376 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.483 ' HD2' ' CZ ' ' A' ' 64' ' ' PHE . 75.3 mtm180 -71.78 -44.99 63.07 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.219 -0.925 . . . . 0.0 109.519 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.503 ' CE ' ' OE1' ' A' ' 61' ' ' GLU . 75.7 mmtt 46.7 63.33 1.95 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.463 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.506 ' HE1' HG13 ' A' ' 118' ' ' VAL . 70.2 m-85 -60.68 -36.16 78.07 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.193 -0.942 . . . . 0.0 109.438 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.429 ' HB3' ' HB2' ' A' ' 68' ' ' TYR . 13.4 m-85 -105.73 106.66 57.27 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.35 70.96 1.86 Allowed 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.694 2.263 . . . . 0.0 111.839 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 74.73 45.48 21.92 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.429 ' HB2' ' HB3' ' A' ' 65' ' ' PHE . 1.3 m-85 -111.95 120.79 43.1 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -1.144 . . . . 0.0 109.485 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 43' ' ' MET . 96.5 t -133.34 146.88 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -0.888 . . . . 0.0 109.577 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.854 HD22 ' N ' ' A' ' 70' ' ' LEU . 1.2 mm? -105.03 131.0 53.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.886 . . . . 0.0 109.341 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.983 HG22 HG23 ' A' ' 42' ' ' VAL . 64.3 t -138.55 125.74 27.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.171 -0.955 . . . . 0.0 109.709 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.473 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.7 tt0 -78.8 119.58 22.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.379 -0.826 . . . . 0.0 109.299 179.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.552 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 48.6 ttp -165.99 163.46 18.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.602 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.738 HG22 ' O ' ' A' ' 6' ' ' LYS . 32.3 t -91.48 147.61 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.297 -0.877 . . . . 0.0 109.445 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.595 ' HE2' ' CD2' ' A' ' 10' ' ' TYR . 10.2 mmt -86.5 114.14 23.0 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.935 . . . . 0.0 109.653 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.1 p-10 -143.25 167.92 21.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.305 -0.872 . . . . 0.0 109.324 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.6 m-20 -66.36 -24.29 66.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.257 -0.902 . . . . 0.0 109.696 -179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.533 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -75.57 -70.26 0.44 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.235 -0.916 . . . . 0.0 109.526 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.475 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 12.4 p -56.07 -49.72 73.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.168 -0.957 . . . . 0.0 109.682 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.476 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.8 t90 -43.97 -44.93 7.53 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 33.0 m-70 -73.54 -32.01 63.96 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.218 -0.926 . . . . 0.0 109.484 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.996 HD11 ' HB3' ' A' ' 29' ' ' HIS . 54.9 tp -63.07 -45.88 90.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.27 -0.894 . . . . 0.0 109.525 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.01 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 82.8 t -55.4 -45.64 78.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.244 -0.91 . . . . 0.0 109.643 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -62.95 -36.39 83.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.638 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 41.0 m -61.48 -38.89 88.95 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.133 -0.979 . . . . 0.0 109.471 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.644 ' O ' HG12 ' A' ' 89' ' ' VAL . 38.5 t -51.73 126.14 31.14 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.289 -0.882 . . . . 0.0 109.531 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.46 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -71.17 156.36 59.55 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.69 2.26 . . . . 0.0 111.714 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.496 ' HD2' ' HD2' ' A' ' 21' ' ' ARG . 82.0 mtt-85 62.06 35.86 15.68 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.857 . . . . 0.0 109.672 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.2 p -129.09 128.31 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.158 -0.964 . . . . 0.0 109.571 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.486 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 92.4 mmm -71.96 -54.59 9.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.261 -0.899 . . . . 0.0 109.285 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 162.03 -148.01 14.87 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 1.01 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 5.3 m-85 -104.62 160.6 14.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -1.162 . . . . 0.0 109.499 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.993 HD11 ' HB2' ' A' ' 13' ' ' GLN . 17.3 mm -118.14 119.11 60.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.22 -0.925 . . . . 0.0 109.453 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -171.63 -143.57 4.11 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -71.98 -35.42 61.36 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.586 HG23 ' H ' ' A' ' 98' ' ' ASP . 7.0 t -140.93 176.16 9.03 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.211 -1.17 . . . . 0.0 109.633 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 13.1 p -92.96 21.57 5.61 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.43 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.586 ' H ' HG23 ' A' ' 96' ' ' THR . 2.6 p30 -137.05 8.79 2.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.46 -0.775 . . . . 0.0 109.133 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -176.69 92.51 0.25 Allowed Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.343 -0.848 . . . . 0.0 108.948 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.525 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 46.0 Cg_endo -68.48 120.78 7.71 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.688 2.259 . . . . 0.0 111.988 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -64.37 148.61 95.95 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.285 -0.884 . . . . 0.0 109.317 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.507 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 49.5 Cg_endo -70.07 153.28 67.68 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.68 2.253 . . . . 0.0 111.82 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.533 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -125.21 157.91 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.333 -0.854 . . . . 0.0 109.336 179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.455 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 39.0 m -75.64 148.71 38.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.239 -0.913 . . . . 0.0 109.554 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -56.51 -40.8 75.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -58.15 -40.37 81.17 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.289 -0.882 . . . . 0.0 109.417 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 93.3 mt-10 -56.03 -43.78 78.13 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.197 -0.939 . . . . 0.0 109.389 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.546 HG21 ' CG ' ' A' ' 9' ' ' TRP . 54.1 t -57.35 -37.83 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -0.902 . . . . 0.0 109.343 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -73.81 -34.1 64.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.326 -0.859 . . . . 0.0 109.367 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.39 -43.41 81.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.388 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.422 HG13 ' O ' ' A' ' 107' ' ' GLU . 89.7 mt -50.05 -50.09 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.454 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . 0.44 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.3 mtp -60.13 -39.94 88.04 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.414 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -59.96 -40.79 90.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.43 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.476 ' O ' ' N ' ' A' ' 117' ' ' GLN . 65.2 mtt180 -56.16 -46.34 79.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.4 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.784 HD21 ' HB2' ' A' ' 47' ' ' GLU . 5.2 tp -44.13 -48.56 9.1 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.225 -0.922 . . . . 0.0 109.438 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -66.46 -25.49 66.75 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.299 -0.875 . . . . 0.0 109.49 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.476 ' N ' ' O ' ' A' ' 114' ' ' ARG . 58.0 tp60 -86.02 141.16 29.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.265 -0.897 . . . . 0.0 109.379 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.506 HG13 ' HE1' ' A' ' 64' ' ' PHE . 39.6 t -125.65 151.27 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.91 . . . . 0.0 109.446 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -53.38 -37.03 54.72 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.438 ' OD1' ' HG2' ' A' ' 122' ' ' PRO . 56.6 t0 -152.19 94.11 1.9 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -1.107 . . . . 0.0 109.449 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.525 ' N ' ' HD2' ' A' ' 122' ' ' PRO . 0.0 OUTLIER -46.59 -58.85 5.97 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.517 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . 0.525 ' HD2' ' N ' ' A' ' 121' ' ' LYS . 49.7 Cg_endo -70.11 145.77 56.06 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.661 2.24 . . . . 0.0 111.815 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.463 ' HG2' ' OXT' ' A' ' 123' ' ' ARG . 67.1 ttt180 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.407 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.6 mtp . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.282 0.563 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.0 m -64.39 152.65 40.85 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.472 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -60.99 -33.45 73.25 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.493 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -56.44 144.76 61.83 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.29 -0.881 . . . . 0.0 109.428 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.56 147.27 63.77 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.751 2.3 . . . . 0.0 111.817 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -90.91 28.68 1.5 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.278 -0.889 . . . . 0.0 109.431 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 80.1 mttt -93.53 134.94 35.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.283 -0.885 . . . . 0.0 109.493 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.556 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 51.3 mtt85 -117.27 156.01 28.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.19 -0.944 . . . . 0.0 109.506 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 83.7 m95 -87.78 128.06 35.32 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.889 . . . . 0.0 109.587 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.618 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 91.2 m-85 -121.18 160.67 23.31 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -0.912 . . . . 0.0 109.542 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 1.006 HG11 HD12 ' A' ' 93' ' ' ILE . 21.1 t -95.13 154.64 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.207 -0.933 . . . . 0.0 109.588 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.6 t -139.44 115.94 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.302 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.565 ' HG2' HD11 ' A' ' 93' ' ' ILE . 78.4 mt-30 -81.01 150.47 28.87 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.692 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.702 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -157.56 158.42 35.59 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 109.405 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.46 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.7 m-85 -62.44 143.97 56.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.227 -0.921 . . . . 0.0 109.497 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 34.0 t -67.78 147.34 52.72 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.25 -33.52 4.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.786 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.5 m-85 -108.07 10.66 28.1 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -1.139 . . . . 0.0 109.476 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.517 ' OE2' ' CB ' ' A' ' 46' ' ' THR . 20.9 pt-20 -61.15 -36.78 80.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.255 -0.903 . . . . 0.0 109.433 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -68.81 -50.02 38.54 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.0 ttt85 -63.77 -37.48 87.51 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -1.144 . . . . 0.0 109.424 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 18' ' ' PHE . 50.3 t -52.21 -41.67 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.206 -0.934 . . . . 0.0 109.271 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.16 -48.93 79.8 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.298 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 78.7 m -59.39 -46.39 88.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.39 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.421 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 21.9 m -51.3 -44.79 61.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.295 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.473 ' O ' HG12 ' A' ' 30' ' ' ILE . 47.5 mt -51.29 -69.68 0.11 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.36 -0.838 . . . . 0.0 109.388 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.48 ' HA ' HG12 ' A' ' 30' ' ' ILE . 48.6 ttt85 -42.78 -42.81 3.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.386 -0.821 . . . . 0.0 109.72 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -55.78 -37.81 69.07 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.208 -0.932 . . . . 0.0 109.512 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.626 ' CD2' HG22 ' A' ' 86' ' ' VAL . 93.3 m-70 -79.85 -27.28 40.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.239 -0.913 . . . . 0.0 109.274 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.987 HD12 ' CD1' ' A' ' 39' ' ' PHE . 11.8 mm -64.01 -43.45 97.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.302 -0.874 . . . . 0.0 109.321 179.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -70.38 -36.41 74.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.434 HD23 ' HA ' ' A' ' 32' ' ' LEU . 39.4 mt -70.61 -55.75 8.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.335 -0.853 . . . . 0.0 109.472 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.937 ' CD2' HD11 ' A' ' 82' ' ' LEU . 93.0 m-70 -81.18 4.82 18.86 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.195 -0.941 . . . . 0.0 109.559 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.6 t30 50.09 46.64 24.42 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.19 -0.944 . . . . 0.0 109.517 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.849 ' HB3' HD12 ' A' ' 38' ' ' LEU . 40.3 mmm -100.05 14.99 28.75 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.25 -0.906 . . . . 0.0 109.357 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.586 ' CG ' HG22 ' A' ' 30' ' ' ILE . 99.4 mt-10 -52.49 -31.31 34.5 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.276 -0.89 . . . . 0.0 109.492 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -60.34 -42.38 95.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.216 -0.927 . . . . 0.0 109.507 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 1.015 HD13 ' OG ' ' A' ' 79' ' ' SER . 2.4 mt -74.06 -53.97 8.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.351 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.987 ' CD1' HD12 ' A' ' 30' ' ' ILE . 94.2 m-85 -69.99 130.0 41.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.351 -0.843 . . . . 0.0 109.332 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.29 -64.27 0.48 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -138.93 146.34 40.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.164 -1.198 . . . . 0.0 109.525 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.991 HG13 HG22 ' A' ' 71' ' ' VAL . 48.2 t -111.12 153.83 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.516 ' SD ' HG11 ' A' ' 108' ' ' VAL . 89.5 mtp -123.62 143.81 50.0 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.164 -0.96 . . . . 0.0 109.499 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.609 HG13 HG22 ' A' ' 46' ' ' THR . 46.7 t -139.87 94.06 9.2 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.152 -0.967 . . . . 0.0 109.428 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.867 ' HB2' HD11 ' A' ' 115' ' ' LEU . 49.4 Cg_endo -70.03 -24.05 28.86 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.636 2.224 . . . . 0.0 111.699 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.702 ' O ' HG23 ' A' ' 46' ' ' THR . 9.3 t -71.68 64.15 0.45 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.251 -0.905 . . . . 0.0 109.506 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -61.82 -38.16 87.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.912 . . . . 0.0 109.371 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -108.31 151.78 25.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.406 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 39.6 t -118.07 137.02 53.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.162 -0.961 . . . . 0.0 109.556 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.3 m -61.4 140.25 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.302 -0.874 . . . . 0.0 109.424 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 51.7 tt0 -95.41 145.29 25.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.164 -0.96 . . . . 0.0 109.447 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 22.9 pt -66.34 -17.07 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.397 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 16.5 ptt180 -152.44 169.53 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.448 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 96.44 175.55 35.74 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.56 147.01 10.39 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -122.96 147.2 46.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.288 -1.125 . . . . 0.0 109.489 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 50.5 ttp180 -56.65 -38.08 71.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.261 -0.899 . . . . 0.0 109.469 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 68.9 mtm-85 -58.6 -32.66 69.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.237 -0.915 . . . . 0.0 109.489 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 8.7 tptp -65.81 130.88 44.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.152 -0.967 . . . . 0.0 109.471 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 46.4 m -65.12 154.23 38.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.225 -0.922 . . . . 0.0 109.513 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.0 mm-40 -120.4 155.27 33.78 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.886 ' HG2' HG13 ' A' ' 118' ' ' VAL . 9.3 mtt85 -118.57 147.45 43.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 109.52 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.1 tttt -80.8 128.24 33.43 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.198 -0.939 . . . . 0.0 109.42 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.587 ' CE2' ' HB2' ' A' ' 62' ' ' ARG . 98.6 m-85 -124.08 154.86 39.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.413 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.48 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 7.2 p90 -117.67 80.79 14.05 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 0.0 109.575 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.52 150.59 63.83 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.654 2.236 . . . . 0.0 111.625 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 95.08 4.59 61.27 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -115.36 119.18 35.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.204 -1.174 . . . . 0.0 109.505 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.522 ' C ' HD12 ' A' ' 70' ' ' LEU . 93.4 t -133.27 138.39 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.219 -0.926 . . . . 0.0 109.591 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 1.11 HD21 HD12 ' A' ' 111' ' ' ILE . 4.1 mp -108.22 131.03 55.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.311 -0.868 . . . . 0.0 109.337 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.991 HG22 HG13 ' A' ' 42' ' ' VAL . 86.3 t -138.42 120.58 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.702 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.477 ' O ' ' HB2' ' A' ' 73' ' ' MET . 36.4 tt0 -69.15 135.55 50.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.228 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.571 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 52.8 ttp 172.94 156.7 0.1 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.115 -0.99 . . . . 0.0 109.66 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.519 ' N ' ' HG2' ' A' ' 73' ' ' MET . 13.9 p -88.96 134.91 27.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.284 -0.885 . . . . 0.0 109.36 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.629 ' HE2' ' HG2' ' A' ' 100' ' ' PRO . 24.6 mmm -79.33 116.94 19.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.248 -0.907 . . . . 0.0 109.469 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.519 ' O ' ' CB ' ' A' ' 80' ' ' TRP . 49.5 p-10 -143.43 171.03 14.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.227 -0.921 . . . . 0.0 109.468 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.556 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 89.1 m-20 -59.76 -33.3 71.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.456 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -72.02 -70.96 0.3 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.27 -0.894 . . . . 0.0 109.481 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 1.015 ' OG ' HD13 ' A' ' 38' ' ' LEU . 6.7 m -52.76 -51.82 59.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.422 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.519 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 29.8 t90 -44.57 -46.65 10.06 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.312 -0.868 . . . . 0.0 109.593 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.556 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 34.7 m-70 -70.39 -36.38 74.06 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.216 -0.928 . . . . 0.0 109.422 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.937 HD11 ' CD2' ' A' ' 33' ' ' HIS . 3.0 tp -53.34 -45.01 68.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.176 -0.952 . . . . 0.0 109.461 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.942 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 11.6 t -62.02 -31.77 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.405 -0.81 . . . . 0.0 109.591 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.517 ' CZ ' ' CH2' ' A' ' 80' ' ' TRP . 40.5 mtt-85 -70.98 -33.2 70.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.205 -0.934 . . . . 0.0 109.407 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.9 p -79.7 -20.22 47.04 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.297 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 82' ' ' LEU . 88.5 t -67.29 127.33 93.44 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.343 -0.848 . . . . 0.0 109.326 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.455 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.21 153.06 67.22 Favored 'Trans proline' 0 C--O 1.214 -0.708 0 C-N-CA 122.687 2.258 . . . . 0.0 111.853 -179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.476 ' HD3' ' HB3' ' A' ' 18' ' ' PHE . 33.7 mtt85 63.09 47.34 4.23 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.237 -0.914 . . . . 0.0 109.605 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.608 HG21 ' HB ' ' A' ' 86' ' ' VAL . 69.1 t -127.33 123.44 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.223 -0.923 . . . . 0.0 109.527 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 85.5 mtp -78.16 -50.72 11.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -0.882 . . . . 0.0 109.41 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 164.07 -160.87 33.84 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.942 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 6.7 m-85 -109.57 160.52 16.18 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -1.154 . . . . 0.0 109.667 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 1.006 HD12 HG11 ' A' ' 11' ' ' VAL . 3.7 mt -117.51 134.16 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.339 -0.851 . . . . 0.0 109.251 179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 168.22 -142.22 7.32 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.25 -50.75 42.9 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.0 p -126.77 179.13 5.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -1.163 . . . . 0.0 109.587 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.47 ' O ' ' OD1' ' A' ' 98' ' ' ASP . 25.6 p -94.38 22.54 5.97 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.261 -0.899 . . . . 0.0 109.309 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.47 ' OD1' ' O ' ' A' ' 97' ' ' SER . 92.2 m-20 -137.0 6.42 2.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.476 -0.765 . . . . 0.0 109.459 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 0.0 OUTLIER -170.88 95.72 0.44 Allowed Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.292 -0.88 . . . . 0.0 109.019 -179.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.629 ' HG2' ' HE2' ' A' ' 75' ' ' MET . 46.5 Cg_endo -68.5 116.78 4.57 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.79 2.327 . . . . 0.0 111.947 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -66.27 148.51 98.46 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.327 -0.858 . . . . 0.0 109.302 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.556 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.9 Cg_endo -69.43 153.15 70.82 Favored 'Trans proline' 0 C--O 1.216 -0.581 0 C-N-CA 122.688 2.259 . . . . 0.0 111.777 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.53 HD11 ' CG2' ' A' ' 108' ' ' VAL . 29.3 pt -126.62 160.05 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.9 m -74.89 153.06 38.81 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.203 -0.936 . . . . 0.0 109.348 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -62.4 -33.36 74.62 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 18.7 tttp -61.58 -35.65 78.41 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.312 -0.868 . . . . 0.0 109.475 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 -63.28 -40.69 98.08 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.297 -0.877 . . . . 0.0 109.434 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.723 HG13 HD22 ' A' ' 70' ' ' LEU . 76.0 t -65.81 -36.62 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.196 -0.94 . . . . 0.0 109.361 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -68.45 -31.16 70.27 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.301 -0.875 . . . . 0.0 109.515 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -67.57 -40.12 84.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.255 -0.903 . . . . 0.0 109.483 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 1.11 HD12 HD21 ' A' ' 70' ' ' LEU . 54.8 mt -55.41 -51.46 56.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 109.415 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . 0.5 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 86.2 mtp -60.71 -35.76 77.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.24 -0.912 . . . . 0.0 109.372 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -58.72 -31.75 68.58 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.884 . . . . 0.0 109.435 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 51.5 mtt180 -58.56 -43.34 89.3 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.235 -0.915 . . . . 0.0 109.514 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.867 HD11 ' HB2' ' A' ' 45' ' ' PRO . 97.7 mt -56.02 -42.65 76.81 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.33 -0.856 . . . . 0.0 109.664 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.1 mt-30 -66.17 -28.41 68.75 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.15 -0.969 . . . . 0.0 109.549 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -71.07 135.74 47.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.553 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.886 HG13 ' HG2' ' A' ' 62' ' ' ARG . 6.7 t -129.9 151.53 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.405 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -56.42 -25.09 48.38 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -119.03 152.41 36.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.259 -1.142 . . . . 0.0 109.486 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.19 74.24 49.73 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.243 -0.911 . . . . 0.0 109.414 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.69 -17.63 37.76 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.69 2.26 . . . . 0.0 111.9 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 117.973 -1.013 . . . . 0.0 109.472 179.958 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.4 mtp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.3 m -58.56 -33.01 69.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.456 ' O ' ' HB3' ' A' ' 4' ' ' ALA . 96.8 mt-10 46.44 25.77 0.42 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -0.912 . . . . 0.0 109.484 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 3' ' ' GLU . . . 62.06 139.96 0.05 OUTLIER Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.25 140.46 40.9 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.659 2.24 . . . . 0.0 111.803 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -90.65 131.41 36.37 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.277 -0.89 . . . . 0.0 109.377 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.419 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 36.3 mttm -92.95 140.17 29.76 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.193 -0.942 . . . . 0.0 109.497 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 79.1 mtt85 -125.95 154.17 43.23 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.259 -0.9 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.427 ' CZ3' ' HG3' ' A' ' 43' ' ' MET . 90.1 m95 -91.0 130.11 36.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.211 -0.931 . . . . 0.0 109.502 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.476 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 93.3 m-85 -123.63 154.33 39.49 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.298 -0.876 . . . . 0.0 109.42 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.506 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 53.2 t -90.98 148.24 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.274 -0.891 . . . . 0.0 109.506 -179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -126.5 122.07 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.219 -0.926 . . . . 0.0 109.404 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.628 ' HB2' HD11 ' A' ' 93' ' ' ILE . 48.6 tt0 -84.9 133.71 34.29 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.211 -0.931 . . . . 0.0 109.432 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.741 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.39 161.88 36.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.899 . . . . 0.0 109.451 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.488 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 96.4 m-85 -70.38 145.64 50.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.28 -0.887 . . . . 0.0 109.544 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.9 t -60.32 139.31 57.7 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.353 -0.842 . . . . 0.0 109.458 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.67 -30.28 6.66 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 22' ' ' VAL . 10.3 m-85 -103.69 8.52 37.37 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.282 -1.129 . . . . 0.0 109.517 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.546 ' HG3' HG23 ' A' ' 69' ' ' VAL . 67.0 tt0 -53.08 -29.72 32.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.539 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -89.62 -55.44 2.04 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 40.2 ttm180 -55.91 -34.53 65.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.239 -1.153 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.741 HG21 ' HB1' ' A' ' 14' ' ' ALA . 54.9 t -58.82 -38.18 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.239 -0.913 . . . . 0.0 109.326 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.92 -34.32 77.86 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.483 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 42.5 m -63.38 -32.94 74.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.214 -0.928 . . . . 0.0 109.426 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.405 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 28.6 m -65.17 -32.57 74.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.231 -0.918 . . . . 0.0 109.472 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.494 HD23 HG21 ' A' ' 86' ' ' VAL . 59.3 mt -60.77 -44.93 96.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.484 ' O ' ' HB2' ' A' ' 31' ' ' LYS . 74.2 ttt180 -58.03 -41.46 83.25 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 109.654 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -69.01 -60.37 2.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.243 -0.911 . . . . 0.0 109.596 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.644 ' CD2' HG22 ' A' ' 86' ' ' VAL . 91.0 m-70 -54.77 -47.09 74.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.219 -0.925 . . . . 0.0 109.453 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.822 HG23 ' HB2' ' A' ' 35' ' ' MET . 87.4 mt -66.21 -44.67 91.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.298 -0.876 . . . . 0.0 109.634 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.484 ' HB2' ' O ' ' A' ' 27' ' ' ARG . 15.3 ttpp -59.27 -41.47 88.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.457 ' HA ' HD23 ' A' ' 32' ' ' LEU . 45.8 mt -70.63 -52.67 19.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.324 -0.86 . . . . 0.0 109.41 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.469 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 99.0 m-70 -74.79 -6.97 51.87 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.261 -0.9 . . . . 0.0 109.391 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.499 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.0 m-20 61.42 46.15 7.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.997 ' HG3' HD13 ' A' ' 82' ' ' LEU . 45.3 mmm -91.87 -2.32 56.9 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.605 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.443 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.2 mt-10 -44.28 -38.81 4.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.198 -0.939 . . . . 0.0 109.593 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -52.13 -43.11 63.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.24 -0.912 . . . . 0.0 109.347 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.645 HD12 ' HB3' ' A' ' 35' ' ' MET . 1.1 mt -73.01 -43.98 61.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.37 -0.831 . . . . 0.0 109.336 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.705 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.2 m-85 -73.19 137.32 44.98 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.282 -0.886 . . . . 0.0 109.427 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -111.78 -66.69 0.52 Allowed Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.415 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 82.6 tt0 -136.68 152.04 49.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.185 -1.185 . . . . 0.0 109.567 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.045 HG13 HG22 ' A' ' 71' ' ' VAL . 48.1 t -117.51 147.61 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.29 -0.881 . . . . 0.0 109.359 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.478 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 90.6 mtp -120.64 141.5 50.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.141 -0.974 . . . . 0.0 109.527 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.0 t -149.83 92.09 4.2 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.241 -0.912 . . . . 0.0 109.436 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.594 ' HG3' ' CE2' ' A' ' 65' ' ' PHE . 51.0 Cg_endo -70.25 -5.58 16.84 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.624 2.216 . . . . 0.0 111.792 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.477 ' HB ' ' NH1' ' A' ' 62' ' ' ARG . 3.7 p -82.12 156.72 24.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 47.72 64.46 1.61 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.54 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -59.48 -34.63 72.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.225 -0.922 . . . . 0.0 109.452 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.482 HG12 ' H ' ' A' ' 51' ' ' GLU . 36.7 t -119.26 131.22 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.269 -0.894 . . . . 0.0 109.455 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 71.1 t -72.66 -28.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.218 -0.926 . . . . 0.0 109.349 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.619 ' O ' HD13 ' A' ' 52' ' ' ILE . 5.5 tt0 -65.31 -46.97 78.2 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.619 HD13 ' O ' ' A' ' 51' ' ' GLU . 30.8 mm -121.46 96.96 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.277 -0.889 . . . . 0.0 109.436 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 74.4 mtp85 -46.54 -37.39 7.9 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.309 -0.87 . . . . 0.0 109.679 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 99.59 -169.68 22.56 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.84 51.01 4.4 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 -56.46 -38.76 72.11 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -1.128 . . . . 0.0 109.646 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -63.73 146.63 53.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.232 -0.917 . . . . 0.0 109.525 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 96.2 mtt-85 -58.41 -34.88 71.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.253 -0.904 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.482 ' O ' ' HG3' ' A' ' 61' ' ' GLU . 97.5 mttt -57.35 -36.02 70.67 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.279 -0.888 . . . . 0.0 109.416 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.404 ' C ' ' O ' ' A' ' 59' ' ' LYS . 24.8 m 45.46 38.59 3.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.865 . . . . 0.0 109.573 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.482 ' HG3' ' O ' ' A' ' 59' ' ' LYS . 94.9 mt-10 -102.48 157.54 16.85 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.211 -0.93 . . . . 0.0 109.403 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.477 ' NH1' ' HB ' ' A' ' 46' ' ' THR . 71.6 mtt85 -116.02 85.8 2.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.289 -0.882 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 95.3 mttt -63.11 -27.44 69.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.298 -0.876 . . . . 0.0 109.454 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -66.99 -39.03 87.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.243 -0.911 . . . . 0.0 109.536 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.611 ' HE2' HG22 ' A' ' 111' ' ' ILE . 81.4 m-85 -134.47 74.11 66.86 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.545 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -71.03 72.42 2.07 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.643 2.229 . . . . 0.0 111.902 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 78.36 26.19 59.92 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.606 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -109.68 126.27 53.51 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.238 -1.154 . . . . 0.0 109.515 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.546 HG23 ' HG3' ' A' ' 19' ' ' GLU . 86.3 t -134.15 142.72 40.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.388 -0.82 . . . . 0.0 109.505 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.85 HD21 HD12 ' A' ' 111' ' ' ILE . 3.8 mp -103.91 132.53 50.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.471 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.045 HG22 HG13 ' A' ' 42' ' ' VAL . 88.0 t -143.77 122.06 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.263 -0.898 . . . . 0.0 109.557 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.419 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 43.1 tt0 -78.36 130.33 36.02 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.224 -0.923 . . . . 0.0 109.187 179.845 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.57 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 41.1 ttp -162.67 154.67 18.49 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.514 ' N ' ' HG2' ' A' ' 73' ' ' MET . 59.2 t -69.81 151.19 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -0.948 . . . . 0.0 109.224 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.863 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -94.33 112.97 24.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 109.496 -179.965 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.619 ' ND2' HD22 ' A' ' 38' ' ' LEU . 42.0 p-10 -148.51 169.17 20.86 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 109.443 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.573 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 86.2 m-20 -72.38 -31.22 65.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -63.48 -61.45 2.33 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.286 -0.884 . . . . 0.0 109.513 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.467 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 17.4 p -53.36 -48.07 68.87 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.275 -0.891 . . . . 0.0 109.753 -179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.528 ' CZ2' ' HA ' ' A' ' 98' ' ' ASP . 39.1 t90 -44.03 -49.32 8.77 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.888 . . . . 0.0 109.581 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.573 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 89.8 m-70 -67.87 -39.38 83.74 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.206 -0.934 . . . . 0.0 109.471 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.997 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.4 OUTLIER -56.92 -45.2 82.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.726 -179.856 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.579 HG21 ' HZ ' ' A' ' 92' ' ' PHE . 78.0 t -62.48 -48.43 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.525 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 23.7 mtp85 -62.45 -37.24 85.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.57 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -66.63 -26.75 67.22 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -0.948 . . . . 0.0 109.491 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.847 HG23 ' O ' ' A' ' 82' ' ' LEU . 56.5 t -65.4 129.66 94.46 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.537 ' HD2' ' NE2' ' A' ' 29' ' ' HIS . 49.7 Cg_endo -70.17 161.03 47.48 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.703 2.269 . . . . 0.0 111.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.488 ' HA ' ' CD2' ' A' ' 15' ' ' PHE . 93.0 mtt-85 61.51 35.76 17.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.898 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 86' ' ' VAL . 91.5 t -129.39 115.51 35.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.288 -0.882 . . . . 0.0 109.566 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.511 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 84.3 mtp -69.97 -43.43 71.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.177 -0.952 . . . . 0.0 109.471 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.57 -146.99 14.03 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.579 ' HZ ' HG21 ' A' ' 83' ' ' VAL . 51.6 m-85 -107.45 163.08 13.35 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.292 -1.122 . . . . 0.0 109.574 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.628 HD11 ' HB2' ' A' ' 13' ' ' GLN . 31.9 mm -119.4 124.22 72.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 109.337 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . . . 147.87 -141.12 8.92 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' GLY . . . -43.43 -89.36 0.01 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 18.9 p -123.7 -179.33 4.33 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.297 -1.12 . . . . 0.0 109.652 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 m -90.9 22.03 3.84 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.338 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.528 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 91.4 m-20 -118.49 -23.52 7.13 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 3.3 mtm180 -155.98 96.86 2.3 Favored Pre-proline 0 N--CA 1.49 1.534 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.863 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 42.2 Cg_endo -65.13 119.99 7.13 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.865 2.376 . . . . 0.0 112.135 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.97 141.85 97.75 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.436 -0.79 . . . . 0.0 109.482 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.33 154.49 61.16 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.706 2.271 . . . . 0.0 111.854 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.873 HD11 HG22 ' A' ' 108' ' ' VAL . 34.0 pt -124.57 158.16 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.874 . . . . 0.0 109.378 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.453 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 42.2 m -69.51 148.18 49.83 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.916 . . . . 0.0 109.439 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -59.41 -37.74 78.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.197 -0.939 . . . . 0.0 109.399 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -61.3 -38.77 87.99 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.459 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.453 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 98.5 mt-10 -59.88 -42.21 93.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.873 HG22 HD11 ' A' ' 103' ' ' ILE . 78.3 t -61.61 -36.99 76.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.262 -0.899 . . . . 0.0 109.377 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -69.7 -33.24 72.24 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.265 -0.897 . . . . 0.0 109.396 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.413 ' HA ' ' OD1' ' A' ' 113' ' ' ASN . . . -65.69 -39.67 91.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.22 -0.925 . . . . 0.0 109.44 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.85 HD12 HD21 ' A' ' 70' ' ' LEU . 56.2 mt -56.84 -52.25 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.525 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . 0.436 ' HE3' ' CE ' ' A' ' 43' ' ' MET . 53.7 ttm -61.45 -38.18 86.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.265 -0.897 . . . . 0.0 109.512 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.413 ' OD1' ' HA ' ' A' ' 110' ' ' ALA . 23.4 m120 -53.31 -37.72 62.51 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.923 . . . . 0.0 109.42 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.3 mtt180 -51.33 -49.99 60.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.233 -0.917 . . . . 0.0 109.544 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 12.1 tp -47.78 -44.33 28.32 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.319 -0.863 . . . . 0.0 109.393 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -63.24 -26.99 69.04 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.384 -0.822 . . . . 0.0 109.525 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -77.44 128.34 34.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.248 -0.907 . . . . 0.0 109.493 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' A' ' 120' ' ' ASP . 37.0 t -118.69 133.1 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -0.92 . . . . 0.0 109.437 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -46.67 95.35 0.01 OUTLIER Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 118' ' ' VAL . 51.6 p30 -89.2 9.46 25.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.222 -1.164 . . . . 0.0 109.441 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 10.2 mttt -64.69 136.82 96.93 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.237 -0.914 . . . . 0.0 109.467 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.28 -19.69 38.06 Favored 'Trans proline' 0 C--O 1.214 -0.703 0 C-N-CA 122.706 2.271 . . . . 0.0 111.917 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 54.9 mtt-85 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.482 -179.988 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.9 mtp . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.299 0.571 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 34.5 t -121.29 138.67 54.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.25 -0.906 . . . . 0.0 109.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.19 -35.47 67.3 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -0.942 . . . . 0.0 109.427 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -124.17 89.7 51.56 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.248 -0.907 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.3 146.89 58.13 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.692 2.261 . . . . 0.0 111.774 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 80.9 mttt -79.81 136.7 36.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.169 -0.957 . . . . 0.0 109.5 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.403 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 46.0 mttp -103.76 146.89 27.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -0.938 . . . . 0.0 109.569 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.502 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 63.4 mtt180 -116.99 153.08 33.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.289 -0.882 . . . . 0.0 109.454 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.55 ' CG ' HG21 ' A' ' 108' ' ' VAL . 82.5 m95 -99.69 131.97 45.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -0.937 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.48 ' OH ' ' HB2' ' A' ' 75' ' ' MET . 62.5 m-85 -122.36 141.83 51.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.213 -0.929 . . . . 0.0 109.463 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.447 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.3 t -86.65 145.66 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.257 -0.902 . . . . 0.0 109.711 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -125.8 125.19 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.284 -0.885 . . . . 0.0 109.284 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.604 ' HB2' HD11 ' A' ' 93' ' ' ILE . 64.0 tp60 -87.58 131.96 34.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.609 -179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.517 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -139.33 164.82 28.82 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.324 -0.86 . . . . 0.0 109.418 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -68.61 140.34 55.53 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.283 -0.885 . . . . 0.0 109.448 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.8 m -66.57 149.42 50.49 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.307 -0.87 . . . . 0.0 109.499 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.63 -33.28 4.44 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.702 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.7 m-85 -109.45 8.46 25.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.18 -1.188 . . . . 0.0 109.506 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.47 ' OE2' HG22 ' A' ' 69' ' ' VAL . 84.4 tt0 -56.76 -39.34 73.84 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.472 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.62 -52.29 44.21 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 56.7 ttt-85 -62.62 -38.74 91.4 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.246 -1.149 . . . . 0.0 109.491 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.702 HG23 ' O ' ' A' ' 18' ' ' PHE . 79.7 t -56.01 -39.88 60.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.88 . . . . 0.0 109.424 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.08 -37.88 89.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.267 -0.896 . . . . 0.0 109.413 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.5 m -65.16 -38.94 92.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.223 -0.923 . . . . 0.0 109.438 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.565 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 97.1 p -60.02 -38.42 82.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.462 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.403 ' CD2' HG21 ' A' ' 86' ' ' VAL . 44.4 mt -56.66 -49.45 75.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -0.871 . . . . 0.0 109.469 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 53.3 ttp85 -65.79 -37.06 85.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.515 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 80.1 tt0 -66.27 -44.76 82.68 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.26 -0.9 . . . . 0.0 109.499 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 1.067 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.9 m-70 -71.82 -51.5 22.2 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.457 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.779 HG22 ' HG3' ' A' ' 36' ' ' GLU . 83.4 mt -56.91 -45.3 83.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.234 -0.917 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 39.8 tttt -56.59 -48.46 77.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -0.904 . . . . 0.0 109.465 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.465 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 48.6 mt -64.84 -51.24 63.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.205 -0.934 . . . . 0.0 109.45 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB3' ' SD ' ' A' ' 35' ' ' MET . 97.8 m-70 -74.86 -2.08 25.2 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.241 -0.912 . . . . 0.0 109.575 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.466 ' N ' ' O ' ' A' ' 30' ' ' ILE . 55.2 t30 55.0 45.44 26.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.216 -0.927 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.73 ' HG3' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -98.66 5.17 47.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.221 -0.925 . . . . 0.0 109.521 179.982 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.779 ' HG3' HG22 ' A' ' 30' ' ' ILE . 97.9 mt-10 -61.02 -16.95 49.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 109.447 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -62.26 -40.57 96.64 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.292 -0.88 . . . . 0.0 109.395 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.896 ' HB2' HG12 ' A' ' 74' ' ' VAL . 0.3 OUTLIER -86.37 -31.39 21.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.258 -0.901 . . . . 0.0 109.353 179.887 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.524 ' CD1' ' HB2' ' A' ' 73' ' ' MET . 42.6 m-85 -76.44 132.08 39.44 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -96.67 -78.12 1.39 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.8 tp10 -139.44 136.53 34.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 71' ' ' VAL . 10.0 p -97.79 143.73 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.265 -0.897 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.627 ' O ' HG13 ' A' ' 69' ' ' VAL . 58.3 mtt -108.53 141.21 40.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.479 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.54 ' O ' HG12 ' A' ' 44' ' ' VAL . 47.8 t -137.35 83.83 25.37 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.39 57.27 1.75 Allowed 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 122.684 2.256 . . . . 0.0 111.779 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 19.2 p -132.97 162.45 31.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -90.98 138.75 31.37 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.18 -0.95 . . . . 0.0 109.494 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -65.11 -33.7 76.66 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.229 -0.919 . . . . 0.0 109.436 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.6 p -134.57 147.15 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.269 -0.894 . . . . 0.0 109.406 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 23.6 m -122.81 156.26 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.494 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.48 ' OE2' ' NE ' ' A' ' 53' ' ' ARG . 86.0 tt0 -106.68 130.81 54.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.288 -0.883 . . . . 0.0 109.48 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 80.4 mt -66.96 -38.01 80.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.477 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.48 ' NE ' ' OE2' ' A' ' 51' ' ' GLU . 71.9 mtm-85 -60.2 152.15 25.38 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.31 -0.869 . . . . 0.0 109.474 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 102.74 -6.97 52.68 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 171.92 177.09 41.27 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.447 ' O ' ' O ' ' A' ' 59' ' ' LYS . 94.5 mm-40 -122.88 153.07 40.13 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.31 -1.112 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.7 mtp85 -60.8 -30.15 69.88 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.436 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.4 tpt85 -62.75 -38.15 89.4 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.266 -0.896 . . . . 0.0 109.509 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.447 ' O ' ' O ' ' A' ' 56' ' ' GLN . 40.4 tttt -127.9 131.52 49.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.284 -0.885 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.5 t -106.54 137.23 44.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.224 -0.923 . . . . 0.0 109.523 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 85.9 mt-10 -122.15 47.2 1.95 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.393 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 84.1 mtm180 -120.49 142.14 49.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.339 -0.851 . . . . 0.0 109.507 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 65.6 mttm -97.73 9.9 41.43 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.328 -0.857 . . . . 0.0 109.637 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.731 ' CE1' HD12 ' A' ' 115' ' ' LEU . 61.6 m-85 -66.65 155.7 37.22 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.232 -0.917 . . . . 0.0 109.423 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.505 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 9.7 p90 -117.49 81.52 14.29 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.929 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.83 155.85 64.66 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.682 2.255 . . . . 0.0 111.764 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.45 1.58 47.14 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.432 ' CZ ' ' OE1' ' A' ' 13' ' ' GLN . 7.2 m-85 -121.74 122.68 40.07 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.282 -1.128 . . . . 0.0 109.388 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 43' ' ' MET . 58.0 t -130.31 142.65 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.913 . . . . 0.0 109.514 -179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 1.035 HD21 HD12 ' A' ' 111' ' ' ILE . 3.6 mp -102.77 129.13 49.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.304 -0.872 . . . . 0.0 109.428 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 42' ' ' VAL . 56.7 t -137.43 127.35 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 109.559 -179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.403 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 41.6 tt0 -84.22 138.75 32.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.284 -0.885 . . . . 0.0 109.32 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.865 ' CG ' HD12 ' A' ' 38' ' ' LEU . 6.1 tmm? -177.89 149.09 0.56 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.097 -1.002 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.896 HG12 ' HB2' ' A' ' 38' ' ' LEU . 7.4 p -75.03 122.87 29.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.186 -0.946 . . . . 0.0 109.458 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.641 ' HA ' ' HE3' ' A' ' 75' ' ' MET . 0.8 OUTLIER -52.82 112.97 0.94 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.682 -179.824 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 48.1 p-10 -146.2 161.79 39.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.371 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.488 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 88.2 m-20 -72.37 -27.48 62.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.185 -0.947 . . . . 0.0 109.466 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.542 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -62.52 -62.94 1.4 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.456 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 24.3 p -53.7 -51.43 63.27 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.263 -0.898 . . . . 0.0 109.56 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.527 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 30.7 t90 -44.31 -55.84 4.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.551 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.488 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 87.7 m-70 -59.7 -40.79 89.12 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.915 . . . . 0.0 109.521 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 1.067 HD11 ' HB3' ' A' ' 29' ' ' HIS . 65.1 tp -60.3 -36.45 77.91 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.262 -0.899 . . . . 0.0 109.657 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.947 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 74.1 t -61.6 -44.69 99.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.525 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 48.5 tpt85 -57.92 -40.81 81.32 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.227 -0.92 . . . . 0.0 109.473 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.4 p -64.45 -27.53 69.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.226 -0.921 . . . . 0.0 109.481 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.752 ' HB ' HG21 ' A' ' 89' ' ' VAL . 79.1 t -61.84 123.18 76.29 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.476 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.447 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.7 Cg_endo -70.4 150.42 64.28 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.602 2.202 . . . . 0.0 111.769 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.447 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 31.8 mtt-85 62.05 51.11 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.184 -0.947 . . . . 0.0 109.434 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.752 HG21 ' HB ' ' A' ' 86' ' ' VAL . 66.9 t -126.3 116.84 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.238 -0.914 . . . . 0.0 109.488 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.517 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.9 mmm -65.57 -45.66 82.45 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.427 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.42 -148.32 18.67 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.947 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 3.6 m-85 -117.84 164.49 14.95 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.238 -1.154 . . . . 0.0 109.54 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.604 HD11 ' HB2' ' A' ' 13' ' ' GLN . 9.2 mm -121.76 120.89 62.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.355 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 177.88 -144.13 6.4 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.27 -43.84 37.16 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 p -129.39 174.34 9.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.264 -1.139 . . . . 0.0 109.549 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 72.3 m -89.86 17.89 6.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.158 -0.964 . . . . 0.0 109.369 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.527 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.7 m-20 -127.84 -30.73 2.48 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.518 -0.739 . . . . 0.0 109.273 179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 8.4 mtt-85 -134.57 91.51 21.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.309 -0.869 . . . . 0.0 108.916 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.535 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 46.6 Cg_endo -67.86 116.66 4.41 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.634 2.223 . . . . 0.0 112.001 -179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.42 146.5 79.16 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.331 -0.856 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.502 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 50.0 Cg_endo -70.14 154.58 66.1 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.7 2.267 . . . . 0.0 111.759 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.682 HD11 HG22 ' A' ' 108' ' ' VAL . 28.7 pt -118.02 158.36 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.181 -0.949 . . . . 0.0 109.46 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 44.2 m -70.66 152.27 44.04 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.33 -0.856 . . . . 0.0 109.417 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -57.22 -38.67 74.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.212 -0.93 . . . . 0.0 109.359 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -59.62 -38.29 80.92 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.204 -0.935 . . . . 0.0 109.389 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 75.2 mm-40 -56.92 -45.77 82.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.315 -0.866 . . . . 0.0 109.408 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.72 HG13 ' CD2' ' A' ' 70' ' ' LEU . 96.4 t -60.07 -40.83 84.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.364 -0.835 . . . . 0.0 109.368 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -65.81 -36.76 84.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.399 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.88 -53.49 57.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 109.463 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 1.035 HD12 HD21 ' A' ' 70' ' ' LEU . 49.1 mt -48.03 -54.05 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.183 -0.948 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.2 mtp -60.7 -37.59 82.17 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.27 -0.894 . . . . 0.0 109.348 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -56.83 -41.93 78.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.272 -0.893 . . . . 0.0 109.401 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.405 ' O ' ' C ' ' A' ' 115' ' ' LEU . 51.9 mtt180 -53.34 -52.94 57.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.398 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.731 HD12 ' CE1' ' A' ' 64' ' ' PHE . 12.6 tp -45.44 -45.25 12.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.449 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . 0.794 ' O ' HG23 ' A' ' 118' ' ' VAL . 50.4 tt0 -60.82 -36.0 77.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.239 -0.913 . . . . 0.0 109.443 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.427 ' C ' HG23 ' A' ' 118' ' ' VAL . 64.4 tt0 -60.46 -34.6 74.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.233 -0.917 . . . . 0.0 109.469 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.794 HG23 ' O ' ' A' ' 116' ' ' GLN . 1.9 t 58.21 16.93 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.385 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 57.49 -106.05 0.69 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 121' ' ' LYS . 61.9 t0 -144.23 152.72 41.23 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.296 -1.12 . . . . 0.0 109.481 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.51 ' N ' ' OD1' ' A' ' 120' ' ' ASP . 7.0 ttmt -121.39 68.48 20.33 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.52 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.77 146.07 59.01 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.688 2.259 . . . . 0.0 111.782 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 47.4 ttt85 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.5 -179.919 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.3 mtt . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.3 m -57.05 -35.57 69.47 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 75.7 mm-40 -59.29 140.72 55.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.486 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB1' ' HD2' ' A' ' 5' ' ' PRO . . . -74.92 161.34 77.99 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.517 ' HD2' ' HB1' ' A' ' 4' ' ' ALA . 48.8 Cg_endo -70.12 147.34 60.32 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.732 2.288 . . . . 0.0 111.738 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 70.7 tttt -122.28 138.06 54.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.926 . . . . 0.0 109.428 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.446 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 23.4 mmtp -90.61 135.11 33.92 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.154 -0.966 . . . . 0.0 109.449 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.531 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 93.6 mtt180 -125.38 152.94 44.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.375 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.48 ' CB ' HG21 ' A' ' 108' ' ' VAL . 85.6 m95 -96.4 129.38 43.77 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.495 ' CE1' ' HA ' ' A' ' 102' ' ' PRO . 64.0 m-85 -129.07 154.19 46.91 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.264 -0.898 . . . . 0.0 109.408 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 22.3 t -99.54 143.59 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.326 -0.858 . . . . 0.0 109.57 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.3 t -117.62 125.87 74.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.379 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.697 ' HB2' HD11 ' A' ' 93' ' ' ILE . 52.3 tt0 -88.79 135.35 33.57 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.158 -0.964 . . . . 0.0 109.521 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.654 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -140.04 -165.24 1.86 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.425 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -104.55 139.8 38.91 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.186 -0.946 . . . . 0.0 109.468 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.2 m -56.61 150.87 14.77 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 109.571 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.03 -34.48 4.25 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.889 ' O ' HG23 ' A' ' 22' ' ' VAL . 77.5 m-85 -118.98 10.18 12.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.309 -1.113 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.458 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.8 tt0 -58.02 -29.31 65.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.213 -0.929 . . . . 0.0 109.534 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -77.62 -53.05 5.2 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -59.63 -39.43 84.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.193 -1.181 . . . . 0.0 109.46 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.889 HG23 ' O ' ' A' ' 18' ' ' PHE . 99.0 t -50.5 -43.84 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.197 -0.939 . . . . 0.0 109.373 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.32 -41.52 85.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.469 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.9 m -64.62 -36.36 83.99 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.538 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 37.5 m -64.65 -37.78 88.74 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.173 -0.954 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.707 ' CD2' HG21 ' A' ' 86' ' ' VAL . 51.2 mt -53.77 -59.71 4.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.215 -0.928 . . . . 0.0 109.579 -179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.412 ' C ' ' O ' ' A' ' 26' ' ' LEU . 71.9 ttt180 -42.98 -51.11 5.75 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.336 -0.852 . . . . 0.0 109.788 -179.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.437 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 94.9 mt-10 -54.1 -41.79 68.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.138 -0.976 . . . . 0.0 109.503 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.82 ' HB3' HD21 ' A' ' 82' ' ' LEU . 98.9 m-70 -66.96 -31.1 71.46 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.419 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 1.025 HD12 ' CD2' ' A' ' 39' ' ' PHE . 13.1 mm -67.32 -52.65 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.537 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.8 mttt -64.21 -43.38 95.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.262 -0.899 . . . . 0.0 109.651 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.453 ' HA ' HD23 ' A' ' 32' ' ' LEU . 27.3 mt -60.46 -51.16 70.64 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.527 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.622 ' CD2' ' CD1' ' A' ' 82' ' ' LEU . 92.6 m-70 -87.27 10.25 17.69 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.264 -0.898 . . . . 0.0 109.55 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 18.1 m120 49.37 49.45 19.75 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.189 -0.944 . . . . 0.0 109.434 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.792 ' CG ' HD21 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -106.48 21.21 17.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.244 -0.91 . . . . 0.0 109.425 -179.926 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.49 ' N ' HG22 ' A' ' 30' ' ' ILE . 70.7 mm-40 -66.22 -12.53 56.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.199 -0.938 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.38 -52.67 24.81 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.288 -0.882 . . . . 0.0 109.523 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.792 HD21 ' CG ' ' A' ' 35' ' ' MET . 0.6 OUTLIER -75.96 -37.77 58.24 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.33 -0.856 . . . . 0.0 109.781 -179.825 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 1.025 ' CD2' HD12 ' A' ' 30' ' ' ILE . 52.0 m-85 -76.68 139.91 40.7 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.177 -0.952 . . . . 0.0 109.253 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.05 -80.22 0.62 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.508 ' HG3' ' N ' ' A' ' 42' ' ' VAL . 45.9 tp10 -131.49 152.74 50.46 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.279 -1.13 . . . . 0.0 109.569 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.077 HG13 HG22 ' A' ' 71' ' ' VAL . 91.9 t -119.42 154.43 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.289 -0.882 . . . . 0.0 109.383 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.773 ' HE1' HG11 ' A' ' 108' ' ' VAL . 61.2 mtm -135.68 145.11 46.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.235 -0.916 . . . . 0.0 109.466 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.566 HG12 ' H ' ' A' ' 46' ' ' THR . 99.1 t -122.98 121.52 27.24 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.211 -0.931 . . . . 0.0 109.546 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -70.25 -14.68 34.79 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.679 2.252 . . . . 0.0 111.876 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.566 ' H ' HG12 ' A' ' 44' ' ' VAL . 7.6 p -91.52 158.19 16.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.213 -0.929 . . . . 0.0 109.588 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -118.94 145.94 45.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.502 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -118.91 148.32 43.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.242 -0.911 . . . . 0.0 109.468 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.688 HG12 HG23 ' A' ' 50' ' ' VAL . 46.9 t -127.35 127.26 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.172 -0.955 . . . . 0.0 109.474 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.688 HG23 HG12 ' A' ' 49' ' ' VAL . 12.2 t 45.9 25.05 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.337 -0.852 . . . . 0.0 109.585 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' A' ' 50' ' ' VAL . 82.8 tt0 57.19 104.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.238 -0.914 . . . . 0.0 109.456 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.687 HG23 ' O ' ' A' ' 52' ' ' ILE . 14.0 tt -132.37 103.86 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.224 -0.922 . . . . 0.0 109.38 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 92.5 mtt-85 -47.52 148.35 1.44 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.185 -0.947 . . . . 0.0 109.523 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -139.69 168.26 25.04 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.05 -7.78 64.77 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 -57.19 -35.12 69.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.166 -1.197 . . . . 0.0 109.445 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 71.8 mtt85 -121.55 149.54 42.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.172 -0.955 . . . . 0.0 109.528 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.9 mtm-85 -57.07 -31.0 64.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.882 . . . . 0.0 109.536 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 73.5 tttt -68.76 133.13 47.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.242 -0.912 . . . . 0.0 109.44 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -111.15 137.69 48.52 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.255 -0.903 . . . . 0.0 109.462 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -65.85 -31.2 72.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.37 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 94.4 mtt180 -127.66 132.01 49.76 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.271 -0.893 . . . . 0.0 109.499 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -108.32 28.98 7.78 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.399 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -107.1 129.56 54.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.315 -0.865 . . . . 0.0 109.506 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 56.7 62.71 6.0 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.526 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.52 94.66 0.6 Allowed 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.657 2.238 . . . . 0.0 111.777 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 76.6 32.23 51.46 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.458 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 1.4 m-85 -111.58 116.03 30.16 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.26 -1.141 . . . . 0.0 109.536 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 70' ' ' LEU . 48.7 t -126.98 151.91 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.27 -0.894 . . . . 0.0 109.57 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.847 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.3 mp -108.05 129.02 55.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.211 -0.93 . . . . 0.0 109.417 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.077 HG22 HG13 ' A' ' 42' ' ' VAL . 90.6 t -138.76 125.21 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.268 -0.895 . . . . 0.0 109.722 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.446 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 43.3 tt0 -78.12 120.14 22.52 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.248 -0.907 . . . . 0.0 109.08 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.682 ' CG ' HD12 ' A' ' 38' ' ' LEU . 8.0 tmm? -167.97 149.24 5.24 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.231 -0.918 . . . . 0.0 109.569 -179.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.453 ' O ' ' SD ' ' A' ' 73' ' ' MET . 45.3 t -85.43 128.56 39.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.224 -0.923 . . . . 0.0 109.163 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.519 ' SD ' ' CG ' ' A' ' 100' ' ' PRO . 11.7 mmt -64.72 107.69 1.5 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.276 -0.89 . . . . 0.0 109.705 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.604 ' ND2' HD22 ' A' ' 38' ' ' LEU . 53.0 p-10 -128.77 -179.66 5.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -75.09 -23.2 57.96 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.254 -0.904 . . . . 0.0 109.852 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.647 ' HB1' ' HE3' ' A' ' 35' ' ' MET . . . -82.27 -67.11 0.81 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.201 -0.937 . . . . 0.0 109.621 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.533 ' HB3' HD13 ' A' ' 38' ' ' LEU . 6.3 p -49.62 -49.78 45.53 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.41 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 48.4 t90 -51.66 -59.56 4.14 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.351 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -58.95 -37.91 77.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.296 -0.878 . . . . 0.0 109.459 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.82 HD21 ' HB3' ' A' ' 29' ' ' HIS . 39.6 tp -63.61 -37.62 88.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.208 -0.933 . . . . 0.0 109.401 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.94 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 54.8 t -56.92 -50.13 76.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.288 -0.883 . . . . 0.0 109.468 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 77.3 ttt180 -55.01 -41.54 71.44 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.2 -0.937 . . . . 0.0 109.499 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.2 t -57.08 -33.15 66.99 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.285 -0.885 . . . . 0.0 109.497 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.707 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.6 t -61.08 121.91 65.85 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.269 -0.895 . . . . 0.0 109.387 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.443 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.5 Cg_endo -70.32 158.29 56.69 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.691 2.261 . . . . 0.0 111.777 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.569 ' HD3' ' CG ' ' A' ' 18' ' ' PHE . 8.9 mtt85 63.11 45.77 5.01 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.932 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.512 HG21 ' HB ' ' A' ' 86' ' ' VAL . 96.8 t -130.92 118.89 43.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.172 -0.955 . . . . 0.0 109.549 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.45 ' SD ' ' HG2' ' A' ' 13' ' ' GLN . 85.9 mtp -68.83 -44.57 73.16 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.2 -0.937 . . . . 0.0 109.404 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.71 -151.8 22.35 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.94 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.3 m-85 -111.8 164.25 13.27 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.155 -1.203 . . . . 0.0 109.502 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.697 HD11 ' HB2' ' A' ' 13' ' ' GLN . 20.9 mm -118.46 120.3 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.283 -0.886 . . . . 0.0 109.647 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.489 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 178.64 -149.76 9.17 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.46 -38.8 91.16 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.688 HG23 ' H ' ' A' ' 98' ' ' ASP . 10.3 t -140.53 176.57 8.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -1.186 . . . . 0.0 109.47 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.8 p -92.62 17.99 9.38 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 109.414 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.688 ' H ' HG23 ' A' ' 96' ' ' THR . 84.6 m-20 -121.72 -14.35 8.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.515 -0.741 . . . . 0.0 109.264 179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.481 ' H ' HG23 ' A' ' 96' ' ' THR . 0.0 OUTLIER -161.42 99.24 1.25 Allowed Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.349 -0.844 . . . . 0.0 109.008 179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.519 ' CG ' ' SD ' ' A' ' 75' ' ' MET . 46.4 Cg_endo -68.09 120.51 7.49 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.706 2.27 . . . . 0.0 112.015 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -63.27 138.31 97.31 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.293 -0.88 . . . . 0.0 109.39 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.531 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.51 153.74 65.28 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.649 2.233 . . . . 0.0 111.765 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.774 HD11 HG22 ' A' ' 108' ' ' VAL . 35.1 pt -124.32 156.23 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.256 -0.903 . . . . 0.0 109.44 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.456 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 32.3 m -71.97 151.11 43.49 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.311 -0.868 . . . . 0.0 109.423 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -54.76 -40.99 69.94 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.358 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -59.31 -38.64 80.76 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.356 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.456 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 77.0 mm-40 -58.86 -44.36 91.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.276 -0.89 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.774 HG22 HD11 ' A' ' 103' ' ' ILE . 58.1 t -57.93 -39.33 71.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -66.42 -40.95 89.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.261 -0.899 . . . . 0.0 109.416 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -63.43 -44.63 94.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.193 -0.942 . . . . 0.0 109.42 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.427 HG13 ' O ' ' A' ' 107' ' ' GLU . 68.8 mt -52.48 -51.39 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.332 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 88.6 mtp -58.85 -38.3 78.42 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -56.88 -35.58 69.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.3 -0.875 . . . . 0.0 109.456 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.5 ' O ' ' N ' ' A' ' 117' ' ' GLN . 99.4 mtt180 -53.92 -44.68 70.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.229 -0.919 . . . . 0.0 109.389 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.402 ' C ' ' O ' ' A' ' 114' ' ' ARG . 8.5 tp -44.05 -46.85 8.67 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.239 -0.913 . . . . 0.0 109.384 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -60.29 -26.64 66.67 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.228 -0.92 . . . . 0.0 109.503 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.5 ' N ' ' O ' ' A' ' 114' ' ' ARG . 52.6 tt0 -83.27 126.31 32.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.207 -0.933 . . . . 0.0 109.462 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 26.5 t -65.42 -32.0 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.315 -0.865 . . . . 0.0 109.506 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 89.9 -3.49 82.9 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -55.76 -39.79 71.7 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.194 -1.18 . . . . 0.0 109.502 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -76.51 142.49 70.87 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.264 -0.898 . . . . 0.0 109.554 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.01 145.6 56.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.745 2.297 . . . . 0.0 111.753 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.445 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.0 mtp . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.4 t -56.99 -37.94 72.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.251 -0.906 . . . . 0.0 109.638 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -54.65 -36.81 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.228 -0.92 . . . . 0.0 109.525 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -121.59 107.52 36.33 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.314 -0.867 . . . . 0.0 109.515 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.83 139.19 39.37 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.682 2.255 . . . . 0.0 111.777 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.449 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 29.5 mttt -122.87 155.26 37.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.273 -0.892 . . . . 0.0 109.489 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 8.6 mmtp 64.45 53.81 1.59 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 109.404 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.418 ' HD3' ' HA ' ' A' ' 8' ' ' ARG . 17.1 mmt85 -110.48 153.13 25.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.334 -0.854 . . . . 0.0 109.455 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.511 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 56.5 m95 -103.81 129.24 51.23 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.928 . . . . 0.0 109.506 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.424 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 87.1 m-85 -124.18 163.83 20.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.208 -0.932 . . . . 0.0 109.407 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.49 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 24.5 t -98.7 147.33 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 50.6 t -124.83 123.64 66.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.329 -0.857 . . . . 0.0 109.331 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.821 ' HB2' HD11 ' A' ' 93' ' ' ILE . 6.1 tt0 -90.8 137.83 32.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.242 -0.911 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.683 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -145.45 159.98 42.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -67.9 143.26 55.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.164 -0.96 . . . . 0.0 109.56 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 46.0 m -59.14 147.62 34.44 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.44 -33.54 4.31 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.756 ' O ' HG23 ' A' ' 22' ' ' VAL . 99.1 m-85 -107.22 5.21 27.47 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.247 -1.149 . . . . 0.0 109.562 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.467 ' OE2' ' HG3' ' A' ' 45' ' ' PRO . 85.1 tt0 -53.55 -36.23 61.62 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.361 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.36 -58.64 3.08 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 45.4 ttm105 -56.5 -42.43 78.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.415 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 18' ' ' PHE . 53.2 t -49.14 -47.57 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.207 -0.933 . . . . 0.0 109.351 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.81 -44.66 82.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.265 -0.897 . . . . 0.0 109.411 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -64.09 -45.52 88.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.324 -0.86 . . . . 0.0 109.389 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.467 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 50.8 m -52.03 -56.45 14.24 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 tp -48.15 -55.52 10.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.307 -0.871 . . . . 0.0 109.365 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.665 ' HA ' HD12 ' A' ' 30' ' ' ILE . 25.2 ttt85 -53.74 -30.65 45.16 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.187 -0.946 . . . . 0.0 109.136 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.467 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.9 tt0 -63.1 -44.45 95.65 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.309 -0.87 . . . . 0.0 109.36 179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.756 ' HB3' HD11 ' A' ' 82' ' ' LEU . 74.3 m-70 -75.79 -33.92 60.18 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.273 -0.892 . . . . 0.0 109.328 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.919 HG23 ' HB2' ' A' ' 35' ' ' MET . 79.8 mt -54.93 -48.83 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.283 -0.885 . . . . 0.0 109.292 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.2 tttt -60.26 -43.15 96.42 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.316 -0.865 . . . . 0.0 109.531 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.426 ' HA ' HD23 ' A' ' 32' ' ' LEU . 61.5 mt -64.2 -50.81 66.62 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.492 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.474 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 91.5 m-70 -82.15 3.1 28.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.244 -0.91 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.409 ' N ' ' O ' ' A' ' 30' ' ' ILE . 21.4 m120 59.4 50.62 7.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.195 -0.941 . . . . 0.0 109.338 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.93 ' HG3' HD22 ' A' ' 82' ' ' LEU . 68.5 mmm -99.58 3.92 45.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.29 -0.881 . . . . 0.0 109.706 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.471 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 97.2 mt-10 -54.89 -34.33 62.91 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.173 -0.954 . . . . 0.0 109.451 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -60.88 -42.47 98.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.894 . . . . 0.0 109.358 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.555 ' CD1' ' CE ' ' A' ' 35' ' ' MET . 1.1 mt -70.88 -50.33 36.27 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.311 -0.868 . . . . 0.0 109.347 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 30' ' ' ILE . 98.9 m-85 -75.99 134.47 40.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.385 -0.822 . . . . 0.0 109.418 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.08 -68.77 0.59 Allowed Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.609 -1.397 . . . . 0.0 109.609 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.433 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 83.3 tt0 -127.6 155.9 43.13 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -1.128 . . . . 0.0 109.533 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.975 HG13 HG22 ' A' ' 71' ' ' VAL . 51.9 t -121.11 150.39 24.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.388 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.767 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -120.98 161.86 20.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.248 -0.907 . . . . 0.0 109.473 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.898 HG12 ' H ' ' A' ' 46' ' ' THR . 75.5 t -157.59 131.03 4.67 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.304 -0.873 . . . . 0.0 109.378 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.574 ' HB3' ' CE2' ' A' ' 65' ' ' PHE . 50.1 Cg_endo -69.69 0.27 5.83 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 122.717 2.278 . . . . 0.0 112.019 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.898 ' H ' HG12 ' A' ' 44' ' ' VAL . 1.3 p -131.95 161.67 32.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.943 . . . . 0.0 109.424 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 54.7 mp0 -51.36 141.02 16.11 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.146 -0.971 . . . . 0.0 109.444 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -60.04 -34.78 73.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.439 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 14.8 p -138.72 142.9 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.31 -0.869 . . . . 0.0 109.384 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 19.4 t -119.74 137.49 53.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.205 -0.935 . . . . 0.0 109.533 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -116.37 130.26 56.68 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.399 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 81.5 mt -64.4 -36.28 76.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 24.6 mmt180 -56.05 -33.68 65.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.201 -0.937 . . . . 0.0 109.528 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -50.62 -32.4 24.29 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -164.79 105.58 0.25 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -57.6 -37.03 72.53 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.252 -1.146 . . . . 0.0 109.511 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 13.3 mtt-85 -68.13 148.72 50.53 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.266 -0.896 . . . . 0.0 109.476 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 22.3 ttt180 -101.39 140.36 35.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.27 -0.894 . . . . 0.0 109.341 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 20.6 mmtp -113.72 150.5 33.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.463 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.452 ' O ' ' O ' ' A' ' 61' ' ' GLU . 21.1 t -55.09 -28.45 52.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.479 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.452 ' O ' ' O ' ' A' ' 60' ' ' SER . 46.9 mt-10 61.13 125.78 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -0.89 . . . . 0.0 109.51 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 68.1 mtm180 -128.75 145.82 51.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.293 -0.879 . . . . 0.0 109.458 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.476 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 28.3 mttp -124.49 125.43 44.22 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.973 . . . . 0.0 109.487 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.537 ' HB2' ' CE1' ' A' ' 65' ' ' PHE . 97.1 m-85 -57.53 -45.11 85.44 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.477 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.621 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 0.3 OUTLIER -136.16 79.58 43.31 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.317 -0.865 . . . . 0.0 109.512 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.476 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 50.4 Cg_endo -70.03 143.58 49.99 Favored 'Trans proline' 0 C--O 1.217 -0.574 0 C-N-CA 122.669 2.246 . . . . 0.0 111.855 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 81.03 10.09 85.39 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.563 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -121.28 119.04 31.08 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.231 -1.158 . . . . 0.0 109.511 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.767 HG13 ' O ' ' A' ' 43' ' ' MET . 95.1 t -132.03 142.35 43.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.226 -0.921 . . . . 0.0 109.449 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.842 HD22 ' N ' ' A' ' 70' ' ' LEU . 2.4 mm? -106.37 129.55 54.35 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.383 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.975 HG22 HG13 ' A' ' 42' ' ' VAL . 84.4 t -139.69 128.88 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.941 . . . . 0.0 109.541 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.415 ' OE1' ' HA ' ' A' ' 7' ' ' LYS . 6.6 tt0 -76.94 137.7 39.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 109.256 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.713 ' HE2' ' HB3' ' A' ' 79' ' ' SER . 7.5 tmm? 177.83 151.19 0.23 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.182 -0.949 . . . . 0.0 109.486 -179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.454 ' O ' ' SD ' ' A' ' 73' ' ' MET . 40.4 t -85.22 124.03 39.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.915 . . . . 0.0 109.458 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.684 ' HE3' ' HG3' ' A' ' 100' ' ' PRO . 10.4 mmt -66.43 120.48 13.43 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.298 -0.876 . . . . 0.0 109.439 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.495 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.7 p-10 -150.3 179.16 8.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.261 -0.9 . . . . 0.0 109.47 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.576 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 93.5 m-20 -65.58 -35.19 80.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.348 -0.845 . . . . 0.0 109.548 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.412 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -74.02 -72.43 0.27 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.193 -0.942 . . . . 0.0 109.653 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.713 ' HB3' ' HE2' ' A' ' 73' ' ' MET . 3.7 m -45.2 -52.81 8.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.262 -0.899 . . . . 0.0 109.608 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.452 ' CB ' ' O ' ' A' ' 76' ' ' ASN . 80.2 t90 -55.53 -53.07 60.93 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.242 -0.911 . . . . 0.0 109.571 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.576 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 24.8 m-70 -62.81 -34.84 78.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.256 -0.903 . . . . 0.0 109.524 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.93 HD22 ' HG3' ' A' ' 35' ' ' MET . 52.5 tp -58.05 -42.34 85.22 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.319 -0.863 . . . . 0.0 109.585 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.716 ' CG1' HG11 ' A' ' 89' ' ' VAL . 79.5 t -57.88 -45.53 87.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.214 -0.929 . . . . 0.0 109.537 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 59.8 ttp180 -67.36 -29.84 69.48 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.203 -0.936 . . . . 0.0 109.461 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 67.5 m -59.59 -50.76 72.64 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.334 -0.854 . . . . 0.0 109.614 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.626 HG13 HG21 ' A' ' 89' ' ' VAL . 7.4 p -78.78 128.67 76.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.242 -0.911 . . . . 0.0 109.677 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.569 ' O ' HG23 ' A' ' 89' ' ' VAL . 50.3 Cg_endo -70.13 -171.06 0.46 Allowed 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.752 2.301 . . . . 0.0 111.664 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.499 ' HB3' HG22 ' A' ' 22' ' ' VAL . 31.6 mtt-85 61.38 21.7 12.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.877 . . . . 0.0 109.48 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.716 HG11 ' CG1' ' A' ' 83' ' ' VAL . 43.6 t -119.78 107.93 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.211 -0.93 . . . . 0.0 109.447 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.479 ' CE ' ' OE1' ' A' ' 13' ' ' GLN . 74.6 mtp -60.22 -43.43 96.03 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.177 -0.952 . . . . 0.0 109.468 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.07 -149.41 21.21 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.711 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 45.4 m-85 -110.36 160.65 16.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.277 -1.131 . . . . 0.0 109.464 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.821 HD11 ' HB2' ' A' ' 13' ' ' GLN . 22.1 mm -115.29 129.95 70.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.385 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 95' ' ' GLY . . . 140.53 -141.47 11.44 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 94' ' ' GLY . . . -44.0 -89.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.0 p -125.16 -178.25 4.14 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.247 -1.149 . . . . 0.0 109.435 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.2 p -90.38 21.57 3.81 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.232 -0.918 . . . . 0.0 109.351 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.2 m-20 -117.55 -22.94 7.88 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.417 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -154.82 94.68 2.68 Favored Pre-proline 0 N--CA 1.488 1.438 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 179.603 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.684 ' HG3' ' HE3' ' A' ' 75' ' ' MET . 41.4 Cg_endo -63.85 118.4 5.34 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.922 2.414 . . . . 0.0 112.138 -179.467 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -58.44 142.1 82.6 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.493 -0.754 . . . . 0.0 109.59 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.54 153.34 65.43 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.784 2.322 . . . . 0.0 111.814 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.558 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -126.13 156.78 36.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.282 -0.886 . . . . 0.0 109.434 179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 49.8 m -70.46 143.55 51.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.262 -0.899 . . . . 0.0 109.586 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.46 -35.87 68.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.897 . . . . 0.0 109.386 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 51.0 tttm -62.43 -40.36 96.33 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.191 -0.943 . . . . 0.0 109.448 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 87.4 tt0 -54.56 -44.76 73.19 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.558 ' CG2' HD11 ' A' ' 103' ' ' ILE . 68.8 t -57.91 -40.44 76.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.345 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -63.91 -37.24 86.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.454 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.11 -47.27 86.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.211 -0.931 . . . . 0.0 109.407 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.523 ' CG2' ' CE2' ' A' ' 65' ' ' PHE . 68.7 mt -51.9 -48.01 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.3 mmm -63.11 -33.34 75.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.284 -0.885 . . . . 0.0 109.357 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -60.44 -34.45 74.0 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.241 -0.912 . . . . 0.0 109.465 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -54.92 -39.85 69.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.538 HD11 ' HA ' ' A' ' 45' ' ' PRO . 87.0 mt -56.93 -40.75 76.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.203 -0.936 . . . . 0.0 109.465 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -65.4 -31.68 72.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.219 -0.926 . . . . 0.0 109.491 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -63.53 141.6 58.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.804 HG11 ' HB2' ' A' ' 121' ' ' LYS . 43.6 t -114.53 142.29 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.29 -0.881 . . . . 0.0 109.385 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.46 -36.48 38.47 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.502 ' H ' HG12 ' A' ' 118' ' ' VAL . 59.9 t0 -171.49 -38.92 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.212 -1.169 . . . . 0.0 109.526 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.804 ' HB2' HG11 ' A' ' 118' ' ' VAL . 0.7 OUTLIER 53.35 63.5 8.15 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 109.517 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.29 147.52 59.67 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.618 2.212 . . . . 0.0 111.796 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.53 179.946 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.7 mtp . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.8 t -57.76 -33.02 68.05 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.509 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -107.36 157.14 18.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.241 -0.912 . . . . 0.0 109.452 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -54.64 150.53 17.59 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.206 -0.933 . . . . 0.0 109.381 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.74 141.89 46.55 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.719 2.279 . . . . 0.0 111.95 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 85.7 mttt -93.06 30.21 1.68 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -93.79 128.02 39.82 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 109.47 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.589 ' HB2' ' CE1' ' A' ' 10' ' ' TYR . 41.7 mtt-85 -126.38 161.53 27.65 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.159 -0.963 . . . . 0.0 109.509 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.514 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 69.2 m95 -91.35 124.79 35.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.253 -0.904 . . . . 0.0 109.548 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.606 ' CE2' ' CG ' ' A' ' 75' ' ' MET . 95.8 m-85 -120.85 147.46 45.36 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 55.2 t -87.04 159.4 3.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.236 -0.915 . . . . 0.0 109.393 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.506 ' N ' HG12 ' A' ' 11' ' ' VAL . 64.4 t -144.56 103.94 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.237 -0.915 . . . . 0.0 109.173 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.475 ' CG ' ' HB2' ' A' ' 90' ' ' MET . 50.0 tt0 -42.18 -47.4 4.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.54 -0.725 . . . . 0.0 109.657 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.478 ' O ' ' HG2' ' A' ' 90' ' ' MET . . . 53.62 -168.28 0.06 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.283 -0.885 . . . . 0.0 109.471 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 18' ' ' PHE . 57.5 t80 -103.17 142.08 34.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.878 . . . . 0.0 109.341 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.425 ' HA ' ' OE2' ' A' ' 19' ' ' GLU . 28.3 p -66.96 131.07 45.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.519 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.62 -28.04 9.84 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.688 ' CD2' ' CD2' ' A' ' 15' ' ' PHE . 17.9 m-30 -103.29 18.26 22.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.223 -1.163 . . . . 0.0 109.506 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.546 ' CG ' HG21 ' A' ' 46' ' ' THR . 33.3 mp0 -51.64 -40.94 60.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.191 -0.943 . . . . 0.0 109.251 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -78.03 -58.39 3.21 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.1 ttm-85 -55.05 -47.48 74.74 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.155 -1.203 . . . . 0.0 109.426 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.655 HG23 ' CB ' ' A' ' 18' ' ' PHE . 46.8 t -46.7 -45.9 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.198 -0.939 . . . . 0.0 109.31 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.77 -45.01 66.92 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.386 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 86.0 m -62.03 -42.99 99.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.336 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.414 ' O ' ' HB3' ' A' ' 28' ' ' GLU . 1.2 t -50.07 -54.97 16.85 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.215 -0.928 . . . . 0.0 109.289 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.492 HD23 HG11 ' A' ' 86' ' ' VAL . 82.8 mt -47.68 -56.33 7.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.267 -0.895 . . . . 0.0 109.235 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.471 ' HA ' ' HB ' ' A' ' 30' ' ' ILE . 70.0 ttt-85 -52.72 -34.1 50.98 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.269 -0.894 . . . . 0.0 109.127 179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' ' 25' ' ' SER . 87.7 tt0 -61.38 -46.09 91.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.306 -0.871 . . . . 0.0 109.183 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.7 ' NE2' HG23 ' A' ' 86' ' ' VAL . 69.3 m-70 -83.45 -30.1 27.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.281 -0.887 . . . . 0.0 109.249 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.862 HG23 ' HB2' ' A' ' 35' ' ' MET . 86.5 mt -64.44 -45.09 96.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.342 -0.849 . . . . 0.0 109.358 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -60.18 -40.56 90.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.261 -0.9 . . . . 0.0 109.271 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.403 HD23 ' HA ' ' A' ' 32' ' ' LEU . 82.8 mt -69.61 -51.77 32.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.299 -0.876 . . . . 0.0 109.354 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.437 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.4 m-70 -79.23 0.02 30.24 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.248 -0.908 . . . . 0.0 109.59 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.475 ' N ' ' O ' ' A' ' 30' ' ' ILE . 83.9 m-20 59.57 49.03 8.9 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.122 -0.986 . . . . 0.0 109.386 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 1.04 ' HG3' HD13 ' A' ' 82' ' ' LEU . 65.7 mmm -95.38 1.37 54.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.327 -0.858 . . . . 0.0 109.554 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -48.8 -36.48 16.77 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.563 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -57.1 -45.2 83.57 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.783 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.5 mt -70.88 -53.72 14.09 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.287 -0.883 . . . . 0.0 109.443 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.583 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 91.7 m-85 -68.76 138.5 54.9 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.863 . . . . 0.0 109.422 -179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -124.03 -70.39 0.22 Allowed Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 74.0 mm-40 -128.63 157.48 41.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -1.16 . . . . 0.0 109.649 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.856 HG13 HG22 ' A' ' 71' ' ' VAL . 57.6 t -121.56 156.98 25.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.624 ' O ' HG13 ' A' ' 69' ' ' VAL . 87.3 mmm -121.64 150.78 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.278 -0.889 . . . . 0.0 109.463 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.71 72.89 68.42 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.265 -0.897 . . . . 0.0 109.398 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.424 ' O ' HD13 ' A' ' 115' ' ' LEU . 50.7 Cg_endo -70.17 -0.64 7.56 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.799 2.333 . . . . 0.0 111.817 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.546 HG21 ' CG ' ' A' ' 19' ' ' GLU . 12.5 t -116.67 176.28 5.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.305 -0.872 . . . . 0.0 109.557 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.456 ' HG2' HG23 ' A' ' 46' ' ' THR . 63.2 mm-40 62.05 126.19 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.3 -0.875 . . . . 0.0 109.557 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -61.77 -37.21 83.46 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.418 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 51' ' ' GLU . 23.2 m -129.44 147.18 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.356 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.5 p -64.31 -26.74 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.211 -0.93 . . . . 0.0 109.619 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.588 ' O ' HG23 ' A' ' 49' ' ' VAL . 77.5 tt0 -80.63 139.79 36.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.208 -0.933 . . . . 0.0 109.524 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 85.5 mt -59.2 -38.88 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.438 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.442 ' HD2' ' OE2' ' A' ' 51' ' ' GLU . 51.4 mtt180 -52.14 148.84 5.82 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.275 -0.89 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.5 35.84 18.73 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . -167.33 -161.99 18.0 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.43 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 93.3 mt-30 61.69 51.37 3.96 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.324 -1.103 . . . . 0.0 109.52 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 86.6 mtt180 -97.66 154.79 17.33 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.229 -0.919 . . . . 0.0 109.472 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -92.07 143.01 26.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.237 -0.915 . . . . 0.0 109.44 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.444 ' HG2' ' O ' ' A' ' 59' ' ' LYS . 20.6 ttpp 55.56 43.65 28.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.292 -0.88 . . . . 0.0 109.489 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 97.5 p -117.17 147.73 42.21 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.259 -0.901 . . . . 0.0 109.473 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 75.6 mm-40 -111.41 156.57 21.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.202 -0.937 . . . . 0.0 109.455 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 94.8 mtt-85 -127.21 143.05 51.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.247 -0.908 . . . . 0.0 109.378 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -98.19 13.89 29.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.231 -0.918 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.422 ' CG ' HD11 ' A' ' 115' ' ' LEU . 14.0 m-85 -111.86 163.02 14.67 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.266 -0.896 . . . . 0.0 109.427 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.479 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 5.3 p90 -105.85 89.24 3.43 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.251 -0.906 . . . . 0.0 109.607 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 48.5 Cg_endo -70.67 155.19 63.4 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.641 2.227 . . . . 0.0 111.601 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.517 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . 107.47 -4.06 34.86 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -123.48 122.2 37.62 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -1.157 . . . . 0.0 109.41 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 43' ' ' MET . 88.1 t -133.02 140.81 46.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.257 -0.902 . . . . 0.0 109.516 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.832 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.1 mp -105.66 134.99 47.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.38 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.856 HG22 HG13 ' A' ' 42' ' ' VAL . 77.2 t -139.98 117.86 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.303 -0.873 . . . . 0.0 109.561 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.448 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.2 tt0 -67.61 135.49 52.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.42 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 44.6 ttp 173.57 154.69 0.11 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.302 -0.874 . . . . 0.0 109.615 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 97.1 t -84.21 140.78 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.606 ' CG ' ' CE2' ' A' ' 10' ' ' TYR . 19.3 mmm -84.8 125.71 32.82 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.311 -0.868 . . . . 0.0 109.536 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.592 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 47.8 p-10 -152.65 173.54 15.09 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.344 -0.848 . . . . 0.0 109.447 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -64.84 -29.4 70.36 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.247 -0.908 . . . . 0.0 109.542 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.592 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -74.87 -72.41 0.3 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.223 -0.923 . . . . 0.0 109.665 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.783 ' OG ' HD13 ' A' ' 38' ' ' LEU . 10.6 m -44.38 -56.82 3.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.257 -0.902 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.517 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 51.7 t90 -44.62 -54.04 6.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.278 -0.889 . . . . 0.0 109.385 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.9 t60 -61.1 -35.79 77.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.362 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 1.04 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -57.25 -37.24 72.03 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.27 -0.894 . . . . 0.0 109.413 179.892 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.947 ' CG1' HG11 ' A' ' 89' ' ' VAL . 44.1 t -73.04 -45.96 52.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.259 -0.901 . . . . 0.0 109.427 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 71.9 ttt180 -68.94 -31.31 70.1 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.262 -0.899 . . . . 0.0 109.475 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 95.1 p -64.8 -45.6 85.56 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.25 -0.906 . . . . 0.0 109.362 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.7 HG23 ' NE2' ' A' ' 29' ' ' HIS . 11.1 p -82.35 133.49 50.23 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.247 -0.908 . . . . 0.0 109.395 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.624 ' O ' HG23 ' A' ' 89' ' ' VAL . 49.3 Cg_endo -69.12 -166.87 0.18 Allowed 'Trans proline' 0 C--O 1.214 -0.722 0 C-N-CA 122.697 2.265 . . . . 0.0 111.876 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.502 ' HB3' HG22 ' A' ' 22' ' ' VAL . 89.6 mtt-85 63.01 16.73 9.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.433 -0.792 . . . . 0.0 109.535 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.947 HG11 ' CG1' ' A' ' 83' ' ' VAL . 11.6 t -119.99 109.27 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -0.909 . . . . 0.0 109.409 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.478 ' HG2' ' O ' ' A' ' 14' ' ' ALA . 90.9 mmm -65.3 -39.89 93.07 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.263 -0.898 . . . . 0.0 109.576 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 158.92 -169.59 35.23 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.569 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 15.3 m-85 -100.37 158.56 15.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.653 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 11' ' ' VAL . 34.3 mm -117.7 115.69 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.298 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 179.8 -142.71 5.28 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.95 -37.55 50.14 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 p -132.39 169.89 15.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -1.156 . . . . 0.0 109.542 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.0 p -88.84 14.93 9.22 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.251 -0.906 . . . . 0.0 109.336 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.517 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 88.5 m-20 -125.15 -22.49 4.4 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.566 -0.709 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.411 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.8 OUTLIER -140.8 101.27 6.5 Favored Pre-proline 0 N--CA 1.487 1.416 0 O-C-N 121.191 -0.943 . . . . 0.0 109.15 179.814 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 48.7 Cg_endo -69.02 109.69 2.23 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.744 2.296 . . . . 0.0 111.922 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.94 139.64 78.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.311 -0.868 . . . . 0.0 109.303 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 154.04 67.41 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.72 2.28 . . . . 0.0 111.842 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 108' ' ' VAL . 34.5 pt -123.83 158.13 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.2 m -70.21 147.74 49.45 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -55.01 -38.86 68.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.258 -0.901 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 26.5 tptp -58.62 -40.34 83.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.217 -0.927 . . . . 0.0 109.306 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -51.77 -48.67 63.66 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.281 -0.887 . . . . 0.0 109.403 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.68 HG22 HD23 ' A' ' 70' ' ' LEU . 74.2 t -57.67 -44.09 84.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.179 -0.951 . . . . 0.0 109.333 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -60.9 -41.38 95.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.184 -0.948 . . . . 0.0 109.344 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.432 ' O ' ' HB2' ' A' ' 113' ' ' ASN . . . -58.45 -52.82 64.04 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.357 -0.84 . . . . 0.0 109.326 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.799 HD12 HD21 ' A' ' 70' ' ' LEU . 69.0 mt -49.79 -53.98 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.378 -0.826 . . . . 0.0 109.373 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 95.3 mmm -59.57 -38.78 82.07 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.265 -0.897 . . . . 0.0 109.254 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.432 ' HB2' ' O ' ' A' ' 110' ' ' ALA . 97.4 m-20 -53.02 -46.89 68.6 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.278 -0.889 . . . . 0.0 109.362 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.459 ' O ' ' N ' ' A' ' 117' ' ' GLN . 56.8 mtt180 -55.53 -54.22 46.68 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.201 -0.937 . . . . 0.0 109.398 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.424 HD13 ' O ' ' A' ' 45' ' ' PRO . 15.4 tp -45.74 -43.77 13.18 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -0.929 . . . . 0.0 109.492 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 -63.57 -21.36 66.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.264 -0.897 . . . . 0.0 109.5 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.459 ' N ' ' O ' ' A' ' 114' ' ' ARG . 50.4 tt0 -85.69 110.12 19.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.278 -0.889 . . . . 0.0 109.454 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 23.8 t -64.38 -19.27 24.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.285 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 86.76 10.31 72.97 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -63.1 156.27 25.49 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -1.173 . . . . 0.0 109.525 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.59 ' CB ' ' CD ' ' A' ' 122' ' ' PRO . 0.0 OUTLIER -160.26 -66.28 0.02 OUTLIER Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.217 -0.927 . . . . 0.0 109.441 179.902 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . 0.59 ' CD ' ' CB ' ' A' ' 121' ' ' LYS . 52.1 Cg_endo -71.28 -14.03 31.11 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.615 2.21 . . . . 0.0 111.741 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 75.4 mtp180 . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.519 179.994 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.5 mtm . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.5 t -121.22 144.29 48.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.21 -0.931 . . . . 0.0 109.515 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -60.03 -33.87 72.61 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.42 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 53.08 68.49 2.94 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.503 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.41 ' O ' ' HB2' ' A' ' 6' ' ' LYS . 48.6 Cg_endo -69.76 -17.52 37.55 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 122.704 2.269 . . . . 0.0 111.71 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.457 ' O ' ' CG1' ' A' ' 74' ' ' VAL . 28.2 mttm 60.64 44.12 11.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.918 . . . . 0.0 109.522 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.424 ' HB3' ' OE1' ' A' ' 72' ' ' GLN . 94.9 mttt -130.53 126.0 35.69 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.499 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.498 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 95.4 mtt-85 -139.51 150.27 44.93 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.249 -0.907 . . . . 0.0 109.396 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.443 ' O ' HG12 ' A' ' 103' ' ' ILE . 72.4 m95 -100.67 136.72 40.09 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.642 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 67.6 m-85 -130.21 149.85 51.73 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.328 -0.857 . . . . 0.0 109.441 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.436 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 12.8 t -98.93 139.16 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.188 -0.945 . . . . 0.0 109.524 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.53 HG22 ' CE1' ' A' ' 92' ' ' PHE . 46.3 t -119.18 130.0 74.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.304 -0.872 . . . . 0.0 109.41 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.876 ' CG ' HD11 ' A' ' 93' ' ' ILE . 95.8 mt-30 -87.68 147.47 25.22 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.329 -0.857 . . . . 0.0 109.468 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -150.3 154.63 38.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.227 -0.921 . . . . 0.0 109.462 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -66.38 146.47 54.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.286 -0.884 . . . . 0.0 109.457 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 42.0 m -58.08 135.97 57.1 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.73 -29.28 7.49 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -104.08 7.15 36.33 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.2 -1.176 . . . . 0.0 109.545 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.86 -37.33 71.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.242 -0.911 . . . . 0.0 109.432 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -79.7 -35.0 29.72 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 63.4 ttt-85 -63.18 -47.4 82.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.233 -1.157 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.474 ' O ' ' HG ' ' A' ' 26' ' ' LEU . 45.6 t -50.71 -39.12 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.187 -0.946 . . . . 0.0 109.451 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.21 -39.55 94.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.244 -0.91 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 67.9 m -67.43 -36.0 80.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.572 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.706 ' HB2' HG13 ' A' ' 86' ' ' VAL . 31.8 m -63.72 -41.38 98.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.157 -0.964 . . . . 0.0 109.484 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.925 ' CD2' HG21 ' A' ' 86' ' ' VAL . 61.9 mt -56.48 -43.78 79.98 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.539 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.509 ' CG ' ' HE3' ' A' ' 31' ' ' LYS . 41.4 ttm180 -57.19 -39.46 75.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.273 -0.892 . . . . 0.0 109.605 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -73.97 -59.82 2.54 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.258 -0.901 . . . . 0.0 109.514 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.453 ' CD2' ' O ' ' A' ' 25' ' ' SER . 93.6 m-70 -52.44 -45.81 66.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.276 -0.89 . . . . 0.0 109.564 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.881 HG23 ' HB2' ' A' ' 35' ' ' MET . 96.5 mt -64.1 -55.58 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.928 . . . . 0.0 109.477 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.509 ' HE3' ' CG ' ' A' ' 27' ' ' ARG . 82.6 mttt -53.89 -37.13 63.43 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 32' ' ' LEU . 51.3 mt -73.06 -48.19 38.15 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.252 -0.905 . . . . 0.0 109.539 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.456 ' CD2' HD12 ' A' ' 82' ' ' LEU . 98.1 m-70 -81.38 0.87 35.45 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.197 -0.939 . . . . 0.0 109.615 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.483 ' N ' ' O ' ' A' ' 30' ' ' ILE . 77.7 m-20 59.08 49.77 8.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.203 -0.936 . . . . 0.0 109.477 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 1.057 ' HG3' HD13 ' A' ' 82' ' ' LEU . 40.0 mmm -101.8 8.98 41.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.259 -0.901 . . . . 0.0 109.557 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.448 ' OE2' ' HG2' ' A' ' 31' ' ' LYS . 97.5 mt-10 -51.73 -37.02 49.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.276 -0.89 . . . . 0.0 109.461 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -60.35 -37.83 81.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.407 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.98 HD13 ' OG ' ' A' ' 79' ' ' SER . 5.8 mt -73.61 -55.06 6.78 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.252 -0.905 . . . . 0.0 109.33 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.634 ' CE1' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -72.47 136.17 45.9 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.331 -0.856 . . . . 0.0 109.407 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -112.39 -66.49 0.5 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -137.94 152.76 49.28 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.203 -1.175 . . . . 0.0 109.562 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.055 HG13 HG22 ' A' ' 71' ' ' VAL . 42.8 t -116.81 155.3 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.262 -0.898 . . . . 0.0 109.341 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.466 ' HB2' ' HB2' ' A' ' 70' ' ' LEU . 87.9 mtp -120.65 138.7 53.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.28 -0.887 . . . . 0.0 109.568 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.513 HG12 ' H ' ' A' ' 47' ' ' GLU . 66.3 t -145.99 90.24 5.86 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.902 . . . . 0.0 109.425 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.02 -19.38 34.96 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.732 2.288 . . . . 0.0 111.919 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.454 ' O ' ' O ' ' A' ' 47' ' ' GLU . 6.3 t -89.53 -4.28 57.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.65 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.513 ' H ' HG12 ' A' ' 44' ' ' VAL . 95.5 mt-10 51.25 177.36 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.246 -0.909 . . . . 0.0 109.443 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -63.57 -35.26 79.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.257 -0.902 . . . . 0.0 109.435 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 43.8 t -122.28 132.6 70.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.516 HG13 ' N ' ' A' ' 51' ' ' GLU . 5.4 p -63.15 -44.3 99.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.241 -0.912 . . . . 0.0 109.494 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.516 ' N ' HG13 ' A' ' 50' ' ' VAL . 83.1 tt0 -139.79 137.33 34.94 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.241 -0.912 . . . . 0.0 109.444 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 81.5 mt -61.69 -41.78 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.318 -0.864 . . . . 0.0 109.566 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 -56.87 -32.75 66.17 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.472 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 84.82 -137.0 15.11 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 24.52 36.08 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 77.4 mt-30 -59.7 -28.78 67.6 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -1.158 . . . . 0.0 109.494 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 46.0 mtp85 -59.2 -30.38 68.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.386 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.491 ' O ' ' CB ' ' A' ' 59' ' ' LYS . 83.0 mtm180 -118.2 160.74 21.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.193 -0.942 . . . . 0.0 109.422 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.491 ' CB ' ' O ' ' A' ' 58' ' ' ARG . 11.4 ttmm 73.77 66.87 0.1 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.249 -0.907 . . . . 0.0 109.434 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 37.4 m -58.37 -32.66 68.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -68.36 147.37 52.21 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.296 -0.877 . . . . 0.0 109.476 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 22.0 mmt85 -116.89 128.21 55.01 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.19 -0.944 . . . . 0.0 109.461 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 30.0 mttt -61.45 -30.83 70.84 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.407 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.503 ' CD1' HD11 ' A' ' 115' ' ' LEU . 9.3 m-30 -94.45 171.35 8.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.91 . . . . 0.0 109.469 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 13.0 p90 -109.59 80.67 1.64 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.887 . . . . 0.0 109.492 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -70.08 164.08 36.16 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.631 2.221 . . . . 0.0 111.745 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 104.76 -11.69 49.76 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -119.98 125.84 49.38 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.197 -1.178 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.435 ' C ' HD12 ' A' ' 70' ' ' LEU . 91.0 t -132.06 143.25 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.24 -0.913 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.954 HD21 HD12 ' A' ' 111' ' ' ILE . 3.3 mp -107.65 127.41 53.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.309 -0.87 . . . . 0.0 109.385 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.055 HG22 HG13 ' A' ' 42' ' ' VAL . 96.9 t -133.27 133.17 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.538 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.424 ' OE1' ' HB3' ' A' ' 7' ' ' LYS . 6.3 tt0 -84.49 133.94 34.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.295 -0.878 . . . . 0.0 109.377 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.568 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 28.5 ttp -175.04 162.71 3.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.233 -0.917 . . . . 0.0 109.475 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.537 ' N ' ' HG2' ' A' ' 73' ' ' MET . 33.3 m -103.51 145.66 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.364 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.548 ' CE ' ' HG2' ' A' ' 100' ' ' PRO . 11.7 mmt -79.42 122.44 26.41 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.27 -0.894 . . . . 0.0 109.751 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.454 ' OD1' ' OG ' ' A' ' 79' ' ' SER . 36.0 p-10 -133.74 -143.76 0.22 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.226 -0.921 . . . . 0.0 109.29 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.2 p30 -117.91 0.85 12.0 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.025 -1.047 . . . . 0.0 110.067 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -122.8 -20.02 6.01 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.103 -0.998 . . . . 0.0 109.785 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.98 ' OG ' HD13 ' A' ' 38' ' ' LEU . 4.5 m -79.1 -36.66 40.34 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.24 -0.912 . . . . 0.0 109.581 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 85.6 t90 -56.24 -51.25 68.78 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.293 -0.879 . . . . 0.0 109.595 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -66.22 -32.21 73.5 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.689 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 1.057 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.6 OUTLIER -62.86 -37.12 85.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.214 -0.929 . . . . 0.0 109.475 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.832 HG21 ' CE2' ' A' ' 92' ' ' PHE . 55.8 t -68.96 -50.02 57.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 23.1 ttp85 -60.98 -35.69 77.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.27 -0.894 . . . . 0.0 109.506 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.3 t -60.5 -30.83 69.96 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.93 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.925 HG21 ' CD2' ' A' ' 26' ' ' LEU . 22.0 t -61.84 117.9 33.25 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.168 -0.958 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 49.2 Cg_endo -70.13 167.71 24.15 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.584 2.189 . . . . 0.0 111.693 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 39.0 mmt180 60.91 29.85 19.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.7 p -122.79 130.09 74.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.212 -0.93 . . . . 0.0 109.407 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 87.5 mtp -70.12 -50.93 35.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.21 -0.931 . . . . 0.0 109.508 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 169.36 -151.24 16.96 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.832 ' CE2' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -115.63 170.21 8.61 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.27 -1.135 . . . . 0.0 109.516 179.998 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.876 HD11 ' CG ' ' A' ' 13' ' ' GLN . 39.6 mm -121.78 125.48 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.355 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 169.71 -163.23 36.73 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -54.57 -56.77 20.51 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 p -125.49 178.96 5.34 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.224 -1.162 . . . . 0.0 109.593 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.3 p -93.76 16.91 12.91 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.483 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -120.11 -28.64 5.06 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 10.1 mtp85 -142.56 90.75 7.78 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.548 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.0 Cg_endo -66.43 120.26 7.37 Favored 'Trans proline' 0 C--O 1.216 -0.595 0 C-N-CA 122.92 2.413 . . . . 0.0 112.239 -179.307 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.28 146.93 97.1 Favored Pre-proline 0 N--CA 1.488 1.445 0 O-C-N 121.33 -0.856 . . . . 0.0 109.254 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.498 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.2 Cg_endo -69.85 152.84 68.99 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.598 2.198 . . . . 0.0 111.903 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.743 HD11 HG22 ' A' ' 108' ' ' VAL . 30.2 pt -113.1 156.12 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.316 -0.865 . . . . 0.0 109.4 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 50.0 m -74.52 152.21 39.4 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.211 -0.931 . . . . 0.0 109.472 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 90.2 m-20 -56.6 -37.83 71.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.35 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 50.9 tttm -58.14 -42.08 85.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.223 -0.923 . . . . 0.0 109.404 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.413 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 90.1 mt-10 -58.76 -45.06 90.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.485 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 103' ' ' ILE . 73.4 t -59.43 -39.62 79.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.322 -0.861 . . . . 0.0 109.379 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -69.6 -34.21 73.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.267 -0.896 . . . . 0.0 109.388 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.27 -44.43 95.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.349 -0.844 . . . . 0.0 109.463 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.954 HD12 HD21 ' A' ' 70' ' ' LEU . 73.9 mt -54.21 -54.16 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.474 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . 0.429 ' HB2' ' HE3' ' A' ' 112' ' ' MET . 55.9 ttm -64.27 -36.73 85.03 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.93 . . . . 0.0 109.515 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 46.8 t-20 -52.17 -44.21 64.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 27.2 mtp180 -49.08 -50.42 36.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.217 -0.927 . . . . 0.0 109.491 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.503 HD11 ' CD1' ' A' ' 64' ' ' PHE . 13.5 tp -53.64 -43.42 68.75 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.271 -0.893 . . . . 0.0 109.417 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 -68.68 -29.58 68.06 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.3 tp60 -53.33 -30.92 41.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.306 -0.872 . . . . 0.0 109.396 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 28.6 t -100.28 134.21 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -77.83 107.18 2.39 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -52.78 -39.59 62.42 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -1.145 . . . . 0.0 109.427 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.6 mtpt -139.03 165.07 34.88 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.38 -20.51 36.54 Favored 'Trans proline' 0 C--O 1.216 -0.584 0 C-N-CA 122.72 2.28 . . . . 0.0 111.831 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 78.0 mtm180 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.948 -1.025 . . . . 0.0 109.502 -179.992 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.8 mtt . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.9 t -55.59 -36.46 66.94 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.32 -0.862 . . . . 0.0 109.495 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 59.0 mp0 -62.55 -32.6 73.59 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.195 -0.941 . . . . 0.0 109.494 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -117.94 78.37 12.78 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.237 -0.914 . . . . 0.0 109.417 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.34 143.22 47.43 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.599 2.2 . . . . 0.0 111.793 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -90.38 149.28 22.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.373 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.511 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 46.9 mttt -121.1 143.1 49.27 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.264 -0.898 . . . . 0.0 109.571 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.472 ' HD2' ' OH ' ' A' ' 10' ' ' TYR . 78.3 mtt180 -125.27 156.72 38.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.304 -0.873 . . . . 0.0 109.392 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.456 ' CZ2' ' HB2' ' A' ' 72' ' ' GLN . 59.4 m95 -104.42 126.8 51.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.184 -0.948 . . . . 0.0 109.591 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.472 ' OH ' ' HD2' ' A' ' 8' ' ' ARG . 85.6 m-85 -125.15 148.13 48.72 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.417 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.548 HG22 ' CD1' ' A' ' 70' ' ' LEU . 22.8 t -92.06 143.0 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.218 -0.926 . . . . 0.0 109.615 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.3 t -120.61 132.79 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.776 ' CG ' HD11 ' A' ' 93' ' ' ILE . 58.1 mt-30 -84.53 151.99 24.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.9 . . . . 0.0 109.483 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.46 ' O ' ' HA3' ' A' ' 67' ' ' GLY . . . -163.96 150.47 11.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.233 -0.917 . . . . 0.0 109.506 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -61.14 143.67 55.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.224 -0.923 . . . . 0.0 109.509 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.9 t -61.62 136.45 58.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.82 -31.53 5.53 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.438 ' HB3' ' HD3' ' A' ' 88' ' ' ARG . 87.2 m-85 -105.08 -2.62 24.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.202 -1.175 . . . . 0.0 109.536 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.602 ' CD ' HG21 ' A' ' 46' ' ' THR . 15.7 pt-20 -56.52 -41.82 77.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.194 -0.941 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.48 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -63.15 -39.09 97.54 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.421 ' O ' ' C ' ' A' ' 22' ' ' VAL . 58.1 ttt85 -59.07 -48.73 80.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.281 -1.129 . . . . 0.0 109.432 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.795 HG13 HG11 ' A' ' 86' ' ' VAL . 40.5 t -43.79 -39.18 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.291 -0.881 . . . . 0.0 109.268 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -54.63 -56.01 23.57 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.915 . . . . 0.0 109.252 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.9 m -63.45 -48.55 77.24 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.361 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.485 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 17.0 m -56.27 -49.04 75.37 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.319 -0.863 . . . . 0.0 109.328 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.673 HD12 HG21 ' A' ' 86' ' ' VAL . 5.1 tp -48.33 -56.46 8.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.287 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 43.1 ttt180 -55.08 -37.48 66.84 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.332 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.796 ' O ' HD12 ' A' ' 32' ' ' LEU . 71.5 tt0 -56.88 -47.78 79.68 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -0.929 . . . . 0.0 109.257 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.885 ' HB3' HD11 ' A' ' 82' ' ' LEU . 62.0 m-70 -71.23 -41.62 69.94 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.243 -0.91 . . . . 0.0 109.344 179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.769 HD13 ' CD1' ' A' ' 39' ' ' PHE . 76.1 mt -59.15 -52.2 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.88 . . . . 0.0 109.394 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 24.0 tttp -54.23 -43.5 70.9 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.247 -0.908 . . . . 0.0 109.448 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.796 HD12 ' O ' ' A' ' 28' ' ' GLU . 4.3 mt -65.44 -48.4 72.88 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -0.915 . . . . 0.0 109.466 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.46 ' HB2' ' SD ' ' A' ' 35' ' ' MET . 96.2 m-70 -85.17 6.39 25.97 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.56 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.516 ' N ' ' O ' ' A' ' 30' ' ' ILE . 49.6 t30 51.97 47.14 25.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.206 -0.934 . . . . 0.0 109.566 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.738 ' SD ' HD22 ' A' ' 82' ' ' LEU . 0.0 OUTLIER -98.36 6.12 47.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.252 -0.905 . . . . 0.0 109.419 179.921 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.573 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.24 -35.5 49.84 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.158 -0.964 . . . . 0.0 109.523 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -55.25 -42.47 73.51 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.532 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 1.04 HD13 ' OG ' ' A' ' 79' ' ' SER . 0.9 OUTLIER -71.1 -54.47 11.0 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.201 -0.937 . . . . 0.0 109.322 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.769 ' CD1' HD13 ' A' ' 30' ' ' ILE . 96.0 m-85 -64.46 137.79 58.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.249 -0.907 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.9 -67.48 0.38 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -132.76 149.74 52.24 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.251 -1.147 . . . . 0.0 109.707 -179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 71' ' ' VAL . 98.6 t -120.01 149.14 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.291 -0.881 . . . . 0.0 109.289 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.822 ' HE1' HG11 ' A' ' 108' ' ' VAL . 73.4 mtm -130.37 146.14 51.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.144 -0.973 . . . . 0.0 109.578 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.611 HG13 HG22 ' A' ' 46' ' ' THR . 74.9 t -130.68 99.47 18.61 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.272 -0.893 . . . . 0.0 109.301 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -70.14 -10.05 27.38 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.696 2.264 . . . . 0.0 111.944 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.611 HG22 HG13 ' A' ' 44' ' ' VAL . 9.0 t -91.31 7.27 41.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.221 -0.925 . . . . 0.0 109.548 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.424 ' C ' ' O ' ' A' ' 46' ' ' THR . 92.5 mt-10 44.11 -163.34 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.165 -0.959 . . . . 0.0 109.434 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 58.6 mp0 -83.42 157.58 22.43 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.393 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 84.2 t -60.57 -39.84 82.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 109.412 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 25.6 t -115.41 140.64 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.491 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -107.62 143.46 36.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.25 -0.906 . . . . 0.0 109.517 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 79.5 mt -51.46 -43.35 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.246 -0.909 . . . . 0.0 109.398 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -82.07 143.65 31.37 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.293 -0.879 . . . . 0.0 109.467 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -57.71 -36.06 77.16 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.75 167.46 43.03 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 -59.93 -40.4 88.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.229 -1.16 . . . . 0.0 109.502 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 79.9 mtm180 -134.29 146.64 50.2 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.344 -0.847 . . . . 0.0 109.423 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 25.6 mtm180 -65.59 -32.54 74.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.3 -0.875 . . . . 0.0 109.46 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 64.3 tttt -128.69 140.66 51.64 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.156 -0.965 . . . . 0.0 109.525 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.3 t -95.38 136.94 35.12 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.2 -0.937 . . . . 0.0 109.458 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -78.67 -21.29 48.49 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.259 -0.901 . . . . 0.0 109.519 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 19.2 mtp180 -122.71 142.38 50.75 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.164 -0.96 . . . . 0.0 109.463 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.5 mttp -114.76 147.74 39.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.411 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.569 ' CG ' HD12 ' A' ' 115' ' ' LEU . 98.4 m-85 -104.62 135.13 46.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.592 -179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.542 ' CE1' HG23 ' A' ' 111' ' ' ILE . 17.9 m-85 44.75 57.58 14.51 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.24 -0.912 . . . . 0.0 109.579 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.08 113.07 3.47 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.677 2.252 . . . . 0.0 111.781 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' A' ' 14' ' ' ALA . . . 81.62 13.46 79.99 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 1.2 m-85 -110.02 128.86 55.66 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.222 -1.164 . . . . 0.0 109.583 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.485 ' C ' HD22 ' A' ' 70' ' ' LEU . 99.9 t -133.55 141.58 43.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.848 HD22 ' N ' ' A' ' 70' ' ' LEU . 2.3 mm? -106.27 131.5 53.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.354 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 42' ' ' VAL . 83.9 t -140.52 120.85 13.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.262 -0.899 . . . . 0.0 109.754 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 4.4 tt0 -76.62 124.74 28.08 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.567 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.2 ttp -162.82 155.97 19.66 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.683 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.513 ' N ' ' HG2' ' A' ' 73' ' ' MET . 39.7 t -86.14 130.11 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.568 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.7 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 18.9 ttm -75.26 135.49 40.96 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.469 HD21 ' HB3' ' A' ' 78' ' ' ALA . 44.7 p-10 -151.58 -161.0 1.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.421 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.6 m-20 -102.99 34.35 2.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.417 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.469 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -149.88 -50.21 0.14 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.275 -0.89 . . . . 0.0 109.447 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 1.04 ' OG ' HD13 ' A' ' 38' ' ' LEU . 14.8 m -63.24 -44.06 96.28 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.51 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 70.3 t90 -50.78 -47.02 59.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -69.25 -34.05 74.2 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.885 HD11 ' HB3' ' A' ' 29' ' ' HIS . 53.9 tp -63.43 -38.69 92.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.28 -0.887 . . . . 0.0 109.398 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 92' ' ' PHE . 70.6 t -60.69 -49.57 83.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.234 -0.916 . . . . 0.0 109.383 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -58.8 -35.3 72.61 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.306 -0.871 . . . . 0.0 109.439 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 24.1 m -62.73 -33.96 76.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.426 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.795 HG11 HG13 ' A' ' 22' ' ' VAL . 49.0 t -49.18 127.71 15.8 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.376 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.7 Cg_endo -70.8 156.77 60.02 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.617 2.211 . . . . 0.0 111.803 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.456 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 75.9 mtt-85 63.51 34.19 12.88 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 109.678 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.4 p -128.52 134.41 64.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.217 -0.927 . . . . 0.0 109.494 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 73.2 mtm -79.56 -44.56 20.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.241 -0.912 . . . . 0.0 109.488 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.74 -147.04 12.25 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -113.25 167.07 10.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.306 -1.114 . . . . 0.0 109.55 -179.976 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.776 HD11 ' CG ' ' A' ' 13' ' ' GLN . 33.5 mm -121.25 137.65 54.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.333 -0.854 . . . . 0.0 109.438 179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 163.09 -148.07 14.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.59 -46.55 14.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.2 p -121.64 171.2 9.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.174 -1.192 . . . . 0.0 109.804 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 59.9 m -91.61 18.56 7.3 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.23 -0.919 . . . . 0.0 109.322 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.51 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 90.2 m-20 -124.82 -30.92 3.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.525 -0.734 . . . . 0.0 109.099 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 6.2 mtt180 -144.64 98.67 4.88 Favored Pre-proline 0 N--CA 1.488 1.464 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.7 ' HG2' ' HE1' ' A' ' 75' ' ' MET . 44.3 Cg_endo -67.12 132.28 27.49 Favored 'Trans proline' 0 C--O 1.216 -0.591 0 C-N-CA 122.695 2.263 . . . . 0.0 112.101 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -65.07 137.02 96.93 Favored Pre-proline 0 N--CA 1.488 1.453 0 O-C-N 121.387 -0.821 . . . . 0.0 109.36 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.19 152.69 72.26 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.645 2.23 . . . . 0.0 111.741 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.801 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.1 pt -123.53 164.46 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.407 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.6 p -83.52 155.32 23.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.215 -0.928 . . . . 0.0 109.447 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -63.74 -30.39 71.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.257 -0.902 . . . . 0.0 109.494 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 23.3 tttt -65.43 -37.1 85.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -0.906 . . . . 0.0 109.4 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.447 ' O ' HG13 ' A' ' 111' ' ' ILE . 85.2 tt0 -65.0 -39.86 94.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.254 -0.904 . . . . 0.0 109.385 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.822 HG11 ' HE1' ' A' ' 43' ' ' MET . 76.3 t -67.02 -34.08 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.273 -0.892 . . . . 0.0 109.354 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 92.2 m-20 -70.5 -34.11 71.97 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.291 -0.88 . . . . 0.0 109.453 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -69.34 -39.51 78.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.334 -0.854 . . . . 0.0 109.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.542 HG23 ' CE1' ' A' ' 65' ' ' PHE . 71.9 mt -56.93 -51.37 69.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.234 -0.916 . . . . 0.0 109.541 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.5 mtp -63.39 -37.86 88.91 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.226 -0.921 . . . . 0.0 109.496 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.445 ' OD1' ' O ' ' A' ' 109' ' ' ASP . 18.7 m120 -54.13 -37.76 64.73 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.321 -0.862 . . . . 0.0 109.514 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.497 ' NH1' ' HA ' ' A' ' 111' ' ' ILE . 52.4 mtt85 -55.56 -52.69 62.87 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.303 -0.873 . . . . 0.0 109.617 -179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.569 HD12 ' CG ' ' A' ' 64' ' ' PHE . 18.5 tp -43.21 -47.79 6.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.319 -0.863 . . . . 0.0 109.626 -179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 -57.89 -27.09 62.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.317 -0.864 . . . . 0.0 109.495 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.495 ' N ' ' O ' ' A' ' 114' ' ' ARG . 43.6 tt0 -83.07 134.11 35.04 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.345 -0.847 . . . . 0.0 109.49 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 42.9 t -63.76 -31.41 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.268 -0.895 . . . . 0.0 109.509 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.54 18.11 75.24 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 51.7 p30 -75.23 172.26 12.73 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.13 -1.217 . . . . 0.0 109.476 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.53 81.0 70.96 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.277 -0.889 . . . . 0.0 109.555 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.53 -18.36 38.12 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.744 2.296 . . . . 0.0 111.775 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 53.6 mtm180 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 117.96 -1.019 . . . . 0.0 109.511 179.946 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.8 mmm . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 26.4 t -60.0 -34.33 73.2 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.244 -0.91 . . . . 0.0 109.478 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -103.25 138.47 39.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.297 -0.877 . . . . 0.0 109.511 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.469 ' HB1' ' HD2' ' A' ' 5' ' ' PRO . . . -126.39 159.78 61.25 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.248 -0.907 . . . . 0.0 109.426 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.469 ' HD2' ' HB1' ' A' ' 4' ' ' ALA . 49.7 Cg_endo -69.93 142.94 48.52 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.701 2.268 . . . . 0.0 111.782 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -88.4 148.43 24.23 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.288 -0.883 . . . . 0.0 109.441 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.436 ' HG3' ' O ' ' A' ' 7' ' ' LYS . 16.0 pttt -132.16 128.34 37.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.281 -0.887 . . . . 0.0 109.516 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.0 mtt-85 -133.53 153.5 51.59 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.237 -0.914 . . . . 0.0 109.491 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 70.4 m95 -101.38 135.81 42.26 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.909 . . . . 0.0 109.415 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.556 ' CE2' ' O ' ' A' ' 73' ' ' MET . 22.9 m-85 -124.58 151.62 44.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.267 -0.896 . . . . 0.0 109.493 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 18.4 t -101.1 137.89 27.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.333 -0.855 . . . . 0.0 109.489 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 30.6 t -115.11 128.7 72.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.306 -0.871 . . . . 0.0 109.234 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.953 ' HB2' HD11 ' A' ' 93' ' ' ILE . 60.4 tt0 -95.6 129.96 42.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.913 . . . . 0.0 109.617 -179.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.44 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -147.42 -178.2 6.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.238 -0.914 . . . . 0.0 109.478 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -75.03 134.26 41.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.451 ' OG ' ' HB2' ' A' ' 66' ' ' PRO . 19.7 m -57.79 140.6 51.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.39 -25.44 15.16 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.49 ' CB ' ' HD3' ' A' ' 88' ' ' ARG . 98.4 m-85 -112.05 13.57 20.71 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.23 -1.159 . . . . 0.0 109.39 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.499 ' OE1' ' CG ' ' A' ' 45' ' ' PRO . 87.2 mt-10 -54.07 -45.31 71.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.12 -42.25 91.85 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.425 ' HD3' ' NE ' ' A' ' 88' ' ' ARG . 52.7 ttt85 -52.16 -54.53 29.61 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.228 -1.16 . . . . 0.0 109.389 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 26.1 t -50.35 -37.23 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.203 -0.936 . . . . 0.0 109.119 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.72 -36.79 85.43 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.211 -0.931 . . . . 0.0 109.231 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 62.6 m -58.83 -43.03 90.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.397 -0.815 . . . . 0.0 109.158 179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.47 ' HB3' ' NE2' ' A' ' 29' ' ' HIS . 20.3 m -58.77 -41.04 85.68 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -0.862 . . . . 0.0 109.319 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.66 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.1 mt -53.45 -44.51 68.93 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.865 . . . . 0.0 109.409 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.437 ' O ' ' CB ' ' A' ' 31' ' ' LYS . 65.9 ttt180 -52.6 -42.49 64.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.34 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.413 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 64.6 mm-40 -75.02 -57.77 3.69 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.276 -0.89 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.631 ' CD2' HG22 ' A' ' 86' ' ' VAL . 87.2 m-70 -55.15 -38.03 67.73 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.192 -0.942 . . . . 0.0 109.268 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.792 HG23 ' HB2' ' A' ' 35' ' ' MET . 82.2 mt -77.17 -54.46 12.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.293 -0.879 . . . . 0.0 109.49 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.437 ' CB ' ' O ' ' A' ' 27' ' ' ARG . 42.2 tttm -59.97 -38.24 81.92 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.251 -0.906 . . . . 0.0 109.286 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.467 HD23 ' HA ' ' A' ' 32' ' ' LEU . 25.2 mt -70.64 -52.05 23.87 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.194 -0.942 . . . . 0.0 109.388 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -81.17 0.84 34.59 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.536 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.509 ' N ' ' O ' ' A' ' 30' ' ' ILE . 20.2 m120 60.37 51.49 5.33 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.242 -0.911 . . . . 0.0 109.408 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.86 ' HG3' HD13 ' A' ' 82' ' ' LEU . 59.9 mmm -99.84 -0.15 40.3 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.291 -0.88 . . . . 0.0 109.599 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.515 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.1 mt-10 -45.67 -37.94 6.26 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.156 -0.965 . . . . 0.0 109.402 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -53.45 -44.24 68.72 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.226 -0.922 . . . . 0.0 109.436 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.777 HD13 ' OG ' ' A' ' 79' ' ' SER . 1.0 OUTLIER -74.62 -46.92 35.19 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.376 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.707 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 92.0 m-85 -75.41 125.87 29.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.261 -0.9 . . . . 0.0 109.497 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -108.69 -67.06 0.6 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -132.46 144.74 50.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -1.154 . . . . 0.0 109.524 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.875 HG13 HG22 ' A' ' 71' ' ' VAL . 19.5 t -109.06 147.65 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.247 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.495 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.2 mtp -122.73 152.32 40.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.118 -0.988 . . . . 0.0 109.757 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 45' ' ' PRO . 12.3 t -149.57 141.18 14.77 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.365 -0.835 . . . . 0.0 109.228 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.529 ' HD2' ' CG1' ' A' ' 44' ' ' VAL . 47.8 Cg_endo -68.59 -2.13 8.72 Favored 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.65 2.233 . . . . 0.0 111.815 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 49' ' ' VAL . 11.3 t -145.98 137.19 24.7 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.339 -0.851 . . . . 0.0 109.291 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.401 ' O ' ' C ' ' A' ' 48' ' ' GLU . 91.8 mt-10 -109.48 137.62 47.05 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.258 -0.901 . . . . 0.0 109.562 -179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.418 ' HA ' ' OE1' ' A' ' 48' ' ' GLU . 73.4 mm-40 43.41 81.43 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.339 -0.851 . . . . 0.0 109.638 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.525 HG11 HG21 ' A' ' 46' ' ' THR . 13.9 p -135.31 140.29 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.161 -0.962 . . . . 0.0 109.54 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.528 ' HB ' ' CB ' ' A' ' 53' ' ' ARG . 23.8 t -118.3 143.25 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.538 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 69.4 tt0 -60.97 -68.65 0.29 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.225 -0.922 . . . . 0.0 109.509 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.416 ' O ' ' C ' ' A' ' 53' ' ' ARG . 77.8 mt -46.76 -52.94 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.239 -0.913 . . . . 0.0 109.318 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.528 ' CB ' ' HB ' ' A' ' 50' ' ' VAL . 59.4 ttp85 -44.56 -49.48 10.07 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.883 . . . . 0.0 109.514 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 68.47 -127.72 23.68 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -113.44 102.19 1.23 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -66.32 -35.81 81.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.264 -1.139 . . . . 0.0 109.487 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -57.4 -44.61 84.7 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.221 -0.924 . . . . 0.0 109.495 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.0 mtt180 -146.77 149.51 33.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.9 . . . . 0.0 109.458 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -50.83 -46.39 59.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.237 -0.915 . . . . 0.0 109.541 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 53.1 p -58.43 164.01 2.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.525 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -133.58 140.27 47.06 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.598 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 60.9 mtt85 -122.78 145.26 48.58 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.325 -0.859 . . . . 0.0 109.381 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 20.4 mttt -135.42 137.03 41.85 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.218 -0.926 . . . . 0.0 109.655 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.587 ' HZ ' HG13 ' A' ' 118' ' ' VAL . 98.3 m-85 -109.75 142.33 41.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.361 -0.837 . . . . 0.0 109.263 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.422 ' O ' ' OE2' ' A' ' 19' ' ' GLU . 39.3 m-85 51.13 66.39 5.45 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.125 -0.984 . . . . 0.0 109.384 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.451 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 48.9 Cg_endo -69.93 128.73 16.28 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.692 2.261 . . . . 0.0 111.778 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.485 ' N ' ' OE2' ' A' ' 19' ' ' GLU . . . 65.37 24.12 70.54 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -129.01 118.29 22.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.288 -1.125 . . . . 0.0 109.503 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.572 ' C ' HD12 ' A' ' 70' ' ' LEU . 79.0 t -130.64 148.82 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.287 -0.883 . . . . 0.0 109.559 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.837 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.0 mp -116.05 132.66 56.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.292 -0.88 . . . . 0.0 109.314 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.875 HG22 HG13 ' A' ' 42' ' ' VAL . 92.4 t -137.03 129.91 44.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.649 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.437 ' O ' ' HB2' ' A' ' 73' ' ' MET . 37.6 tt0 -79.87 132.74 36.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.225 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.569 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 50.3 ttp 174.07 165.19 0.2 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.162 -0.961 . . . . 0.0 109.621 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.525 ' N ' ' HG2' ' A' ' 73' ' ' MET . 15.0 p -94.6 138.57 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.286 -0.884 . . . . 0.0 109.237 179.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.6 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 34.3 tpp -79.15 119.52 22.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.515 ' OD1' ' N ' ' A' ' 79' ' ' SER . 51.3 p-10 -141.94 179.06 7.09 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.247 -0.908 . . . . 0.0 109.35 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -64.97 -36.7 85.24 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -0.931 . . . . 0.0 109.676 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.486 ' HB1' ' HE2' ' A' ' 35' ' ' MET . . . -74.47 -72.78 0.26 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.173 -0.954 . . . . 0.0 109.827 -179.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.777 ' OG ' HD13 ' A' ' 38' ' ' LEU . 3.6 m -42.24 -47.5 4.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.392 -0.818 . . . . 0.0 109.741 -179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.579 ' CZ2' ' HD2' ' A' ' 84' ' ' ARG . 63.7 t90 -50.63 -49.72 56.09 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.226 -0.921 . . . . 0.0 109.577 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -68.34 -25.16 64.96 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.218 -0.926 . . . . 0.0 109.527 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.86 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.9 OUTLIER -60.52 -54.75 41.7 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.297 -0.877 . . . . 0.0 109.562 -179.969 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.033 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 2.7 t -62.26 -49.09 85.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.504 -0.747 . . . . 0.0 109.896 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.579 ' HD2' ' CZ2' ' A' ' 80' ' ' TRP . 58.2 mtp180 -62.77 -29.38 70.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.134 -0.979 . . . . 0.0 109.509 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 86.1 p -79.6 -17.8 53.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.408 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.802 HG23 ' O ' ' A' ' 82' ' ' LEU . 71.8 t -73.01 125.9 90.79 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.267 -0.896 . . . . 0.0 109.449 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -71.01 160.34 49.65 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.626 2.218 . . . . 0.0 111.782 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.537 ' CZ ' ' HB2' ' A' ' 88' ' ' ARG . 13.0 ttm105 64.74 31.72 11.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.281 -0.887 . . . . 0.0 109.58 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.602 HG12 ' O ' ' A' ' 86' ' ' VAL . 8.9 p -126.59 130.93 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.192 -0.942 . . . . 0.0 109.451 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.505 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 95.7 mmm -71.29 -46.85 59.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.55 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.09 -155.5 26.35 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 1.033 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 2.0 m-85 -104.74 162.45 13.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -1.086 . . . . 0.0 109.588 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.953 HD11 ' HB2' ' A' ' 13' ' ' GLN . 10.7 mm -119.02 118.27 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.257 -0.902 . . . . 0.0 109.41 179.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . -174.52 -145.57 5.33 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.93 -46.01 24.62 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.8 p -127.36 173.37 9.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.195 -1.179 . . . . 0.0 109.604 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.2 p -90.49 18.78 5.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.111 -0.993 . . . . 0.0 109.253 179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -126.62 -6.3 6.33 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.579 -0.701 . . . . 0.0 109.428 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.415 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -164.73 99.57 0.85 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.252 -0.905 . . . . 0.0 109.07 179.935 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.6 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 47.6 Cg_endo -68.55 114.21 3.41 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.678 2.252 . . . . 0.0 111.891 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -57.57 137.37 82.19 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.519 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.82 153.9 68.12 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.707 2.271 . . . . 0.0 111.813 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.615 HD11 ' CG2' ' A' ' 108' ' ' VAL . 32.1 pt -124.44 161.04 28.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.444 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.441 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 49.9 m -70.94 147.95 48.2 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 109.5 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -62.26 -36.28 81.57 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.197 -0.94 . . . . 0.0 109.34 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 77.9 tttt -61.59 -35.96 79.33 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.28 -0.887 . . . . 0.0 109.42 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.441 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 99.8 mt-10 -60.8 -43.15 98.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.887 . . . . 0.0 109.366 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.615 ' CG2' HD11 ' A' ' 103' ' ' ILE . 75.4 t -62.53 -35.14 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.252 -0.905 . . . . 0.0 109.455 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -66.99 -38.04 85.29 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.285 -0.885 . . . . 0.0 109.412 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.6 -44.31 91.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.171 -0.955 . . . . 0.0 109.441 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 67.9 mt -53.53 -52.54 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.226 -0.922 . . . . 0.0 109.47 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 93.2 mmm -58.32 -38.79 77.8 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.251 -0.906 . . . . 0.0 109.498 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -52.75 -41.71 64.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.203 -0.936 . . . . 0.0 109.452 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.493 ' O ' ' N ' ' A' ' 117' ' ' GLN . 37.6 mtp85 -57.28 -43.89 83.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.455 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.488 HD12 ' CB ' ' A' ' 64' ' ' PHE . 6.7 tp -43.98 -49.42 8.58 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -0.876 . . . . 0.0 109.511 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -57.56 -26.32 61.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.299 -0.876 . . . . 0.0 109.474 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.493 ' N ' ' O ' ' A' ' 114' ' ' ARG . 44.5 tt0 -85.82 125.01 32.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.468 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.587 HG13 ' HZ ' ' A' ' 64' ' ' PHE . 1.6 t -120.61 134.34 64.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.909 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.36 -21.49 6.24 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -95.34 139.45 31.63 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -1.116 . . . . 0.0 109.493 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 8.1 mmtp -119.86 74.64 19.48 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.514 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.08 144.16 51.51 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.665 2.244 . . . . 0.0 111.805 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 33.2 ttt-85 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.976 -1.012 . . . . 0.0 109.483 -179.997 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.3 mmm . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.3 t -60.38 -28.82 68.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.283 -0.886 . . . . 0.0 109.421 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -62.04 141.62 57.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.227 -0.921 . . . . 0.0 109.372 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -120.52 81.52 31.72 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.13 -0.981 . . . . 0.0 109.597 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.85 145.91 58.05 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.753 2.302 . . . . 0.0 111.719 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 48.1 tttp -91.3 27.82 1.82 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.159 -0.963 . . . . 0.0 109.533 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.421 ' HB3' ' CD ' ' A' ' 72' ' ' GLN . 98.6 mttt -99.39 133.13 44.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.246 -0.909 . . . . 0.0 109.509 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.514 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 54.3 mtt180 -123.42 153.96 39.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.427 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.575 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 73.8 m95 -96.16 123.74 39.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.227 -0.92 . . . . 0.0 109.581 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.591 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 88.1 m-85 -119.19 159.64 23.64 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -0.943 . . . . 0.0 109.473 179.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.47 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 27.0 t -94.33 149.18 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.637 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.4 ' N ' ' O ' ' A' ' 69' ' ' VAL . 57.3 t -124.64 118.74 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.246 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.957 ' HB2' HD11 ' A' ' 93' ' ' ILE . 59.3 tt0 -84.85 140.07 31.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.26 -0.9 . . . . 0.0 109.58 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.438 ' N ' ' O ' ' A' ' 67' ' ' GLY . . . -156.92 -153.39 0.41 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.205 -0.934 . . . . 0.0 109.391 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.96 140.62 46.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.446 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 28.3 t -59.24 132.73 54.89 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.213 -0.929 . . . . 0.0 109.549 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.48 -16.92 60.29 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -109.48 0.19 19.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -1.143 . . . . 0.0 109.576 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.51 ' OE2' ' N ' ' A' ' 68' ' ' TYR . 99.0 mt-10 -56.35 -44.34 79.99 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.186 -0.946 . . . . 0.0 109.367 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -62.55 -50.15 67.11 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.531 ' NH2' ' HG3' ' A' ' 88' ' ' ARG . 12.4 ttp180 -57.3 -56.26 24.12 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.291 -1.123 . . . . 0.0 109.416 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.699 HG13 HG11 ' A' ' 86' ' ' VAL . 40.7 t -45.46 -38.68 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.233 -0.917 . . . . 0.0 109.215 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.87 -44.85 96.49 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.342 -0.849 . . . . 0.0 109.266 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 90.4 m -69.44 -47.28 64.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.677 ' HG ' ' HE2' ' A' ' 29' ' ' HIS . 15.3 t -57.4 -56.21 24.83 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.338 -0.851 . . . . 0.0 109.489 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.442 ' CD1' HG21 ' A' ' 86' ' ' VAL . 14.0 tp -46.82 -49.71 19.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.261 -0.899 . . . . 0.0 109.377 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.487 ' CG ' ' HE2' ' A' ' 31' ' ' LYS . 46.7 ttm-85 -60.71 -34.59 74.62 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.186 -0.946 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -64.18 -48.07 77.35 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.225 -0.922 . . . . 0.0 109.322 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.677 ' HE2' ' HG ' ' A' ' 25' ' ' SER . 60.1 m-70 -66.3 -37.29 85.06 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 109.341 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.815 HG23 ' HB2' ' A' ' 35' ' ' MET . 90.8 mt -65.26 -49.03 81.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.256 -0.903 . . . . 0.0 109.451 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.487 ' HE2' ' CG ' ' A' ' 27' ' ' ARG . 25.3 mttm -56.84 -40.05 75.35 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.216 -0.927 . . . . 0.0 109.389 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 ' HA ' ' A' ' 32' ' ' LEU . 29.8 mt -69.91 -52.02 28.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.308 -0.87 . . . . 0.0 109.481 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.488 ' HB2' ' HG2' ' A' ' 35' ' ' MET . 97.7 m-70 -81.12 4.34 20.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.248 -0.908 . . . . 0.0 109.591 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' ILE . 78.8 m-20 54.76 47.65 21.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.248 -0.907 . . . . 0.0 109.511 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 1.008 ' HG3' HD13 ' A' ' 82' ' ' LEU . 61.1 mmm -94.2 6.54 48.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.932 . . . . 0.0 109.594 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.502 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 96.4 mt-10 -52.53 -31.19 34.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.394 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -61.85 -41.84 98.31 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.297 -0.877 . . . . 0.0 109.351 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.496 HD12 ' HB3' ' A' ' 35' ' ' MET . 10.3 mt -70.93 -53.68 14.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 109.421 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.699 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 73.9 m-85 -75.2 143.33 43.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.306 -0.871 . . . . 0.0 109.474 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -120.34 -58.84 0.24 Allowed Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -136.29 156.48 48.6 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -1.223 . . . . 0.0 109.734 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.889 HG13 HG22 ' A' ' 71' ' ' VAL . 54.5 t -121.01 154.66 24.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.229 -0.919 . . . . 0.0 109.433 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.582 ' O ' HG13 ' A' ' 69' ' ' VAL . 88.7 mmm -121.99 147.68 45.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.159 -0.963 . . . . 0.0 109.633 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 38.9 t -138.45 103.95 7.81 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.268 -0.895 . . . . 0.0 109.379 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.584 ' HB2' ' CG ' ' A' ' 65' ' ' PHE . 48.7 Cg_endo -70.03 -9.26 25.61 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.643 2.229 . . . . 0.0 111.853 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.4 p -76.04 142.39 41.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.127 -0.983 . . . . 0.0 109.53 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -63.23 -40.47 97.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.209 -0.932 . . . . 0.0 109.412 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -143.18 150.4 39.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.895 . . . . 0.0 109.374 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 70.3 t -63.66 -37.86 80.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 43.2 t -111.82 142.09 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.495 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 87.7 tt0 -82.05 143.62 31.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.248 -0.908 . . . . 0.0 109.543 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 65.1 mt -137.05 107.92 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.255 -0.903 . . . . 0.0 109.379 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 98.0 mtt180 -48.32 -33.12 8.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.23 -0.919 . . . . 0.0 109.497 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -80.13 -113.6 0.28 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 68.49 -120.35 11.36 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 91.8 mt-30 -103.99 152.29 22.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.323 -1.104 . . . . 0.0 109.491 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -58.98 -34.4 71.78 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.443 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 44.8 mtp85 -54.5 145.06 19.44 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.286 -0.884 . . . . 0.0 109.481 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 20.8 tttm -96.74 135.34 38.82 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 50.1 m -119.83 146.72 45.46 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.188 -0.945 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -122.23 150.52 42.18 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.288 -0.882 . . . . 0.0 109.501 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 11.7 mtt85 -104.76 6.13 33.83 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.616 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . 0.453 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 62.4 mttm -62.06 -25.14 67.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.215 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -57.42 -36.62 71.57 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.257 -0.902 . . . . 0.0 109.597 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.584 ' CG ' ' HB2' ' A' ' 45' ' ' PRO . 32.7 m-85 -130.26 80.62 70.28 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.524 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 63' ' ' LYS . 50.9 Cg_endo -70.79 76.73 1.51 Allowed 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.667 2.244 . . . . 0.0 111.964 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 14' ' ' ALA . . . 75.31 33.73 52.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.51 ' N ' ' OE2' ' A' ' 19' ' ' GLU . 0.5 OUTLIER -111.0 119.47 39.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 109.366 179.946 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -134.17 140.62 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.554 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.851 HD12 ' N ' ' A' ' 70' ' ' LEU . 4.0 mp -104.3 141.76 35.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.308 -0.87 . . . . 0.0 109.382 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.889 HG22 HG13 ' A' ' 42' ' ' VAL . 68.9 t -145.26 123.67 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.178 -0.951 . . . . 0.0 109.705 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.421 ' CD ' ' HB3' ' A' ' 7' ' ' LYS . 38.5 tt0 -73.96 124.87 27.02 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.309 -0.869 . . . . 0.0 109.127 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.458 ' SD ' ' OG ' ' A' ' 79' ' ' SER . 8.8 tmm? -169.22 151.52 4.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.293 -0.88 . . . . 0.0 109.398 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.582 ' O ' HG23 ' A' ' 74' ' ' VAL . 28.6 m -77.59 118.97 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.281 -0.887 . . . . 0.0 109.585 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.596 ' HE3' ' CG ' ' A' ' 100' ' ' PRO . 8.5 mmt -61.72 115.84 4.31 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.172 -0.955 . . . . 0.0 109.585 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' A' ' 79' ' ' SER . 50.2 p-10 -151.28 172.74 15.39 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.36 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -63.4 -33.78 76.29 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.645 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.535 ' HB1' ' CE ' ' A' ' 35' ' ' MET . . . -71.5 -72.36 0.22 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.268 -0.895 . . . . 0.0 109.661 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.524 ' N ' ' OD1' ' A' ' 76' ' ' ASN . 18.0 p -46.63 -57.59 4.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.128 -0.983 . . . . 0.0 109.488 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.525 ' NE1' ' O ' ' A' ' 98' ' ' ASP . 44.0 t90 -43.65 -53.89 5.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.34 -0.85 . . . . 0.0 109.574 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -62.53 -43.41 98.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.179 -0.951 . . . . 0.0 109.61 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 1.008 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.8 OUTLIER -55.81 -43.1 76.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.199 -0.938 . . . . 0.0 109.491 -179.843 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.684 HG11 ' CE2' ' A' ' 92' ' ' PHE . 98.2 t -61.01 -52.11 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 57.4 ttt85 -55.63 -35.08 65.5 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.253 -0.905 . . . . 0.0 109.566 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 39.9 m -59.58 -37.22 77.93 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.187 -0.946 . . . . 0.0 109.555 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.699 HG11 HG13 ' A' ' 22' ' ' VAL . 91.8 t -54.99 125.56 56.92 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 109.516 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.7 Cg_endo -71.25 160.28 49.39 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.624 2.216 . . . . 0.0 111.769 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.531 ' HG3' ' NH2' ' A' ' 21' ' ' ARG . 50.1 mmt-85 63.66 30.79 14.79 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.695 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.68 HG12 ' O ' ' A' ' 86' ' ' VAL . 6.1 p -129.24 130.63 67.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.157 -0.964 . . . . 0.0 109.375 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.509 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.1 mmm -76.46 -54.98 5.97 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.538 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 166.67 -150.12 16.74 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.684 ' CE2' HG11 ' A' ' 83' ' ' VAL . 6.5 m-85 -105.5 161.86 13.98 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -1.131 . . . . 0.0 109.561 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.957 HD11 ' HB2' ' A' ' 13' ' ' GLN . 19.3 mm -120.3 122.13 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.262 -0.899 . . . . 0.0 109.415 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -179.66 -144.39 5.88 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -63.62 -45.25 95.04 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 p -130.76 171.01 13.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.219 -1.165 . . . . 0.0 109.463 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.9 p -89.02 16.61 6.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.144 -0.972 . . . . 0.0 109.37 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.525 ' O ' ' NE1' ' A' ' 80' ' ' TRP . 86.1 m-20 -125.64 -27.14 3.42 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.533 -0.729 . . . . 0.0 109.261 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 30.3 mtt180 -140.16 97.63 7.73 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.339 -0.851 . . . . 0.0 108.846 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' CG ' ' HE3' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.72 127.12 15.73 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.79 2.327 . . . . 0.0 112.067 -179.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.63 138.51 93.5 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.256 -0.902 . . . . 0.0 109.234 179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.514 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.8 Cg_endo -70.45 153.66 65.6 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.603 2.202 . . . . 0.0 111.845 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 34.9 pt -127.55 161.08 35.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.452 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.484 ' HB2' ' HG2' ' A' ' 107' ' ' GLU . 43.7 m -71.79 150.56 44.27 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.348 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -56.93 -37.91 72.15 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.335 -0.853 . . . . 0.0 109.456 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 79.3 tttt -60.35 -34.02 73.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.441 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.484 ' HG2' ' HB2' ' A' ' 104' ' ' SER . 76.5 mm-40 -59.12 -41.85 89.17 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.922 . . . . 0.0 109.384 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.491 HG21 ' CG ' ' A' ' 9' ' ' TRP . 90.0 t -63.33 -36.2 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.24 -0.913 . . . . 0.0 109.434 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -66.6 -38.71 87.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.276 -0.89 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.69 -47.7 77.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.586 HD12 HD21 ' A' ' 70' ' ' LEU . 45.2 mt -50.49 -51.41 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.497 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 96.2 mmm -60.32 -35.87 76.63 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.156 -0.965 . . . . 0.0 109.387 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -61.82 -32.7 73.03 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.246 -0.909 . . . . 0.0 109.42 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.415 ' O ' ' C ' ' A' ' 115' ' ' LEU . 59.2 mtt180 -56.23 -50.69 70.57 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.283 -0.885 . . . . 0.0 109.458 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.415 ' C ' ' O ' ' A' ' 114' ' ' ARG . 10.3 tp -44.88 -47.9 11.16 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.292 -0.88 . . . . 0.0 109.354 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -71.43 -29.66 65.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.208 -0.933 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -75.47 131.21 39.98 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.474 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 75.5 t -68.08 -35.74 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.296 -0.878 . . . . 0.0 109.516 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.56 45.7 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -55.51 -36.7 67.0 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.209 -1.171 . . . . 0.0 109.515 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 53.76 68.52 2.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.206 -0.934 . . . . 0.0 109.526 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -69.95 147.0 60.67 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 122.631 2.22 . . . . 0.0 111.825 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 66.0 mtp85 . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.48 -179.963 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.0 mtm . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.7 p -63.23 -22.72 67.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.21 -0.931 . . . . 0.0 109.499 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -91.92 150.7 20.89 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.167 -0.958 . . . . 0.0 109.453 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 58.12 62.07 5.16 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.09 -19.22 34.85 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.714 2.276 . . . . 0.0 111.782 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 31.5 mmtm -90.43 155.87 18.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 40.1 mttt -82.61 139.89 33.51 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -0.93 . . . . 0.0 109.399 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.505 ' HD2' ' HB3' ' A' ' 102' ' ' PRO . 23.1 mtm180 -122.26 154.85 37.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.231 -0.918 . . . . 0.0 109.532 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -93.56 137.69 32.58 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.549 ' CE1' ' O ' ' A' ' 100' ' ' PRO . 46.0 m-85 -131.85 164.19 26.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.868 . . . . 0.0 109.567 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.428 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 40.9 t -99.2 139.89 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.223 -0.923 . . . . 0.0 109.53 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.9 t -122.74 119.54 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.172 -0.955 . . . . 0.0 109.437 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.588 ' HB2' HD11 ' A' ' 93' ' ' ILE . 49.8 tt0 -87.24 135.44 33.31 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.223 -0.923 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.887 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -141.32 161.28 38.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.369 -0.832 . . . . 0.0 109.41 -179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CD2' ' HA ' ' A' ' 88' ' ' ARG . 97.4 m-85 -57.75 149.99 20.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.511 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 35.0 t -71.9 145.94 48.18 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.202 -0.936 . . . . 0.0 109.403 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.51 -34.37 4.21 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.843 ' O ' HG23 ' A' ' 22' ' ' VAL . 17.9 m-30 -108.48 6.61 26.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.261 -1.141 . . . . 0.0 109.502 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.866 ' OE2' HG21 ' A' ' 46' ' ' THR . 22.8 pt-20 -51.62 -43.84 62.69 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.331 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.505 ' N ' ' CG ' ' A' ' 19' ' ' GLU . . . -67.29 -54.35 20.76 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -58.68 -40.57 83.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.174 -1.192 . . . . 0.0 109.389 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.887 HG21 ' HB1' ' A' ' 14' ' ' ALA . 76.6 t -50.75 -48.67 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.272 -0.893 . . . . 0.0 109.408 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.029 ' HB1' HG11 ' A' ' 42' ' ' VAL . . . -55.32 -40.73 71.49 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.243 -0.911 . . . . 0.0 109.336 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 39.2 m -65.83 -39.94 91.32 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.249 -0.907 . . . . 0.0 109.418 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.463 ' O ' ' HB2' ' A' ' 28' ' ' GLU . 21.1 m -57.85 -46.35 84.93 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.254 -0.904 . . . . 0.0 109.398 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.465 ' O ' HG12 ' A' ' 30' ' ' ILE . 34.9 mt -52.27 -55.98 17.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.348 -0.845 . . . . 0.0 109.357 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.408 ' C ' ' O ' ' A' ' 26' ' ' LEU . 49.3 ttt-85 -42.58 -40.75 2.8 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.417 -0.802 . . . . 0.0 109.57 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.463 ' HB2' ' O ' ' A' ' 25' ' ' SER . 89.7 mt-10 -58.85 -39.05 80.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.21 -0.931 . . . . 0.0 109.393 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.574 ' NE2' ' CG2' ' A' ' 86' ' ' VAL . 66.0 m-70 -82.18 -19.85 39.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.268 -0.895 . . . . 0.0 109.352 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.708 HD12 ' CE1' ' A' ' 39' ' ' PHE . 20.5 mm -75.34 -48.46 31.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.239 -0.913 . . . . 0.0 109.225 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.8 tttt -71.53 -41.22 69.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.338 -0.851 . . . . 0.0 109.236 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.45 HD23 ' HA ' ' A' ' 32' ' ' LEU . 67.0 mt -63.9 -47.42 80.66 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.449 -0.782 . . . . 0.0 109.404 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.633 ' CD2' HD11 ' A' ' 82' ' ' LEU . 88.8 m-70 -84.05 9.25 12.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 109.503 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 34.8 t-20 49.08 48.47 20.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.214 -0.929 . . . . 0.0 109.394 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.636 ' SD ' HD22 ' A' ' 82' ' ' LEU . 41.4 mtt -102.79 -0.66 31.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 35' ' ' MET . 97.2 mt-10 -43.89 -36.04 2.23 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.243 -0.91 . . . . 0.0 109.647 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -56.96 -50.25 73.21 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.205 -0.934 . . . . 0.0 109.713 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.543 HD12 ' CA ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -71.31 -48.52 50.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.306 -0.871 . . . . 0.0 109.52 -179.691 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.708 ' CE1' HD12 ' A' ' 30' ' ' ILE . 66.1 m-85 -70.4 141.35 52.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.323 -0.861 . . . . 0.0 109.452 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.472 ' HA3' ' OE1' ' A' ' 72' ' ' GLN . . . -102.65 -70.12 0.84 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -158.66 147.21 18.53 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.187 -1.184 . . . . 0.0 109.495 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.029 HG11 ' HB1' ' A' ' 23' ' ' ALA . 60.1 t -95.79 138.45 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.499 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.623 ' HE1' HG11 ' A' ' 108' ' ' VAL . 65.1 mtm -121.32 150.09 41.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.368 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.82 HG12 ' H ' ' A' ' 46' ' ' THR . 93.4 t -144.58 127.02 8.3 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 109.576 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.5 ' HB2' HD13 ' A' ' 115' ' ' LEU . 50.0 Cg_endo -70.47 -8.54 23.84 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.687 2.258 . . . . 0.0 111.684 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.866 HG21 ' OE2' ' A' ' 19' ' ' GLU . 16.2 p -104.81 37.96 2.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.908 . . . . 0.0 109.492 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -47.33 -34.66 7.1 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.214 -0.929 . . . . 0.0 109.379 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -101.8 131.98 47.81 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.356 -0.84 . . . . 0.0 109.419 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 40.8 t -121.88 136.45 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.307 -0.871 . . . . 0.0 109.426 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.21 148.65 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.229 -0.919 . . . . 0.0 109.563 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.461 ' OE2' ' HD3' ' A' ' 53' ' ' ARG . 65.3 tt0 -121.58 138.57 54.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.295 -0.878 . . . . 0.0 109.454 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.2 tt -57.23 -31.33 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.499 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.461 ' HD3' ' OE2' ' A' ' 51' ' ' GLU . 72.5 mtp85 -57.93 -32.38 67.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.221 -0.924 . . . . 0.0 109.479 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.456 ' O ' ' O ' ' A' ' 53' ' ' ARG . . . -54.78 -167.87 0.04 OUTLIER Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 54' ' ' GLY . . . -45.01 103.92 0.06 OUTLIER Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 96.1 mt-30 -61.13 -32.2 71.91 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -1.135 . . . . 0.0 109.47 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 20.9 ttp85 -53.44 -38.6 63.67 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.2 -0.937 . . . . 0.0 109.47 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 89.6 mtt-85 -83.56 131.66 34.97 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.236 -0.915 . . . . 0.0 109.529 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 63.6 tttm -139.65 125.23 19.28 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.869 . . . . 0.0 109.467 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 27.3 t -177.48 112.15 0.08 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.206 -0.934 . . . . 0.0 109.383 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -132.79 145.69 51.21 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.635 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.43 ' HB2' ' CE2' ' A' ' 64' ' ' PHE . 77.0 mtt180 -120.87 148.21 44.35 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.259 -0.901 . . . . 0.0 109.338 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 56.3 mttp -107.33 121.97 45.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.263 -0.898 . . . . 0.0 109.62 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.569 ' CE1' ' HA ' ' A' ' 115' ' ' LEU . 77.8 m-85 -127.5 156.94 41.37 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.352 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.425 ' C ' ' O ' ' A' ' 64' ' ' PHE . 1.4 p90 -42.19 101.08 0.24 Allowed Pre-proline 0 N--CA 1.492 1.652 0 O-C-N 121.346 -0.846 . . . . 0.0 109.647 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.466 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 53.2 Cg_endo -72.81 152.09 52.13 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.637 2.225 . . . . 0.0 111.806 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.457 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . 67.75 29.84 74.1 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.722 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.2 m-85 -128.61 115.3 17.86 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.196 -1.179 . . . . 0.0 109.375 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 43' ' ' MET . 87.3 t -132.9 144.85 35.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.262 -0.899 . . . . 0.0 109.609 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.854 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.1 mp -101.06 129.53 46.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.278 -0.889 . . . . 0.0 109.328 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.745 HG22 HG13 ' A' ' 42' ' ' VAL . 91.0 t -140.75 115.36 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.23 -0.919 . . . . 0.0 109.76 -179.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.472 ' OE1' ' HA3' ' A' ' 40' ' ' GLY . 36.9 tt0 -65.98 135.9 55.33 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.928 . . . . 0.0 109.171 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.575 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 10.9 ttp -173.78 152.1 1.95 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.16 -0.962 . . . . 0.0 109.587 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.526 ' N ' ' HG2' ' A' ' 73' ' ' MET . 38.7 t -81.67 141.2 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.281 179.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.559 ' HE1' ' HG2' ' A' ' 100' ' ' PRO . 15.1 tpp -78.1 100.12 6.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.212 -0.93 . . . . 0.0 109.74 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.507 ' ND2' HD22 ' A' ' 38' ' ' LEU . 51.4 p-10 -140.87 169.39 17.71 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.216 -0.928 . . . . 0.0 109.306 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -72.67 -26.39 61.61 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.271 -0.893 . . . . 0.0 109.5 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.58 -71.31 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.221 -0.925 . . . . 0.0 109.584 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 83' ' ' VAL . 11.4 p -53.47 -45.19 69.47 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.537 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.433 ' HB2' ' O ' ' A' ' 76' ' ' ASN . 74.9 t90 -56.44 -59.01 5.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.551 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -54.92 -44.01 73.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.181 -0.949 . . . . 0.0 109.327 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.636 HD22 ' SD ' ' A' ' 35' ' ' MET . 41.1 tp -56.13 -47.8 77.44 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.813 HG11 ' CE2' ' A' ' 92' ' ' PHE . 80.0 t -50.41 -48.05 25.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 109.245 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 16.5 ttt-85 -70.63 -28.17 64.62 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.32 -0.863 . . . . 0.0 109.383 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 50.4 m -58.82 -47.15 85.8 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.222 -0.924 . . . . 0.0 109.35 179.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.574 ' CG2' ' NE2' ' A' ' 29' ' ' HIS . 4.4 p -76.08 132.39 73.93 Favored Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.222 -0.924 . . . . 0.0 109.459 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.532 ' O ' HG23 ' A' ' 89' ' ' VAL . 47.7 Cg_endo -69.02 -174.03 0.7 Allowed 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.672 2.248 . . . . 0.0 111.892 -179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.616 ' HB3' HG22 ' A' ' 22' ' ' VAL . 70.1 mtt85 63.69 32.04 14.01 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.359 -0.838 . . . . 0.0 109.444 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.532 HG23 ' O ' ' A' ' 87' ' ' PRO . 6.4 t -131.89 117.26 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.521 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 83.2 mtp -73.73 -38.29 64.84 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.484 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 148.62 -176.26 27.5 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.813 ' CE2' HG11 ' A' ' 83' ' ' VAL . 15.7 m-85 -94.98 158.25 15.55 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.311 -1.111 . . . . 0.0 109.649 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.722 HG21 ' OH ' ' A' ' 68' ' ' TYR . 18.9 mm -118.55 114.24 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.301 -0.875 . . . . 0.0 109.378 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -167.01 -141.77 3.25 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -75.55 -29.12 60.2 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 21.0 p -136.33 169.32 17.85 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.199 -1.177 . . . . 0.0 109.655 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -91.72 19.61 6.29 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.356 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.432 ' OD1' ' C ' ' A' ' 98' ' ' ASP . 48.1 p30 -140.73 11.05 2.25 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.55 -0.718 . . . . 0.0 109.081 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 0.3 OUTLIER -171.88 97.8 0.39 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.327 -0.858 . . . . 0.0 108.916 179.986 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.571 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 49.7 Cg_endo -68.94 113.75 3.34 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.752 2.301 . . . . 0.0 111.949 -179.612 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -56.91 142.02 74.17 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.229 -0.92 . . . . 0.0 109.357 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.505 ' HB3' ' HD2' ' A' ' 8' ' ' ARG . 50.9 Cg_endo -70.22 153.98 66.33 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.715 2.277 . . . . 0.0 111.922 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.632 HD11 HG22 ' A' ' 108' ' ' VAL . 31.3 pt -129.23 152.73 37.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.287 -0.883 . . . . 0.0 109.448 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.9 m -67.0 145.29 55.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.617 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -53.75 -41.03 66.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.888 . . . . 0.0 109.497 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 30.3 tttm -59.19 -44.57 92.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.257 -0.902 . . . . 0.0 109.397 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.462 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 83.2 tt0 -51.17 -46.32 62.04 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.343 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.632 HG22 HD11 ' A' ' 103' ' ' ILE . 60.4 t -53.97 -41.56 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.229 -0.919 . . . . 0.0 109.282 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -59.77 -41.18 90.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.197 -0.939 . . . . 0.0 109.247 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.453 ' O ' ' HB2' ' A' ' 113' ' ' ASN . . . -59.52 -52.62 64.77 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.278 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.4 HG21 HD13 ' A' ' 111' ' ' ILE . 54.1 mt -47.05 -51.91 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.299 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 87.8 mtp -56.5 -37.02 69.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.233 -0.917 . . . . 0.0 109.322 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.453 ' HB2' ' O ' ' A' ' 110' ' ' ALA . 97.4 m-20 -58.13 -34.93 70.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.91 . . . . 0.0 109.366 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 117' ' ' GLN . 59.2 mtt180 -50.54 -45.83 57.11 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.233 -0.917 . . . . 0.0 109.435 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.569 ' HA ' ' CE1' ' A' ' 64' ' ' PHE . 7.3 tp -44.08 -44.14 7.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.432 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 62.7 tt0 -62.6 -29.84 70.9 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.885 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.492 ' N ' ' O ' ' A' ' 114' ' ' ARG . 63.3 tt0 -69.14 139.29 54.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.325 -0.859 . . . . 0.0 109.51 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.514 ' CG1' ' OD1' ' A' ' 120' ' ' ASP . 86.2 t -54.76 -44.05 69.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -0.894 . . . . 0.0 109.491 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 86.93 26.13 32.56 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.514 ' OD1' ' CG1' ' A' ' 118' ' ' VAL . 96.9 m-20 -55.76 -36.03 66.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.305 -1.115 . . . . 0.0 109.447 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 11.7 mtmt -91.95 110.8 46.35 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.278 -0.889 . . . . 0.0 109.485 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -69.97 147.49 61.66 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.686 2.258 . . . . 0.0 111.83 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.5 mtt-85 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.45 -179.936 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.1 mtp . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 85.5 p -61.85 -30.78 71.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.536 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -61.11 -36.23 79.13 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.301 -0.875 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -73.6 149.97 88.68 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.422 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.17 147.31 59.94 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.658 2.239 . . . . 0.0 111.768 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 23.3 mttp -89.99 143.45 26.77 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.301 -0.874 . . . . 0.0 109.431 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 54.7 mttp -89.44 134.66 33.99 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.229 -0.92 . . . . 0.0 109.536 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.413 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 96.2 mtt180 -126.14 158.95 34.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.251 -0.905 . . . . 0.0 109.466 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.51 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 58.8 m95 -99.82 121.09 40.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.955 . . . . 0.0 109.788 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.589 ' CE2' ' HG2' ' A' ' 75' ' ' MET . 96.6 m-85 -114.77 157.59 23.01 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.31 -0.869 . . . . 0.0 109.229 179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.459 ' HB ' ' HB ' ' A' ' 93' ' ' ILE . 88.6 t -105.89 143.48 16.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 109.599 -179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.0 t -120.99 127.96 76.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.314 -0.866 . . . . 0.0 109.472 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.915 ' HB2' HD11 ' A' ' 93' ' ' ILE . 68.2 tp60 -86.98 145.32 26.55 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.26 -0.9 . . . . 0.0 109.48 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -152.09 153.87 34.8 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.54 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -58.72 144.27 44.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.267 -0.895 . . . . 0.0 109.517 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 26.2 t -61.9 141.09 58.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.18 -0.95 . . . . 0.0 109.43 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.94 -31.18 5.43 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.5 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 90.3 m-85 -105.01 7.33 33.99 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.267 -1.137 . . . . 0.0 109.585 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.576 ' CG ' ' CG2' ' A' ' 69' ' ' VAL . 85.5 tt0 -58.44 -42.59 87.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.117 -0.99 . . . . 0.0 109.382 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -70.82 -38.0 65.91 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD2' ' HD2' ' A' ' 88' ' ' ARG . 22.2 ttm180 -62.02 -50.63 71.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.246 -1.15 . . . . 0.0 109.442 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.476 HG13 HG11 ' A' ' 86' ' ' VAL . 37.4 t -49.45 -41.02 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 109.181 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 -42.39 99.13 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.299 -0.876 . . . . 0.0 109.234 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 41.5 m -67.38 -47.12 71.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.273 -0.892 . . . . 0.0 109.341 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.9 m -64.66 -34.41 78.23 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.253 -0.904 . . . . 0.0 109.375 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.817 ' CD2' HD11 ' A' ' 30' ' ' ILE . 5.4 tt -58.57 -53.54 57.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.304 -0.873 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.403 ' NE ' ' NZ ' ' A' ' 31' ' ' LYS . 23.0 tpt180 -45.14 -46.0 11.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.254 -0.904 . . . . 0.0 109.598 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -53.5 -50.88 64.46 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.558 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.582 ' HB3' HD11 ' A' ' 82' ' ' LEU . 94.7 m-70 -56.92 -29.1 62.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.286 -0.883 . . . . 0.0 109.533 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 1.052 HD12 ' CD1' ' A' ' 39' ' ' PHE . 10.2 mm -68.94 -53.72 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.227 -0.921 . . . . 0.0 109.567 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.51 ' CD ' ' OE2' ' A' ' 36' ' ' GLU . 24.8 mmtm -66.05 -44.18 85.3 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.238 -0.914 . . . . 0.0 109.658 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.453 ' HA ' HD23 ' A' ' 32' ' ' LEU . 49.0 mt -61.32 -55.95 25.99 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.277 -0.89 . . . . 0.0 109.611 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.843 ' CD2' HD11 ' A' ' 82' ' ' LEU . 90.8 m-70 -81.87 7.53 12.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 109.525 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 53.1 t30 48.83 45.76 22.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.19 -0.944 . . . . 0.0 109.585 179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.933 ' HG3' HD22 ' A' ' 82' ' ' LEU . 35.2 mmm -99.55 20.57 13.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.374 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' OE2' ' CD ' ' A' ' 31' ' ' LYS . 83.9 mt-10 -53.83 -36.86 63.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.303 -0.873 . . . . 0.0 109.482 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -59.16 -44.97 92.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.221 -0.925 . . . . 0.0 109.486 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.882 HD13 ' HB3' ' A' ' 79' ' ' SER . 35.2 mt -66.94 -56.66 9.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.918 . . . . 0.0 109.507 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 1.052 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.6 m-85 -72.01 141.08 49.33 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.256 -0.902 . . . . 0.0 109.472 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -125.62 -61.99 0.17 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.55 149.34 43.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.189 -1.183 . . . . 0.0 109.698 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.001 HG13 HG22 ' A' ' 71' ' ' VAL . 45.3 t -117.48 151.86 19.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.344 -0.847 . . . . 0.0 109.328 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.516 ' O ' HG13 ' A' ' 69' ' ' VAL . 80.8 mmm -117.11 137.41 52.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.231 -0.918 . . . . 0.0 109.676 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 44' ' ' VAL . 43.2 t -145.12 82.33 9.95 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.313 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.72 0.68 6.0 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.649 2.233 . . . . 0.0 111.988 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 14.5 t -125.96 144.08 50.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.169 -0.957 . . . . 0.0 109.58 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 47.59 50.27 15.25 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.296 -0.878 . . . . 0.0 109.484 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 44' ' ' VAL . 84.6 tt0 -103.16 129.47 50.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.314 -0.866 . . . . 0.0 109.515 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 80.8 t -63.41 -40.02 87.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.302 -0.874 . . . . 0.0 109.503 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 63.4 t -52.92 -39.01 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -77.89 154.28 31.86 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.219 -0.925 . . . . 0.0 109.474 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 65.0 mt -133.25 94.58 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.269 -0.894 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 50.1 ttm-85 -82.49 149.02 27.8 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.305 -0.872 . . . . 0.0 109.426 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -162.64 -178.84 36.82 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.83 38.64 41.41 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -83.08 139.76 33.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.218 -1.166 . . . . 0.0 109.526 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 15.2 mmt85 -115.74 161.25 18.99 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.261 -0.899 . . . . 0.0 109.446 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.9 ttp180 -51.52 -38.33 53.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.162 -0.961 . . . . 0.0 109.519 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 53.0 tttm -129.95 116.69 18.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.412 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 23.0 t -153.5 156.51 38.25 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -97.2 137.04 36.84 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.275 -0.89 . . . . 0.0 109.424 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.5 mtp180 -134.0 145.58 49.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.207 -0.933 . . . . 0.0 109.576 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.5 ttpt -136.88 121.67 18.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.273 -0.892 . . . . 0.0 109.468 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -131.92 156.05 46.83 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.235 -0.916 . . . . 0.0 109.518 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.556 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 23.3 p90 -116.65 68.39 4.09 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.167 -0.958 . . . . 0.0 109.583 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.49 155.77 62.83 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.429 ' O ' ' NE2' ' A' ' 13' ' ' GLN . . . 101.21 -6.65 56.28 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.419 ' CE1' ' OE1' ' A' ' 13' ' ' GLN . 1.8 m-85 -119.71 117.21 27.64 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.2 -1.176 . . . . 0.0 109.455 179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG ' ' A' ' 19' ' ' GLU . 78.4 t -131.61 141.85 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.232 -0.917 . . . . 0.0 109.657 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.843 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.7 mp -106.97 132.96 52.32 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.292 -0.88 . . . . 0.0 109.271 179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.001 HG22 HG13 ' A' ' 42' ' ' VAL . 86.5 t -137.94 121.67 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.178 -0.951 . . . . 0.0 109.639 -179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.475 ' O ' ' HB2' ' A' ' 73' ' ' MET . 38.0 tt0 -72.16 137.1 46.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.267 -0.895 . . . . 0.0 109.199 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.524 ' HG2' ' N ' ' A' ' 74' ' ' VAL . 45.8 ttp 171.81 157.73 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.263 -0.898 . . . . 0.0 109.604 -179.783 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.59 ' CG1' HD22 ' A' ' 38' ' ' LEU . 12.2 p -85.69 138.31 19.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.305 -0.872 . . . . 0.0 109.174 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.589 ' HG2' ' CE2' ' A' ' 10' ' ' TYR . 16.4 mmt -90.04 115.36 27.26 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.208 -0.932 . . . . 0.0 109.491 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.489 ' OD1' ' N ' ' A' ' 79' ' ' SER . 48.8 p-10 -140.48 -176.59 4.69 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.351 -0.843 . . . . 0.0 109.425 -179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -73.37 -11.6 60.54 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.207 -0.933 . . . . 0.0 109.456 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.598 ' HA ' ' CE1' ' A' ' 81' ' ' HIS . . . -94.23 -71.1 0.68 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.466 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.882 ' HB3' HD13 ' A' ' 38' ' ' LEU . 68.9 p -50.69 -48.13 58.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.379 -0.826 . . . . 0.0 109.516 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.61 ' NE1' ' CE2' ' A' ' 92' ' ' PHE . 79.7 t90 -48.51 -58.92 3.95 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.216 -0.928 . . . . 0.0 109.694 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.625 ' CD2' ' N ' ' A' ' 82' ' ' LEU . 1.5 p-80 -57.84 -30.84 66.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.085 -1.009 . . . . 0.0 109.213 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.933 HD22 ' HG3' ' A' ' 35' ' ' MET . 19.0 tp -68.52 -36.34 78.73 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.384 -0.823 . . . . 0.0 109.328 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.545 HG11 ' CE1' ' A' ' 92' ' ' PHE . 77.5 t -62.04 -42.63 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.248 -0.908 . . . . 0.0 109.399 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 4.4 tpt85 -65.96 -33.25 75.4 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.306 -0.871 . . . . 0.0 109.377 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 35.8 m -60.07 -32.96 71.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.173 -0.954 . . . . 0.0 109.38 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 89' ' ' VAL . 18.8 t -55.37 123.41 49.48 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.244 -0.91 . . . . 0.0 109.487 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.9 Cg_endo -70.83 156.48 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.618 2.212 . . . . 0.0 111.712 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.5 ' HD3' ' CD1' ' A' ' 18' ' ' PHE . 42.4 mtt-85 62.44 35.29 14.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.31 -0.869 . . . . 0.0 109.586 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.588 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.4 p -123.39 125.82 72.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.231 -0.918 . . . . 0.0 109.436 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.539 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 51.3 mtt -68.93 -62.01 1.56 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.87 . . . . 0.0 109.459 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 171.13 -151.57 16.03 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.704 ' O ' HG22 ' A' ' 96' ' ' THR . 93.1 m-85 -96.27 162.96 13.29 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.327 -1.102 . . . . 0.0 109.53 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.915 HD11 ' HB2' ' A' ' 13' ' ' GLN . 47.3 mm -110.97 152.7 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.223 179.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.82 -108.95 3.44 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.409 ' O ' ' C ' ' A' ' 96' ' ' THR . . . -57.06 -37.24 78.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.704 HG22 ' O ' ' A' ' 92' ' ' PHE . 68.8 p 43.73 -148.66 0.05 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -1.167 . . . . 0.0 109.477 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.456 ' O ' ' HB2' ' A' ' 98' ' ' ASP . 26.7 t 44.67 39.92 3.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.249 -0.907 . . . . 0.0 109.173 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.565 ' HB3' ' CZ2' ' A' ' 80' ' ' TRP . 22.8 m-20 67.09 38.2 3.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.347 -0.846 . . . . 0.0 109.313 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.404 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 4.2 mtp180 -161.48 88.41 1.57 Allowed Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.281 -0.887 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.575 ' CG ' ' CE ' ' A' ' 75' ' ' MET . 48.2 Cg_endo -69.96 135.27 29.56 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.783 2.322 . . . . 0.0 111.952 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -99.14 143.48 26.47 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.451 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.45 155.51 63.52 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.823 2.349 . . . . 0.0 111.759 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.431 HG12 ' O ' ' A' ' 9' ' ' TRP . 24.0 pt -125.5 156.32 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.212 -0.93 . . . . 0.0 109.479 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.403 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 48.3 m -69.8 150.22 47.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.303 -0.873 . . . . 0.0 109.531 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -59.68 -42.38 92.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.262 -0.899 . . . . 0.0 109.442 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -53.94 -43.09 69.52 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.314 -0.866 . . . . 0.0 109.424 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.403 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.8 mt-10 -53.78 -44.69 70.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.421 HG22 HD23 ' A' ' 70' ' ' LEU . 98.0 t -55.91 -37.95 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.26 -0.9 . . . . 0.0 109.354 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -70.44 -34.91 72.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.208 -0.933 . . . . 0.0 109.381 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.28 -36.71 84.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.27 -0.894 . . . . 0.0 109.397 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.761 HG13 HD21 ' A' ' 70' ' ' LEU . 32.1 mm -49.6 -56.48 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.241 -0.912 . . . . 0.0 109.28 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . 0.492 ' CE ' ' CE ' ' A' ' 43' ' ' MET . 54.2 mtt -59.84 -31.48 69.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.289 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -61.6 -38.55 87.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.393 -0.817 . . . . 0.0 109.446 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 31.9 mtp85 -56.88 -46.33 81.93 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.249 -0.907 . . . . 0.0 109.399 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 9.4 tp -54.3 -40.19 67.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.269 -0.894 . . . . 0.0 109.416 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -80.3 -4.19 52.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.209 -0.932 . . . . 0.0 109.508 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -78.32 144.72 35.82 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.184 -0.947 . . . . 0.0 109.451 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.6 t -99.59 146.71 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.347 -0.845 . . . . 0.0 109.507 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -48.12 -23.83 3.01 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 83.7 m-20 -67.59 141.08 56.91 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.234 -1.156 . . . . 0.0 109.483 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.9 122.17 74.36 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.307 -0.87 . . . . 0.0 109.452 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.4 144.35 50.38 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.781 2.321 . . . . 0.0 111.759 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 48.4 ttt85 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.052 -0.975 . . . . 0.0 109.489 179.962 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.4 m -122.05 146.51 47.12 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.296 -0.878 . . . . 0.0 109.441 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -52.42 -36.02 53.35 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.226 -0.921 . . . . 0.0 109.468 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 58.7 99.78 0.04 OUTLIER Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.228 -0.92 . . . . 0.0 109.42 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.438 ' O ' ' HB2' ' A' ' 6' ' ' LYS . 50.4 Cg_endo -70.68 -2.45 10.86 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.73 2.287 . . . . 0.0 111.811 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.438 ' HB2' ' O ' ' A' ' 5' ' ' PRO . 57.5 mttp 61.72 42.49 10.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.274 -0.891 . . . . 0.0 109.471 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.514 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 68.4 mttm -87.27 137.54 32.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.219 -0.925 . . . . 0.0 109.54 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.43 ' HB2' ' CE2' ' A' ' 10' ' ' TYR . 63.0 mtt180 -128.16 152.22 48.29 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.332 -0.855 . . . . 0.0 109.419 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.404 ' CZ3' ' HE2' ' A' ' 43' ' ' MET . 92.9 m95 -85.38 129.84 34.72 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.486 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 75' ' ' MET . 81.2 m-85 -122.84 155.77 35.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.391 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 93' ' ' ILE . 43.1 t -92.02 150.76 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.294 -0.879 . . . . 0.0 109.512 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.5 t -132.49 124.29 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.308 -0.87 . . . . 0.0 109.387 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.549 ' HB3' ' HE2' ' A' ' 90' ' ' MET . 96.3 mt-30 -85.18 147.22 26.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.282 -0.886 . . . . 0.0 109.528 -179.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -154.2 155.27 34.97 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.892 . . . . 0.0 109.382 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.519 ' CD1' ' HA ' ' A' ' 88' ' ' ARG . 97.0 m-85 -72.16 147.22 46.82 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.0 m -55.56 144.08 27.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.292 -0.88 . . . . 0.0 109.471 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.436 ' HA2' ' OE1' ' A' ' 51' ' ' GLU . . . 89.91 -33.67 4.36 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -106.45 15.34 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.29 -1.123 . . . . 0.0 109.49 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.427 ' OE2' ' O ' ' A' ' 68' ' ' TYR . 80.5 tt0 -52.43 -39.27 60.81 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.146 -0.971 . . . . 0.0 109.408 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -90.93 -35.61 7.09 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.402 ' O ' ' C ' ' A' ' 22' ' ' VAL . 35.5 ttt-85 -51.72 -52.64 46.87 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.212 -1.169 . . . . 0.0 109.489 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 21' ' ' ARG . 38.9 t -45.64 -38.04 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.175 -0.953 . . . . 0.0 109.314 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.83 -43.04 94.36 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.297 179.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 58.2 m -67.03 -47.03 72.66 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.287 -0.883 . . . . 0.0 109.3 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 20.7 m -61.75 -40.59 95.67 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.36 -0.837 . . . . 0.0 109.435 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.898 ' CD1' HG21 ' A' ' 86' ' ' VAL . 11.5 tp -56.12 -40.98 74.57 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.9 . . . . 0.0 109.488 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 60.3 ttt85 -53.32 -44.14 68.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.309 -0.87 . . . . 0.0 109.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.589 ' O ' HD12 ' A' ' 32' ' ' LEU . 97.4 mt-10 -60.68 -47.82 84.54 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.493 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.51 ' C ' HD11 ' A' ' 82' ' ' LEU . 95.3 m-70 -63.46 -43.5 97.18 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.264 -0.898 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.916 HG23 ' HB2' ' A' ' 35' ' ' MET . 89.3 mt -67.83 -50.76 57.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.902 . . . . 0.0 109.482 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 60.9 tttm -59.6 -40.0 86.04 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.303 -0.873 . . . . 0.0 109.447 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 28' ' ' GLU . 16.0 mt -63.22 -53.98 44.55 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.47 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.458 ' O ' ' HB2' ' A' ' 34' ' ' ASN . 97.4 m-70 -82.99 -0.6 49.56 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.226 -0.921 . . . . 0.0 109.56 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.508 ' N ' ' O ' ' A' ' 30' ' ' ILE . 82.2 m-20 62.56 47.11 5.13 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.18 -0.95 . . . . 0.0 109.356 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.99 ' HG3' HD13 ' A' ' 82' ' ' LEU . 57.8 mmm -90.35 0.57 57.2 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.263 -0.898 . . . . 0.0 109.586 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.451 ' N ' ' CG2' ' A' ' 30' ' ' ILE . 95.4 mt-10 -47.83 -33.38 7.27 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.906 . . . . 0.0 109.489 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -60.4 -42.32 95.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.222 -0.924 . . . . 0.0 109.473 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.617 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.42 -49.41 49.12 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.303 -0.873 . . . . 0.0 109.313 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.61 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 88.5 m-85 -74.74 140.73 44.3 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -110.05 -64.69 0.53 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -140.52 157.44 45.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.182 -1.187 . . . . 0.0 109.53 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.032 HG13 HG22 ' A' ' 71' ' ' VAL . 61.6 t -120.16 147.41 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.203 -0.936 . . . . 0.0 109.517 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.725 ' HE1' HG11 ' A' ' 108' ' ' VAL . 60.7 mtm -131.46 141.9 49.88 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.442 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 42.8 t -124.77 105.01 30.03 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.238 -0.914 . . . . 0.0 109.449 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.83 60.75 2.27 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.721 2.281 . . . . 0.0 111.803 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 29.2 p -137.19 147.61 45.99 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 109.447 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.444 ' HA ' ' OE1' ' A' ' 47' ' ' GLU . 70.8 mm-40 -63.63 -34.8 78.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.234 -0.916 . . . . 0.0 109.373 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 37.4 tp10 -131.63 145.92 51.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.298 -0.876 . . . . 0.0 109.365 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.92 HG23 HG23 ' A' ' 50' ' ' VAL . 18.3 m -63.53 -31.03 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 109.499 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.92 HG23 HG23 ' A' ' 49' ' ' VAL . 31.4 t -110.04 139.62 32.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.289 -0.882 . . . . 0.0 109.525 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.436 ' OE1' ' HA2' ' A' ' 17' ' ' GLY . 86.0 tt0 -85.34 125.55 33.04 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.891 . . . . 0.0 109.411 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.435 HG13 ' HG3' ' A' ' 53' ' ' ARG . 24.9 pt -102.45 -7.87 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.313 -0.867 . . . . 0.0 109.597 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . 0.435 ' HG3' HG13 ' A' ' 52' ' ' ILE . 84.3 mtm180 -110.97 153.8 25.02 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.137 -0.977 . . . . 0.0 109.511 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -136.62 169.02 23.99 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . 94.27 -0.17 65.95 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.418 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 52.8 mt-30 61.55 42.55 11.11 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.231 -1.158 . . . . 0.0 109.537 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 97.2 mtt180 -68.38 139.65 55.83 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.406 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 92.5 mtm-85 -134.77 145.08 48.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.25 -0.906 . . . . 0.0 109.477 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 77.7 mttt -105.36 128.92 53.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.179 -0.951 . . . . 0.0 109.464 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 15.7 m -62.93 -19.47 64.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.368 -0.832 . . . . 0.0 109.463 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 90.0 mt-10 -65.55 -32.24 73.73 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.269 -0.894 . . . . 0.0 109.514 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.576 ' HG2' HG12 ' A' ' 118' ' ' VAL . 65.1 mtt85 -140.32 139.95 35.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.327 -0.858 . . . . 0.0 109.566 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 90.2 mttt -97.9 125.73 42.93 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.215 -0.928 . . . . 0.0 109.541 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -119.11 155.66 31.14 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.234 -0.917 . . . . 0.0 109.46 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.523 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 0.9 OUTLIER -124.34 87.21 54.16 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.235 -0.916 . . . . 0.0 109.538 -179.983 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -70.85 153.65 63.8 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.73 2.287 . . . . 0.0 111.836 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 85.23 9.68 79.35 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.591 ' CE1' HG13 ' A' ' 11' ' ' VAL . 51.7 t80 -108.9 136.14 48.94 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.226 -1.161 . . . . 0.0 109.521 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 39.9 t -144.26 144.8 22.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.298 -0.876 . . . . 0.0 109.567 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.921 ' CD2' HG13 ' A' ' 108' ' ' VAL . 4.3 mp -113.91 130.9 56.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.293 -0.879 . . . . 0.0 109.144 179.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.032 HG22 HG13 ' A' ' 42' ' ' VAL . 93.8 t -144.1 120.73 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.199 -0.938 . . . . 0.0 109.728 -179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.514 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 6.1 tt0 -75.07 129.65 37.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.324 -0.86 . . . . 0.0 109.237 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.604 ' HE2' ' HB2' ' A' ' 79' ' ' SER . 9.8 tmm? -168.63 147.94 4.32 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.313 -0.867 . . . . 0.0 109.58 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 41.4 t -75.81 109.84 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.282 -0.886 . . . . 0.0 109.477 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.578 ' HB2' ' CZ ' ' A' ' 10' ' ' TYR . 22.3 tpp -59.43 120.33 9.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.285 -0.884 . . . . 0.0 109.504 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.659 HD21 ' HB3' ' A' ' 78' ' ' ALA . 31.2 p-10 -155.89 170.55 21.84 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -56.01 -36.54 68.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.557 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.659 ' HB3' HD21 ' A' ' 76' ' ' ASN . . . -70.48 -71.7 0.23 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.339 -0.851 . . . . 0.0 109.623 -179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.604 ' HB2' ' HE2' ' A' ' 73' ' ' MET . 10.0 p -47.14 -48.04 23.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.19 -0.944 . . . . 0.0 109.56 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 77.6 t90 -51.65 -50.07 61.06 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.236 -0.915 . . . . 0.0 109.465 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -66.36 -39.6 89.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.179 -0.951 . . . . 0.0 109.482 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.99 HD13 ' HG3' ' A' ' 35' ' ' MET . 0.5 OUTLIER -59.13 -47.38 85.48 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.945 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.565 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 55.9 t -56.46 -48.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -0.87 . . . . 0.0 109.551 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 53.0 ttt180 -59.4 -36.77 76.45 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.201 -0.937 . . . . 0.0 109.507 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -60.59 -34.2 73.86 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.211 -0.931 . . . . 0.0 109.489 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.898 HG21 ' CD1' ' A' ' 26' ' ' LEU . 14.1 t -60.13 123.95 75.12 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.393 -0.817 . . . . 0.0 109.51 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.442 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.6 Cg_endo -70.75 163.21 39.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.545 2.163 . . . . 0.0 111.7 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.519 ' HA ' ' CD1' ' A' ' 15' ' ' PHE . 78.9 mmt-85 64.61 28.31 13.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.644 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 86' ' ' VAL . 5.8 p -128.93 137.11 58.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.918 . . . . 0.0 109.597 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.549 ' HE2' ' HB3' ' A' ' 13' ' ' GLN . 69.4 mtm -89.97 -42.1 11.37 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.253 -0.904 . . . . 0.0 109.45 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 157.83 -149.73 20.31 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.565 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 90.6 m-85 -102.73 157.21 17.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -1.163 . . . . 0.0 109.52 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 11' ' ' VAL . 8.4 mt -109.3 130.69 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.229 -0.919 . . . . 0.0 109.398 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 148.6 -119.19 1.04 Allowed Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -66.4 -82.94 0.11 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 17.4 p -130.43 -173.98 3.22 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.178 -1.19 . . . . 0.0 109.662 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 42.2 p -97.22 17.66 16.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 109.519 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.447 ' O ' ' HG2' ' A' ' 99' ' ' ARG . 82.0 m-20 -120.98 -24.67 5.53 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.463 -0.773 . . . . 0.0 109.102 179.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 98' ' ' ASP . 7.6 mtt180 -147.87 87.79 5.75 Favored Pre-proline 0 C--N 1.304 -1.405 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.524 ' HB3' ' HB3' ' A' ' 92' ' ' PHE . 42.9 Cg_endo -65.07 120.55 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.939 2.426 . . . . 0.0 112.416 -179.184 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -74.0 134.07 78.19 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.435 -0.791 . . . . 0.0 109.217 179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.411 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 48.7 Cg_endo -69.37 152.82 71.35 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.692 2.261 . . . . 0.0 111.904 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.819 HD11 HG22 ' A' ' 108' ' ' VAL . 30.7 pt -118.5 160.57 18.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.336 -0.853 . . . . 0.0 109.231 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 45.2 m -70.05 150.47 46.57 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.249 -0.907 . . . . 0.0 109.431 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -62.74 -37.81 88.05 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.244 -0.91 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 56.5 tttm -63.24 -37.7 88.26 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -0.85 . . . . 0.0 109.47 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.448 ' OE1' ' HB ' ' A' ' 103' ' ' ILE . 85.5 tt0 -59.82 -39.7 85.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.251 -0.905 . . . . 0.0 109.464 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.921 HG13 ' CD2' ' A' ' 70' ' ' LEU . 73.3 t -62.9 -35.97 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.265 -0.897 . . . . 0.0 109.381 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -68.19 -34.19 75.82 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.247 -0.908 . . . . 0.0 109.489 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -65.78 -38.24 88.49 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.428 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 74.3 mt -55.73 -51.74 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.307 -0.871 . . . . 0.0 109.476 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 53.2 ttm -61.05 -35.52 77.15 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.181 -0.949 . . . . 0.0 109.426 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.0 m120 -59.59 -32.85 70.76 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.252 -0.905 . . . . 0.0 109.494 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -55.91 -36.8 68.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -0.866 . . . . 0.0 109.583 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 69.2 mt -56.39 -37.69 70.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.284 -0.885 . . . . 0.0 109.56 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -88.34 7.36 32.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.259 -0.9 . . . . 0.0 109.645 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 63.2 tt0 -93.74 137.92 32.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.23 -0.919 . . . . 0.0 109.524 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.576 HG12 ' HG2' ' A' ' 62' ' ' ARG . 11.7 m -130.1 152.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.177 -0.952 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.422 ' O ' ' HD3' ' A' ' 122' ' ' PRO . . . -104.83 30.74 9.51 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -56.99 -35.95 69.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.26 -1.141 . . . . 0.0 109.422 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 4.2 pttp -120.03 78.8 25.02 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.251 -0.906 . . . . 0.0 109.396 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 119' ' ' GLY . 49.1 Cg_endo -69.86 -20.42 34.39 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.725 2.283 . . . . 0.0 111.805 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 117.919 -1.039 . . . . 0.0 109.51 179.956 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.5 mtp . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.6 t -53.9 -38.83 65.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.514 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -102.71 156.9 17.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.229 -0.92 . . . . 0.0 109.556 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . 54.65 70.56 1.61 Allowed Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.256 -0.902 . . . . 0.0 109.507 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.22 149.81 64.5 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.651 2.234 . . . . 0.0 111.785 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.447 ' O ' ' HB2' ' A' ' 7' ' ' LYS . 78.1 tttt -126.24 138.92 53.67 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.543 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 25.0 mttt 61.41 118.7 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.343 -0.848 . . . . 0.0 109.518 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.537 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 80.7 mtt85 -117.76 158.27 25.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.582 ' CZ3' ' HG2' ' A' ' 43' ' ' MET . 46.0 m95 -109.53 130.64 55.49 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.255 -0.903 . . . . 0.0 109.506 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CE2' ' O ' ' A' ' 73' ' ' MET . 23.9 m-85 -122.51 143.82 49.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.231 -0.918 . . . . 0.0 109.462 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.524 HG11 ' CE2' ' A' ' 68' ' ' TYR . 15.7 t -99.7 129.99 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.297 -0.877 . . . . 0.0 109.515 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.608 HG22 ' CE1' ' A' ' 92' ' ' PHE . 37.9 t -109.82 131.27 61.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.884 . . . . 0.0 109.458 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.997 ' CG ' HD11 ' A' ' 93' ' ' ILE . 91.8 mt-30 -78.73 150.07 32.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.322 -0.861 . . . . 0.0 109.462 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.708 ' HB1' HG21 ' A' ' 22' ' ' VAL . . . -152.53 151.74 31.06 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.196 -0.94 . . . . 0.0 109.418 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -68.42 143.75 54.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -0.944 . . . . 0.0 109.446 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.3 m -59.3 142.92 50.85 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.227 -0.921 . . . . 0.0 109.421 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.12 -32.33 5.48 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.406 -1.477 . . . . 0.0 109.406 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.828 ' O ' HG23 ' A' ' 22' ' ' VAL . 98.7 m-85 -106.53 7.95 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.297 -1.119 . . . . 0.0 109.489 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.528 ' HG3' HG23 ' A' ' 69' ' ' VAL . 83.5 tt0 -53.74 -32.6 52.77 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.966 . . . . 0.0 109.46 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -83.53 -55.27 2.9 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.3 ttt85 -57.94 -33.66 69.05 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.145 -1.209 . . . . 0.0 109.441 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.828 HG23 ' O ' ' A' ' 18' ' ' PHE . 55.0 t -57.74 -40.89 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -0.908 . . . . 0.0 109.402 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.86 -36.76 85.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.393 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 47.1 m -61.52 -37.31 83.27 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.21 -0.931 . . . . 0.0 109.466 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.477 ' CB ' HG13 ' A' ' 86' ' ' VAL . 24.3 m -60.45 -35.93 77.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.198 -0.939 . . . . 0.0 109.457 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.88 ' CD2' HG21 ' A' ' 86' ' ' VAL . 48.2 mt -60.27 -40.5 90.6 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.302 -0.873 . . . . 0.0 109.393 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -58.35 -45.27 88.49 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.301 -0.874 . . . . 0.0 109.571 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -64.14 -60.8 2.78 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.228 -0.92 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.692 ' CD2' HG22 ' A' ' 86' ' ' VAL . 98.7 m-70 -53.18 -50.78 63.93 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.256 -0.902 . . . . 0.0 109.378 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 82' ' ' LEU . 96.9 mt -58.14 -54.19 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.454 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -53.81 -45.19 70.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.246 -0.909 . . . . 0.0 109.426 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.441 ' HA ' HD23 ' A' ' 32' ' ' LEU . 71.0 mt -64.29 -55.88 18.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.253 -0.904 . . . . 0.0 109.455 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.711 ' CD2' HD12 ' A' ' 82' ' ' LEU . 97.0 m-70 -68.34 -10.54 55.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.312 -0.867 . . . . 0.0 109.384 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.457 ' N ' ' O ' ' A' ' 30' ' ' ILE . 76.1 m-20 61.58 46.63 7.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.331 -0.856 . . . . 0.0 109.389 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.661 ' HB3' HD21 ' A' ' 38' ' ' LEU . 2.6 mtt -95.9 5.67 50.71 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.354 -0.841 . . . . 0.0 109.551 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -50.82 -22.95 2.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.164 -0.96 . . . . 0.0 109.419 179.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -63.38 -40.83 98.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 109.507 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.959 HD12 ' SD ' ' A' ' 73' ' ' MET . 0.4 OUTLIER -91.36 -32.02 15.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.289 -0.882 . . . . 0.0 109.414 -179.953 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.721 ' CZ ' HD22 ' A' ' 82' ' ' LEU . 58.2 m-85 -75.27 136.9 40.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.363 -0.836 . . . . 0.0 109.395 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -118.22 -79.94 0.7 Allowed Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 41' ' ' GLU . 56.7 mp0 -129.38 163.96 24.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.271 -1.135 . . . . 0.0 109.549 -179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 1.093 HG13 HG22 ' A' ' 71' ' ' VAL . 55.2 t -123.16 160.74 25.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.269 -0.894 . . . . 0.0 109.316 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.896 ' O ' HG13 ' A' ' 69' ' ' VAL . 94.4 mmm -117.99 138.43 52.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.935 . . . . 0.0 109.573 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.812 HG12 HG22 ' A' ' 46' ' ' THR . 57.2 t -132.32 74.69 75.55 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.897 . . . . 0.0 109.478 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -70.19 61.01 1.95 Allowed 'Trans proline' 0 C--O 1.214 -0.696 0 C-N-CA 122.673 2.248 . . . . 0.0 111.764 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.812 HG22 HG12 ' A' ' 44' ' ' VAL . 13.5 t -135.0 150.42 50.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.425 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -62.06 -27.43 68.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.312 -0.867 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -49.93 -38.62 37.12 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.164 -0.96 . . . . 0.0 109.526 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 1.059 HG13 HG23 ' A' ' 50' ' ' VAL . 8.2 p -49.95 -35.8 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.231 -0.918 . . . . 0.0 109.415 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 1.059 HG23 HG13 ' A' ' 49' ' ' VAL . 22.4 t -112.61 141.82 26.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.182 -0.949 . . . . 0.0 109.559 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.462 ' C ' HG23 ' A' ' 52' ' ' ILE . 86.8 tt0 -99.19 138.11 36.76 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.414 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.498 ' CG1' ' O ' ' A' ' 52' ' ' ILE . 5.3 pt -155.49 117.53 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.175 -0.953 . . . . 0.0 109.412 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 54.0 mtt180 -47.15 143.93 2.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.314 -0.866 . . . . 0.0 109.431 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -56.95 100.4 0.12 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.367 -1.493 . . . . 0.0 109.367 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.427 ' O ' ' HB2' ' A' ' 56' ' ' GLN . . . -64.72 -30.19 77.27 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.427 ' HB2' ' O ' ' A' ' 55' ' ' GLY . 97.4 mm-40 62.63 42.13 8.7 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.338 -1.095 . . . . 0.0 109.439 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 92.1 mtt180 -75.09 148.29 39.85 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.335 -0.853 . . . . 0.0 109.408 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 50.3 mtt180 -53.51 -34.86 59.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.467 ' HE3' ' HB2' ' A' ' 120' ' ' ASP . 63.6 tttm -88.19 135.89 33.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.188 -0.945 . . . . 0.0 109.392 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 94.2 p -112.77 152.8 28.71 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -106.35 153.21 22.55 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.92 . . . . 0.0 109.495 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 98.3 mtt180 -126.22 149.63 48.92 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.197 -0.939 . . . . 0.0 109.447 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.2 mttt -83.22 126.87 33.11 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.293 -0.88 . . . . 0.0 109.381 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.402 ' HB2' ' CD1' ' A' ' 65' ' ' PHE . 97.7 m-85 -66.37 -42.96 87.24 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.874 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 65' ' ' PHE . 1.9 p90 -139.74 80.6 21.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.547 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -70.01 146.18 57.91 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.733 2.288 . . . . 0.0 111.903 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 74.91 24.49 71.82 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.524 ' CE2' HG11 ' A' ' 11' ' ' VAL . 0.1 OUTLIER -114.89 123.29 48.77 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.189 -1.183 . . . . 0.0 109.502 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.896 HG13 ' O ' ' A' ' 43' ' ' MET . 86.0 t -132.52 144.66 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.326 -0.859 . . . . 0.0 109.572 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.853 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.6 mp -115.91 138.48 51.14 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.278 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 1.093 HG22 HG13 ' A' ' 42' ' ' VAL . 59.5 t -132.46 120.89 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.179 -0.951 . . . . 0.0 109.777 -179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.449 ' O ' ' HB2' ' A' ' 73' ' ' MET . 35.8 tt0 -69.82 142.12 53.18 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.036 179.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.959 ' SD ' HD12 ' A' ' 38' ' ' LEU . 46.9 ttp 173.67 158.41 0.14 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.083 -1.01 . . . . 0.0 109.578 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.765 HG12 ' HB2' ' A' ' 38' ' ' LEU . 9.1 p -82.84 142.74 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.225 -0.922 . . . . 0.0 109.406 179.87 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.592 ' HA ' ' HE3' ' A' ' 75' ' ' MET . 0.0 OUTLIER -72.66 116.1 12.73 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 109.657 -179.77 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.546 ' ND2' ' HB3' ' A' ' 78' ' ' ALA . 51.3 p-10 -143.93 175.48 9.99 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 109.33 179.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -84.6 -18.34 35.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.21 -0.931 . . . . 0.0 109.621 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.546 ' HB3' ' ND2' ' A' ' 76' ' ' ASN . . . -73.67 -57.54 3.92 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.242 -0.912 . . . . 0.0 109.319 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.517 ' HB3' ' CD1' ' A' ' 38' ' ' LEU . 53.4 p -59.34 -41.45 89.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -0.897 . . . . 0.0 109.41 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.417 ' C ' ' O ' ' A' ' 79' ' ' SER . 47.1 t90 -43.98 -45.78 7.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.354 -0.841 . . . . 0.0 109.615 -179.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -79.59 -25.84 41.44 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.231 -0.918 . . . . 0.0 109.43 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.811 ' O ' HG23 ' A' ' 86' ' ' VAL . 0.7 OUTLIER -64.03 -41.45 97.42 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.291 -0.881 . . . . 0.0 109.532 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.875 HG21 ' CZ ' ' A' ' 92' ' ' PHE . 88.6 t -65.94 -48.28 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.257 -0.902 . . . . 0.0 109.521 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 14.8 ttm180 -59.56 -41.41 90.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.509 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 89.0 p -61.96 -27.88 69.16 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.208 -0.933 . . . . 0.0 109.54 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.88 HG21 ' CD2' ' A' ' 26' ' ' LEU . 43.9 t -67.77 126.04 92.09 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.165 -0.959 . . . . 0.0 109.515 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.407 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 48.6 Cg_endo -70.31 163.48 38.55 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 122.653 2.235 . . . . 0.0 111.727 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.443 ' HB2' HG22 ' A' ' 22' ' ' VAL . 63.1 mtt-85 61.54 44.63 8.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.21 -0.931 . . . . 0.0 109.47 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 99.0 t -131.21 118.9 42.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.271 -0.893 . . . . 0.0 109.539 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.51 ' CE ' ' HB3' ' A' ' 13' ' ' GLN . 74.8 mtm -70.57 -42.22 71.38 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 163.81 -162.41 35.06 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.875 ' CZ ' HG21 ' A' ' 83' ' ' VAL . 0.1 OUTLIER -104.82 171.26 7.42 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.235 -1.156 . . . . 0.0 109.453 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.997 HD11 ' CG ' ' A' ' 13' ' ' GLN . 32.6 mm -124.43 128.45 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.452 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 100' ' ' PRO . . . 172.71 -148.96 10.95 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.45 -39.54 50.25 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.412 ' OG1' ' OD1' ' A' ' 98' ' ' ASP . 29.2 p -130.7 171.98 12.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.185 -1.185 . . . . 0.0 109.497 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 p -88.55 14.73 9.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.169 -0.957 . . . . 0.0 109.443 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.429 ' OD1' ' N ' ' A' ' 99' ' ' ARG . 17.8 p30 -130.21 -13.64 3.94 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.542 -0.724 . . . . 0.0 109.772 179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.429 ' N ' ' OD1' ' A' ' 98' ' ' ASP . 49.5 mtt180 -145.75 91.42 5.66 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.231 -0.918 . . . . 0.0 108.884 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.555 ' HG2' ' CE ' ' A' ' 75' ' ' MET . 45.8 Cg_endo -67.48 113.89 3.08 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.774 2.316 . . . . 0.0 112.007 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -67.21 136.84 93.89 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.263 -0.898 . . . . 0.0 109.395 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.537 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 51.2 Cg_endo -70.41 154.67 65.0 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.654 2.236 . . . . 0.0 111.814 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 30.4 pt -124.03 159.7 29.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.237 -0.914 . . . . 0.0 109.496 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 38.5 m -66.04 148.41 51.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.258 -0.902 . . . . 0.0 109.453 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 73.6 m-20 -57.41 -41.59 80.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 19.9 tttt -57.74 -39.81 78.19 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.231 -0.918 . . . . 0.0 109.482 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -51.43 -40.75 59.99 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.224 -0.923 . . . . 0.0 109.417 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.517 HG21 ' CG ' ' A' ' 9' ' ' TRP . 73.8 t -63.02 -34.6 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.388 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -63.24 -38.11 89.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -64.61 -40.4 95.44 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.903 . . . . 0.0 109.386 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 27.0 mm -51.55 -57.32 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.376 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . 0.462 ' SD ' ' CE ' ' A' ' 43' ' ' MET . 88.2 mtp -60.86 -35.71 77.29 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.271 -0.893 . . . . 0.0 109.318 179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 53.0 t-20 -55.17 -43.45 74.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -0.889 . . . . 0.0 109.38 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.43 ' O ' ' N ' ' A' ' 117' ' ' GLN . 90.5 mtt-85 -51.54 -54.29 28.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . . . . . . . . . 11.8 tp -45.63 -46.67 14.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 109.388 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.1 mt-30 -61.31 -28.94 69.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.201 -0.937 . . . . 0.0 109.411 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.43 ' N ' ' O ' ' A' ' 114' ' ' ARG . 56.0 tt0 -73.35 141.02 47.06 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.524 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 3.3 t -120.67 136.09 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.452 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -46.35 -26.83 2.54 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.467 ' HB2' ' HE3' ' A' ' 59' ' ' LYS . 83.7 m-20 -110.48 139.98 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.321 -1.105 . . . . 0.0 109.438 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 6.8 mtpp -122.26 79.64 44.55 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.254 -0.904 . . . . 0.0 109.443 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -69.57 144.3 54.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.772 2.314 . . . . 0.0 111.801 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 23.2 mmt180 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 117.993 -1.004 . . . . 0.0 109.464 179.994 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.0 mtm . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.332 0.587 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 88.0 p -63.0 -25.84 68.57 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.935 . . . . 0.0 109.465 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -107.31 148.16 29.37 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.145 -0.972 . . . . 0.0 109.486 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.99 74.84 71.72 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.302 -0.874 . . . . 0.0 109.46 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.64 140.42 39.36 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.682 2.255 . . . . 0.0 111.822 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.4 mttt -105.45 139.37 40.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.239 -0.913 . . . . 0.0 109.404 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.518 ' CB ' ' OE1' ' A' ' 72' ' ' GLN . 69.5 mttt -127.52 139.35 52.84 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.915 . . . . 0.0 109.468 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.511 ' HD3' ' HB3' ' A' ' 102' ' ' PRO . 96.3 mtt180 -118.62 150.64 39.35 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.261 -0.9 . . . . 0.0 109.293 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.401 ' O ' HG12 ' A' ' 103' ' ' ILE . 65.7 m95 -99.04 135.65 40.14 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 109.668 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.417 ' CD2' ' CE ' ' A' ' 75' ' ' MET . 55.5 m-85 -128.35 153.61 46.85 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.874 . . . . 0.0 109.398 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.916 ' CG1' HD12 ' A' ' 93' ' ' ILE . 3.1 t -100.16 137.46 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.251 -0.906 . . . . 0.0 109.511 -179.816 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.53 124.63 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.214 -0.929 . . . . 0.0 109.365 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.526 ' CB ' ' HB2' ' A' ' 90' ' ' MET . 98.0 mt-30 -90.47 145.73 24.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.512 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -149.63 163.47 37.8 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.259 -0.901 . . . . 0.0 109.332 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -67.02 140.88 57.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.189 -0.944 . . . . 0.0 109.52 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.9 m -58.07 145.78 35.35 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 90.55 -31.07 5.67 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . 0.514 ' CD1' ' HD3' ' A' ' 88' ' ' ARG . 96.5 m-85 -111.21 9.82 21.8 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.189 -1.183 . . . . 0.0 109.436 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.514 ' OE2' ' CG ' ' A' ' 45' ' ' PRO . 81.6 tt0 -61.11 -29.9 70.04 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.253 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -81.45 -36.9 18.99 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 30.4 ttt180 -66.87 -49.05 66.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.281 -1.129 . . . . 0.0 109.419 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.619 HG21 ' O ' ' A' ' 88' ' ' ARG . 21.8 t -48.33 -41.56 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.132 -0.98 . . . . 0.0 109.038 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -57.7 -46.59 84.14 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.312 -0.867 . . . . 0.0 109.504 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 88.4 m -62.38 -37.13 84.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.557 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.572 ' O ' ' CD2' ' A' ' 29' ' ' HIS . 98.6 p -65.99 -37.0 84.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.17 -0.956 . . . . 0.0 109.435 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.688 ' CD2' HG21 ' A' ' 86' ' ' VAL . 50.4 mt -52.44 -72.06 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.186 -0.946 . . . . 0.0 109.35 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.402 ' C ' ' O ' ' A' ' 26' ' ' LEU . 41.8 ttm180 -44.25 -41.48 5.91 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.351 -0.843 . . . . 0.0 109.534 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 60.6 tt0 -56.1 -37.36 69.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.909 . . . . 0.0 109.479 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.572 ' CD2' ' O ' ' A' ' 25' ' ' SER . 89.8 m-70 -79.27 -29.24 42.45 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.892 . . . . 0.0 109.374 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.958 HD12 ' CD1' ' A' ' 39' ' ' PHE . 17.6 mm -66.79 -43.4 89.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.279 -0.888 . . . . 0.0 109.559 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 85.9 mttt -67.19 -36.87 82.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.525 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.452 ' HA ' HD23 ' A' ' 32' ' ' LEU . 38.4 mt -70.18 -53.51 16.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.218 -0.926 . . . . 0.0 109.545 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.691 ' CD2' HD12 ' A' ' 82' ' ' LEU . 97.6 m-70 -84.76 10.95 10.04 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.514 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 69.9 m-20 46.34 46.74 13.77 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.235 -0.916 . . . . 0.0 109.443 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.853 ' HG3' HD13 ' A' ' 82' ' ' LEU . 56.8 mmm -97.25 15.76 21.88 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.195 -0.941 . . . . 0.0 109.499 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.51 ' N ' HG22 ' A' ' 30' ' ' ILE . 74.9 mm-40 -55.34 -33.21 63.15 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.897 . . . . 0.0 109.447 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -65.43 -45.91 81.99 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.277 -0.889 . . . . 0.0 109.357 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.477 HD13 ' CE ' ' A' ' 35' ' ' MET . 1.5 mt -68.04 -55.26 13.23 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.303 -0.873 . . . . 0.0 109.26 179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.958 ' CD1' HD12 ' A' ' 30' ' ' ILE . 77.6 m-85 -67.37 141.6 57.03 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.323 -0.861 . . . . 0.0 109.435 179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -104.99 -69.28 0.76 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -143.14 166.17 25.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.253 -1.145 . . . . 0.0 109.542 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 83.3 t -117.4 138.38 48.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.206 -0.934 . . . . 0.0 109.412 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.771 ' O ' HG13 ' A' ' 69' ' ' VAL . 83.2 mtp -127.87 156.35 42.71 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.208 -0.933 . . . . 0.0 109.466 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.69 HG12 ' H ' ' A' ' 46' ' ' THR . 31.9 t -146.79 132.34 9.25 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.271 -0.893 . . . . 0.0 109.382 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.514 ' CG ' ' OE2' ' A' ' 19' ' ' GLU . 49.1 Cg_endo -69.98 -0.65 7.41 Favored 'Trans proline' 0 C--O 1.215 -0.625 0 C-N-CA 122.605 2.203 . . . . 0.0 111.792 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.69 ' H ' HG12 ' A' ' 44' ' ' VAL . 2.4 p -133.84 151.43 51.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.152 -0.967 . . . . 0.0 109.45 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -119.11 135.54 54.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.164 -0.96 . . . . 0.0 109.487 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -65.82 143.87 57.2 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 109.567 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.626 ' O ' HG13 ' A' ' 50' ' ' VAL . 21.7 m -127.13 155.76 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.243 -0.911 . . . . 0.0 109.485 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 49' ' ' VAL . 13.9 m -160.23 -41.4 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.251 -0.906 . . . . 0.0 109.441 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.42 ' N ' HG23 ' A' ' 50' ' ' VAL . 23.9 pt-20 -67.94 -26.55 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.741 HG23 ' O ' ' A' ' 52' ' ' ILE . 6.2 tp -133.46 101.49 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.199 -0.938 . . . . 0.0 109.58 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 30.1 mmm-85 -56.76 -35.58 68.82 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.26 -0.9 . . . . 0.0 109.434 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 92.03 -164.56 28.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 58' ' ' ARG . . . -140.43 178.05 20.26 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -60.82 -32.39 71.76 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.263 -1.139 . . . . 0.0 109.573 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -56.42 -35.28 67.63 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.197 -0.939 . . . . 0.0 109.494 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . 0.461 ' O ' ' O ' ' A' ' 55' ' ' GLY . 90.9 mtt180 -118.97 146.91 44.61 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 109.46 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 34.0 tttp -132.77 132.05 41.82 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.287 -0.883 . . . . 0.0 109.514 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 24.5 m -50.89 -43.32 59.65 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.204 -0.935 . . . . 0.0 109.458 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -68.66 144.28 54.51 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.47 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.443 ' NE ' HD11 ' A' ' 115' ' ' LEU . 92.6 mtt-85 -121.45 146.48 46.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.246 -0.909 . . . . 0.0 109.496 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 34.9 mttm -87.15 -8.38 57.02 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.553 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.512 ' C ' ' CG ' ' A' ' 65' ' ' PHE . 20.3 m-85 -48.43 -37.19 16.51 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.583 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.946 ' CE2' HG23 ' A' ' 111' ' ' ILE . 0.0 OUTLIER 169.96 76.14 0.03 OUTLIER Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.956 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -71.25 153.07 61.99 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.691 2.261 . . . . 0.0 111.802 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 13' ' ' GLN . . . 71.93 10.12 72.14 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.529 ' CE2' HD13 ' A' ' 93' ' ' ILE . 2.7 m-85 -112.25 121.4 44.81 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.112 -1.228 . . . . 0.0 109.574 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 43' ' ' MET . 57.8 t -129.41 144.12 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.217 -0.927 . . . . 0.0 109.571 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.992 HD21 HD12 ' A' ' 111' ' ' ILE . 4.3 mp -109.04 130.05 55.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.248 -0.907 . . . . 0.0 109.497 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.5 t -140.91 126.4 19.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.319 -0.863 . . . . 0.0 109.574 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.518 ' OE1' ' CB ' ' A' ' 7' ' ' LYS . 2.6 tt0 -69.54 138.95 53.71 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.21 -0.932 . . . . 0.0 109.268 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.493 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 14.9 ttp 178.76 152.86 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.226 -0.922 . . . . 0.0 109.468 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.471 ' N ' ' HG2' ' A' ' 73' ' ' MET . 23.6 m -99.2 160.48 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.376 -0.827 . . . . 0.0 109.557 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.566 ' HE3' ' HG2' ' A' ' 100' ' ' PRO . 14.6 mmt -94.24 120.5 34.57 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.295 -0.878 . . . . 0.0 109.421 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.8 p-10 -146.21 -161.18 1.26 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.565 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 80.9 m-20 -101.49 42.4 1.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.296 -0.878 . . . . 0.0 109.452 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -159.33 -51.11 0.06 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.291 -0.881 . . . . 0.0 109.337 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 83' ' ' VAL . 53.4 p -65.98 -30.19 70.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.348 -0.845 . . . . 0.0 109.31 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -66.52 -46.58 75.71 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.271 -0.893 . . . . 0.0 109.427 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -69.35 -33.15 72.66 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.34 -0.85 . . . . 0.0 109.35 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.853 HD13 ' HG3' ' A' ' 35' ' ' MET . 5.1 tt -65.79 -35.58 81.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.244 -0.91 . . . . 0.0 109.426 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.937 HG11 ' CE2' ' A' ' 92' ' ' PHE . 72.3 t -69.38 -47.49 72.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.415 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . . . . . . . . . 42.2 ttt-85 -61.15 -33.59 73.66 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.236 -0.915 . . . . 0.0 109.431 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 80.3 p -63.15 -22.89 67.16 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.424 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.688 HG21 ' CD2' ' A' ' 26' ' ' LEU . 12.7 t -60.93 120.33 52.82 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.343 -0.848 . . . . 0.0 109.51 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.413 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 51.1 Cg_endo -71.2 160.11 49.98 Favored 'Trans proline' 0 C--O 1.214 -0.679 0 C-N-CA 122.588 2.192 . . . . 0.0 111.862 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.619 ' O ' HG21 ' A' ' 22' ' ' VAL . 50.0 mtt85 60.94 33.14 19.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.209 -0.932 . . . . 0.0 109.683 179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.585 HG12 ' O ' ' A' ' 86' ' ' VAL . 7.3 p -122.28 132.4 71.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.194 -0.941 . . . . 0.0 109.423 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.526 ' HB2' ' CB ' ' A' ' 13' ' ' GLN . 95.4 mtp -72.51 -43.03 64.15 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.265 -0.897 . . . . 0.0 109.472 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.36 -153.86 25.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.937 ' CE2' HG11 ' A' ' 83' ' ' VAL . 0.6 OUTLIER -107.15 164.26 12.31 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.348 -1.09 . . . . 0.0 109.507 -179.92 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.916 HD12 ' CG1' ' A' ' 11' ' ' VAL . 58.3 mt -116.39 139.6 42.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.255 -0.903 . . . . 0.0 109.593 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 113.76 134.77 5.99 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 48.51 -93.29 0.01 OUTLIER Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.525 ' OG1' ' N ' ' A' ' 97' ' ' SER . 0.8 OUTLIER -141.16 -172.08 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.346 -1.091 . . . . 0.0 109.421 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.525 ' N ' ' OG1' ' A' ' 96' ' ' THR . 35.4 p -91.32 20.97 4.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.201 -0.937 . . . . 0.0 109.633 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -121.29 -29.56 4.46 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.342 -0.849 . . . . 0.0 108.931 179.479 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -149.23 83.39 6.61 Favored Pre-proline 0 N--CA 1.489 1.494 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 179.442 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HG2' ' HE3' ' A' ' 75' ' ' MET . 44.0 Cg_endo -65.6 128.32 19.86 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.948 2.432 . . . . 0.0 112.484 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -69.63 141.93 90.93 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.489 -0.757 . . . . 0.0 109.269 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.511 ' HB3' ' HD3' ' A' ' 8' ' ' ARG . 49.0 Cg_endo -69.41 153.59 70.32 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.693 2.262 . . . . 0.0 111.924 -179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.736 HD11 ' CG2' ' A' ' 108' ' ' VAL . 26.7 pt -116.22 158.65 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 109.35 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.436 ' HB2' ' HG3' ' A' ' 107' ' ' GLU . 45.4 m -71.66 147.91 47.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.26 -0.9 . . . . 0.0 109.493 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -58.94 -36.38 74.67 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.228 -0.92 . . . . 0.0 109.318 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -59.83 -39.19 84.25 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.319 -0.863 . . . . 0.0 109.4 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.436 ' HG3' ' HB2' ' A' ' 104' ' ' SER . 91.5 mt-10 -57.57 -46.4 84.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.29 -0.881 . . . . 0.0 109.361 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.736 ' CG2' HD11 ' A' ' 103' ' ' ILE . 71.5 t -61.64 -39.63 83.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.388 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -66.82 -37.51 84.65 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.258 -0.901 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.2 -52.9 63.62 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.353 -0.842 . . . . 0.0 109.426 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.992 HD12 HD21 ' A' ' 70' ' ' LEU . 55.0 mt -50.51 -56.41 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.325 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . 0.498 ' HG3' ' CE ' ' A' ' 43' ' ' MET . 96.0 mmm -60.82 -39.26 88.31 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.242 -0.912 . . . . 0.0 109.418 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -50.38 -49.24 54.91 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.268 -0.895 . . . . 0.0 109.362 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 62.9 mtt180 -55.7 -52.71 62.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.296 -0.878 . . . . 0.0 109.471 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.443 HD11 ' NE ' ' A' ' 62' ' ' ARG . 9.5 tp -46.72 -45.19 19.39 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.295 -0.878 . . . . 0.0 109.442 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -62.21 -28.46 69.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.898 . . . . 0.0 109.534 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -73.2 129.66 38.53 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.215 -0.928 . . . . 0.0 109.443 -179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.6 t -122.52 139.47 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.212 -0.93 . . . . 0.0 109.432 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -51.96 -20.85 6.79 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -84.42 140.25 31.66 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.237 -1.155 . . . . 0.0 109.506 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 1.5 ttpp -123.53 73.27 51.46 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.191 -0.943 . . . . 0.0 109.429 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . 0.436 ' O ' ' O ' ' A' ' 123' ' ' ARG . 49.4 Cg_endo -70.26 -20.24 32.72 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.723 2.282 . . . . 0.0 111.663 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.436 ' O ' ' O ' ' A' ' 122' ' ' PRO . 60.6 mtt180 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.502 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtt . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.315 0.578 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 50.2 m -118.12 147.11 43.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.227 -0.921 . . . . 0.0 109.501 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -108.49 140.47 41.77 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.265 -0.897 . . . . 0.0 109.44 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 5' ' ' PRO . . . -96.67 165.33 16.22 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.237 -0.914 . . . . 0.0 109.449 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 4' ' ' ALA . 50.2 Cg_endo -69.8 144.6 54.35 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.727 2.284 . . . . 0.0 111.811 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 80.0 mttt -121.14 151.62 39.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.445 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.448 ' HB3' ' HG2' ' A' ' 72' ' ' GLN . 63.0 mttm -80.27 136.87 36.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.349 -0.845 . . . . 0.0 109.464 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.536 ' HD3' ' CB ' ' A' ' 102' ' ' PRO . 88.2 mtt-85 -121.88 157.89 30.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TRP . . . . . 0.489 ' CG ' HG21 ' A' ' 108' ' ' VAL . 90.3 m95 -88.01 133.92 33.85 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.2 -0.938 . . . . 0.0 109.536 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 73' ' ' MET . 20.1 m-85 -119.05 156.47 29.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.248 -0.907 . . . . 0.0 109.441 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 93' ' ' ILE . 44.7 t -99.09 143.59 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.254 -0.904 . . . . 0.0 109.428 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.7 t -125.21 123.19 64.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.309 -0.87 . . . . 0.0 109.314 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLN . . . . . 0.783 ' HB2' HD11 ' A' ' 93' ' ' ILE . 62.5 tt0 -94.57 135.16 36.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.661 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.427 ' O ' ' HA2' ' A' ' 67' ' ' GLY . . . -152.88 155.8 37.76 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.315 -0.866 . . . . 0.0 109.317 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -56.41 140.74 44.65 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.259 -0.901 . . . . 0.0 109.576 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.507 ' HB2' ' HB2' ' A' ' 66' ' ' PRO . 47.0 p -65.45 151.97 45.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.276 -0.89 . . . . 0.0 109.487 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.56 -31.34 5.24 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -118.89 8.82 11.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -1.175 . . . . 0.0 109.466 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.534 ' HG3' ' N ' ' A' ' 20' ' ' GLY . 23.4 pt-20 -55.41 -46.19 76.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.395 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.534 ' N ' ' HG3' ' A' ' 19' ' ' GLU . . . -59.98 -38.6 94.43 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttm-85 -55.62 -49.37 73.0 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.3 -1.118 . . . . 0.0 109.38 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.935 HG13 HG11 ' A' ' 86' ' ' VAL . 39.2 t -47.24 -39.72 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.267 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.13 -44.57 95.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.288 -0.882 . . . . 0.0 109.339 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 89.4 m -65.93 -51.34 59.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.309 -0.87 . . . . 0.0 109.391 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 83.1 p -59.65 -36.06 75.64 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.402 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.459 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 tp -56.57 -53.1 61.54 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.2 -0.937 . . . . 0.0 109.494 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.417 ' C ' ' O ' ' A' ' 26' ' ' LEU . 57.0 ttt180 -43.7 -49.82 7.75 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.236 -0.915 . . . . 0.0 109.41 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.418 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 96.3 mt-10 -54.04 -45.39 71.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.296 -0.878 . . . . 0.0 109.361 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.402 ' HD2' HG22 ' A' ' 86' ' ' VAL . 76.3 m-70 -61.32 -34.34 75.1 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.306 -0.871 . . . . 0.0 109.297 179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.961 HD12 ' CD1' ' A' ' 39' ' ' PHE . 20.2 mm -63.22 -54.5 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.252 -0.905 . . . . 0.0 109.472 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.465 ' HG2' ' OE2' ' A' ' 36' ' ' GLU . 36.0 mttt -66.96 -37.59 84.56 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.221 -0.924 . . . . 0.0 109.389 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.418 ' HG ' ' O ' ' A' ' 28' ' ' GLU . 66.4 mt -60.58 -55.32 34.81 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.371 -0.831 . . . . 0.0 109.433 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.455 ' CD2' HD12 ' A' ' 82' ' ' LEU . 96.7 m-70 -89.46 0.09 57.11 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.315 -0.866 . . . . 0.0 109.56 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.49 ' N ' ' O ' ' A' ' 30' ' ' ILE . 79.3 m-20 60.18 49.5 7.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.264 -0.898 . . . . 0.0 109.48 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.987 ' HG3' HD13 ' A' ' 82' ' ' LEU . 51.2 mmm -101.87 14.08 32.98 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.223 -0.923 . . . . 0.0 109.512 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.63 ' CG ' HG22 ' A' ' 30' ' ' ILE . 97.8 mt-10 -52.06 -36.81 51.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.503 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -60.86 -40.75 94.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.229 -0.919 . . . . 0.0 109.548 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.857 HD12 ' HB3' ' A' ' 35' ' ' MET . 5.7 mt -70.48 -49.05 52.48 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.506 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PHE . . . . . 0.961 ' CD1' HD12 ' A' ' 30' ' ' ILE . 93.2 m-85 -75.76 138.03 40.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.22 -0.925 . . . . 0.0 109.399 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -116.1 -68.62 0.42 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.426 ' HG2' ' N ' ' A' ' 42' ' ' VAL . 84.7 tt0 -129.96 155.93 45.28 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.205 -1.174 . . . . 0.0 109.525 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.969 HG13 HG22 ' A' ' 71' ' ' VAL . 39.2 t -123.74 145.37 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.443 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' MET . . . . . 0.524 ' O ' HG13 ' A' ' 69' ' ' VAL . 92.9 mtp -124.44 150.48 45.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 109.556 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.936 HG12 ' H ' ' A' ' 46' ' ' THR . 66.6 t -142.08 132.04 12.52 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.383 -0.823 . . . . 0.0 109.235 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.405 ' HB2' ' CD2' ' A' ' 64' ' ' PHE . 47.8 Cg_endo -68.76 -0.38 6.03 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.758 2.305 . . . . 0.0 112.105 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.936 ' H ' HG12 ' A' ' 44' ' ' VAL . 11.6 p -121.74 159.16 27.21 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.097 -1.002 . . . . 0.0 109.485 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -111.48 153.84 25.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.414 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -103.66 137.79 41.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.266 -0.896 . . . . 0.0 109.463 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 42.1 t -118.31 134.85 60.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.199 -0.938 . . . . 0.0 109.475 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.445 HG23 ' N ' ' A' ' 51' ' ' GLU . 17.2 m -68.29 -36.59 75.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -0.919 . . . . 0.0 109.486 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.445 ' N ' HG23 ' A' ' 50' ' ' VAL . 85.1 tt0 -111.17 136.66 49.91 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.529 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 82.1 mt -58.77 -44.65 90.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.171 -0.956 . . . . 0.0 109.479 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ARG . . . . . . . . . . . . . 50.8 mtp85 -60.27 -35.91 76.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.891 . . . . 0.0 109.519 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 78.31 -166.23 52.4 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -81.11 6.24 63.89 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -114.54 155.1 27.08 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 83.8 mtt180 -61.3 -33.79 74.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.451 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 21.6 mtm180 -124.46 149.23 47.05 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.271 -0.893 . . . . 0.0 109.494 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 17.4 tttt -82.42 136.18 34.99 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.305 -0.872 . . . . 0.0 109.514 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.8 p -115.4 153.15 31.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.124 -0.985 . . . . 0.0 109.566 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.56 154.47 23.69 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.269 -0.894 . . . . 0.0 109.436 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.467 ' HD2' ' OD2' ' A' ' 120' ' ' ASP . 25.2 mtm180 -128.51 146.66 50.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.175 -0.953 . . . . 0.0 109.54 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 23.1 mttm -97.24 131.79 43.62 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.913 . . . . 0.0 109.367 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.763 ' HB2' HD12 ' A' ' 115' ' ' LEU . 41.8 p90 -154.97 153.7 31.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.599 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.589 ' O ' ' CD2' ' A' ' 65' ' ' PHE . 33.5 p90 -54.67 105.99 0.6 Allowed Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.21 -0.931 . . . . 0.0 109.461 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.507 ' HB2' ' HB2' ' A' ' 16' ' ' SER . 52.9 Cg_endo -91.53 152.33 3.55 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.04 2.493 . . . . 0.0 111.9 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 14' ' ' ALA . . . 92.84 13.84 55.98 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.655 ' OH ' HG21 ' A' ' 93' ' ' ILE . 1.7 m-85 -133.19 121.92 23.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.192 -1.181 . . . . 0.0 109.475 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.524 HG13 ' O ' ' A' ' 43' ' ' MET . 60.7 t -131.02 147.03 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.335 -0.853 . . . . 0.0 109.521 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.813 HD12 ' N ' ' A' ' 70' ' ' LEU . 3.8 mp -111.82 128.01 55.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.351 -0.843 . . . . 0.0 109.42 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.969 HG22 HG13 ' A' ' 42' ' ' VAL . 98.6 t -139.85 124.58 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.527 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . 0.448 ' HG2' ' HB3' ' A' ' 7' ' ' LYS . 37.9 tt0 -77.74 132.3 38.05 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.26 -0.9 . . . . 0.0 109.363 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.565 ' SD ' ' CZ ' ' A' ' 39' ' ' PHE . 46.6 ttp -165.39 164.31 19.69 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.2 -0.937 . . . . 0.0 109.493 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.522 ' N ' ' HG2' ' A' ' 73' ' ' MET . 42.2 t -82.47 142.76 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.229 -0.92 . . . . 0.0 109.504 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' MET . . . . . 0.629 ' HA ' ' HE2' ' A' ' 75' ' ' MET . 1.2 tpt -81.15 111.38 17.53 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.259 -0.901 . . . . 0.0 109.462 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.558 ' ND2' HD22 ' A' ' 38' ' ' LEU . 37.6 p-10 -150.46 164.04 36.91 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.313 -0.867 . . . . 0.0 109.393 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.442 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 85.2 m-20 -74.51 -26.81 60.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.158 -0.964 . . . . 0.0 109.405 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -65.44 -58.02 6.88 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.268 -0.895 . . . . 0.0 109.499 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.461 ' HB2' ' SD ' ' A' ' 73' ' ' MET . 11.2 p -56.62 -46.44 80.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.302 -0.874 . . . . 0.0 109.695 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' TRP . . . . . 0.59 ' CH2' ' HD2' ' A' ' 84' ' ' ARG . 37.9 t90 -43.63 -59.35 2.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.236 -0.915 . . . . 0.0 109.62 -179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.442 ' CD2' ' O ' ' A' ' 77' ' ' ASP . 94.5 m-70 -57.24 -35.95 70.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.205 -0.935 . . . . 0.0 109.614 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.987 HD13 ' HG3' ' A' ' 35' ' ' MET . 1.0 OUTLIER -62.91 -41.32 99.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.23 -0.919 . . . . 0.0 109.66 -179.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.55 HG11 ' CZ ' ' A' ' 92' ' ' PHE . 50.5 t -60.55 -46.09 96.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.259 -0.901 . . . . 0.0 109.488 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.59 ' HD2' ' CH2' ' A' ' 80' ' ' TRP . 29.5 mtp180 -56.6 -36.0 68.89 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.221 -0.924 . . . . 0.0 109.504 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 23.1 t -61.12 -28.78 69.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.24 -0.913 . . . . 0.0 109.537 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.935 HG11 HG13 ' A' ' 22' ' ' VAL . 40.2 t -55.4 121.28 36.8 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.276 -0.89 . . . . 0.0 109.446 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.444 ' O ' ' HB2' ' A' ' 88' ' ' ARG . 50.3 Cg_endo -70.5 149.94 62.95 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.684 2.256 . . . . 0.0 111.819 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.444 ' HB2' ' O ' ' A' ' 87' ' ' PRO . 63.9 mtt85 61.3 40.19 14.63 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.339 -0.85 . . . . 0.0 109.521 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.587 HG12 ' O ' ' A' ' 86' ' ' VAL . 9.9 p -122.33 128.19 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.338 -0.851 . . . . 0.0 109.316 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . 0.49 ' HB2' ' CG ' ' A' ' 13' ' ' GLN . 96.0 mmm -71.66 -53.72 12.68 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.16 -0.962 . . . . 0.0 109.506 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 160.42 -150.69 20.92 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.554 ' CD1' ' HG3' ' A' ' 100' ' ' PRO . 82.7 m-85 -100.53 157.68 16.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.339 -1.095 . . . . 0.0 109.56 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.783 HD11 ' HB2' ' A' ' 13' ' ' GLN . 38.8 mm -117.6 135.94 56.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.237 -0.914 . . . . 0.0 109.331 179.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' A' ' 96' ' ' THR . . . 110.12 145.86 10.86 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 50.75 -95.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 94' ' ' GLY . 19.3 p -140.33 -173.04 3.56 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.178 -1.19 . . . . 0.0 109.558 -179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 p -95.53 22.24 7.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.215 -0.928 . . . . 0.0 109.485 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.551 ' HA ' ' CZ2' ' A' ' 80' ' ' TRP . 73.4 m-20 -120.51 -25.13 5.63 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.371 -0.831 . . . . 0.0 109.215 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.445 ' HA ' ' HD2' ' A' ' 100' ' ' PRO . 15.2 mtp180 -153.04 102.36 2.64 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.358 -0.839 . . . . 0.0 109.013 179.732 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.554 ' HG3' ' CD1' ' A' ' 92' ' ' PHE . 44.3 Cg_endo -66.46 114.58 3.13 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.769 2.313 . . . . 0.0 112.012 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -59.54 140.29 88.89 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.397 -0.814 . . . . 0.0 109.487 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.536 ' CB ' ' HD3' ' A' ' 8' ' ' ARG . 49.4 Cg_endo -70.42 153.4 65.95 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.669 2.246 . . . . 0.0 111.823 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.608 HD11 HG22 ' A' ' 108' ' ' VAL . 31.8 pt -126.96 157.4 38.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.282 -0.887 . . . . 0.0 109.49 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 53.0 p -72.36 151.07 42.92 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.26 -0.9 . . . . 0.0 109.618 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 86.4 m-20 -61.6 -35.03 76.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.439 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' LYS . . . . . . . . . . . . . 16.3 tttt -61.84 -40.12 94.21 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 109.404 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.457 ' O ' HG13 ' A' ' 111' ' ' ILE . 86.5 tt0 -59.52 -41.88 90.99 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.293 -0.88 . . . . 0.0 109.467 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.608 HG22 HD11 ' A' ' 103' ' ' ILE . 70.6 t -60.29 -37.51 74.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.315 -0.866 . . . . 0.0 109.471 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -64.7 -40.27 95.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.973 . . . . 0.0 109.378 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -66.04 -43.13 88.46 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.207 -0.933 . . . . 0.0 109.379 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 107' ' ' GLU . 70.8 mt -52.44 -49.53 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.213 -0.929 . . . . 0.0 109.468 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' MET . . . . . . . . . . . . . 94.9 mmm -60.15 -36.67 78.04 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.431 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -58.13 -34.61 70.43 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.276 -0.89 . . . . 0.0 109.576 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.412 ' O ' ' N ' ' A' ' 117' ' ' GLN . 49.4 ttt85 -52.58 -46.23 66.8 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.42 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.763 HD12 ' HB2' ' A' ' 64' ' ' PHE . 3.1 tp -45.33 -45.36 12.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.284 -0.885 . . . . 0.0 109.584 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -69.26 -28.48 66.35 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.279 -0.888 . . . . 0.0 109.471 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.412 ' N ' ' O ' ' A' ' 114' ' ' ARG . 64.1 tt0 -50.57 -38.07 43.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.232 -0.918 . . . . 0.0 109.478 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 17.2 t -68.91 132.29 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.237 -0.915 . . . . 0.0 109.544 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.458 ' O ' ' HD3' ' A' ' 122' ' ' PRO . . . -83.43 98.26 2.07 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.365 -1.494 . . . . 0.0 109.365 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.467 ' OD2' ' HD2' ' A' ' 62' ' ' ARG . 87.8 m-20 -53.36 -41.33 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.232 -1.158 . . . . 0.0 109.563 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.82 83.43 66.2 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.215 -0.928 . . . . 0.0 109.495 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 119' ' ' GLY . 48.7 Cg_endo -69.43 -18.47 38.56 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.719 2.28 . . . . 0.0 111.848 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 27.3 mtm180 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.033 -0.984 . . . . 0.0 109.468 -179.997 . . . . . . . . 0 0 . 1 stop_ save_